data_2mk5_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mk5 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . 0.48 ' CZ3' HG13 ' A' ' 90' ' ' ILE . 60.3 m95 . . . . . 0 N--CA 1.444 -0.751 0 CA-C-O 120.901 0.382 . . . . 0.0 110.798 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 38.7 ttmt -114.45 151.18 33.6 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 61.7 tttm -93.26 144.74 25.02 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.513 0.673 . . . . 0.0 112.368 -175.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -107.91 156.12 19.54 Favored 'General case' 0 C--O 1.253 1.274 0 C-N-CA 125.182 1.393 . . . . 0.0 108.763 175.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 16.6 pm0 -62.08 -23.29 66.42 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.462 1.105 . . . . 0.0 113.183 -178.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -84.26 -3.26 58.1 Favored 'General case' 0 C--N 1.322 -0.6 0 O-C-N 121.819 -0.551 . . . . 0.0 111.4 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.9 -6.46 60.22 Favored Glycine 0 CA--C 1.5 -0.902 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 17.0 m -73.32 144.79 46.41 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 68.1 m95 -114.92 138.94 50.22 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 175.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -138.23 149.05 45.39 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 120.663 0.268 . . . . 0.0 111.676 -175.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.7 pttt -130.68 140.51 38.89 Favored Pre-proline 0 C--N 1.3 -1.567 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 176.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -75.2 121.99 6.83 Favored 'Trans proline' 0 C--O 1.254 1.309 0 C-N-CA 121.86 1.707 . . . . 0.0 109.354 172.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -166.24 122.33 1.27 Allowed 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -178.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.441 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 20.1 m120 -94.17 123.89 37.84 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.213 -178.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.423 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -149.39 175.09 11.76 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 176.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 11.8 m -115.91 148.62 39.83 Favored 'General case' 0 N--CA 1.419 -2.013 0 CA-C-O 121.349 0.595 . . . . 0.0 110.589 -174.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -131.46 122.67 26.63 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 175.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.3 t -104.11 112.68 38.58 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.242 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 176.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -75.12 138.5 42.1 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 120.124 -0.63 . . . . 0.0 110.17 -177.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -167.41 174.53 42.56 Favored Glycine 0 N--CA 1.423 -2.202 0 N-CA-C 107.913 -2.075 . . . . 0.0 107.913 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 36.8 t30 79.58 -45.6 0.33 Allowed 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 124.91 1.284 . . . . 0.0 110.209 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.468 HE21 HG12 ' A' ' 60' ' ' ILE . 10.8 pt20 -158.18 153.16 21.32 Favored Pre-proline 0 N--CA 1.413 -2.303 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.581 178.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -72.34 131.03 17.05 Favored 'Trans proline' 0 N--CA 1.444 -1.418 0 N-CA-C 107.418 -1.801 . . . . 0.0 107.418 167.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.468 HG12 HE21 ' A' ' 58' ' ' GLN . 49.2 mt -108.47 124.3 64.79 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 C-N-CA 120.3 -0.56 . . . . 0.0 109.745 -174.457 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.0 p -76.44 127.8 37.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 176.151 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 37.1 p -106.3 167.99 9.45 Favored 'General case' 0 N--CA 1.416 -2.157 0 CA-C-O 121.264 0.554 . . . . 0.0 111.41 -173.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 18.2 mmt180 -114.96 143.9 44.43 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 55.4 mt -111.93 134.63 53.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 C-N-CA 120.384 -0.527 . . . . 0.0 111.913 -175.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.09 -23.32 3.9 Favored Glycine 0 C--N 1.32 -0.329 0 N-CA-C 116.344 1.298 . . . . 0.0 116.344 171.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.8 m -155.87 137.1 9.36 Favored Pre-proline 0 C--N 1.301 -1.54 0 CA-C-N 118.228 1.014 . . . . 0.0 110.118 -179.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -89.86 121.44 0.99 Allowed 'Trans proline' 0 N--CA 1.444 -1.416 0 C-N-CA 122.24 1.96 . . . . 0.0 112.168 175.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -163.27 170.25 17.94 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 104.414 -2.439 . . . . 0.0 104.414 178.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -82.41 -26.08 33.11 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.255 0.55 . . . . 0.0 110.294 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -107.09 25.7 11.06 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 122.396 1.093 . . . . 0.0 108.498 178.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -68.64 157.57 88.0 Favored Pre-proline 0 C--N 1.318 -0.791 0 CA-C-N 115.186 -0.916 . . . . 0.0 111.336 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -53.96 133.47 55.0 Favored 'Trans proline' 0 C--N 1.361 1.205 0 C-N-CA 123.274 2.65 . . . . 0.0 113.623 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.7 m -99.22 176.23 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.012 0 C-N-CA 124.626 1.17 . . . . 0.0 110.662 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.59 4.53 10.67 Favored Glycine 0 CA--C 1.498 -0.972 0 C-N-CA 121.13 -0.557 . . . . 0.0 111.732 -178.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -122.12 124.48 5.76 Favored Glycine 0 N--CA 1.419 -2.434 0 N-CA-C 108.401 -1.88 . . . . 0.0 108.401 174.026 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -128.62 126.79 40.96 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 117.881 0.841 . . . . 0.0 109.668 176.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 49.4 tp -97.58 114.7 65.28 Favored Pre-proline 0 C--N 1.301 -1.511 0 C-N-CA 122.346 0.258 . . . . 0.0 110.337 -177.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -73.1 160.21 46.03 Favored 'Trans proline' 0 C--O 1.243 0.763 0 C-N-CA 122.348 2.032 . . . . 0.0 111.185 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.31 153.86 35.54 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.4 10.42 79.93 Favored Glycine 0 C--N 1.313 -0.738 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -178.446 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.16 126.41 38.25 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 60.1 m -96.82 108.78 21.52 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 177.093 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.6 mm -108.69 119.29 58.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.636 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.1 p -99.74 107.77 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.37 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 174.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.441 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 44.4 p90 -98.32 163.86 12.53 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.282 -174.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -125.38 -11.17 6.9 Favored 'General case' 0 C--N 1.318 -0.768 0 O-C-N 123.443 0.464 . . . . 0.0 111.538 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.426 ' HB2' ' NH2' ' A' ' 106' ' ' ARG . 31.1 tt0 -126.39 124.17 39.6 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -175.322 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 40.6 t -112.59 120.8 63.6 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.491 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.585 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 26.4 p -130.96 152.23 50.5 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 120.328 -0.549 . . . . 0.0 112.377 -176.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.48 HG13 ' CZ3' ' A' ' 37' ' ' TRP . 76.5 mt -112.74 113.64 44.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.169 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.049 177.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.51 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -112.1 113.66 26.06 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 103.363 -2.828 . . . . 0.0 103.363 169.102 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.6 109.76 0.28 Allowed 'General case' 0 C--O 1.241 0.635 0 O-C-N 124.722 1.264 . . . . 0.0 113.21 -164.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 137.4 -36.74 1.92 Allowed Glycine 0 N--CA 1.424 -2.118 0 CA-C-N 113.636 -1.62 . . . . 0.0 109.185 -176.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 52.9 m80 -149.02 165.33 31.97 Favored 'General case' 0 CA--C 1.5 -0.946 0 O-C-N 122.478 -0.424 . . . . 0.0 109.911 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.5 tt -103.24 135.84 38.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 N-CA-C 104.491 -2.411 . . . . 0.0 104.491 171.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.585 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 49.4 m95 -119.25 135.23 54.79 Favored 'General case' 0 C--N 1.275 -2.646 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 -173.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.484 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 47.0 pt -100.5 132.38 46.25 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 177.4 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.94 124.64 8.14 Favored Glycine 0 N--CA 1.425 -2.085 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -137.72 164.83 27.89 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 29.1 p-10 -117.54 137.5 52.54 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.982 0.42 . . . . 0.0 110.615 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.402 ' HB1' ' OD1' ' A' ' 105' ' ' ASN . . . -91.12 174.64 7.3 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -66.88 -12.08 58.12 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 121.263 0.554 . . . . 0.0 112.131 -177.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -81.01 -12.7 59.31 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 87.82 9.11 71.91 Favored Glycine 0 CA--C 1.505 -0.583 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.995 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.402 ' OD1' ' HB1' ' A' ' 101' ' ' ALA . 18.2 p-10 -91.86 147.58 22.87 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.126 0.489 . . . . 0.0 110.165 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . 0.426 ' NH2' ' HB2' ' A' ' 87' ' ' GLU . 18.0 tpt180 -94.61 115.3 27.4 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -175.46 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 24.3 t -111.39 139.9 33.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -176.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.484 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 94.1 m-85 -118.47 132.32 56.24 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 123.641 0.776 . . . . 0.0 110.943 -178.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 45.9 t -111.78 131.95 22.16 Favored Pre-proline 0 C--N 1.308 -1.201 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.363 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -70.69 -13.85 32.67 Favored 'Trans proline' 0 C--N 1.367 1.552 0 C-N-CA 123.311 2.674 . . . . 0.0 114.763 -176.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.31 35.9 m 38.86 -60.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.459 0 N-CA-C 119.072 2.99 . . . . 0.0 119.072 175.329 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 37.5 ptt180 -155.08 156.71 36.34 Favored 'General case' 0 C--O 1.248 0.977 0 O-C-N 121.894 -0.504 . . . . 0.0 109.717 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 25.3 m -64.54 136.78 57.39 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 174.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.453 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 65.3 m -149.67 128.05 12.19 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.727 0.775 . . . . 0.0 110.657 176.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -119.68 161.77 20.14 Favored 'General case' 0 C--N 1.286 -2.157 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.14 -167.13 12.85 Favored Glycine 0 C--N 1.286 -2.214 0 C-N-CA 118.918 -1.611 . . . . 0.0 112.284 177.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 24.6 m -140.91 147.33 47.66 Favored Pre-proline 0 C--N 1.306 -1.323 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.4 ' HB3' ' CG ' ' A' ' 37' ' ' TRP . 85.6 Cg_exo -48.63 136.1 27.18 Favored 'Trans proline' 0 CA--C 1.543 0.943 0 C-N-CA 123.24 2.627 . . . . 0.0 113.013 178.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -88.73 -19.72 15.55 Favored 'Cis proline' 0 CA--C 1.544 1.005 0 C-N-CA 123.779 -1.342 . . . . 0.0 113.176 -0.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 90.0 m-20 -77.34 102.2 6.66 Favored 'General case' 0 C--O 1.244 0.791 0 CA-C-O 122.244 1.021 . . . . 0.0 112.877 -172.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 32.4 p-80 -104.69 131.05 52.59 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 113.847 -1.524 . . . . 0.0 109.867 178.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.453 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 55.4 mt -96.66 108.6 43.7 Favored Pre-proline 0 C--N 1.286 -2.161 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -178.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -78.88 161.39 27.11 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.584 2.189 . . . . 0.0 112.521 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -134.74 -124.31 2.44 Favored Glycine 0 N--CA 1.437 -1.265 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 177.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.6 t -77.26 124.01 34.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 116.938 0.369 . . . . 0.0 110.795 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.5 151.32 19.44 Favored 'General case' 0 C--O 1.246 0.908 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.217 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.6 m-90 -124.98 29.64 6.09 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.93 178.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -169.4 -173.27 36.85 Favored Glycine 0 N--CA 1.434 -1.461 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 -179.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 47.4 t -114.63 115.28 49.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.164 0.507 . . . . 0.0 109.983 -178.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -83.72 130.19 34.95 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.007 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? . . . . . 0 N--CA 1.421 -1.908 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 -176.083 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.3 m95 . . . . . 0 N--CA 1.432 -1.372 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.4 mptt -113.91 155.2 26.22 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 176.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -102.99 132.48 49.23 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.803 -0.759 . . . . 0.0 108.967 178.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . 0.449 ' ND2' ' HB ' ' A' ' 44' ' ' THR . 38.7 p30 -86.5 178.19 7.17 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 175.222 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 -70.1 -23.12 63.0 Favored 'General case' 0 C--N 1.31 -1.134 0 CA-C-O 121.114 0.483 . . . . 0.0 111.144 -176.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . 0.46 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 26.7 m-85 -74.87 -13.92 60.61 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.163 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.41 7.07 57.25 Favored Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.829 178.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.449 ' HB ' ' ND2' ' A' ' 40' ' ' ASN . 5.8 m -88.34 137.57 32.2 Favored 'General case' 0 N--CA 1.424 -1.755 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 92.2 m95 -96.44 122.29 39.17 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 176.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 54.4 p90 -123.58 152.34 41.97 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 120.869 0.366 . . . . 0.0 111.973 -174.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.0 ptmt -141.03 147.18 46.67 Favored Pre-proline 0 N--CA 1.433 -1.292 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 171.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -77.09 122.09 6.06 Favored 'Trans proline' 0 N--CA 1.445 -1.327 0 C-N-CA 121.492 1.461 . . . . 0.0 109.222 172.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.5 tp10 -153.35 125.74 8.09 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 -179.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.488 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 7.7 t30 -109.57 107.49 17.6 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.203 0.525 . . . . 0.0 111.098 -175.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.416 ' HB2' ' CZ ' ' A' ' 85' ' ' TYR . . . -143.56 171.42 14.18 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.414 ' HB ' ' HB2' ' A' ' 131' ' ' LYS . 6.4 m -104.32 147.76 27.15 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -176.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -127.08 138.26 53.17 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 175.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.3 t -118.65 117.0 53.01 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 176.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.48 ' ND2' ' HA ' ' A' ' 79' ' ' ALA . 48.4 t30 -70.61 148.43 48.12 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.291 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -83.42 -132.7 2.05 Favored Glycine 0 N--CA 1.434 -1.471 0 N-CA-C 114.364 0.506 . . . . 0.0 114.364 -174.177 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -91.05 -4.32 56.45 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -171.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -131.95 153.09 81.28 Favored Pre-proline 0 C--N 1.306 -1.285 0 C-N-CA 120.007 -0.677 . . . . 0.0 112.261 179.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.431 ' HB3' HD22 ' A' ' 76' ' ' ASN . 7.4 Cg_exo -74.76 136.72 21.31 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.056 1.837 . . . . 0.0 111.079 176.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 61.0 mt -107.81 133.63 52.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -177.483 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.9 p -82.09 137.53 20.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 177.09 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 54.7 p -117.07 179.03 4.14 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.565 -172.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.422 ' NH1' HG11 ' A' ' 73' ' ' VAL . 47.2 mmt-85 -122.05 144.3 48.99 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 59.1 mt -106.35 125.99 62.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.868 -177.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.51 -22.64 1.68 Allowed Glycine 0 CA--C 1.527 0.812 0 N-CA-C 116.569 1.388 . . . . 0.0 116.569 171.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.5 m -145.68 134.17 10.86 Favored Pre-proline 0 C--N 1.3 -1.558 0 CA-C-N 118.562 1.181 . . . . 0.0 110.315 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -90.08 120.41 0.86 Allowed 'Trans proline' 0 N--CA 1.441 -1.614 0 C-N-CA 121.732 1.622 . . . . 0.0 111.624 174.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.468 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 93.1 m-85 -168.16 175.54 6.51 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 104.873 -2.269 . . . . 0.0 104.873 178.528 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -81.85 -45.3 15.7 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 176.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -94.04 25.93 3.48 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.108 -0.951 . . . . 0.0 111.151 -178.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.468 ' HB1' ' HB2' ' A' ' 68' ' ' PHE . . . -72.55 162.9 71.75 Favored Pre-proline 0 C--N 1.317 -0.835 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.468 178.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_exo -48.87 123.31 9.54 Favored 'Trans proline' 0 C--N 1.369 1.652 0 C-N-CA 123.537 2.825 . . . . 0.0 114.158 179.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.422 HG11 ' NH1' ' A' ' 63' ' ' ARG . 31.2 m -97.55 174.38 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.184 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.34 28.8 1.89 Allowed Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -150.94 126.61 2.16 Favored Glycine 0 N--CA 1.428 -1.896 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.431 HD22 ' HB3' ' A' ' 59' ' ' PRO . 8.0 t30 -127.39 136.79 52.35 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 57.2 tp -97.45 115.64 65.77 Favored Pre-proline 0 C--N 1.302 -1.463 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -59.24 152.67 58.4 Favored 'Trans proline' 0 C--O 1.245 0.856 0 C-N-CA 123.005 2.47 . . . . 0.0 112.609 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . 0.48 ' HA ' ' ND2' ' A' ' 55' ' ' ASN . . . -73.42 139.97 46.22 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.13 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.74 -4.82 77.71 Favored Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 116.113 -0.494 . . . . 0.0 113.108 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.93 134.06 40.34 Favored 'General case' 0 N--CA 1.439 -1.018 0 CA-C-O 120.774 0.321 . . . . 0.0 110.893 -177.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 14.6 t -108.0 134.66 50.59 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 177.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 44.6 mm -132.05 140.14 48.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -177.223 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.5 p -103.96 113.41 40.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-O 121.965 0.888 . . . . 0.0 109.582 175.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.488 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 43.2 p90 -97.15 152.95 18.3 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.417 -175.019 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -119.77 4.28 11.04 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.657 0.741 . . . . 0.0 110.345 -178.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -142.06 132.96 25.83 Favored 'General case' 0 N--CA 1.426 -1.656 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.391 -175.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.8 t -124.68 128.27 73.31 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 20.5 p -139.49 140.83 37.33 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-O 121.236 0.541 . . . . 0.0 111.421 -178.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 75.1 mt -101.03 114.87 41.51 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.731 179.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.569 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 50.0 tp60 -116.04 127.63 55.05 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 104.813 -2.292 . . . . 0.0 104.813 173.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.04 110.93 0.37 Allowed 'General case' 0 C--O 1.243 0.731 0 N-CA-C 113.275 0.842 . . . . 0.0 113.275 -167.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 124.23 -28.87 5.22 Favored Glycine 0 N--CA 1.438 -1.183 0 CA-C-N 114.498 -1.228 . . . . 0.0 112.729 179.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 74.8 m80 -151.12 169.9 20.74 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -176.342 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 19.0 tt -110.96 128.0 67.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.095 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 172.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.569 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 65.2 m95 -110.46 131.14 55.32 Favored 'General case' 0 C--N 1.274 -2.692 0 CA-C-O 120.966 0.412 . . . . 0.0 110.196 -173.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.493 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.5 pt -100.3 134.61 39.4 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.96 128.14 9.32 Favored Glycine 0 N--CA 1.428 -1.879 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 -178.607 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -151.38 163.93 37.85 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -97.77 116.81 30.72 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 174.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.09 178.25 6.5 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.999 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 46.5 p90 -47.49 -27.93 1.97 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 126.044 1.737 . . . . 0.0 113.858 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -99.27 2.42 45.54 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 112.222 0.453 . . . . 0.0 112.222 -175.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.85 0.67 81.07 Favored Glycine 0 C--N 1.32 -0.329 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.158 176.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -81.03 135.89 35.9 Favored 'General case' 0 C--N 1.306 -1.32 0 O-C-N 122.651 -0.323 . . . . 0.0 111.038 -178.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 4.1 tpp180 -75.29 102.24 4.99 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 173.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 67.6 t -108.27 143.87 17.89 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.029 0 CA-C-N 114.674 -1.148 . . . . 0.0 109.725 -174.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.493 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 96.5 m-85 -117.74 124.08 47.58 Favored 'General case' 0 N--CA 1.426 -1.647 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.273 178.671 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.8 t -104.13 133.71 20.08 Favored Pre-proline 0 C--N 1.298 -1.673 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -68.71 -22.88 36.76 Favored 'Trans proline' 0 C--N 1.359 1.115 0 C-N-CA 122.967 2.445 . . . . 0.0 113.472 -177.253 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.295 34.2 m 46.99 -53.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.207 0 N-CA-C 118.41 2.744 . . . . 0.0 118.41 175.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . 0.47 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 38.9 ptt180 -158.93 156.77 30.11 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 122.832 0.453 . . . . 0.0 110.553 -178.298 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 2.6 p -72.83 136.99 45.46 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 175.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.45 ' SG ' ' HA ' ' A' ' 123' ' ' PRO . 96.1 m -154.37 133.04 12.16 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.838 0.352 . . . . 0.0 111.54 -178.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 29.9 mm-40 -97.11 113.38 24.95 Favored 'General case' 0 N--CA 1.427 -1.595 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 171.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -122.01 113.96 2.39 Favored Glycine 0 C--N 1.259 -3.697 0 C-N-CA 119.779 -1.201 . . . . 0.0 114.014 -173.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 7.0 m -125.97 97.14 35.91 Favored Pre-proline 0 C--N 1.293 -1.878 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 172.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 61.9 Cg_exo -42.84 130.77 5.66 Favored 'Trans proline' 0 C--N 1.357 0.994 0 C-N-CA 124.327 3.351 . . . . 0.0 114.774 -170.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 7.4 Cg_endo -92.71 8.0 59.8 Favored 'Cis proline' 0 CA--C 1.549 1.236 0 C-N-CA 124.412 -1.078 . . . . 0.0 113.046 1.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -74.93 102.03 4.64 Favored 'General case' 0 CA--C 1.508 -0.672 0 CA-C-O 121.563 0.697 . . . . 0.0 110.229 -175.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.428 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 37.4 p-80 -104.78 107.03 17.77 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.592 177.429 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.5 mt -100.2 100.44 11.77 Favored Pre-proline 0 C--N 1.318 -0.791 0 C-N-CA 122.703 0.401 . . . . 0.0 109.925 -177.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . 0.45 ' HA ' ' SG ' ' A' ' 114' ' ' CYS . 2.9 Cg_endo -81.48 150.69 17.15 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 122.774 2.316 . . . . 0.0 113.265 -178.209 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.45 -116.13 3.3 Favored Glycine 0 N--CA 1.423 -2.228 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 175.022 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.3 t -97.39 124.45 50.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-O 120.801 0.334 . . . . 0.0 110.426 -176.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.47 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -95.02 146.88 23.96 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.708 177.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.7 m-90 -101.49 12.82 36.63 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 121.555 0.693 . . . . 0.0 109.246 177.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.74 179.24 37.24 Favored Glycine 0 N--CA 1.43 -1.705 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 49.4 t -112.08 137.79 43.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.398 -0.594 . . . . 0.0 109.398 -176.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -102.27 135.52 43.72 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-O 120.954 0.407 . . . . 0.0 110.11 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.414 ' HB2' ' HB ' ' A' ' 52' ' ' THR . 55.9 mtpt . . . . . 0 C--N 1.295 -1.776 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 47.8 m95 . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 109.13 -0.692 . . . . 0.0 109.13 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 47.9 mmtm -113.32 149.94 33.24 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.601 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -101.52 122.05 43.1 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-O 121.123 0.487 . . . . 0.0 111.086 -175.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -88.62 155.14 19.79 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 175.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -63.47 -20.51 65.65 Favored 'General case' 0 CA--C 1.546 0.815 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -175.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -75.64 5.2 6.41 Favored 'General case' 0 CA--C 1.542 0.665 0 CA-C-O 121.225 0.536 . . . . 0.0 110.994 176.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.07 22.67 70.75 Favored Glycine 0 CA--C 1.496 -1.121 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 48.0 m -105.42 128.03 53.31 Favored 'General case' 0 N--CA 1.416 -2.127 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 -179.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.509 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 84.5 m95 -95.34 120.84 36.27 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 177.643 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -121.87 150.64 41.65 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.824 0.345 . . . . 0.0 111.66 -175.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 52.0 pttt -135.57 135.48 22.2 Favored Pre-proline 0 C--N 1.299 -1.623 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 173.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -70.78 125.68 11.86 Favored 'Trans proline' 0 C--O 1.249 1.057 0 C-N-CA 121.764 1.643 . . . . 0.0 109.933 174.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -165.7 120.39 1.24 Allowed 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.531 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 25.7 t-20 -102.08 107.86 19.1 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.481 0.658 . . . . 0.0 111.114 -175.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -143.18 179.47 7.04 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.524 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 42.0 m -115.59 150.13 37.15 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.048 0.451 . . . . 0.0 110.641 -177.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 82.6 t80 -131.71 127.5 36.98 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 175.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.8 t -111.4 106.19 20.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -71.48 152.31 43.16 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -156.02 -41.14 0.02 OUTLIER Glycine 0 N--CA 1.435 -1.423 0 C-N-CA 118.589 -1.767 . . . . 0.0 115.16 -177.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 45.0 t30 -71.21 -49.02 47.84 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 117.406 0.603 . . . . 0.0 112.538 -172.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -146.86 153.64 46.35 Favored Pre-proline 0 C--N 1.305 -1.335 0 C-N-CA 119.979 -0.688 . . . . 0.0 110.385 -176.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_exo -65.66 123.18 11.03 Favored 'Trans proline' 0 C--O 1.248 1.019 0 C-N-CA 121.76 1.64 . . . . 0.0 108.411 170.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 55.1 mt -107.18 125.03 63.38 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 -173.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 9.9 p -76.52 119.93 25.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 43.2 p -95.43 151.46 19.27 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.236 -175.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -102.44 137.19 41.01 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -175.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.1 mt -106.0 135.12 45.5 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.922 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -171.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.66 -23.45 5.69 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 116.405 1.322 . . . . 0.0 116.405 170.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 51.3 m -157.63 142.19 11.86 Favored Pre-proline 0 C--N 1.307 -1.254 0 CA-C-N 118.102 0.951 . . . . 0.0 109.524 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -90.05 119.54 0.8 Allowed 'Trans proline' 0 N--CA 1.439 -1.695 0 C-N-CA 121.559 1.506 . . . . 0.0 111.193 175.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -168.38 165.77 12.63 Favored 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 126.16 1.784 . . . . 0.0 106.321 -179.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 89.8 mt -85.25 -14.62 46.14 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 175.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -106.95 13.59 27.47 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.52 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -72.88 155.61 90.46 Favored Pre-proline 0 C--N 1.314 -0.973 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.021 -177.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -56.52 140.6 89.81 Favored 'Trans proline' 0 C--N 1.364 1.364 0 C-N-CA 123.6 2.867 . . . . 0.0 114.626 -178.079 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 33.3 m -97.81 175.63 0.79 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.747 0 C-N-CA 124.668 1.187 . . . . 0.0 110.609 178.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 121.0 -9.17 10.41 Favored Glycine 0 CA--C 1.496 -1.101 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 -178.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.89 126.97 9.07 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 108.198 -1.961 . . . . 0.0 108.198 172.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.9 t30 -128.26 125.3 38.61 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 118.057 0.929 . . . . 0.0 110.468 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 54.4 tp -96.84 108.5 43.62 Favored Pre-proline 0 C--N 1.296 -1.755 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.005 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -67.73 159.14 54.04 Favored 'Trans proline' 0 C--O 1.245 0.86 0 C-N-CA 122.389 2.06 . . . . 0.0 112.104 178.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.3 136.46 39.61 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.51 -2.38 64.93 Favored Glycine 0 C--N 1.31 -0.883 0 N-CA-C 111.664 -0.574 . . . . 0.0 111.664 -179.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.59 134.37 37.22 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-O 120.845 0.355 . . . . 0.0 111.711 -177.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 22.1 m -98.73 109.05 21.87 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.155 -0.93 . . . . 0.0 108.837 178.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 43.0 mm -110.78 135.35 50.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.45 -177.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.3 p -108.51 129.8 62.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 176.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.531 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 48.4 p90 -124.65 151.9 44.33 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -177.049 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -114.81 4.93 15.06 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 120.864 0.364 . . . . 0.0 110.537 -179.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -148.15 139.64 23.61 Favored 'General case' 0 N--CA 1.428 -1.562 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.383 -176.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 41.5 t -120.38 128.19 75.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 N-CA-C 105.725 -1.954 . . . . 0.0 105.725 175.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 8.7 p -139.91 143.37 36.62 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -175.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 67.8 mt -105.66 117.24 51.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.094 0.473 . . . . 0.0 110.751 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.505 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 6.1 tp-100 -115.66 113.52 23.64 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 103.021 -2.955 . . . . 0.0 103.021 168.154 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.59 115.88 1.4 Allowed 'General case' 0 CA--C 1.512 -0.512 0 O-C-N 124.458 1.099 . . . . 0.0 113.189 -165.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 133.02 -39.11 1.78 Allowed Glycine 0 N--CA 1.419 -2.459 0 CA-C-N 113.642 -1.617 . . . . 0.0 109.066 -176.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 64.4 m80 -148.16 161.15 42.03 Favored 'General case' 0 CA--C 1.506 -0.72 0 C-N-CA 122.921 0.488 . . . . 0.0 110.363 -179.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.449 ' O ' HG23 ' A' ' 111' ' ' VAL . 16.0 tt -106.75 121.44 59.47 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 175.201 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.505 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 52.9 m95 -104.77 138.25 41.33 Favored 'General case' 0 C--N 1.279 -2.469 0 CA-C-O 120.868 0.366 . . . . 0.0 110.881 -170.345 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.455 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.5 pt -100.34 132.51 45.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 175.757 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.14 116.07 5.45 Favored Glycine 0 N--CA 1.431 -1.67 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -178.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -136.08 175.25 9.77 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -115.29 127.42 55.44 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 177.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.28 -179.42 6.97 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.5 p90 -68.0 -20.39 65.02 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 118.488 0.585 . . . . 0.0 112.432 -176.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 59.3 t30 -73.7 -12.29 60.67 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-O 121.637 0.732 . . . . 0.0 109.532 175.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 92.26 -12.43 69.66 Favored Glycine 0 CA--C 1.501 -0.786 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.627 178.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -72.57 147.67 45.67 Favored 'General case' 0 C--O 1.253 1.245 0 C-N-CA 123.252 0.621 . . . . 0.0 109.841 -175.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.3 tpt180 -80.66 108.29 14.19 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 124.539 1.136 . . . . 0.0 108.414 -178.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 38.2 t -112.32 145.99 17.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 -176.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.455 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 91.9 m-85 -121.49 130.86 53.81 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.038 0.447 . . . . 0.0 110.671 -177.251 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 52.5 t -109.11 130.49 22.67 Favored Pre-proline 0 C--N 1.304 -1.396 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 177.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -70.07 -14.15 34.76 Favored 'Trans proline' 0 C--O 1.21 -0.883 0 C-N-CA 122.962 2.442 . . . . 0.0 114.564 -177.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 95' ' ' ILE 0.295 21.5 m 43.29 -54.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.518 2.949 0 N-CA-C 118.431 2.752 . . . . 0.0 118.431 176.173 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 12.1 ptm180 -156.09 150.43 25.64 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 55.1 m -64.31 144.68 56.97 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 177.004 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.441 ' SG ' ' HB2' ' A' ' 121' ' ' HIS . 27.0 t -161.16 134.18 6.35 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-O 120.954 0.407 . . . . 0.0 110.738 -178.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -123.81 160.92 26.31 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 176.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.62 178.04 15.48 Favored Glycine 0 N--CA 1.423 -2.195 0 C-N-CA 119.055 -1.545 . . . . 0.0 113.455 174.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 16.5 m -128.39 128.12 23.64 Favored Pre-proline 0 C--N 1.3 -1.574 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.509 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 64.5 Cg_exo -48.46 139.63 22.54 Favored 'Trans proline' 0 C--O 1.237 0.459 0 C-N-CA 123.433 2.755 . . . . 0.0 113.788 -179.294 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -81.15 -18.71 24.29 Favored 'Cis proline' 0 C--O 1.246 0.91 0 C-N-CA 123.581 -1.424 . . . . 0.0 114.018 0.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -70.67 102.0 2.19 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 122.053 0.93 . . . . 0.0 112.665 -172.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.441 ' HB2' ' SG ' ' A' ' 114' ' ' CYS . 48.8 p-80 -104.64 130.35 52.67 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-N 114.65 -1.159 . . . . 0.0 110.188 178.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 60.9 mt -96.49 114.32 64.18 Favored Pre-proline 0 C--N 1.301 -1.524 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -75.88 162.27 35.08 Favored 'Trans proline' 0 C--O 1.245 0.862 0 C-N-CA 122.571 2.181 . . . . 0.0 113.181 -179.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.85 -164.31 11.0 Favored Glycine 0 N--CA 1.433 -1.535 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 177.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.1 t -52.84 115.97 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.818 0.847 . . . . 0.0 112.562 -176.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -93.85 148.85 21.75 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.248 177.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.9 m-90 -111.17 10.91 21.86 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-O 121.103 0.478 . . . . 0.0 111.252 178.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.5 -175.9 33.03 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.665 -178.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 54.7 t -111.33 138.98 37.53 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -176.205 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -101.22 147.49 26.21 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-O 120.597 0.237 . . . . 0.0 110.396 -178.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.2 mtpt . . . . . 0 C--O 1.26 1.621 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 175.087 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 93.1 m95 . . . . . 0 N--CA 1.437 -1.078 0 CA-C-O 121.158 0.504 . . . . 0.0 109.715 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -113.92 141.95 46.74 Favored 'General case' 0 C--N 1.286 -2.169 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 -177.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 66.1 tttm -100.2 144.51 29.13 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 119.681 -0.808 . . . . 0.0 110.138 -179.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 33.0 p30 -114.73 -179.18 3.55 Favored 'General case' 0 C--O 1.254 1.326 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.545 175.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -81.51 0.63 37.09 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -175.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -91.79 -0.77 57.55 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 121.846 0.832 . . . . 0.0 109.073 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.95 19.65 74.76 Favored Glycine 0 CA--C 1.5 -0.885 0 CA-C-N 115.235 -0.893 . . . . 0.0 111.191 -179.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.435 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 28.3 m -105.65 141.13 37.64 Favored 'General case' 0 N--CA 1.41 -2.458 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 -179.512 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.528 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 63.3 m95 -104.64 125.3 50.62 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 174.008 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -127.42 145.07 50.95 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-O 120.729 0.3 . . . . 0.0 110.614 -176.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.432 ' CG ' ' HB ' ' A' ' 88' ' ' VAL . 21.1 ptmt -124.86 132.78 24.37 Favored Pre-proline 0 C--N 1.294 -1.836 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 176.044 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -76.05 121.06 5.98 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 121.458 1.438 . . . . 0.0 109.555 174.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -166.71 120.91 1.07 Allowed 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -95.43 120.2 35.25 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.091 -175.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.72 164.18 35.93 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 51.2 m -103.83 149.18 25.29 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.933 -177.415 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.5 t80 -126.42 134.13 51.08 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 177.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.8 t -114.2 118.11 57.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.923 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 49.9 t-20 -68.62 130.68 43.54 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -95.58 -68.29 1.01 Allowed Glycine 0 N--CA 1.421 -2.344 0 C-N-CA 120.005 -1.093 . . . . 0.0 114.253 -172.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -135.31 14.4 3.5 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -170.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.47 ' O ' HG13 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -135.48 122.07 14.47 Favored Pre-proline 0 C--N 1.298 -1.642 0 C-N-CA 119.729 -0.788 . . . . 0.0 112.949 -177.802 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -67.22 120.66 7.74 Favored 'Trans proline' 0 N--CA 1.447 -1.209 0 N-CA-C 105.767 -2.436 . . . . 0.0 105.767 167.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.47 HG13 ' O ' ' A' ' 58' ' ' GLN . 49.4 mt -113.58 120.74 64.24 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.057 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.639 -171.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -73.84 122.78 27.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 176.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 44.8 p -102.42 170.35 8.11 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.884 -173.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -117.47 149.28 40.85 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 2.8 mp -111.58 133.19 58.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 121.082 0.468 . . . . 0.0 111.111 -178.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 84.29 -24.11 6.59 Favored Glycine 0 C--N 1.315 -0.615 0 N-CA-C 115.861 1.104 . . . . 0.0 115.861 171.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 65.5 m -160.46 146.67 11.67 Favored Pre-proline 0 C--N 1.311 -1.068 0 CA-C-N 118.216 1.008 . . . . 0.0 110.144 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -89.82 119.9 0.87 Allowed 'Trans proline' 0 N--CA 1.44 -1.638 0 C-N-CA 121.771 1.647 . . . . 0.0 111.732 175.221 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 -169.89 177.66 4.3 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 103.487 -2.782 . . . . 0.0 103.487 -179.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -89.95 -37.47 14.34 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 171.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -89.14 25.48 1.85 Allowed 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 114.751 -1.113 . . . . 0.0 111.138 -177.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -84.49 161.38 54.22 Favored Pre-proline 0 C--N 1.306 -1.309 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 178.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -47.66 135.12 21.98 Favored 'Trans proline' 0 C--N 1.364 1.35 0 C-N-CA 123.715 2.943 . . . . 0.0 114.722 -178.286 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 18.0 m -90.42 173.92 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 114.362 -1.29 . . . . 0.0 110.636 -178.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.86 28.53 2.04 Favored Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.535 177.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -151.08 128.59 2.64 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 120.001 -1.095 . . . . 0.0 112.567 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -128.12 127.76 43.61 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.751 -1.204 . . . . 0.0 107.751 173.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 55.0 tp -101.41 109.9 60.15 Favored Pre-proline 0 C--N 1.301 -1.509 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 178.151 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.22 154.06 51.54 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 122.46 2.107 . . . . 0.0 112.515 -178.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.53 141.48 51.9 Favored 'General case' 0 N--CA 1.438 -1.045 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.855 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.0 -7.13 67.14 Favored Glycine 0 N--CA 1.435 -1.412 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.618 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.04 136.56 34.45 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.902 0.351 . . . . 0.0 111.366 -178.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 47.6 m -103.77 112.9 26.05 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.7 mm -127.27 133.77 67.35 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -176.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.469 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 11.6 p -93.3 135.19 28.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -118.18 159.55 23.11 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -178.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -130.12 -7.78 4.35 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 112.367 0.506 . . . . 0.0 112.367 -177.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.461 ' HG2' ' SG ' ' A' ' 89' ' ' CYS . 29.4 tt0 -131.36 120.83 23.67 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 -176.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.432 ' HB ' ' CG ' ' A' ' 47' ' ' LYS . 39.9 t -105.67 119.07 54.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.461 ' SG ' ' HG2' ' A' ' 87' ' ' GLU . 46.9 m -123.23 133.2 54.22 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -172.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 56.6 mt -97.7 113.86 33.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 CA-C-O 121.291 0.567 . . . . 0.0 109.942 173.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.492 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -121.42 134.04 55.09 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 172.145 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.62 117.05 1.84 Allowed 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 114.081 1.141 . . . . 0.0 114.081 -164.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 107.96 -22.61 27.33 Favored Glycine 0 N--CA 1.431 -1.681 0 CA-C-N 115.115 -0.948 . . . . 0.0 112.426 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . 0.423 ' HB2' ' NE1' ' A' ' 96' ' ' TRP . 57.9 m80 -144.45 169.22 18.36 Favored 'General case' 0 CA--C 1.509 -0.626 0 O-C-N 122.108 -0.642 . . . . 0.0 110.445 -176.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.6 tt -126.09 109.58 21.74 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.152 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 173.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.492 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 42.5 m95 -95.27 138.91 32.33 Favored 'General case' 0 C--N 1.279 -2.48 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.563 -167.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.448 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.8 pt -100.58 127.74 53.35 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 176.498 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.88 127.93 9.37 Favored Glycine 0 N--CA 1.421 -2.307 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 41.3 p90 -142.63 150.46 40.3 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 178.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -102.08 119.15 38.33 Favored 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.411 ' HB2' ' OD1' ' A' ' 105' ' ' ASN . . . -87.19 168.12 13.51 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 120.954 0.407 . . . . 0.0 110.838 -177.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -52.88 -25.52 11.93 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.397 1.479 . . . . 0.0 112.897 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -83.69 -3.44 57.77 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.454 0.645 . . . . 0.0 110.497 -176.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.19 7.07 73.88 Favored Glycine 0 CA--C 1.501 -0.8 0 CA-C-O 121.422 0.456 . . . . 0.0 112.038 176.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.411 ' OD1' ' HB2' ' A' ' 101' ' ' ALA . 13.8 p-10 -94.66 130.21 41.24 Favored 'General case' 0 C--N 1.29 -1.991 0 C-N-CA 123.147 0.579 . . . . 0.0 111.008 -177.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 26.6 tpt180 -84.1 102.93 12.9 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 178.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.8 t -97.71 139.34 20.22 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -173.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 79.0 m-85 -119.69 122.55 41.72 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 123.336 0.654 . . . . 0.0 109.725 177.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . 0.42 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 48.6 t -111.38 130.87 22.62 Favored Pre-proline 0 C--N 1.305 -1.369 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.1 -27.41 41.98 Favored 'Trans proline' 0 C--N 1.355 0.884 0 C-N-CA 122.815 2.343 . . . . 0.0 114.112 -176.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.303 18.9 m 51.19 -42.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.505 0 N-CA-C 118.446 2.758 . . . . 0.0 118.446 176.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . 0.454 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 37.9 ptt180 -161.5 165.08 29.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-O 121.112 0.482 . . . . 0.0 110.634 -179.409 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.5 m -75.93 139.72 41.74 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 176.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.448 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 49.5 t -155.97 128.01 7.51 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.47 0.652 . . . . 0.0 110.962 178.209 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . 0.432 ' HA ' ' OE1' ' A' ' 115' ' ' GLN . 7.9 mm-40 -121.69 162.45 20.72 Favored 'General case' 0 C--N 1.288 -2.106 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.493 177.718 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 124.58 -174.38 17.07 Favored Glycine 0 N--CA 1.418 -2.51 0 C-N-CA 119.947 -1.121 . . . . 0.0 112.021 177.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 18.9 m -131.87 133.22 23.82 Favored Pre-proline 0 C--N 1.3 -1.549 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.528 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 88.2 Cg_exo -48.74 137.13 27.34 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 123.332 2.688 . . . . 0.0 113.417 -178.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -91.09 1.09 64.32 Favored 'Cis proline' 0 C--O 1.245 0.86 0 C-N-CA 123.584 -1.423 . . . . 0.0 113.079 1.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -80.7 100.18 8.58 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 121.76 0.791 . . . . 0.0 110.36 -173.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.419 ' HB2' ' SG ' ' A' ' 114' ' ' CYS . 47.1 p-80 -105.5 131.33 53.03 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 114.606 -1.179 . . . . 0.0 112.098 -177.442 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.448 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.1 mm -105.74 99.8 23.83 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 178.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -84.96 139.69 7.47 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.391 2.061 . . . . 0.0 112.29 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -102.39 -133.01 7.89 Favored Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 177.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 61.5 t -82.97 129.3 37.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 110.129 -0.322 . . . . 0.0 110.129 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.454 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -93.62 143.82 25.96 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.823 176.543 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . 0.437 ' HB3' ' HB2' ' A' ' 58' ' ' GLN . 4.8 m0 -101.99 12.59 36.66 Favored 'General case' 0 C--O 1.251 1.154 0 CA-C-O 122.031 0.92 . . . . 0.0 110.345 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.63 179.59 36.92 Favored Glycine 0 N--CA 1.426 -1.99 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.936 -179.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.5 t -113.54 134.97 54.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -177.012 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -87.62 122.1 30.89 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? . . . . . 0 C--N 1.291 -1.943 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.866 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 73.0 m95 . . . . . 0 N--CA 1.443 -0.822 0 CA-C-O 120.88 0.371 . . . . 0.0 110.296 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.93 146.68 52.25 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 174.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -93.77 133.6 36.98 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 -178.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 33.3 p30 -96.84 176.81 5.85 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 175.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -77.22 1.75 17.56 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.515 0.674 . . . . 0.0 112.214 -175.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.7 m-85 -98.72 7.9 45.56 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.139 178.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.19 17.51 77.41 Favored Glycine 0 C--N 1.338 0.65 0 CA-C-N 115.128 -0.942 . . . . 0.0 112.32 177.14 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.416 HG21 ' HG2' ' A' ' 67' ' ' PRO . 5.3 m -105.01 141.9 35.76 Favored 'General case' 0 N--CA 1.42 -1.937 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -177.341 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.442 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 87.5 m95 -96.46 129.18 43.87 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.403 ' HA ' ' O ' ' A' ' 88' ' ' VAL . 51.8 p90 -125.89 150.28 48.04 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 123.199 0.312 . . . . 0.0 110.383 -178.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 14.1 ptmm? -135.66 148.06 63.98 Favored Pre-proline 0 C--N 1.303 -1.43 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 175.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -71.24 128.86 15.21 Favored 'Trans proline' 0 N--CA 1.444 -1.386 0 C-N-CA 121.27 1.313 . . . . 0.0 109.013 170.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.2 tp10 -162.64 120.18 2.04 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.518 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 6.6 t30 -105.87 113.48 27.06 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.684 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.403 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.55 175.62 12.57 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 89.0 m -118.9 133.19 56.0 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 120.253 -0.579 . . . . 0.0 112.32 -176.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -107.89 129.11 55.11 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 176.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.1 t -110.35 115.1 48.88 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 176.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -69.16 148.64 49.63 Favored 'General case' 0 C--N 1.309 -1.178 0 O-C-N 123.408 0.442 . . . . 0.0 110.466 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -81.58 -144.76 4.55 Favored Glycine 0 N--CA 1.43 -1.756 0 CA-C-N 115.998 -0.547 . . . . 0.0 113.84 -177.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 31.2 p-10 -85.65 12.22 9.23 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 -171.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -142.4 143.46 27.04 Favored Pre-proline 0 C--N 1.301 -1.516 0 C-N-CA 120.592 -0.443 . . . . 0.0 112.065 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_exo -71.98 131.75 18.69 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.138 1.892 . . . . 0.0 111.437 177.382 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -107.58 132.7 54.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.037 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.5 p -79.97 136.2 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 176.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 53.4 p -111.98 167.03 10.71 Favored 'General case' 0 C--N 1.287 -2.138 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.651 -175.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 21.7 mmt180 -114.68 137.14 52.26 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.041 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.7 mt -93.33 123.85 45.57 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 CA-C-N 115.396 -0.82 . . . . 0.0 113.156 -172.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.79 -23.19 3.75 Favored Glycine 0 C--O 1.237 0.291 0 N-CA-C 115.906 1.123 . . . . 0.0 115.906 172.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 50.7 m -151.7 144.53 16.96 Favored Pre-proline 0 C--N 1.306 -1.288 0 CA-C-N 118.53 1.165 . . . . 0.0 111.54 -177.004 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.416 ' HG2' HG21 ' A' ' 44' ' ' THR . 1.2 Cg_endo -89.35 120.95 1.06 Allowed 'Trans proline' 0 N--CA 1.448 -1.168 0 C-N-CA 122.457 2.105 . . . . 0.0 110.597 173.245 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.48 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . 59.6 m-85 -168.53 170.43 9.66 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 126.355 1.862 . . . . 0.0 106.322 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 95.8 mt -82.51 -30.96 29.48 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 172.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 17.6 m120 -102.97 26.22 8.42 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.732 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.48 ' HB3' ' HB2' ' A' ' 68' ' ' PHE . . . -75.2 156.79 85.58 Favored Pre-proline 0 C--N 1.308 -1.198 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.397 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -50.7 131.44 33.47 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 123.651 2.901 . . . . 0.0 113.48 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 6.8 p -101.31 174.17 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 C-N-CA 124.051 0.94 . . . . 0.0 108.928 -176.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.44 -4.74 13.36 Favored Glycine 0 N--CA 1.443 -0.84 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.023 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -110.81 123.78 6.71 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 177.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -122.09 134.48 54.77 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 117.356 0.578 . . . . 0.0 110.139 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.5 tp -100.83 118.87 59.79 Favored Pre-proline 0 C--N 1.308 -1.217 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -66.62 160.06 47.96 Favored 'Trans proline' 0 C--O 1.243 0.764 0 C-N-CA 122.478 2.119 . . . . 0.0 112.709 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.56 136.65 47.56 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.666 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.64 1.49 90.53 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 121.423 -0.418 . . . . 0.0 113.365 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.59 127.09 31.05 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.179 0.514 . . . . 0.0 111.861 -177.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 46.2 m -96.97 109.0 21.84 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 177.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.3 mm -118.79 120.8 65.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.096 -174.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.6 p -89.06 127.46 41.77 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.134 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.518 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 48.5 p90 -116.43 154.55 30.11 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -178.509 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -120.31 4.93 10.74 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-O 121.469 0.652 . . . . 0.0 110.561 -179.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -147.45 140.7 25.24 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.713 -175.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 46' ' ' TYR . 86.7 t -124.04 133.19 69.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 176.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.442 ' HA ' ' O ' ' A' ' 45' ' ' TRP . 61.5 m -130.27 135.18 47.83 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 122.315 0.246 . . . . 0.0 111.369 -176.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.4 mt -103.03 111.84 34.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 176.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.1 tp-100 -115.69 145.1 43.05 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 105.448 -2.056 . . . . 0.0 105.448 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.37 104.81 0.08 Allowed 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -174.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 115.31 -30.89 6.48 Favored Glycine 0 N--CA 1.434 -1.456 0 CA-C-N 115.61 -0.723 . . . . 0.0 113.836 177.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 64.0 m80 -145.46 150.97 37.47 Favored 'General case' 0 CA--C 1.504 -0.827 0 CA-C-N 118.196 0.998 . . . . 0.0 110.743 -175.018 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.8 tt -106.41 111.78 36.78 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 176.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 47.9 m95 -95.87 148.43 22.62 Favored 'General case' 0 C--N 1.285 -2.233 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.424 -169.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.484 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.4 pt -107.34 139.23 29.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.411 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -106.49 121.46 6.65 Favored Glycine 0 N--CA 1.431 -1.675 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -135.65 167.96 20.15 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.667 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -102.42 131.06 49.32 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.891 179.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -83.51 175.52 9.73 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 173.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 29.9 p90 -53.37 -36.24 61.19 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -178.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 25.6 p-10 -88.63 1.91 54.15 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 120.68 0.276 . . . . 0.0 111.322 -178.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.11 5.79 72.58 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 121.306 -0.473 . . . . 0.0 112.009 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 60.8 t30 -67.94 129.7 40.71 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 22.9 tpt180 -82.68 107.7 15.5 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 -178.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 27.8 t -111.62 142.85 22.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -178.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.484 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 85.0 m-85 -117.63 131.35 56.67 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 120.963 0.411 . . . . 0.0 110.628 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 45.3 t -112.9 134.47 21.75 Favored Pre-proline 0 C--N 1.302 -1.483 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -68.16 -27.14 35.68 Favored 'Trans proline' 0 C--N 1.358 1.038 0 C-N-CA 122.626 2.217 . . . . 0.0 113.35 -177.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.29 21.9 m 52.52 -46.59 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.284 0 N-CA-C 117.968 2.581 . . . . 0.0 117.968 176.47 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . 0.46 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 37.1 ptt180 -161.63 163.55 29.87 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 123.157 0.583 . . . . 0.0 110.068 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.8 t -81.69 141.51 33.54 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 175.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.9 t -156.18 127.78 7.24 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -109.17 139.12 44.51 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 142.49 177.91 17.98 Favored Glycine 0 N--CA 1.42 -2.393 0 C-N-CA 119.059 -1.543 . . . . 0.0 113.668 175.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 16.2 m -141.42 145.4 37.77 Favored Pre-proline 0 C--N 1.299 -1.593 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 178.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_exo -49.2 138.41 28.94 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 122.897 2.398 . . . . 0.0 112.922 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -85.29 -16.04 29.78 Favored 'Cis proline' 0 C--O 1.25 1.118 0 C-N-CA 123.366 -1.514 . . . . 0.0 113.618 0.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -80.54 100.98 8.85 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -171.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -106.41 123.95 48.85 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 114.336 -1.302 . . . . 0.0 111.29 178.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 70.4 mt -95.46 108.19 37.82 Favored Pre-proline 0 C--N 1.319 -0.73 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -84.23 130.67 4.76 Favored 'Trans proline' 0 C--O 1.249 1.04 0 C-N-CA 122.37 2.047 . . . . 0.0 112.841 -179.059 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -115.35 -147.93 9.26 Favored Glycine 0 N--CA 1.435 -1.374 0 C-N-CA 120.562 -0.827 . . . . 0.0 112.017 178.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.6 t -57.63 116.13 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.823 0 C-N-CA 123.819 0.848 . . . . 0.0 112.047 -179.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.46 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.19 143.87 26.0 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.431 173.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.6 m-90 -104.51 19.74 19.78 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.635 0.731 . . . . 0.0 109.584 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -165.77 -175.74 36.54 Favored Glycine 0 N--CA 1.428 -1.882 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 179.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 60.8 t -112.88 141.59 28.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -177.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -107.14 122.15 45.93 Favored 'General case' 0 C--N 1.321 -0.653 0 O-C-N 123.231 0.332 . . . . 0.0 110.54 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt . . . . . 0 C--N 1.297 -1.676 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 177.994 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 48.3 m95 . . . . . 0 N--CA 1.435 -1.217 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -114.13 133.58 55.47 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -89.45 129.83 35.89 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 120.985 0.421 . . . . 0.0 111.201 -177.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 45.9 t-20 -99.83 160.0 14.64 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -65.26 -11.86 45.64 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -77.2 -5.57 49.7 Favored 'General case' 0 CA--C 1.541 0.633 0 CA-C-O 121.357 0.598 . . . . 0.0 109.996 176.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.26 1.83 83.7 Favored Glycine 0 CA--C 1.506 -0.492 0 N-CA-C 110.145 -1.182 . . . . 0.0 110.145 -177.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.414 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 9.2 m -89.42 141.01 28.94 Favored 'General case' 0 N--CA 1.415 -2.208 0 CA-C-N 113.86 -1.17 . . . . 0.0 109.299 -178.02 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.497 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 71.9 m95 -102.45 135.94 43.18 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 173.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.433 ' HA ' ' O ' ' A' ' 88' ' ' VAL . 32.0 p90 -137.4 155.47 49.33 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.702 -177.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -147.29 135.59 10.95 Favored Pre-proline 0 C--N 1.305 -1.364 0 CA-C-N 115.318 -0.855 . . . . 0.0 108.738 173.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -67.08 129.57 20.89 Favored 'Trans proline' 0 C--O 1.248 0.992 0 C-N-CA 122.264 1.976 . . . . 0.0 111.42 173.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -168.02 120.99 0.89 Allowed 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.57 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 15.9 m120 -88.57 109.5 20.13 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-O 120.906 0.384 . . . . 0.0 110.88 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.451 ' HB2' ' CZ ' ' A' ' 85' ' ' TYR . . . -135.45 165.73 24.8 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 178.09 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.413 ' HB ' ' HG3' ' A' ' 131' ' ' LYS . 25.9 m -114.0 136.51 52.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-O 121.479 0.656 . . . . 0.0 111.964 -175.492 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 69.6 t80 -117.74 127.01 53.49 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 114.986 -1.007 . . . . 0.0 108.288 176.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 46.0 t -105.41 105.6 18.97 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 178.301 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -76.42 121.51 23.16 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 178.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -149.63 -24.45 0.06 OUTLIER Glycine 0 C--N 1.309 -0.923 0 C-N-CA 118.325 -1.893 . . . . 0.0 114.654 -175.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -71.72 -53.14 14.45 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.172 0.511 . . . . 0.0 110.096 -177.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -156.21 159.83 31.2 Favored Pre-proline 0 C--N 1.312 -1.031 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.078 -176.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -67.77 131.67 24.8 Favored 'Trans proline' 0 C--O 1.248 0.991 0 C-N-CA 122.372 2.048 . . . . 0.0 110.135 173.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 47.4 mt -114.51 132.35 63.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -176.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.3 p -76.07 131.68 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 177.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 40.7 p -103.74 157.62 16.95 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.531 -177.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -110.78 143.88 40.63 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.3 mp -109.68 134.4 51.91 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 C-N-CA 120.531 -0.468 . . . . 0.0 111.22 -175.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.29 -22.74 1.99 Allowed Glycine 0 C--O 1.244 0.728 0 N-CA-C 117.157 1.623 . . . . 0.0 117.157 171.593 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.4 m -152.85 138.86 11.98 Favored Pre-proline 0 C--N 1.308 -1.197 0 CA-C-N 118.81 1.305 . . . . 0.0 111.462 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -89.75 120.49 0.94 Allowed 'Trans proline' 0 N--CA 1.441 -1.577 0 C-N-CA 121.992 1.795 . . . . 0.0 111.006 171.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -166.58 166.33 16.21 Favored 'General case' 0 CA--C 1.493 -1.216 0 C-N-CA 126.63 1.972 . . . . 0.0 105.819 -178.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 86.3 mt -72.23 -41.28 67.03 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.436 0.636 . . . . 0.0 109.296 176.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 21.8 p-10 -97.47 25.63 5.55 Favored 'General case' 0 C--O 1.246 0.894 0 C-N-CA 124.477 1.111 . . . . 0.0 110.709 -177.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -65.84 153.32 91.51 Favored Pre-proline 0 C--O 1.249 1.077 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.627 -178.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -47.44 128.62 15.23 Favored 'Trans proline' 0 C--N 1.368 1.555 0 C-N-CA 124.205 3.27 . . . . 0.0 114.077 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.3 p -102.73 172.99 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.44 28.61 1.92 Allowed Glycine 0 N--CA 1.442 -0.903 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.649 -176.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -161.66 131.23 2.51 Favored Glycine 0 N--CA 1.433 -1.566 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 176.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -127.82 141.38 51.58 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 117.336 0.568 . . . . 0.0 110.272 -179.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 50.7 tp -100.96 113.26 65.78 Favored Pre-proline 0 C--N 1.301 -1.521 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.007 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -73.64 156.8 49.07 Favored 'Trans proline' 0 C--O 1.252 1.209 0 C-N-CA 122.405 2.07 . . . . 0.0 111.456 179.05 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.52 142.77 42.77 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 108.35 -22.46 26.8 Favored Glycine 0 N--CA 1.434 -1.475 0 N-CA-C 110.438 -1.065 . . . . 0.0 110.438 -176.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.5 126.77 30.56 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-O 121.349 0.595 . . . . 0.0 111.298 -178.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 17.0 m -98.67 110.77 23.31 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 177.613 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.1 mm -111.51 131.07 63.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.286 -173.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.6 p -108.67 112.48 40.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 CA-C-O 122.04 0.924 . . . . 0.0 109.074 175.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.57 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 46.9 p90 -97.45 149.32 22.28 Favored 'General case' 0 C--N 1.296 -1.744 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.363 -177.517 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -112.92 -9.9 13.58 Favored 'General case' 0 C--N 1.31 -1.139 0 O-C-N 123.804 0.69 . . . . 0.0 111.238 -176.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 46.3 tt0 -134.94 128.98 33.54 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -175.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 46' ' ' TYR . 13.8 t -107.89 126.71 64.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.414 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 62.5 m -128.94 139.02 52.3 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -177.135 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 46.9 mt -112.22 119.37 60.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 173.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.486 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -124.94 144.1 50.53 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 104.638 -2.356 . . . . 0.0 104.638 174.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -51.15 104.13 0.07 Allowed 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 113.353 0.871 . . . . 0.0 113.353 -172.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.45 -39.97 1.76 Allowed Glycine 0 N--CA 1.431 -1.642 0 CA-C-N 115.436 -0.802 . . . . 0.0 113.236 177.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 53.0 m80 -147.74 157.58 43.61 Favored 'General case' 0 CA--C 1.497 -1.091 0 O-C-N 122.083 -0.657 . . . . 0.0 110.602 -174.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.9 tt -96.78 128.28 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.714 0 N-CA-C 105.296 -2.112 . . . . 0.0 105.296 172.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.486 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 72.1 m95 -106.41 135.45 47.87 Favored 'General case' 0 C--N 1.266 -3.023 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -173.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.5 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.4 pt -100.38 126.38 53.97 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.894 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 177.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -100.29 124.23 8.18 Favored Glycine 0 N--CA 1.42 -2.422 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.173 -177.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -148.23 173.07 13.37 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 177.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -119.17 145.51 45.94 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 177.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.404 ' HB3' ' OD1' ' A' ' 105' ' ' ASN . . . -93.85 170.23 9.71 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.336 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -73.35 -9.8 59.07 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.141 0.496 . . . . 0.0 111.64 -176.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -72.63 -16.41 61.72 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 174.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 98.57 4.14 57.19 Favored Glycine 0 C--N 1.33 0.208 0 C-N-CA 121.062 -0.59 . . . . 0.0 111.964 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.404 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 23.5 p-10 -96.06 145.15 25.7 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 120.938 0.399 . . . . 0.0 110.968 -179.385 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 28.9 tpt180 -86.15 122.36 30.04 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 179.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 43.0 t -119.21 143.2 31.18 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.261 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 -173.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.5 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 86.3 m-85 -125.52 129.17 49.22 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 123.579 0.751 . . . . 0.0 110.134 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.4 t -109.3 135.06 20.29 Favored Pre-proline 0 C--N 1.299 -1.592 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 178.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -68.24 -23.24 39.2 Favored 'Trans proline' 0 C--N 1.365 1.416 0 C-N-CA 123.202 2.602 . . . . 0.0 114.38 -177.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.3 35.4 m 45.22 -53.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.286 0 N-CA-C 119.077 2.992 . . . . 0.0 119.077 176.054 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -158.7 152.87 23.86 Favored 'General case' 0 C--N 1.314 -0.964 0 O-C-N 121.718 -0.614 . . . . 0.0 110.47 -178.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.52 ' O ' ' HA ' ' A' ' 123' ' ' PRO . 13.7 m -63.88 127.48 31.58 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 174.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.421 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 99.6 m -152.92 118.76 5.39 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 123.477 0.711 . . . . 0.0 109.361 177.044 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 26.7 mt-30 -129.58 148.83 51.52 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.34 -167.86 30.82 Favored Glycine 0 N--CA 1.417 -2.602 0 C-N-CA 119.11 -1.519 . . . . 0.0 112.149 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 10.8 m -123.99 108.03 30.45 Favored Pre-proline 0 C--N 1.291 -1.971 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.497 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 60.6 Cg_exo -43.17 129.2 5.92 Favored 'Trans proline' 0 C--N 1.349 0.584 0 C-N-CA 124.004 3.136 . . . . 0.0 113.024 -175.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -90.53 10.77 60.32 Favored 'Cis proline' 0 C--O 1.242 0.694 0 C-N-CA 124.115 -1.202 . . . . 0.0 115.114 8.44 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -75.28 100.06 4.25 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 -179.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.425 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 45.8 p-80 -106.08 109.83 21.89 Favored 'General case' 0 C--N 1.289 -2.053 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.112 177.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.421 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.5 mt -94.82 105.21 17.49 Favored Pre-proline 0 C--N 1.299 -1.606 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . 0.52 ' HA ' ' O ' ' A' ' 113' ' ' THR . 72.8 Cg_endo -84.4 153.67 12.22 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.58 2.187 . . . . 0.0 113.121 -176.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -125.81 -97.53 1.09 Allowed Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 178.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 40.5 t -96.68 118.67 43.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -178.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.06 120.34 34.19 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.179 178.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.8 m-90 -101.5 58.02 0.85 Allowed 'General case' 0 C--N 1.31 -1.149 0 CA-C-O 120.661 0.267 . . . . 0.0 111.345 -179.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . 155.85 -169.78 33.59 Favored Glycine 0 CA--C 1.497 -1.082 0 C-N-CA 119.693 -1.241 . . . . 0.0 112.499 178.15 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 97.9 t -111.94 128.68 68.38 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -112.07 136.87 50.89 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.152 -176.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.413 ' HG3' ' HB ' ' A' ' 52' ' ' THR . 18.1 ptpt . . . . . 0 N--CA 1.433 -1.315 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 175.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 92.1 m95 . . . . . 0 N--CA 1.436 -1.144 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -125.08 154.64 41.07 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -94.15 127.27 39.88 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 120.359 -0.536 . . . . 0.0 111.207 -176.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -84.48 151.28 24.72 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 174.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.9 pt20 -51.2 -27.45 8.92 Favored 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 123.739 0.816 . . . . 0.0 113.189 -178.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . 0.438 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 50.2 m-85 -81.73 3.16 26.66 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -177.257 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.71 18.82 59.27 Favored Glycine 0 CA--C 1.5 -0.844 0 C-N-CA 120.333 -0.937 . . . . 0.0 111.628 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 12.3 m -105.21 132.98 50.73 Favored 'General case' 0 N--CA 1.416 -2.134 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -96.39 129.73 43.67 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 177.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -129.54 154.67 46.81 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.422 -175.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -135.76 145.91 54.96 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 173.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_exo -69.3 121.86 8.65 Favored 'Trans proline' 0 C--O 1.249 1.041 0 C-N-CA 121.737 1.625 . . . . 0.0 109.469 172.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -150.18 120.9 7.53 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.43 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 3.0 t-20 -114.19 106.49 14.42 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.926 -0.71 . . . . 0.0 110.154 -175.617 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.89 -177.58 5.98 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.443 -178.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.444 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 13.3 m -104.68 150.12 24.98 Favored 'General case' 0 N--CA 1.429 -1.487 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -177.299 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -127.39 127.21 43.8 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 173.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.1 t -113.09 113.29 43.64 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.232 0 N-CA-C 106.795 -1.558 . . . . 0.0 106.795 176.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 53.2 t30 -64.76 152.57 42.27 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.639 -178.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -78.59 -146.3 3.12 Favored Glycine 0 N--CA 1.434 -1.434 0 CA-C-N 116.16 -0.473 . . . . 0.0 113.173 -177.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -86.97 7.54 27.07 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -173.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -138.92 137.25 19.29 Favored Pre-proline 0 C--N 1.302 -1.484 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.209 -175.213 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_exo -65.58 128.99 21.27 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.415 2.077 . . . . 0.0 110.757 176.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.2 mt -108.02 125.81 64.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -177.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.3 p -78.89 137.58 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.669 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 60.2 p -117.26 178.41 4.38 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.003 -172.472 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 33.9 mmt180 -116.81 146.59 42.77 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 60.7 mt -109.82 131.32 61.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.43 -175.28 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.2 -22.86 4.19 Favored Glycine 0 C--N 1.318 -0.42 0 N-CA-C 115.969 1.148 . . . . 0.0 115.969 171.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 39.1 m -153.61 140.77 13.24 Favored Pre-proline 0 C--N 1.298 -1.669 0 CA-C-N 117.875 0.837 . . . . 0.0 109.154 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -89.69 119.4 0.86 Allowed 'Trans proline' 0 N--CA 1.433 -2.036 0 C-N-CA 121.189 1.259 . . . . 0.0 110.347 173.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.467 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 82.4 m-85 -168.89 173.9 6.77 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 104.716 -2.328 . . . . 0.0 104.716 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -89.28 -34.25 16.66 Favored 'General case' 0 C--N 1.291 -1.969 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 176.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -97.87 22.49 9.16 Favored 'General case' 0 CA--C 1.548 0.904 0 CA-C-O 121.993 0.901 . . . . 0.0 109.803 -178.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.467 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -77.57 162.72 67.43 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.79 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -48.87 124.35 11.14 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 123.343 2.695 . . . . 0.0 113.559 178.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.0 p -97.83 173.73 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.195 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.367 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.62 -1.68 13.84 Favored Glycine 0 CA--C 1.502 -0.77 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.517 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -113.88 117.49 4.17 Favored Glycine 0 N--CA 1.429 -1.793 0 N-CA-C 108.849 -1.701 . . . . 0.0 108.849 174.36 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -126.8 128.14 46.12 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 117.737 0.769 . . . . 0.0 110.344 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 41.2 tp -96.55 119.76 63.39 Favored Pre-proline 0 C--N 1.309 -1.154 0 C-N-CA 123.282 0.633 . . . . 0.0 110.19 -175.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.02 165.08 25.09 Favored 'Trans proline' 0 CA--C 1.542 0.912 0 C-N-CA 122.805 2.337 . . . . 0.0 112.728 179.28 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.75 147.31 45.71 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.784 -177.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 69.52 5.91 52.34 Favored Glycine 0 N--CA 1.463 0.446 0 N-CA-C 114.247 0.459 . . . . 0.0 114.247 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.76 126.59 29.89 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-O 120.892 0.377 . . . . 0.0 111.417 -177.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 25.7 m -92.59 113.09 25.27 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 177.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.9 mm -122.55 138.97 50.89 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -176.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 p -103.47 129.33 55.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 175.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.43 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 32.2 p90 -117.71 150.56 38.87 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.591 -177.809 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -108.57 -12.36 14.99 Favored 'General case' 0 C--N 1.316 -0.856 0 O-C-N 123.473 0.483 . . . . 0.0 110.42 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -140.4 136.59 33.24 Favored 'General case' 0 N--CA 1.428 -1.54 0 C-N-CA 120.346 -0.542 . . . . 0.0 111.206 -172.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 71.4 t -118.62 127.85 75.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 176.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 19.6 p -135.46 147.73 49.01 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 120.898 0.38 . . . . 0.0 111.613 -175.252 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.5 mt -109.5 113.81 45.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-O 121.225 0.536 . . . . 0.0 110.546 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.583 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -110.42 122.56 47.99 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 104.761 -2.311 . . . . 0.0 104.761 174.457 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -47.85 114.29 0.88 Allowed 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 121.845 0.831 . . . . 0.0 113.068 -165.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 120.58 -25.15 7.38 Favored Glycine 0 N--CA 1.429 -1.826 0 CA-C-N 114.1 -1.409 . . . . 0.0 112.42 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 75.8 m80 -152.05 170.11 20.72 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 15.9 tt -111.62 136.44 47.72 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.179 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 172.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.583 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 48.2 m95 -121.96 139.07 54.12 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -173.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.49 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 47.5 pt -100.52 136.02 33.86 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.92 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 175.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -105.03 119.46 6.21 Favored Glycine 0 N--CA 1.419 -2.459 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -136.83 152.83 50.71 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 120.408 -0.517 . . . . 0.0 109.954 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -86.25 127.38 34.75 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 174.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.27 163.33 17.79 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 27.7 p90 -54.81 -31.36 59.03 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -176.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -76.29 -14.44 60.11 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-O 121.055 0.455 . . . . 0.0 111.046 -179.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 108.92 -9.58 34.19 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 121.137 -0.554 . . . . 0.0 113.279 178.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -75.84 148.08 38.63 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-O 120.754 0.311 . . . . 0.0 111.226 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -89.41 109.27 20.2 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 177.685 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 52.2 t -107.66 136.92 41.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.199 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -176.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.49 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 91.4 m-85 -116.33 126.0 52.91 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.4 t -105.44 131.85 21.39 Favored Pre-proline 0 C--N 1.301 -1.536 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -69.26 -11.4 31.39 Favored 'Trans proline' 0 C--N 1.364 1.375 0 C-N-CA 123.374 2.716 . . . . 0.0 113.794 -177.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.277 27.0 m 37.83 -63.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.148 0 N-CA-C 118.286 2.698 . . . . 0.0 118.286 174.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . 0.46 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 34.9 ptt180 -153.06 149.79 28.48 Favored 'General case' 0 N--CA 1.429 -1.488 0 C-N-CA 122.872 0.469 . . . . 0.0 110.219 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 19.4 m -67.8 136.76 54.66 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 41.8 t -150.39 139.24 20.88 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -176.324 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 78.3 mm-40 -119.6 161.61 20.36 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 130.22 -171.75 20.45 Favored Glycine 0 N--CA 1.421 -2.363 0 C-N-CA 120.034 -1.079 . . . . 0.0 112.448 174.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.6 m -141.41 138.57 17.69 Favored Pre-proline 0 C--N 1.295 -1.787 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_exo -47.73 131.64 20.36 Favored 'Trans proline' 0 CA--C 1.539 0.736 0 C-N-CA 122.945 2.43 . . . . 0.0 112.786 -177.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -96.65 7.5 40.89 Favored 'Cis proline' 0 CA--C 1.547 1.155 0 C-N-CA 124.492 -1.045 . . . . 0.0 113.884 1.19 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 44.4 t30 -76.27 102.39 5.83 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.636 0.732 . . . . 0.0 110.911 -175.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 -104.82 112.6 25.77 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 114.748 -1.115 . . . . 0.0 111.602 -178.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 59.3 mt -101.46 100.84 14.92 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -85.22 140.39 7.57 Favored 'Trans proline' 0 N--CA 1.452 -0.944 0 C-N-CA 122.87 2.38 . . . . 0.0 113.647 -177.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -110.66 -117.62 3.81 Favored Glycine 0 N--CA 1.436 -1.35 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 177.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 81.6 t -78.24 115.46 20.34 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 120.84 0.352 . . . . 0.0 110.861 -179.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.46 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.37 132.91 38.49 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.788 177.129 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.3 m-90 -102.35 8.07 40.36 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-O 121.488 0.661 . . . . 0.0 110.401 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.09 169.51 36.7 Favored Glycine 0 N--CA 1.431 -1.696 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 64.3 t -111.72 134.86 52.78 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 C-N-CA 122.895 0.478 . . . . 0.0 110.189 -175.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -97.68 132.62 43.16 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 178.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.444 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 48.7 tptt . . . . . 0 N--CA 1.413 -2.315 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -179.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 34.5 m95 . . . . . 0 N--CA 1.432 -1.333 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -113.35 150.56 32.43 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.401 ' HG2' ' O ' ' A' ' 40' ' ' ASN . 38.2 ttpt -110.15 136.2 49.75 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 118.376 -1.33 . . . . 0.0 111.528 -178.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . 0.401 ' O ' ' HG2' ' A' ' 39' ' ' LYS . 45.9 t-20 -94.35 161.67 14.14 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 105.955 -1.869 . . . . 0.0 105.955 175.079 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 34.7 mt-30 -67.28 -13.31 61.87 Favored 'General case' 0 C--O 1.213 -0.836 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -173.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 47.9 m-85 -76.3 -1.24 25.67 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.352 0.596 . . . . 0.0 110.214 177.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.39 24.26 59.3 Favored Glycine 0 CA--C 1.494 -1.266 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.44 HG21 ' HB2' ' A' ' 89' ' ' CYS . 13.5 m -105.37 124.66 49.92 Favored 'General case' 0 N--CA 1.414 -2.231 0 CA-C-N 114.662 -0.769 . . . . 0.0 109.608 -178.503 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.548 ' CG ' ' HG3' ' A' ' 118' ' ' PRO . 84.1 m95 -93.3 131.11 38.74 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.18 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 54.2 p90 -132.75 151.85 51.89 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -175.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 16.8 ptmt -129.02 132.47 24.39 Favored Pre-proline 0 C--N 1.303 -1.443 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.664 175.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_exo -72.78 122.05 7.87 Favored 'Trans proline' 0 C--O 1.244 0.79 0 C-N-CA 121.835 1.69 . . . . 0.0 111.001 175.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -162.25 131.49 4.38 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 177.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.408 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 23.8 t-20 -110.03 123.46 49.71 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 120.699 -0.4 . . . . 0.0 110.182 -177.657 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -160.07 177.2 10.95 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -108.22 152.01 25.16 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 121.022 0.439 . . . . 0.0 112.126 -178.752 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.45 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 91.4 t80 -122.55 123.66 41.73 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 176.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 43.7 t -103.17 104.88 17.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 29.1 t30 -76.98 123.52 26.44 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 175.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -147.1 24.32 1.59 Allowed Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 118.973 -1.584 . . . . 0.0 113.308 -177.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -113.77 -50.71 2.82 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.256 179.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -158.22 164.96 19.65 Favored Pre-proline 0 C--N 1.315 -0.921 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -69.27 125.87 12.93 Favored 'Trans proline' 0 C--O 1.254 1.301 0 N-CA-C 108.121 -1.531 . . . . 0.0 108.121 170.164 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 41.4 mt -108.12 130.17 61.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 110.127 -0.323 . . . . 0.0 110.127 -173.267 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 39.7 t -69.16 122.16 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.817 0 CA-C-O 121.968 0.889 . . . . 0.0 110.308 176.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -96.16 155.9 16.56 Favored 'General case' 0 N--CA 1.405 -2.689 0 CA-C-N 114.181 -1.372 . . . . 0.0 108.651 -176.242 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 15.6 mmt180 -112.24 141.64 45.7 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -178.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.2 mt -109.39 120.29 60.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 113.11 0.782 . . . . 0.0 113.11 -173.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.67 -22.51 27.49 Favored Glycine 0 C--O 1.236 0.249 0 N-CA-C 116.343 1.297 . . . . 0.0 116.343 170.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.7 m -155.01 140.26 12.28 Favored Pre-proline 0 C--N 1.307 -1.257 0 CA-C-N 118.502 1.151 . . . . 0.0 111.292 -178.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -89.93 119.96 0.86 Allowed 'Trans proline' 0 N--CA 1.437 -1.844 0 C-N-CA 121.716 1.611 . . . . 0.0 110.778 172.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -162.5 162.76 27.58 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 68.3 mt -80.1 -13.99 58.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 121.748 0.785 . . . . 0.0 109.434 177.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.4 p-10 -116.19 19.52 14.85 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.606 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.83 146.1 95.33 Favored Pre-proline 0 C--O 1.243 0.757 0 CA-C-N 115.386 -0.825 . . . . 0.0 112.201 -176.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -48.76 131.66 24.92 Favored 'Trans proline' 0 C--O 1.249 1.035 0 C-N-CA 124.104 3.203 . . . . 0.0 113.916 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.1 m -97.41 174.59 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 CA-C-N 114.552 -1.204 . . . . 0.0 110.483 -178.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.92 28.12 2.12 Favored Glycine 0 C--N 1.305 -1.192 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.021 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.81 132.67 4.1 Favored Glycine 0 N--CA 1.427 -1.924 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 176.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -128.35 125.77 39.38 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 117.597 0.699 . . . . 0.0 110.918 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 65.3 tp -88.26 111.69 44.86 Favored Pre-proline 0 N--CA 1.426 -1.634 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -63.43 152.4 80.26 Favored 'Trans proline' 0 C--O 1.251 1.146 0 C-N-CA 122.147 1.898 . . . . 0.0 112.553 -179.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.41 138.16 41.5 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.292 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.82 3.13 62.45 Favored Glycine 0 N--CA 1.441 -0.997 0 N-CA-C 111.434 -0.666 . . . . 0.0 111.434 -178.6 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.49 139.07 31.15 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-O 121.171 0.51 . . . . 0.0 111.188 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 39.0 m -113.53 113.55 25.27 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 177.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.1 mm -110.18 139.87 31.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -176.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.0 p -95.31 127.13 47.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 176.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.408 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 46.3 p90 -110.11 154.44 23.28 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.472 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -116.35 -9.09 11.57 Favored 'General case' 0 C--O 1.25 1.089 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.36 -177.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -144.84 131.69 20.18 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.876 -174.114 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 32.1 t -109.61 124.56 66.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 105.832 -1.914 . . . . 0.0 105.832 175.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.44 ' HB2' HG21 ' A' ' 44' ' ' THR . 24.6 p -137.5 148.49 46.06 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.871 -0.732 . . . . 0.0 112.624 -175.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 68.8 mt -111.4 124.15 67.9 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-O 121.061 0.458 . . . . 0.0 110.623 179.389 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.49 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -125.14 112.98 17.11 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 103.827 -2.657 . . . . 0.0 103.827 171.446 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.96 106.12 0.1 Allowed 'General case' 0 N--CA 1.479 0.983 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -164.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 141.63 -33.03 2.0 Favored Glycine 0 N--CA 1.439 -1.149 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -177.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 56.3 m80 -152.02 163.37 39.44 Favored 'General case' 0 CA--C 1.505 -0.786 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.3 tt -106.65 135.07 46.38 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 171.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.49 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 58.7 m95 -118.12 140.31 49.96 Favored 'General case' 0 C--N 1.28 -2.419 0 O-C-N 122.209 -0.307 . . . . 0.0 110.475 -171.118 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 48.1 pt -100.6 131.53 48.0 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 174.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.34 121.52 7.21 Favored Glycine 0 N--CA 1.417 -2.599 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . 0.403 ' HB3' ' HA ' ' A' ' 85' ' ' TYR . 39.0 p90 -132.17 146.58 52.12 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-O 121.466 0.651 . . . . 0.0 111.122 178.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -99.74 119.97 38.98 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.82 -1.082 . . . . 0.0 108.455 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.9 176.31 7.4 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.395 -177.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -66.0 -21.34 66.39 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.464 0.649 . . . . 0.0 112.019 -179.066 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -80.04 -14.52 58.48 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.985 177.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 84.62 5.59 86.53 Favored Glycine 0 C--O 1.24 0.475 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -174.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -80.79 132.98 35.56 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 27.2 tpt180 -88.48 104.89 17.23 Favored 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -178.082 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 15.5 t -107.12 142.75 19.13 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -175.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -125.61 127.1 45.81 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.088 0.471 . . . . 0.0 111.75 -178.184 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 52.8 t -107.51 135.4 19.73 Favored Pre-proline 0 C--N 1.307 -1.278 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -72.21 -12.63 27.93 Favored 'Trans proline' 0 C--N 1.36 1.156 0 C-N-CA 123.19 2.593 . . . . 0.0 114.503 -176.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.282 32.8 m 43.77 -56.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.516 2.827 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 175.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . 0.514 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 38.2 ptt180 -159.98 151.05 19.29 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.03 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.2 t -73.42 143.14 46.86 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.9 t -155.26 136.98 14.35 Favored 'General case' 0 N--CA 1.421 -1.919 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -177.185 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 21.6 mt-30 -122.52 157.1 32.78 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 133.91 -163.83 24.47 Favored Glycine 0 N--CA 1.429 -1.815 0 C-N-CA 120.048 -1.072 . . . . 0.0 112.018 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 18.5 m -142.22 149.92 53.52 Favored Pre-proline 0 C--N 1.307 -1.272 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.548 ' HG3' ' CG ' ' A' ' 45' ' ' TRP . 33.3 Cg_endo -60.2 131.21 37.68 Favored 'Trans proline' 0 CA--C 1.541 0.843 0 C-N-CA 122.388 2.059 . . . . 0.0 112.412 -177.007 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.408 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 11.1 Cg_endo -99.59 8.81 26.2 Favored 'Cis proline' 0 C--O 1.251 1.154 0 C-N-CA 125.28 -0.717 . . . . 0.0 113.351 -0.454 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.1 t30 -75.04 100.63 4.24 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 122.106 0.955 . . . . 0.0 109.896 -177.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 48.3 p-80 -105.72 119.78 40.01 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 114.416 -1.266 . . . . 0.0 111.578 -177.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 62.1 mt -100.83 101.61 16.42 Favored Pre-proline 0 C--N 1.305 -1.35 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -85.06 130.45 4.08 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.732 2.288 . . . . 0.0 113.109 -177.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -103.87 -131.12 7.11 Favored Glycine 0 N--CA 1.433 -1.564 0 N-CA-C 111.199 -0.761 . . . . 0.0 111.199 177.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 48.8 t -68.05 120.03 14.77 Favored 'Isoleucine or valine' 0 C--O 1.252 1.195 0 C-N-CA 123.005 0.522 . . . . 0.0 111.003 -178.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.514 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -94.22 148.75 21.89 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.685 177.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.4 m-90 -116.2 8.28 14.32 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.399 0.619 . . . . 0.0 110.033 177.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.45 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -167.09 171.86 41.99 Favored Glycine 0 N--CA 1.431 -1.66 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 60.2 t -112.51 135.25 52.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 -177.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -85.8 121.99 29.23 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 176.148 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.284 -2.265 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 -175.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . 0.422 ' CZ2' ' HE2' ' A' ' 47' ' ' LYS . 30.4 m95 . . . . . 0 N--CA 1.442 -0.849 0 CA-C-O 120.717 0.294 . . . . 0.0 110.712 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -114.19 152.4 31.27 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 175.224 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -102.76 121.24 42.06 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.616 179.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . 0.437 ' HB3' ' CE1' ' A' ' 46' ' ' TYR . 37.2 p30 -85.42 -178.29 6.67 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.774 -176.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -66.73 -16.67 64.4 Favored 'General case' 0 C--N 1.323 -0.575 0 C-N-CA 123.674 0.789 . . . . 0.0 113.037 -178.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 67.8 m-85 -93.77 2.69 56.18 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.449 0.643 . . . . 0.0 110.096 -177.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.8 25.56 66.91 Favored Glycine 0 N--CA 1.442 -0.942 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.444 ' HG1' ' NE2' ' A' ' 91' ' ' GLN . 12.8 m -105.26 141.21 37.19 Favored 'General case' 0 N--CA 1.425 -1.71 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -92.78 120.56 33.28 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 174.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.437 ' CE1' ' HB3' ' A' ' 40' ' ' ASN . 23.9 p90 -128.02 149.68 50.26 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 120.623 0.249 . . . . 0.0 110.611 -175.599 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.422 ' HE2' ' CZ2' ' A' ' 37' ' ' TRP . 52.2 pttt -139.33 140.4 25.75 Favored Pre-proline 0 C--N 1.295 -1.797 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 173.737 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_exo -71.23 127.23 13.18 Favored 'Trans proline' 0 C--O 1.255 1.36 0 C-N-CA 122.057 1.838 . . . . 0.0 110.314 174.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -164.78 120.85 1.46 Allowed 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -179.116 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.483 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 19.8 t-20 -103.02 109.54 21.12 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 120.962 0.41 . . . . 0.0 110.883 -174.647 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.47 ' HB2' ' CZ ' ' A' ' 85' ' ' TYR . . . -145.28 172.35 13.27 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 14.1 m -107.68 134.76 50.19 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.939 0.4 . . . . 0.0 111.412 -173.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 72.9 t80 -112.36 122.46 47.77 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 39.0 t -108.23 103.77 16.01 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.866 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 178.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 30.2 t30 -76.4 131.61 39.21 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -144.68 2.52 1.25 Allowed Glycine 0 N--CA 1.432 -1.623 0 C-N-CA 119.307 -1.425 . . . . 0.0 113.546 -179.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -93.74 -52.06 4.63 Favored 'General case' 0 C--N 1.318 -0.789 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.826 -175.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 17.1 pt20 -159.25 171.64 7.12 Favored Pre-proline 0 C--N 1.314 -0.96 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -173.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -69.0 122.11 8.99 Favored 'Trans proline' 0 N--CA 1.44 -1.655 0 N-CA-C 107.604 -1.729 . . . . 0.0 107.604 166.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 58.7 mt -107.84 123.32 63.19 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -175.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 25.9 m -79.93 139.42 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.366 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 175.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.5 p -118.36 178.94 4.26 Favored 'General case' 0 C--N 1.272 -2.781 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.918 -172.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.413 ' HG3' ' O ' ' A' ' 68' ' ' PHE . 82.0 mmt-85 -115.48 136.64 52.88 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 176.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 63.8 mt -97.24 121.29 47.61 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.64 -174.08 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 77.56 -16.87 5.89 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 116.034 1.173 . . . . 0.0 116.034 172.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.2 m -151.82 137.77 11.36 Favored Pre-proline 0 C--N 1.305 -1.336 0 CA-C-N 118.24 1.02 . . . . 0.0 110.204 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -89.93 119.19 0.8 Allowed 'Trans proline' 0 N--CA 1.434 -1.975 0 C-N-CA 121.163 1.242 . . . . 0.0 110.811 173.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.423 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 92.9 m-85 -169.55 168.73 9.14 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 178.6 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.96 -31.77 27.45 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 171.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -95.27 17.01 15.16 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.179 -0.918 . . . . 0.0 112.204 -178.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -79.0 162.75 63.43 Favored Pre-proline 0 C--N 1.311 -1.095 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -54.69 122.14 11.07 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 122.343 2.029 . . . . 0.0 112.438 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 13.8 p -104.1 172.94 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.944 -179.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.33 -13.32 10.29 Favored Glycine 0 CA--C 1.502 -0.745 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 -179.067 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.46 108.83 3.08 Favored Glycine 0 N--CA 1.432 -1.597 0 N-CA-C 108.338 -1.905 . . . . 0.0 108.338 172.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -111.5 123.43 50.21 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 117.697 0.748 . . . . 0.0 110.339 -176.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 40.6 tp -98.83 114.27 65.27 Favored Pre-proline 0 C--N 1.302 -1.496 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -68.43 161.64 44.07 Favored 'Trans proline' 0 C--O 1.249 1.058 0 C-N-CA 122.236 1.957 . . . . 0.0 112.642 -178.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.41 139.42 42.32 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.83 5.82 58.41 Favored Glycine 0 N--CA 1.436 -1.352 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -85.86 128.84 34.92 Favored 'General case' 0 N--CA 1.432 -1.357 0 CA-C-O 121.033 0.444 . . . . 0.0 111.233 -178.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 37.0 m -103.91 110.25 22.31 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.1 mm -126.32 130.74 71.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 -175.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.9 p -88.69 133.93 29.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 176.246 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.483 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 40.1 p90 -109.98 151.17 27.47 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -124.67 -0.4 8.05 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 122.075 0.941 . . . . 0.0 110.391 -174.091 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -146.34 133.0 19.88 Favored 'General case' 0 N--CA 1.428 -1.526 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 -176.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 51.4 t -119.34 128.14 75.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.413 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 23.5 p -141.51 145.46 35.21 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -176.314 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.421 HG13 ' CZ3' ' A' ' 37' ' ' TRP . 58.4 mt -107.16 117.04 52.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 175.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.492 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -118.12 117.59 29.59 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 103.327 -2.842 . . . . 0.0 103.327 171.211 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.47 110.44 0.34 Allowed 'General case' 0 C--N 1.315 -0.91 0 O-C-N 124.822 1.326 . . . . 0.0 112.876 -167.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 143.37 -42.86 1.05 Allowed Glycine 0 N--CA 1.42 -2.394 0 CA-C-N 113.582 -1.645 . . . . 0.0 109.345 -176.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . 0.448 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 73.7 m80 -153.4 165.93 34.26 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -179.256 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.5 tt -99.98 129.32 50.82 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 105.223 -2.14 . . . . 0.0 105.223 171.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.492 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 57.0 m95 -112.5 134.53 53.98 Favored 'General case' 0 C--N 1.274 -2.682 0 CA-C-O 120.997 0.427 . . . . 0.0 110.039 -172.029 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 44.8 pt -100.44 128.82 52.08 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 175.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -94.22 114.78 4.86 Favored Glycine 0 N--CA 1.416 -2.695 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 178.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 54.5 p90 -127.2 167.67 15.74 Favored 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 -178.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.1 m-80 -108.16 129.49 55.17 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.54 176.46 9.77 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -55.95 -27.16 51.2 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.961 0.905 . . . . 0.0 112.152 -178.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 32.9 p-10 -104.31 13.11 32.72 Favored 'General case' 0 C--N 1.322 -0.628 0 C-N-CA 123.241 0.616 . . . . 0.0 111.247 -175.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 77.88 21.78 70.54 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 121.089 -0.577 . . . . 0.0 113.28 177.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 50.2 t-20 -85.84 132.51 34.09 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 178.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -85.76 98.35 10.68 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 21.6 t -108.95 147.01 13.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 -175.322 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.528 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 94.7 m-85 -117.19 121.62 41.73 Favored 'General case' 0 C--N 1.314 -0.964 0 C-N-CA 122.494 0.317 . . . . 0.0 110.758 -178.072 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . 0.443 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 53.7 t -101.03 135.1 20.02 Favored Pre-proline 0 C--N 1.315 -0.902 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.05 -16.11 36.22 Favored 'Trans proline' 0 C--N 1.361 1.205 0 C-N-CA 123.322 2.681 . . . . 0.0 114.863 -176.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.308 33.0 m 42.21 -55.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.519 3.0 0 N-CA-C 118.837 2.903 . . . . 0.0 118.837 176.322 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . 0.453 ' CZ ' ' HB2' ' A' ' 126' ' ' ALA . 8.2 ptp180 -153.97 148.98 26.76 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 123.868 0.867 . . . . 0.0 108.704 175.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.448 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 24.3 m -66.33 135.33 54.23 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 177.476 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 97.5 m -150.78 124.94 9.36 Favored 'General case' 0 CA--C 1.511 -0.524 0 CA-C-O 121.431 0.634 . . . . 0.0 112.467 -178.784 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -110.44 151.57 27.35 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 174.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.37 -171.25 22.64 Favored Glycine 0 C--N 1.3 -1.462 0 C-N-CA 118.251 -1.928 . . . . 0.0 114.092 177.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 64.9 t -137.44 127.67 15.69 Favored Pre-proline 0 C--N 1.309 -1.191 0 N-CA-C 105.947 -1.871 . . . . 0.0 105.947 -178.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_exo -46.36 137.18 14.72 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.371 2.714 . . . . 0.0 112.804 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -86.61 -15.54 29.39 Favored 'Cis proline' 0 CA--C 1.542 0.877 0 C-N-CA 123.228 -1.572 . . . . 0.0 113.896 1.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -75.85 100.16 4.69 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 122.136 0.969 . . . . 0.0 111.645 -173.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 54.7 p-80 -106.34 138.53 42.35 Favored 'General case' 0 C--N 1.296 -1.717 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.808 176.109 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.537 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.0 mm -90.22 108.83 29.09 Favored Pre-proline 0 C--N 1.3 -1.565 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 176.33 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -84.66 123.91 2.98 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.457 2.105 . . . . 0.0 113.587 -176.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -95.25 -134.62 7.79 Favored Glycine 0 N--CA 1.436 -1.33 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 175.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 69.4 t -81.74 126.69 39.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 C-N-CA 122.982 0.513 . . . . 0.0 110.475 -179.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.453 ' HB2' ' CZ ' ' A' ' 112' ' ' ARG . . . -93.87 145.74 24.4 Favored 'General case' 0 CA--C 1.507 -0.689 0 O-C-N 123.75 0.657 . . . . 0.0 109.294 174.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.0 m-90 -110.33 18.3 20.0 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.344 0.592 . . . . 0.0 111.278 179.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -166.57 -173.12 34.62 Favored Glycine 0 N--CA 1.432 -1.579 0 C-N-CA 120.045 -1.074 . . . . 0.0 112.173 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 48.7 t -110.98 131.11 63.1 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -103.54 120.44 40.87 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.299 -1.61 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 71.6 m95 . . . . . 0 CA--C 1.513 -0.476 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 53.2 tptt -120.31 153.9 35.76 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -95.94 125.44 40.49 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 118.917 -1.113 . . . . 0.0 110.458 -177.349 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . 0.444 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 53.0 t30 -77.2 166.44 23.21 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.116 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 66.7 mm-40 -71.2 4.72 2.6 Favored 'General case' 0 C--N 1.312 -1.044 0 C-N-CA 123.548 0.739 . . . . 0.0 112.488 -174.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -104.5 -0.42 27.88 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.249 0.547 . . . . 0.0 110.493 175.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 91.51 -2.8 78.16 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.794 178.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.538 ' HG1' ' NE2' ' A' ' 91' ' ' GLN . 5.3 m -88.72 139.57 30.33 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 70.3 m95 -92.98 123.95 36.6 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.444 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 11.8 p90 -133.0 159.18 40.77 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.404 -174.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -147.96 142.29 16.42 Favored Pre-proline 0 C--N 1.297 -1.712 0 N-CA-C 106.031 -1.841 . . . . 0.0 106.031 172.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -72.4 134.38 22.54 Favored 'Trans proline' 0 N--CA 1.45 -1.073 0 C-N-CA 121.397 1.398 . . . . 0.0 110.475 174.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -150.94 121.4 7.38 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -101.84 106.14 17.08 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.542 ' HB1' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.78 176.56 11.66 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.412 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 24.0 m -113.58 151.03 32.21 Favored 'General case' 0 C--N 1.292 -1.904 0 CA-C-O 121.002 0.429 . . . . 0.0 111.163 -174.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.458 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 84.0 t80 -129.21 124.83 35.54 Favored 'General case' 0 N--CA 1.428 -1.526 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 174.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 33.6 t -108.54 110.04 30.55 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.11 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 62.5 t30 -77.07 130.4 37.36 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 177.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -122.58 -64.0 0.22 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 118.52 -1.8 . . . . 0.0 115.901 -173.135 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -68.71 -56.33 8.46 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 114.05 1.13 . . . . 0.0 114.05 -171.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 20.2 pt20 -134.39 157.88 76.45 Favored Pre-proline 0 C--N 1.292 -1.913 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.212 -170.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -68.5 138.28 41.7 Favored 'Trans proline' 0 N--CA 1.445 -1.325 0 C-N-CA 121.76 1.64 . . . . 0.0 109.071 170.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.7 mt -113.39 133.38 59.48 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -177.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 9.5 p -84.3 128.05 39.26 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.083 0 CA-C-O 121.42 0.629 . . . . 0.0 109.76 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 74.1 p -109.98 178.94 4.25 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.099 -173.488 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.541 ' HG2' ' CZ3' ' A' ' 96' ' ' TRP . 1.6 mmp_? -112.15 154.77 25.0 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 174.375 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 54.5 mt -119.26 126.1 75.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 120.759 -0.376 . . . . 0.0 111.045 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 85.08 -22.75 9.04 Favored Glycine 0 CA--C 1.519 0.337 0 N-CA-C 115.983 1.153 . . . . 0.0 115.983 171.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.1 m -153.99 142.65 14.49 Favored Pre-proline 0 C--N 1.309 -1.192 0 CA-C-N 118.276 1.038 . . . . 0.0 109.933 -178.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -90.63 119.14 0.67 Allowed 'Trans proline' 0 N--CA 1.443 -1.442 0 C-N-CA 121.806 1.67 . . . . 0.0 111.865 175.125 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.426 ' HA ' ' HG2' ' A' ' 91' ' ' GLN . 91.9 m-85 -168.9 168.94 10.06 Favored 'General case' 0 CA--C 1.49 -1.348 0 N-CA-C 104.584 -2.376 . . . . 0.0 104.584 179.216 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 85.2 mt -79.53 -37.86 35.57 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 171.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -88.84 12.09 16.12 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 114.32 -1.309 . . . . 0.0 112.101 -176.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.413 ' HB3' ' HB2' ' A' ' 68' ' ' PHE . . . -72.99 162.65 73.52 Favored Pre-proline 0 C--N 1.314 -0.966 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.561 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -46.94 123.18 7.03 Favored 'Trans proline' 0 C--N 1.367 1.518 0 C-N-CA 123.371 2.714 . . . . 0.0 113.797 -178.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.8 t -97.37 172.27 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.35 -30.03 5.94 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.84 126.98 10.02 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 178.011 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -128.47 130.5 47.64 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 117.118 0.459 . . . . 0.0 110.505 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 64.0 tp -97.63 113.55 63.67 Favored Pre-proline 0 C--N 1.3 -1.561 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -66.76 155.65 69.54 Favored 'Trans proline' 0 C--O 1.247 0.947 0 C-N-CA 122.505 2.136 . . . . 0.0 112.421 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.96 142.61 41.92 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.899 -0.592 . . . . 0.0 109.695 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.35 -4.57 70.29 Favored Glycine 0 N--CA 1.447 -0.602 0 N-CA-C 111.774 -0.531 . . . . 0.0 111.774 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -82.47 126.75 32.59 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 121.215 0.531 . . . . 0.0 111.528 -177.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 24.0 m -95.09 114.26 26.05 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 176.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.9 mm -119.02 134.0 64.06 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 -176.123 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.4 p -99.26 135.43 34.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.542 ' CZ ' ' HB1' ' A' ' 51' ' ' ALA . 16.5 p90 -109.38 160.61 16.03 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.943 -0.703 . . . . 0.0 112.164 -178.272 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -124.8 -37.23 2.49 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.878 -1.056 . . . . 0.0 111.105 -176.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -118.26 131.92 56.33 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -175.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.4 t -121.43 125.27 73.42 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 176.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.518 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 13.8 p -134.09 140.45 46.63 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -175.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 71.8 mt -101.2 115.45 42.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 109.128 -0.694 . . . . 0.0 109.128 178.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.538 ' NE2' ' HG1' ' A' ' 44' ' ' THR . 6.2 tp-100 -118.59 144.68 45.95 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 105.493 -2.04 . . . . 0.0 105.493 175.492 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -57.0 104.23 0.15 Allowed 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -175.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.58 -38.05 2.07 Favored Glycine 0 N--CA 1.439 -1.15 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.688 177.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 46.2 m80 -152.99 153.23 32.5 Favored 'General case' 0 N--CA 1.478 0.932 0 O-C-N 122.118 -0.636 . . . . 0.0 110.06 -176.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 13.6 tt -97.16 117.75 42.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.541 ' CZ3' ' HG2' ' A' ' 63' ' ' ARG . 65.2 m95 -100.61 134.11 44.05 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-O 120.922 0.391 . . . . 0.0 110.86 -171.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.6 pt -100.5 125.35 54.32 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.869 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 174.588 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -99.06 125.72 8.66 Favored Glycine 0 N--CA 1.414 -2.805 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 38.5 p90 -138.58 172.72 12.46 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-O 120.81 0.338 . . . . 0.0 110.524 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.434 ' HA ' ' O ' ' A' ' 105' ' ' ASN . 1.7 p-10 -115.5 120.04 38.18 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.687 -178.471 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -90.46 -174.7 4.22 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.447 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 45.1 p90 -45.84 -32.25 2.51 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 116.246 1.943 . . . . 0.0 116.246 -176.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -108.37 15.79 23.68 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.034 0.921 . . . . 0.0 109.899 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 81.05 22.28 61.4 Favored Glycine 0 C--N 1.315 -0.621 0 N-CA-C 110.214 -1.155 . . . . 0.0 110.214 -177.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.434 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 8.9 m120 -67.78 121.1 15.24 Favored 'General case' 0 CA--C 1.494 -1.193 0 CA-C-N 114.732 -0.734 . . . . 0.0 109.141 -178.277 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 21.2 tpt180 -86.16 95.75 9.68 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 178.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.9 t -102.95 142.23 17.33 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.3 -174.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.487 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 86.8 m-85 -118.96 116.19 25.94 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 123.642 0.589 . . . . 0.0 110.163 -179.277 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . 0.411 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 46.3 t -99.94 133.89 21.33 Favored Pre-proline 0 C--N 1.304 -1.376 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -69.7 -23.57 30.9 Favored 'Trans proline' 0 C--N 1.358 1.027 0 C-N-CA 123.227 2.618 . . . . 0.0 113.679 -176.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.291 30.8 m 48.95 -53.56 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.164 0 N-CA-C 117.972 2.582 . . . . 0.0 117.972 177.551 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . 0.408 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 21.0 ptt180 -159.22 150.59 20.22 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 123.782 0.833 . . . . 0.0 108.837 -178.513 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 71.2 m -69.74 137.82 52.29 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 175.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.41 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 46.6 t -153.91 129.16 9.73 Favored 'General case' 0 N--CA 1.41 -2.473 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -177.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . 0.413 ' HA ' HE21 ' A' ' 115' ' ' GLN . 0.1 OUTLIER -96.72 146.0 25.28 Favored 'General case' 0 N--CA 1.408 -2.53 0 N-CA-C 103.285 -2.857 . . . . 0.0 103.285 172.288 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -167.07 142.12 7.36 Favored Glycine 0 N--CA 1.406 -3.31 0 C-N-CA 116.66 -2.686 . . . . 0.0 114.994 -177.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 6.2 m -131.59 97.47 19.22 Favored Pre-proline 0 C--N 1.279 -2.457 0 N-CA-C 104.501 -2.407 . . . . 0.0 104.501 171.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -48.31 139.68 21.6 Favored 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 123.456 2.771 . . . . 0.0 113.803 -170.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -85.97 6.74 63.45 Favored 'Cis proline' 0 CA--C 1.558 1.724 0 C-N-CA 124.288 -1.13 . . . . 0.0 114.051 0.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -70.46 102.64 2.25 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-O 121.541 0.686 . . . . 0.0 110.977 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 36.6 p-80 -105.3 117.25 33.53 Favored 'General case' 0 C--N 1.296 -1.717 0 CA-C-N 114.832 -1.077 . . . . 0.0 111.49 -178.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 53.1 mt -110.18 99.34 39.35 Favored Pre-proline 0 C--N 1.318 -0.782 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.53 141.73 8.98 Favored 'Trans proline' 0 C--O 1.247 0.931 0 C-N-CA 122.549 2.166 . . . . 0.0 112.683 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -106.84 -114.55 3.91 Favored Glycine 0 N--CA 1.433 -1.515 0 N-CA-C 110.616 -0.994 . . . . 0.0 110.616 176.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 85.8 t -88.97 127.17 41.88 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.065 0 CA-C-N 116.734 0.267 . . . . 0.0 110.43 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.408 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -94.16 143.05 26.72 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.306 177.208 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.1 m-90 -113.81 27.78 9.27 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 120.861 0.363 . . . . 0.0 110.551 179.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.458 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -169.92 -179.11 41.38 Favored Glycine 0 N--CA 1.429 -1.814 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 37.7 t -111.0 130.31 64.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -178.107 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -98.88 145.76 26.67 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-O 121.004 0.431 . . . . 0.0 110.792 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.412 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 88.1 tttt . . . . . 0 C--N 1.291 -1.967 0 N-CA-C 107.544 -1.28 . . . . 0.0 107.544 178.054 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 98.8 m95 . . . . . 0 N--CA 1.448 -0.562 0 CA-C-O 121.253 0.549 . . . . 0.0 109.962 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 7.1 tmtt? -120.56 139.15 53.36 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 105.461 -2.052 . . . . 0.0 105.461 -178.771 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -86.49 136.61 33.02 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.818 -0.753 . . . . 0.0 111.0 -175.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 45.3 t-20 -93.22 159.01 15.47 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 105.944 -1.873 . . . . 0.0 105.944 175.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -60.54 -22.28 63.46 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 123.467 0.707 . . . . 0.0 112.383 -174.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -79.13 2.34 21.2 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.865 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.11 10.72 80.05 Favored Glycine 0 CA--C 1.509 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.2 178.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 19.9 m -97.65 143.69 28.06 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 179.237 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 75.9 m95 -101.44 129.93 47.57 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 29.7 p90 -134.25 156.62 48.08 Favored 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.429 -177.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 49.2 pttt -135.96 132.23 19.24 Favored Pre-proline 0 C--N 1.293 -1.865 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 174.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -72.82 120.6 6.75 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 121.098 1.199 . . . . 0.0 109.007 174.126 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -154.45 130.14 10.01 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 -176.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -97.27 106.39 18.7 Favored 'General case' 0 C--N 1.307 -1.262 0 O-C-N 123.374 0.422 . . . . 0.0 109.963 -176.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.43 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -148.66 169.52 20.19 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 7.8 m -111.5 149.18 31.71 Favored 'General case' 0 C--N 1.298 -1.674 0 CA-C-O 120.981 0.42 . . . . 0.0 111.522 -173.172 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.4 t80 -130.58 131.36 44.96 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 174.291 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 36.2 t -117.66 117.19 54.23 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 177.631 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -69.89 140.34 53.12 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -102.72 -73.97 1.0 Allowed Glycine 0 N--CA 1.432 -1.63 0 C-N-CA 120.306 -0.95 . . . . 0.0 114.75 -172.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -91.79 -69.13 0.75 Allowed 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 116.011 1.856 . . . . 0.0 116.011 -170.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -109.21 151.49 42.05 Favored Pre-proline 0 C--N 1.292 -1.914 0 O-C-N 121.828 -0.545 . . . . 0.0 111.192 -173.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.404 ' HA ' ' O ' ' A' ' 77' ' ' LEU . 50.0 Cg_exo -57.28 131.11 42.93 Favored 'Trans proline' 0 C--O 1.249 1.025 0 C-N-CA 122.171 1.914 . . . . 0.0 109.437 170.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -107.85 118.83 56.32 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -176.529 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 35.0 m -74.41 143.1 13.87 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.194 175.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 59.2 p -118.42 173.61 6.73 Favored 'General case' 0 C--N 1.277 -2.56 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.141 -173.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.456 ' HG3' ' O ' ' A' ' 68' ' ' PHE . 2.2 mmp_? -116.21 148.64 40.2 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.157 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 66.4 mt -112.21 131.26 64.15 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-O 120.62 0.248 . . . . 0.0 111.122 -177.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 85.98 -23.18 9.68 Favored Glycine 0 C--N 1.318 -0.423 0 N-CA-C 115.646 1.019 . . . . 0.0 115.646 171.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.0 m -157.87 142.23 11.67 Favored Pre-proline 0 C--N 1.296 -1.719 0 CA-C-N 117.51 0.655 . . . . 0.0 109.271 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -89.23 118.51 0.87 Allowed 'Trans proline' 0 N--CA 1.429 -2.306 0 C-N-CA 120.497 0.798 . . . . 0.0 110.089 172.276 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.456 ' O ' ' HG3' ' A' ' 63' ' ' ARG . 90.8 m-85 -170.03 177.05 4.44 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 103.669 -2.715 . . . . 0.0 103.669 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -90.53 -37.81 13.62 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.411 0.624 . . . . 0.0 109.775 175.524 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -81.57 -2.33 49.62 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 114.772 -1.103 . . . . 0.0 111.035 -178.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -58.25 158.95 12.49 Favored Pre-proline 0 CA--C 1.547 0.828 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.547 -179.115 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_exo -47.11 134.73 18.9 Favored 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 123.823 3.015 . . . . 0.0 114.701 -178.289 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 26.6 m -90.63 173.53 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 CA-C-N 114.392 -1.276 . . . . 0.0 110.393 -178.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.44 6.22 12.04 Favored Glycine 0 C--N 1.314 -0.682 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.836 177.278 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -118.77 125.54 6.45 Favored Glycine 0 N--CA 1.432 -1.593 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.902 179.454 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -128.46 135.26 49.22 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 174.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' A' ' 59' ' ' PRO . 53.9 tp -111.59 110.39 55.25 Favored Pre-proline 0 C--N 1.303 -1.422 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 176.523 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -67.47 166.14 24.78 Favored 'Trans proline' 0 CA--C 1.539 0.758 0 C-N-CA 122.699 2.266 . . . . 0.0 112.988 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.54 134.85 40.64 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.245 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.3 -10.81 73.56 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 121.236 -0.506 . . . . 0.0 112.298 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.76 129.38 39.56 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.902 0.382 . . . . 0.0 111.885 -176.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 52.9 m -104.98 117.02 32.96 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.121 179.545 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.0 mm -125.92 140.48 48.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -177.02 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.89 119.23 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-O 121.806 0.812 . . . . 0.0 108.864 175.362 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.43 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 39.4 p90 -97.37 148.4 23.2 Favored 'General case' 0 C--N 1.295 -1.799 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.929 -178.774 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -121.5 9.79 10.33 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 121.578 0.704 . . . . 0.0 110.231 -178.068 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -152.7 130.13 11.38 Favored 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -177.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 33.6 t -118.89 126.61 75.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 178.018 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.533 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 24.6 p -135.77 143.64 45.35 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.543 0.572 . . . . 0.0 112.543 -177.31 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 60.9 mt -102.32 116.83 46.7 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 CA-C-O 120.96 0.41 . . . . 0.0 110.003 177.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.571 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -124.27 121.77 35.94 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 174.117 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.89 107.95 0.16 Allowed 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 123.851 0.86 . . . . 0.0 113.14 -166.367 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 133.91 -33.97 2.46 Favored Glycine 0 N--CA 1.429 -1.81 0 CA-C-N 114.388 -1.278 . . . . 0.0 110.888 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -151.37 166.15 31.88 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -177.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 tt -107.71 119.13 56.78 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 171.211 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.571 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 55.4 m95 -100.77 134.11 44.23 Favored 'General case' 0 C--N 1.276 -2.612 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.9 -170.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.4 pt -100.12 133.7 42.2 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 176.272 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.13 121.97 7.21 Favored Glycine 0 N--CA 1.418 -2.564 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -126.13 147.04 49.7 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 176.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -93.96 112.85 24.75 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 -177.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.39 152.52 38.03 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -177.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -51.7 -30.12 20.95 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 124.313 1.045 . . . . 0.0 113.025 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -80.8 -5.52 57.33 Favored 'General case' 0 C--O 1.217 -0.644 0 CA-C-O 121.409 0.623 . . . . 0.0 110.829 -178.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 96.01 11.26 55.13 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.667 176.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -94.67 145.45 24.84 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.3 tpt180 -93.99 105.02 17.05 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 28.2 t -101.84 136.3 34.5 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -174.254 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.475 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 96.0 m-85 -116.09 126.04 53.2 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 123.419 0.688 . . . . 0.0 110.72 -178.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . 0.437 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 47.2 t -108.04 132.76 20.83 Favored Pre-proline 0 C--N 1.31 -1.123 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.143 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.06 -21.35 36.88 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 123.061 2.508 . . . . 0.0 114.683 -176.475 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.292 28.9 m 45.25 -53.71 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.914 0 N-CA-C 118.564 2.801 . . . . 0.0 118.564 176.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 28.8 ptt180 -154.67 142.05 19.61 Favored 'General case' 0 N--CA 1.44 -0.954 0 C-N-CA 123.826 0.851 . . . . 0.0 109.643 178.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 13.6 m -60.61 131.48 50.87 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.675 177.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.652 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 99.5 m -151.9 119.78 6.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.49 0.662 . . . . 0.0 112.091 -178.234 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -114.98 134.67 54.98 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 177.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 154.17 -175.97 32.2 Favored Glycine 0 CA--C 1.486 -1.768 0 C-N-CA 118.903 -1.618 . . . . 0.0 113.045 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.8 m -126.08 136.16 28.12 Favored Pre-proline 0 C--N 1.298 -1.644 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 179.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_exo -46.54 129.5 13.87 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 123.469 2.78 . . . . 0.0 113.332 -177.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -96.18 -4.44 31.48 Favored 'Cis proline' 0 CA--C 1.542 0.908 0 C-N-CA 124.045 -1.231 . . . . 0.0 113.711 1.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -76.99 99.81 5.4 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-O 121.659 0.742 . . . . 0.0 110.868 -172.645 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 38.8 p-80 -106.99 132.79 52.53 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.334 176.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.652 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.6 mm -77.4 113.24 29.72 Favored Pre-proline 0 C--N 1.307 -1.262 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 174.302 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -84.55 124.42 3.13 Favored 'Trans proline' 0 N--CA 1.443 -1.457 0 C-N-CA 122.113 1.875 . . . . 0.0 112.528 -178.04 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.74 -139.19 9.85 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 176.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 58.4 t -80.62 123.43 37.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 -177.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -93.91 130.65 39.9 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 173.632 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.0 m-90 -95.66 12.63 29.12 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.635 0.731 . . . . 0.0 110.311 -178.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.03 -177.7 34.36 Favored Glycine 0 N--CA 1.421 -2.334 0 CA-C-N 115.196 -0.911 . . . . 0.0 111.298 -178.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 22.8 t -114.17 142.95 24.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -175.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -110.31 141.77 42.86 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.796 0.331 . . . . 0.0 111.289 -176.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? . . . . . 0 C--N 1.307 -1.27 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 172.534 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 95.5 m95 . . . . . 0 N--CA 1.43 -1.448 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -113.66 149.67 34.31 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.3 tttm -92.13 120.48 32.77 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 121.806 0.812 . . . . 0.0 111.158 -177.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 30.3 t-20 -84.5 147.87 26.83 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 176.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.0 tm0? -53.61 -28.66 33.77 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.209 1.004 . . . . 0.0 111.869 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 -74.0 -6.02 44.86 Favored 'General case' 0 CA--C 1.54 0.56 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -178.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.36 22.78 39.48 Favored Glycine 0 CA--C 1.495 -1.212 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -178.308 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.402 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 16.9 m -105.88 139.06 41.03 Favored 'General case' 0 N--CA 1.415 -2.222 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.175 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -102.59 133.25 47.9 Favored 'General case' 0 C--N 1.282 -2.366 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 175.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 35.9 p90 -138.94 158.97 43.23 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.436 -0.905 . . . . 0.0 112.286 -175.313 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.0 pttp -140.67 134.42 15.06 Favored Pre-proline 0 N--CA 1.431 -1.411 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 174.324 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -70.76 134.46 25.91 Favored 'Trans proline' 0 C--N 1.327 -0.597 0 C-N-CA 121.626 1.551 . . . . 0.0 110.566 177.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -163.62 121.09 1.83 Allowed 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.526 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 26.4 t-20 -95.35 106.06 18.07 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 177.376 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.466 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -144.03 168.83 19.06 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 -178.564 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 17.2 m -109.61 140.85 42.94 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.256 -174.769 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.474 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 91.7 t80 -120.9 133.65 55.29 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 176.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.418 ' HA ' ' O ' ' A' ' 81' ' ' ALA . 42.5 t -119.4 119.53 60.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.696 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.137 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -59.67 145.62 44.14 Favored 'General case' 0 C--O 1.246 0.916 0 O-C-N 123.518 0.511 . . . . 0.0 111.874 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -81.77 -122.34 0.63 Allowed Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.664 -0.698 . . . . 0.0 113.213 -178.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -95.88 -6.3 39.61 Favored 'General case' 0 C--N 1.315 -0.907 0 O-C-N 122.374 -0.486 . . . . 0.0 112.276 -175.427 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 9.5 pt20 -121.45 148.08 49.11 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.554 -178.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -72.37 135.59 24.81 Favored 'Trans proline' 0 N--CA 1.439 -1.722 0 C-N-CA 121.932 1.755 . . . . 0.0 107.813 168.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 57.8 mt -107.81 127.83 63.56 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -176.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.4 p -78.37 136.67 23.52 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 37.9 p -113.29 164.16 13.91 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 121.134 0.492 . . . . 0.0 112.043 -174.243 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.452 ' HE ' ' HA ' ' A' ' 63' ' ' ARG . 0.8 OUTLIER -109.63 147.01 33.81 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.392 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.0 mt -99.33 123.4 52.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 112.378 0.511 . . . . 0.0 112.378 -176.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 70.9 -22.27 0.58 Allowed Glycine 0 CA--C 1.521 0.41 0 N-CA-C 118.054 1.981 . . . . 0.0 118.054 170.705 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 41.6 m -140.73 136.16 16.18 Favored Pre-proline 0 C--N 1.298 -1.662 0 CA-C-N 119.074 1.437 . . . . 0.0 111.075 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -89.91 119.57 0.83 Allowed 'Trans proline' 0 N--CA 1.44 -1.661 0 C-N-CA 121.781 1.654 . . . . 0.0 110.484 172.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.412 ' HA ' ' HG2' ' A' ' 91' ' ' GLN . 55.3 m-85 -168.46 168.98 10.81 Favored 'General case' 0 CA--C 1.489 -1.367 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 -177.643 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.73 -8.77 53.89 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.536 0.684 . . . . 0.0 110.194 176.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 31.0 p30 -116.62 14.97 15.53 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.243 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.09 152.89 86.75 Favored Pre-proline 0 C--O 1.247 0.962 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.491 -175.229 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_exo -54.29 134.59 61.62 Favored 'Trans proline' 0 C--N 1.364 1.385 0 C-N-CA 123.66 2.907 . . . . 0.0 113.878 -179.064 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 32.3 m -90.1 174.42 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-N 114.564 -1.198 . . . . 0.0 110.234 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.36 28.75 1.9 Allowed Glycine 0 C--N 1.315 -0.611 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.851 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -148.06 127.99 2.74 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -128.12 127.14 42.48 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 26.1 tp -110.61 113.29 55.83 Favored Pre-proline 0 C--N 1.306 -1.325 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -62.21 162.31 23.73 Favored 'Trans proline' 0 N--CA 1.483 0.904 0 C-N-CA 123.461 2.774 . . . . 0.0 114.043 -176.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.96 144.67 48.81 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 178.456 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.73 11.15 85.61 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.478 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . 0.418 ' O ' ' HA ' ' A' ' 54' ' ' VAL . . . -78.77 134.21 37.04 Favored 'General case' 0 N--CA 1.439 -1.01 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 178.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 42.1 m -104.47 108.84 20.46 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 45.5 mm -124.05 126.59 72.62 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-O 120.936 0.398 . . . . 0.0 110.518 -176.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.4 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 12.4 p -90.32 123.41 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.647 0 CA-C-O 121.486 0.66 . . . . 0.0 109.56 176.34 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.526 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 45.5 p90 -101.96 159.25 15.52 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.137 -178.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -118.29 -16.19 9.68 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 121.379 0.609 . . . . 0.0 111.786 -175.204 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -141.11 137.76 33.03 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.341 -175.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 67.6 t -112.28 125.76 69.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.74 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.402 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 57.9 m -127.24 142.5 51.46 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -175.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 55.0 mt -108.46 117.04 53.11 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 172.174 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.412 ' HG2' ' HA ' ' A' ' 68' ' ' PHE . 7.7 tp-100 -113.97 121.33 43.58 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 103.107 -2.923 . . . . 0.0 103.107 170.171 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.17 104.07 0.06 Allowed 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 113.697 0.999 . . . . 0.0 113.697 -165.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 132.56 -36.36 2.19 Favored Glycine 0 N--CA 1.435 -1.411 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.15 -177.439 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 41.5 m80 -146.09 149.39 33.96 Favored 'General case' 0 CA--C 1.504 -0.81 0 O-C-N 122.293 -0.533 . . . . 0.0 111.621 -178.253 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.8 tt -97.86 138.11 23.56 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.913 0 N-CA-C 105.777 -1.934 . . . . 0.0 105.777 175.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -120.22 138.06 53.85 Favored 'General case' 0 C--N 1.283 -2.308 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 -174.35 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.432 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.1 pt -101.05 128.9 52.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 175.312 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.19 119.87 6.6 Favored Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 179.246 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 55.2 p90 -138.35 171.97 13.6 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -109.21 131.97 54.57 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.331 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -98.12 170.9 8.59 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.703 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 31.1 p90 -50.18 -24.02 2.56 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 115.516 1.672 . . . . 0.0 115.516 -176.537 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -86.03 -9.92 55.92 Favored 'General case' 0 C--N 1.315 -0.926 0 O-C-N 121.498 -0.751 . . . . 0.0 110.59 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.94 17.14 56.89 Favored Glycine 0 CA--C 1.499 -0.926 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -174.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 42.2 t30 -93.95 136.14 34.56 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 113.822 -1.189 . . . . 0.0 109.399 -175.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 -78.57 113.71 16.85 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 47.3 t -121.14 143.37 33.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 -175.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.432 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 92.6 m-85 -120.79 127.21 51.74 Favored 'General case' 0 C--O 1.242 0.698 0 C-N-CA 122.977 0.511 . . . . 0.0 110.977 -179.138 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 53.0 t -104.48 133.46 20.18 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 178.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.59 -10.81 27.31 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 123.409 2.739 . . . . 0.0 114.267 -176.341 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.279 35.5 m 38.71 -61.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 N-CA-C 118.706 2.854 . . . . 0.0 118.706 174.6 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . 0.465 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 35.6 ptt180 -154.99 150.33 27.24 Favored 'General case' 0 N--CA 1.439 -0.982 0 C-N-CA 123.287 0.635 . . . . 0.0 109.997 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 123' ' ' PRO . 82.4 m -68.95 135.61 51.23 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.632 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 95.2 m -151.09 110.92 4.06 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 123.001 0.52 . . . . 0.0 110.868 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 23.3 mp0 -98.71 160.95 13.92 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 176.545 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 128.02 -167.05 20.42 Favored Glycine 0 CA--C 1.487 -1.667 0 C-N-CA 118.768 -1.682 . . . . 0.0 113.508 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 27.9 m -138.13 151.13 69.22 Favored Pre-proline 0 C--N 1.304 -1.38 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -56.0 137.01 77.74 Favored 'Trans proline' 0 CA--C 1.54 0.775 0 C-N-CA 122.349 2.033 . . . . 0.0 112.992 -179.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -92.11 -11.65 27.86 Favored 'Cis proline' 0 C--O 1.25 1.087 0 C-N-CA 124.098 -1.209 . . . . 0.0 113.06 -2.242 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -75.82 101.15 4.99 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-O 122.207 1.003 . . . . 0.0 112.168 -173.093 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.4 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 32.6 p-80 -105.44 132.71 51.28 Favored 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 114.194 -1.366 . . . . 0.0 110.537 177.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.632 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 3.1 mp -94.15 105.5 17.8 Favored Pre-proline 0 C--N 1.299 -1.591 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 179.412 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . 0.415 ' HA ' ' O ' ' A' ' 113' ' ' THR . 50.2 Cg_endo -84.31 143.18 9.93 Favored 'Trans proline' 0 N--CA 1.436 -1.864 0 C-N-CA 121.769 1.646 . . . . 0.0 112.813 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.7 -114.62 3.98 Favored Glycine 0 N--CA 1.426 -1.993 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 176.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 62.0 t -94.44 126.8 46.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.465 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.38 136.92 34.15 Favored 'General case' 0 N--CA 1.439 -1.015 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.349 175.199 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.0 m-90 -102.32 19.93 17.84 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.394 0.616 . . . . 0.0 110.939 -178.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.474 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -172.55 179.81 43.84 Favored Glycine 0 N--CA 1.427 -1.933 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.242 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 37.7 t -111.71 135.44 50.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -176.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -97.75 127.36 43.65 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.255 179.174 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 97.3 mttt . . . . . 0 C--N 1.29 -1.997 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 175.419 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 45.6 m95 . . . . . 0 N--CA 1.444 -0.729 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.8 mtpp -121.84 152.06 39.97 Favored 'General case' 0 C--N 1.309 -1.196 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 177.449 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 56.7 tttp -101.65 135.41 43.22 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 34.9 p30 -95.09 174.69 6.95 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -64.18 -22.31 66.89 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 122.924 0.49 . . . . 0.0 111.937 -178.263 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -82.43 -5.56 58.75 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.486 -178.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 95.34 -3.82 66.55 Favored Glycine 0 N--CA 1.439 -1.114 0 C-N-CA 121.151 -0.547 . . . . 0.0 112.615 176.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 7.1 m -84.58 141.08 30.94 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 122.706 0.402 . . . . 0.0 110.126 -176.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 98.2 m95 -92.52 135.87 33.7 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 174.344 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -137.97 159.13 42.83 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 120.84 0.352 . . . . 0.0 110.983 -177.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 58.7 pttt -141.97 152.32 61.64 Favored Pre-proline 0 C--N 1.301 -1.507 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 174.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -80.21 121.85 4.51 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.017 1.812 . . . . 0.0 110.572 175.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -155.42 130.72 9.58 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.539 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 27.2 t-20 -117.95 115.31 24.65 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -177.078 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.516 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -154.49 178.29 10.23 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -179.086 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 28.5 m -103.35 131.14 50.67 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 121.066 0.46 . . . . 0.0 111.038 -176.225 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.422 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 79.8 t80 -107.08 121.95 45.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 173.403 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 41.4 t -106.65 102.25 13.66 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.045 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.668 -178.379 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 56.0 t30 -77.44 151.63 34.64 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 173.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -142.05 -71.8 0.03 OUTLIER Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.017 -1.563 . . . . 0.0 115.537 -176.195 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.402 ' OD1' ' HG3' ' A' ' 58' ' ' GLN . 26.7 p30 -72.1 -38.27 69.37 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 116.161 1.912 . . . . 0.0 116.161 -169.146 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.402 ' HG3' ' OD1' ' A' ' 57' ' ' ASN . 0.1 OUTLIER -138.54 161.4 58.98 Favored Pre-proline 0 C--N 1.296 -1.752 0 C-N-CA 120.494 -0.482 . . . . 0.0 112.123 -177.031 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -78.08 151.0 26.76 Favored 'Trans proline' 0 N--CA 1.439 -1.717 0 C-N-CA 121.722 1.614 . . . . 0.0 109.578 175.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.6 mt -125.04 126.22 70.77 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -178.388 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.6 p -82.21 117.75 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.218 0 CA-C-O 122.119 0.961 . . . . 0.0 109.527 176.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.3 p -91.28 173.62 7.82 Favored 'General case' 0 C--N 1.289 -2.065 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.333 -176.131 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 74.4 mmt-85 -111.25 145.72 38.24 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-O 121.285 0.564 . . . . 0.0 110.23 -178.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.3 mt -94.89 112.35 27.23 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 CA-C-N 115.203 -0.908 . . . . 0.0 112.717 -176.156 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.11 -23.13 1.16 Allowed Glycine 0 CA--C 1.518 0.279 0 N-CA-C 116.849 1.5 . . . . 0.0 116.849 171.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.1 m -137.11 135.96 20.36 Favored Pre-proline 0 C--N 1.301 -1.541 0 CA-C-N 118.329 1.064 . . . . 0.0 111.168 -175.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -89.98 120.28 0.87 Allowed 'Trans proline' 0 N--CA 1.438 -1.745 0 C-N-CA 121.888 1.725 . . . . 0.0 111.525 173.681 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.449 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 92.9 m-85 -165.42 161.92 19.11 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 103.848 -2.649 . . . . 0.0 103.848 179.024 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 64.9 mt -72.85 -40.08 66.0 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.17 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -97.36 17.49 17.34 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.221 -0.9 . . . . 0.0 111.172 -178.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.449 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -60.68 161.69 14.04 Favored Pre-proline 0 N--CA 1.48 1.06 0 C-N-CA 122.959 0.504 . . . . 0.0 111.624 -179.078 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -57.11 130.71 41.06 Favored 'Trans proline' 0 C--N 1.366 1.5 0 C-N-CA 122.955 2.436 . . . . 0.0 113.185 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 22.2 m -102.92 175.75 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 C-N-CA 124.56 1.144 . . . . 0.0 110.874 -179.537 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.84 3.84 10.76 Favored Glycine 0 C--N 1.309 -0.919 0 C-N-CA 121.308 -0.473 . . . . 0.0 112.175 -178.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -110.18 94.3 0.79 Allowed Glycine 0 N--CA 1.434 -1.442 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 173.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -87.38 122.31 30.97 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.989 -0.713 . . . . 0.0 110.463 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.9 tp -96.78 113.33 62.64 Favored Pre-proline 0 C--N 1.304 -1.384 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.33 159.89 47.94 Favored 'Trans proline' 0 C--O 1.251 1.154 0 C-N-CA 122.591 2.194 . . . . 0.0 113.348 -176.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.28 124.86 25.97 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.889 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.09 -0.54 54.68 Favored Glycine 0 C--N 1.306 -1.106 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.18 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.36 126.52 29.88 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.299 0.571 . . . . 0.0 111.247 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 14.4 m -99.45 108.87 21.44 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 178.217 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.9 mm -119.16 128.56 75.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 120.723 0.296 . . . . 0.0 111.333 -173.192 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.2 p -87.98 128.97 39.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 173.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.539 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 21.1 p90 -104.01 157.98 16.73 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.955 -0.298 . . . . 0.0 111.472 -178.512 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -114.97 -23.6 9.01 Favored 'General case' 0 C--O 1.247 0.945 0 CA-C-O 121.665 0.745 . . . . 0.0 111.495 -176.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -141.52 137.42 32.03 Favored 'General case' 0 C--N 1.294 -1.807 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.911 -170.575 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 96.0 t -113.73 132.86 61.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.426 ' HB2' ' HB2' ' A' ' 96' ' ' TRP . 56.9 m -131.85 153.75 49.87 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 120.548 0.214 . . . . 0.0 111.235 -176.141 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 55.3 mt -122.12 119.71 59.26 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 173.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.469 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 6.2 tp-100 -122.58 146.31 47.54 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 176.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.71 104.76 0.07 Allowed 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -169.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 108.47 -19.75 31.02 Favored Glycine 0 N--CA 1.436 -1.322 0 CA-C-N 114.853 -1.067 . . . . 0.0 113.999 175.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -145.17 147.01 32.0 Favored 'General case' 0 C--N 1.316 -0.858 0 O-C-N 121.535 -0.979 . . . . 0.0 111.998 -176.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.7 tt -92.64 143.85 10.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 105.461 -2.052 . . . . 0.0 105.461 174.132 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.469 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 70.0 m95 -126.92 148.61 50.03 Favored 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 -175.46 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.479 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.8 pt -117.67 137.52 51.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 174.148 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -110.83 131.62 10.48 Favored Glycine 0 N--CA 1.421 -2.329 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -138.62 169.7 17.32 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 177.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 51.8 t-20 -106.56 114.64 28.88 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.32 162.62 28.25 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -178.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -57.54 -17.9 16.4 Favored 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 -177.024 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 7.3 t30 -79.23 -14.83 58.8 Favored 'General case' 0 CA--C 1.547 0.861 0 CA-C-O 121.18 0.514 . . . . 0.0 110.598 178.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 92.21 17.02 48.38 Favored Glycine 0 C--N 1.325 -0.079 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -174.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 38.1 t30 -97.49 142.89 28.78 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 114.648 -0.776 . . . . 0.0 110.68 -178.267 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 19.2 tpt180 -88.39 107.34 18.79 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 179.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 43.0 t -107.96 139.61 29.41 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -176.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.479 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 90.5 m-85 -117.5 128.34 54.89 Favored 'General case' 0 C--N 1.32 -0.695 0 O-C-N 123.331 0.395 . . . . 0.0 110.817 -179.317 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 41.9 t -104.7 133.29 20.25 Favored Pre-proline 0 C--N 1.3 -1.547 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.03 -9.49 25.74 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 123.135 2.557 . . . . 0.0 114.001 -177.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.307 27.1 m 39.1 -63.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 N-CA-C 118.361 2.726 . . . . 0.0 118.361 175.133 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . 0.533 ' HB2' ' O ' ' A' ' 125' ' ' VAL . 36.0 ptt180 -162.59 164.38 26.78 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-O 121.177 0.513 . . . . 0.0 111.468 177.357 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 58.4 m -75.37 134.72 40.9 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.265 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.481 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 89.6 m -154.58 124.26 6.59 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 123.787 0.835 . . . . 0.0 110.026 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -105.48 160.54 15.07 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 179.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 134.83 -176.24 20.08 Favored Glycine 0 C--N 1.292 -1.872 0 C-N-CA 118.262 -1.923 . . . . 0.0 114.209 175.272 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 76.7 t -127.37 121.33 22.45 Favored Pre-proline 0 C--N 1.298 -1.632 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 99.5 Cg_exo -43.76 136.25 6.97 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 124.043 3.162 . . . . 0.0 113.18 -178.182 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -86.13 -11.17 42.48 Favored 'Cis proline' 0 C--O 1.25 1.103 0 C-N-CA 124.007 -1.247 . . . . 0.0 114.25 3.77 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -76.22 102.16 5.7 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.951 0.881 . . . . 0.0 112.19 -172.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -106.09 124.87 50.25 Favored 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 114.073 -1.421 . . . . 0.0 110.83 176.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.481 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 55.3 mt -93.74 109.43 41.23 Favored Pre-proline 0 C--N 1.295 -1.768 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.83 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -81.97 150.38 16.04 Favored 'Trans proline' 0 C--O 1.246 0.907 0 C-N-CA 122.485 2.123 . . . . 0.0 114.295 -175.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.33 -125.36 4.3 Favored Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 175.003 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.533 ' O ' ' HB2' ' A' ' 112' ' ' ARG . 60.3 t -79.09 133.68 29.44 Favored 'Isoleucine or valine' 0 C--O 1.244 0.805 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.434 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -93.22 132.94 36.93 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 123.268 0.627 . . . . 0.0 109.857 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 8.6 m0 -107.68 13.38 26.63 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.462 0.649 . . . . 0.0 109.995 178.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.422 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -173.58 170.69 43.85 Favored Glycine 0 N--CA 1.425 -2.089 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 179.569 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 73.3 t -111.41 129.57 66.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.981 0.391 . . . . 0.0 110.316 -176.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -94.4 129.58 41.07 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.079 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 28.0 ttpp . . . . . 0 N--CA 1.423 -1.817 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 -179.731 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . 0.411 ' CE2' ' HD3' ' A' ' 47' ' ' LYS . 66.2 m95 . . . . . 0 N--CA 1.433 -1.319 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.425 ' HD3' ' N ' ' A' ' 39' ' ' LYS . 12.4 tmtt? -135.18 137.89 43.13 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 177.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.425 ' N ' ' HD3' ' A' ' 38' ' ' LYS . 2.6 ttmp? -83.3 116.85 22.62 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . 0.459 ' HB3' ' CE1' ' A' ' 46' ' ' TYR . 36.3 p30 -77.98 177.66 8.1 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 177.154 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -65.33 -7.41 13.36 Favored 'General case' 0 C--N 1.317 -0.819 0 C-N-CA 123.527 0.731 . . . . 0.0 112.525 -178.448 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.4 m-85 -102.25 4.27 39.08 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.497 0.665 . . . . 0.0 110.041 -178.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.44 16.15 79.85 Favored Glycine 0 N--CA 1.447 -0.591 0 CA-C-N 115.511 -0.768 . . . . 0.0 112.086 178.006 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 25.3 m -100.22 132.95 45.3 Favored 'General case' 0 N--CA 1.424 -1.743 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.042 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 75.1 m95 -87.93 125.31 34.44 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 176.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.459 ' CE1' ' HB3' ' A' ' 40' ' ' ASN . 50.9 p90 -130.31 151.52 50.73 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 121.184 -0.207 . . . . 0.0 111.156 -178.292 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.411 ' HD3' ' CE2' ' A' ' 37' ' ' TRP . 18.1 pttp -146.64 140.91 15.62 Favored Pre-proline 0 C--N 1.313 -0.985 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 173.104 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -79.61 120.96 4.51 Favored 'Trans proline' 0 C--O 1.244 0.8 0 C-N-CA 121.635 1.557 . . . . 0.0 112.559 -179.27 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.8 tt0 -158.14 125.21 4.97 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -87.25 121.38 29.62 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.709 -175.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -150.27 169.52 21.17 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 19.9 m -116.14 143.41 45.53 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 -173.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -130.19 126.39 37.31 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 124.062 0.945 . . . . 0.0 108.964 175.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.1 t -111.41 109.01 26.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 37.9 t30 -77.09 131.27 38.28 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 175.428 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -156.91 83.27 0.15 Allowed Glycine 0 C--N 1.306 -1.103 0 C-N-CA 118.979 -1.581 . . . . 0.0 113.992 -176.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.473 ' HB3' ' OE1' ' A' ' 58' ' ' GLN . 40.3 t30 168.59 -67.86 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 125.269 1.427 . . . . 0.0 109.203 172.577 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.484 ' NE2' ' HB3' ' A' ' 127' ' ' TRP . 4.7 pm0 -111.89 152.24 44.08 Favored Pre-proline 0 C--N 1.304 -1.374 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.266 -175.244 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_exo -73.48 133.98 19.88 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.698 1.598 . . . . 0.0 108.051 170.046 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 61.1 mt -108.1 125.7 64.72 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -176.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.4 p -81.05 111.77 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.626 0 CA-C-O 122.066 0.936 . . . . 0.0 108.737 176.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 64.7 p -92.22 164.62 13.48 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.399 -176.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 17.2 mmt180 -105.41 135.49 46.7 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.635 -175.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.4 mt -98.9 125.56 52.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 N-CA-C 112.68 0.622 . . . . 0.0 112.68 -173.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.75 -21.87 1.52 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 116.388 1.315 . . . . 0.0 116.388 172.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 22.1 m -146.84 136.99 12.13 Favored Pre-proline 0 C--N 1.305 -1.335 0 CA-C-N 118.678 1.239 . . . . 0.0 111.063 -177.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -90.3 120.43 0.82 Allowed 'Trans proline' 0 N--CA 1.437 -1.804 0 C-N-CA 121.925 1.75 . . . . 0.0 110.971 172.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.423 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 51.7 m-85 -167.03 171.45 11.07 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 179.685 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 69.4 mt -84.65 -28.46 26.42 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 107.481 -1.304 . . . . 0.0 107.481 172.418 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -96.68 19.78 11.88 Favored 'General case' 0 CA--C 1.549 0.936 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.294 179.524 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -71.21 155.28 93.24 Favored Pre-proline 0 C--N 1.315 -0.908 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.505 -176.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_exo -55.89 131.16 44.34 Favored 'Trans proline' 0 C--N 1.353 0.801 0 C-N-CA 123.404 2.736 . . . . 0.0 113.927 -179.726 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.3 m -97.54 174.62 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.259 178.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.66 -0.57 15.65 Favored Glycine 0 CA--C 1.496 -1.105 0 C-N-CA 120.071 -1.061 . . . . 0.0 112.235 178.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.43 96.23 0.87 Allowed Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 175.035 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -94.46 118.42 31.61 Favored 'General case' 0 C--N 1.288 -2.071 0 O-C-N 122.186 -0.596 . . . . 0.0 109.967 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 48.4 tp -90.69 117.75 68.18 Favored Pre-proline 0 C--N 1.306 -1.311 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.29 152.51 80.87 Favored 'Trans proline' 0 C--O 1.249 1.061 0 C-N-CA 122.289 1.992 . . . . 0.0 113.029 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.96 135.55 40.04 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 115.142 -0.935 . . . . 0.0 108.982 176.547 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.43 4.91 57.14 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.425 -179.568 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.28 130.48 38.99 Favored 'General case' 0 C--O 1.243 0.731 0 CA-C-O 121.151 0.501 . . . . 0.0 111.882 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.2 m -93.28 120.16 33.25 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.239 176.082 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.6 mm -119.94 118.63 57.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.884 -179.138 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 5.0 p -99.48 112.64 32.34 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 175.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 45.5 p90 -97.2 155.78 16.69 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.536 -173.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -115.54 -9.0 12.11 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -175.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -136.88 131.23 32.86 Favored 'General case' 0 C--N 1.309 -1.194 0 C-N-CA 120.531 -0.467 . . . . 0.0 109.755 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 24.2 t -102.02 129.4 53.42 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.627 ' SG ' ' HE2' ' A' ' 108' ' ' TYR . 43.9 m -134.88 145.93 48.73 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-N 117.84 0.291 . . . . 0.0 111.493 -176.406 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 65.1 mt -120.69 116.89 51.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 175.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.584 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -125.89 136.43 53.04 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 105.854 -1.906 . . . . 0.0 105.854 175.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.04 112.65 0.7 Allowed 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -171.132 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 125.43 -32.62 3.86 Favored Glycine 0 N--CA 1.437 -1.294 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.128 179.071 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 61.2 m80 -153.51 168.8 24.94 Favored 'General case' 0 N--CA 1.473 0.714 0 O-C-N 122.005 -0.703 . . . . 0.0 110.581 -176.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.9 tt -100.5 137.79 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.846 0 N-CA-C 103.449 -2.797 . . . . 0.0 103.449 167.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.584 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 69.5 m95 -118.73 136.76 53.78 Favored 'General case' 0 C--N 1.269 -2.913 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -173.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.444 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.3 pt -100.72 128.68 52.58 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.148 0 C-N-CA 119.896 -0.722 . . . . 0.0 109.43 177.592 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.33 118.83 6.25 Favored Glycine 0 N--CA 1.419 -2.458 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -142.83 168.68 19.14 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -114.72 138.08 51.15 Favored 'General case' 0 C--N 1.291 -1.967 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 176.322 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.98 -177.14 6.48 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.164 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -64.36 -21.67 66.7 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.319 0.581 . . . . 0.0 112.416 -177.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 48.8 t30 -77.74 -8.31 57.78 Favored 'General case' 0 CA--C 1.554 1.134 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.243 176.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 82.73 6.74 88.21 Favored Glycine 0 N--CA 1.461 0.354 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -177.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 43.3 t30 -82.87 133.38 35.13 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 124.067 0.947 . . . . 0.0 109.894 -176.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 16.3 tpp85 -75.29 119.37 19.3 Favored 'General case' 0 C--N 1.316 -0.858 0 O-C-N 123.849 0.718 . . . . 0.0 110.663 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.8 t -124.3 146.63 29.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.627 ' HE2' ' SG ' ' A' ' 89' ' ' CYS . 65.0 m-85 -119.39 131.71 55.71 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 123.477 0.711 . . . . 0.0 110.556 178.204 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 46.7 t -109.76 134.43 20.63 Favored Pre-proline 0 C--N 1.303 -1.454 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -68.7 -19.48 41.48 Favored 'Trans proline' 0 C--N 1.363 1.292 0 C-N-CA 123.135 2.556 . . . . 0.0 114.112 -177.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.296 30.6 m 44.79 -59.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.487 0 N-CA-C 118.394 2.738 . . . . 0.0 118.394 175.159 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 6.4 ptp180 -152.68 160.22 43.16 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.6 p -76.15 140.45 41.76 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.007 176.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.408 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 96.4 m -152.46 145.41 24.47 Favored 'General case' 0 CA--C 1.499 -1.019 0 CA-C-O 120.934 0.397 . . . . 0.0 111.177 -179.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -133.56 160.9 36.08 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.28 -1.748 . . . . 0.0 106.28 178.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.85 -173.44 21.83 Favored Glycine 0 C--N 1.3 -1.429 0 C-N-CA 118.596 -1.764 . . . . 0.0 113.939 175.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 21.1 m -138.24 123.88 12.51 Favored Pre-proline 0 C--N 1.311 -1.097 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.231 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -46.53 128.43 12.69 Favored 'Trans proline' 0 CA--C 1.543 0.937 0 C-N-CA 123.521 2.814 . . . . 0.0 113.05 -178.62 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -93.67 3.31 55.67 Favored 'Cis proline' 0 CA--C 1.551 1.373 0 N-CA-C 115.239 1.207 . . . . 0.0 115.239 5.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -78.71 102.27 7.98 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 122.199 1.0 . . . . 0.0 110.691 -176.359 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.42 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 35.6 p-80 -105.19 121.77 44.51 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-N 114.012 -1.449 . . . . 0.0 110.958 -177.454 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.408 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 58.3 mt -102.08 100.67 15.73 Favored Pre-proline 0 C--N 1.305 -1.36 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.094 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . 0.42 ' HD3' ' O ' ' A' ' 121' ' ' HIS . 63.7 Cg_endo -85.7 135.14 4.86 Favored 'Trans proline' 0 CA--C 1.544 0.981 0 C-N-CA 122.872 2.381 . . . . 0.0 114.209 -177.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -112.11 -151.97 11.7 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 175.294 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 90.4 t -52.63 124.49 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.336 0 C-N-CA 123.938 0.895 . . . . 0.0 112.535 -178.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -93.77 143.7 26.09 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.871 175.29 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . 0.484 ' HB3' ' NE2' ' A' ' 58' ' ' GLN . 5.3 m-90 -105.47 17.24 24.21 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.327 0.584 . . . . 0.0 110.986 178.347 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -165.57 -170.43 30.5 Favored Glycine 0 N--CA 1.429 -1.804 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 98.8 t -111.23 133.04 58.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -178.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -104.43 127.6 52.14 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.7 tppt? . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -179.842 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . 0.513 ' CE2' ' HD2' ' A' ' 47' ' ' LYS . 86.2 m95 . . . . . 0 C--O 1.245 0.837 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 53.5 mtmt -135.49 148.92 49.38 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 175.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -88.08 125.86 34.8 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . 0.558 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 55.1 t30 -93.78 169.36 10.36 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 123.687 0.795 . . . . 0.0 110.545 -176.618 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -47.66 -34.81 8.54 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.926 2.091 . . . . 0.0 113.005 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -88.21 7.55 31.39 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.113 0.482 . . . . 0.0 111.703 -175.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.87 -13.02 60.15 Favored Glycine 0 CA--C 1.507 -0.462 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.44 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 5.3 m -71.84 137.09 47.27 Favored 'General case' 0 N--CA 1.42 -1.965 0 C-N-CA 124.55 1.14 . . . . 0.0 110.413 -177.79 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 66.5 m95 -90.03 133.75 34.65 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 173.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.558 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 8.6 p90 -132.3 149.12 52.43 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.865 -177.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.513 ' HD2' ' CE2' ' A' ' 37' ' ' TRP . 21.9 ptmt -137.19 146.85 56.05 Favored Pre-proline 0 C--N 1.305 -1.328 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 175.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -77.02 121.85 5.99 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.057 1.838 . . . . 0.0 109.862 173.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -157.98 120.86 3.86 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -178.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.48 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 4.9 t30 -103.35 117.03 33.56 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 -177.009 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.428 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.93 -177.9 6.57 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.442 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 32.3 m -118.05 152.68 35.07 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 120.627 0.251 . . . . 0.0 110.577 -177.044 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.494 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 92.5 t80 -134.61 132.65 39.27 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 177.606 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.1 t -115.56 127.77 73.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.457 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -65.16 135.72 55.82 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.085 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -73.82 -90.91 0.15 Allowed Glycine 0 N--CA 1.44 -1.067 0 O-C-N 123.654 0.596 . . . . 0.0 113.804 -175.545 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -109.72 -47.03 3.41 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 114.097 1.147 . . . . 0.0 114.097 -174.528 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -116.95 152.25 48.44 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -174.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.424 ' HB3' HD22 ' A' ' 76' ' ' ASN . 51.9 Cg_exo -57.13 137.46 81.93 Favored 'Trans proline' 0 C--O 1.242 0.699 0 C-N-CA 122.856 2.37 . . . . 0.0 112.106 178.434 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -108.98 125.85 66.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 -176.266 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 33.6 m -72.93 148.43 9.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 175.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 35.9 p -127.15 163.01 24.78 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 110.337 -0.245 . . . . 0.0 110.337 -175.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -110.18 141.85 42.53 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -178.523 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.7 mt -94.1 119.01 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.493 -175.561 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 72.18 -22.95 0.75 Allowed Glycine 0 CA--C 1.529 0.922 0 N-CA-C 117.273 1.669 . . . . 0.0 117.273 170.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.3 m -141.32 136.35 15.71 Favored Pre-proline 0 C--N 1.297 -1.69 0 CA-C-N 118.958 1.379 . . . . 0.0 110.862 -178.417 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -89.64 119.53 0.88 Allowed 'Trans proline' 0 N--CA 1.433 -2.055 0 C-N-CA 121.325 1.35 . . . . 0.0 110.47 172.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.405 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 72.0 m-85 -169.37 169.46 9.02 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 127.954 2.502 . . . . 0.0 104.61 -179.295 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -90.13 -17.87 26.86 Favored 'General case' 0 C--N 1.293 -1.879 0 CA-C-O 121.222 0.534 . . . . 0.0 110.75 175.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 27.8 p-10 -106.7 20.32 19.19 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.801 0.81 . . . . 0.0 109.665 177.303 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.405 ' HB1' ' HB2' ' A' ' 68' ' ' PHE . . . -72.59 156.4 90.18 Favored Pre-proline 0 C--O 1.25 1.101 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.734 179.022 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -54.58 122.97 12.52 Favored 'Trans proline' 0 C--N 1.357 1.024 0 C-N-CA 122.922 2.414 . . . . 0.0 112.372 -179.452 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 8.5 p -103.45 174.24 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-N 114.916 -1.038 . . . . 0.0 108.235 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.9 -6.43 12.26 Favored Glycine 0 CA--C 1.494 -1.258 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -178.383 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.23 131.55 10.62 Favored Glycine 0 N--CA 1.429 -1.773 0 N-CA-C 108.399 -1.88 . . . . 0.0 108.399 173.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.424 HD22 ' HB3' ' A' ' 59' ' ' PRO . 9.2 t30 -126.98 141.38 51.81 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 118.113 0.956 . . . . 0.0 111.564 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 51.5 tp -104.18 114.72 64.09 Favored Pre-proline 0 C--N 1.309 -1.171 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 176.09 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -62.7 160.42 32.76 Favored 'Trans proline' 0 C--O 1.243 0.75 0 C-N-CA 123.072 2.515 . . . . 0.0 112.81 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.67 137.49 46.06 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.327 -178.683 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.32 19.6 78.1 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.804 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -85.72 140.12 30.78 Favored 'General case' 0 C--N 1.317 -0.814 0 O-C-N 122.554 -0.38 . . . . 0.0 110.346 178.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 40.5 m -111.68 108.73 18.28 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.8 mm -116.52 136.51 53.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 122.889 0.475 . . . . 0.0 110.565 -175.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.4 p -102.92 128.24 55.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 174.46 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.48 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 42.5 p90 -117.63 157.74 25.88 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.559 -175.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -121.26 -5.99 9.39 Favored 'General case' 0 C--O 1.247 0.972 0 O-C-N 123.653 0.595 . . . . 0.0 111.261 -178.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -133.71 126.88 31.67 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -173.624 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.0 t -114.1 127.37 71.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 177.74 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.44 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 63.0 m -129.68 150.51 50.97 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 122.983 0.177 . . . . 0.0 111.469 -176.039 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 45.0 mt -121.28 117.29 52.3 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 172.526 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.402 ' NE2' ' HG1' ' A' ' 44' ' ' THR . 6.0 tp-100 -111.39 144.46 40.56 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 104.261 -2.496 . . . . 0.0 104.261 173.185 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.8 104.07 0.07 Allowed 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -170.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 115.77 -23.94 10.58 Favored Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.471 -0.786 . . . . 0.0 113.677 178.304 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . 0.451 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 50.8 m80 -147.77 145.55 28.84 Favored 'General case' 0 CA--C 1.505 -0.786 0 O-C-N 121.559 -0.965 . . . . 0.0 112.204 -177.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.5 tt -93.9 139.01 19.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 105.552 -2.018 . . . . 0.0 105.552 173.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 74.5 m95 -124.02 139.01 54.36 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -174.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.3 pt -102.46 132.22 48.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 173.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.48 124.68 8.1 Favored Glycine 0 N--CA 1.425 -2.053 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -179.691 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -138.55 155.56 48.27 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 178.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -97.99 120.33 38.19 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 176.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.31 161.55 20.4 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -58.41 -14.09 6.9 Favored 'General case' 0 N--CA 1.483 1.212 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.245 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -77.62 -13.56 59.87 Favored 'General case' 0 CA--C 1.548 0.895 0 CA-C-O 121.5 0.667 . . . . 0.0 110.713 177.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 87.64 15.9 60.93 Favored Glycine 0 CA--C 1.497 -1.079 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -176.219 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 39.4 t-20 -97.1 132.82 42.51 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 114.239 -0.98 . . . . 0.0 109.226 -177.573 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 25.9 tpt180 -90.17 99.06 12.15 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 175.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 36.8 t -100.32 142.42 15.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.989 -173.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.441 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 81.5 m-85 -115.23 129.38 56.62 Favored 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 123.081 0.552 . . . . 0.0 110.223 178.23 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.1 t -108.32 133.45 20.56 Favored Pre-proline 0 C--N 1.306 -1.303 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.56 -10.06 24.8 Favored 'Trans proline' 0 C--N 1.364 1.344 0 C-N-CA 123.397 2.731 . . . . 0.0 114.729 -174.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.293 27.2 m 38.19 -67.26 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 N-CA-C 118.026 2.602 . . . . 0.0 118.026 175.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 6.3 ptp85 -147.44 148.81 31.67 Favored 'General case' 0 N--CA 1.445 -0.7 0 C-N-CA 123.239 0.616 . . . . 0.0 109.603 176.078 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.451 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 66.8 m -67.95 133.98 50.0 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 176.386 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.558 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 86.3 m -151.34 103.82 3.03 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 122.886 0.474 . . . . 0.0 110.363 -179.173 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 45.8 mt-30 -88.85 141.14 28.75 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.193 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 139.7 178.04 16.31 Favored Glycine 0 N--CA 1.42 -2.386 0 C-N-CA 119.015 -1.564 . . . . 0.0 113.273 178.449 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 87.0 t -133.31 130.61 21.22 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 179.182 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_exo -43.46 132.51 7.1 Favored 'Trans proline' 0 CA--C 1.548 1.195 0 C-N-CA 123.44 2.76 . . . . 0.0 113.456 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -89.31 -5.98 51.67 Favored 'Cis proline' 0 CA--C 1.541 0.826 0 C-N-CA 123.373 -1.511 . . . . 0.0 114.832 4.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -76.51 100.65 5.34 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-O 122.161 0.981 . . . . 0.0 112.409 -173.588 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 28.7 p-80 -105.43 126.57 52.27 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 113.845 -1.525 . . . . 0.0 111.007 178.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.558 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 60.7 mt -100.6 104.39 30.52 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 174.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -76.97 123.65 6.9 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.564 2.176 . . . . 0.0 113.171 -175.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -108.51 -141.86 9.76 Favored Glycine 0 N--CA 1.424 -2.12 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.586 177.242 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 67.0 t -75.21 122.28 28.57 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 C-N-CA 122.948 0.499 . . . . 0.0 111.996 -176.623 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -93.23 143.36 26.33 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.719 173.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.8 m-90 -106.03 14.61 27.61 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.951 0.881 . . . . 0.0 109.686 177.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.494 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -162.13 177.61 38.26 Favored Glycine 0 N--CA 1.407 -3.251 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.491 -179.426 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 57.5 t -111.52 118.82 58.45 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.192 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 -177.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 41.8 m-85 -78.74 132.77 37.08 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.442 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 53.9 tptt . . . . . 0 N--CA 1.404 -2.767 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 95.1 m95 . . . . . 0 C--O 1.237 0.418 0 CA-C-O 120.965 0.412 . . . . 0.0 110.419 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 8.3 tmtm? -118.44 133.46 55.85 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -81.67 128.74 34.28 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 120.91 0.386 . . . . 0.0 111.723 -176.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -96.67 166.08 11.83 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 176.136 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -51.65 -27.79 12.56 Favored 'General case' 0 N--CA 1.489 1.485 0 C-N-CA 125.184 1.394 . . . . 0.0 113.082 -176.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 69.0 m-85 -87.5 10.11 18.76 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 121.498 0.666 . . . . 0.0 111.535 -175.445 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.54 14.36 82.1 Favored Glycine 0 CA--C 1.5 -0.89 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 178.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.459 ' HG1' ' NE2' ' A' ' 91' ' ' GLN . 6.8 m -96.14 127.7 42.38 Favored 'General case' 0 N--CA 1.409 -2.517 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -177.334 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 71.8 m95 -95.31 120.99 36.5 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.092 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -120.14 148.69 43.32 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.106 -177.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.1 pttm -134.95 151.4 75.45 Favored Pre-proline 0 C--N 1.305 -1.342 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -71.88 132.51 20.1 Favored 'Trans proline' 0 N--CA 1.45 -1.043 0 C-N-CA 121.678 1.585 . . . . 0.0 111.471 175.523 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -159.16 120.61 3.34 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 176.098 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.435 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 3.7 t-20 -107.39 115.73 30.68 Favored 'General case' 0 C--N 1.295 -1.783 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.328 -175.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -160.94 178.63 9.2 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.241 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 17.4 m -116.82 151.98 35.38 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -178.539 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.4 t80 -124.95 127.96 47.86 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 175.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 46.6 t -112.27 112.69 41.57 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.037 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 55.3 t30 -65.72 136.25 56.01 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.2 -179.026 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -119.07 -83.19 0.84 Allowed Glycine 0 N--CA 1.43 -1.739 0 N-CA-C 115.77 1.068 . . . . 0.0 115.77 -170.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -79.07 -23.28 44.31 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 115.365 1.617 . . . . 0.0 115.365 -166.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.79 150.1 23.72 Favored Pre-proline 0 C--N 1.311 -1.102 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.277 -178.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -68.37 131.24 22.82 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.369 2.046 . . . . 0.0 109.739 177.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 51.2 mt -106.81 127.52 62.28 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.828 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -171.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -81.5 138.03 20.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 178.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 50.9 p -110.51 170.11 8.3 Favored 'General case' 0 C--N 1.295 -1.791 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.751 -174.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -117.29 138.12 51.96 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.185 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.7 mt -99.09 125.68 52.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.889 -174.086 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.39 -22.93 3.58 Favored Glycine 0 N--CA 1.448 -0.534 0 N-CA-C 115.772 1.069 . . . . 0.0 115.772 172.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.5 m -152.3 138.1 11.5 Favored Pre-proline 0 C--N 1.297 -1.696 0 CA-C-N 118.074 0.937 . . . . 0.0 110.065 -177.694 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -89.84 120.87 0.95 Allowed 'Trans proline' 0 N--CA 1.44 -1.674 0 C-N-CA 121.64 1.56 . . . . 0.0 111.008 173.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.425 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 93.5 m-85 -168.58 166.24 12.03 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 127.246 2.218 . . . . 0.0 105.021 179.174 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 96.5 mt -82.01 -19.74 39.83 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-O 121.357 0.598 . . . . 0.0 109.994 175.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -111.02 19.69 18.21 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.294 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.425 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -73.38 156.88 88.69 Favored Pre-proline 0 C--O 1.249 1.05 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.573 -178.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -46.97 127.36 12.32 Favored 'Trans proline' 0 C--N 1.365 1.404 0 C-N-CA 123.754 2.969 . . . . 0.0 113.806 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 10.9 p -99.89 172.71 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-N 114.304 -1.316 . . . . 0.0 107.95 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.91 11.55 7.6 Favored Glycine 0 C--N 1.318 -0.469 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -177.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -137.1 121.11 2.25 Favored Glycine 0 N--CA 1.423 -2.228 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 175.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -126.17 141.54 51.89 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 117.519 0.66 . . . . 0.0 109.899 -178.266 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 27.4 tp -101.41 113.61 65.8 Favored Pre-proline 0 N--CA 1.429 -1.48 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.21 166.72 22.32 Favored 'Trans proline' 0 C--O 1.249 1.033 0 C-N-CA 122.272 1.981 . . . . 0.0 113.32 -177.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.15 128.64 36.32 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.225 179.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.99 -5.34 61.47 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.873 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.84 128.55 36.72 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.013 0.435 . . . . 0.0 111.22 -179.199 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 44.3 m -104.08 111.55 24.17 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.593 -179.574 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.6 mm -116.99 130.27 72.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.28 -176.314 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.2 p -99.11 139.34 21.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 174.71 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.435 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 46.2 p90 -135.3 158.16 45.08 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.802 -176.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -128.34 -0.39 5.69 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.589 177.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -129.64 127.8 41.32 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.06 -178.236 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.6 t -123.66 126.94 73.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.507 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 27.2 p -135.84 148.46 48.68 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -174.24 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 68.8 mt -106.03 121.96 59.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.996 178.123 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.459 ' NE2' ' HG1' ' A' ' 44' ' ' THR . 5.9 tp-100 -125.7 144.85 50.43 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 173.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -51.05 107.23 0.16 Allowed 'General case' 0 C--N 1.317 -0.805 0 O-C-N 123.51 0.506 . . . . 0.0 111.535 -177.3 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.7 -41.62 1.52 Allowed Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.117 178.694 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . 0.5 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 69.9 m80 -154.16 166.02 34.42 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 117.294 0.547 . . . . 0.0 110.915 -175.524 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.8 tt -105.26 110.15 30.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 173.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.507 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 45.2 m95 -96.74 142.66 28.5 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.784 -168.825 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.8 pt -100.2 134.22 40.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 174.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -101.96 124.63 8.27 Favored Glycine 0 N--CA 1.424 -2.158 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -149.72 169.92 19.93 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-O 121.018 0.437 . . . . 0.0 109.832 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -104.33 143.13 33.4 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.611 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -94.43 159.32 15.16 Favored 'General case' 0 C--N 1.291 -1.964 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 173.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -54.12 -21.92 9.83 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -179.064 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 11.4 t30 -92.59 7.31 43.87 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-O 121.973 0.892 . . . . 0.0 110.738 -177.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 83.02 13.41 77.53 Favored Glycine 0 C--N 1.321 -0.251 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.677 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 18.7 m120 -83.72 141.05 31.73 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 30.2 tpt180 -89.83 106.27 18.36 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 176.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.3 t -112.6 138.26 42.44 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 C-N-CA 119.895 -0.722 . . . . 0.0 110.512 -173.766 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -117.17 126.8 53.36 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.452 -0.794 . . . . 0.0 110.002 176.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.7 t -109.07 130.63 22.5 Favored Pre-proline 0 C--N 1.304 -1.4 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -68.89 -22.26 36.49 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 122.819 2.346 . . . . 0.0 114.133 -176.423 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.298 34.4 m 49.3 -54.9 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.579 0 N-CA-C 117.771 2.508 . . . . 0.0 117.771 177.045 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -150.77 143.42 24.46 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 123.464 0.706 . . . . 0.0 109.67 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.5 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 69.1 m -71.61 127.87 33.96 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.732 178.443 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.537 ' SG ' ' HA ' ' A' ' 123' ' ' PRO . 94.5 m -149.49 140.51 22.93 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.06 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -125.12 153.99 42.14 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 105.788 -1.93 . . . . 0.0 105.788 178.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.84 -168.6 31.19 Favored Glycine 0 CA--C 1.483 -1.919 0 C-N-CA 118.633 -1.746 . . . . 0.0 112.275 178.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 65.6 t -138.82 121.52 10.63 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 179.134 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_exo -48.03 136.23 23.64 Favored 'Trans proline' 0 C--O 1.238 0.517 0 C-N-CA 123.175 2.583 . . . . 0.0 111.952 -179.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -95.32 25.04 23.18 Favored 'Cis proline' 0 CA--C 1.548 1.193 0 C-N-CA 124.461 -1.058 . . . . 0.0 114.043 3.674 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -106.15 106.02 16.34 Favored 'General case' 0 C--N 1.315 -0.928 0 O-C-N 121.789 -0.57 . . . . 0.0 111.274 -178.383 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 25.2 p-80 -104.17 139.85 38.65 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.175 176.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 44.7 mm -104.02 107.4 56.9 Favored Pre-proline 0 C--N 1.293 -1.852 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . 0.537 ' HA ' ' SG ' ' A' ' 114' ' ' CYS . 86.0 Cg_endo -79.57 147.57 19.94 Favored 'Trans proline' 0 C--O 1.247 0.933 0 C-N-CA 122.623 2.215 . . . . 0.0 113.989 -175.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -131.49 -124.73 2.6 Favored Glycine 0 N--CA 1.428 -1.854 0 CA-C-N 115.415 -0.812 . . . . 0.0 111.266 176.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.0 t -85.62 121.37 37.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -175.424 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.38 151.23 19.55 Favored 'General case' 0 C--O 1.246 0.894 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.158 173.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.5 m-90 -109.1 6.54 25.02 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 179.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -160.82 -171.74 27.18 Favored Glycine 0 N--CA 1.428 -1.899 0 C-N-CA 120.64 -0.79 . . . . 0.0 111.271 -178.153 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 44.0 t -111.7 131.97 61.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -174.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -91.9 137.46 32.34 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 176.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt . . . . . 0 C--N 1.288 -2.078 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.684 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 96.9 m95 . . . . . 0 N--CA 1.442 -0.841 0 CA-C-O 121.551 0.691 . . . . 0.0 111.791 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.6 tmtt? -130.3 140.98 50.63 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -85.84 146.16 26.88 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.396 0.617 . . . . 0.0 112.371 -173.049 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 48.2 t-20 -109.75 153.83 23.78 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 124.988 1.315 . . . . 0.0 107.622 178.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 7.9 tt0 -53.88 -26.5 25.18 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 125.443 1.497 . . . . 0.0 112.48 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -75.3 -7.91 55.23 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.359 0.6 . . . . 0.0 111.63 -179.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.02 -13.32 63.59 Favored Glycine 0 N--CA 1.437 -1.275 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 -178.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 7.3 m -68.63 147.98 51.12 Favored 'General case' 0 N--CA 1.421 -1.879 0 C-N-CA 124.954 1.301 . . . . 0.0 109.073 179.285 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.446 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 64.7 m95 -111.31 142.28 43.74 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 173.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -139.1 156.99 46.75 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-O 121.087 0.47 . . . . 0.0 111.531 -179.084 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -138.48 132.51 16.57 Favored Pre-proline 0 C--N 1.295 -1.779 0 CA-C-N 114.905 -1.043 . . . . 0.0 108.223 174.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.52 121.16 7.9 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 N-CA-C 108.752 -1.288 . . . . 0.0 108.752 173.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -168.03 124.9 1.09 Allowed 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -176.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -93.47 138.91 31.31 Favored 'General case' 0 CA--C 1.483 -1.61 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.341 -176.342 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.467 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -164.01 160.71 22.1 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 175.074 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.45 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 16.1 m -105.6 132.58 51.57 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.378 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -108.15 121.06 44.07 Favored 'General case' 0 N--CA 1.422 -1.825 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 175.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 42.5 t -107.19 119.25 56.49 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.078 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 176.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.408 ' ND2' HG12 ' A' ' 60' ' ' ILE . 46.4 t-20 -68.99 123.21 20.41 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.248 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -143.44 39.85 1.27 Allowed Glycine 0 N--CA 1.417 -2.624 0 C-N-CA 120.098 -1.048 . . . . 0.0 111.937 -176.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 20.7 t-20 -145.55 -66.73 0.31 Allowed 'General case' 0 C--N 1.31 -1.119 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.074 177.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -157.43 161.34 29.41 Favored Pre-proline 0 C--N 1.317 -0.806 0 CA-C-O 118.872 -0.585 . . . . 0.0 109.76 -178.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.24 137.88 81.38 Favored 'Trans proline' 0 C--N 1.357 0.994 0 C-N-CA 122.96 2.44 . . . . 0.0 112.279 -179.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.583 HG21 ' SG ' ' A' ' 109' ' ' CYS . 32.7 mm -106.95 140.55 24.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.996 -174.799 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.27 107.85 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.256 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 172.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 57.7 p -93.72 153.67 18.2 Favored 'General case' 0 C--N 1.294 -1.836 0 CA-C-N 115.067 -0.969 . . . . 0.0 110.37 -176.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -106.44 140.39 39.43 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -177.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.3 mp -105.53 125.14 60.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-O 121.282 0.563 . . . . 0.0 111.672 -175.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.32 -22.78 11.4 Favored Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 115.533 0.973 . . . . 0.0 115.533 172.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 41.9 m -152.91 136.67 10.19 Favored Pre-proline 0 C--N 1.305 -1.337 0 CA-C-N 118.12 0.96 . . . . 0.0 110.385 -178.076 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -90.04 119.61 0.81 Allowed 'Trans proline' 0 N--CA 1.439 -1.718 0 C-N-CA 121.434 1.422 . . . . 0.0 110.986 173.544 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -169.41 175.09 5.66 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 105.151 -2.166 . . . . 0.0 105.151 -179.46 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -88.62 -29.74 19.74 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 172.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -92.32 20.39 6.15 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.784 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -80.56 159.38 69.63 Favored Pre-proline 0 C--N 1.309 -1.161 0 CA-C-O 119.644 -0.217 . . . . 0.0 110.733 -176.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -57.12 144.06 91.29 Favored 'Trans proline' 0 C--N 1.358 1.063 0 C-N-CA 123.405 2.737 . . . . 0.0 113.989 -177.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.7 m -101.81 174.53 1.04 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.062 0 C-N-CA 124.437 1.095 . . . . 0.0 110.458 -179.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.8 26.91 2.43 Favored Glycine 0 C--N 1.306 -1.118 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -179.255 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.88 109.63 0.59 Allowed Glycine 0 N--CA 1.423 -2.185 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -108.04 126.04 52.26 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-O 120.856 0.36 . . . . 0.0 110.102 178.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.44 ' HB3' ' HB ' ' A' ' 60' ' ' ILE . 33.1 tp -107.56 109.22 62.42 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 107.043 -1.466 . . . . 0.0 107.043 175.323 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -71.08 159.94 50.74 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.191 1.928 . . . . 0.0 112.195 -177.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.78 133.52 46.62 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 177.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.5 -10.52 56.31 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 121.046 -0.597 . . . . 0.0 111.971 -178.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.09 138.24 51.83 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.904 0.383 . . . . 0.0 110.682 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.7 m -117.89 110.17 17.42 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.259 -179.191 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.1 mm -120.89 120.3 61.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 CA-C-O 120.732 0.301 . . . . 0.0 110.62 -176.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 6.6 p -91.67 111.37 23.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-O 121.649 0.738 . . . . 0.0 109.404 175.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.467 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 46.6 p90 -97.12 168.6 10.35 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.963 -174.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -117.68 -17.59 9.87 Favored 'General case' 0 C--N 1.316 -0.857 0 O-C-N 123.858 0.724 . . . . 0.0 112.255 -176.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -135.66 133.92 38.66 Favored 'General case' 0 N--CA 1.432 -1.339 0 C-N-CA 119.891 -0.723 . . . . 0.0 110.905 -173.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.7 t -105.55 127.1 60.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 35.1 m -127.35 148.44 50.26 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 117.742 0.246 . . . . 0.0 110.927 -176.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 39.9 mt -119.14 120.18 63.09 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 CA-C-O 121.039 0.447 . . . . 0.0 109.964 172.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.487 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.2 tp-100 -122.51 118.58 28.62 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 103.514 -2.773 . . . . 0.0 103.514 172.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.45 107.3 0.12 Allowed 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 113.728 1.01 . . . . 0.0 113.728 -165.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 137.41 -31.4 2.52 Favored Glycine 0 N--CA 1.435 -1.391 0 CA-C-N 114.417 -1.265 . . . . 0.0 110.533 -179.252 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 73.0 m80 -151.13 163.97 37.57 Favored 'General case' 0 CA--C 1.483 -1.633 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.2 tt -103.9 133.92 46.57 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.742 0 N-CA-C 104.504 -2.406 . . . . 0.0 104.504 170.009 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.487 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 68.3 m95 -115.59 140.07 49.52 Favored 'General case' 0 C--N 1.27 -2.86 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -172.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.6 pt -100.98 130.02 51.0 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.315 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -101.27 120.4 6.86 Favored Glycine 0 N--CA 1.419 -2.464 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.163 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 44.4 p90 -142.83 144.47 32.54 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -101.93 126.13 48.77 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 175.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -93.45 167.84 11.45 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.238 -176.618 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 31.6 p90 -63.19 -2.21 1.29 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 113.859 1.059 . . . . 0.0 113.859 -178.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -88.09 -6.7 57.77 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 175.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 90.72 -0.47 76.94 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 111.808 -0.517 . . . . 0.0 111.808 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 21.2 p30 -96.36 147.67 23.57 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -177.046 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 9.7 tpp85 -92.13 111.56 23.16 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 175.128 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.5 t -111.99 143.58 21.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 -176.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.415 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 95.4 m-85 -119.33 129.28 54.78 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.027 0.441 . . . . 0.0 110.915 178.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . 0.583 ' SG ' HG21 ' A' ' 60' ' ' ILE . 43.1 t -110.56 127.97 26.1 Favored Pre-proline 0 C--N 1.302 -1.497 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.259 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -71.57 -5.63 17.46 Favored 'Trans proline' 0 C--N 1.359 1.123 0 C-N-CA 123.462 2.775 . . . . 0.0 115.243 -175.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.304 30.1 m 37.33 -59.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.515 2.775 0 N-CA-C 118.881 2.919 . . . . 0.0 118.881 175.26 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . 0.456 ' CZ ' ' HB3' ' A' ' 126' ' ' ALA . 7.8 ptp180 -150.72 156.36 41.15 Favored 'General case' 0 C--O 1.248 0.994 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.485 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.2 m -67.27 132.63 48.11 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 176.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.41 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 53.5 m -152.09 110.52 3.75 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.803 0.811 . . . . 0.0 111.449 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -102.93 143.72 32.14 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 106.119 -1.808 . . . . 0.0 106.119 178.144 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 147.71 -170.85 28.37 Favored Glycine 0 CA--C 1.489 -1.566 0 C-N-CA 118.207 -1.949 . . . . 0.0 113.488 178.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 84.7 t -134.67 123.27 16.11 Favored Pre-proline 0 C--N 1.304 -1.386 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 179.221 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.446 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 96.0 Cg_exo -45.86 135.53 13.76 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.76 2.974 . . . . 0.0 113.304 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -95.1 17.82 37.08 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 C-N-CA 124.283 -1.132 . . . . 0.0 113.493 1.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -94.8 101.91 13.75 Favored 'General case' 0 C--N 1.312 -1.028 0 C-N-CA 120.491 -0.484 . . . . 0.0 110.405 -177.625 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 10.9 p-80 -104.63 138.99 40.14 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.902 177.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 50.6 mm -102.31 99.54 13.09 Favored Pre-proline 0 C--N 1.301 -1.502 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 172.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -84.52 147.61 11.14 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 122.82 2.347 . . . . 0.0 113.989 -174.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.07 -145.02 6.61 Favored Glycine 0 N--CA 1.419 -2.497 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.28 175.414 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.5 t -60.67 122.72 11.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 C-N-CA 123.727 0.811 . . . . 0.0 111.868 -177.26 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.456 ' HB3' ' CZ ' ' A' ' 112' ' ' ARG . . . -94.22 145.06 24.99 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.501 174.608 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.8 m-90 -105.59 18.69 21.79 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.341 0.591 . . . . 0.0 110.907 177.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -166.99 -165.89 25.16 Favored Glycine 0 N--CA 1.427 -1.933 0 C-N-CA 119.788 -1.196 . . . . 0.0 112.791 -179.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 48.7 t -124.03 139.12 51.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -178.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -105.09 134.41 48.24 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 177.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.298 -1.667 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 98.7 m95 . . . . . 0 CA--C 1.502 -0.904 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -140.41 145.53 37.15 Favored 'General case' 0 C--N 1.281 -2.406 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 179.571 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 24.5 ttmm -84.7 109.25 17.88 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-O 121.182 0.515 . . . . 0.0 109.83 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . 0.453 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 44.2 t30 -78.35 168.5 19.73 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.655 -179.44 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -58.28 -12.11 3.37 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -174.524 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -91.84 2.26 56.63 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-O 121.195 0.521 . . . . 0.0 109.87 179.249 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.07 -12.51 57.84 Favored Glycine 0 C--N 1.33 0.205 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -178.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 14.6 m -76.56 140.57 41.14 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 124.638 1.175 . . . . 0.0 110.592 -176.316 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -90.8 131.97 36.14 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 175.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.453 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 11.0 p90 -136.88 159.43 41.89 Favored 'General case' 0 C--N 1.292 -1.915 0 C-N-CA 120.006 -0.677 . . . . 0.0 109.733 -179.541 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.7 pttm -155.09 141.33 13.04 Favored Pre-proline 0 N--CA 1.431 -1.394 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 170.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -71.23 122.46 8.73 Favored 'Trans proline' 0 C--O 1.247 0.941 0 C-N-CA 121.873 1.715 . . . . 0.0 110.593 175.517 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -154.71 120.95 5.3 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 -178.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.533 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 7.6 t30 -104.93 117.68 34.64 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.625 -172.747 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.467 ' HB2' ' CZ ' ' A' ' 85' ' ' TYR . . . -151.69 173.57 14.54 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 179.674 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 31.1 m -113.58 129.78 56.5 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -176.125 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -107.98 131.69 54.29 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 176.341 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 52.4 t -113.94 112.89 42.14 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 175.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -71.19 139.87 50.3 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -76.89 -117.8 0.16 Allowed Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 114.865 0.706 . . . . 0.0 114.865 -173.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -109.98 10.49 24.23 Favored 'General case' 0 C--N 1.311 -1.08 0 O-C-N 122.303 -0.528 . . . . 0.0 112.016 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -131.38 138.53 32.97 Favored Pre-proline 0 C--N 1.299 -1.609 0 C-N-CA 120.805 -0.358 . . . . 0.0 110.286 -175.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -69.7 141.43 45.45 Favored 'Trans proline' 0 C--O 1.242 0.695 0 C-N-CA 121.898 1.732 . . . . 0.0 109.822 174.344 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 64.4 mt -121.04 125.15 73.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -178.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 29.1 m -80.97 140.05 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.172 0 CA-C-O 121.803 0.811 . . . . 0.0 109.19 175.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 37.3 p -124.24 164.16 20.13 Favored 'General case' 0 C--N 1.272 -2.796 0 CA-C-N 115.095 -0.957 . . . . 0.0 110.814 -171.412 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -107.81 143.58 36.18 Favored 'General case' 0 C--N 1.317 -0.804 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -177.087 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.5 mt -106.09 130.21 58.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-O 121.229 0.538 . . . . 0.0 112.128 -174.247 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.48 -23.05 5.8 Favored Glycine 0 CA--C 1.521 0.417 0 N-CA-C 116.207 1.243 . . . . 0.0 116.207 171.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 52.1 m -156.94 142.28 12.51 Favored Pre-proline 0 C--N 1.308 -1.202 0 CA-C-N 118.448 1.124 . . . . 0.0 110.077 179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -89.95 119.8 0.84 Allowed 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 121.581 1.521 . . . . 0.0 111.856 175.159 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.433 ' HA ' ' HG2' ' A' ' 91' ' ' GLN . 91.7 m-85 -168.78 164.18 11.91 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 104.764 -2.31 . . . . 0.0 104.764 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 81.0 mt -85.79 -17.84 34.65 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 173.297 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -95.38 -0.47 52.56 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.921 178.402 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -68.83 157.7 88.08 Favored Pre-proline 0 N--CA 1.472 0.654 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.256 -176.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -55.71 122.18 11.27 Favored 'Trans proline' 0 C--N 1.365 1.404 0 C-N-CA 122.951 2.434 . . . . 0.0 112.749 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.95 173.38 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 179.094 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.78 -3.37 13.29 Favored Glycine 0 C--N 1.308 -1.015 0 C-N-CA 120.319 -0.943 . . . . 0.0 111.565 -178.74 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.94 127.09 9.14 Favored Glycine 0 N--CA 1.432 -1.609 0 N-CA-C 107.932 -2.067 . . . . 0.0 107.932 172.059 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -116.82 140.6 49.25 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 118.292 1.046 . . . . 0.0 110.582 -177.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 48.6 tp -114.19 112.5 46.79 Favored Pre-proline 0 C--N 1.307 -1.273 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 177.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.41 164.3 34.72 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 122.344 2.03 . . . . 0.0 113.06 -178.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.86 139.79 45.28 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.471 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.98 -0.59 86.32 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 121.314 -0.47 . . . . 0.0 112.396 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -72.76 126.26 29.48 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 121.099 0.476 . . . . 0.0 110.865 -178.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 53.6 m -99.7 115.76 30.24 Favored 'General case' 0 N--CA 1.425 -1.677 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.018 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.4 mm -126.05 128.84 72.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 110.256 -0.275 . . . . 0.0 110.256 -175.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.6 p -93.46 123.3 45.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 175.15 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.533 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 40.9 p90 -107.37 145.23 33.16 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.899 -178.666 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -111.93 -15.75 13.26 Favored 'General case' 0 C--N 1.31 -1.143 0 O-C-N 124.002 0.814 . . . . 0.0 112.494 -175.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -136.58 138.51 41.3 Favored 'General case' 0 N--CA 1.437 -1.09 0 C-N-CA 120.21 -0.596 . . . . 0.0 109.758 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 61.5 t -114.84 132.02 65.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 69.6 m -127.47 135.32 50.24 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 120.743 0.306 . . . . 0.0 110.924 -177.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 65.6 mt -103.66 116.88 48.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 CA-C-O 121.296 0.569 . . . . 0.0 110.121 177.053 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.543 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 7.5 tp-100 -124.96 118.96 27.42 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 103.981 -2.6 . . . . 0.0 103.981 175.806 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.14 106.19 0.1 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 -167.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 138.78 -41.17 1.38 Allowed Glycine 0 N--CA 1.421 -2.333 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.798 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 57.3 m80 -147.2 154.77 41.44 Favored 'General case' 0 CA--C 1.494 -1.181 0 O-C-N 122.142 -0.622 . . . . 0.0 110.206 -178.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.9 tt -96.98 125.77 49.9 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 175.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.543 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 68.2 m95 -105.03 133.97 48.91 Favored 'General case' 0 C--N 1.274 -2.683 0 CA-C-O 121.178 0.513 . . . . 0.0 110.355 -173.407 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.456 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 43.8 pt -100.12 120.84 50.1 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.323 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 175.486 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -94.77 114.15 4.76 Favored Glycine 0 N--CA 1.411 -2.97 0 N-CA-C 109.326 -1.509 . . . . 0.0 109.326 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -132.2 154.16 49.85 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -177.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -89.28 114.96 26.39 Favored 'General case' 0 C--N 1.272 -2.77 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 174.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.23 165.35 24.01 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-O 121.114 0.483 . . . . 0.0 110.846 -176.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.6 p90 -69.19 -2.79 11.33 Favored 'General case' 0 C--N 1.312 -1.034 0 C-N-CA 123.9 0.88 . . . . 0.0 112.162 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -95.45 -7.0 39.47 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.321 177.344 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 96.51 -7.8 66.14 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.907 -0.588 . . . . 0.0 113.665 176.062 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 15.3 p-10 -96.69 151.12 19.93 Favored 'General case' 0 C--N 1.296 -1.72 0 C-N-CA 122.972 0.509 . . . . 0.0 112.039 -178.244 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 14.5 tpp180 -84.29 108.47 17.17 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.067 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 25.8 t -110.94 146.62 15.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.022 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -176.525 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.456 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 88.2 m-85 -117.05 123.19 46.24 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 50.8 t -104.67 132.2 21.14 Favored Pre-proline 0 C--N 1.303 -1.424 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -69.84 -17.07 37.44 Favored 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 123.051 2.501 . . . . 0.0 114.372 -177.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.299 33.2 m 40.91 -58.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.52 3.032 0 N-CA-C 118.815 2.894 . . . . 0.0 118.815 175.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 33.3 ptt180 -153.96 150.6 28.49 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 123.577 0.751 . . . . 0.0 109.009 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 17.8 m -66.66 139.05 57.84 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.742 179.042 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.585 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 92.1 m -154.65 127.03 7.89 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 123.009 0.524 . . . . 0.0 111.17 179.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -125.83 122.49 36.3 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 177.655 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 168.84 175.03 37.96 Favored Glycine 0 N--CA 1.416 -2.696 0 C-N-CA 119.932 -1.128 . . . . 0.0 111.897 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 60.2 t -129.17 128.32 23.29 Favored Pre-proline 0 C--N 1.288 -2.076 0 N-CA-C 105.248 -2.13 . . . . 0.0 105.248 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -43.26 137.53 5.11 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 123.71 2.94 . . . . 0.0 113.027 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -81.88 -14.87 33.76 Favored 'Cis proline' 0 CA--C 1.553 1.467 0 C-N-CA 123.331 -1.529 . . . . 0.0 114.543 3.052 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -79.41 100.33 7.6 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.768 0.794 . . . . 0.0 112.952 -171.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 38.9 p-80 -106.99 112.73 25.83 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 114.869 -1.059 . . . . 0.0 111.164 175.628 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.585 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 49.4 mt -91.94 113.51 59.16 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 110.607 -0.146 . . . . 0.0 110.607 -178.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -84.48 164.75 12.54 Favored 'Trans proline' 0 C--O 1.246 0.918 0 C-N-CA 123.029 2.486 . . . . 0.0 113.36 -178.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.92 -130.96 2.92 Favored Glycine 0 N--CA 1.434 -1.473 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 176.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 80.7 t -73.81 122.3 26.62 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 C-N-CA 122.387 0.275 . . . . 0.0 111.287 -178.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.49 147.46 23.23 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.281 176.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.5 m0 -107.57 11.4 28.69 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.923 0.392 . . . . 0.0 111.792 179.213 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.66 -168.38 23.47 Favored Glycine 0 N--CA 1.436 -1.365 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.616 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 27.1 t -111.88 139.98 33.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -178.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 -118.32 123.16 44.67 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.426 0.155 . . . . 0.0 111.341 -175.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.1 pttm . . . . . 0 N--CA 1.433 -1.291 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 171.932 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.6 m95 . . . . . 0 N--CA 1.445 -0.707 0 CA-C-O 120.902 0.382 . . . . 0.0 110.956 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -113.64 156.14 24.23 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 175.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -101.4 126.2 48.14 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.559 -178.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 36.6 t-20 -89.39 164.57 14.82 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 -177.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -64.91 -15.14 61.67 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.309 1.043 . . . . 0.0 111.213 -176.164 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 46.0 m-85 -74.66 -18.02 60.6 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.916 177.4 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.12 -8.13 59.01 Favored Glycine 0 CA--C 1.507 -0.453 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -175.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.443 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 11.2 m -80.67 138.84 36.41 Favored 'General case' 0 N--CA 1.427 -1.611 0 C-N-CA 124.724 1.21 . . . . 0.0 110.703 -178.072 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.405 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 65.2 m95 -93.44 139.05 31.14 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 174.463 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 37.0 p90 -142.47 151.37 41.64 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 120.691 -0.403 . . . . 0.0 111.241 -178.455 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 pttm -144.18 151.48 51.91 Favored Pre-proline 0 C--O 1.25 1.081 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 173.222 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -73.5 122.12 7.64 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 121.952 1.768 . . . . 0.0 110.548 175.494 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -156.57 121.6 4.64 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.479 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 20.5 t-20 -101.55 115.71 31.12 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.146 -176.005 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.84 176.49 10.68 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.5 m -118.47 138.36 52.55 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 121.192 0.52 . . . . 0.0 111.978 -175.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 80.5 t80 -115.63 123.17 47.72 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 175.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 45.1 t -104.87 110.86 32.13 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 177.204 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.572 ' OD1' ' HA ' ' A' ' 79' ' ' ALA . 22.6 t-20 -66.15 128.09 34.72 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.318 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -136.5 -11.28 1.16 Allowed Glycine 0 N--CA 1.441 -0.993 0 C-N-CA 118.997 -1.573 . . . . 0.0 114.71 -176.787 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.487 ' OD1' ' HG3' ' A' ' 58' ' ' GLN . 15.5 t-20 -95.26 -74.51 0.55 Allowed 'General case' 0 C--N 1.319 -0.753 0 C-N-CA 119.073 -1.051 . . . . 0.0 110.876 -178.051 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.487 ' HG3' ' OD1' ' A' ' 57' ' ' ASN . 0.0 OUTLIER -141.14 167.4 17.44 Favored Pre-proline 0 C--N 1.305 -1.329 0 CA-C-O 118.948 -0.549 . . . . 0.0 110.471 -179.199 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -62.35 130.33 29.9 Favored 'Trans proline' 0 C--N 1.356 0.951 0 C-N-CA 121.824 1.683 . . . . 0.0 109.264 173.339 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 58.9 mt -107.13 125.03 63.3 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 C-N-CA 120.323 -0.551 . . . . 0.0 109.708 -173.641 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.7 p -82.66 119.4 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.83 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 176.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 75.6 p -95.86 178.96 5.26 Favored 'General case' 0 C--N 1.285 -2.209 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.131 -172.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.436 ' HD2' ' O ' ' A' ' 71' ' ' ALA . 82.2 mmt-85 -118.35 139.93 50.61 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 175.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 67.4 mt -99.13 129.84 48.96 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 CA-C-O 121.451 0.643 . . . . 0.0 111.895 -175.584 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 77.11 -22.51 2.41 Favored Glycine 0 C--N 1.318 -0.426 0 N-CA-C 116.023 1.169 . . . . 0.0 116.023 173.028 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 16.5 m -147.22 138.24 13.0 Favored Pre-proline 0 C--N 1.303 -1.44 0 CA-C-N 117.981 0.89 . . . . 0.0 109.941 -176.324 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -89.73 118.62 0.79 Allowed 'Trans proline' 0 N--CA 1.433 -2.062 0 C-N-CA 120.776 0.984 . . . . 0.0 110.006 171.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.424 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 68.9 m-85 -169.06 178.35 4.49 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 104.27 -2.492 . . . . 0.0 104.27 -179.195 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -89.0 -40.12 13.22 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 174.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -96.84 25.46 5.26 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 121.942 0.877 . . . . 0.0 110.524 -177.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.436 ' O ' ' HD2' ' A' ' 63' ' ' ARG . . . -75.61 159.74 80.83 Favored Pre-proline 0 C--N 1.307 -1.254 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.391 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_exo -47.4 123.03 7.36 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 122.98 2.454 . . . . 0.0 113.482 -179.002 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 6.4 t -98.52 172.6 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 -178.108 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.6 3.48 14.16 Favored Glycine 0 C--N 1.312 -0.77 0 C-N-CA 120.057 -1.068 . . . . 0.0 112.227 -179.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -115.51 111.77 2.52 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 175.607 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 38.6 t30 -107.49 130.13 54.88 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 117.318 0.559 . . . . 0.0 109.716 -178.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 46.8 tp -95.56 112.28 58.41 Favored Pre-proline 0 N--CA 1.431 -1.385 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 177.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -61.87 152.1 76.89 Favored 'Trans proline' 0 C--O 1.243 0.761 0 C-N-CA 122.471 2.114 . . . . 0.0 112.379 -177.119 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . 0.572 ' HA ' ' OD1' ' A' ' 55' ' ' ASN . . . -68.18 134.52 50.62 Favored 'General case' 0 N--CA 1.436 -1.145 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.332 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.72 7.96 65.99 Favored Glycine 0 N--CA 1.436 -1.365 0 CA-C-N 115.417 -0.81 . . . . 0.0 112.623 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.33 132.75 37.55 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.116 0.484 . . . . 0.0 111.126 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 26.2 m -102.34 112.63 25.42 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 40.2 mm -115.65 121.8 68.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.836 -176.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.2 p -87.9 123.51 40.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 172.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.479 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 39.2 p90 -108.88 142.41 39.52 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -178.618 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -115.9 -10.96 11.58 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.719 0.771 . . . . 0.0 110.915 -174.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -131.65 134.42 45.95 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 50.3 t -117.87 133.11 65.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.503 ' SG ' ' HE2' ' A' ' 108' ' ' TYR . 67.1 m -132.02 140.4 48.9 Favored 'General case' 0 C--N 1.312 -1.051 0 O-C-N 123.317 0.386 . . . . 0.0 111.446 -177.403 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 52.0 mt -107.69 112.57 40.69 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.906 -0.496 . . . . 0.0 109.745 174.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.578 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -118.64 120.37 37.24 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 174.397 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.61 109.63 0.26 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 113.48 0.919 . . . . 0.0 113.48 -165.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 132.44 -34.82 2.44 Favored Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.27 -1.332 . . . . 0.0 110.793 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 68.5 m80 -148.8 159.33 44.25 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.7 tt -102.09 119.03 49.81 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 172.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.578 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 61.7 m95 -99.81 134.73 42.28 Favored 'General case' 0 C--N 1.276 -2.596 0 CA-C-O 121.186 0.517 . . . . 0.0 110.581 -171.445 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.471 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.0 pt -100.22 131.92 46.8 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.131 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.847 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.15 127.04 9.05 Favored Glycine 0 N--CA 1.425 -2.099 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -178.078 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 27.4 p90 -151.36 166.64 30.39 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 120.976 0.417 . . . . 0.0 109.975 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -118.84 130.39 55.74 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.331 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -96.17 147.78 23.39 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.046 -178.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 29.8 p90 -46.96 -21.52 0.23 Allowed 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 126.246 1.818 . . . . 0.0 115.158 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -89.16 3.99 50.03 Favored 'General case' 0 CA--C 1.561 1.398 0 CA-C-O 121.665 0.745 . . . . 0.0 111.053 -177.579 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 91.59 16.92 51.13 Favored Glycine 0 CA--C 1.502 -0.748 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.135 177.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -96.06 124.08 39.93 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 120.991 0.424 . . . . 0.0 111.35 -176.322 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 30.3 tpt180 -82.91 109.09 16.73 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 105.127 -2.175 . . . . 0.0 105.127 172.397 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 20.1 t -118.81 140.19 43.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 C-N-CA 119.449 -0.901 . . . . 0.0 112.029 -171.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.503 ' HE2' ' SG ' ' A' ' 89' ' ' CYS . 66.8 m-85 -122.58 124.14 42.82 Favored 'General case' 0 N--CA 1.435 -1.219 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.205 174.664 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . 0.402 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 48.7 t -108.83 132.66 21.03 Favored Pre-proline 0 C--N 1.304 -1.372 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.358 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.74 -21.16 33.96 Favored 'Trans proline' 0 C--N 1.358 1.064 0 C-N-CA 123.092 2.528 . . . . 0.0 114.214 -176.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.317 33.2 m 45.85 -55.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.51 2.529 0 N-CA-C 118.67 2.841 . . . . 0.0 118.67 176.193 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . 0.406 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 34.2 ptt180 -153.6 149.11 27.26 Favored 'General case' 0 N--CA 1.441 -0.914 0 C-N-CA 122.966 0.507 . . . . 0.0 110.639 177.592 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.4 m -63.0 127.98 33.76 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 177.324 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.642 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 88.3 m -151.94 117.32 5.31 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.592 0.711 . . . . 0.0 111.363 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -114.35 144.84 42.62 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.121 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 141.41 -169.49 25.08 Favored Glycine 0 N--CA 1.429 -1.83 0 C-N-CA 119.769 -1.205 . . . . 0.0 111.454 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 15.4 m -136.68 142.23 38.23 Favored Pre-proline 0 C--N 1.298 -1.656 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_exo -43.92 127.46 6.61 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 123.784 2.989 . . . . 0.0 113.207 -178.235 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -96.21 -9.97 19.97 Favored 'Cis proline' 0 C--O 1.245 0.828 0 C-N-CA 124.195 -1.169 . . . . 0.0 114.12 1.384 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 57.9 t30 -72.67 100.86 2.91 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 121.998 0.904 . . . . 0.0 111.557 -172.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 33.4 p-80 -106.66 125.15 50.63 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.304 -1.316 . . . . 0.0 110.699 177.086 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.642 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 49.8 mm -85.66 107.96 14.62 Favored Pre-proline 0 C--N 1.306 -1.286 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 176.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_endo -84.89 123.8 2.86 Favored 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 122.723 2.282 . . . . 0.0 112.967 -177.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -98.74 -110.25 3.0 Favored Glycine 0 N--CA 1.433 -1.543 0 N-CA-C 111.374 -0.69 . . . . 0.0 111.374 177.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 48.1 t -94.79 122.38 46.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 -177.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.406 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.27 136.5 34.49 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.272 175.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.6 m-90 -102.04 16.07 27.15 Favored 'General case' 0 C--O 1.251 1.162 0 CA-C-O 121.581 0.705 . . . . 0.0 111.467 179.48 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -171.29 -171.57 36.6 Favored Glycine 0 N--CA 1.43 -1.74 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.064 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 59.1 t -111.51 125.41 68.83 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 123.508 0.723 . . . . 0.0 109.167 -177.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -93.58 135.12 35.17 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.015 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 96.0 mttt . . . . . 0 C--N 1.293 -1.856 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 179.067 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . 0.507 ' CZ2' ' HD2' ' A' ' 47' ' ' LYS . 94.1 m95 . . . . . 0 N--CA 1.433 -1.293 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -125.51 140.73 52.51 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 -179.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 59.8 tttp -89.63 118.04 28.95 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.192 0.52 . . . . 0.0 110.596 -177.509 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -89.85 152.24 21.36 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 175.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.7 tp60 -61.04 -13.68 18.3 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 123.745 0.818 . . . . 0.0 113.094 -173.675 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 62.9 m-85 -74.84 -9.05 58.18 Favored 'General case' 0 CA--C 1.542 0.649 0 CA-C-O 121.247 0.546 . . . . 0.0 109.838 176.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.77 20.17 54.47 Favored Glycine 0 CA--C 1.496 -1.116 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -176.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.447 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 22.1 m -105.81 129.08 54.06 Favored 'General case' 0 N--CA 1.408 -2.542 0 CA-C-N 114.13 -1.035 . . . . 0.0 108.679 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 81.0 m95 -92.48 132.07 37.1 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 175.344 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 31.8 p90 -130.69 147.74 52.4 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.991 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.507 ' HD2' ' CZ2' ' A' ' 37' ' ' TRP . 20.7 ptmt -125.1 141.99 40.07 Favored Pre-proline 0 C--N 1.294 -1.844 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.57 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -73.22 120.83 6.78 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 N-CA-C 108.699 -1.308 . . . . 0.0 108.699 172.403 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -168.12 121.53 0.9 Allowed 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 -178.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.436 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 19.8 t-20 -104.79 128.55 52.98 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.929 -173.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.528 ' HB2' ' CZ ' ' A' ' 85' ' ' TYR . . . -156.59 170.15 23.04 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 177.525 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 2.4 m -112.92 122.25 47.08 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.668 -174.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -95.82 124.24 39.75 Favored 'General case' 0 C--N 1.312 -1.062 0 O-C-N 121.969 -0.457 . . . . 0.0 110.582 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 38.2 t -110.56 112.59 41.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 176.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -68.34 137.03 54.29 Favored 'General case' 0 C--O 1.248 0.995 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -124.73 -57.63 0.17 Allowed Glycine 0 N--CA 1.424 -2.135 0 C-N-CA 118.934 -1.603 . . . . 0.0 115.654 -170.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -83.02 -53.46 5.8 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -170.058 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -142.62 154.68 63.32 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 119.942 -0.703 . . . . 0.0 111.082 -174.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -60.03 132.75 46.28 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 122.707 2.271 . . . . 0.0 110.213 176.251 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 41.8 mt -108.19 120.83 60.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -174.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.5 p -79.38 115.09 21.12 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.136 0 CA-C-O 121.753 0.787 . . . . 0.0 109.471 175.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 56.3 p -89.49 178.87 6.19 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 115.191 -0.913 . . . . 0.0 111.657 -173.104 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 84.6 mmt-85 -117.52 137.67 52.41 Favored 'General case' 0 N--CA 1.439 -0.978 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 176.203 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 72.3 mt -95.29 123.7 47.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.139 -176.247 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.87 -22.55 3.42 Favored Glycine 0 C--N 1.317 -0.505 0 N-CA-C 116.205 1.242 . . . . 0.0 116.205 171.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.3 m -152.32 140.61 13.54 Favored Pre-proline 0 C--N 1.306 -1.311 0 CA-C-N 118.322 1.061 . . . . 0.0 110.455 -177.208 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -90.05 118.89 0.76 Allowed 'Trans proline' 0 N--CA 1.433 -2.05 0 C-N-CA 121.03 1.154 . . . . 0.0 110.662 172.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.413 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 97.0 m-85 -169.04 166.99 10.86 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 104.134 -2.543 . . . . 0.0 104.134 179.076 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -79.22 -36.14 40.54 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 175.336 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.5 p-10 -96.06 19.99 10.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.336 -177.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.413 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -74.96 156.25 86.28 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 176.089 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -48.07 123.33 8.58 Favored 'Trans proline' 0 C--O 1.255 1.345 0 C-N-CA 123.385 2.723 . . . . 0.0 113.828 179.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 34.2 m -94.29 174.43 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.609 -1.178 . . . . 0.0 109.949 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.43 11.34 7.38 Favored Glycine 0 N--CA 1.439 -1.132 0 C-N-CA 120.17 -1.014 . . . . 0.0 112.909 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -119.78 130.13 8.31 Favored Glycine 0 N--CA 1.436 -1.324 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 174.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -128.36 130.16 47.31 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 118.024 0.912 . . . . 0.0 110.439 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 46.1 tp -101.16 110.31 60.95 Favored Pre-proline 0 C--N 1.3 -1.552 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.074 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -69.13 166.91 25.2 Favored 'Trans proline' 0 C--O 1.244 0.822 0 C-N-CA 122.57 2.18 . . . . 0.0 112.481 -177.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.43 141.08 43.24 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.468 -179.215 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.53 -23.78 32.3 Favored Glycine 0 C--O 1.244 0.761 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.05 128.22 35.13 Favored 'General case' 0 C--O 1.244 0.78 0 CA-C-O 121.13 0.49 . . . . 0.0 110.453 -178.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 39.9 m -111.88 121.58 45.44 Favored 'General case' 0 N--CA 1.416 -2.151 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.437 -178.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.1 mm -125.87 128.55 72.12 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 -178.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.9 p -83.92 133.2 29.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 175.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.528 ' CZ ' ' HB2' ' A' ' 51' ' ' ALA . 50.6 p90 -116.09 137.66 51.93 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.01 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -111.36 -10.5 14.22 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 122.232 1.015 . . . . 0.0 109.568 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -125.71 120.05 29.62 Favored 'General case' 0 N--CA 1.423 -1.804 0 CA-C-N 114.454 -1.248 . . . . 0.0 109.119 -176.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 45.0 t -106.58 130.51 58.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.447 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 62.1 m -129.08 153.18 47.89 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 120.882 0.372 . . . . 0.0 111.97 -174.41 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.3 mt -124.91 117.04 49.01 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 171.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.558 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -124.13 126.8 46.8 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 104.469 -2.419 . . . . 0.0 104.469 174.18 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.2 113.2 0.75 Allowed 'General case' 0 C--N 1.321 -0.645 0 O-C-N 124.789 1.306 . . . . 0.0 112.586 -168.704 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 131.68 -35.8 2.34 Favored Glycine 0 N--CA 1.432 -1.602 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.66 -176.606 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -154.19 168.41 26.63 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 122.418 -0.46 . . . . 0.0 110.257 -178.07 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.403 HG21 ' O ' ' A' ' 112' ' ' ARG . 15.4 tt -98.36 140.81 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 N-CA-C 103.724 -2.695 . . . . 0.0 103.724 168.159 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . 0.558 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 49.8 m95 -125.15 147.83 48.85 Favored 'General case' 0 C--N 1.28 -2.447 0 CA-C-N 118.117 0.417 . . . . 0.0 110.308 -172.155 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 49.9 pt -110.49 131.31 61.93 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.022 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 172.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.55 121.1 7.05 Favored Glycine 0 N--CA 1.424 -2.113 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.324 -178.575 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -140.29 164.3 30.45 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-O 121.074 0.464 . . . . 0.0 110.688 178.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 31.0 t30 -120.74 127.02 51.6 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 178.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.55 172.32 11.73 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.064 0.459 . . . . 0.0 111.717 -176.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -60.47 -25.9 66.38 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.199 1.0 . . . . 0.0 112.603 -176.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 26.5 p-10 -92.78 -0.6 57.23 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.253 -177.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 91.67 9.62 62.59 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.481 178.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -78.55 122.3 25.71 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 11.2 tpt85 -88.18 98.29 11.48 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 16.5 t -103.86 139.91 23.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 CA-C-O 121.126 0.488 . . . . 0.0 111.066 -171.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -118.34 122.27 42.45 Favored 'General case' 0 N--CA 1.432 -1.367 0 CA-C-N 115.407 -0.815 . . . . 0.0 108.991 174.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.2 t -104.06 129.77 24.6 Favored Pre-proline 0 C--N 1.301 -1.541 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -178.511 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.98 -2.83 12.82 Favored 'Trans proline' 0 C--N 1.361 1.206 0 C-N-CA 123.329 2.686 . . . . 0.0 114.852 -177.195 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 28.3 m 29.59 -52.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.522 3.147 0 N-CA-C 120.116 3.376 . . . . 0.0 120.116 172.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . 0.403 ' O ' HG21 ' A' ' 95' ' ' ILE . 59.5 ttt180 -156.8 141.65 17.0 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 123.828 0.851 . . . . 0.0 109.23 -176.183 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 28.1 m -71.83 132.09 43.95 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 120.797 0.332 . . . . 0.0 110.183 177.756 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.434 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 86.1 m -151.47 143.52 23.92 Favored 'General case' 0 N--CA 1.437 -1.086 0 C-N-CA 123.729 0.812 . . . . 0.0 109.054 178.507 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 7.8 tt0 -134.26 133.78 41.19 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 178.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 156.25 -172.59 34.11 Favored Glycine 0 N--CA 1.437 -1.287 0 C-N-CA 119.925 -1.131 . . . . 0.0 112.096 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 31.0 m -129.68 148.51 69.74 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 75.4 Cg_exo -51.55 131.79 38.29 Favored 'Trans proline' 0 CA--C 1.545 1.063 0 C-N-CA 122.801 2.334 . . . . 0.0 113.125 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 6.4 Cg_endo -100.24 10.17 23.42 Favored 'Cis proline' 0 CA--C 1.544 1.005 0 C-N-CA 124.779 -0.925 . . . . 0.0 113.044 -3.235 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -93.55 102.31 14.51 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.793 0.806 . . . . 0.0 112.096 -174.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 39.3 p-80 -104.68 138.52 40.87 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.11 178.648 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.434 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 70.2 mt -92.68 110.37 44.87 Favored Pre-proline 0 C--N 1.305 -1.351 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 173.702 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -84.59 126.09 3.46 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 122.659 2.239 . . . . 0.0 113.942 -177.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -102.76 -138.34 9.95 Favored Glycine 0 N--CA 1.437 -1.28 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 176.374 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 60.4 t -73.85 127.83 35.92 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 C-N-CA 122.996 0.518 . . . . 0.0 111.801 -177.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.11 141.72 28.22 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.147 177.49 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.6 m0 -99.59 -4.89 30.07 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 119.59 -0.844 . . . . 0.0 111.615 177.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -160.61 -175.27 31.43 Favored Glycine 0 N--CA 1.43 -1.703 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -177.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 46.9 t -110.95 134.76 52.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 C-N-CA 122.963 0.505 . . . . 0.0 109.675 -174.084 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -101.03 110.92 23.0 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.6 tptt . . . . . 0 C--N 1.294 -1.84 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -177.786 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 24.0 m . . . . . 0 N--CA 1.445 -0.709 0 CA-C-O 120.2 0.048 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -124.3 162.11 24.44 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -100.16 -60.67 1.48 Allowed 'General case' 0 N--CA 1.428 -1.564 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.662 -177.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.583 ' HA ' ' CE2' ' A' ' 6' ' ' TYR . 6.9 mtpm? -133.25 7.77 3.95 Favored 'General case' 0 C--O 1.246 0.871 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -177.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.404 ' ND2' ' H ' ' A' ' 18' ' ' LYS . 48.1 t-20 -88.0 82.46 7.21 Favored 'General case' 0 CA--C 1.504 -0.82 0 C-N-CA 118.832 -1.147 . . . . 0.0 108.954 175.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . 0.583 ' CE2' ' HA ' ' A' ' 4' ' ' LYS . 8.9 p90 -142.7 154.01 43.91 Favored 'General case' 0 N--CA 1.411 -2.392 0 CA-C-N 113.691 -1.595 . . . . 0.0 108.248 178.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' MET . . . . . 0.444 ' SD ' ' HB3' ' A' ' 9' ' ' LYS . 0.0 OUTLIER 179.04 89.16 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 104.864 -2.273 . . . . 0.0 104.864 177.671 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -87.13 92.07 8.93 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-O 121.312 0.577 . . . . 0.0 110.454 -176.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.444 ' HB3' ' SD ' ' A' ' 7' ' ' MET . 25.3 ttmm -178.5 160.9 1.29 Allowed 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 104.422 -2.436 . . . . 0.0 104.422 178.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -114.64 78.96 0.27 Allowed Glycine 0 N--CA 1.428 -1.894 0 C-N-CA 120.295 -0.955 . . . . 0.0 110.801 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 12.9 p -77.56 -39.12 46.9 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-O 120.934 0.397 . . . . 0.0 111.293 -177.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 75.4 m -159.34 -69.12 0.08 Allowed 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 123.476 0.711 . . . . 0.0 110.021 176.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 10.7 m -139.27 43.2 2.04 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 p -79.37 -179.11 6.6 Favored 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.017 -178.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 29.9 p 59.81 16.11 5.37 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -176.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 17.6 m -67.04 -41.52 87.36 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.781 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.036 177.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 45.8 t 59.67 94.19 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.88 0 N-CA-C 115.264 1.579 . . . . 0.0 115.264 173.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.404 ' H ' ' ND2' ' A' ' 5' ' ' ASN . 56.3 mtpt -135.19 96.17 3.44 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 173.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -170.37 155.8 5.35 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -177.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 143.88 -144.96 14.22 Favored Glycine 0 N--CA 1.41 -3.093 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 -178.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt 62.14 -88.78 0.03 OUTLIER 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.395 1.078 . . . . 0.0 110.944 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -158.18 73.79 0.68 Allowed 'General case' 0 C--N 1.31 -1.112 0 C-N-CA 124.187 0.995 . . . . 0.0 109.015 177.038 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 25.1 m -114.92 -32.14 5.86 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.289 -177.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 58.2 m -146.59 25.2 1.2 Allowed 'General case' 0 C--N 1.317 -0.83 0 O-C-N 121.957 -0.465 . . . . 0.0 110.455 177.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -64.03 -45.15 90.17 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-O 121.281 0.562 . . . . 0.0 110.54 -179.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 30.2 m -102.63 12.08 36.85 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.526 178.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 62.0 p 65.48 153.08 0.12 Allowed Pre-proline 0 CA--C 1.55 0.972 0 C-N-CA 126.805 2.042 . . . . 0.0 111.956 -175.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_exo -43.29 -49.36 7.44 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 123.721 2.947 . . . . 0.0 114.412 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 53.41 58.29 5.36 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 121.772 0.796 . . . . 0.0 110.006 -177.107 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.9 m 69.87 9.39 7.12 Favored 'General case' 0 CA--C 1.577 2.018 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.865 -177.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 21.5 tpp180 -139.68 77.14 28.37 Favored Pre-proline 0 CA--C 1.551 1.018 0 O-C-N 121.236 -0.915 . . . . 0.0 112.485 177.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.69 140.9 83.28 Favored 'Trans proline' 0 C--O 1.239 0.554 0 C-N-CA 122.198 1.932 . . . . 0.0 109.982 169.377 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 22.8 m -84.84 4.95 2.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-O 121.4 0.619 . . . . 0.0 111.349 -177.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 3.7 p -84.81 -0.21 53.08 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.769 178.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 78.23 -135.42 15.94 Favored Glycine 0 N--CA 1.429 -1.779 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.729 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 10.0 m -91.27 10.09 28.7 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 123.203 0.601 . . . . 0.0 110.964 -177.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . 0.48 ' CZ3' HG13 ' A' ' 90' ' ' ILE . 60.3 m95 -89.16 140.16 29.75 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 120.901 0.382 . . . . 0.0 110.798 -176.501 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 38.7 ttmt -114.45 151.18 33.6 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 61.7 tttm -93.26 144.74 25.02 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.513 0.673 . . . . 0.0 112.368 -175.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -107.91 156.12 19.54 Favored 'General case' 0 C--O 1.253 1.274 0 C-N-CA 125.182 1.393 . . . . 0.0 108.763 175.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 16.6 pm0 -62.08 -23.29 66.42 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.462 1.105 . . . . 0.0 113.183 -178.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -84.26 -3.26 58.1 Favored 'General case' 0 C--N 1.322 -0.6 0 O-C-N 121.819 -0.551 . . . . 0.0 111.4 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.9 -6.46 60.22 Favored Glycine 0 CA--C 1.5 -0.902 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 17.0 m -73.32 144.79 46.41 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 68.1 m95 -114.92 138.94 50.22 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 175.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -138.23 149.05 45.39 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 120.663 0.268 . . . . 0.0 111.676 -175.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.7 pttt -130.68 140.51 38.89 Favored Pre-proline 0 C--N 1.3 -1.567 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 176.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -75.2 121.99 6.83 Favored 'Trans proline' 0 C--O 1.254 1.309 0 C-N-CA 121.86 1.707 . . . . 0.0 109.354 172.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -166.24 122.33 1.27 Allowed 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -178.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.441 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 20.1 m120 -94.17 123.89 37.84 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.213 -178.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.423 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -149.39 175.09 11.76 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 176.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 11.8 m -115.91 148.62 39.83 Favored 'General case' 0 N--CA 1.419 -2.013 0 CA-C-O 121.349 0.595 . . . . 0.0 110.589 -174.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -131.46 122.67 26.63 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 175.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.3 t -104.11 112.68 38.58 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.242 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 176.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -75.12 138.5 42.1 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 120.124 -0.63 . . . . 0.0 110.17 -177.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -167.41 174.53 42.56 Favored Glycine 0 N--CA 1.423 -2.202 0 N-CA-C 107.913 -2.075 . . . . 0.0 107.913 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 36.8 t30 79.58 -45.6 0.33 Allowed 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 124.91 1.284 . . . . 0.0 110.209 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.468 HE21 HG12 ' A' ' 60' ' ' ILE . 10.8 pt20 -158.18 153.16 21.32 Favored Pre-proline 0 N--CA 1.413 -2.303 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.581 178.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -72.34 131.03 17.05 Favored 'Trans proline' 0 N--CA 1.444 -1.418 0 N-CA-C 107.418 -1.801 . . . . 0.0 107.418 167.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.468 HG12 HE21 ' A' ' 58' ' ' GLN . 49.2 mt -108.47 124.3 64.79 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 C-N-CA 120.3 -0.56 . . . . 0.0 109.745 -174.457 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.0 p -76.44 127.8 37.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 176.151 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 37.1 p -106.3 167.99 9.45 Favored 'General case' 0 N--CA 1.416 -2.157 0 CA-C-O 121.264 0.554 . . . . 0.0 111.41 -173.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 18.2 mmt180 -114.96 143.9 44.43 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 55.4 mt -111.93 134.63 53.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 C-N-CA 120.384 -0.527 . . . . 0.0 111.913 -175.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.09 -23.32 3.9 Favored Glycine 0 C--N 1.32 -0.329 0 N-CA-C 116.344 1.298 . . . . 0.0 116.344 171.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.8 m -155.87 137.1 9.36 Favored Pre-proline 0 C--N 1.301 -1.54 0 CA-C-N 118.228 1.014 . . . . 0.0 110.118 -179.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -89.86 121.44 0.99 Allowed 'Trans proline' 0 N--CA 1.444 -1.416 0 C-N-CA 122.24 1.96 . . . . 0.0 112.168 175.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -163.27 170.25 17.94 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 104.414 -2.439 . . . . 0.0 104.414 178.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -82.41 -26.08 33.11 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.255 0.55 . . . . 0.0 110.294 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -107.09 25.7 11.06 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 122.396 1.093 . . . . 0.0 108.498 178.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -68.64 157.57 88.0 Favored Pre-proline 0 C--N 1.318 -0.791 0 CA-C-N 115.186 -0.916 . . . . 0.0 111.336 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -53.96 133.47 55.0 Favored 'Trans proline' 0 C--N 1.361 1.205 0 C-N-CA 123.274 2.65 . . . . 0.0 113.623 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.7 m -99.22 176.23 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.012 0 C-N-CA 124.626 1.17 . . . . 0.0 110.662 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.59 4.53 10.67 Favored Glycine 0 CA--C 1.498 -0.972 0 C-N-CA 121.13 -0.557 . . . . 0.0 111.732 -178.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -122.12 124.48 5.76 Favored Glycine 0 N--CA 1.419 -2.434 0 N-CA-C 108.401 -1.88 . . . . 0.0 108.401 174.026 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -128.62 126.79 40.96 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 117.881 0.841 . . . . 0.0 109.668 176.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 49.4 tp -97.58 114.7 65.28 Favored Pre-proline 0 C--N 1.301 -1.511 0 C-N-CA 122.346 0.258 . . . . 0.0 110.337 -177.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -73.1 160.21 46.03 Favored 'Trans proline' 0 C--O 1.243 0.763 0 C-N-CA 122.348 2.032 . . . . 0.0 111.185 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.31 153.86 35.54 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.4 10.42 79.93 Favored Glycine 0 C--N 1.313 -0.738 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -178.446 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.16 126.41 38.25 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 60.1 m -96.82 108.78 21.52 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 177.093 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.6 mm -108.69 119.29 58.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.636 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.1 p -99.74 107.77 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.37 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 174.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.441 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 44.4 p90 -98.32 163.86 12.53 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.282 -174.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -125.38 -11.17 6.9 Favored 'General case' 0 C--N 1.318 -0.768 0 O-C-N 123.443 0.464 . . . . 0.0 111.538 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.426 ' HB2' ' NH2' ' A' ' 106' ' ' ARG . 31.1 tt0 -126.39 124.17 39.6 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -175.322 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 40.6 t -112.59 120.8 63.6 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.491 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.585 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 26.4 p -130.96 152.23 50.5 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 120.328 -0.549 . . . . 0.0 112.377 -176.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.48 HG13 ' CZ3' ' A' ' 37' ' ' TRP . 76.5 mt -112.74 113.64 44.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.169 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.049 177.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.51 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -112.1 113.66 26.06 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 103.363 -2.828 . . . . 0.0 103.363 169.102 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.6 109.76 0.28 Allowed 'General case' 0 C--O 1.241 0.635 0 O-C-N 124.722 1.264 . . . . 0.0 113.21 -164.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 137.4 -36.74 1.92 Allowed Glycine 0 N--CA 1.424 -2.118 0 CA-C-N 113.636 -1.62 . . . . 0.0 109.185 -176.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 52.9 m80 -149.02 165.33 31.97 Favored 'General case' 0 CA--C 1.5 -0.946 0 O-C-N 122.478 -0.424 . . . . 0.0 109.911 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.5 tt -103.24 135.84 38.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 N-CA-C 104.491 -2.411 . . . . 0.0 104.491 171.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.585 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 49.4 m95 -119.25 135.23 54.79 Favored 'General case' 0 C--N 1.275 -2.646 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 -173.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.484 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 47.0 pt -100.5 132.38 46.25 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 177.4 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.94 124.64 8.14 Favored Glycine 0 N--CA 1.425 -2.085 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -137.72 164.83 27.89 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 29.1 p-10 -117.54 137.5 52.54 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.982 0.42 . . . . 0.0 110.615 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.402 ' HB1' ' OD1' ' A' ' 105' ' ' ASN . . . -91.12 174.64 7.3 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -66.88 -12.08 58.12 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 121.263 0.554 . . . . 0.0 112.131 -177.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -81.01 -12.7 59.31 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 87.82 9.11 71.91 Favored Glycine 0 CA--C 1.505 -0.583 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.995 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.402 ' OD1' ' HB1' ' A' ' 101' ' ' ALA . 18.2 p-10 -91.86 147.58 22.87 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.126 0.489 . . . . 0.0 110.165 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . 0.426 ' NH2' ' HB2' ' A' ' 87' ' ' GLU . 18.0 tpt180 -94.61 115.3 27.4 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -175.46 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 24.3 t -111.39 139.9 33.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -176.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.484 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 94.1 m-85 -118.47 132.32 56.24 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 123.641 0.776 . . . . 0.0 110.943 -178.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 45.9 t -111.78 131.95 22.16 Favored Pre-proline 0 C--N 1.308 -1.201 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.363 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -70.69 -13.85 32.67 Favored 'Trans proline' 0 C--N 1.367 1.552 0 C-N-CA 123.311 2.674 . . . . 0.0 114.763 -176.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.31 35.9 m 38.86 -60.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.459 0 N-CA-C 119.072 2.99 . . . . 0.0 119.072 175.329 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 37.5 ptt180 -155.08 156.71 36.34 Favored 'General case' 0 C--O 1.248 0.977 0 O-C-N 121.894 -0.504 . . . . 0.0 109.717 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 25.3 m -64.54 136.78 57.39 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 174.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.453 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 65.3 m -149.67 128.05 12.19 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.727 0.775 . . . . 0.0 110.657 176.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -119.68 161.77 20.14 Favored 'General case' 0 C--N 1.286 -2.157 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.14 -167.13 12.85 Favored Glycine 0 C--N 1.286 -2.214 0 C-N-CA 118.918 -1.611 . . . . 0.0 112.284 177.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 24.6 m -140.91 147.33 47.66 Favored Pre-proline 0 C--N 1.306 -1.323 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.4 ' HB3' ' CG ' ' A' ' 37' ' ' TRP . 85.6 Cg_exo -48.63 136.1 27.18 Favored 'Trans proline' 0 CA--C 1.543 0.943 0 C-N-CA 123.24 2.627 . . . . 0.0 113.013 178.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -88.73 -19.72 15.55 Favored 'Cis proline' 0 CA--C 1.544 1.005 0 C-N-CA 123.779 -1.342 . . . . 0.0 113.176 -0.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 90.0 m-20 -77.34 102.2 6.66 Favored 'General case' 0 C--O 1.244 0.791 0 CA-C-O 122.244 1.021 . . . . 0.0 112.877 -172.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 32.4 p-80 -104.69 131.05 52.59 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 113.847 -1.524 . . . . 0.0 109.867 178.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.453 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 55.4 mt -96.66 108.6 43.7 Favored Pre-proline 0 C--N 1.286 -2.161 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -178.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -78.88 161.39 27.11 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.584 2.189 . . . . 0.0 112.521 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -134.74 -124.31 2.44 Favored Glycine 0 N--CA 1.437 -1.265 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 177.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.6 t -77.26 124.01 34.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 116.938 0.369 . . . . 0.0 110.795 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.5 151.32 19.44 Favored 'General case' 0 C--O 1.246 0.908 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.217 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.6 m-90 -124.98 29.64 6.09 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.93 178.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -169.4 -173.27 36.85 Favored Glycine 0 N--CA 1.434 -1.461 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 -179.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 47.4 t -114.63 115.28 49.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.164 0.507 . . . . 0.0 109.983 -178.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -83.72 130.19 34.95 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.007 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? . . . . . 0 N--CA 1.421 -1.908 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 -176.083 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 22.2 t . . . . . 0 N--CA 1.449 -0.487 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -143.53 147.02 33.84 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 -177.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -158.64 89.47 0.96 Allowed 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -89.2 95.8 10.45 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.187 -179.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -101.19 109.33 21.18 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.59 0.709 . . . . 0.0 110.838 178.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -131.54 174.61 9.92 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 178.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 47.8 ttm 71.42 -43.23 0.56 Allowed 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 124.322 1.049 . . . . 0.0 112.571 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -64.45 155.12 33.69 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 123.685 0.794 . . . . 0.0 110.512 178.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.541 ' HD2' ' N ' ' A' ' 10' ' ' GLY . 0.5 OUTLIER -51.19 -28.68 11.89 Favored 'General case' 0 CA--C 1.547 0.839 0 N-CA-C 113.34 0.867 . . . . 0.0 113.34 177.671 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.541 ' N ' ' HD2' ' A' ' 9' ' ' LYS . . . 68.75 -113.5 5.3 Favored Glycine 0 N--CA 1.441 -0.989 0 N-CA-C 114.004 0.362 . . . . 0.0 114.004 174.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 15.8 p -71.24 98.6 1.75 Allowed 'General case' 0 N--CA 1.435 -1.195 0 CA-C-O 121.389 0.614 . . . . 0.0 111.216 -178.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 20.2 m -145.05 74.48 1.41 Allowed 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 177.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.4 m -87.47 -42.93 12.44 Favored 'General case' 0 N--CA 1.422 -1.85 0 CA-C-N 114.011 -1.449 . . . . 0.0 111.049 -174.164 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.8 m -82.81 3.97 27.28 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.768 0.794 . . . . 0.0 110.394 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 4.0 m -87.74 22.01 2.42 Favored 'General case' 0 CA--C 1.559 1.299 0 C-N-CA 124.296 1.038 . . . . 0.0 109.68 179.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.7 m -92.13 150.39 3.84 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 175.012 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 17.8 t 67.97 23.15 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.562 1.409 0 CA-C-O 123.621 1.677 . . . . 0.0 107.847 -175.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 52.5 tptt -77.27 -31.26 54.76 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 113.279 -1.782 . . . . 0.0 108.11 176.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -91.2 -167.25 1.76 Allowed 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 114.826 -1.079 . . . . 0.0 108.17 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 165.96 -47.04 0.27 Allowed Glycine 0 N--CA 1.43 -1.742 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 -178.294 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 58.4 tptt -93.68 104.07 16.19 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 32.2 p 54.97 79.84 0.14 Allowed 'General case' 0 C--O 1.243 0.718 0 C-N-CA 124.618 1.167 . . . . 0.0 112.977 -178.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 37.5 m -75.6 136.23 40.5 Favored 'General case' 0 N--CA 1.429 -1.504 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.956 -177.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.8 t 66.86 23.66 9.93 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.163 0.985 . . . . 0.0 110.017 -179.212 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.14 -45.07 87.99 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 176.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 19.7 m -103.08 94.98 5.83 Favored 'General case' 0 N--CA 1.414 -2.237 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 170.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 16.8 m -76.59 130.25 77.19 Favored Pre-proline 0 N--CA 1.431 -1.408 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.281 -174.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -69.46 91.72 0.48 Allowed 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 121.958 1.772 . . . . 0.0 110.416 173.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -136.89 -39.51 0.62 Allowed 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.968 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.9 m -87.9 -35.41 17.73 Favored 'General case' 0 N--CA 1.435 -1.192 0 CA-C-O 121.061 0.458 . . . . 0.0 110.153 -179.462 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -73.45 -56.91 2.89 Favored Pre-proline 0 CA--C 1.554 1.102 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 -175.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -61.61 103.07 0.26 Allowed 'Trans proline' 0 C--N 1.374 1.916 0 C-N-CA 121.724 1.616 . . . . 0.0 112.965 178.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.3 m -83.55 136.13 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 176.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 55.2 m 73.5 132.99 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.025 0 O-C-N 124.051 0.844 . . . . 0.0 110.119 -175.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 128.09 -38.18 2.14 Favored Glycine 0 CA--C 1.489 -1.535 0 N-CA-C 108.168 -1.973 . . . . 0.0 108.168 -174.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 2.9 p -70.15 -53.1 18.71 Favored 'General case' 0 N--CA 1.426 -1.658 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 172.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.3 m95 -87.04 133.22 33.61 Favored 'General case' 0 N--CA 1.432 -1.372 0 CA-C-N 114.051 -1.431 . . . . 0.0 107.725 173.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.4 mptt -113.91 155.2 26.22 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 176.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -102.99 132.48 49.23 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.803 -0.759 . . . . 0.0 108.967 178.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.449 ' ND2' ' HB ' ' A' ' 44' ' ' THR . 38.7 p30 -86.5 178.19 7.17 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 175.222 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 -70.1 -23.12 63.0 Favored 'General case' 0 C--N 1.31 -1.134 0 CA-C-O 121.114 0.483 . . . . 0.0 111.144 -176.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . 0.46 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 26.7 m-85 -74.87 -13.92 60.61 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.163 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.41 7.07 57.25 Favored Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.829 178.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.449 ' HB ' ' ND2' ' A' ' 40' ' ' ASN . 5.8 m -88.34 137.57 32.2 Favored 'General case' 0 N--CA 1.424 -1.755 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 92.2 m95 -96.44 122.29 39.17 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 176.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 54.4 p90 -123.58 152.34 41.97 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 120.869 0.366 . . . . 0.0 111.973 -174.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.0 ptmt -141.03 147.18 46.67 Favored Pre-proline 0 N--CA 1.433 -1.292 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 171.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -77.09 122.09 6.06 Favored 'Trans proline' 0 N--CA 1.445 -1.327 0 C-N-CA 121.492 1.461 . . . . 0.0 109.222 172.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.5 tp10 -153.35 125.74 8.09 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 -179.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.488 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 7.7 t30 -109.57 107.49 17.6 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.203 0.525 . . . . 0.0 111.098 -175.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.416 ' HB2' ' CZ ' ' A' ' 85' ' ' TYR . . . -143.56 171.42 14.18 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.414 ' HB ' ' HB2' ' A' ' 131' ' ' LYS . 6.4 m -104.32 147.76 27.15 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -176.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -127.08 138.26 53.17 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 175.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.3 t -118.65 117.0 53.01 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 176.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.48 ' ND2' ' HA ' ' A' ' 79' ' ' ALA . 48.4 t30 -70.61 148.43 48.12 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.291 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -83.42 -132.7 2.05 Favored Glycine 0 N--CA 1.434 -1.471 0 N-CA-C 114.364 0.506 . . . . 0.0 114.364 -174.177 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -91.05 -4.32 56.45 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -171.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -131.95 153.09 81.28 Favored Pre-proline 0 C--N 1.306 -1.285 0 C-N-CA 120.007 -0.677 . . . . 0.0 112.261 179.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.431 ' HB3' HD22 ' A' ' 76' ' ' ASN . 7.4 Cg_exo -74.76 136.72 21.31 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.056 1.837 . . . . 0.0 111.079 176.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 61.0 mt -107.81 133.63 52.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -177.483 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.9 p -82.09 137.53 20.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 177.09 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 54.7 p -117.07 179.03 4.14 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.565 -172.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.422 ' NH1' HG11 ' A' ' 73' ' ' VAL . 47.2 mmt-85 -122.05 144.3 48.99 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 59.1 mt -106.35 125.99 62.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.868 -177.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.51 -22.64 1.68 Allowed Glycine 0 CA--C 1.527 0.812 0 N-CA-C 116.569 1.388 . . . . 0.0 116.569 171.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.5 m -145.68 134.17 10.86 Favored Pre-proline 0 C--N 1.3 -1.558 0 CA-C-N 118.562 1.181 . . . . 0.0 110.315 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -90.08 120.41 0.86 Allowed 'Trans proline' 0 N--CA 1.441 -1.614 0 C-N-CA 121.732 1.622 . . . . 0.0 111.624 174.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.468 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 93.1 m-85 -168.16 175.54 6.51 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 104.873 -2.269 . . . . 0.0 104.873 178.528 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -81.85 -45.3 15.7 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 176.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -94.04 25.93 3.48 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.108 -0.951 . . . . 0.0 111.151 -178.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.468 ' HB1' ' HB2' ' A' ' 68' ' ' PHE . . . -72.55 162.9 71.75 Favored Pre-proline 0 C--N 1.317 -0.835 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.468 178.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_exo -48.87 123.31 9.54 Favored 'Trans proline' 0 C--N 1.369 1.652 0 C-N-CA 123.537 2.825 . . . . 0.0 114.158 179.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.422 HG11 ' NH1' ' A' ' 63' ' ' ARG . 31.2 m -97.55 174.38 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.184 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.34 28.8 1.89 Allowed Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -150.94 126.61 2.16 Favored Glycine 0 N--CA 1.428 -1.896 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.431 HD22 ' HB3' ' A' ' 59' ' ' PRO . 8.0 t30 -127.39 136.79 52.35 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 57.2 tp -97.45 115.64 65.77 Favored Pre-proline 0 C--N 1.302 -1.463 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -59.24 152.67 58.4 Favored 'Trans proline' 0 C--O 1.245 0.856 0 C-N-CA 123.005 2.47 . . . . 0.0 112.609 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . 0.48 ' HA ' ' ND2' ' A' ' 55' ' ' ASN . . . -73.42 139.97 46.22 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.13 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.74 -4.82 77.71 Favored Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 116.113 -0.494 . . . . 0.0 113.108 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.93 134.06 40.34 Favored 'General case' 0 N--CA 1.439 -1.018 0 CA-C-O 120.774 0.321 . . . . 0.0 110.893 -177.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 14.6 t -108.0 134.66 50.59 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 177.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 44.6 mm -132.05 140.14 48.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -177.223 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.5 p -103.96 113.41 40.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-O 121.965 0.888 . . . . 0.0 109.582 175.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.488 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 43.2 p90 -97.15 152.95 18.3 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.417 -175.019 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -119.77 4.28 11.04 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.657 0.741 . . . . 0.0 110.345 -178.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -142.06 132.96 25.83 Favored 'General case' 0 N--CA 1.426 -1.656 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.391 -175.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.8 t -124.68 128.27 73.31 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 20.5 p -139.49 140.83 37.33 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-O 121.236 0.541 . . . . 0.0 111.421 -178.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 75.1 mt -101.03 114.87 41.51 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.731 179.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.569 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 50.0 tp60 -116.04 127.63 55.05 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 104.813 -2.292 . . . . 0.0 104.813 173.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.04 110.93 0.37 Allowed 'General case' 0 C--O 1.243 0.731 0 N-CA-C 113.275 0.842 . . . . 0.0 113.275 -167.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 124.23 -28.87 5.22 Favored Glycine 0 N--CA 1.438 -1.183 0 CA-C-N 114.498 -1.228 . . . . 0.0 112.729 179.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 74.8 m80 -151.12 169.9 20.74 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -176.342 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 19.0 tt -110.96 128.0 67.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.095 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 172.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.569 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 65.2 m95 -110.46 131.14 55.32 Favored 'General case' 0 C--N 1.274 -2.692 0 CA-C-O 120.966 0.412 . . . . 0.0 110.196 -173.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.493 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.5 pt -100.3 134.61 39.4 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.96 128.14 9.32 Favored Glycine 0 N--CA 1.428 -1.879 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 -178.607 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -151.38 163.93 37.85 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -97.77 116.81 30.72 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 174.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.09 178.25 6.5 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.999 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 46.5 p90 -47.49 -27.93 1.97 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 126.044 1.737 . . . . 0.0 113.858 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -99.27 2.42 45.54 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 112.222 0.453 . . . . 0.0 112.222 -175.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.85 0.67 81.07 Favored Glycine 0 C--N 1.32 -0.329 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.158 176.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -81.03 135.89 35.9 Favored 'General case' 0 C--N 1.306 -1.32 0 O-C-N 122.651 -0.323 . . . . 0.0 111.038 -178.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 4.1 tpp180 -75.29 102.24 4.99 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 173.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 67.6 t -108.27 143.87 17.89 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.029 0 CA-C-N 114.674 -1.148 . . . . 0.0 109.725 -174.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.493 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 96.5 m-85 -117.74 124.08 47.58 Favored 'General case' 0 N--CA 1.426 -1.647 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.273 178.671 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.8 t -104.13 133.71 20.08 Favored Pre-proline 0 C--N 1.298 -1.673 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -68.71 -22.88 36.76 Favored 'Trans proline' 0 C--N 1.359 1.115 0 C-N-CA 122.967 2.445 . . . . 0.0 113.472 -177.253 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.295 34.2 m 46.99 -53.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.207 0 N-CA-C 118.41 2.744 . . . . 0.0 118.41 175.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . 0.47 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 38.9 ptt180 -158.93 156.77 30.11 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 122.832 0.453 . . . . 0.0 110.553 -178.298 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 2.6 p -72.83 136.99 45.46 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 175.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.45 ' SG ' ' HA ' ' A' ' 123' ' ' PRO . 96.1 m -154.37 133.04 12.16 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.838 0.352 . . . . 0.0 111.54 -178.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 29.9 mm-40 -97.11 113.38 24.95 Favored 'General case' 0 N--CA 1.427 -1.595 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 171.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -122.01 113.96 2.39 Favored Glycine 0 C--N 1.259 -3.697 0 C-N-CA 119.779 -1.201 . . . . 0.0 114.014 -173.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 7.0 m -125.97 97.14 35.91 Favored Pre-proline 0 C--N 1.293 -1.878 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 172.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 61.9 Cg_exo -42.84 130.77 5.66 Favored 'Trans proline' 0 C--N 1.357 0.994 0 C-N-CA 124.327 3.351 . . . . 0.0 114.774 -170.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 7.4 Cg_endo -92.71 8.0 59.8 Favored 'Cis proline' 0 CA--C 1.549 1.236 0 C-N-CA 124.412 -1.078 . . . . 0.0 113.046 1.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -74.93 102.03 4.64 Favored 'General case' 0 CA--C 1.508 -0.672 0 CA-C-O 121.563 0.697 . . . . 0.0 110.229 -175.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.428 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 37.4 p-80 -104.78 107.03 17.77 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.592 177.429 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.5 mt -100.2 100.44 11.77 Favored Pre-proline 0 C--N 1.318 -0.791 0 C-N-CA 122.703 0.401 . . . . 0.0 109.925 -177.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . 0.45 ' HA ' ' SG ' ' A' ' 114' ' ' CYS . 2.9 Cg_endo -81.48 150.69 17.15 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 122.774 2.316 . . . . 0.0 113.265 -178.209 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.45 -116.13 3.3 Favored Glycine 0 N--CA 1.423 -2.228 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 175.022 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.3 t -97.39 124.45 50.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-O 120.801 0.334 . . . . 0.0 110.426 -176.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.47 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -95.02 146.88 23.96 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.708 177.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.7 m-90 -101.49 12.82 36.63 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 121.555 0.693 . . . . 0.0 109.246 177.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.74 179.24 37.24 Favored Glycine 0 N--CA 1.43 -1.705 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 49.4 t -112.08 137.79 43.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.398 -0.594 . . . . 0.0 109.398 -176.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -102.27 135.52 43.72 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-O 120.954 0.407 . . . . 0.0 110.11 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.414 ' HB2' ' HB ' ' A' ' 52' ' ' THR . 55.9 mtpt . . . . . 0 C--N 1.295 -1.776 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.241 0.655 0 CA-C-O 121.114 0.483 . . . . 0.0 111.048 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 56.3 t30 -84.53 -37.73 20.9 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 175.156 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.77 177.34 9.17 Favored 'General case' 0 N--CA 1.429 -1.516 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 177.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt 64.74 80.28 0.23 Allowed 'General case' 0 C--N 1.323 -0.544 0 O-C-N 124.249 0.968 . . . . 0.0 113.354 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -87.47 139.71 30.27 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 16.0 t80 -105.96 24.23 12.71 Favored 'General case' 0 CA--C 1.554 1.13 0 CA-C-O 121.45 0.643 . . . . 0.0 110.908 -174.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 24.6 ttt 79.42 -9.14 1.51 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 125.18 1.392 . . . . 0.0 113.131 174.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 17.2 t70 73.45 119.01 0.05 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 123.859 0.864 . . . . 0.0 109.27 -174.308 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 62.1 mttp 80.18 -43.58 0.25 Allowed 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 125.449 1.5 . . . . 0.0 110.666 -177.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.37 60.72 1.97 Allowed Glycine 0 N--CA 1.445 -0.755 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.609 177.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 27.3 p 54.24 88.51 0.04 OUTLIER 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 178.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.3 m -88.37 52.22 2.39 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 177.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.8 m -60.68 126.57 27.9 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.037 0.935 . . . . 0.0 111.975 -176.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.4 t -117.54 116.57 27.39 Favored 'General case' 0 N--CA 1.434 -1.251 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 60.0 m -56.18 -32.82 64.7 Favored 'General case' 0 CA--C 1.555 1.142 0 C-N-CA 124.795 1.238 . . . . 0.0 113.712 -175.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.7 p -75.56 -20.18 15.9 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.005 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -176.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.7 p -113.84 -39.71 3.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 C-N-CA 120.095 -0.642 . . . . 0.0 111.83 -178.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -106.2 99.07 8.67 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-O 121.718 0.771 . . . . 0.0 112.057 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.439 ' OD1' ' HA ' ' A' ' 22' ' ' THR . 4.9 p-10 -86.43 -25.11 25.42 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 114.7 -1.136 . . . . 0.0 108.144 173.46 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 129.25 -55.91 0.75 Allowed Glycine 0 N--CA 1.428 -1.857 0 CA-C-N 115.523 -0.762 . . . . 0.0 112.264 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -109.1 -10.49 15.0 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 121.007 0.432 . . . . 0.0 111.2 -174.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.439 ' HA ' ' OD1' ' A' ' 19' ' ' ASP . 14.6 m 82.84 84.13 0.03 OUTLIER 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 125.163 1.385 . . . . 0.0 111.406 178.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.0 t -127.75 -178.09 4.36 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 114.43 -1.259 . . . . 0.0 107.955 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 37.4 m 58.47 42.45 21.06 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 123.75 0.82 . . . . 0.0 111.734 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.23 -59.33 2.75 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.887 0.375 . . . . 0.0 111.312 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 19.5 m -82.9 -46.39 13.04 Favored 'General case' 0 C--O 1.25 1.12 0 CA-C-O 121.33 0.586 . . . . 0.0 109.662 -178.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.8 p -106.99 115.58 59.96 Favored Pre-proline 0 N--CA 1.421 -1.885 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.791 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -70.15 -18.56 35.09 Favored 'Trans proline' 0 CA--C 1.535 0.537 0 C-N-CA 121.651 1.568 . . . . 0.0 110.786 176.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 62.56 -87.52 0.02 OUTLIER 'General case' 0 C--O 1.24 0.595 0 C-N-CA 125.286 1.434 . . . . 0.0 112.895 175.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.7 m -92.53 -2.29 56.32 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.56 ' HD2' ' O ' ' A' ' 35' ' ' GLY . 39.2 ptt180 53.94 85.03 0.2 Allowed Pre-proline 0 N--CA 1.478 0.96 0 C-N-CA 125.76 1.624 . . . . 0.0 112.921 177.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_exo -43.46 -69.55 0.08 OUTLIER 'Trans proline' 0 C--N 1.362 1.243 0 C-N-CA 124.798 3.665 . . . . 0.0 116.219 -173.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 41.5 t -137.94 -61.63 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-O 121.308 0.575 . . . . 0.0 110.762 -174.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.6 m -81.56 41.84 0.65 Allowed 'General case' 0 CA--C 1.558 1.274 0 C-N-CA 123.862 0.865 . . . . 0.0 110.504 -175.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.56 ' O ' ' HD2' ' A' ' 31' ' ' ARG . . . -121.79 62.09 0.53 Allowed Glycine 0 N--CA 1.433 -1.521 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.486 -177.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 74.2 m -167.82 -68.23 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.062 0 C-N-CA 124.905 1.282 . . . . 0.0 108.509 177.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 47.8 m95 -92.39 152.68 19.6 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.13 -179.232 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 47.9 mmtm -113.32 149.94 33.24 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.601 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -101.52 122.05 43.1 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-O 121.123 0.487 . . . . 0.0 111.086 -175.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -88.62 155.14 19.79 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 175.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -63.47 -20.51 65.65 Favored 'General case' 0 CA--C 1.546 0.815 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -175.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -75.64 5.2 6.41 Favored 'General case' 0 CA--C 1.542 0.665 0 CA-C-O 121.225 0.536 . . . . 0.0 110.994 176.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.07 22.67 70.75 Favored Glycine 0 CA--C 1.496 -1.121 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 48.0 m -105.42 128.03 53.31 Favored 'General case' 0 N--CA 1.416 -2.127 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 -179.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.509 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 84.5 m95 -95.34 120.84 36.27 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 177.643 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -121.87 150.64 41.65 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.824 0.345 . . . . 0.0 111.66 -175.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 52.0 pttt -135.57 135.48 22.2 Favored Pre-proline 0 C--N 1.299 -1.623 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 173.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -70.78 125.68 11.86 Favored 'Trans proline' 0 C--O 1.249 1.057 0 C-N-CA 121.764 1.643 . . . . 0.0 109.933 174.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -165.7 120.39 1.24 Allowed 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.531 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 25.7 t-20 -102.08 107.86 19.1 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.481 0.658 . . . . 0.0 111.114 -175.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -143.18 179.47 7.04 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.524 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 42.0 m -115.59 150.13 37.15 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.048 0.451 . . . . 0.0 110.641 -177.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 82.6 t80 -131.71 127.5 36.98 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 175.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.8 t -111.4 106.19 20.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -71.48 152.31 43.16 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -156.02 -41.14 0.02 OUTLIER Glycine 0 N--CA 1.435 -1.423 0 C-N-CA 118.589 -1.767 . . . . 0.0 115.16 -177.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 45.0 t30 -71.21 -49.02 47.84 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 117.406 0.603 . . . . 0.0 112.538 -172.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -146.86 153.64 46.35 Favored Pre-proline 0 C--N 1.305 -1.335 0 C-N-CA 119.979 -0.688 . . . . 0.0 110.385 -176.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_exo -65.66 123.18 11.03 Favored 'Trans proline' 0 C--O 1.248 1.019 0 C-N-CA 121.76 1.64 . . . . 0.0 108.411 170.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 55.1 mt -107.18 125.03 63.38 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 -173.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 9.9 p -76.52 119.93 25.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 43.2 p -95.43 151.46 19.27 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.236 -175.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -102.44 137.19 41.01 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -175.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.1 mt -106.0 135.12 45.5 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.922 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -171.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.66 -23.45 5.69 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 116.405 1.322 . . . . 0.0 116.405 170.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 51.3 m -157.63 142.19 11.86 Favored Pre-proline 0 C--N 1.307 -1.254 0 CA-C-N 118.102 0.951 . . . . 0.0 109.524 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -90.05 119.54 0.8 Allowed 'Trans proline' 0 N--CA 1.439 -1.695 0 C-N-CA 121.559 1.506 . . . . 0.0 111.193 175.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -168.38 165.77 12.63 Favored 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 126.16 1.784 . . . . 0.0 106.321 -179.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 89.8 mt -85.25 -14.62 46.14 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 175.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -106.95 13.59 27.47 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.52 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -72.88 155.61 90.46 Favored Pre-proline 0 C--N 1.314 -0.973 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.021 -177.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -56.52 140.6 89.81 Favored 'Trans proline' 0 C--N 1.364 1.364 0 C-N-CA 123.6 2.867 . . . . 0.0 114.626 -178.079 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 33.3 m -97.81 175.63 0.79 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.747 0 C-N-CA 124.668 1.187 . . . . 0.0 110.609 178.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 121.0 -9.17 10.41 Favored Glycine 0 CA--C 1.496 -1.101 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 -178.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.89 126.97 9.07 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 108.198 -1.961 . . . . 0.0 108.198 172.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.9 t30 -128.26 125.3 38.61 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 118.057 0.929 . . . . 0.0 110.468 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 54.4 tp -96.84 108.5 43.62 Favored Pre-proline 0 C--N 1.296 -1.755 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.005 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -67.73 159.14 54.04 Favored 'Trans proline' 0 C--O 1.245 0.86 0 C-N-CA 122.389 2.06 . . . . 0.0 112.104 178.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.3 136.46 39.61 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.51 -2.38 64.93 Favored Glycine 0 C--N 1.31 -0.883 0 N-CA-C 111.664 -0.574 . . . . 0.0 111.664 -179.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.59 134.37 37.22 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-O 120.845 0.355 . . . . 0.0 111.711 -177.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 22.1 m -98.73 109.05 21.87 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.155 -0.93 . . . . 0.0 108.837 178.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 43.0 mm -110.78 135.35 50.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.45 -177.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.3 p -108.51 129.8 62.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 176.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.531 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 48.4 p90 -124.65 151.9 44.33 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -177.049 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -114.81 4.93 15.06 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 120.864 0.364 . . . . 0.0 110.537 -179.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -148.15 139.64 23.61 Favored 'General case' 0 N--CA 1.428 -1.562 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.383 -176.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 41.5 t -120.38 128.19 75.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 N-CA-C 105.725 -1.954 . . . . 0.0 105.725 175.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 8.7 p -139.91 143.37 36.62 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -175.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 67.8 mt -105.66 117.24 51.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.094 0.473 . . . . 0.0 110.751 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.505 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 6.1 tp-100 -115.66 113.52 23.64 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 103.021 -2.955 . . . . 0.0 103.021 168.154 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.59 115.88 1.4 Allowed 'General case' 0 CA--C 1.512 -0.512 0 O-C-N 124.458 1.099 . . . . 0.0 113.189 -165.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 133.02 -39.11 1.78 Allowed Glycine 0 N--CA 1.419 -2.459 0 CA-C-N 113.642 -1.617 . . . . 0.0 109.066 -176.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 64.4 m80 -148.16 161.15 42.03 Favored 'General case' 0 CA--C 1.506 -0.72 0 C-N-CA 122.921 0.488 . . . . 0.0 110.363 -179.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.449 ' O ' HG23 ' A' ' 111' ' ' VAL . 16.0 tt -106.75 121.44 59.47 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 175.201 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.505 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 52.9 m95 -104.77 138.25 41.33 Favored 'General case' 0 C--N 1.279 -2.469 0 CA-C-O 120.868 0.366 . . . . 0.0 110.881 -170.345 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.455 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.5 pt -100.34 132.51 45.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 175.757 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.14 116.07 5.45 Favored Glycine 0 N--CA 1.431 -1.67 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -178.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -136.08 175.25 9.77 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -115.29 127.42 55.44 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 177.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.28 -179.42 6.97 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.5 p90 -68.0 -20.39 65.02 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 118.488 0.585 . . . . 0.0 112.432 -176.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 59.3 t30 -73.7 -12.29 60.67 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-O 121.637 0.732 . . . . 0.0 109.532 175.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 92.26 -12.43 69.66 Favored Glycine 0 CA--C 1.501 -0.786 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.627 178.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -72.57 147.67 45.67 Favored 'General case' 0 C--O 1.253 1.245 0 C-N-CA 123.252 0.621 . . . . 0.0 109.841 -175.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.3 tpt180 -80.66 108.29 14.19 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 124.539 1.136 . . . . 0.0 108.414 -178.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 38.2 t -112.32 145.99 17.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 -176.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.455 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 91.9 m-85 -121.49 130.86 53.81 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.038 0.447 . . . . 0.0 110.671 -177.251 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 52.5 t -109.11 130.49 22.67 Favored Pre-proline 0 C--N 1.304 -1.396 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 177.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -70.07 -14.15 34.76 Favored 'Trans proline' 0 C--O 1.21 -0.883 0 C-N-CA 122.962 2.442 . . . . 0.0 114.564 -177.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 95' ' ' ILE 0.295 21.5 m 43.29 -54.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.518 2.949 0 N-CA-C 118.431 2.752 . . . . 0.0 118.431 176.173 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 12.1 ptm180 -156.09 150.43 25.64 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 55.1 m -64.31 144.68 56.97 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 177.004 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.441 ' SG ' ' HB2' ' A' ' 121' ' ' HIS . 27.0 t -161.16 134.18 6.35 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-O 120.954 0.407 . . . . 0.0 110.738 -178.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -123.81 160.92 26.31 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 176.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.62 178.04 15.48 Favored Glycine 0 N--CA 1.423 -2.195 0 C-N-CA 119.055 -1.545 . . . . 0.0 113.455 174.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 16.5 m -128.39 128.12 23.64 Favored Pre-proline 0 C--N 1.3 -1.574 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.509 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 64.5 Cg_exo -48.46 139.63 22.54 Favored 'Trans proline' 0 C--O 1.237 0.459 0 C-N-CA 123.433 2.755 . . . . 0.0 113.788 -179.294 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -81.15 -18.71 24.29 Favored 'Cis proline' 0 C--O 1.246 0.91 0 C-N-CA 123.581 -1.424 . . . . 0.0 114.018 0.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -70.67 102.0 2.19 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 122.053 0.93 . . . . 0.0 112.665 -172.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.441 ' HB2' ' SG ' ' A' ' 114' ' ' CYS . 48.8 p-80 -104.64 130.35 52.67 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-N 114.65 -1.159 . . . . 0.0 110.188 178.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 60.9 mt -96.49 114.32 64.18 Favored Pre-proline 0 C--N 1.301 -1.524 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -75.88 162.27 35.08 Favored 'Trans proline' 0 C--O 1.245 0.862 0 C-N-CA 122.571 2.181 . . . . 0.0 113.181 -179.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.85 -164.31 11.0 Favored Glycine 0 N--CA 1.433 -1.535 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 177.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.1 t -52.84 115.97 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.818 0.847 . . . . 0.0 112.562 -176.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -93.85 148.85 21.75 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.248 177.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.9 m-90 -111.17 10.91 21.86 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-O 121.103 0.478 . . . . 0.0 111.252 178.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.5 -175.9 33.03 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.665 -178.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 54.7 t -111.33 138.98 37.53 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -176.205 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -101.22 147.49 26.21 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-O 120.597 0.237 . . . . 0.0 110.396 -178.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.2 mtpt . . . . . 0 C--O 1.26 1.621 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 175.087 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 19.4 p . . . . . 0 N--CA 1.443 -0.79 0 CA-C-O 120.245 0.069 . . . . 0.0 111.061 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 24.2 t30 69.75 113.74 0.05 OUTLIER 'General case' 0 C--O 1.237 0.4 0 C-N-CA 124.151 0.98 . . . . 0.0 111.023 -177.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.77 2.19 27.23 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.223 -0.898 . . . . 0.0 112.165 -177.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt 78.18 -20.28 0.39 Allowed 'General case' 0 N--CA 1.494 1.727 0 C-N-CA 125.994 1.717 . . . . 0.0 111.586 177.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -146.77 128.56 15.3 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -130.17 71.72 1.46 Allowed 'General case' 0 C--N 1.308 -1.214 0 O-C-N 123.529 0.518 . . . . 0.0 110.022 177.267 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 49.6 tpp -152.31 95.46 2.05 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.902 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -97.09 79.89 2.9 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 175.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 tppp? -163.23 99.89 0.95 Allowed 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.491 -1.299 . . . . 0.0 107.491 -179.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -75.82 -2.68 71.35 Favored Glycine 0 C--N 1.313 -0.732 0 CA-C-N 115.491 -0.777 . . . . 0.0 113.691 -175.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 33.4 m -55.45 101.82 0.06 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.148 0.979 . . . . 0.0 111.151 178.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 31.0 m 62.44 19.15 10.94 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.808 0.843 . . . . 0.0 111.282 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 8.6 t -94.49 82.6 4.03 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-O 121.677 0.751 . . . . 0.0 109.15 -178.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.5 m -156.88 152.91 27.37 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 105.801 -1.926 . . . . 0.0 105.801 177.309 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.0 m -95.72 77.25 3.26 Favored 'General case' 0 C--N 1.294 -1.834 0 CA-C-O 121.738 0.78 . . . . 0.0 109.571 178.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 84.8 t -107.02 -53.09 6.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.769 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.8 t -90.4 125.69 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 178.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.496 ' N ' ' HD2' ' A' ' 18' ' ' LYS . 0.1 OUTLIER -94.13 92.58 7.36 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.161 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -82.0 140.08 34.16 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.713 -178.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.92 -15.02 68.77 Favored Glycine 0 C--N 1.317 -0.478 0 O-C-N 123.412 0.445 . . . . 0.0 113.184 -177.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.524 ' HE2' ' HA ' ' A' ' 21' ' ' LYS . 9.6 mmpt? 71.54 77.43 0.17 Allowed 'General case' 0 CA--C 1.509 -0.604 0 C-N-CA 124.783 1.233 . . . . 0.0 111.179 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 87.5 m -86.78 111.17 20.47 Favored 'General case' 0 N--CA 1.415 -2.21 0 CA-C-N 114.48 -1.236 . . . . 0.0 108.173 177.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.8 t -88.34 -169.63 2.64 Favored 'General case' 0 N--CA 1.417 -2.119 0 CA-C-N 114.98 -1.009 . . . . 0.0 109.567 -176.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.0 m -68.43 102.19 1.38 Allowed 'General case' 0 N--CA 1.423 -1.802 0 C-N-CA 123.858 0.863 . . . . 0.0 111.051 -178.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 67.59 86.15 0.13 Allowed 'General case' 0 C--O 1.243 0.73 0 C-N-CA 125.512 1.525 . . . . 0.0 113.977 176.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 19.7 m -73.16 133.73 44.17 Favored 'General case' 0 N--CA 1.435 -1.225 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 172.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 27.6 m 68.16 89.86 0.09 OUTLIER Pre-proline 0 CA--C 1.552 1.032 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -175.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_exo -63.09 -32.28 75.21 Favored 'Trans proline' 0 C--N 1.354 0.821 0 C-N-CA 123.0 2.467 . . . . 0.0 113.665 -175.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 60.26 -163.47 0.24 Allowed 'General case' 0 C--O 1.252 1.206 0 O-C-N 124.06 0.85 . . . . 0.0 109.009 -175.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 32.3 m -84.95 95.34 9.02 Favored 'General case' 0 N--CA 1.422 -1.834 0 CA-C-O 121.95 0.881 . . . . 0.0 109.357 175.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.4 ' H ' ' HD2' ' A' ' 32' ' ' PRO . 44.1 ttp180 -142.19 -52.23 0.02 OUTLIER Pre-proline 0 C--N 1.3 -1.565 0 CA-C-N 113.855 -1.521 . . . . 0.0 109.567 -179.428 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.4 ' HD2' ' H ' ' A' ' 31' ' ' ARG . 10.5 Cg_endo -57.49 125.95 20.4 Favored 'Trans proline' 0 C--N 1.386 2.521 0 N-CA-C 108.847 -1.251 . . . . 0.0 108.847 170.838 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 23.1 m -64.62 111.47 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 CA-C-O 121.76 0.791 . . . . 0.0 112.942 -175.054 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 19.0 p -96.59 25.98 4.77 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.113 -178.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -71.84 -66.33 2.15 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 121.186 -0.53 . . . . 0.0 112.011 -179.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 24.8 t -87.06 -47.07 9.22 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -86.93 122.65 31.08 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-N 115.586 -0.733 . . . . 0.0 109.715 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -113.92 141.95 46.74 Favored 'General case' 0 C--N 1.286 -2.169 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 -177.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 66.1 tttm -100.2 144.51 29.13 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 119.681 -0.808 . . . . 0.0 110.138 -179.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 33.0 p30 -114.73 -179.18 3.55 Favored 'General case' 0 C--O 1.254 1.326 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.545 175.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -81.51 0.63 37.09 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -175.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -91.79 -0.77 57.55 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 121.846 0.832 . . . . 0.0 109.073 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.95 19.65 74.76 Favored Glycine 0 CA--C 1.5 -0.885 0 CA-C-N 115.235 -0.893 . . . . 0.0 111.191 -179.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.435 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 28.3 m -105.65 141.13 37.64 Favored 'General case' 0 N--CA 1.41 -2.458 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 -179.512 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.528 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 63.3 m95 -104.64 125.3 50.62 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 174.008 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -127.42 145.07 50.95 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-O 120.729 0.3 . . . . 0.0 110.614 -176.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.432 ' CG ' ' HB ' ' A' ' 88' ' ' VAL . 21.1 ptmt -124.86 132.78 24.37 Favored Pre-proline 0 C--N 1.294 -1.836 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 176.044 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -76.05 121.06 5.98 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 121.458 1.438 . . . . 0.0 109.555 174.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -166.71 120.91 1.07 Allowed 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -95.43 120.2 35.25 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.091 -175.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.72 164.18 35.93 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 51.2 m -103.83 149.18 25.29 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.933 -177.415 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.5 t80 -126.42 134.13 51.08 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 177.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.8 t -114.2 118.11 57.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.923 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 49.9 t-20 -68.62 130.68 43.54 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -95.58 -68.29 1.01 Allowed Glycine 0 N--CA 1.421 -2.344 0 C-N-CA 120.005 -1.093 . . . . 0.0 114.253 -172.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -135.31 14.4 3.5 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -170.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.47 ' O ' HG13 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -135.48 122.07 14.47 Favored Pre-proline 0 C--N 1.298 -1.642 0 C-N-CA 119.729 -0.788 . . . . 0.0 112.949 -177.802 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -67.22 120.66 7.74 Favored 'Trans proline' 0 N--CA 1.447 -1.209 0 N-CA-C 105.767 -2.436 . . . . 0.0 105.767 167.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.47 HG13 ' O ' ' A' ' 58' ' ' GLN . 49.4 mt -113.58 120.74 64.24 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.057 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.639 -171.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -73.84 122.78 27.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 176.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 44.8 p -102.42 170.35 8.11 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.884 -173.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -117.47 149.28 40.85 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 2.8 mp -111.58 133.19 58.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 121.082 0.468 . . . . 0.0 111.111 -178.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 84.29 -24.11 6.59 Favored Glycine 0 C--N 1.315 -0.615 0 N-CA-C 115.861 1.104 . . . . 0.0 115.861 171.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 65.5 m -160.46 146.67 11.67 Favored Pre-proline 0 C--N 1.311 -1.068 0 CA-C-N 118.216 1.008 . . . . 0.0 110.144 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -89.82 119.9 0.87 Allowed 'Trans proline' 0 N--CA 1.44 -1.638 0 C-N-CA 121.771 1.647 . . . . 0.0 111.732 175.221 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 -169.89 177.66 4.3 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 103.487 -2.782 . . . . 0.0 103.487 -179.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -89.95 -37.47 14.34 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 171.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -89.14 25.48 1.85 Allowed 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 114.751 -1.113 . . . . 0.0 111.138 -177.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -84.49 161.38 54.22 Favored Pre-proline 0 C--N 1.306 -1.309 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 178.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -47.66 135.12 21.98 Favored 'Trans proline' 0 C--N 1.364 1.35 0 C-N-CA 123.715 2.943 . . . . 0.0 114.722 -178.286 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 18.0 m -90.42 173.92 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 114.362 -1.29 . . . . 0.0 110.636 -178.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.86 28.53 2.04 Favored Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.535 177.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -151.08 128.59 2.64 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 120.001 -1.095 . . . . 0.0 112.567 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -128.12 127.76 43.61 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.751 -1.204 . . . . 0.0 107.751 173.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 55.0 tp -101.41 109.9 60.15 Favored Pre-proline 0 C--N 1.301 -1.509 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 178.151 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.22 154.06 51.54 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 122.46 2.107 . . . . 0.0 112.515 -178.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.53 141.48 51.9 Favored 'General case' 0 N--CA 1.438 -1.045 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.855 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.0 -7.13 67.14 Favored Glycine 0 N--CA 1.435 -1.412 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.618 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.04 136.56 34.45 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.902 0.351 . . . . 0.0 111.366 -178.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 47.6 m -103.77 112.9 26.05 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.7 mm -127.27 133.77 67.35 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -176.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.469 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 11.6 p -93.3 135.19 28.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -118.18 159.55 23.11 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -178.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -130.12 -7.78 4.35 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 112.367 0.506 . . . . 0.0 112.367 -177.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.461 ' HG2' ' SG ' ' A' ' 89' ' ' CYS . 29.4 tt0 -131.36 120.83 23.67 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 -176.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.432 ' HB ' ' CG ' ' A' ' 47' ' ' LYS . 39.9 t -105.67 119.07 54.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.461 ' SG ' ' HG2' ' A' ' 87' ' ' GLU . 46.9 m -123.23 133.2 54.22 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -172.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 56.6 mt -97.7 113.86 33.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 CA-C-O 121.291 0.567 . . . . 0.0 109.942 173.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.492 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -121.42 134.04 55.09 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 172.145 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.62 117.05 1.84 Allowed 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 114.081 1.141 . . . . 0.0 114.081 -164.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 107.96 -22.61 27.33 Favored Glycine 0 N--CA 1.431 -1.681 0 CA-C-N 115.115 -0.948 . . . . 0.0 112.426 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . 0.423 ' HB2' ' NE1' ' A' ' 96' ' ' TRP . 57.9 m80 -144.45 169.22 18.36 Favored 'General case' 0 CA--C 1.509 -0.626 0 O-C-N 122.108 -0.642 . . . . 0.0 110.445 -176.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.6 tt -126.09 109.58 21.74 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.152 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 173.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.492 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 42.5 m95 -95.27 138.91 32.33 Favored 'General case' 0 C--N 1.279 -2.48 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.563 -167.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.448 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.8 pt -100.58 127.74 53.35 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 176.498 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.88 127.93 9.37 Favored Glycine 0 N--CA 1.421 -2.307 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 41.3 p90 -142.63 150.46 40.3 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 178.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -102.08 119.15 38.33 Favored 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.411 ' HB2' ' OD1' ' A' ' 105' ' ' ASN . . . -87.19 168.12 13.51 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 120.954 0.407 . . . . 0.0 110.838 -177.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -52.88 -25.52 11.93 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.397 1.479 . . . . 0.0 112.897 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -83.69 -3.44 57.77 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.454 0.645 . . . . 0.0 110.497 -176.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.19 7.07 73.88 Favored Glycine 0 CA--C 1.501 -0.8 0 CA-C-O 121.422 0.456 . . . . 0.0 112.038 176.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.411 ' OD1' ' HB2' ' A' ' 101' ' ' ALA . 13.8 p-10 -94.66 130.21 41.24 Favored 'General case' 0 C--N 1.29 -1.991 0 C-N-CA 123.147 0.579 . . . . 0.0 111.008 -177.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 26.6 tpt180 -84.1 102.93 12.9 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 178.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.8 t -97.71 139.34 20.22 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -173.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 79.0 m-85 -119.69 122.55 41.72 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 123.336 0.654 . . . . 0.0 109.725 177.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . 0.42 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 48.6 t -111.38 130.87 22.62 Favored Pre-proline 0 C--N 1.305 -1.369 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.1 -27.41 41.98 Favored 'Trans proline' 0 C--N 1.355 0.884 0 C-N-CA 122.815 2.343 . . . . 0.0 114.112 -176.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.303 18.9 m 51.19 -42.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.505 0 N-CA-C 118.446 2.758 . . . . 0.0 118.446 176.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . 0.454 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 37.9 ptt180 -161.5 165.08 29.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-O 121.112 0.482 . . . . 0.0 110.634 -179.409 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.5 m -75.93 139.72 41.74 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 176.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.448 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 49.5 t -155.97 128.01 7.51 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.47 0.652 . . . . 0.0 110.962 178.209 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . 0.432 ' HA ' ' OE1' ' A' ' 115' ' ' GLN . 7.9 mm-40 -121.69 162.45 20.72 Favored 'General case' 0 C--N 1.288 -2.106 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.493 177.718 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 124.58 -174.38 17.07 Favored Glycine 0 N--CA 1.418 -2.51 0 C-N-CA 119.947 -1.121 . . . . 0.0 112.021 177.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 18.9 m -131.87 133.22 23.82 Favored Pre-proline 0 C--N 1.3 -1.549 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.528 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 88.2 Cg_exo -48.74 137.13 27.34 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 123.332 2.688 . . . . 0.0 113.417 -178.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -91.09 1.09 64.32 Favored 'Cis proline' 0 C--O 1.245 0.86 0 C-N-CA 123.584 -1.423 . . . . 0.0 113.079 1.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -80.7 100.18 8.58 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 121.76 0.791 . . . . 0.0 110.36 -173.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.419 ' HB2' ' SG ' ' A' ' 114' ' ' CYS . 47.1 p-80 -105.5 131.33 53.03 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 114.606 -1.179 . . . . 0.0 112.098 -177.442 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.448 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.1 mm -105.74 99.8 23.83 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 178.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -84.96 139.69 7.47 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.391 2.061 . . . . 0.0 112.29 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -102.39 -133.01 7.89 Favored Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 177.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 61.5 t -82.97 129.3 37.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 110.129 -0.322 . . . . 0.0 110.129 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.454 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -93.62 143.82 25.96 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.823 176.543 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . 0.437 ' HB3' ' HB2' ' A' ' 58' ' ' GLN . 4.8 m0 -101.99 12.59 36.66 Favored 'General case' 0 C--O 1.251 1.154 0 CA-C-O 122.031 0.92 . . . . 0.0 110.345 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.63 179.59 36.92 Favored Glycine 0 N--CA 1.426 -1.99 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.936 -179.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.5 t -113.54 134.97 54.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -177.012 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -87.62 122.1 30.89 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? . . . . . 0 C--N 1.291 -1.943 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.866 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 12.4 m . . . . . 0 N--CA 1.44 -0.946 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -142.83 107.65 4.88 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.121 -179.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.86 115.69 22.39 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 174.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 51.6 tptt -77.03 -8.53 57.58 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 120.855 0.359 . . . . 0.0 111.337 -174.284 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 72.14 -54.04 0.69 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 124.762 1.225 . . . . 0.0 112.962 177.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 70.37 -65.1 0.34 Allowed 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.848 1.659 . . . . 0.0 108.318 -175.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 23.8 ptt? -100.12 102.22 13.48 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 172.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -85.57 115.07 23.05 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -176.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.9 ptmm? -148.14 -4.57 0.47 Allowed 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 -175.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.05 -131.07 4.25 Favored Glycine 0 N--CA 1.439 -1.126 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.164 -178.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 38.0 m -99.91 82.83 2.63 Favored 'General case' 0 C--N 1.291 -1.935 0 CA-C-O 121.81 0.814 . . . . 0.0 111.155 -179.329 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.0 m -94.9 -10.56 30.83 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.175 -0.92 . . . . 0.0 108.603 174.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.0 m -70.29 145.53 51.22 Favored 'General case' 0 N--CA 1.439 -1.012 0 CA-C-N 115.253 -0.885 . . . . 0.0 108.972 176.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.9 t -159.44 173.0 16.89 Favored 'General case' 0 N--CA 1.424 -1.746 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 -178.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 5.8 m -78.33 79.99 4.75 Favored 'General case' 0 N--CA 1.428 -1.563 0 CA-C-O 121.876 0.846 . . . . 0.0 109.301 -178.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 50.2 t -88.29 101.85 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 CA-C-N 115.217 -0.901 . . . . 0.0 108.93 -179.221 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 30.6 m -78.7 144.28 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 60.9 mttp 66.15 24.72 10.81 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 124.244 1.017 . . . . 0.0 111.229 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -58.12 119.07 6.18 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 123.49 0.716 . . . . 0.0 111.406 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.87 166.15 28.11 Favored Glycine 0 CA--C 1.493 -1.297 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -178.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -76.57 86.74 3.26 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 118.093 0.947 . . . . 0.0 109.588 179.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.7 m -101.82 -57.22 2.11 Favored 'General case' 0 N--CA 1.423 -1.824 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.6 -176.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.0 m -82.76 131.73 35.19 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.271 -177.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.4 p -81.71 -15.12 55.45 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 122.013 0.911 . . . . 0.0 109.376 176.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -150.37 141.11 22.71 Favored 'General case' 0 N--CA 1.429 -1.52 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 175.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.405 ' O ' ' HD3' ' A' ' 28' ' ' PRO . 19.6 m -66.21 -30.64 71.14 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.092 0.472 . . . . 0.0 110.231 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 28.5 m -102.91 99.82 14.95 Favored Pre-proline 0 N--CA 1.423 -1.802 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 173.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.405 ' HD3' ' O ' ' A' ' 26' ' ' SER . 3.8 Cg_exo -75.89 66.32 6.77 Favored 'Trans proline' 0 C--O 1.243 0.727 0 C-N-CA 123.124 2.55 . . . . 0.0 111.494 -178.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.411 ' HA ' ' HA ' ' A' ' 33' ' ' VAL . . . -112.75 3.43 16.5 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 114.169 -1.378 . . . . 0.0 108.676 177.467 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.8 p -91.02 -78.34 0.39 Allowed 'General case' 0 N--CA 1.428 -1.57 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.565 -178.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.487 ' HB3' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -88.34 -61.97 0.23 Allowed Pre-proline 0 C--N 1.309 -1.183 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.936 -177.78 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.487 ' HD3' ' HB3' ' A' ' 31' ' ' ARG . 56.7 Cg_endo -89.5 46.92 0.93 Allowed 'Trans proline' 0 C--N 1.368 1.566 0 CA-C-N 121.092 1.426 . . . . 0.0 110.133 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 5.8 p -45.02 98.12 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.35 0.606 0 C-N-CA 124.642 1.177 . . . . 0.0 113.342 -176.352 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.3 p 156.13 -35.96 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 129.657 3.183 . . . . 0.0 106.316 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 136.42 -88.01 0.23 Allowed Glycine 0 N--CA 1.423 -2.178 0 N-CA-C 108.451 -1.859 . . . . 0.0 108.451 -177.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 49.4 m -157.61 28.43 0.28 Allowed 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.013 -1.476 . . . . 0.0 107.013 174.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 73.0 m95 -90.03 145.66 24.92 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.296 -174.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.93 146.68 52.25 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 174.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -93.77 133.6 36.98 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 -178.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 33.3 p30 -96.84 176.81 5.85 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 175.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -77.22 1.75 17.56 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.515 0.674 . . . . 0.0 112.214 -175.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.7 m-85 -98.72 7.9 45.56 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.139 178.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.19 17.51 77.41 Favored Glycine 0 C--N 1.338 0.65 0 CA-C-N 115.128 -0.942 . . . . 0.0 112.32 177.14 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.416 HG21 ' HG2' ' A' ' 67' ' ' PRO . 5.3 m -105.01 141.9 35.76 Favored 'General case' 0 N--CA 1.42 -1.937 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -177.341 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.442 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 87.5 m95 -96.46 129.18 43.87 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.403 ' HA ' ' O ' ' A' ' 88' ' ' VAL . 51.8 p90 -125.89 150.28 48.04 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 123.199 0.312 . . . . 0.0 110.383 -178.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 14.1 ptmm? -135.66 148.06 63.98 Favored Pre-proline 0 C--N 1.303 -1.43 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 175.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -71.24 128.86 15.21 Favored 'Trans proline' 0 N--CA 1.444 -1.386 0 C-N-CA 121.27 1.313 . . . . 0.0 109.013 170.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.2 tp10 -162.64 120.18 2.04 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.518 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 6.6 t30 -105.87 113.48 27.06 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.684 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.403 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.55 175.62 12.57 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 89.0 m -118.9 133.19 56.0 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 120.253 -0.579 . . . . 0.0 112.32 -176.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -107.89 129.11 55.11 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 176.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.1 t -110.35 115.1 48.88 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 176.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -69.16 148.64 49.63 Favored 'General case' 0 C--N 1.309 -1.178 0 O-C-N 123.408 0.442 . . . . 0.0 110.466 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -81.58 -144.76 4.55 Favored Glycine 0 N--CA 1.43 -1.756 0 CA-C-N 115.998 -0.547 . . . . 0.0 113.84 -177.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 31.2 p-10 -85.65 12.22 9.23 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 -171.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -142.4 143.46 27.04 Favored Pre-proline 0 C--N 1.301 -1.516 0 C-N-CA 120.592 -0.443 . . . . 0.0 112.065 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_exo -71.98 131.75 18.69 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.138 1.892 . . . . 0.0 111.437 177.382 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -107.58 132.7 54.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.037 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.5 p -79.97 136.2 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 176.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 53.4 p -111.98 167.03 10.71 Favored 'General case' 0 C--N 1.287 -2.138 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.651 -175.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 21.7 mmt180 -114.68 137.14 52.26 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.041 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.7 mt -93.33 123.85 45.57 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 CA-C-N 115.396 -0.82 . . . . 0.0 113.156 -172.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.79 -23.19 3.75 Favored Glycine 0 C--O 1.237 0.291 0 N-CA-C 115.906 1.123 . . . . 0.0 115.906 172.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 50.7 m -151.7 144.53 16.96 Favored Pre-proline 0 C--N 1.306 -1.288 0 CA-C-N 118.53 1.165 . . . . 0.0 111.54 -177.004 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.416 ' HG2' HG21 ' A' ' 44' ' ' THR . 1.2 Cg_endo -89.35 120.95 1.06 Allowed 'Trans proline' 0 N--CA 1.448 -1.168 0 C-N-CA 122.457 2.105 . . . . 0.0 110.597 173.245 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.48 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . 59.6 m-85 -168.53 170.43 9.66 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 126.355 1.862 . . . . 0.0 106.322 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 95.8 mt -82.51 -30.96 29.48 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 172.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 17.6 m120 -102.97 26.22 8.42 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.732 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.48 ' HB3' ' HB2' ' A' ' 68' ' ' PHE . . . -75.2 156.79 85.58 Favored Pre-proline 0 C--N 1.308 -1.198 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.397 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -50.7 131.44 33.47 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 123.651 2.901 . . . . 0.0 113.48 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 6.8 p -101.31 174.17 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 C-N-CA 124.051 0.94 . . . . 0.0 108.928 -176.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.44 -4.74 13.36 Favored Glycine 0 N--CA 1.443 -0.84 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.023 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -110.81 123.78 6.71 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 177.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -122.09 134.48 54.77 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 117.356 0.578 . . . . 0.0 110.139 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.5 tp -100.83 118.87 59.79 Favored Pre-proline 0 C--N 1.308 -1.217 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -66.62 160.06 47.96 Favored 'Trans proline' 0 C--O 1.243 0.764 0 C-N-CA 122.478 2.119 . . . . 0.0 112.709 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.56 136.65 47.56 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.666 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.64 1.49 90.53 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 121.423 -0.418 . . . . 0.0 113.365 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.59 127.09 31.05 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.179 0.514 . . . . 0.0 111.861 -177.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 46.2 m -96.97 109.0 21.84 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 177.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.3 mm -118.79 120.8 65.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.096 -174.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.6 p -89.06 127.46 41.77 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.134 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.518 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 48.5 p90 -116.43 154.55 30.11 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -178.509 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -120.31 4.93 10.74 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-O 121.469 0.652 . . . . 0.0 110.561 -179.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -147.45 140.7 25.24 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.713 -175.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 46' ' ' TYR . 86.7 t -124.04 133.19 69.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 176.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.442 ' HA ' ' O ' ' A' ' 45' ' ' TRP . 61.5 m -130.27 135.18 47.83 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 122.315 0.246 . . . . 0.0 111.369 -176.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.4 mt -103.03 111.84 34.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 176.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.1 tp-100 -115.69 145.1 43.05 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 105.448 -2.056 . . . . 0.0 105.448 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.37 104.81 0.08 Allowed 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -174.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 115.31 -30.89 6.48 Favored Glycine 0 N--CA 1.434 -1.456 0 CA-C-N 115.61 -0.723 . . . . 0.0 113.836 177.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 64.0 m80 -145.46 150.97 37.47 Favored 'General case' 0 CA--C 1.504 -0.827 0 CA-C-N 118.196 0.998 . . . . 0.0 110.743 -175.018 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.8 tt -106.41 111.78 36.78 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 176.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 47.9 m95 -95.87 148.43 22.62 Favored 'General case' 0 C--N 1.285 -2.233 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.424 -169.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.484 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.4 pt -107.34 139.23 29.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.411 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -106.49 121.46 6.65 Favored Glycine 0 N--CA 1.431 -1.675 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -135.65 167.96 20.15 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.667 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -102.42 131.06 49.32 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.891 179.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -83.51 175.52 9.73 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 173.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 29.9 p90 -53.37 -36.24 61.19 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -178.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 25.6 p-10 -88.63 1.91 54.15 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 120.68 0.276 . . . . 0.0 111.322 -178.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.11 5.79 72.58 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 121.306 -0.473 . . . . 0.0 112.009 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 60.8 t30 -67.94 129.7 40.71 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 22.9 tpt180 -82.68 107.7 15.5 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 -178.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 27.8 t -111.62 142.85 22.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -178.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.484 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 85.0 m-85 -117.63 131.35 56.67 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 120.963 0.411 . . . . 0.0 110.628 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 45.3 t -112.9 134.47 21.75 Favored Pre-proline 0 C--N 1.302 -1.483 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -68.16 -27.14 35.68 Favored 'Trans proline' 0 C--N 1.358 1.038 0 C-N-CA 122.626 2.217 . . . . 0.0 113.35 -177.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.29 21.9 m 52.52 -46.59 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.284 0 N-CA-C 117.968 2.581 . . . . 0.0 117.968 176.47 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . 0.46 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 37.1 ptt180 -161.63 163.55 29.87 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 123.157 0.583 . . . . 0.0 110.068 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.8 t -81.69 141.51 33.54 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 175.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.9 t -156.18 127.78 7.24 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -109.17 139.12 44.51 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 142.49 177.91 17.98 Favored Glycine 0 N--CA 1.42 -2.393 0 C-N-CA 119.059 -1.543 . . . . 0.0 113.668 175.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 16.2 m -141.42 145.4 37.77 Favored Pre-proline 0 C--N 1.299 -1.593 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 178.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_exo -49.2 138.41 28.94 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 122.897 2.398 . . . . 0.0 112.922 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -85.29 -16.04 29.78 Favored 'Cis proline' 0 C--O 1.25 1.118 0 C-N-CA 123.366 -1.514 . . . . 0.0 113.618 0.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -80.54 100.98 8.85 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -171.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -106.41 123.95 48.85 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 114.336 -1.302 . . . . 0.0 111.29 178.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 70.4 mt -95.46 108.19 37.82 Favored Pre-proline 0 C--N 1.319 -0.73 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -84.23 130.67 4.76 Favored 'Trans proline' 0 C--O 1.249 1.04 0 C-N-CA 122.37 2.047 . . . . 0.0 112.841 -179.059 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -115.35 -147.93 9.26 Favored Glycine 0 N--CA 1.435 -1.374 0 C-N-CA 120.562 -0.827 . . . . 0.0 112.017 178.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.6 t -57.63 116.13 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.823 0 C-N-CA 123.819 0.848 . . . . 0.0 112.047 -179.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.46 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.19 143.87 26.0 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.431 173.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.6 m-90 -104.51 19.74 19.78 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.635 0.731 . . . . 0.0 109.584 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -165.77 -175.74 36.54 Favored Glycine 0 N--CA 1.428 -1.882 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 179.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 60.8 t -112.88 141.59 28.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -177.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -107.14 122.15 45.93 Favored 'General case' 0 C--N 1.321 -0.653 0 O-C-N 123.231 0.332 . . . . 0.0 110.54 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt . . . . . 0 C--N 1.297 -1.676 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 177.994 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 26.0 m . . . . . 0 N--CA 1.439 -1.013 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -166.56 108.19 0.69 Allowed 'General case' 0 C--N 1.319 -0.732 0 C-N-CA 123.473 0.709 . . . . 0.0 109.408 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -123.05 152.26 41.17 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 176.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 41.9 tttm -82.26 124.51 30.0 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -178.143 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 45.5 t30 -90.23 122.46 33.17 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 176.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 84.0 m-85 74.56 124.39 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.942 1.297 . . . . 0.0 110.92 -175.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 94.8 mmm -93.9 75.31 4.2 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 121.51 0.671 . . . . 0.0 109.289 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 31.3 p-10 -104.44 -176.1 2.98 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.985 -178.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 11.9 mptt 67.19 27.53 8.42 Favored 'General case' 0 N--CA 1.489 1.523 0 C-N-CA 124.427 1.091 . . . . 0.0 108.969 -172.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -94.23 80.67 0.96 Allowed Glycine 0 N--CA 1.421 -2.313 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.709 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 6.2 m -49.03 104.55 0.06 Allowed 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 123.744 0.818 . . . . 0.0 109.966 178.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.7 m -87.54 20.85 2.73 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 112.905 0.706 . . . . 0.0 112.905 -172.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.3 m -76.43 151.71 36.43 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.611 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.2 m -83.76 -26.08 29.97 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 120.618 -0.433 . . . . 0.0 111.395 -178.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.5 m 72.3 -28.79 0.19 Allowed 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 124.622 1.169 . . . . 0.0 113.11 178.028 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 15.7 m -76.61 83.73 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-O 122.188 0.994 . . . . 0.0 110.838 175.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 30.2 m -102.18 -9.31 9.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.821 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 23.2 tptm -74.22 88.92 2.01 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-O 121.336 0.589 . . . . 0.0 109.861 -178.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -155.96 104.16 2.27 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-N 115.321 -0.854 . . . . 0.0 108.723 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -159.95 58.61 0.32 Allowed Glycine 0 N--CA 1.431 -1.64 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.02 91.44 0.68 Allowed 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 -178.27 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.7 p -140.0 94.2 2.73 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.877 -177.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.0 m -82.18 104.39 12.48 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 11.9 m -62.17 -35.28 78.32 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.503 0.668 . . . . 0.0 109.402 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -126.82 109.47 12.03 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 173.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.2 m -100.99 -72.09 0.69 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 16.9 p -142.9 118.06 6.49 Favored Pre-proline 0 C--N 1.302 -1.46 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -59.19 -44.28 35.29 Favored 'Trans proline' 0 C--O 1.243 0.726 0 C-N-CA 121.934 1.756 . . . . 0.0 109.67 173.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 63.31 -175.24 0.15 Allowed 'General case' 0 C--O 1.246 0.88 0 C-N-CA 124.886 1.275 . . . . 0.0 111.274 179.066 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -82.15 79.53 8.61 Favored 'General case' 0 N--CA 1.431 -1.391 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.483 ' HB3' ' HD3' ' A' ' 32' ' ' PRO . 1.5 tmt_? -147.57 -54.92 0.02 OUTLIER Pre-proline 0 C--N 1.308 -1.236 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.267 -179.028 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.483 ' HD3' ' HB3' ' A' ' 31' ' ' ARG . 3.5 Cg_exo -81.91 92.09 1.01 Allowed 'Trans proline' 0 C--N 1.369 1.63 0 CA-C-N 120.66 1.271 . . . . 0.0 109.546 175.519 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 93.2 t -73.85 108.41 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.019 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.608 ' HA ' ' O ' ' A' ' 118' ' ' PRO . 7.6 p -80.43 148.75 30.41 Favored 'General case' 0 N--CA 1.411 -2.383 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.879 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -99.6 -146.05 19.26 Favored Glycine 0 N--CA 1.43 -1.733 0 CA-C-N 115.294 -0.866 . . . . 0.0 112.858 -179.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 6.0 m -85.44 27.41 0.82 Allowed 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 124.261 1.025 . . . . 0.0 111.278 -175.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 48.3 m95 -91.96 153.22 19.61 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.752 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -114.13 133.58 55.47 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -89.45 129.83 35.89 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 120.985 0.421 . . . . 0.0 111.201 -177.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 45.9 t-20 -99.83 160.0 14.64 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -65.26 -11.86 45.64 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -77.2 -5.57 49.7 Favored 'General case' 0 CA--C 1.541 0.633 0 CA-C-O 121.357 0.598 . . . . 0.0 109.996 176.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.26 1.83 83.7 Favored Glycine 0 CA--C 1.506 -0.492 0 N-CA-C 110.145 -1.182 . . . . 0.0 110.145 -177.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.414 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 9.2 m -89.42 141.01 28.94 Favored 'General case' 0 N--CA 1.415 -2.208 0 CA-C-N 113.86 -1.17 . . . . 0.0 109.299 -178.02 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.497 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 71.9 m95 -102.45 135.94 43.18 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 173.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.433 ' HA ' ' O ' ' A' ' 88' ' ' VAL . 32.0 p90 -137.4 155.47 49.33 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.702 -177.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -147.29 135.59 10.95 Favored Pre-proline 0 C--N 1.305 -1.364 0 CA-C-N 115.318 -0.855 . . . . 0.0 108.738 173.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -67.08 129.57 20.89 Favored 'Trans proline' 0 C--O 1.248 0.992 0 C-N-CA 122.264 1.976 . . . . 0.0 111.42 173.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -168.02 120.99 0.89 Allowed 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.57 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 15.9 m120 -88.57 109.5 20.13 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-O 120.906 0.384 . . . . 0.0 110.88 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.451 ' HB2' ' CZ ' ' A' ' 85' ' ' TYR . . . -135.45 165.73 24.8 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 178.09 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.413 ' HB ' ' HG3' ' A' ' 131' ' ' LYS . 25.9 m -114.0 136.51 52.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-O 121.479 0.656 . . . . 0.0 111.964 -175.492 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 69.6 t80 -117.74 127.01 53.49 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 114.986 -1.007 . . . . 0.0 108.288 176.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 46.0 t -105.41 105.6 18.97 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 178.301 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -76.42 121.51 23.16 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 178.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -149.63 -24.45 0.06 OUTLIER Glycine 0 C--N 1.309 -0.923 0 C-N-CA 118.325 -1.893 . . . . 0.0 114.654 -175.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -71.72 -53.14 14.45 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.172 0.511 . . . . 0.0 110.096 -177.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -156.21 159.83 31.2 Favored Pre-proline 0 C--N 1.312 -1.031 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.078 -176.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -67.77 131.67 24.8 Favored 'Trans proline' 0 C--O 1.248 0.991 0 C-N-CA 122.372 2.048 . . . . 0.0 110.135 173.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 47.4 mt -114.51 132.35 63.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -176.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.3 p -76.07 131.68 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 177.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 40.7 p -103.74 157.62 16.95 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.531 -177.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -110.78 143.88 40.63 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.3 mp -109.68 134.4 51.91 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 C-N-CA 120.531 -0.468 . . . . 0.0 111.22 -175.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.29 -22.74 1.99 Allowed Glycine 0 C--O 1.244 0.728 0 N-CA-C 117.157 1.623 . . . . 0.0 117.157 171.593 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.4 m -152.85 138.86 11.98 Favored Pre-proline 0 C--N 1.308 -1.197 0 CA-C-N 118.81 1.305 . . . . 0.0 111.462 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -89.75 120.49 0.94 Allowed 'Trans proline' 0 N--CA 1.441 -1.577 0 C-N-CA 121.992 1.795 . . . . 0.0 111.006 171.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -166.58 166.33 16.21 Favored 'General case' 0 CA--C 1.493 -1.216 0 C-N-CA 126.63 1.972 . . . . 0.0 105.819 -178.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 86.3 mt -72.23 -41.28 67.03 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.436 0.636 . . . . 0.0 109.296 176.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 21.8 p-10 -97.47 25.63 5.55 Favored 'General case' 0 C--O 1.246 0.894 0 C-N-CA 124.477 1.111 . . . . 0.0 110.709 -177.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -65.84 153.32 91.51 Favored Pre-proline 0 C--O 1.249 1.077 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.627 -178.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -47.44 128.62 15.23 Favored 'Trans proline' 0 C--N 1.368 1.555 0 C-N-CA 124.205 3.27 . . . . 0.0 114.077 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.3 p -102.73 172.99 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.44 28.61 1.92 Allowed Glycine 0 N--CA 1.442 -0.903 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.649 -176.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -161.66 131.23 2.51 Favored Glycine 0 N--CA 1.433 -1.566 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 176.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -127.82 141.38 51.58 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 117.336 0.568 . . . . 0.0 110.272 -179.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 50.7 tp -100.96 113.26 65.78 Favored Pre-proline 0 C--N 1.301 -1.521 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.007 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -73.64 156.8 49.07 Favored 'Trans proline' 0 C--O 1.252 1.209 0 C-N-CA 122.405 2.07 . . . . 0.0 111.456 179.05 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.52 142.77 42.77 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 108.35 -22.46 26.8 Favored Glycine 0 N--CA 1.434 -1.475 0 N-CA-C 110.438 -1.065 . . . . 0.0 110.438 -176.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.5 126.77 30.56 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-O 121.349 0.595 . . . . 0.0 111.298 -178.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 17.0 m -98.67 110.77 23.31 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 177.613 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.1 mm -111.51 131.07 63.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.286 -173.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.6 p -108.67 112.48 40.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 CA-C-O 122.04 0.924 . . . . 0.0 109.074 175.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.57 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 46.9 p90 -97.45 149.32 22.28 Favored 'General case' 0 C--N 1.296 -1.744 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.363 -177.517 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -112.92 -9.9 13.58 Favored 'General case' 0 C--N 1.31 -1.139 0 O-C-N 123.804 0.69 . . . . 0.0 111.238 -176.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 46.3 tt0 -134.94 128.98 33.54 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -175.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 46' ' ' TYR . 13.8 t -107.89 126.71 64.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.414 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 62.5 m -128.94 139.02 52.3 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -177.135 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 46.9 mt -112.22 119.37 60.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 173.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.486 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -124.94 144.1 50.53 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 104.638 -2.356 . . . . 0.0 104.638 174.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -51.15 104.13 0.07 Allowed 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 113.353 0.871 . . . . 0.0 113.353 -172.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.45 -39.97 1.76 Allowed Glycine 0 N--CA 1.431 -1.642 0 CA-C-N 115.436 -0.802 . . . . 0.0 113.236 177.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 53.0 m80 -147.74 157.58 43.61 Favored 'General case' 0 CA--C 1.497 -1.091 0 O-C-N 122.083 -0.657 . . . . 0.0 110.602 -174.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.9 tt -96.78 128.28 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.714 0 N-CA-C 105.296 -2.112 . . . . 0.0 105.296 172.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.486 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 72.1 m95 -106.41 135.45 47.87 Favored 'General case' 0 C--N 1.266 -3.023 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -173.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.5 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.4 pt -100.38 126.38 53.97 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.894 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 177.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -100.29 124.23 8.18 Favored Glycine 0 N--CA 1.42 -2.422 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.173 -177.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -148.23 173.07 13.37 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 177.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -119.17 145.51 45.94 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 177.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.404 ' HB3' ' OD1' ' A' ' 105' ' ' ASN . . . -93.85 170.23 9.71 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.336 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -73.35 -9.8 59.07 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.141 0.496 . . . . 0.0 111.64 -176.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -72.63 -16.41 61.72 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 174.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 98.57 4.14 57.19 Favored Glycine 0 C--N 1.33 0.208 0 C-N-CA 121.062 -0.59 . . . . 0.0 111.964 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.404 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 23.5 p-10 -96.06 145.15 25.7 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 120.938 0.399 . . . . 0.0 110.968 -179.385 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 28.9 tpt180 -86.15 122.36 30.04 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 179.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 43.0 t -119.21 143.2 31.18 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.261 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 -173.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.5 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 86.3 m-85 -125.52 129.17 49.22 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 123.579 0.751 . . . . 0.0 110.134 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.4 t -109.3 135.06 20.29 Favored Pre-proline 0 C--N 1.299 -1.592 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 178.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -68.24 -23.24 39.2 Favored 'Trans proline' 0 C--N 1.365 1.416 0 C-N-CA 123.202 2.602 . . . . 0.0 114.38 -177.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.3 35.4 m 45.22 -53.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.286 0 N-CA-C 119.077 2.992 . . . . 0.0 119.077 176.054 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -158.7 152.87 23.86 Favored 'General case' 0 C--N 1.314 -0.964 0 O-C-N 121.718 -0.614 . . . . 0.0 110.47 -178.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.52 ' O ' ' HA ' ' A' ' 123' ' ' PRO . 13.7 m -63.88 127.48 31.58 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 174.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.421 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 99.6 m -152.92 118.76 5.39 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 123.477 0.711 . . . . 0.0 109.361 177.044 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 26.7 mt-30 -129.58 148.83 51.52 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.34 -167.86 30.82 Favored Glycine 0 N--CA 1.417 -2.602 0 C-N-CA 119.11 -1.519 . . . . 0.0 112.149 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 10.8 m -123.99 108.03 30.45 Favored Pre-proline 0 C--N 1.291 -1.971 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.608 ' O ' ' HA ' ' A' ' 34' ' ' THR . 60.6 Cg_exo -43.17 129.2 5.92 Favored 'Trans proline' 0 C--N 1.349 0.584 0 C-N-CA 124.004 3.136 . . . . 0.0 113.024 -175.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -90.53 10.77 60.32 Favored 'Cis proline' 0 C--O 1.242 0.694 0 C-N-CA 124.115 -1.202 . . . . 0.0 115.114 8.44 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -75.28 100.06 4.25 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 -179.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.425 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 45.8 p-80 -106.08 109.83 21.89 Favored 'General case' 0 C--N 1.289 -2.053 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.112 177.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.421 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.5 mt -94.82 105.21 17.49 Favored Pre-proline 0 C--N 1.299 -1.606 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . 0.52 ' HA ' ' O ' ' A' ' 113' ' ' THR . 72.8 Cg_endo -84.4 153.67 12.22 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.58 2.187 . . . . 0.0 113.121 -176.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -125.81 -97.53 1.09 Allowed Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 178.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 40.5 t -96.68 118.67 43.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -178.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.06 120.34 34.19 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.179 178.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.8 m-90 -101.5 58.02 0.85 Allowed 'General case' 0 C--N 1.31 -1.149 0 CA-C-O 120.661 0.267 . . . . 0.0 111.345 -179.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . 155.85 -169.78 33.59 Favored Glycine 0 CA--C 1.497 -1.082 0 C-N-CA 119.693 -1.241 . . . . 0.0 112.499 178.15 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 97.9 t -111.94 128.68 68.38 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -112.07 136.87 50.89 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.152 -176.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.413 ' HG3' ' HB ' ' A' ' 52' ' ' THR . 18.1 ptpt . . . . . 0 N--CA 1.433 -1.315 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 175.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 20.0 m . . . . . 0 N--CA 1.443 -0.794 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -88.36 -34.62 17.53 Favored 'General case' 0 CA--C 1.497 -1.061 0 C-N-CA 120.925 -0.31 . . . . 0.0 110.251 178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 65.37 173.1 0.22 Allowed 'General case' 0 C--O 1.241 0.646 0 C-N-CA 124.732 1.213 . . . . 0.0 111.36 -177.392 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -125.55 94.06 4.03 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -81.95 139.38 34.63 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 176.164 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 68.75 38.21 2.23 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 -173.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 23.1 ptp -57.15 121.8 10.92 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.904 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -112.0 -168.22 1.28 Allowed 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 120.118 -0.633 . . . . 0.0 109.477 -175.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.506 ' HD3' ' N ' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -132.42 -174.99 3.61 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -171.754 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.6 -97.68 0.55 Allowed Glycine 0 C--N 1.296 -1.659 0 C-N-CA 119.884 -1.15 . . . . 0.0 113.629 175.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.403 ' C ' ' H ' ' A' ' 13' ' ' SER . 26.3 m -61.41 -49.99 74.63 Favored 'General case' 0 C--O 1.245 0.845 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 -174.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.0 m 70.03 -35.38 0.32 Allowed 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 124.728 1.211 . . . . 0.0 112.202 -177.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.403 ' H ' ' C ' ' A' ' 11' ' ' THR . 22.8 t -76.27 110.55 10.88 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 176.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 43.7 m -77.92 -35.53 50.47 Favored 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 46.1 m -69.9 127.96 34.69 Favored 'General case' 0 C--O 1.251 1.15 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 174.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.6 m -75.92 121.03 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.761 0 CA-C-O 121.613 0.72 . . . . 0.0 111.264 -178.06 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 12.0 p -85.57 -25.72 6.62 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.398 -0.819 . . . . 0.0 112.165 -173.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 74.7 mmtt -72.08 -27.48 62.69 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.27 -179.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -70.66 108.9 4.6 Favored 'General case' 0 C--O 1.249 1.049 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.175 177.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -133.71 56.15 0.73 Allowed Glycine 0 N--CA 1.42 -2.371 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 17.6 pttm -74.32 112.78 10.82 Favored 'General case' 0 N--CA 1.436 -1.164 0 CA-C-O 121.568 0.699 . . . . 0.0 110.292 178.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.3 p -125.62 -174.27 3.03 Favored 'General case' 0 C--N 1.289 -2.027 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.152 -178.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 38.0 t -57.89 121.83 11.48 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.7 m -102.76 116.59 32.88 Favored 'General case' 0 N--CA 1.429 -1.498 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.294 -175.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -99.9 101.23 12.28 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.395 -177.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 17.5 m -93.04 -37.92 11.91 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.362 -1.348 . . . . 0.0 107.362 173.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.6 m 48.33 93.45 0.05 OUTLIER Pre-proline 0 CA--C 1.546 0.827 0 C-N-CA 126.523 1.929 . . . . 0.0 114.623 173.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -69.07 85.75 0.51 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.701 2.268 . . . . 0.0 110.928 174.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -90.56 -44.9 9.26 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 18.7 m -74.06 -41.17 62.15 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 175.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 11.2 mtp-105 74.4 141.04 0.08 OUTLIER Pre-proline 0 C--N 1.356 0.87 0 C-N-CA 125.964 1.706 . . . . 0.0 111.823 177.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_endo -68.32 -61.74 0.07 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.961 0 N-CA-C 107.741 -1.677 . . . . 0.0 107.741 169.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 91.3 t -153.71 -48.77 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 105.708 -1.96 . . . . 0.0 105.708 172.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.581 ' HB ' ' O ' ' A' ' 37' ' ' TRP . 7.1 p -76.04 95.91 3.7 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 113.939 -1.482 . . . . 0.0 112.691 -179.125 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -107.96 -41.32 1.57 Allowed Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 176.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 49.8 m -81.34 -42.33 20.71 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 174.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . 0.581 ' O ' ' HB ' ' A' ' 34' ' ' THR . 92.1 m95 -85.47 127.25 34.34 Favored 'General case' 0 N--CA 1.436 -1.144 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.949 178.444 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -125.08 154.64 41.07 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -94.15 127.27 39.88 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 120.359 -0.536 . . . . 0.0 111.207 -176.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -84.48 151.28 24.72 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 174.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.9 pt20 -51.2 -27.45 8.92 Favored 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 123.739 0.816 . . . . 0.0 113.189 -178.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . 0.438 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 50.2 m-85 -81.73 3.16 26.66 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -177.257 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.71 18.82 59.27 Favored Glycine 0 CA--C 1.5 -0.844 0 C-N-CA 120.333 -0.937 . . . . 0.0 111.628 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 12.3 m -105.21 132.98 50.73 Favored 'General case' 0 N--CA 1.416 -2.134 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -96.39 129.73 43.67 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 177.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -129.54 154.67 46.81 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.422 -175.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -135.76 145.91 54.96 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 173.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_exo -69.3 121.86 8.65 Favored 'Trans proline' 0 C--O 1.249 1.041 0 C-N-CA 121.737 1.625 . . . . 0.0 109.469 172.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -150.18 120.9 7.53 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.43 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 3.0 t-20 -114.19 106.49 14.42 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.926 -0.71 . . . . 0.0 110.154 -175.617 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.89 -177.58 5.98 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.443 -178.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.444 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 13.3 m -104.68 150.12 24.98 Favored 'General case' 0 N--CA 1.429 -1.487 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -177.299 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -127.39 127.21 43.8 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 173.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.1 t -113.09 113.29 43.64 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.232 0 N-CA-C 106.795 -1.558 . . . . 0.0 106.795 176.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 53.2 t30 -64.76 152.57 42.27 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.639 -178.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -78.59 -146.3 3.12 Favored Glycine 0 N--CA 1.434 -1.434 0 CA-C-N 116.16 -0.473 . . . . 0.0 113.173 -177.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -86.97 7.54 27.07 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -173.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -138.92 137.25 19.29 Favored Pre-proline 0 C--N 1.302 -1.484 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.209 -175.213 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_exo -65.58 128.99 21.27 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.415 2.077 . . . . 0.0 110.757 176.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.2 mt -108.02 125.81 64.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -177.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.3 p -78.89 137.58 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.669 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 60.2 p -117.26 178.41 4.38 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.003 -172.472 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 33.9 mmt180 -116.81 146.59 42.77 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 60.7 mt -109.82 131.32 61.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.43 -175.28 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.2 -22.86 4.19 Favored Glycine 0 C--N 1.318 -0.42 0 N-CA-C 115.969 1.148 . . . . 0.0 115.969 171.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 39.1 m -153.61 140.77 13.24 Favored Pre-proline 0 C--N 1.298 -1.669 0 CA-C-N 117.875 0.837 . . . . 0.0 109.154 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -89.69 119.4 0.86 Allowed 'Trans proline' 0 N--CA 1.433 -2.036 0 C-N-CA 121.189 1.259 . . . . 0.0 110.347 173.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.467 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 82.4 m-85 -168.89 173.9 6.77 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 104.716 -2.328 . . . . 0.0 104.716 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -89.28 -34.25 16.66 Favored 'General case' 0 C--N 1.291 -1.969 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 176.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -97.87 22.49 9.16 Favored 'General case' 0 CA--C 1.548 0.904 0 CA-C-O 121.993 0.901 . . . . 0.0 109.803 -178.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.467 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -77.57 162.72 67.43 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.79 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -48.87 124.35 11.14 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 123.343 2.695 . . . . 0.0 113.559 178.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.0 p -97.83 173.73 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.195 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.367 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.62 -1.68 13.84 Favored Glycine 0 CA--C 1.502 -0.77 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.517 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -113.88 117.49 4.17 Favored Glycine 0 N--CA 1.429 -1.793 0 N-CA-C 108.849 -1.701 . . . . 0.0 108.849 174.36 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -126.8 128.14 46.12 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 117.737 0.769 . . . . 0.0 110.344 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 41.2 tp -96.55 119.76 63.39 Favored Pre-proline 0 C--N 1.309 -1.154 0 C-N-CA 123.282 0.633 . . . . 0.0 110.19 -175.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.02 165.08 25.09 Favored 'Trans proline' 0 CA--C 1.542 0.912 0 C-N-CA 122.805 2.337 . . . . 0.0 112.728 179.28 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.75 147.31 45.71 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.784 -177.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 69.52 5.91 52.34 Favored Glycine 0 N--CA 1.463 0.446 0 N-CA-C 114.247 0.459 . . . . 0.0 114.247 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.76 126.59 29.89 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-O 120.892 0.377 . . . . 0.0 111.417 -177.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 25.7 m -92.59 113.09 25.27 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 177.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.9 mm -122.55 138.97 50.89 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -176.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 p -103.47 129.33 55.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 175.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.43 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 32.2 p90 -117.71 150.56 38.87 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.591 -177.809 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -108.57 -12.36 14.99 Favored 'General case' 0 C--N 1.316 -0.856 0 O-C-N 123.473 0.483 . . . . 0.0 110.42 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -140.4 136.59 33.24 Favored 'General case' 0 N--CA 1.428 -1.54 0 C-N-CA 120.346 -0.542 . . . . 0.0 111.206 -172.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 71.4 t -118.62 127.85 75.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 176.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 19.6 p -135.46 147.73 49.01 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 120.898 0.38 . . . . 0.0 111.613 -175.252 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.5 mt -109.5 113.81 45.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-O 121.225 0.536 . . . . 0.0 110.546 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.583 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -110.42 122.56 47.99 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 104.761 -2.311 . . . . 0.0 104.761 174.457 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -47.85 114.29 0.88 Allowed 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 121.845 0.831 . . . . 0.0 113.068 -165.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 120.58 -25.15 7.38 Favored Glycine 0 N--CA 1.429 -1.826 0 CA-C-N 114.1 -1.409 . . . . 0.0 112.42 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 75.8 m80 -152.05 170.11 20.72 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 15.9 tt -111.62 136.44 47.72 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.179 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 172.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.583 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 48.2 m95 -121.96 139.07 54.12 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -173.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.49 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 47.5 pt -100.52 136.02 33.86 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.92 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 175.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -105.03 119.46 6.21 Favored Glycine 0 N--CA 1.419 -2.459 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -136.83 152.83 50.71 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 120.408 -0.517 . . . . 0.0 109.954 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -86.25 127.38 34.75 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 174.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.27 163.33 17.79 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 27.7 p90 -54.81 -31.36 59.03 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -176.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -76.29 -14.44 60.11 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-O 121.055 0.455 . . . . 0.0 111.046 -179.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 108.92 -9.58 34.19 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 121.137 -0.554 . . . . 0.0 113.279 178.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -75.84 148.08 38.63 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-O 120.754 0.311 . . . . 0.0 111.226 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -89.41 109.27 20.2 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 177.685 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 52.2 t -107.66 136.92 41.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.199 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -176.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.49 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 91.4 m-85 -116.33 126.0 52.91 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.4 t -105.44 131.85 21.39 Favored Pre-proline 0 C--N 1.301 -1.536 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -69.26 -11.4 31.39 Favored 'Trans proline' 0 C--N 1.364 1.375 0 C-N-CA 123.374 2.716 . . . . 0.0 113.794 -177.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.277 27.0 m 37.83 -63.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.148 0 N-CA-C 118.286 2.698 . . . . 0.0 118.286 174.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . 0.46 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 34.9 ptt180 -153.06 149.79 28.48 Favored 'General case' 0 N--CA 1.429 -1.488 0 C-N-CA 122.872 0.469 . . . . 0.0 110.219 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 19.4 m -67.8 136.76 54.66 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 41.8 t -150.39 139.24 20.88 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -176.324 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 78.3 mm-40 -119.6 161.61 20.36 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 130.22 -171.75 20.45 Favored Glycine 0 N--CA 1.421 -2.363 0 C-N-CA 120.034 -1.079 . . . . 0.0 112.448 174.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.6 m -141.41 138.57 17.69 Favored Pre-proline 0 C--N 1.295 -1.787 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_exo -47.73 131.64 20.36 Favored 'Trans proline' 0 CA--C 1.539 0.736 0 C-N-CA 122.945 2.43 . . . . 0.0 112.786 -177.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -96.65 7.5 40.89 Favored 'Cis proline' 0 CA--C 1.547 1.155 0 C-N-CA 124.492 -1.045 . . . . 0.0 113.884 1.19 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 44.4 t30 -76.27 102.39 5.83 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.636 0.732 . . . . 0.0 110.911 -175.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 -104.82 112.6 25.77 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 114.748 -1.115 . . . . 0.0 111.602 -178.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 59.3 mt -101.46 100.84 14.92 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -85.22 140.39 7.57 Favored 'Trans proline' 0 N--CA 1.452 -0.944 0 C-N-CA 122.87 2.38 . . . . 0.0 113.647 -177.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -110.66 -117.62 3.81 Favored Glycine 0 N--CA 1.436 -1.35 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 177.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 81.6 t -78.24 115.46 20.34 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 120.84 0.352 . . . . 0.0 110.861 -179.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.46 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.37 132.91 38.49 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.788 177.129 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.3 m-90 -102.35 8.07 40.36 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-O 121.488 0.661 . . . . 0.0 110.401 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.09 169.51 36.7 Favored Glycine 0 N--CA 1.431 -1.696 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 64.3 t -111.72 134.86 52.78 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 C-N-CA 122.895 0.478 . . . . 0.0 110.189 -175.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -97.68 132.62 43.16 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 178.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.444 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 48.7 tptt . . . . . 0 N--CA 1.413 -2.315 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -179.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 17.3 m . . . . . 0 N--CA 1.439 -1.004 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 31.7 p-10 -150.93 16.6 0.76 Allowed 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 122.426 0.291 . . . . 0.0 110.475 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -59.67 -48.58 81.1 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 123.199 0.312 . . . . 0.0 110.166 -178.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 12.7 mptt -93.0 -46.69 7.35 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 174.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 56.0 t30 70.69 137.21 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.426 1.491 . . . . 0.0 112.731 176.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -90.65 124.25 34.92 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 171.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -134.66 147.2 50.09 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -177.418 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -129.04 43.42 3.15 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 174.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.9 tpmt? -61.73 128.32 35.65 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.887 -175.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 102.29 -24.49 30.9 Favored Glycine 0 C--N 1.317 -0.502 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 -177.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.8 m -126.62 26.06 6.34 Favored 'General case' 0 C--N 1.308 -1.204 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 178.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.8 m -77.06 87.46 3.56 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 114.872 -1.058 . . . . 0.0 111.916 -174.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 25.8 m -146.2 75.57 1.41 Allowed 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 175.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 13.1 m -73.51 -51.32 17.48 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.358 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 31.6 m -123.92 124.24 42.19 Favored 'General case' 0 N--CA 1.419 -2.009 0 CA-C-N 115.549 -0.751 . . . . 0.0 108.994 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 35.0 m -86.2 142.82 12.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 174.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.9 t -115.61 -64.3 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 C-N-CA 120.798 -0.361 . . . . 0.0 111.683 -174.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 34.7 mtmm 65.51 -74.53 0.05 Allowed 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 125.344 1.458 . . . . 0.0 109.673 -174.164 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -169.71 144.51 2.89 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 105.578 -2.008 . . . . 0.0 105.578 177.122 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -89.84 -33.17 9.25 Favored Glycine 0 C--N 1.291 -1.956 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.793 -174.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 59.14 66.04 1.1 Allowed 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 -173.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 13.2 p -79.03 -74.9 0.26 Allowed 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.22 -179.527 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 39.2 m -132.7 11.07 4.37 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-O 122.601 1.191 . . . . 0.0 108.076 173.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 44.5 m -117.88 134.93 54.45 Favored 'General case' 0 N--CA 1.419 -1.994 0 CA-C-N 113.778 -1.555 . . . . 0.0 107.755 178.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 76.4 -49.67 0.58 Allowed 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 125.737 1.615 . . . . 0.0 111.106 -175.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.3 t -168.6 174.45 6.74 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 67.9 m -139.17 96.59 8.92 Favored Pre-proline 0 C--N 1.303 -1.45 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 175.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -76.69 96.29 1.08 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.795 2.33 . . . . 0.0 112.607 -178.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -149.69 -41.88 0.14 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.609 179.002 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 m -89.51 -37.11 14.98 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.094 -178.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.468 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 15.6 mmm180 -70.32 -58.53 4.81 Favored Pre-proline 0 CA--C 1.543 0.703 0 C-N-CA 120.772 -0.371 . . . . 0.0 110.487 175.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.468 ' HD3' ' HB2' ' A' ' 31' ' ' ARG . 5.4 Cg_exo -84.08 80.02 2.49 Favored 'Trans proline' 0 C--N 1.365 1.411 0 N-CA-C 108.273 -1.472 . . . . 0.0 108.273 169.183 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 14.7 p -98.27 143.02 13.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.112 -173.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 8.9 m -75.37 98.92 3.97 Favored 'General case' 0 N--CA 1.431 -1.398 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 167.98 -26.5 0.14 Allowed Glycine 0 C--N 1.305 -1.183 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -177.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 6.8 m -66.37 -31.99 73.11 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.709 0.766 . . . . 0.0 109.022 174.691 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 34.5 m95 -92.0 145.93 24.14 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 114.741 -1.118 . . . . 0.0 108.231 177.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -113.35 150.56 32.43 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.401 ' HG2' ' O ' ' A' ' 40' ' ' ASN . 38.2 ttpt -110.15 136.2 49.75 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 118.376 -1.33 . . . . 0.0 111.528 -178.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.401 ' O ' ' HG2' ' A' ' 39' ' ' LYS . 45.9 t-20 -94.35 161.67 14.14 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 105.955 -1.869 . . . . 0.0 105.955 175.079 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 34.7 mt-30 -67.28 -13.31 61.87 Favored 'General case' 0 C--O 1.213 -0.836 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -173.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 47.9 m-85 -76.3 -1.24 25.67 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.352 0.596 . . . . 0.0 110.214 177.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.39 24.26 59.3 Favored Glycine 0 CA--C 1.494 -1.266 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.44 HG21 ' HB2' ' A' ' 89' ' ' CYS . 13.5 m -105.37 124.66 49.92 Favored 'General case' 0 N--CA 1.414 -2.231 0 CA-C-N 114.662 -0.769 . . . . 0.0 109.608 -178.503 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.548 ' CG ' ' HG3' ' A' ' 118' ' ' PRO . 84.1 m95 -93.3 131.11 38.74 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.18 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 54.2 p90 -132.75 151.85 51.89 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -175.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 16.8 ptmt -129.02 132.47 24.39 Favored Pre-proline 0 C--N 1.303 -1.443 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.664 175.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_exo -72.78 122.05 7.87 Favored 'Trans proline' 0 C--O 1.244 0.79 0 C-N-CA 121.835 1.69 . . . . 0.0 111.001 175.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -162.25 131.49 4.38 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 177.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.408 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 23.8 t-20 -110.03 123.46 49.71 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 120.699 -0.4 . . . . 0.0 110.182 -177.657 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -160.07 177.2 10.95 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -108.22 152.01 25.16 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 121.022 0.439 . . . . 0.0 112.126 -178.752 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.45 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 91.4 t80 -122.55 123.66 41.73 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 176.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 43.7 t -103.17 104.88 17.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 29.1 t30 -76.98 123.52 26.44 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 175.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -147.1 24.32 1.59 Allowed Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 118.973 -1.584 . . . . 0.0 113.308 -177.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -113.77 -50.71 2.82 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.256 179.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -158.22 164.96 19.65 Favored Pre-proline 0 C--N 1.315 -0.921 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -69.27 125.87 12.93 Favored 'Trans proline' 0 C--O 1.254 1.301 0 N-CA-C 108.121 -1.531 . . . . 0.0 108.121 170.164 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 41.4 mt -108.12 130.17 61.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 110.127 -0.323 . . . . 0.0 110.127 -173.267 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 39.7 t -69.16 122.16 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.817 0 CA-C-O 121.968 0.889 . . . . 0.0 110.308 176.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -96.16 155.9 16.56 Favored 'General case' 0 N--CA 1.405 -2.689 0 CA-C-N 114.181 -1.372 . . . . 0.0 108.651 -176.242 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 15.6 mmt180 -112.24 141.64 45.7 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -178.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.2 mt -109.39 120.29 60.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 113.11 0.782 . . . . 0.0 113.11 -173.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.67 -22.51 27.49 Favored Glycine 0 C--O 1.236 0.249 0 N-CA-C 116.343 1.297 . . . . 0.0 116.343 170.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.7 m -155.01 140.26 12.28 Favored Pre-proline 0 C--N 1.307 -1.257 0 CA-C-N 118.502 1.151 . . . . 0.0 111.292 -178.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -89.93 119.96 0.86 Allowed 'Trans proline' 0 N--CA 1.437 -1.844 0 C-N-CA 121.716 1.611 . . . . 0.0 110.778 172.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -162.5 162.76 27.58 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 68.3 mt -80.1 -13.99 58.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 121.748 0.785 . . . . 0.0 109.434 177.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.4 p-10 -116.19 19.52 14.85 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.606 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.83 146.1 95.33 Favored Pre-proline 0 C--O 1.243 0.757 0 CA-C-N 115.386 -0.825 . . . . 0.0 112.201 -176.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -48.76 131.66 24.92 Favored 'Trans proline' 0 C--O 1.249 1.035 0 C-N-CA 124.104 3.203 . . . . 0.0 113.916 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.1 m -97.41 174.59 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 CA-C-N 114.552 -1.204 . . . . 0.0 110.483 -178.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.92 28.12 2.12 Favored Glycine 0 C--N 1.305 -1.192 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.021 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.81 132.67 4.1 Favored Glycine 0 N--CA 1.427 -1.924 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 176.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -128.35 125.77 39.38 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 117.597 0.699 . . . . 0.0 110.918 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 65.3 tp -88.26 111.69 44.86 Favored Pre-proline 0 N--CA 1.426 -1.634 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -63.43 152.4 80.26 Favored 'Trans proline' 0 C--O 1.251 1.146 0 C-N-CA 122.147 1.898 . . . . 0.0 112.553 -179.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.41 138.16 41.5 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.292 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.82 3.13 62.45 Favored Glycine 0 N--CA 1.441 -0.997 0 N-CA-C 111.434 -0.666 . . . . 0.0 111.434 -178.6 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.49 139.07 31.15 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-O 121.171 0.51 . . . . 0.0 111.188 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 39.0 m -113.53 113.55 25.27 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 177.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.1 mm -110.18 139.87 31.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -176.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.0 p -95.31 127.13 47.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 176.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.408 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 46.3 p90 -110.11 154.44 23.28 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.472 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -116.35 -9.09 11.57 Favored 'General case' 0 C--O 1.25 1.089 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.36 -177.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -144.84 131.69 20.18 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.876 -174.114 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 32.1 t -109.61 124.56 66.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 105.832 -1.914 . . . . 0.0 105.832 175.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.44 ' HB2' HG21 ' A' ' 44' ' ' THR . 24.6 p -137.5 148.49 46.06 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.871 -0.732 . . . . 0.0 112.624 -175.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 68.8 mt -111.4 124.15 67.9 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-O 121.061 0.458 . . . . 0.0 110.623 179.389 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.49 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -125.14 112.98 17.11 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 103.827 -2.657 . . . . 0.0 103.827 171.446 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.96 106.12 0.1 Allowed 'General case' 0 N--CA 1.479 0.983 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -164.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 141.63 -33.03 2.0 Favored Glycine 0 N--CA 1.439 -1.149 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -177.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 56.3 m80 -152.02 163.37 39.44 Favored 'General case' 0 CA--C 1.505 -0.786 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.3 tt -106.65 135.07 46.38 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 171.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.49 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 58.7 m95 -118.12 140.31 49.96 Favored 'General case' 0 C--N 1.28 -2.419 0 O-C-N 122.209 -0.307 . . . . 0.0 110.475 -171.118 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 48.1 pt -100.6 131.53 48.0 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 174.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.34 121.52 7.21 Favored Glycine 0 N--CA 1.417 -2.599 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . 0.403 ' HB3' ' HA ' ' A' ' 85' ' ' TYR . 39.0 p90 -132.17 146.58 52.12 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-O 121.466 0.651 . . . . 0.0 111.122 178.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -99.74 119.97 38.98 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.82 -1.082 . . . . 0.0 108.455 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.9 176.31 7.4 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.395 -177.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -66.0 -21.34 66.39 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.464 0.649 . . . . 0.0 112.019 -179.066 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -80.04 -14.52 58.48 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.985 177.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 84.62 5.59 86.53 Favored Glycine 0 C--O 1.24 0.475 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -174.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -80.79 132.98 35.56 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 27.2 tpt180 -88.48 104.89 17.23 Favored 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -178.082 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 15.5 t -107.12 142.75 19.13 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -175.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -125.61 127.1 45.81 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.088 0.471 . . . . 0.0 111.75 -178.184 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 52.8 t -107.51 135.4 19.73 Favored Pre-proline 0 C--N 1.307 -1.278 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -72.21 -12.63 27.93 Favored 'Trans proline' 0 C--N 1.36 1.156 0 C-N-CA 123.19 2.593 . . . . 0.0 114.503 -176.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.282 32.8 m 43.77 -56.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.516 2.827 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 175.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . 0.514 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 38.2 ptt180 -159.98 151.05 19.29 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.03 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.2 t -73.42 143.14 46.86 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.9 t -155.26 136.98 14.35 Favored 'General case' 0 N--CA 1.421 -1.919 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -177.185 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 21.6 mt-30 -122.52 157.1 32.78 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 133.91 -163.83 24.47 Favored Glycine 0 N--CA 1.429 -1.815 0 C-N-CA 120.048 -1.072 . . . . 0.0 112.018 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 18.5 m -142.22 149.92 53.52 Favored Pre-proline 0 C--N 1.307 -1.272 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.548 ' HG3' ' CG ' ' A' ' 45' ' ' TRP . 33.3 Cg_endo -60.2 131.21 37.68 Favored 'Trans proline' 0 CA--C 1.541 0.843 0 C-N-CA 122.388 2.059 . . . . 0.0 112.412 -177.007 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.408 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 11.1 Cg_endo -99.59 8.81 26.2 Favored 'Cis proline' 0 C--O 1.251 1.154 0 C-N-CA 125.28 -0.717 . . . . 0.0 113.351 -0.454 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.1 t30 -75.04 100.63 4.24 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 122.106 0.955 . . . . 0.0 109.896 -177.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 48.3 p-80 -105.72 119.78 40.01 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 114.416 -1.266 . . . . 0.0 111.578 -177.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 62.1 mt -100.83 101.61 16.42 Favored Pre-proline 0 C--N 1.305 -1.35 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -85.06 130.45 4.08 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.732 2.288 . . . . 0.0 113.109 -177.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -103.87 -131.12 7.11 Favored Glycine 0 N--CA 1.433 -1.564 0 N-CA-C 111.199 -0.761 . . . . 0.0 111.199 177.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 48.8 t -68.05 120.03 14.77 Favored 'Isoleucine or valine' 0 C--O 1.252 1.195 0 C-N-CA 123.005 0.522 . . . . 0.0 111.003 -178.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.514 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -94.22 148.75 21.89 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.685 177.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.4 m-90 -116.2 8.28 14.32 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.399 0.619 . . . . 0.0 110.033 177.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.45 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -167.09 171.86 41.99 Favored Glycine 0 N--CA 1.431 -1.66 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 60.2 t -112.51 135.25 52.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 -177.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -85.8 121.99 29.23 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 176.148 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.284 -2.265 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 -175.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.444 -0.767 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -70.11 -46.27 65.18 Favored 'General case' 0 CA--C 1.502 -0.876 0 CA-C-O 121.308 0.575 . . . . 0.0 110.415 -179.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -94.3 120.0 33.91 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 175.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -115.42 133.28 56.18 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-O 121.081 0.467 . . . . 0.0 111.085 -176.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -157.01 97.65 1.69 Allowed 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 175.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -62.72 -49.7 74.01 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.131 -0.94 . . . . 0.0 111.267 -174.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 69.9 mtm -97.64 92.24 5.8 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 177.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -118.13 93.27 4.07 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.738 -174.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 31.2 mmtp 64.32 9.7 5.07 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 124.344 1.058 . . . . 0.0 112.392 173.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -81.83 68.29 3.51 Favored Glycine 0 N--CA 1.438 -1.221 0 N-CA-C 115.753 1.061 . . . . 0.0 115.753 -170.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 12.5 p -70.8 96.12 1.21 Allowed 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 171.007 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.7 m -64.73 -54.87 24.66 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 113.469 0.914 . . . . 0.0 113.469 -172.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.5 m -124.19 147.94 47.63 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -176.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.5 m -87.34 90.06 8.23 Favored 'General case' 0 N--CA 1.418 -2.057 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.595 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.6 t -77.95 -22.04 50.1 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 122.617 1.198 . . . . 0.0 107.835 177.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p -134.73 129.65 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.479 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 172.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 9.1 m -79.23 84.79 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 CA-C-O 122.283 1.039 . . . . 0.0 111.516 -178.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 22.5 ttmm -65.58 116.39 6.78 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 113.757 -1.565 . . . . 0.0 110.386 -177.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -121.52 114.33 21.08 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.011 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 164.75 -32.07 0.25 Allowed Glycine 0 N--CA 1.432 -1.608 0 C-N-CA 120.464 -0.874 . . . . 0.0 112.393 -179.294 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 60.9 tttm -89.7 65.31 6.81 Favored 'General case' 0 C--O 1.245 0.838 0 CA-C-O 121.818 0.818 . . . . 0.0 110.734 -178.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 94.0 m -163.97 104.82 0.9 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 124.857 1.263 . . . . 0.0 107.992 177.432 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.1 m -81.82 113.37 19.72 Favored 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 177.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 5.5 m -56.11 -45.18 79.55 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 124.176 0.99 . . . . 0.0 112.726 -174.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -143.79 105.25 4.28 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.213 0.53 . . . . 0.0 110.624 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 17.1 m -113.22 -32.19 6.38 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.954 177.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.5 p -78.44 121.57 83.91 Favored Pre-proline 0 N--CA 1.434 -1.266 0 CA-C-N 115.496 -0.775 . . . . 0.0 112.386 -176.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_exo -67.23 -25.4 42.99 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 122.913 2.409 . . . . 0.0 112.247 174.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 64.73 -163.33 0.26 Allowed 'General case' 0 C--O 1.248 0.999 0 C-N-CA 124.077 0.951 . . . . 0.0 109.581 -177.033 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.9 p -81.45 66.17 6.88 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.801 0.81 . . . . 0.0 111.184 179.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 40.1 ttm180 -120.69 -53.44 0.04 OUTLIER Pre-proline 0 C--N 1.305 -1.354 0 CA-C-N 114.937 -1.029 . . . . 0.0 112.909 -177.09 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -70.23 98.52 0.74 Allowed 'Trans proline' 0 C--N 1.375 1.942 0 CA-C-N 120.643 1.265 . . . . 0.0 110.062 173.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 54.6 t -123.1 111.99 31.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 CA-C-O 121.085 0.469 . . . . 0.0 112.015 -173.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 15.0 t -115.79 0.97 13.33 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 170.101 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 81.89 -150.16 29.03 Favored Glycine 0 N--CA 1.426 -1.978 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.665 -178.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 3.3 p -93.12 19.19 8.23 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 123.792 0.837 . . . . 0.0 111.054 -179.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . 0.422 ' CZ2' ' HE2' ' A' ' 47' ' ' LYS . 30.4 m95 -91.67 141.37 28.77 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.712 -175.404 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -114.19 152.4 31.27 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 175.224 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -102.76 121.24 42.06 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.616 179.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.437 ' HB3' ' CE1' ' A' ' 46' ' ' TYR . 37.2 p30 -85.42 -178.29 6.67 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.774 -176.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -66.73 -16.67 64.4 Favored 'General case' 0 C--N 1.323 -0.575 0 C-N-CA 123.674 0.789 . . . . 0.0 113.037 -178.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 67.8 m-85 -93.77 2.69 56.18 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.449 0.643 . . . . 0.0 110.096 -177.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.8 25.56 66.91 Favored Glycine 0 N--CA 1.442 -0.942 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.444 ' HG1' ' NE2' ' A' ' 91' ' ' GLN . 12.8 m -105.26 141.21 37.19 Favored 'General case' 0 N--CA 1.425 -1.71 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -92.78 120.56 33.28 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 174.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.437 ' CE1' ' HB3' ' A' ' 40' ' ' ASN . 23.9 p90 -128.02 149.68 50.26 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 120.623 0.249 . . . . 0.0 110.611 -175.599 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.422 ' HE2' ' CZ2' ' A' ' 37' ' ' TRP . 52.2 pttt -139.33 140.4 25.75 Favored Pre-proline 0 C--N 1.295 -1.797 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 173.737 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_exo -71.23 127.23 13.18 Favored 'Trans proline' 0 C--O 1.255 1.36 0 C-N-CA 122.057 1.838 . . . . 0.0 110.314 174.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -164.78 120.85 1.46 Allowed 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -179.116 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.483 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 19.8 t-20 -103.02 109.54 21.12 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 120.962 0.41 . . . . 0.0 110.883 -174.647 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.47 ' HB2' ' CZ ' ' A' ' 85' ' ' TYR . . . -145.28 172.35 13.27 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 14.1 m -107.68 134.76 50.19 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.939 0.4 . . . . 0.0 111.412 -173.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 72.9 t80 -112.36 122.46 47.77 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 39.0 t -108.23 103.77 16.01 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.866 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 178.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 30.2 t30 -76.4 131.61 39.21 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -144.68 2.52 1.25 Allowed Glycine 0 N--CA 1.432 -1.623 0 C-N-CA 119.307 -1.425 . . . . 0.0 113.546 -179.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -93.74 -52.06 4.63 Favored 'General case' 0 C--N 1.318 -0.789 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.826 -175.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 17.1 pt20 -159.25 171.64 7.12 Favored Pre-proline 0 C--N 1.314 -0.96 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -173.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -69.0 122.11 8.99 Favored 'Trans proline' 0 N--CA 1.44 -1.655 0 N-CA-C 107.604 -1.729 . . . . 0.0 107.604 166.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 58.7 mt -107.84 123.32 63.19 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -175.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 25.9 m -79.93 139.42 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.366 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 175.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.5 p -118.36 178.94 4.26 Favored 'General case' 0 C--N 1.272 -2.781 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.918 -172.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.413 ' HG3' ' O ' ' A' ' 68' ' ' PHE . 82.0 mmt-85 -115.48 136.64 52.88 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 176.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 63.8 mt -97.24 121.29 47.61 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.64 -174.08 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 77.56 -16.87 5.89 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 116.034 1.173 . . . . 0.0 116.034 172.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.2 m -151.82 137.77 11.36 Favored Pre-proline 0 C--N 1.305 -1.336 0 CA-C-N 118.24 1.02 . . . . 0.0 110.204 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -89.93 119.19 0.8 Allowed 'Trans proline' 0 N--CA 1.434 -1.975 0 C-N-CA 121.163 1.242 . . . . 0.0 110.811 173.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.423 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 92.9 m-85 -169.55 168.73 9.14 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 178.6 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.96 -31.77 27.45 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 171.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -95.27 17.01 15.16 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.179 -0.918 . . . . 0.0 112.204 -178.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -79.0 162.75 63.43 Favored Pre-proline 0 C--N 1.311 -1.095 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -54.69 122.14 11.07 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 122.343 2.029 . . . . 0.0 112.438 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 13.8 p -104.1 172.94 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.944 -179.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.33 -13.32 10.29 Favored Glycine 0 CA--C 1.502 -0.745 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 -179.067 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.46 108.83 3.08 Favored Glycine 0 N--CA 1.432 -1.597 0 N-CA-C 108.338 -1.905 . . . . 0.0 108.338 172.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -111.5 123.43 50.21 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 117.697 0.748 . . . . 0.0 110.339 -176.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 40.6 tp -98.83 114.27 65.27 Favored Pre-proline 0 C--N 1.302 -1.496 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -68.43 161.64 44.07 Favored 'Trans proline' 0 C--O 1.249 1.058 0 C-N-CA 122.236 1.957 . . . . 0.0 112.642 -178.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.41 139.42 42.32 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.83 5.82 58.41 Favored Glycine 0 N--CA 1.436 -1.352 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -85.86 128.84 34.92 Favored 'General case' 0 N--CA 1.432 -1.357 0 CA-C-O 121.033 0.444 . . . . 0.0 111.233 -178.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 37.0 m -103.91 110.25 22.31 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.1 mm -126.32 130.74 71.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 -175.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.9 p -88.69 133.93 29.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 176.246 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.483 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 40.1 p90 -109.98 151.17 27.47 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -124.67 -0.4 8.05 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 122.075 0.941 . . . . 0.0 110.391 -174.091 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -146.34 133.0 19.88 Favored 'General case' 0 N--CA 1.428 -1.526 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 -176.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 51.4 t -119.34 128.14 75.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.413 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 23.5 p -141.51 145.46 35.21 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -176.314 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.421 HG13 ' CZ3' ' A' ' 37' ' ' TRP . 58.4 mt -107.16 117.04 52.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 175.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.492 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -118.12 117.59 29.59 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 103.327 -2.842 . . . . 0.0 103.327 171.211 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.47 110.44 0.34 Allowed 'General case' 0 C--N 1.315 -0.91 0 O-C-N 124.822 1.326 . . . . 0.0 112.876 -167.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 143.37 -42.86 1.05 Allowed Glycine 0 N--CA 1.42 -2.394 0 CA-C-N 113.582 -1.645 . . . . 0.0 109.345 -176.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . 0.448 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 73.7 m80 -153.4 165.93 34.26 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -179.256 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.5 tt -99.98 129.32 50.82 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 105.223 -2.14 . . . . 0.0 105.223 171.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.492 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 57.0 m95 -112.5 134.53 53.98 Favored 'General case' 0 C--N 1.274 -2.682 0 CA-C-O 120.997 0.427 . . . . 0.0 110.039 -172.029 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 44.8 pt -100.44 128.82 52.08 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 175.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -94.22 114.78 4.86 Favored Glycine 0 N--CA 1.416 -2.695 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 178.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 54.5 p90 -127.2 167.67 15.74 Favored 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 -178.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.1 m-80 -108.16 129.49 55.17 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.54 176.46 9.77 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -55.95 -27.16 51.2 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.961 0.905 . . . . 0.0 112.152 -178.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 32.9 p-10 -104.31 13.11 32.72 Favored 'General case' 0 C--N 1.322 -0.628 0 C-N-CA 123.241 0.616 . . . . 0.0 111.247 -175.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 77.88 21.78 70.54 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 121.089 -0.577 . . . . 0.0 113.28 177.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 50.2 t-20 -85.84 132.51 34.09 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 178.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -85.76 98.35 10.68 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 21.6 t -108.95 147.01 13.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 -175.322 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.528 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 94.7 m-85 -117.19 121.62 41.73 Favored 'General case' 0 C--N 1.314 -0.964 0 C-N-CA 122.494 0.317 . . . . 0.0 110.758 -178.072 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . 0.443 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 53.7 t -101.03 135.1 20.02 Favored Pre-proline 0 C--N 1.315 -0.902 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.05 -16.11 36.22 Favored 'Trans proline' 0 C--N 1.361 1.205 0 C-N-CA 123.322 2.681 . . . . 0.0 114.863 -176.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.308 33.0 m 42.21 -55.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.519 3.0 0 N-CA-C 118.837 2.903 . . . . 0.0 118.837 176.322 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . 0.453 ' CZ ' ' HB2' ' A' ' 126' ' ' ALA . 8.2 ptp180 -153.97 148.98 26.76 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 123.868 0.867 . . . . 0.0 108.704 175.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.448 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 24.3 m -66.33 135.33 54.23 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 177.476 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 97.5 m -150.78 124.94 9.36 Favored 'General case' 0 CA--C 1.511 -0.524 0 CA-C-O 121.431 0.634 . . . . 0.0 112.467 -178.784 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -110.44 151.57 27.35 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 174.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.37 -171.25 22.64 Favored Glycine 0 C--N 1.3 -1.462 0 C-N-CA 118.251 -1.928 . . . . 0.0 114.092 177.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 64.9 t -137.44 127.67 15.69 Favored Pre-proline 0 C--N 1.309 -1.191 0 N-CA-C 105.947 -1.871 . . . . 0.0 105.947 -178.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_exo -46.36 137.18 14.72 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.371 2.714 . . . . 0.0 112.804 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -86.61 -15.54 29.39 Favored 'Cis proline' 0 CA--C 1.542 0.877 0 C-N-CA 123.228 -1.572 . . . . 0.0 113.896 1.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -75.85 100.16 4.69 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 122.136 0.969 . . . . 0.0 111.645 -173.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 54.7 p-80 -106.34 138.53 42.35 Favored 'General case' 0 C--N 1.296 -1.717 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.808 176.109 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.537 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.0 mm -90.22 108.83 29.09 Favored Pre-proline 0 C--N 1.3 -1.565 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 176.33 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -84.66 123.91 2.98 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.457 2.105 . . . . 0.0 113.587 -176.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -95.25 -134.62 7.79 Favored Glycine 0 N--CA 1.436 -1.33 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 175.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 69.4 t -81.74 126.69 39.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 C-N-CA 122.982 0.513 . . . . 0.0 110.475 -179.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.453 ' HB2' ' CZ ' ' A' ' 112' ' ' ARG . . . -93.87 145.74 24.4 Favored 'General case' 0 CA--C 1.507 -0.689 0 O-C-N 123.75 0.657 . . . . 0.0 109.294 174.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.0 m-90 -110.33 18.3 20.0 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.344 0.592 . . . . 0.0 111.278 179.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -166.57 -173.12 34.62 Favored Glycine 0 N--CA 1.432 -1.579 0 C-N-CA 120.045 -1.074 . . . . 0.0 112.173 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 48.7 t -110.98 131.11 63.1 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -103.54 120.44 40.87 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.299 -1.61 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 17.6 m . . . . . 0 N--CA 1.444 -0.767 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -85.5 79.96 9.24 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 177.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -162.67 115.77 1.67 Allowed 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.853 -177.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -93.44 124.37 37.39 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 173.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 7.9 t30 70.44 85.36 0.13 Allowed 'General case' 0 CA--C 1.508 -0.646 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 -169.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -74.82 89.1 2.31 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.084 -174.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 52.6 ttm -143.08 74.69 1.45 Allowed 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 172.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -165.26 73.77 0.21 Allowed 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 114.324 -1.307 . . . . 0.0 108.89 -178.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.427 ' HZ2' ' HB2' ' A' ' 9' ' ' LYS . 4.3 ttmp? 173.78 122.65 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 125.09 1.356 . . . . 0.0 108.851 177.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -119.12 160.73 14.07 Favored Glycine 0 N--CA 1.421 -2.32 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 176.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 20.1 m -115.36 71.46 0.77 Allowed 'General case' 0 N--CA 1.419 -2.024 0 CA-C-O 121.915 0.864 . . . . 0.0 109.839 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 20.2 m -89.31 -15.83 32.53 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.298 177.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 34.9 t -120.82 121.18 37.59 Favored 'General case' 0 N--CA 1.423 -1.809 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 177.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.403 ' O ' ' HB ' ' A' ' 15' ' ' THR . 7.3 m -77.59 109.28 11.42 Favored 'General case' 0 N--CA 1.432 -1.339 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 175.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.403 ' HB ' ' O ' ' A' ' 14' ' ' SER . 31.8 m 76.64 160.12 0.22 Allowed 'General case' 0 CA--C 1.566 1.589 0 O-C-N 124.44 1.088 . . . . 0.0 108.234 -175.298 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 34.1 m -68.46 -20.31 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 O-C-N 121.378 -0.827 . . . . 0.0 111.137 -179.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.9 t 66.01 83.01 0.06 OUTLIER 'Isoleucine or valine' 0 C--O 1.247 0.954 0 C-N-CA 124.287 1.035 . . . . 0.0 109.599 -179.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 2.7 tmtp? -80.74 84.54 6.26 Favored 'General case' 0 N--CA 1.428 -1.532 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 178.488 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -167.15 141.69 3.88 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 -177.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -82.07 -78.37 1.01 Allowed Glycine 0 N--CA 1.43 -1.754 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 177.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 3.1 tppp? -153.08 75.36 1.07 Allowed 'General case' 0 N--CA 1.422 -1.836 0 CA-C-O 121.313 0.578 . . . . 0.0 109.804 177.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 31.7 m -97.6 -20.09 17.9 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-O 121.798 0.809 . . . . 0.0 109.169 176.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 34.0 t -82.33 102.58 11.31 Favored 'General case' 0 N--CA 1.425 -1.678 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.419 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 65.3 m -87.72 120.88 29.48 Favored 'General case' 0 N--CA 1.428 -1.527 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 173.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 70.25 -83.9 0.03 OUTLIER 'General case' 0 C--O 1.225 -0.198 0 C-N-CA 124.708 1.203 . . . . 0.0 110.349 -175.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 33.8 t -156.49 140.96 16.76 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.2 p -111.2 97.19 34.22 Favored Pre-proline 0 C--N 1.296 -1.728 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -61.39 -80.42 0.01 OUTLIER 'Trans proline' 0 N--CA 1.448 -1.183 0 C-N-CA 122.358 2.038 . . . . 0.0 113.384 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 52.71 26.3 4.36 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.366 0.666 . . . . 0.0 111.756 -178.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 m 65.85 16.47 10.49 Favored 'General case' 0 CA--C 1.57 1.748 0 C-N-CA 124.11 0.964 . . . . 0.0 111.349 -177.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.496 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 26.2 mtp180 -72.46 -46.93 10.1 Favored Pre-proline 0 CA--C 1.546 0.82 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 175.207 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.496 ' HD3' ' HB2' ' A' ' 31' ' ' ARG . 1.2 Cg_endo -91.81 136.87 1.81 Allowed 'Trans proline' 0 N--CA 1.439 -1.679 0 C-N-CA 121.805 1.67 . . . . 0.0 108.129 163.189 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.3 p -74.54 -41.44 48.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.886 -0.725 . . . . 0.0 111.338 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 22.5 p -88.73 74.43 8.35 Favored 'General case' 0 N--CA 1.429 -1.514 0 CA-C-O 121.202 0.525 . . . . 0.0 111.574 -177.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 66.49 -116.96 8.85 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.123 179.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.6 m -106.91 4.59 27.47 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-O 120.894 0.378 . . . . 0.0 110.438 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -91.95 130.53 37.68 Favored 'General case' 0 CA--C 1.513 -0.476 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.047 -177.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 53.2 tptt -120.31 153.9 35.76 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -95.94 125.44 40.49 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 118.917 -1.113 . . . . 0.0 110.458 -177.349 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.444 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 53.0 t30 -77.2 166.44 23.21 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.116 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 66.7 mm-40 -71.2 4.72 2.6 Favored 'General case' 0 C--N 1.312 -1.044 0 C-N-CA 123.548 0.739 . . . . 0.0 112.488 -174.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -104.5 -0.42 27.88 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.249 0.547 . . . . 0.0 110.493 175.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 91.51 -2.8 78.16 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.794 178.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.538 ' HG1' ' NE2' ' A' ' 91' ' ' GLN . 5.3 m -88.72 139.57 30.33 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 70.3 m95 -92.98 123.95 36.6 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.444 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 11.8 p90 -133.0 159.18 40.77 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.404 -174.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -147.96 142.29 16.42 Favored Pre-proline 0 C--N 1.297 -1.712 0 N-CA-C 106.031 -1.841 . . . . 0.0 106.031 172.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -72.4 134.38 22.54 Favored 'Trans proline' 0 N--CA 1.45 -1.073 0 C-N-CA 121.397 1.398 . . . . 0.0 110.475 174.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -150.94 121.4 7.38 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -101.84 106.14 17.08 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.542 ' HB1' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.78 176.56 11.66 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.412 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 24.0 m -113.58 151.03 32.21 Favored 'General case' 0 C--N 1.292 -1.904 0 CA-C-O 121.002 0.429 . . . . 0.0 111.163 -174.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.458 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 84.0 t80 -129.21 124.83 35.54 Favored 'General case' 0 N--CA 1.428 -1.526 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 174.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 33.6 t -108.54 110.04 30.55 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.11 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 62.5 t30 -77.07 130.4 37.36 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 177.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -122.58 -64.0 0.22 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 118.52 -1.8 . . . . 0.0 115.901 -173.135 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -68.71 -56.33 8.46 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 114.05 1.13 . . . . 0.0 114.05 -171.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 20.2 pt20 -134.39 157.88 76.45 Favored Pre-proline 0 C--N 1.292 -1.913 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.212 -170.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -68.5 138.28 41.7 Favored 'Trans proline' 0 N--CA 1.445 -1.325 0 C-N-CA 121.76 1.64 . . . . 0.0 109.071 170.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.7 mt -113.39 133.38 59.48 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -177.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 9.5 p -84.3 128.05 39.26 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.083 0 CA-C-O 121.42 0.629 . . . . 0.0 109.76 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 74.1 p -109.98 178.94 4.25 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.099 -173.488 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.541 ' HG2' ' CZ3' ' A' ' 96' ' ' TRP . 1.6 mmp_? -112.15 154.77 25.0 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 174.375 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 54.5 mt -119.26 126.1 75.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 120.759 -0.376 . . . . 0.0 111.045 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 85.08 -22.75 9.04 Favored Glycine 0 CA--C 1.519 0.337 0 N-CA-C 115.983 1.153 . . . . 0.0 115.983 171.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.1 m -153.99 142.65 14.49 Favored Pre-proline 0 C--N 1.309 -1.192 0 CA-C-N 118.276 1.038 . . . . 0.0 109.933 -178.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -90.63 119.14 0.67 Allowed 'Trans proline' 0 N--CA 1.443 -1.442 0 C-N-CA 121.806 1.67 . . . . 0.0 111.865 175.125 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.426 ' HA ' ' HG2' ' A' ' 91' ' ' GLN . 91.9 m-85 -168.9 168.94 10.06 Favored 'General case' 0 CA--C 1.49 -1.348 0 N-CA-C 104.584 -2.376 . . . . 0.0 104.584 179.216 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 85.2 mt -79.53 -37.86 35.57 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 171.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -88.84 12.09 16.12 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 114.32 -1.309 . . . . 0.0 112.101 -176.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.413 ' HB3' ' HB2' ' A' ' 68' ' ' PHE . . . -72.99 162.65 73.52 Favored Pre-proline 0 C--N 1.314 -0.966 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.561 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -46.94 123.18 7.03 Favored 'Trans proline' 0 C--N 1.367 1.518 0 C-N-CA 123.371 2.714 . . . . 0.0 113.797 -178.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.8 t -97.37 172.27 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.35 -30.03 5.94 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.84 126.98 10.02 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 178.011 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -128.47 130.5 47.64 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 117.118 0.459 . . . . 0.0 110.505 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 64.0 tp -97.63 113.55 63.67 Favored Pre-proline 0 C--N 1.3 -1.561 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -66.76 155.65 69.54 Favored 'Trans proline' 0 C--O 1.247 0.947 0 C-N-CA 122.505 2.136 . . . . 0.0 112.421 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.96 142.61 41.92 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.899 -0.592 . . . . 0.0 109.695 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.35 -4.57 70.29 Favored Glycine 0 N--CA 1.447 -0.602 0 N-CA-C 111.774 -0.531 . . . . 0.0 111.774 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -82.47 126.75 32.59 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 121.215 0.531 . . . . 0.0 111.528 -177.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 24.0 m -95.09 114.26 26.05 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 176.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.9 mm -119.02 134.0 64.06 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 -176.123 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.4 p -99.26 135.43 34.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.542 ' CZ ' ' HB1' ' A' ' 51' ' ' ALA . 16.5 p90 -109.38 160.61 16.03 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.943 -0.703 . . . . 0.0 112.164 -178.272 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -124.8 -37.23 2.49 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.878 -1.056 . . . . 0.0 111.105 -176.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -118.26 131.92 56.33 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -175.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.4 t -121.43 125.27 73.42 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 176.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.518 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 13.8 p -134.09 140.45 46.63 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -175.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 71.8 mt -101.2 115.45 42.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 109.128 -0.694 . . . . 0.0 109.128 178.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.538 ' NE2' ' HG1' ' A' ' 44' ' ' THR . 6.2 tp-100 -118.59 144.68 45.95 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 105.493 -2.04 . . . . 0.0 105.493 175.492 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -57.0 104.23 0.15 Allowed 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -175.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.58 -38.05 2.07 Favored Glycine 0 N--CA 1.439 -1.15 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.688 177.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 46.2 m80 -152.99 153.23 32.5 Favored 'General case' 0 N--CA 1.478 0.932 0 O-C-N 122.118 -0.636 . . . . 0.0 110.06 -176.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 13.6 tt -97.16 117.75 42.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.541 ' CZ3' ' HG2' ' A' ' 63' ' ' ARG . 65.2 m95 -100.61 134.11 44.05 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-O 120.922 0.391 . . . . 0.0 110.86 -171.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.6 pt -100.5 125.35 54.32 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.869 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 174.588 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -99.06 125.72 8.66 Favored Glycine 0 N--CA 1.414 -2.805 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 38.5 p90 -138.58 172.72 12.46 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-O 120.81 0.338 . . . . 0.0 110.524 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.434 ' HA ' ' O ' ' A' ' 105' ' ' ASN . 1.7 p-10 -115.5 120.04 38.18 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.687 -178.471 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -90.46 -174.7 4.22 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.447 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 45.1 p90 -45.84 -32.25 2.51 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 116.246 1.943 . . . . 0.0 116.246 -176.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -108.37 15.79 23.68 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.034 0.921 . . . . 0.0 109.899 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 81.05 22.28 61.4 Favored Glycine 0 C--N 1.315 -0.621 0 N-CA-C 110.214 -1.155 . . . . 0.0 110.214 -177.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.434 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 8.9 m120 -67.78 121.1 15.24 Favored 'General case' 0 CA--C 1.494 -1.193 0 CA-C-N 114.732 -0.734 . . . . 0.0 109.141 -178.277 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 21.2 tpt180 -86.16 95.75 9.68 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 178.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.9 t -102.95 142.23 17.33 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.3 -174.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.487 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 86.8 m-85 -118.96 116.19 25.94 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 123.642 0.589 . . . . 0.0 110.163 -179.277 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . 0.411 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 46.3 t -99.94 133.89 21.33 Favored Pre-proline 0 C--N 1.304 -1.376 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -69.7 -23.57 30.9 Favored 'Trans proline' 0 C--N 1.358 1.027 0 C-N-CA 123.227 2.618 . . . . 0.0 113.679 -176.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.291 30.8 m 48.95 -53.56 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.164 0 N-CA-C 117.972 2.582 . . . . 0.0 117.972 177.551 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . 0.408 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 21.0 ptt180 -159.22 150.59 20.22 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 123.782 0.833 . . . . 0.0 108.837 -178.513 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 71.2 m -69.74 137.82 52.29 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 175.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.41 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 46.6 t -153.91 129.16 9.73 Favored 'General case' 0 N--CA 1.41 -2.473 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -177.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . 0.413 ' HA ' HE21 ' A' ' 115' ' ' GLN . 0.1 OUTLIER -96.72 146.0 25.28 Favored 'General case' 0 N--CA 1.408 -2.53 0 N-CA-C 103.285 -2.857 . . . . 0.0 103.285 172.288 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -167.07 142.12 7.36 Favored Glycine 0 N--CA 1.406 -3.31 0 C-N-CA 116.66 -2.686 . . . . 0.0 114.994 -177.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 6.2 m -131.59 97.47 19.22 Favored Pre-proline 0 C--N 1.279 -2.457 0 N-CA-C 104.501 -2.407 . . . . 0.0 104.501 171.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -48.31 139.68 21.6 Favored 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 123.456 2.771 . . . . 0.0 113.803 -170.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -85.97 6.74 63.45 Favored 'Cis proline' 0 CA--C 1.558 1.724 0 C-N-CA 124.288 -1.13 . . . . 0.0 114.051 0.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -70.46 102.64 2.25 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-O 121.541 0.686 . . . . 0.0 110.977 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 36.6 p-80 -105.3 117.25 33.53 Favored 'General case' 0 C--N 1.296 -1.717 0 CA-C-N 114.832 -1.077 . . . . 0.0 111.49 -178.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 53.1 mt -110.18 99.34 39.35 Favored Pre-proline 0 C--N 1.318 -0.782 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.53 141.73 8.98 Favored 'Trans proline' 0 C--O 1.247 0.931 0 C-N-CA 122.549 2.166 . . . . 0.0 112.683 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -106.84 -114.55 3.91 Favored Glycine 0 N--CA 1.433 -1.515 0 N-CA-C 110.616 -0.994 . . . . 0.0 110.616 176.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 85.8 t -88.97 127.17 41.88 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.065 0 CA-C-N 116.734 0.267 . . . . 0.0 110.43 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.408 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -94.16 143.05 26.72 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.306 177.208 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.1 m-90 -113.81 27.78 9.27 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 120.861 0.363 . . . . 0.0 110.551 179.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.458 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -169.92 -179.11 41.38 Favored Glycine 0 N--CA 1.429 -1.814 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 37.7 t -111.0 130.31 64.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -178.107 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -98.88 145.76 26.67 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-O 121.004 0.431 . . . . 0.0 110.792 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.412 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 88.1 tttt . . . . . 0 C--N 1.291 -1.967 0 N-CA-C 107.544 -1.28 . . . . 0.0 107.544 178.054 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 24.4 m . . . . . 0 N--CA 1.444 -0.755 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 43.6 t-20 -106.62 139.25 41.37 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 174.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' A' ' 7' ' ' MET . . . -155.74 -153.53 0.44 Allowed 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 121.061 -0.255 . . . . 0.0 111.072 -171.139 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 81.33 -69.08 0.09 Allowed 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 126.561 1.944 . . . . 0.0 110.753 179.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -89.09 -70.26 0.66 Allowed 'General case' 0 C--N 1.324 -0.535 0 C-N-CA 119.47 -0.892 . . . . 0.0 111.55 -177.172 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 23.3 p90 -87.71 68.01 9.34 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -175.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 3' ' ' ALA . 58.0 mtm 60.61 -158.62 0.32 Allowed 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 114.446 -1.252 . . . . 0.0 110.066 177.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -117.59 110.59 18.11 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 175.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.9 tppp? -95.67 105.39 17.38 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.32 56.97 2.41 Favored Glycine 0 C--O 1.245 0.817 0 N-CA-C 116.233 1.253 . . . . 0.0 116.233 -171.386 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 10.1 t -166.12 151.0 8.21 Favored 'General case' 0 N--CA 1.42 -1.945 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 175.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.1 m 72.76 132.36 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 124.751 1.22 . . . . 0.0 113.505 176.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.6 p -79.64 -18.33 51.72 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.386 177.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.5 m 74.74 86.91 0.09 Allowed 'General case' 0 N--CA 1.447 -0.604 0 C-N-CA 125.485 1.514 . . . . 0.0 111.278 177.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 49.3 m -94.92 104.14 16.02 Favored 'General case' 0 N--CA 1.417 -2.105 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.947 -178.218 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 28.9 t -114.72 78.59 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 104.852 -2.277 . . . . 0.0 104.852 171.137 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.7 t 68.22 -81.62 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 C-N-CA 124.734 1.214 . . . . 0.0 108.67 -169.7 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -162.24 -77.4 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 124.973 1.309 . . . . 0.0 108.625 177.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -159.74 146.29 16.24 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 105.68 -1.97 . . . . 0.0 105.68 -177.41 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -163.71 -104.0 0.18 Allowed Glycine 0 C--N 1.291 -1.938 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.08 24.47 1.54 Allowed 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.762 0.792 . . . . 0.0 111.06 177.774 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -70.42 -18.26 63.01 Favored 'General case' 0 N--CA 1.437 -1.122 0 C-N-CA 125.076 1.35 . . . . 0.0 110.263 176.544 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 38.0 t -150.12 147.01 27.24 Favored 'General case' 0 N--CA 1.413 -2.291 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.4 t -89.54 167.33 13.05 Favored 'General case' 0 C--O 1.265 1.88 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 173.243 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 58.15 37.41 26.33 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-O 121.987 0.899 . . . . 0.0 108.775 -175.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.499 ' O ' ' HD3' ' A' ' 28' ' ' PRO . 6.5 p -71.65 -1.97 15.59 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.262 -1.335 . . . . 0.0 114.026 -173.46 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.8 p -113.29 78.94 3.57 Favored Pre-proline 0 N--CA 1.434 -1.265 0 CA-C-O 120.828 0.347 . . . . 0.0 110.968 177.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.499 ' HD3' ' O ' ' A' ' 26' ' ' SER . 3.7 Cg_endo -88.36 2.77 6.16 Favored 'Trans proline' 0 C--N 1.36 1.173 0 C-N-CA 122.565 2.176 . . . . 0.0 112.092 -176.678 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -68.22 110.38 4.01 Favored 'General case' 0 N--CA 1.439 -1.005 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.776 -178.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . 0.276 73.4 p 66.78 -9.07 0.37 Allowed 'General case' 0 CA--C 1.549 0.936 0 N-CA-C 116.264 1.95 . . . . 0.0 116.264 176.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.478 ' HB2' ' HD3' ' A' ' 32' ' ' PRO 0.251 9.9 mpt_? -77.42 -66.89 0.29 Allowed Pre-proline 0 CA--C 1.54 0.58 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.265 177.144 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.478 ' HD3' ' HB2' ' A' ' 31' ' ' ARG . 2.4 Cg_endo -84.68 162.1 12.37 Favored 'Trans proline' 0 N--CA 1.437 -1.814 0 N-CA-C 107.439 -1.793 . . . . 0.0 107.439 167.34 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 t -84.2 73.05 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 C-N-CA 119.251 -0.979 . . . . 0.0 109.896 179.602 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 20.5 p -147.62 90.27 1.84 Allowed 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 125.145 1.378 . . . . 0.0 108.423 177.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.26 -66.47 2.02 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.813 -0.708 . . . . 0.0 111.472 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 35.8 t -123.45 -4.1 8.32 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 122.773 -0.251 . . . . 0.0 110.732 178.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 98.8 m95 -71.97 116.42 12.34 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 121.253 0.549 . . . . 0.0 109.962 179.15 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 7.1 tmtt? -120.56 139.15 53.36 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 105.461 -2.052 . . . . 0.0 105.461 -178.771 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -86.49 136.61 33.02 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.818 -0.753 . . . . 0.0 111.0 -175.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 45.3 t-20 -93.22 159.01 15.47 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 105.944 -1.873 . . . . 0.0 105.944 175.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -60.54 -22.28 63.46 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 123.467 0.707 . . . . 0.0 112.383 -174.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -79.13 2.34 21.2 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.865 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.11 10.72 80.05 Favored Glycine 0 CA--C 1.509 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.2 178.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 19.9 m -97.65 143.69 28.06 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 179.237 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 75.9 m95 -101.44 129.93 47.57 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 29.7 p90 -134.25 156.62 48.08 Favored 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.429 -177.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 49.2 pttt -135.96 132.23 19.24 Favored Pre-proline 0 C--N 1.293 -1.865 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 174.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -72.82 120.6 6.75 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 121.098 1.199 . . . . 0.0 109.007 174.126 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -154.45 130.14 10.01 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 -176.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -97.27 106.39 18.7 Favored 'General case' 0 C--N 1.307 -1.262 0 O-C-N 123.374 0.422 . . . . 0.0 109.963 -176.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.43 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -148.66 169.52 20.19 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 7.8 m -111.5 149.18 31.71 Favored 'General case' 0 C--N 1.298 -1.674 0 CA-C-O 120.981 0.42 . . . . 0.0 111.522 -173.172 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.4 t80 -130.58 131.36 44.96 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 174.291 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 36.2 t -117.66 117.19 54.23 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 177.631 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -69.89 140.34 53.12 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -102.72 -73.97 1.0 Allowed Glycine 0 N--CA 1.432 -1.63 0 C-N-CA 120.306 -0.95 . . . . 0.0 114.75 -172.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -91.79 -69.13 0.75 Allowed 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 116.011 1.856 . . . . 0.0 116.011 -170.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -109.21 151.49 42.05 Favored Pre-proline 0 C--N 1.292 -1.914 0 O-C-N 121.828 -0.545 . . . . 0.0 111.192 -173.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.404 ' HA ' ' O ' ' A' ' 77' ' ' LEU . 50.0 Cg_exo -57.28 131.11 42.93 Favored 'Trans proline' 0 C--O 1.249 1.025 0 C-N-CA 122.171 1.914 . . . . 0.0 109.437 170.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -107.85 118.83 56.32 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -176.529 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 35.0 m -74.41 143.1 13.87 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.194 175.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 59.2 p -118.42 173.61 6.73 Favored 'General case' 0 C--N 1.277 -2.56 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.141 -173.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.456 ' HG3' ' O ' ' A' ' 68' ' ' PHE . 2.2 mmp_? -116.21 148.64 40.2 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.157 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 66.4 mt -112.21 131.26 64.15 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-O 120.62 0.248 . . . . 0.0 111.122 -177.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 85.98 -23.18 9.68 Favored Glycine 0 C--N 1.318 -0.423 0 N-CA-C 115.646 1.019 . . . . 0.0 115.646 171.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.0 m -157.87 142.23 11.67 Favored Pre-proline 0 C--N 1.296 -1.719 0 CA-C-N 117.51 0.655 . . . . 0.0 109.271 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -89.23 118.51 0.87 Allowed 'Trans proline' 0 N--CA 1.429 -2.306 0 C-N-CA 120.497 0.798 . . . . 0.0 110.089 172.276 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.456 ' O ' ' HG3' ' A' ' 63' ' ' ARG . 90.8 m-85 -170.03 177.05 4.44 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 103.669 -2.715 . . . . 0.0 103.669 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -90.53 -37.81 13.62 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.411 0.624 . . . . 0.0 109.775 175.524 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -81.57 -2.33 49.62 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 114.772 -1.103 . . . . 0.0 111.035 -178.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -58.25 158.95 12.49 Favored Pre-proline 0 CA--C 1.547 0.828 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.547 -179.115 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_exo -47.11 134.73 18.9 Favored 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 123.823 3.015 . . . . 0.0 114.701 -178.289 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 26.6 m -90.63 173.53 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 CA-C-N 114.392 -1.276 . . . . 0.0 110.393 -178.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.44 6.22 12.04 Favored Glycine 0 C--N 1.314 -0.682 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.836 177.278 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -118.77 125.54 6.45 Favored Glycine 0 N--CA 1.432 -1.593 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.902 179.454 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -128.46 135.26 49.22 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 174.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' A' ' 59' ' ' PRO . 53.9 tp -111.59 110.39 55.25 Favored Pre-proline 0 C--N 1.303 -1.422 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 176.523 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -67.47 166.14 24.78 Favored 'Trans proline' 0 CA--C 1.539 0.758 0 C-N-CA 122.699 2.266 . . . . 0.0 112.988 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.54 134.85 40.64 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.245 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.3 -10.81 73.56 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 121.236 -0.506 . . . . 0.0 112.298 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.76 129.38 39.56 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.902 0.382 . . . . 0.0 111.885 -176.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 52.9 m -104.98 117.02 32.96 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.121 179.545 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.0 mm -125.92 140.48 48.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -177.02 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.89 119.23 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-O 121.806 0.812 . . . . 0.0 108.864 175.362 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.43 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 39.4 p90 -97.37 148.4 23.2 Favored 'General case' 0 C--N 1.295 -1.799 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.929 -178.774 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -121.5 9.79 10.33 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 121.578 0.704 . . . . 0.0 110.231 -178.068 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -152.7 130.13 11.38 Favored 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -177.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 33.6 t -118.89 126.61 75.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 178.018 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.533 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 24.6 p -135.77 143.64 45.35 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.543 0.572 . . . . 0.0 112.543 -177.31 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 60.9 mt -102.32 116.83 46.7 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 CA-C-O 120.96 0.41 . . . . 0.0 110.003 177.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.571 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -124.27 121.77 35.94 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 174.117 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.89 107.95 0.16 Allowed 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 123.851 0.86 . . . . 0.0 113.14 -166.367 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 133.91 -33.97 2.46 Favored Glycine 0 N--CA 1.429 -1.81 0 CA-C-N 114.388 -1.278 . . . . 0.0 110.888 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -151.37 166.15 31.88 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -177.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 tt -107.71 119.13 56.78 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 171.211 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.571 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 55.4 m95 -100.77 134.11 44.23 Favored 'General case' 0 C--N 1.276 -2.612 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.9 -170.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.4 pt -100.12 133.7 42.2 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 176.272 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.13 121.97 7.21 Favored Glycine 0 N--CA 1.418 -2.564 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -126.13 147.04 49.7 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 176.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -93.96 112.85 24.75 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 -177.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.39 152.52 38.03 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -177.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -51.7 -30.12 20.95 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 124.313 1.045 . . . . 0.0 113.025 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -80.8 -5.52 57.33 Favored 'General case' 0 C--O 1.217 -0.644 0 CA-C-O 121.409 0.623 . . . . 0.0 110.829 -178.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 96.01 11.26 55.13 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.667 176.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -94.67 145.45 24.84 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.3 tpt180 -93.99 105.02 17.05 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 28.2 t -101.84 136.3 34.5 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -174.254 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.475 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 96.0 m-85 -116.09 126.04 53.2 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 123.419 0.688 . . . . 0.0 110.72 -178.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . 0.437 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 47.2 t -108.04 132.76 20.83 Favored Pre-proline 0 C--N 1.31 -1.123 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.143 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.06 -21.35 36.88 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 123.061 2.508 . . . . 0.0 114.683 -176.475 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.292 28.9 m 45.25 -53.71 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.914 0 N-CA-C 118.564 2.801 . . . . 0.0 118.564 176.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 28.8 ptt180 -154.67 142.05 19.61 Favored 'General case' 0 N--CA 1.44 -0.954 0 C-N-CA 123.826 0.851 . . . . 0.0 109.643 178.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 13.6 m -60.61 131.48 50.87 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.675 177.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.652 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 99.5 m -151.9 119.78 6.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.49 0.662 . . . . 0.0 112.091 -178.234 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -114.98 134.67 54.98 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 177.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 154.17 -175.97 32.2 Favored Glycine 0 CA--C 1.486 -1.768 0 C-N-CA 118.903 -1.618 . . . . 0.0 113.045 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.8 m -126.08 136.16 28.12 Favored Pre-proline 0 C--N 1.298 -1.644 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 179.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_exo -46.54 129.5 13.87 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 123.469 2.78 . . . . 0.0 113.332 -177.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -96.18 -4.44 31.48 Favored 'Cis proline' 0 CA--C 1.542 0.908 0 C-N-CA 124.045 -1.231 . . . . 0.0 113.711 1.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -76.99 99.81 5.4 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-O 121.659 0.742 . . . . 0.0 110.868 -172.645 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 38.8 p-80 -106.99 132.79 52.53 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.334 176.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.652 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.6 mm -77.4 113.24 29.72 Favored Pre-proline 0 C--N 1.307 -1.262 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 174.302 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -84.55 124.42 3.13 Favored 'Trans proline' 0 N--CA 1.443 -1.457 0 C-N-CA 122.113 1.875 . . . . 0.0 112.528 -178.04 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.74 -139.19 9.85 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 176.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 58.4 t -80.62 123.43 37.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 -177.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -93.91 130.65 39.9 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 173.632 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.0 m-90 -95.66 12.63 29.12 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.635 0.731 . . . . 0.0 110.311 -178.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.03 -177.7 34.36 Favored Glycine 0 N--CA 1.421 -2.334 0 CA-C-N 115.196 -0.911 . . . . 0.0 111.298 -178.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 22.8 t -114.17 142.95 24.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -175.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -110.31 141.77 42.86 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.796 0.331 . . . . 0.0 111.289 -176.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? . . . . . 0 C--N 1.307 -1.27 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 172.534 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 N--CA 1.45 -0.462 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -94.87 83.82 4.07 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 172.137 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -70.68 131.95 44.68 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.63 -1.168 . . . . 0.0 110.43 -175.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 21.8 pttm -76.37 121.1 22.53 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 177.613 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 30.4 t30 69.76 89.97 0.1 Allowed 'General case' 0 C--N 1.313 -1.014 0 C-N-CA 123.941 0.897 . . . . 0.0 112.399 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -122.03 145.31 48.26 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 172.255 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 14.4 tpt 59.09 74.03 0.46 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.194 0.934 . . . . 0.0 108.737 -170.24 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -52.56 -58.04 8.04 Favored 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 114.514 -1.221 . . . . 0.0 112.815 -175.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.1 tttm 58.4 84.75 0.1 Allowed 'General case' 0 C--O 1.245 0.818 0 O-C-N 124.097 0.873 . . . . 0.0 110.645 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -156.09 37.25 0.6 Allowed Glycine 0 CA--C 1.489 -1.549 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -178.587 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 30.0 m -67.73 -43.52 79.75 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -178.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 20.3 m -86.01 91.37 8.38 Favored 'General case' 0 N--CA 1.427 -1.614 0 CA-C-O 121.43 0.633 . . . . 0.0 110.448 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 23.4 m -108.59 -41.85 4.7 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 175.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 13.8 m -91.21 85.84 5.98 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 177.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 88.3 m -155.63 128.86 8.22 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 -178.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 28.3 m -94.35 160.05 2.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 5.6 p -65.23 -47.85 85.78 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 CA-C-O 121.147 0.499 . . . . 0.0 109.942 178.107 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 49.9 tttm -165.81 147.97 7.31 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 178.543 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -140.34 -67.76 0.42 Allowed 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 175.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.87 -28.21 8.92 Favored Glycine 0 C--N 1.308 -0.973 0 C-N-CA 120.934 -0.65 . . . . 0.0 113.681 176.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 2.1 mppt? -88.85 -39.61 13.72 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 117.561 0.681 . . . . 0.0 109.871 -176.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 27.6 m -65.75 107.51 1.8 Allowed 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.195 -178.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.5 m -78.27 -12.97 60.04 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.558 -178.214 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.8 m -72.2 114.64 10.54 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.16 -179.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.11 99.55 9.27 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 176.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 14.2 m -51.4 138.28 21.94 Favored 'General case' 0 C--O 1.25 1.117 0 C-N-CA 124.024 0.93 . . . . 0.0 111.693 -178.191 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 27.6 p 52.69 68.91 2.67 Favored Pre-proline 0 CA--C 1.539 0.525 0 C-N-CA 124.69 1.196 . . . . 0.0 111.768 -175.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_exo -69.32 88.21 0.49 Allowed 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.13 2.553 . . . . 0.0 113.783 -174.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -111.1 -64.57 1.26 Allowed 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 174.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 p -65.0 -26.78 68.43 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 -176.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 8.9 mpt_? -77.69 -59.24 0.83 Allowed Pre-proline 0 C--N 1.318 -0.782 0 N-CA-C 113.167 0.802 . . . . 0.0 113.167 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -71.43 -33.59 10.75 Favored 'Trans proline' 0 C--N 1.37 1.707 0 C-N-CA 121.489 1.459 . . . . 0.0 112.932 178.703 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 76.4 t -94.21 98.5 8.21 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 CA-C-O 121.717 0.77 . . . . 0.0 110.898 -177.23 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 46.5 m -149.3 95.69 2.4 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 176.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -117.32 -95.35 1.82 Allowed Glycine 0 N--CA 1.437 -1.268 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.447 -178.249 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 27.9 m -70.94 -35.73 72.33 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 179.235 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 95.5 m95 -86.07 120.49 27.5 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 175.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -113.66 149.67 34.31 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.3 tttm -92.13 120.48 32.77 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 121.806 0.812 . . . . 0.0 111.158 -177.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 30.3 t-20 -84.5 147.87 26.83 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 176.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.0 tm0? -53.61 -28.66 33.77 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.209 1.004 . . . . 0.0 111.869 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 -74.0 -6.02 44.86 Favored 'General case' 0 CA--C 1.54 0.56 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -178.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.36 22.78 39.48 Favored Glycine 0 CA--C 1.495 -1.212 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -178.308 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.402 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 16.9 m -105.88 139.06 41.03 Favored 'General case' 0 N--CA 1.415 -2.222 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.175 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -102.59 133.25 47.9 Favored 'General case' 0 C--N 1.282 -2.366 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 175.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 35.9 p90 -138.94 158.97 43.23 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.436 -0.905 . . . . 0.0 112.286 -175.313 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.0 pttp -140.67 134.42 15.06 Favored Pre-proline 0 N--CA 1.431 -1.411 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 174.324 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -70.76 134.46 25.91 Favored 'Trans proline' 0 C--N 1.327 -0.597 0 C-N-CA 121.626 1.551 . . . . 0.0 110.566 177.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -163.62 121.09 1.83 Allowed 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.526 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 26.4 t-20 -95.35 106.06 18.07 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 177.376 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.466 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -144.03 168.83 19.06 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 -178.564 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 17.2 m -109.61 140.85 42.94 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.256 -174.769 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.474 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 91.7 t80 -120.9 133.65 55.29 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 176.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.418 ' HA ' ' O ' ' A' ' 81' ' ' ALA . 42.5 t -119.4 119.53 60.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.696 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.137 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -59.67 145.62 44.14 Favored 'General case' 0 C--O 1.246 0.916 0 O-C-N 123.518 0.511 . . . . 0.0 111.874 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -81.77 -122.34 0.63 Allowed Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.664 -0.698 . . . . 0.0 113.213 -178.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -95.88 -6.3 39.61 Favored 'General case' 0 C--N 1.315 -0.907 0 O-C-N 122.374 -0.486 . . . . 0.0 112.276 -175.427 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 9.5 pt20 -121.45 148.08 49.11 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.554 -178.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -72.37 135.59 24.81 Favored 'Trans proline' 0 N--CA 1.439 -1.722 0 C-N-CA 121.932 1.755 . . . . 0.0 107.813 168.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 57.8 mt -107.81 127.83 63.56 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -176.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.4 p -78.37 136.67 23.52 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 37.9 p -113.29 164.16 13.91 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 121.134 0.492 . . . . 0.0 112.043 -174.243 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.452 ' HE ' ' HA ' ' A' ' 63' ' ' ARG . 0.8 OUTLIER -109.63 147.01 33.81 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.392 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.0 mt -99.33 123.4 52.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 112.378 0.511 . . . . 0.0 112.378 -176.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 70.9 -22.27 0.58 Allowed Glycine 0 CA--C 1.521 0.41 0 N-CA-C 118.054 1.981 . . . . 0.0 118.054 170.705 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 41.6 m -140.73 136.16 16.18 Favored Pre-proline 0 C--N 1.298 -1.662 0 CA-C-N 119.074 1.437 . . . . 0.0 111.075 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -89.91 119.57 0.83 Allowed 'Trans proline' 0 N--CA 1.44 -1.661 0 C-N-CA 121.781 1.654 . . . . 0.0 110.484 172.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.412 ' HA ' ' HG2' ' A' ' 91' ' ' GLN . 55.3 m-85 -168.46 168.98 10.81 Favored 'General case' 0 CA--C 1.489 -1.367 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 -177.643 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.73 -8.77 53.89 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.536 0.684 . . . . 0.0 110.194 176.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 31.0 p30 -116.62 14.97 15.53 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.243 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.09 152.89 86.75 Favored Pre-proline 0 C--O 1.247 0.962 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.491 -175.229 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_exo -54.29 134.59 61.62 Favored 'Trans proline' 0 C--N 1.364 1.385 0 C-N-CA 123.66 2.907 . . . . 0.0 113.878 -179.064 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 32.3 m -90.1 174.42 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-N 114.564 -1.198 . . . . 0.0 110.234 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.36 28.75 1.9 Allowed Glycine 0 C--N 1.315 -0.611 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.851 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -148.06 127.99 2.74 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -128.12 127.14 42.48 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 26.1 tp -110.61 113.29 55.83 Favored Pre-proline 0 C--N 1.306 -1.325 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -62.21 162.31 23.73 Favored 'Trans proline' 0 N--CA 1.483 0.904 0 C-N-CA 123.461 2.774 . . . . 0.0 114.043 -176.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.96 144.67 48.81 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 178.456 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.73 11.15 85.61 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.478 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . 0.418 ' O ' ' HA ' ' A' ' 54' ' ' VAL . . . -78.77 134.21 37.04 Favored 'General case' 0 N--CA 1.439 -1.01 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 178.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 42.1 m -104.47 108.84 20.46 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 45.5 mm -124.05 126.59 72.62 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-O 120.936 0.398 . . . . 0.0 110.518 -176.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.4 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 12.4 p -90.32 123.41 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.647 0 CA-C-O 121.486 0.66 . . . . 0.0 109.56 176.34 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.526 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 45.5 p90 -101.96 159.25 15.52 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.137 -178.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -118.29 -16.19 9.68 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 121.379 0.609 . . . . 0.0 111.786 -175.204 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -141.11 137.76 33.03 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.341 -175.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 67.6 t -112.28 125.76 69.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.74 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.402 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 57.9 m -127.24 142.5 51.46 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -175.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 55.0 mt -108.46 117.04 53.11 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 172.174 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.412 ' HG2' ' HA ' ' A' ' 68' ' ' PHE . 7.7 tp-100 -113.97 121.33 43.58 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 103.107 -2.923 . . . . 0.0 103.107 170.171 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.17 104.07 0.06 Allowed 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 113.697 0.999 . . . . 0.0 113.697 -165.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 132.56 -36.36 2.19 Favored Glycine 0 N--CA 1.435 -1.411 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.15 -177.439 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 41.5 m80 -146.09 149.39 33.96 Favored 'General case' 0 CA--C 1.504 -0.81 0 O-C-N 122.293 -0.533 . . . . 0.0 111.621 -178.253 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.8 tt -97.86 138.11 23.56 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.913 0 N-CA-C 105.777 -1.934 . . . . 0.0 105.777 175.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -120.22 138.06 53.85 Favored 'General case' 0 C--N 1.283 -2.308 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 -174.35 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.432 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.1 pt -101.05 128.9 52.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 175.312 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.19 119.87 6.6 Favored Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 179.246 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 55.2 p90 -138.35 171.97 13.6 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -109.21 131.97 54.57 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.331 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -98.12 170.9 8.59 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.703 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 31.1 p90 -50.18 -24.02 2.56 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 115.516 1.672 . . . . 0.0 115.516 -176.537 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -86.03 -9.92 55.92 Favored 'General case' 0 C--N 1.315 -0.926 0 O-C-N 121.498 -0.751 . . . . 0.0 110.59 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.94 17.14 56.89 Favored Glycine 0 CA--C 1.499 -0.926 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -174.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 42.2 t30 -93.95 136.14 34.56 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 113.822 -1.189 . . . . 0.0 109.399 -175.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 -78.57 113.71 16.85 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 47.3 t -121.14 143.37 33.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 -175.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.432 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 92.6 m-85 -120.79 127.21 51.74 Favored 'General case' 0 C--O 1.242 0.698 0 C-N-CA 122.977 0.511 . . . . 0.0 110.977 -179.138 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 53.0 t -104.48 133.46 20.18 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 178.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.59 -10.81 27.31 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 123.409 2.739 . . . . 0.0 114.267 -176.341 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.279 35.5 m 38.71 -61.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 N-CA-C 118.706 2.854 . . . . 0.0 118.706 174.6 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . 0.465 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 35.6 ptt180 -154.99 150.33 27.24 Favored 'General case' 0 N--CA 1.439 -0.982 0 C-N-CA 123.287 0.635 . . . . 0.0 109.997 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 123' ' ' PRO . 82.4 m -68.95 135.61 51.23 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.632 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 95.2 m -151.09 110.92 4.06 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 123.001 0.52 . . . . 0.0 110.868 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 23.3 mp0 -98.71 160.95 13.92 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 176.545 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 128.02 -167.05 20.42 Favored Glycine 0 CA--C 1.487 -1.667 0 C-N-CA 118.768 -1.682 . . . . 0.0 113.508 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 27.9 m -138.13 151.13 69.22 Favored Pre-proline 0 C--N 1.304 -1.38 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -56.0 137.01 77.74 Favored 'Trans proline' 0 CA--C 1.54 0.775 0 C-N-CA 122.349 2.033 . . . . 0.0 112.992 -179.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -92.11 -11.65 27.86 Favored 'Cis proline' 0 C--O 1.25 1.087 0 C-N-CA 124.098 -1.209 . . . . 0.0 113.06 -2.242 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -75.82 101.15 4.99 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-O 122.207 1.003 . . . . 0.0 112.168 -173.093 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.4 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 32.6 p-80 -105.44 132.71 51.28 Favored 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 114.194 -1.366 . . . . 0.0 110.537 177.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.632 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 3.1 mp -94.15 105.5 17.8 Favored Pre-proline 0 C--N 1.299 -1.591 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 179.412 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . 0.415 ' HA ' ' O ' ' A' ' 113' ' ' THR . 50.2 Cg_endo -84.31 143.18 9.93 Favored 'Trans proline' 0 N--CA 1.436 -1.864 0 C-N-CA 121.769 1.646 . . . . 0.0 112.813 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.7 -114.62 3.98 Favored Glycine 0 N--CA 1.426 -1.993 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 176.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 62.0 t -94.44 126.8 46.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.465 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.38 136.92 34.15 Favored 'General case' 0 N--CA 1.439 -1.015 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.349 175.199 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.0 m-90 -102.32 19.93 17.84 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.394 0.616 . . . . 0.0 110.939 -178.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.474 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -172.55 179.81 43.84 Favored Glycine 0 N--CA 1.427 -1.933 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.242 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 37.7 t -111.71 135.44 50.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -176.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -97.75 127.36 43.65 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.255 179.174 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 97.3 mttt . . . . . 0 C--N 1.29 -1.997 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 175.419 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 35.1 t . . . . . 0 N--CA 1.444 -0.739 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 16.0 m120 -87.39 110.27 20.15 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-O 120.651 0.263 . . . . 0.0 110.732 -178.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.22 65.69 8.37 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 176.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 65.7 tttp -118.98 -17.26 9.08 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 114.603 -1.18 . . . . 0.0 110.586 -176.535 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 31.3 p30 -84.75 -6.64 59.36 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.901 -177.353 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 70.29 1.17 3.47 Favored 'General case' 0 C--O 1.246 0.909 0 C-N-CA 124.365 1.066 . . . . 0.0 112.54 178.666 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 28.6 mmt -87.21 72.74 9.86 Favored 'General case' 0 N--CA 1.425 -1.702 0 CA-C-O 121.674 0.75 . . . . 0.0 109.935 -177.355 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -147.0 -39.09 0.2 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 114.326 -1.307 . . . . 0.0 107.529 173.318 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.2 tppp? -82.21 -59.88 2.4 Favored 'General case' 0 C--O 1.242 0.675 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 173.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -81.04 80.84 1.67 Allowed Glycine 0 N--CA 1.433 -1.561 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 176.382 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 34.3 m -145.03 133.84 22.32 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.8 p -76.95 114.8 16.14 Favored 'General case' 0 N--CA 1.42 -1.925 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 177.036 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 44.1 t -115.18 105.03 12.43 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -178.627 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 54.5 m 63.84 24.65 13.81 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 123.999 0.92 . . . . 0.0 110.561 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 5.6 m -95.97 71.35 2.92 Favored 'General case' 0 N--CA 1.424 -1.745 0 CA-C-O 121.825 0.822 . . . . 0.0 110.881 -175.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.6 m -113.06 23.99 4.7 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 177.544 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 9.2 p -62.07 133.04 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 CA-C-N 113.068 -1.878 . . . . 0.0 112.779 -175.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 28.1 tptp -100.78 116.87 33.7 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 106.155 -1.794 . . . . 0.0 106.155 171.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -56.58 110.25 0.75 Allowed 'General case' 0 C--O 1.239 0.508 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 176.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -80.31 144.91 26.23 Favored Glycine 0 N--CA 1.427 -1.915 0 CA-C-N 115.76 -0.655 . . . . 0.0 113.87 -171.088 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 61.1 tttm -72.58 107.93 5.35 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 177.25 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 8.5 m -130.55 154.49 47.76 Favored 'General case' 0 C--N 1.288 -2.085 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -174.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 30.2 m -80.94 131.94 35.37 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 173.337 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.3 m -47.39 116.42 1.42 Allowed 'General case' 0 C--O 1.243 0.763 0 C-N-CA 124.109 0.964 . . . . 0.0 111.838 -177.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -100.79 -163.88 1.06 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.135 -175.595 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 41.6 m 71.63 78.48 0.16 Allowed 'General case' 0 C--O 1.246 0.876 0 C-N-CA 124.187 0.995 . . . . 0.0 112.427 178.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.1 p -72.69 126.18 90.85 Favored Pre-proline 0 N--CA 1.42 -1.946 0 CA-C-N 114.567 -1.197 . . . . 0.0 108.461 175.024 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -44.88 -49.14 10.0 Favored 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 123.858 3.039 . . . . 0.0 113.623 -178.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 59.97 28.1 17.57 Favored 'General case' 0 C--O 1.246 0.896 0 O-C-N 124.203 0.939 . . . . 0.0 110.836 178.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.0 m 60.86 80.15 0.22 Allowed 'General case' 0 N--CA 1.438 -1.05 0 C-N-CA 124.74 1.216 . . . . 0.0 109.924 -176.454 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 41.0 ttm180 -153.81 -58.09 0.02 OUTLIER Pre-proline 0 CA--C 1.552 1.057 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.01 -177.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -78.07 87.86 1.49 Allowed 'Trans proline' 0 C--N 1.377 2.061 0 N-CA-C 108.961 -1.207 . . . . 0.0 108.961 169.638 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -112.31 175.16 2.06 Favored 'Isoleucine or valine' 0 C--O 1.261 1.675 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.047 -175.142 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.2 m -74.18 70.76 1.63 Allowed 'General case' 0 N--CA 1.434 -1.255 0 CA-C-O 121.556 0.693 . . . . 0.0 109.771 178.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -119.31 -18.96 4.38 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 177.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 5.5 m -94.66 -21.9 18.5 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 121.706 0.765 . . . . 0.0 109.927 179.258 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 45.6 m95 -92.14 147.54 22.86 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.431 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.8 mtpp -121.84 152.06 39.97 Favored 'General case' 0 C--N 1.309 -1.196 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 177.449 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 56.7 tttp -101.65 135.41 43.22 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 34.9 p30 -95.09 174.69 6.95 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -64.18 -22.31 66.89 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 122.924 0.49 . . . . 0.0 111.937 -178.263 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -82.43 -5.56 58.75 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.486 -178.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 95.34 -3.82 66.55 Favored Glycine 0 N--CA 1.439 -1.114 0 C-N-CA 121.151 -0.547 . . . . 0.0 112.615 176.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 7.1 m -84.58 141.08 30.94 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 122.706 0.402 . . . . 0.0 110.126 -176.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 98.2 m95 -92.52 135.87 33.7 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 174.344 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -137.97 159.13 42.83 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 120.84 0.352 . . . . 0.0 110.983 -177.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 58.7 pttt -141.97 152.32 61.64 Favored Pre-proline 0 C--N 1.301 -1.507 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 174.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -80.21 121.85 4.51 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.017 1.812 . . . . 0.0 110.572 175.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -155.42 130.72 9.58 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.539 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 27.2 t-20 -117.95 115.31 24.65 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -177.078 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.516 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -154.49 178.29 10.23 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -179.086 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 28.5 m -103.35 131.14 50.67 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 121.066 0.46 . . . . 0.0 111.038 -176.225 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.422 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 79.8 t80 -107.08 121.95 45.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 173.403 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 41.4 t -106.65 102.25 13.66 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.045 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.668 -178.379 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 56.0 t30 -77.44 151.63 34.64 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 173.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -142.05 -71.8 0.03 OUTLIER Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.017 -1.563 . . . . 0.0 115.537 -176.195 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.402 ' OD1' ' HG3' ' A' ' 58' ' ' GLN . 26.7 p30 -72.1 -38.27 69.37 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 116.161 1.912 . . . . 0.0 116.161 -169.146 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.402 ' HG3' ' OD1' ' A' ' 57' ' ' ASN . 0.1 OUTLIER -138.54 161.4 58.98 Favored Pre-proline 0 C--N 1.296 -1.752 0 C-N-CA 120.494 -0.482 . . . . 0.0 112.123 -177.031 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -78.08 151.0 26.76 Favored 'Trans proline' 0 N--CA 1.439 -1.717 0 C-N-CA 121.722 1.614 . . . . 0.0 109.578 175.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.6 mt -125.04 126.22 70.77 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -178.388 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.6 p -82.21 117.75 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.218 0 CA-C-O 122.119 0.961 . . . . 0.0 109.527 176.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.3 p -91.28 173.62 7.82 Favored 'General case' 0 C--N 1.289 -2.065 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.333 -176.131 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 74.4 mmt-85 -111.25 145.72 38.24 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-O 121.285 0.564 . . . . 0.0 110.23 -178.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.3 mt -94.89 112.35 27.23 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 CA-C-N 115.203 -0.908 . . . . 0.0 112.717 -176.156 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.11 -23.13 1.16 Allowed Glycine 0 CA--C 1.518 0.279 0 N-CA-C 116.849 1.5 . . . . 0.0 116.849 171.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.1 m -137.11 135.96 20.36 Favored Pre-proline 0 C--N 1.301 -1.541 0 CA-C-N 118.329 1.064 . . . . 0.0 111.168 -175.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -89.98 120.28 0.87 Allowed 'Trans proline' 0 N--CA 1.438 -1.745 0 C-N-CA 121.888 1.725 . . . . 0.0 111.525 173.681 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.449 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 92.9 m-85 -165.42 161.92 19.11 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 103.848 -2.649 . . . . 0.0 103.848 179.024 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 64.9 mt -72.85 -40.08 66.0 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.17 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -97.36 17.49 17.34 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.221 -0.9 . . . . 0.0 111.172 -178.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.449 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -60.68 161.69 14.04 Favored Pre-proline 0 N--CA 1.48 1.06 0 C-N-CA 122.959 0.504 . . . . 0.0 111.624 -179.078 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -57.11 130.71 41.06 Favored 'Trans proline' 0 C--N 1.366 1.5 0 C-N-CA 122.955 2.436 . . . . 0.0 113.185 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 22.2 m -102.92 175.75 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 C-N-CA 124.56 1.144 . . . . 0.0 110.874 -179.537 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.84 3.84 10.76 Favored Glycine 0 C--N 1.309 -0.919 0 C-N-CA 121.308 -0.473 . . . . 0.0 112.175 -178.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -110.18 94.3 0.79 Allowed Glycine 0 N--CA 1.434 -1.442 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 173.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -87.38 122.31 30.97 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.989 -0.713 . . . . 0.0 110.463 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.9 tp -96.78 113.33 62.64 Favored Pre-proline 0 C--N 1.304 -1.384 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.33 159.89 47.94 Favored 'Trans proline' 0 C--O 1.251 1.154 0 C-N-CA 122.591 2.194 . . . . 0.0 113.348 -176.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.28 124.86 25.97 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.889 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.09 -0.54 54.68 Favored Glycine 0 C--N 1.306 -1.106 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.18 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.36 126.52 29.88 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.299 0.571 . . . . 0.0 111.247 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 14.4 m -99.45 108.87 21.44 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 178.217 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.9 mm -119.16 128.56 75.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 120.723 0.296 . . . . 0.0 111.333 -173.192 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.2 p -87.98 128.97 39.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 173.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.539 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 21.1 p90 -104.01 157.98 16.73 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.955 -0.298 . . . . 0.0 111.472 -178.512 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -114.97 -23.6 9.01 Favored 'General case' 0 C--O 1.247 0.945 0 CA-C-O 121.665 0.745 . . . . 0.0 111.495 -176.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -141.52 137.42 32.03 Favored 'General case' 0 C--N 1.294 -1.807 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.911 -170.575 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 96.0 t -113.73 132.86 61.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.426 ' HB2' ' HB2' ' A' ' 96' ' ' TRP . 56.9 m -131.85 153.75 49.87 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 120.548 0.214 . . . . 0.0 111.235 -176.141 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 55.3 mt -122.12 119.71 59.26 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 173.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.469 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 6.2 tp-100 -122.58 146.31 47.54 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 176.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.71 104.76 0.07 Allowed 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -169.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 108.47 -19.75 31.02 Favored Glycine 0 N--CA 1.436 -1.322 0 CA-C-N 114.853 -1.067 . . . . 0.0 113.999 175.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -145.17 147.01 32.0 Favored 'General case' 0 C--N 1.316 -0.858 0 O-C-N 121.535 -0.979 . . . . 0.0 111.998 -176.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.7 tt -92.64 143.85 10.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 105.461 -2.052 . . . . 0.0 105.461 174.132 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.469 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 70.0 m95 -126.92 148.61 50.03 Favored 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 -175.46 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.479 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.8 pt -117.67 137.52 51.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 174.148 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -110.83 131.62 10.48 Favored Glycine 0 N--CA 1.421 -2.329 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -138.62 169.7 17.32 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 177.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 51.8 t-20 -106.56 114.64 28.88 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.32 162.62 28.25 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -178.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -57.54 -17.9 16.4 Favored 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 -177.024 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 7.3 t30 -79.23 -14.83 58.8 Favored 'General case' 0 CA--C 1.547 0.861 0 CA-C-O 121.18 0.514 . . . . 0.0 110.598 178.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 92.21 17.02 48.38 Favored Glycine 0 C--N 1.325 -0.079 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -174.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 38.1 t30 -97.49 142.89 28.78 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 114.648 -0.776 . . . . 0.0 110.68 -178.267 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 19.2 tpt180 -88.39 107.34 18.79 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 179.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 43.0 t -107.96 139.61 29.41 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -176.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.479 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 90.5 m-85 -117.5 128.34 54.89 Favored 'General case' 0 C--N 1.32 -0.695 0 O-C-N 123.331 0.395 . . . . 0.0 110.817 -179.317 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 41.9 t -104.7 133.29 20.25 Favored Pre-proline 0 C--N 1.3 -1.547 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.03 -9.49 25.74 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 123.135 2.557 . . . . 0.0 114.001 -177.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.307 27.1 m 39.1 -63.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 N-CA-C 118.361 2.726 . . . . 0.0 118.361 175.133 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . 0.533 ' HB2' ' O ' ' A' ' 125' ' ' VAL . 36.0 ptt180 -162.59 164.38 26.78 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-O 121.177 0.513 . . . . 0.0 111.468 177.357 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 58.4 m -75.37 134.72 40.9 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.265 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.481 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 89.6 m -154.58 124.26 6.59 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 123.787 0.835 . . . . 0.0 110.026 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -105.48 160.54 15.07 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 179.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 134.83 -176.24 20.08 Favored Glycine 0 C--N 1.292 -1.872 0 C-N-CA 118.262 -1.923 . . . . 0.0 114.209 175.272 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 76.7 t -127.37 121.33 22.45 Favored Pre-proline 0 C--N 1.298 -1.632 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 99.5 Cg_exo -43.76 136.25 6.97 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 124.043 3.162 . . . . 0.0 113.18 -178.182 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -86.13 -11.17 42.48 Favored 'Cis proline' 0 C--O 1.25 1.103 0 C-N-CA 124.007 -1.247 . . . . 0.0 114.25 3.77 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -76.22 102.16 5.7 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.951 0.881 . . . . 0.0 112.19 -172.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -106.09 124.87 50.25 Favored 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 114.073 -1.421 . . . . 0.0 110.83 176.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.481 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 55.3 mt -93.74 109.43 41.23 Favored Pre-proline 0 C--N 1.295 -1.768 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.83 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -81.97 150.38 16.04 Favored 'Trans proline' 0 C--O 1.246 0.907 0 C-N-CA 122.485 2.123 . . . . 0.0 114.295 -175.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.33 -125.36 4.3 Favored Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 175.003 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.533 ' O ' ' HB2' ' A' ' 112' ' ' ARG . 60.3 t -79.09 133.68 29.44 Favored 'Isoleucine or valine' 0 C--O 1.244 0.805 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.434 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -93.22 132.94 36.93 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 123.268 0.627 . . . . 0.0 109.857 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 8.6 m0 -107.68 13.38 26.63 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.462 0.649 . . . . 0.0 109.995 178.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.422 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -173.58 170.69 43.85 Favored Glycine 0 N--CA 1.425 -2.089 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 179.569 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 73.3 t -111.41 129.57 66.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.981 0.391 . . . . 0.0 110.316 -176.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -94.4 129.58 41.07 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.079 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 28.0 ttpp . . . . . 0 N--CA 1.423 -1.817 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 -179.731 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 26.3 m . . . . . 0 N--CA 1.44 -0.935 0 CA-C-O 121.076 0.465 . . . . 0.0 110.908 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -78.5 108.19 11.69 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 176.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 75.03 153.56 0.14 Allowed 'General case' 0 C--O 1.253 1.239 0 C-N-CA 125.228 1.411 . . . . 0.0 111.08 -173.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 23.4 tptm -70.67 120.12 15.82 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -87.0 84.79 7.26 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.341 0.591 . . . . 0.0 111.926 -177.023 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 20.7 m-85 -165.04 113.06 1.02 Allowed 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 126.218 1.807 . . . . 0.0 108.917 177.469 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 94.9 mmm -81.79 91.8 6.55 Favored 'General case' 0 C--N 1.311 -1.091 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 173.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -62.85 144.41 56.64 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -177.123 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.505 ' HZ1' ' HB3' ' A' ' 9' ' ' LYS 0.314 0.4 OUTLIER -79.36 81.73 5.58 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -174.227 . . . . . . . . 4 4 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.48 62.51 0.54 Allowed Glycine 0 N--CA 1.414 -2.821 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 171.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 5.4 t -78.27 78.38 4.75 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-O 122.606 1.193 . . . . 0.0 111.595 -175.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.7 m -140.1 81.09 1.8 Allowed 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 175.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 5.4 m -67.62 124.91 24.58 Favored 'General case' 0 N--CA 1.435 -1.201 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.376 -178.439 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.8 m -71.68 67.83 0.58 Allowed 'General case' 0 C--N 1.314 -0.953 0 C-N-CA 123.547 0.739 . . . . 0.0 111.369 -177.272 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 46.5 m -170.62 -42.45 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 126.207 1.803 . . . . 0.0 106.872 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.9 m -93.31 159.8 2.75 Favored 'Isoleucine or valine' 0 C--O 1.245 0.848 0 CA-C-N 115.067 -0.97 . . . . 0.0 111.373 -173.048 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 50.1 t -108.25 134.92 48.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 176.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -89.74 -68.28 0.79 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -171.62 151.93 3.05 Favored 'General case' 0 C--O 1.248 1.004 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.1 61.23 3.81 Favored Glycine 0 N--CA 1.443 -0.871 0 N-CA-C 111.196 -0.762 . . . . 0.0 111.196 177.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -84.93 -34.03 22.58 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.405 ' HB ' ' O ' ' A' ' 25' ' ' ALA . 2.5 p -77.98 79.85 4.43 Favored 'General case' 0 N--CA 1.419 -1.987 0 CA-C-O 122.086 0.946 . . . . 0.0 111.977 -178.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 20.7 p -97.32 -34.05 11.21 Favored 'General case' 0 N--CA 1.424 -1.74 0 CA-C-N 114.57 -1.196 . . . . 0.0 109.834 179.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.3 m -84.38 -24.3 29.74 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 175.753 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.405 ' O ' ' HB ' ' A' ' 22' ' ' THR . . . -103.25 92.73 4.64 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 175.303 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 16.8 m -60.66 103.67 0.27 Allowed 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.42 -176.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.8 m -85.31 120.99 73.81 Favored Pre-proline 0 N--CA 1.427 -1.597 0 CA-C-N 115.217 -0.901 . . . . 0.0 108.772 -179.224 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -61.88 -53.97 1.82 Allowed 'Trans proline' 0 C--N 1.357 1.02 0 C-N-CA 121.869 1.713 . . . . 0.0 111.572 179.103 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 59.3 -85.17 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 124.756 1.222 . . . . 0.0 112.144 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.4 t -85.63 -19.99 30.15 Favored 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 176.397 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -76.34 165.73 50.56 Favored Pre-proline 0 C--O 1.241 0.639 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 174.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -69.91 101.84 0.98 Allowed 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 122.319 2.012 . . . . 0.0 112.857 -173.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 48.6 t -70.72 -69.92 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.855 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 173.011 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 29.8 m 63.92 -48.43 0.27 Allowed 'General case' 0 CA--C 1.561 1.386 0 C-N-CA 125.433 1.493 . . . . 0.0 114.342 174.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -67.74 78.17 0.2 Allowed Glycine 0 C--N 1.337 0.625 0 C-N-CA 124.0 0.809 . . . . 0.0 111.838 178.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 47.6 m -168.09 -39.53 0.02 OUTLIER 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 103.941 -2.614 . . . . 0.0 103.941 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . 0.411 ' CE2' ' HD3' ' A' ' 47' ' ' LYS . 66.2 m95 -90.54 150.21 21.85 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.788 176.31 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.425 ' HD3' ' N ' ' A' ' 39' ' ' LYS . 12.4 tmtt? -135.18 137.89 43.13 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 177.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.425 ' N ' ' HD3' ' A' ' 38' ' ' LYS . 2.6 ttmp? -83.3 116.85 22.62 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.459 ' HB3' ' CE1' ' A' ' 46' ' ' TYR . 36.3 p30 -77.98 177.66 8.1 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 177.154 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -65.33 -7.41 13.36 Favored 'General case' 0 C--N 1.317 -0.819 0 C-N-CA 123.527 0.731 . . . . 0.0 112.525 -178.448 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.4 m-85 -102.25 4.27 39.08 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.497 0.665 . . . . 0.0 110.041 -178.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.44 16.15 79.85 Favored Glycine 0 N--CA 1.447 -0.591 0 CA-C-N 115.511 -0.768 . . . . 0.0 112.086 178.006 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 25.3 m -100.22 132.95 45.3 Favored 'General case' 0 N--CA 1.424 -1.743 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.042 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 75.1 m95 -87.93 125.31 34.44 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 176.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.459 ' CE1' ' HB3' ' A' ' 40' ' ' ASN . 50.9 p90 -130.31 151.52 50.73 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 121.184 -0.207 . . . . 0.0 111.156 -178.292 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.411 ' HD3' ' CE2' ' A' ' 37' ' ' TRP . 18.1 pttp -146.64 140.91 15.62 Favored Pre-proline 0 C--N 1.313 -0.985 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 173.104 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -79.61 120.96 4.51 Favored 'Trans proline' 0 C--O 1.244 0.8 0 C-N-CA 121.635 1.557 . . . . 0.0 112.559 -179.27 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.8 tt0 -158.14 125.21 4.97 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -87.25 121.38 29.62 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.709 -175.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -150.27 169.52 21.17 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 19.9 m -116.14 143.41 45.53 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 -173.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -130.19 126.39 37.31 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 124.062 0.945 . . . . 0.0 108.964 175.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.1 t -111.41 109.01 26.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 37.9 t30 -77.09 131.27 38.28 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 175.428 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -156.91 83.27 0.15 Allowed Glycine 0 C--N 1.306 -1.103 0 C-N-CA 118.979 -1.581 . . . . 0.0 113.992 -176.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.473 ' HB3' ' OE1' ' A' ' 58' ' ' GLN . 40.3 t30 168.59 -67.86 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 125.269 1.427 . . . . 0.0 109.203 172.577 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.484 ' NE2' ' HB3' ' A' ' 127' ' ' TRP . 4.7 pm0 -111.89 152.24 44.08 Favored Pre-proline 0 C--N 1.304 -1.374 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.266 -175.244 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_exo -73.48 133.98 19.88 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.698 1.598 . . . . 0.0 108.051 170.046 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 61.1 mt -108.1 125.7 64.72 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -176.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.4 p -81.05 111.77 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.626 0 CA-C-O 122.066 0.936 . . . . 0.0 108.737 176.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 64.7 p -92.22 164.62 13.48 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.399 -176.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 17.2 mmt180 -105.41 135.49 46.7 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.635 -175.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.4 mt -98.9 125.56 52.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 N-CA-C 112.68 0.622 . . . . 0.0 112.68 -173.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.75 -21.87 1.52 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 116.388 1.315 . . . . 0.0 116.388 172.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 22.1 m -146.84 136.99 12.13 Favored Pre-proline 0 C--N 1.305 -1.335 0 CA-C-N 118.678 1.239 . . . . 0.0 111.063 -177.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -90.3 120.43 0.82 Allowed 'Trans proline' 0 N--CA 1.437 -1.804 0 C-N-CA 121.925 1.75 . . . . 0.0 110.971 172.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.423 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 51.7 m-85 -167.03 171.45 11.07 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 179.685 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 69.4 mt -84.65 -28.46 26.42 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 107.481 -1.304 . . . . 0.0 107.481 172.418 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -96.68 19.78 11.88 Favored 'General case' 0 CA--C 1.549 0.936 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.294 179.524 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -71.21 155.28 93.24 Favored Pre-proline 0 C--N 1.315 -0.908 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.505 -176.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_exo -55.89 131.16 44.34 Favored 'Trans proline' 0 C--N 1.353 0.801 0 C-N-CA 123.404 2.736 . . . . 0.0 113.927 -179.726 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.3 m -97.54 174.62 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.259 178.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.66 -0.57 15.65 Favored Glycine 0 CA--C 1.496 -1.105 0 C-N-CA 120.071 -1.061 . . . . 0.0 112.235 178.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.43 96.23 0.87 Allowed Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 175.035 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -94.46 118.42 31.61 Favored 'General case' 0 C--N 1.288 -2.071 0 O-C-N 122.186 -0.596 . . . . 0.0 109.967 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 48.4 tp -90.69 117.75 68.18 Favored Pre-proline 0 C--N 1.306 -1.311 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.29 152.51 80.87 Favored 'Trans proline' 0 C--O 1.249 1.061 0 C-N-CA 122.289 1.992 . . . . 0.0 113.029 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.96 135.55 40.04 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 115.142 -0.935 . . . . 0.0 108.982 176.547 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.43 4.91 57.14 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.425 -179.568 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.28 130.48 38.99 Favored 'General case' 0 C--O 1.243 0.731 0 CA-C-O 121.151 0.501 . . . . 0.0 111.882 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.2 m -93.28 120.16 33.25 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.239 176.082 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.6 mm -119.94 118.63 57.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.884 -179.138 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 5.0 p -99.48 112.64 32.34 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 175.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 45.5 p90 -97.2 155.78 16.69 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.536 -173.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -115.54 -9.0 12.11 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -175.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -136.88 131.23 32.86 Favored 'General case' 0 C--N 1.309 -1.194 0 C-N-CA 120.531 -0.467 . . . . 0.0 109.755 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 24.2 t -102.02 129.4 53.42 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.627 ' SG ' ' HE2' ' A' ' 108' ' ' TYR . 43.9 m -134.88 145.93 48.73 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-N 117.84 0.291 . . . . 0.0 111.493 -176.406 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 65.1 mt -120.69 116.89 51.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 175.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.584 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -125.89 136.43 53.04 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 105.854 -1.906 . . . . 0.0 105.854 175.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.04 112.65 0.7 Allowed 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -171.132 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 125.43 -32.62 3.86 Favored Glycine 0 N--CA 1.437 -1.294 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.128 179.071 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 61.2 m80 -153.51 168.8 24.94 Favored 'General case' 0 N--CA 1.473 0.714 0 O-C-N 122.005 -0.703 . . . . 0.0 110.581 -176.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.9 tt -100.5 137.79 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.846 0 N-CA-C 103.449 -2.797 . . . . 0.0 103.449 167.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.584 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 69.5 m95 -118.73 136.76 53.78 Favored 'General case' 0 C--N 1.269 -2.913 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -173.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.444 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.3 pt -100.72 128.68 52.58 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.148 0 C-N-CA 119.896 -0.722 . . . . 0.0 109.43 177.592 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.33 118.83 6.25 Favored Glycine 0 N--CA 1.419 -2.458 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -142.83 168.68 19.14 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -114.72 138.08 51.15 Favored 'General case' 0 C--N 1.291 -1.967 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 176.322 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.98 -177.14 6.48 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.164 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -64.36 -21.67 66.7 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.319 0.581 . . . . 0.0 112.416 -177.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 48.8 t30 -77.74 -8.31 57.78 Favored 'General case' 0 CA--C 1.554 1.134 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.243 176.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 82.73 6.74 88.21 Favored Glycine 0 N--CA 1.461 0.354 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -177.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 43.3 t30 -82.87 133.38 35.13 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 124.067 0.947 . . . . 0.0 109.894 -176.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 16.3 tpp85 -75.29 119.37 19.3 Favored 'General case' 0 C--N 1.316 -0.858 0 O-C-N 123.849 0.718 . . . . 0.0 110.663 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.8 t -124.3 146.63 29.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.627 ' HE2' ' SG ' ' A' ' 89' ' ' CYS . 65.0 m-85 -119.39 131.71 55.71 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 123.477 0.711 . . . . 0.0 110.556 178.204 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 46.7 t -109.76 134.43 20.63 Favored Pre-proline 0 C--N 1.303 -1.454 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -68.7 -19.48 41.48 Favored 'Trans proline' 0 C--N 1.363 1.292 0 C-N-CA 123.135 2.556 . . . . 0.0 114.112 -177.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.296 30.6 m 44.79 -59.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.487 0 N-CA-C 118.394 2.738 . . . . 0.0 118.394 175.159 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 6.4 ptp180 -152.68 160.22 43.16 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.6 p -76.15 140.45 41.76 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.007 176.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.408 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 96.4 m -152.46 145.41 24.47 Favored 'General case' 0 CA--C 1.499 -1.019 0 CA-C-O 120.934 0.397 . . . . 0.0 111.177 -179.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -133.56 160.9 36.08 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.28 -1.748 . . . . 0.0 106.28 178.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.85 -173.44 21.83 Favored Glycine 0 C--N 1.3 -1.429 0 C-N-CA 118.596 -1.764 . . . . 0.0 113.939 175.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 21.1 m -138.24 123.88 12.51 Favored Pre-proline 0 C--N 1.311 -1.097 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.231 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -46.53 128.43 12.69 Favored 'Trans proline' 0 CA--C 1.543 0.937 0 C-N-CA 123.521 2.814 . . . . 0.0 113.05 -178.62 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -93.67 3.31 55.67 Favored 'Cis proline' 0 CA--C 1.551 1.373 0 N-CA-C 115.239 1.207 . . . . 0.0 115.239 5.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -78.71 102.27 7.98 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 122.199 1.0 . . . . 0.0 110.691 -176.359 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.42 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 35.6 p-80 -105.19 121.77 44.51 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-N 114.012 -1.449 . . . . 0.0 110.958 -177.454 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.408 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 58.3 mt -102.08 100.67 15.73 Favored Pre-proline 0 C--N 1.305 -1.36 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.094 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . 0.42 ' HD3' ' O ' ' A' ' 121' ' ' HIS . 63.7 Cg_endo -85.7 135.14 4.86 Favored 'Trans proline' 0 CA--C 1.544 0.981 0 C-N-CA 122.872 2.381 . . . . 0.0 114.209 -177.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -112.11 -151.97 11.7 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 175.294 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 90.4 t -52.63 124.49 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.336 0 C-N-CA 123.938 0.895 . . . . 0.0 112.535 -178.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -93.77 143.7 26.09 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.871 175.29 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . 0.484 ' HB3' ' NE2' ' A' ' 58' ' ' GLN . 5.3 m-90 -105.47 17.24 24.21 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.327 0.584 . . . . 0.0 110.986 178.347 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -165.57 -170.43 30.5 Favored Glycine 0 N--CA 1.429 -1.804 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 98.8 t -111.23 133.04 58.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -178.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -104.43 127.6 52.14 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.7 tppt? . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -179.842 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 42.8 m . . . . . 0 CA--C 1.539 0.546 0 N-CA-C 108.798 -0.815 . . . . 0.0 108.798 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -80.51 -80.17 0.14 Allowed 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 112.957 0.725 . . . . 0.0 112.957 -176.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -124.25 19.11 9.04 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 120.856 0.36 . . . . 0.0 110.938 -174.401 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 60.6 tttm 64.34 12.64 7.4 Favored 'General case' 0 CA--C 1.557 1.233 0 C-N-CA 123.978 0.911 . . . . 0.0 111.92 177.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -91.41 85.22 5.72 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.639 0.733 . . . . 0.0 109.491 179.537 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -133.86 24.45 3.96 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 107.278 -1.378 . . . . 0.0 107.278 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 48.3 ttm -139.8 141.71 36.74 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 113.902 -1.499 . . . . 0.0 107.386 -179.507 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -96.5 157.39 15.92 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 178.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.5 pttm -126.24 72.05 1.29 Allowed 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.24 1.019 . . . . 0.0 111.254 176.229 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 80.66 -80.99 1.62 Allowed Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.473 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 6.3 t -124.94 104.2 8.45 Favored 'General case' 0 N--CA 1.418 -2.066 0 CA-C-O 122.348 1.07 . . . . 0.0 109.537 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.5 m -126.17 93.36 3.79 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 106.519 -1.66 . . . . 0.0 106.519 176.46 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.0 m -47.32 -36.16 9.0 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 115.21 1.559 . . . . 0.0 115.21 -171.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.1 m -78.35 -46.95 18.74 Favored 'General case' 0 C--N 1.31 -1.125 0 C-N-CA 120.051 -0.66 . . . . 0.0 110.696 178.61 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 21.9 m -67.34 -32.81 74.01 Favored 'General case' 0 CA--C 1.547 0.855 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -177.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 17.6 m -82.64 -5.48 9.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 O-C-N 122.291 -0.255 . . . . 0.0 110.945 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.0 t 60.63 74.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.243 0.749 0 C-N-CA 124.604 1.161 . . . . 0.0 110.001 -177.527 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 75.46 116.08 0.06 Allowed 'General case' 0 C--O 1.236 0.367 0 CA-C-N 114.191 -1.368 . . . . 0.0 112.059 -178.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -109.76 148.94 30.54 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.168 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -110.24 0.15 29.73 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 119.901 -1.142 . . . . 0.0 112.909 -177.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 34.8 mtmm -90.23 -51.04 5.65 Favored 'General case' 0 C--N 1.312 -1.027 0 O-C-N 122.296 -0.532 . . . . 0.0 111.395 -177.303 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 13.3 t -118.75 114.04 22.07 Favored 'General case' 0 N--CA 1.428 -1.547 0 CA-C-O 122.234 1.016 . . . . 0.0 110.677 179.4 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.8 p -129.58 165.39 21.82 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 114.726 -1.124 . . . . 0.0 110.169 -175.683 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.3 m -68.79 123.28 20.51 Favored 'General case' 0 C--O 1.252 1.199 0 C-N-CA 122.221 0.208 . . . . 0.0 110.648 -178.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 57.81 26.58 13.36 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 124.808 1.243 . . . . 0.0 111.871 177.615 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 28.0 m 65.79 -78.26 0.04 OUTLIER 'General case' 0 C--O 1.245 0.864 0 C-N-CA 124.344 1.058 . . . . 0.0 110.69 -175.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.9 t -155.28 87.3 3.24 Favored Pre-proline 0 N--CA 1.434 -1.273 0 N-CA-C 114.498 1.296 . . . . 0.0 114.498 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -97.88 4.2 1.39 Allowed 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 122.926 2.417 . . . . 0.0 108.477 164.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 52.93 -97.34 0.06 Allowed 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 126.066 1.746 . . . . 0.0 111.317 -174.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.6 m -143.71 25.01 1.67 Allowed 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 177.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 38.6 ttt180 -60.76 -55.31 46.05 Favored Pre-proline 0 C--N 1.346 0.445 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.618 178.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -78.81 92.25 1.15 Allowed 'Trans proline' 0 N--CA 1.441 -1.559 0 CA-C-N 120.192 1.104 . . . . 0.0 109.402 169.489 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 13.7 p -66.63 -41.9 88.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.961 0.41 . . . . 0.0 111.205 -176.307 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.7 t -108.17 -26.3 10.66 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 121.369 0.604 . . . . 0.0 110.36 178.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.78 128.47 6.03 Favored Glycine 0 N--CA 1.433 -1.551 0 C-N-CA 120.99 -0.624 . . . . 0.0 111.593 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 10.5 t 75.29 -40.58 0.43 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.43 1.492 . . . . 0.0 111.952 177.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . 0.513 ' CE2' ' HD2' ' A' ' 47' ' ' LYS . 86.2 m95 -70.28 138.4 51.54 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 177.824 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 53.5 mtmt -135.49 148.92 49.38 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 175.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -88.08 125.86 34.8 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.558 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 55.1 t30 -93.78 169.36 10.36 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 123.687 0.795 . . . . 0.0 110.545 -176.618 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -47.66 -34.81 8.54 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.926 2.091 . . . . 0.0 113.005 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -88.21 7.55 31.39 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.113 0.482 . . . . 0.0 111.703 -175.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.87 -13.02 60.15 Favored Glycine 0 CA--C 1.507 -0.462 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.44 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 5.3 m -71.84 137.09 47.27 Favored 'General case' 0 N--CA 1.42 -1.965 0 C-N-CA 124.55 1.14 . . . . 0.0 110.413 -177.79 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 66.5 m95 -90.03 133.75 34.65 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 173.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.558 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 8.6 p90 -132.3 149.12 52.43 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.865 -177.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.513 ' HD2' ' CE2' ' A' ' 37' ' ' TRP . 21.9 ptmt -137.19 146.85 56.05 Favored Pre-proline 0 C--N 1.305 -1.328 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 175.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -77.02 121.85 5.99 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.057 1.838 . . . . 0.0 109.862 173.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -157.98 120.86 3.86 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -178.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.48 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 4.9 t30 -103.35 117.03 33.56 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 -177.009 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.428 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.93 -177.9 6.57 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.442 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 32.3 m -118.05 152.68 35.07 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 120.627 0.251 . . . . 0.0 110.577 -177.044 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.494 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 92.5 t80 -134.61 132.65 39.27 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 177.606 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.1 t -115.56 127.77 73.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.457 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -65.16 135.72 55.82 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.085 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -73.82 -90.91 0.15 Allowed Glycine 0 N--CA 1.44 -1.067 0 O-C-N 123.654 0.596 . . . . 0.0 113.804 -175.545 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -109.72 -47.03 3.41 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 114.097 1.147 . . . . 0.0 114.097 -174.528 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -116.95 152.25 48.44 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -174.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.424 ' HB3' HD22 ' A' ' 76' ' ' ASN . 51.9 Cg_exo -57.13 137.46 81.93 Favored 'Trans proline' 0 C--O 1.242 0.699 0 C-N-CA 122.856 2.37 . . . . 0.0 112.106 178.434 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -108.98 125.85 66.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 -176.266 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 33.6 m -72.93 148.43 9.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 175.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 35.9 p -127.15 163.01 24.78 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 110.337 -0.245 . . . . 0.0 110.337 -175.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -110.18 141.85 42.53 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -178.523 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.7 mt -94.1 119.01 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.493 -175.561 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 72.18 -22.95 0.75 Allowed Glycine 0 CA--C 1.529 0.922 0 N-CA-C 117.273 1.669 . . . . 0.0 117.273 170.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.3 m -141.32 136.35 15.71 Favored Pre-proline 0 C--N 1.297 -1.69 0 CA-C-N 118.958 1.379 . . . . 0.0 110.862 -178.417 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -89.64 119.53 0.88 Allowed 'Trans proline' 0 N--CA 1.433 -2.055 0 C-N-CA 121.325 1.35 . . . . 0.0 110.47 172.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.405 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 72.0 m-85 -169.37 169.46 9.02 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 127.954 2.502 . . . . 0.0 104.61 -179.295 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -90.13 -17.87 26.86 Favored 'General case' 0 C--N 1.293 -1.879 0 CA-C-O 121.222 0.534 . . . . 0.0 110.75 175.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 27.8 p-10 -106.7 20.32 19.19 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.801 0.81 . . . . 0.0 109.665 177.303 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.405 ' HB1' ' HB2' ' A' ' 68' ' ' PHE . . . -72.59 156.4 90.18 Favored Pre-proline 0 C--O 1.25 1.101 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.734 179.022 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -54.58 122.97 12.52 Favored 'Trans proline' 0 C--N 1.357 1.024 0 C-N-CA 122.922 2.414 . . . . 0.0 112.372 -179.452 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 8.5 p -103.45 174.24 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-N 114.916 -1.038 . . . . 0.0 108.235 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.9 -6.43 12.26 Favored Glycine 0 CA--C 1.494 -1.258 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -178.383 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.23 131.55 10.62 Favored Glycine 0 N--CA 1.429 -1.773 0 N-CA-C 108.399 -1.88 . . . . 0.0 108.399 173.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.424 HD22 ' HB3' ' A' ' 59' ' ' PRO . 9.2 t30 -126.98 141.38 51.81 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 118.113 0.956 . . . . 0.0 111.564 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 51.5 tp -104.18 114.72 64.09 Favored Pre-proline 0 C--N 1.309 -1.171 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 176.09 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -62.7 160.42 32.76 Favored 'Trans proline' 0 C--O 1.243 0.75 0 C-N-CA 123.072 2.515 . . . . 0.0 112.81 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.67 137.49 46.06 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.327 -178.683 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.32 19.6 78.1 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.804 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -85.72 140.12 30.78 Favored 'General case' 0 C--N 1.317 -0.814 0 O-C-N 122.554 -0.38 . . . . 0.0 110.346 178.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 40.5 m -111.68 108.73 18.28 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.8 mm -116.52 136.51 53.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 122.889 0.475 . . . . 0.0 110.565 -175.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.4 p -102.92 128.24 55.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 174.46 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.48 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 42.5 p90 -117.63 157.74 25.88 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.559 -175.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -121.26 -5.99 9.39 Favored 'General case' 0 C--O 1.247 0.972 0 O-C-N 123.653 0.595 . . . . 0.0 111.261 -178.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -133.71 126.88 31.67 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -173.624 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.0 t -114.1 127.37 71.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 177.74 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.44 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 63.0 m -129.68 150.51 50.97 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 122.983 0.177 . . . . 0.0 111.469 -176.039 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 45.0 mt -121.28 117.29 52.3 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 172.526 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.402 ' NE2' ' HG1' ' A' ' 44' ' ' THR . 6.0 tp-100 -111.39 144.46 40.56 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 104.261 -2.496 . . . . 0.0 104.261 173.185 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.8 104.07 0.07 Allowed 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -170.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 115.77 -23.94 10.58 Favored Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.471 -0.786 . . . . 0.0 113.677 178.304 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . 0.451 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 50.8 m80 -147.77 145.55 28.84 Favored 'General case' 0 CA--C 1.505 -0.786 0 O-C-N 121.559 -0.965 . . . . 0.0 112.204 -177.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.5 tt -93.9 139.01 19.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 105.552 -2.018 . . . . 0.0 105.552 173.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 74.5 m95 -124.02 139.01 54.36 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -174.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.3 pt -102.46 132.22 48.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 173.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.48 124.68 8.1 Favored Glycine 0 N--CA 1.425 -2.053 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -179.691 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -138.55 155.56 48.27 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 178.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -97.99 120.33 38.19 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 176.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.31 161.55 20.4 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -58.41 -14.09 6.9 Favored 'General case' 0 N--CA 1.483 1.212 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.245 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -77.62 -13.56 59.87 Favored 'General case' 0 CA--C 1.548 0.895 0 CA-C-O 121.5 0.667 . . . . 0.0 110.713 177.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 87.64 15.9 60.93 Favored Glycine 0 CA--C 1.497 -1.079 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -176.219 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 39.4 t-20 -97.1 132.82 42.51 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 114.239 -0.98 . . . . 0.0 109.226 -177.573 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 25.9 tpt180 -90.17 99.06 12.15 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 175.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 36.8 t -100.32 142.42 15.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.989 -173.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.441 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 81.5 m-85 -115.23 129.38 56.62 Favored 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 123.081 0.552 . . . . 0.0 110.223 178.23 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.1 t -108.32 133.45 20.56 Favored Pre-proline 0 C--N 1.306 -1.303 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.56 -10.06 24.8 Favored 'Trans proline' 0 C--N 1.364 1.344 0 C-N-CA 123.397 2.731 . . . . 0.0 114.729 -174.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.293 27.2 m 38.19 -67.26 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 N-CA-C 118.026 2.602 . . . . 0.0 118.026 175.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 6.3 ptp85 -147.44 148.81 31.67 Favored 'General case' 0 N--CA 1.445 -0.7 0 C-N-CA 123.239 0.616 . . . . 0.0 109.603 176.078 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.451 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 66.8 m -67.95 133.98 50.0 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 176.386 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.558 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 86.3 m -151.34 103.82 3.03 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 122.886 0.474 . . . . 0.0 110.363 -179.173 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 45.8 mt-30 -88.85 141.14 28.75 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.193 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 139.7 178.04 16.31 Favored Glycine 0 N--CA 1.42 -2.386 0 C-N-CA 119.015 -1.564 . . . . 0.0 113.273 178.449 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 87.0 t -133.31 130.61 21.22 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 179.182 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_exo -43.46 132.51 7.1 Favored 'Trans proline' 0 CA--C 1.548 1.195 0 C-N-CA 123.44 2.76 . . . . 0.0 113.456 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -89.31 -5.98 51.67 Favored 'Cis proline' 0 CA--C 1.541 0.826 0 C-N-CA 123.373 -1.511 . . . . 0.0 114.832 4.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -76.51 100.65 5.34 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-O 122.161 0.981 . . . . 0.0 112.409 -173.588 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 28.7 p-80 -105.43 126.57 52.27 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 113.845 -1.525 . . . . 0.0 111.007 178.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.558 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 60.7 mt -100.6 104.39 30.52 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 174.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -76.97 123.65 6.9 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.564 2.176 . . . . 0.0 113.171 -175.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -108.51 -141.86 9.76 Favored Glycine 0 N--CA 1.424 -2.12 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.586 177.242 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 67.0 t -75.21 122.28 28.57 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 C-N-CA 122.948 0.499 . . . . 0.0 111.996 -176.623 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -93.23 143.36 26.33 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.719 173.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.8 m-90 -106.03 14.61 27.61 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.951 0.881 . . . . 0.0 109.686 177.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.494 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -162.13 177.61 38.26 Favored Glycine 0 N--CA 1.407 -3.251 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.491 -179.426 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 57.5 t -111.52 118.82 58.45 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.192 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 -177.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 41.8 m-85 -78.74 132.77 37.08 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.442 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 53.9 tptt . . . . . 0 N--CA 1.404 -2.767 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 19.4 m . . . . . 0 N--CA 1.446 -0.669 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 54.3 t30 -87.31 -75.01 0.42 Allowed 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.336 -176.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -98.34 -28.56 13.6 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-O 121.436 0.636 . . . . 0.0 110.865 -175.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -92.52 79.48 4.9 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 121.673 0.749 . . . . 0.0 109.503 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 42.0 t30 -166.63 138.48 3.55 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 106.584 -1.635 . . . . 0.0 106.584 178.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -130.05 137.03 50.02 Favored 'General case' 0 C--N 1.295 -1.784 0 C-N-CA 120.592 -0.443 . . . . 0.0 111.358 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 84.9 mtp -81.23 -38.27 27.22 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 174.228 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 37.0 t70 51.05 81.5 0.07 Allowed 'General case' 0 CA--C 1.516 -0.36 0 C-N-CA 125.46 1.504 . . . . 0.0 113.553 177.455 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 27.6 mmtp -145.2 86.94 1.79 Allowed 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.814 174.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.47 -35.09 18.04 Favored Glycine 0 N--CA 1.434 -1.455 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 175.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.4 m -91.35 102.65 15.34 Favored 'General case' 0 N--CA 1.427 -1.613 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.377 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.8 p -72.55 -42.44 64.67 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 122.149 0.976 . . . . 0.0 109.702 178.303 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 4.5 p -146.8 136.39 22.98 Favored 'General case' 0 N--CA 1.422 -1.828 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.227 178.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.8 p -103.59 104.61 14.69 Favored 'General case' 0 C--N 1.309 -1.152 0 N-CA-C 114.573 1.323 . . . . 0.0 114.573 -173.046 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 12.9 m 60.17 31.03 20.37 Favored 'General case' 0 CA--C 1.564 1.507 0 C-N-CA 124.383 1.073 . . . . 0.0 112.443 172.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.1 p -86.88 86.13 2.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 O-C-N 120.916 -1.115 . . . . 0.0 110.401 179.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.9 m -96.27 -12.81 8.34 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.473 178.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.44 ' HA ' ' HE2' ' A' ' 18' ' ' LYS . 0.2 OUTLIER -149.21 139.02 21.9 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 -179.255 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -92.22 24.35 3.39 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 122.792 0.437 . . . . 0.0 109.867 178.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -80.95 49.13 3.9 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 56.2 mtpt -140.31 -170.09 2.9 Favored 'General case' 0 C--N 1.288 -2.067 0 N-CA-C 105.804 -1.925 . . . . 0.0 105.804 -175.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.3 m -75.41 88.36 2.61 Favored 'General case' 0 N--CA 1.428 -1.554 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 174.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 55.0 m -157.99 -50.27 0.07 Allowed 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.178 -177.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.8 t -158.87 -41.29 0.06 Allowed 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 120.032 -0.667 . . . . 0.0 111.908 -178.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -62.1 -36.72 82.57 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 113.699 1.0 . . . . 0.0 113.699 -175.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 19.8 m -81.07 108.64 14.91 Favored 'General case' 0 C--O 1.248 1.015 0 CA-C-O 121.238 0.542 . . . . 0.0 111.121 -178.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.4 p -82.99 150.67 62.11 Favored Pre-proline 0 N--CA 1.436 -1.149 0 CA-C-N 115.298 -0.865 . . . . 0.0 111.618 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -75.57 85.64 1.57 Allowed 'Trans proline' 0 N--CA 1.451 -1.024 0 C-N-CA 122.791 2.327 . . . . 0.0 113.626 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -89.67 -14.26 35.2 Favored 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 170.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.406 ' O ' ' HD2' ' A' ' 32' ' ' PRO . 10.1 t -174.39 -172.69 0.7 Allowed 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 103.65 -2.722 . . . . 0.0 103.65 179.412 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . 0.349 10.5 mmt180 86.5 -91.02 0.0 OUTLIER Pre-proline 0 CA--C 1.565 1.521 0 C-N-CA 125.294 1.437 . . . . 0.0 113.667 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.406 ' HD2' ' O ' ' A' ' 30' ' ' THR . 98.0 Cg_endo -82.84 33.66 0.53 Allowed 'Trans proline' 0 C--N 1.384 2.435 0 CA-C-N 123.104 2.144 . . . . 0.0 112.133 -178.555 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.2 m -80.68 4.18 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.718 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 12.0 p -73.15 -37.99 66.39 Favored 'General case' 0 N--CA 1.423 -1.819 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.443 176.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 56.07 -95.72 0.04 OUTLIER Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.319 -0.855 . . . . 0.0 114.261 175.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 21.8 t -77.58 -23.3 49.98 Favored 'General case' 0 C--N 1.311 -1.089 0 C-N-CA 123.603 0.761 . . . . 0.0 109.923 -178.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -77.74 117.23 18.93 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.965 0.412 . . . . 0.0 110.419 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 8.3 tmtm? -118.44 133.46 55.85 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -81.67 128.74 34.28 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 120.91 0.386 . . . . 0.0 111.723 -176.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -96.67 166.08 11.83 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 176.136 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -51.65 -27.79 12.56 Favored 'General case' 0 N--CA 1.489 1.485 0 C-N-CA 125.184 1.394 . . . . 0.0 113.082 -176.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 69.0 m-85 -87.5 10.11 18.76 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 121.498 0.666 . . . . 0.0 111.535 -175.445 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.54 14.36 82.1 Favored Glycine 0 CA--C 1.5 -0.89 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 178.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.459 ' HG1' ' NE2' ' A' ' 91' ' ' GLN . 6.8 m -96.14 127.7 42.38 Favored 'General case' 0 N--CA 1.409 -2.517 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -177.334 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 71.8 m95 -95.31 120.99 36.5 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.092 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -120.14 148.69 43.32 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.106 -177.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.1 pttm -134.95 151.4 75.45 Favored Pre-proline 0 C--N 1.305 -1.342 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -71.88 132.51 20.1 Favored 'Trans proline' 0 N--CA 1.45 -1.043 0 C-N-CA 121.678 1.585 . . . . 0.0 111.471 175.523 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -159.16 120.61 3.34 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 176.098 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.435 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 3.7 t-20 -107.39 115.73 30.68 Favored 'General case' 0 C--N 1.295 -1.783 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.328 -175.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -160.94 178.63 9.2 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.241 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 17.4 m -116.82 151.98 35.38 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -178.539 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.4 t80 -124.95 127.96 47.86 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 175.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 46.6 t -112.27 112.69 41.57 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.037 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 55.3 t30 -65.72 136.25 56.01 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.2 -179.026 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -119.07 -83.19 0.84 Allowed Glycine 0 N--CA 1.43 -1.739 0 N-CA-C 115.77 1.068 . . . . 0.0 115.77 -170.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -79.07 -23.28 44.31 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 115.365 1.617 . . . . 0.0 115.365 -166.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.79 150.1 23.72 Favored Pre-proline 0 C--N 1.311 -1.102 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.277 -178.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -68.37 131.24 22.82 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.369 2.046 . . . . 0.0 109.739 177.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 51.2 mt -106.81 127.52 62.28 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.828 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -171.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -81.5 138.03 20.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 178.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 50.9 p -110.51 170.11 8.3 Favored 'General case' 0 C--N 1.295 -1.791 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.751 -174.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -117.29 138.12 51.96 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.185 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.7 mt -99.09 125.68 52.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.889 -174.086 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.39 -22.93 3.58 Favored Glycine 0 N--CA 1.448 -0.534 0 N-CA-C 115.772 1.069 . . . . 0.0 115.772 172.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.5 m -152.3 138.1 11.5 Favored Pre-proline 0 C--N 1.297 -1.696 0 CA-C-N 118.074 0.937 . . . . 0.0 110.065 -177.694 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -89.84 120.87 0.95 Allowed 'Trans proline' 0 N--CA 1.44 -1.674 0 C-N-CA 121.64 1.56 . . . . 0.0 111.008 173.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.425 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 93.5 m-85 -168.58 166.24 12.03 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 127.246 2.218 . . . . 0.0 105.021 179.174 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 96.5 mt -82.01 -19.74 39.83 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-O 121.357 0.598 . . . . 0.0 109.994 175.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -111.02 19.69 18.21 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.294 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.425 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -73.38 156.88 88.69 Favored Pre-proline 0 C--O 1.249 1.05 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.573 -178.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -46.97 127.36 12.32 Favored 'Trans proline' 0 C--N 1.365 1.404 0 C-N-CA 123.754 2.969 . . . . 0.0 113.806 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 10.9 p -99.89 172.71 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-N 114.304 -1.316 . . . . 0.0 107.95 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.91 11.55 7.6 Favored Glycine 0 C--N 1.318 -0.469 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -177.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -137.1 121.11 2.25 Favored Glycine 0 N--CA 1.423 -2.228 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 175.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -126.17 141.54 51.89 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 117.519 0.66 . . . . 0.0 109.899 -178.266 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 27.4 tp -101.41 113.61 65.8 Favored Pre-proline 0 N--CA 1.429 -1.48 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.21 166.72 22.32 Favored 'Trans proline' 0 C--O 1.249 1.033 0 C-N-CA 122.272 1.981 . . . . 0.0 113.32 -177.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.15 128.64 36.32 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.225 179.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.99 -5.34 61.47 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.873 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.84 128.55 36.72 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.013 0.435 . . . . 0.0 111.22 -179.199 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 44.3 m -104.08 111.55 24.17 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.593 -179.574 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.6 mm -116.99 130.27 72.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.28 -176.314 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.2 p -99.11 139.34 21.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 174.71 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.435 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 46.2 p90 -135.3 158.16 45.08 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.802 -176.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -128.34 -0.39 5.69 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.589 177.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -129.64 127.8 41.32 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.06 -178.236 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.6 t -123.66 126.94 73.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.507 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 27.2 p -135.84 148.46 48.68 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -174.24 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 68.8 mt -106.03 121.96 59.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.996 178.123 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.459 ' NE2' ' HG1' ' A' ' 44' ' ' THR . 5.9 tp-100 -125.7 144.85 50.43 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 173.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -51.05 107.23 0.16 Allowed 'General case' 0 C--N 1.317 -0.805 0 O-C-N 123.51 0.506 . . . . 0.0 111.535 -177.3 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.7 -41.62 1.52 Allowed Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.117 178.694 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . 0.5 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 69.9 m80 -154.16 166.02 34.42 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 117.294 0.547 . . . . 0.0 110.915 -175.524 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.8 tt -105.26 110.15 30.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 173.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.507 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 45.2 m95 -96.74 142.66 28.5 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.784 -168.825 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.8 pt -100.2 134.22 40.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 174.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -101.96 124.63 8.27 Favored Glycine 0 N--CA 1.424 -2.158 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -149.72 169.92 19.93 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-O 121.018 0.437 . . . . 0.0 109.832 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -104.33 143.13 33.4 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.611 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -94.43 159.32 15.16 Favored 'General case' 0 C--N 1.291 -1.964 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 173.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -54.12 -21.92 9.83 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -179.064 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 11.4 t30 -92.59 7.31 43.87 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-O 121.973 0.892 . . . . 0.0 110.738 -177.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 83.02 13.41 77.53 Favored Glycine 0 C--N 1.321 -0.251 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.677 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 18.7 m120 -83.72 141.05 31.73 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 30.2 tpt180 -89.83 106.27 18.36 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 176.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.3 t -112.6 138.26 42.44 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 C-N-CA 119.895 -0.722 . . . . 0.0 110.512 -173.766 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -117.17 126.8 53.36 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.452 -0.794 . . . . 0.0 110.002 176.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.7 t -109.07 130.63 22.5 Favored Pre-proline 0 C--N 1.304 -1.4 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -68.89 -22.26 36.49 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 122.819 2.346 . . . . 0.0 114.133 -176.423 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.298 34.4 m 49.3 -54.9 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.579 0 N-CA-C 117.771 2.508 . . . . 0.0 117.771 177.045 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -150.77 143.42 24.46 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 123.464 0.706 . . . . 0.0 109.67 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.5 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 69.1 m -71.61 127.87 33.96 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.732 178.443 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.537 ' SG ' ' HA ' ' A' ' 123' ' ' PRO . 94.5 m -149.49 140.51 22.93 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.06 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -125.12 153.99 42.14 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 105.788 -1.93 . . . . 0.0 105.788 178.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.84 -168.6 31.19 Favored Glycine 0 CA--C 1.483 -1.919 0 C-N-CA 118.633 -1.746 . . . . 0.0 112.275 178.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 65.6 t -138.82 121.52 10.63 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 179.134 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_exo -48.03 136.23 23.64 Favored 'Trans proline' 0 C--O 1.238 0.517 0 C-N-CA 123.175 2.583 . . . . 0.0 111.952 -179.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -95.32 25.04 23.18 Favored 'Cis proline' 0 CA--C 1.548 1.193 0 C-N-CA 124.461 -1.058 . . . . 0.0 114.043 3.674 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -106.15 106.02 16.34 Favored 'General case' 0 C--N 1.315 -0.928 0 O-C-N 121.789 -0.57 . . . . 0.0 111.274 -178.383 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 25.2 p-80 -104.17 139.85 38.65 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.175 176.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 44.7 mm -104.02 107.4 56.9 Favored Pre-proline 0 C--N 1.293 -1.852 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . 0.537 ' HA ' ' SG ' ' A' ' 114' ' ' CYS . 86.0 Cg_endo -79.57 147.57 19.94 Favored 'Trans proline' 0 C--O 1.247 0.933 0 C-N-CA 122.623 2.215 . . . . 0.0 113.989 -175.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -131.49 -124.73 2.6 Favored Glycine 0 N--CA 1.428 -1.854 0 CA-C-N 115.415 -0.812 . . . . 0.0 111.266 176.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.0 t -85.62 121.37 37.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -175.424 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.38 151.23 19.55 Favored 'General case' 0 C--O 1.246 0.894 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.158 173.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.5 m-90 -109.1 6.54 25.02 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 179.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -160.82 -171.74 27.18 Favored Glycine 0 N--CA 1.428 -1.899 0 C-N-CA 120.64 -0.79 . . . . 0.0 111.271 -178.153 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 44.0 t -111.7 131.97 61.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -174.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -91.9 137.46 32.34 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 176.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt . . . . . 0 C--N 1.288 -2.078 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.684 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 14.6 m . . . . . 0 N--CA 1.438 -1.067 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 60.8 t30 -62.6 -40.97 98.62 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.349 0.595 . . . . 0.0 109.446 178.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -128.47 117.95 22.24 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.665 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 34.0 mmtp 66.22 178.24 0.21 Allowed 'General case' 0 C--O 1.242 0.663 0 CA-C-O 122.134 0.969 . . . . 0.0 112.961 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 29.1 p-10 -142.03 16.27 2.1 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 174.415 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 53.3 t80 -141.36 116.67 10.08 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 114.146 -1.388 . . . . 0.0 108.794 -173.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 53.0 ttm -103.64 132.99 49.4 Favored 'General case' 0 C--N 1.293 -1.868 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 175.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -67.12 -30.06 69.96 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 120.411 -0.516 . . . . 0.0 110.894 -178.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -91.3 96.61 10.64 Favored 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 174.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -127.86 54.81 0.77 Allowed Glycine 0 N--CA 1.43 -1.712 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -178.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 89.4 m -146.58 106.66 4.0 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.48 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.1 m -66.48 104.23 1.21 Allowed 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 173.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.1 m -65.25 107.26 1.54 Allowed 'General case' 0 N--CA 1.435 -1.178 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.427 -173.452 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 42.4 m 69.96 -18.9 0.21 Allowed 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 125.303 1.441 . . . . 0.0 114.263 177.256 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.5 m -84.11 97.59 9.42 Favored 'General case' 0 N--CA 1.434 -1.23 0 CA-C-O 120.923 0.392 . . . . 0.0 110.581 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 31.6 m -125.46 -37.39 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.884 178.034 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.0 m -143.18 164.34 16.06 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -178.606 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.6 tttp -110.38 76.76 1.0 Allowed 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 106.062 -1.829 . . . . 0.0 106.062 173.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -76.72 -35.51 57.77 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 113.555 -1.657 . . . . 0.0 113.92 -170.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -101.63 145.48 16.8 Favored Glycine 0 N--CA 1.436 -1.35 0 C-N-CA 119.867 -1.159 . . . . 0.0 115.838 -171.089 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.4 tttm 59.58 64.76 1.26 Allowed 'General case' 0 C--O 1.245 0.822 0 C-N-CA 126.055 1.742 . . . . 0.0 111.944 174.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 23.6 m -116.18 -2.83 12.09 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-N 114.376 -1.284 . . . . 0.0 108.468 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.411 ' C ' ' HG ' ' A' ' 24' ' ' SER . 88.7 p 62.29 -87.61 0.02 OUTLIER 'General case' 0 C--O 1.236 0.369 0 C-N-CA 126.609 1.964 . . . . 0.0 110.166 -173.048 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' SER . . . . . 0.411 ' HG ' ' C ' ' A' ' 23' ' ' SER . 49.2 m -161.7 -70.04 0.06 Allowed 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 123.731 0.812 . . . . 0.0 109.244 175.471 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 174.92 -164.38 0.03 OUTLIER 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 -177.353 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.3 p -70.6 -12.52 61.62 Favored 'General case' 0 CA--C 1.548 0.896 0 CA-C-O 121.521 0.677 . . . . 0.0 111.194 175.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 21.5 m -108.33 99.47 32.52 Favored Pre-proline 0 N--CA 1.436 -1.139 0 N-CA-C 106.189 -1.782 . . . . 0.0 106.189 171.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -90.66 -26.03 0.36 Allowed 'Trans proline' 0 N--CA 1.452 -0.92 0 N-CA-C 117.228 1.972 . . . . 0.0 117.228 -172.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 64.6 36.11 8.69 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -173.305 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 m 60.72 83.9 0.14 Allowed 'General case' 0 CA--C 1.549 0.917 0 CA-C-N 114.151 -1.386 . . . . 0.0 111.818 -178.028 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -132.12 -64.89 0.02 OUTLIER Pre-proline 0 CA--C 1.544 0.713 0 N-CA-C 112.818 0.673 . . . . 0.0 112.818 -178.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.26 -20.3 32.65 Favored 'Trans proline' 0 C--N 1.373 1.833 0 CA-C-N 120.692 1.283 . . . . 0.0 111.431 177.305 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.4 t 73.42 68.68 0.06 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-O 123.143 1.449 . . . . 0.0 109.925 -178.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.0 p -102.41 80.07 1.9 Allowed 'General case' 0 N--CA 1.408 -2.548 0 CA-C-N 113.382 -1.736 . . . . 0.0 109.742 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -87.8 -53.53 2.7 Favored Glycine 0 N--CA 1.43 -1.751 0 CA-C-N 115.298 -0.865 . . . . 0.0 111.127 -178.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.7 m -89.55 -28.56 19.51 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 178.624 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -78.35 127.38 32.13 Favored 'General case' 0 N--CA 1.442 -0.841 0 CA-C-O 121.551 0.691 . . . . 0.0 111.791 -177.072 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.6 tmtt? -130.3 140.98 50.63 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -85.84 146.16 26.88 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.396 0.617 . . . . 0.0 112.371 -173.049 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 48.2 t-20 -109.75 153.83 23.78 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 124.988 1.315 . . . . 0.0 107.622 178.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 7.9 tt0 -53.88 -26.5 25.18 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 125.443 1.497 . . . . 0.0 112.48 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -75.3 -7.91 55.23 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.359 0.6 . . . . 0.0 111.63 -179.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.02 -13.32 63.59 Favored Glycine 0 N--CA 1.437 -1.275 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 -178.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 7.3 m -68.63 147.98 51.12 Favored 'General case' 0 N--CA 1.421 -1.879 0 C-N-CA 124.954 1.301 . . . . 0.0 109.073 179.285 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.446 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 64.7 m95 -111.31 142.28 43.74 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 173.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -139.1 156.99 46.75 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-O 121.087 0.47 . . . . 0.0 111.531 -179.084 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -138.48 132.51 16.57 Favored Pre-proline 0 C--N 1.295 -1.779 0 CA-C-N 114.905 -1.043 . . . . 0.0 108.223 174.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.52 121.16 7.9 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 N-CA-C 108.752 -1.288 . . . . 0.0 108.752 173.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -168.03 124.9 1.09 Allowed 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -176.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -93.47 138.91 31.31 Favored 'General case' 0 CA--C 1.483 -1.61 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.341 -176.342 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.467 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -164.01 160.71 22.1 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 175.074 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.45 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 16.1 m -105.6 132.58 51.57 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.378 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -108.15 121.06 44.07 Favored 'General case' 0 N--CA 1.422 -1.825 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 175.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 42.5 t -107.19 119.25 56.49 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.078 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 176.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.408 ' ND2' HG12 ' A' ' 60' ' ' ILE . 46.4 t-20 -68.99 123.21 20.41 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.248 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -143.44 39.85 1.27 Allowed Glycine 0 N--CA 1.417 -2.624 0 C-N-CA 120.098 -1.048 . . . . 0.0 111.937 -176.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 20.7 t-20 -145.55 -66.73 0.31 Allowed 'General case' 0 C--N 1.31 -1.119 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.074 177.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -157.43 161.34 29.41 Favored Pre-proline 0 C--N 1.317 -0.806 0 CA-C-O 118.872 -0.585 . . . . 0.0 109.76 -178.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.24 137.88 81.38 Favored 'Trans proline' 0 C--N 1.357 0.994 0 C-N-CA 122.96 2.44 . . . . 0.0 112.279 -179.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.583 HG21 ' SG ' ' A' ' 109' ' ' CYS . 32.7 mm -106.95 140.55 24.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.996 -174.799 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.27 107.85 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.256 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 172.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 57.7 p -93.72 153.67 18.2 Favored 'General case' 0 C--N 1.294 -1.836 0 CA-C-N 115.067 -0.969 . . . . 0.0 110.37 -176.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -106.44 140.39 39.43 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -177.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.3 mp -105.53 125.14 60.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-O 121.282 0.563 . . . . 0.0 111.672 -175.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.32 -22.78 11.4 Favored Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 115.533 0.973 . . . . 0.0 115.533 172.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 41.9 m -152.91 136.67 10.19 Favored Pre-proline 0 C--N 1.305 -1.337 0 CA-C-N 118.12 0.96 . . . . 0.0 110.385 -178.076 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -90.04 119.61 0.81 Allowed 'Trans proline' 0 N--CA 1.439 -1.718 0 C-N-CA 121.434 1.422 . . . . 0.0 110.986 173.544 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -169.41 175.09 5.66 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 105.151 -2.166 . . . . 0.0 105.151 -179.46 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -88.62 -29.74 19.74 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 172.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -92.32 20.39 6.15 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.784 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -80.56 159.38 69.63 Favored Pre-proline 0 C--N 1.309 -1.161 0 CA-C-O 119.644 -0.217 . . . . 0.0 110.733 -176.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -57.12 144.06 91.29 Favored 'Trans proline' 0 C--N 1.358 1.063 0 C-N-CA 123.405 2.737 . . . . 0.0 113.989 -177.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.7 m -101.81 174.53 1.04 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.062 0 C-N-CA 124.437 1.095 . . . . 0.0 110.458 -179.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.8 26.91 2.43 Favored Glycine 0 C--N 1.306 -1.118 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -179.255 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.88 109.63 0.59 Allowed Glycine 0 N--CA 1.423 -2.185 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -108.04 126.04 52.26 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-O 120.856 0.36 . . . . 0.0 110.102 178.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.44 ' HB3' ' HB ' ' A' ' 60' ' ' ILE . 33.1 tp -107.56 109.22 62.42 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 107.043 -1.466 . . . . 0.0 107.043 175.323 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -71.08 159.94 50.74 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.191 1.928 . . . . 0.0 112.195 -177.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.78 133.52 46.62 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 177.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.5 -10.52 56.31 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 121.046 -0.597 . . . . 0.0 111.971 -178.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.09 138.24 51.83 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.904 0.383 . . . . 0.0 110.682 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.7 m -117.89 110.17 17.42 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.259 -179.191 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.1 mm -120.89 120.3 61.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 CA-C-O 120.732 0.301 . . . . 0.0 110.62 -176.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 6.6 p -91.67 111.37 23.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-O 121.649 0.738 . . . . 0.0 109.404 175.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.467 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 46.6 p90 -97.12 168.6 10.35 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.963 -174.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -117.68 -17.59 9.87 Favored 'General case' 0 C--N 1.316 -0.857 0 O-C-N 123.858 0.724 . . . . 0.0 112.255 -176.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -135.66 133.92 38.66 Favored 'General case' 0 N--CA 1.432 -1.339 0 C-N-CA 119.891 -0.723 . . . . 0.0 110.905 -173.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.7 t -105.55 127.1 60.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 35.1 m -127.35 148.44 50.26 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 117.742 0.246 . . . . 0.0 110.927 -176.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 39.9 mt -119.14 120.18 63.09 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 CA-C-O 121.039 0.447 . . . . 0.0 109.964 172.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.487 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.2 tp-100 -122.51 118.58 28.62 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 103.514 -2.773 . . . . 0.0 103.514 172.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.45 107.3 0.12 Allowed 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 113.728 1.01 . . . . 0.0 113.728 -165.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 137.41 -31.4 2.52 Favored Glycine 0 N--CA 1.435 -1.391 0 CA-C-N 114.417 -1.265 . . . . 0.0 110.533 -179.252 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 73.0 m80 -151.13 163.97 37.57 Favored 'General case' 0 CA--C 1.483 -1.633 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.2 tt -103.9 133.92 46.57 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.742 0 N-CA-C 104.504 -2.406 . . . . 0.0 104.504 170.009 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.487 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 68.3 m95 -115.59 140.07 49.52 Favored 'General case' 0 C--N 1.27 -2.86 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -172.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.6 pt -100.98 130.02 51.0 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.315 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -101.27 120.4 6.86 Favored Glycine 0 N--CA 1.419 -2.464 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.163 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 44.4 p90 -142.83 144.47 32.54 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -101.93 126.13 48.77 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 175.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -93.45 167.84 11.45 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.238 -176.618 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 31.6 p90 -63.19 -2.21 1.29 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 113.859 1.059 . . . . 0.0 113.859 -178.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -88.09 -6.7 57.77 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 175.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 90.72 -0.47 76.94 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 111.808 -0.517 . . . . 0.0 111.808 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 21.2 p30 -96.36 147.67 23.57 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -177.046 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 9.7 tpp85 -92.13 111.56 23.16 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 175.128 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.5 t -111.99 143.58 21.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 -176.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.415 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 95.4 m-85 -119.33 129.28 54.78 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.027 0.441 . . . . 0.0 110.915 178.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . 0.583 ' SG ' HG21 ' A' ' 60' ' ' ILE . 43.1 t -110.56 127.97 26.1 Favored Pre-proline 0 C--N 1.302 -1.497 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.259 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -71.57 -5.63 17.46 Favored 'Trans proline' 0 C--N 1.359 1.123 0 C-N-CA 123.462 2.775 . . . . 0.0 115.243 -175.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.304 30.1 m 37.33 -59.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.515 2.775 0 N-CA-C 118.881 2.919 . . . . 0.0 118.881 175.26 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . 0.456 ' CZ ' ' HB3' ' A' ' 126' ' ' ALA . 7.8 ptp180 -150.72 156.36 41.15 Favored 'General case' 0 C--O 1.248 0.994 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.485 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.2 m -67.27 132.63 48.11 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 176.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.41 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 53.5 m -152.09 110.52 3.75 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.803 0.811 . . . . 0.0 111.449 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -102.93 143.72 32.14 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 106.119 -1.808 . . . . 0.0 106.119 178.144 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 147.71 -170.85 28.37 Favored Glycine 0 CA--C 1.489 -1.566 0 C-N-CA 118.207 -1.949 . . . . 0.0 113.488 178.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 84.7 t -134.67 123.27 16.11 Favored Pre-proline 0 C--N 1.304 -1.386 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 179.221 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.446 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 96.0 Cg_exo -45.86 135.53 13.76 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.76 2.974 . . . . 0.0 113.304 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -95.1 17.82 37.08 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 C-N-CA 124.283 -1.132 . . . . 0.0 113.493 1.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -94.8 101.91 13.75 Favored 'General case' 0 C--N 1.312 -1.028 0 C-N-CA 120.491 -0.484 . . . . 0.0 110.405 -177.625 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 10.9 p-80 -104.63 138.99 40.14 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.902 177.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 50.6 mm -102.31 99.54 13.09 Favored Pre-proline 0 C--N 1.301 -1.502 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 172.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -84.52 147.61 11.14 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 122.82 2.347 . . . . 0.0 113.989 -174.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.07 -145.02 6.61 Favored Glycine 0 N--CA 1.419 -2.497 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.28 175.414 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.5 t -60.67 122.72 11.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 C-N-CA 123.727 0.811 . . . . 0.0 111.868 -177.26 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.456 ' HB3' ' CZ ' ' A' ' 112' ' ' ARG . . . -94.22 145.06 24.99 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.501 174.608 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.8 m-90 -105.59 18.69 21.79 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.341 0.591 . . . . 0.0 110.907 177.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -166.99 -165.89 25.16 Favored Glycine 0 N--CA 1.427 -1.933 0 C-N-CA 119.788 -1.196 . . . . 0.0 112.791 -179.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 48.7 t -124.03 139.12 51.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -178.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -105.09 134.41 48.24 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 177.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.298 -1.667 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 42.6 t . . . . . 0 CA--C 1.514 -0.412 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 0.458 ' O ' ' HD2' ' A' ' 6' ' ' TYR . 3.4 m-20 -75.55 -44.01 45.62 Favored 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -179.172 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 56.0 -74.01 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 125.47 1.508 . . . . 0.0 114.25 175.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -142.49 -73.3 0.3 Allowed 'General case' 0 N--CA 1.431 -1.414 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -129.2 94.83 3.89 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.38 0.609 . . . . 0.0 111.876 -177.468 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . 0.458 ' HD2' ' O ' ' A' ' 2' ' ' ASN . 97.2 m-85 -137.69 74.99 1.5 Allowed 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 104.21 -2.515 . . . . 0.0 104.21 168.165 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 66.6 mtt -108.26 15.2 24.3 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 114.444 -1.253 . . . . 0.0 113.257 -167.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -68.36 99.24 0.91 Allowed 'General case' 0 C--O 1.247 0.923 0 CA-C-O 121.372 0.606 . . . . 0.0 111.187 177.1 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.8 tptt -79.66 127.48 32.22 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 178.213 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.43 -21.51 12.84 Favored Glycine 0 N--CA 1.435 -1.375 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -177.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 23.6 p 55.03 74.08 0.38 Allowed 'General case' 0 C--O 1.24 0.558 0 C-N-CA 125.092 1.357 . . . . 0.0 113.611 -178.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.2 m -77.54 125.84 29.97 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.503 -1.226 . . . . 0.0 108.287 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 41.4 m -148.62 143.8 26.79 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 73.5 m 66.56 -172.22 0.19 Allowed 'General case' 0 C--O 1.242 0.687 0 C-N-CA 124.521 1.128 . . . . 0.0 112.695 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.0 m -78.66 87.72 4.58 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-O 121.421 0.629 . . . . 0.0 111.026 -177.317 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 31.4 m -118.76 145.23 25.09 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 174.422 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.4 p -87.0 -34.08 7.34 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.167 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.842 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt 60.05 69.48 0.7 Allowed 'General case' 0 C--O 1.242 0.669 0 N-CA-C 106.016 -1.846 . . . . 0.0 106.016 -172.254 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -69.28 107.42 3.26 Favored 'General case' 0 CA--C 1.505 -0.756 0 CA-C-N 114.109 -1.405 . . . . 0.0 110.808 -171.578 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.93 -128.48 7.55 Favored Glycine 0 N--CA 1.422 -2.273 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -177.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -138.53 -62.22 0.57 Allowed 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.219 0.533 . . . . 0.0 110.346 178.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 44.7 m -84.73 130.01 34.75 Favored 'General case' 0 N--CA 1.425 -1.683 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.628 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.3 m -65.74 127.75 33.21 Favored 'General case' 0 C--O 1.248 1.004 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.085 -177.517 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.1 m 61.12 33.93 19.23 Favored 'General case' 0 C--O 1.239 0.51 0 C-N-CA 124.236 1.015 . . . . 0.0 111.457 177.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -67.75 -42.13 82.29 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 176.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 22.5 t -113.17 161.11 17.54 Favored 'General case' 0 N--CA 1.411 -2.382 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 173.472 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 43.5 p 53.94 62.71 8.62 Favored Pre-proline 0 CA--C 1.557 1.215 0 C-N-CA 123.631 0.772 . . . . 0.0 112.148 -175.593 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -80.99 98.53 1.05 Allowed 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 122.453 2.102 . . . . 0.0 112.401 -178.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -102.95 -63.9 1.12 Allowed 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 176.035 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 m -79.6 30.86 0.24 Allowed 'General case' 0 CA--C 1.561 1.372 0 C-N-CA 124.027 0.931 . . . . 0.0 111.319 -176.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 12.4 mmt180 -124.03 -63.16 0.03 OUTLIER Pre-proline 0 C--N 1.312 -1.045 0 O-C-N 121.428 -0.795 . . . . 0.0 110.618 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -68.62 -11.26 31.42 Favored 'Trans proline' 0 C--N 1.385 2.451 0 C-N-CA 122.197 1.932 . . . . 0.0 113.967 178.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 96.7 t -68.29 -49.56 65.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 174.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.7 p -94.26 60.14 2.69 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 114.753 -1.112 . . . . 0.0 109.501 178.023 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -78.58 90.81 1.15 Allowed Glycine 0 CA--C 1.495 -1.158 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.392 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 46.5 m 75.58 -39.87 0.4 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.252 1.421 . . . . 0.0 111.084 -176.294 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 98.7 m95 -70.35 125.01 25.58 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 175.498 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -140.41 145.53 37.15 Favored 'General case' 0 C--N 1.281 -2.406 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 179.571 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 24.5 ttmm -84.7 109.25 17.88 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-O 121.182 0.515 . . . . 0.0 109.83 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.453 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 44.2 t30 -78.35 168.5 19.73 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.655 -179.44 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -58.28 -12.11 3.37 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -174.524 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -91.84 2.26 56.63 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-O 121.195 0.521 . . . . 0.0 109.87 179.249 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.07 -12.51 57.84 Favored Glycine 0 C--N 1.33 0.205 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -178.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 14.6 m -76.56 140.57 41.14 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 124.638 1.175 . . . . 0.0 110.592 -176.316 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -90.8 131.97 36.14 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 175.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.453 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 11.0 p90 -136.88 159.43 41.89 Favored 'General case' 0 C--N 1.292 -1.915 0 C-N-CA 120.006 -0.677 . . . . 0.0 109.733 -179.541 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.7 pttm -155.09 141.33 13.04 Favored Pre-proline 0 N--CA 1.431 -1.394 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 170.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -71.23 122.46 8.73 Favored 'Trans proline' 0 C--O 1.247 0.941 0 C-N-CA 121.873 1.715 . . . . 0.0 110.593 175.517 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -154.71 120.95 5.3 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 -178.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.533 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 7.6 t30 -104.93 117.68 34.64 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.625 -172.747 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.467 ' HB2' ' CZ ' ' A' ' 85' ' ' TYR . . . -151.69 173.57 14.54 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 179.674 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 31.1 m -113.58 129.78 56.5 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -176.125 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -107.98 131.69 54.29 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 176.341 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 52.4 t -113.94 112.89 42.14 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 175.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -71.19 139.87 50.3 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -76.89 -117.8 0.16 Allowed Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 114.865 0.706 . . . . 0.0 114.865 -173.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -109.98 10.49 24.23 Favored 'General case' 0 C--N 1.311 -1.08 0 O-C-N 122.303 -0.528 . . . . 0.0 112.016 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -131.38 138.53 32.97 Favored Pre-proline 0 C--N 1.299 -1.609 0 C-N-CA 120.805 -0.358 . . . . 0.0 110.286 -175.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -69.7 141.43 45.45 Favored 'Trans proline' 0 C--O 1.242 0.695 0 C-N-CA 121.898 1.732 . . . . 0.0 109.822 174.344 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 64.4 mt -121.04 125.15 73.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -178.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 29.1 m -80.97 140.05 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.172 0 CA-C-O 121.803 0.811 . . . . 0.0 109.19 175.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 37.3 p -124.24 164.16 20.13 Favored 'General case' 0 C--N 1.272 -2.796 0 CA-C-N 115.095 -0.957 . . . . 0.0 110.814 -171.412 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -107.81 143.58 36.18 Favored 'General case' 0 C--N 1.317 -0.804 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -177.087 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.5 mt -106.09 130.21 58.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-O 121.229 0.538 . . . . 0.0 112.128 -174.247 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.48 -23.05 5.8 Favored Glycine 0 CA--C 1.521 0.417 0 N-CA-C 116.207 1.243 . . . . 0.0 116.207 171.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 52.1 m -156.94 142.28 12.51 Favored Pre-proline 0 C--N 1.308 -1.202 0 CA-C-N 118.448 1.124 . . . . 0.0 110.077 179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -89.95 119.8 0.84 Allowed 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 121.581 1.521 . . . . 0.0 111.856 175.159 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.433 ' HA ' ' HG2' ' A' ' 91' ' ' GLN . 91.7 m-85 -168.78 164.18 11.91 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 104.764 -2.31 . . . . 0.0 104.764 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 81.0 mt -85.79 -17.84 34.65 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 173.297 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -95.38 -0.47 52.56 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.921 178.402 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -68.83 157.7 88.08 Favored Pre-proline 0 N--CA 1.472 0.654 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.256 -176.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -55.71 122.18 11.27 Favored 'Trans proline' 0 C--N 1.365 1.404 0 C-N-CA 122.951 2.434 . . . . 0.0 112.749 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.95 173.38 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 179.094 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.78 -3.37 13.29 Favored Glycine 0 C--N 1.308 -1.015 0 C-N-CA 120.319 -0.943 . . . . 0.0 111.565 -178.74 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.94 127.09 9.14 Favored Glycine 0 N--CA 1.432 -1.609 0 N-CA-C 107.932 -2.067 . . . . 0.0 107.932 172.059 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -116.82 140.6 49.25 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 118.292 1.046 . . . . 0.0 110.582 -177.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 48.6 tp -114.19 112.5 46.79 Favored Pre-proline 0 C--N 1.307 -1.273 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 177.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.41 164.3 34.72 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 122.344 2.03 . . . . 0.0 113.06 -178.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.86 139.79 45.28 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.471 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.98 -0.59 86.32 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 121.314 -0.47 . . . . 0.0 112.396 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -72.76 126.26 29.48 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 121.099 0.476 . . . . 0.0 110.865 -178.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 53.6 m -99.7 115.76 30.24 Favored 'General case' 0 N--CA 1.425 -1.677 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.018 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.4 mm -126.05 128.84 72.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 110.256 -0.275 . . . . 0.0 110.256 -175.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.6 p -93.46 123.3 45.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 175.15 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.533 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 40.9 p90 -107.37 145.23 33.16 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.899 -178.666 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -111.93 -15.75 13.26 Favored 'General case' 0 C--N 1.31 -1.143 0 O-C-N 124.002 0.814 . . . . 0.0 112.494 -175.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -136.58 138.51 41.3 Favored 'General case' 0 N--CA 1.437 -1.09 0 C-N-CA 120.21 -0.596 . . . . 0.0 109.758 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 61.5 t -114.84 132.02 65.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 69.6 m -127.47 135.32 50.24 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 120.743 0.306 . . . . 0.0 110.924 -177.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 65.6 mt -103.66 116.88 48.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 CA-C-O 121.296 0.569 . . . . 0.0 110.121 177.053 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.543 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 7.5 tp-100 -124.96 118.96 27.42 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 103.981 -2.6 . . . . 0.0 103.981 175.806 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.14 106.19 0.1 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 -167.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 138.78 -41.17 1.38 Allowed Glycine 0 N--CA 1.421 -2.333 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.798 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 57.3 m80 -147.2 154.77 41.44 Favored 'General case' 0 CA--C 1.494 -1.181 0 O-C-N 122.142 -0.622 . . . . 0.0 110.206 -178.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.9 tt -96.98 125.77 49.9 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 175.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.543 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 68.2 m95 -105.03 133.97 48.91 Favored 'General case' 0 C--N 1.274 -2.683 0 CA-C-O 121.178 0.513 . . . . 0.0 110.355 -173.407 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.456 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 43.8 pt -100.12 120.84 50.1 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.323 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 175.486 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -94.77 114.15 4.76 Favored Glycine 0 N--CA 1.411 -2.97 0 N-CA-C 109.326 -1.509 . . . . 0.0 109.326 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -132.2 154.16 49.85 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -177.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -89.28 114.96 26.39 Favored 'General case' 0 C--N 1.272 -2.77 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 174.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.23 165.35 24.01 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-O 121.114 0.483 . . . . 0.0 110.846 -176.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.6 p90 -69.19 -2.79 11.33 Favored 'General case' 0 C--N 1.312 -1.034 0 C-N-CA 123.9 0.88 . . . . 0.0 112.162 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -95.45 -7.0 39.47 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.321 177.344 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 96.51 -7.8 66.14 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.907 -0.588 . . . . 0.0 113.665 176.062 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 15.3 p-10 -96.69 151.12 19.93 Favored 'General case' 0 C--N 1.296 -1.72 0 C-N-CA 122.972 0.509 . . . . 0.0 112.039 -178.244 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 14.5 tpp180 -84.29 108.47 17.17 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.067 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 25.8 t -110.94 146.62 15.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.022 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -176.525 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.456 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 88.2 m-85 -117.05 123.19 46.24 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 50.8 t -104.67 132.2 21.14 Favored Pre-proline 0 C--N 1.303 -1.424 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -69.84 -17.07 37.44 Favored 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 123.051 2.501 . . . . 0.0 114.372 -177.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.299 33.2 m 40.91 -58.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.52 3.032 0 N-CA-C 118.815 2.894 . . . . 0.0 118.815 175.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 33.3 ptt180 -153.96 150.6 28.49 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 123.577 0.751 . . . . 0.0 109.009 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 17.8 m -66.66 139.05 57.84 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.742 179.042 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.585 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 92.1 m -154.65 127.03 7.89 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 123.009 0.524 . . . . 0.0 111.17 179.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -125.83 122.49 36.3 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 177.655 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 168.84 175.03 37.96 Favored Glycine 0 N--CA 1.416 -2.696 0 C-N-CA 119.932 -1.128 . . . . 0.0 111.897 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 60.2 t -129.17 128.32 23.29 Favored Pre-proline 0 C--N 1.288 -2.076 0 N-CA-C 105.248 -2.13 . . . . 0.0 105.248 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -43.26 137.53 5.11 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 123.71 2.94 . . . . 0.0 113.027 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -81.88 -14.87 33.76 Favored 'Cis proline' 0 CA--C 1.553 1.467 0 C-N-CA 123.331 -1.529 . . . . 0.0 114.543 3.052 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -79.41 100.33 7.6 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.768 0.794 . . . . 0.0 112.952 -171.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 38.9 p-80 -106.99 112.73 25.83 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 114.869 -1.059 . . . . 0.0 111.164 175.628 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.585 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 49.4 mt -91.94 113.51 59.16 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 110.607 -0.146 . . . . 0.0 110.607 -178.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -84.48 164.75 12.54 Favored 'Trans proline' 0 C--O 1.246 0.918 0 C-N-CA 123.029 2.486 . . . . 0.0 113.36 -178.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.92 -130.96 2.92 Favored Glycine 0 N--CA 1.434 -1.473 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 176.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 80.7 t -73.81 122.3 26.62 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 C-N-CA 122.387 0.275 . . . . 0.0 111.287 -178.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.49 147.46 23.23 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.281 176.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.5 m0 -107.57 11.4 28.69 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.923 0.392 . . . . 0.0 111.792 179.213 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.66 -168.38 23.47 Favored Glycine 0 N--CA 1.436 -1.365 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.616 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 27.1 t -111.88 139.98 33.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -178.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 -118.32 123.16 44.67 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.426 0.155 . . . . 0.0 111.341 -175.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.1 pttm . . . . . 0 N--CA 1.433 -1.291 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 171.932 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 13.3 m . . . . . 0 N--CA 1.443 -0.793 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -67.63 -48.11 67.69 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 174.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -89.44 95.79 10.43 Favored 'General case' 0 N--CA 1.427 -1.62 0 N-CA-C 107.767 -1.198 . . . . 0.0 107.767 175.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 59.2 mttm -71.61 -39.23 70.6 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 -178.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.555 ' HB3' ' HA ' ' A' ' 8' ' ' ASP . 85.1 m-20 -122.35 132.61 54.47 Favored 'General case' 0 N--CA 1.426 -1.656 0 N-CA-C 106.314 -1.735 . . . . 0.0 106.314 172.293 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 35.5 t80 -88.0 -51.36 5.86 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 120.795 0.331 . . . . 0.0 110.617 -176.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 1.6 pmm? -105.59 -7.58 18.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.125 0.488 . . . . 0.0 109.88 177.493 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.555 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . 25.0 t70 75.49 92.17 0.07 Allowed 'General case' 0 CA--C 1.498 -1.047 0 C-N-CA 125.437 1.495 . . . . 0.0 112.053 -178.825 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.6 tmtm? -125.93 116.51 21.61 Favored 'General case' 0 N--CA 1.427 -1.588 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 147.27 -72.02 0.32 Allowed Glycine 0 N--CA 1.436 -1.321 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 6.8 t -163.23 135.9 5.43 Favored 'General case' 0 N--CA 1.428 -1.548 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.3 m -97.99 3.15 49.52 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 178.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.2 m 64.77 89.27 0.1 Allowed 'General case' 0 C--N 1.347 0.485 0 C-N-CA 124.901 1.28 . . . . 0.0 110.528 -177.561 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.4 m -140.91 108.36 5.56 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.637 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.9 m -77.17 109.66 11.21 Favored 'General case' 0 N--CA 1.427 -1.581 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.313 -178.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 33.7 m -92.73 -4.26 10.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -175.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 7.1 p -76.23 78.66 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.068 0 CA-C-O 122.935 1.35 . . . . 0.0 110.914 176.733 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 53.7 pttt -163.99 120.27 1.65 Allowed 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 113.504 -1.68 . . . . 0.0 108.358 -178.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -170.21 176.26 4.63 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -178.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 126.71 141.63 5.48 Favored Glycine 0 N--CA 1.434 -1.472 0 C-N-CA 120.426 -0.892 . . . . 0.0 112.131 176.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.25 112.5 4.55 Favored 'General case' 0 C--O 1.249 1.07 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 176.232 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 27.4 m 72.06 117.76 0.05 OUTLIER 'General case' 0 CA--C 1.547 0.856 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -171.537 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 12.8 m -53.95 -46.96 71.75 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 113.58 0.955 . . . . 0.0 113.58 -174.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.8 t -140.42 140.82 35.52 Favored 'General case' 0 N--CA 1.421 -1.903 0 C-N-CA 120.424 -0.51 . . . . 0.0 109.808 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.14 103.07 4.45 Favored 'General case' 0 N--CA 1.431 -1.395 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.158 177.376 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 12.7 m -89.67 114.1 25.68 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.317 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 23.9 m -121.26 94.73 48.74 Favored Pre-proline 0 C--N 1.303 -1.448 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.652 -179.024 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.501 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 2.0 Cg_endo -89.1 -77.18 0.0 OUTLIER 'Trans proline' 0 N--CA 1.434 -1.979 0 C-N-CA 122.002 1.801 . . . . 0.0 112.97 173.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 65.63 -72.26 0.08 Allowed 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 124.81 1.244 . . . . 0.0 109.242 -175.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 32.1 m -103.28 -49.48 3.72 Favored 'General case' 0 N--CA 1.423 -1.788 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 173.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 64.1 mtp180 -145.62 127.36 7.73 Favored Pre-proline 0 N--CA 1.467 0.423 0 C-N-CA 123.901 0.88 . . . . 0.0 109.14 -179.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.501 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 12.9 Cg_endo -57.19 90.91 0.05 OUTLIER 'Trans proline' 0 C--N 1.362 1.251 0 C-N-CA 123.243 2.628 . . . . 0.0 113.54 175.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.6 m -73.31 -27.49 24.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.76 0.79 . . . . 0.0 109.112 178.55 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 20.1 p -134.28 134.4 41.87 Favored 'General case' 0 N--CA 1.413 -2.282 0 CA-C-N 114.214 -1.357 . . . . 0.0 107.546 174.247 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -118.74 -136.21 5.36 Favored Glycine 0 C--N 1.3 -1.459 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 11.1 m -85.77 1.03 51.23 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 121.541 0.686 . . . . 0.0 109.467 177.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.6 m95 -75.12 127.76 33.95 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.956 -178.585 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -113.64 156.14 24.23 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 175.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -101.4 126.2 48.14 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.559 -178.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 36.6 t-20 -89.39 164.57 14.82 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 -177.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -64.91 -15.14 61.67 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.309 1.043 . . . . 0.0 111.213 -176.164 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 46.0 m-85 -74.66 -18.02 60.6 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.916 177.4 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.12 -8.13 59.01 Favored Glycine 0 CA--C 1.507 -0.453 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -175.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.443 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 11.2 m -80.67 138.84 36.41 Favored 'General case' 0 N--CA 1.427 -1.611 0 C-N-CA 124.724 1.21 . . . . 0.0 110.703 -178.072 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.405 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 65.2 m95 -93.44 139.05 31.14 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 174.463 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 37.0 p90 -142.47 151.37 41.64 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 120.691 -0.403 . . . . 0.0 111.241 -178.455 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 pttm -144.18 151.48 51.91 Favored Pre-proline 0 C--O 1.25 1.081 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 173.222 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -73.5 122.12 7.64 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 121.952 1.768 . . . . 0.0 110.548 175.494 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -156.57 121.6 4.64 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.479 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 20.5 t-20 -101.55 115.71 31.12 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.146 -176.005 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.84 176.49 10.68 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.5 m -118.47 138.36 52.55 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 121.192 0.52 . . . . 0.0 111.978 -175.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 80.5 t80 -115.63 123.17 47.72 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 175.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 45.1 t -104.87 110.86 32.13 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 177.204 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.572 ' OD1' ' HA ' ' A' ' 79' ' ' ALA . 22.6 t-20 -66.15 128.09 34.72 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.318 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -136.5 -11.28 1.16 Allowed Glycine 0 N--CA 1.441 -0.993 0 C-N-CA 118.997 -1.573 . . . . 0.0 114.71 -176.787 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.487 ' OD1' ' HG3' ' A' ' 58' ' ' GLN . 15.5 t-20 -95.26 -74.51 0.55 Allowed 'General case' 0 C--N 1.319 -0.753 0 C-N-CA 119.073 -1.051 . . . . 0.0 110.876 -178.051 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.487 ' HG3' ' OD1' ' A' ' 57' ' ' ASN . 0.0 OUTLIER -141.14 167.4 17.44 Favored Pre-proline 0 C--N 1.305 -1.329 0 CA-C-O 118.948 -0.549 . . . . 0.0 110.471 -179.199 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -62.35 130.33 29.9 Favored 'Trans proline' 0 C--N 1.356 0.951 0 C-N-CA 121.824 1.683 . . . . 0.0 109.264 173.339 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 58.9 mt -107.13 125.03 63.3 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 C-N-CA 120.323 -0.551 . . . . 0.0 109.708 -173.641 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.7 p -82.66 119.4 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.83 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 176.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 75.6 p -95.86 178.96 5.26 Favored 'General case' 0 C--N 1.285 -2.209 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.131 -172.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.436 ' HD2' ' O ' ' A' ' 71' ' ' ALA . 82.2 mmt-85 -118.35 139.93 50.61 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 175.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 67.4 mt -99.13 129.84 48.96 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 CA-C-O 121.451 0.643 . . . . 0.0 111.895 -175.584 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 77.11 -22.51 2.41 Favored Glycine 0 C--N 1.318 -0.426 0 N-CA-C 116.023 1.169 . . . . 0.0 116.023 173.028 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 16.5 m -147.22 138.24 13.0 Favored Pre-proline 0 C--N 1.303 -1.44 0 CA-C-N 117.981 0.89 . . . . 0.0 109.941 -176.324 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -89.73 118.62 0.79 Allowed 'Trans proline' 0 N--CA 1.433 -2.062 0 C-N-CA 120.776 0.984 . . . . 0.0 110.006 171.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.424 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 68.9 m-85 -169.06 178.35 4.49 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 104.27 -2.492 . . . . 0.0 104.27 -179.195 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -89.0 -40.12 13.22 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 174.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -96.84 25.46 5.26 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 121.942 0.877 . . . . 0.0 110.524 -177.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.436 ' O ' ' HD2' ' A' ' 63' ' ' ARG . . . -75.61 159.74 80.83 Favored Pre-proline 0 C--N 1.307 -1.254 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.391 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_exo -47.4 123.03 7.36 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 122.98 2.454 . . . . 0.0 113.482 -179.002 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 6.4 t -98.52 172.6 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 -178.108 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.6 3.48 14.16 Favored Glycine 0 C--N 1.312 -0.77 0 C-N-CA 120.057 -1.068 . . . . 0.0 112.227 -179.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -115.51 111.77 2.52 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 175.607 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 38.6 t30 -107.49 130.13 54.88 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 117.318 0.559 . . . . 0.0 109.716 -178.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 46.8 tp -95.56 112.28 58.41 Favored Pre-proline 0 N--CA 1.431 -1.385 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 177.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -61.87 152.1 76.89 Favored 'Trans proline' 0 C--O 1.243 0.761 0 C-N-CA 122.471 2.114 . . . . 0.0 112.379 -177.119 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . 0.572 ' HA ' ' OD1' ' A' ' 55' ' ' ASN . . . -68.18 134.52 50.62 Favored 'General case' 0 N--CA 1.436 -1.145 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.332 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.72 7.96 65.99 Favored Glycine 0 N--CA 1.436 -1.365 0 CA-C-N 115.417 -0.81 . . . . 0.0 112.623 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.33 132.75 37.55 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.116 0.484 . . . . 0.0 111.126 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 26.2 m -102.34 112.63 25.42 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 40.2 mm -115.65 121.8 68.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.836 -176.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.2 p -87.9 123.51 40.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 172.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.479 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 39.2 p90 -108.88 142.41 39.52 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -178.618 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -115.9 -10.96 11.58 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.719 0.771 . . . . 0.0 110.915 -174.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -131.65 134.42 45.95 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 50.3 t -117.87 133.11 65.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.503 ' SG ' ' HE2' ' A' ' 108' ' ' TYR . 67.1 m -132.02 140.4 48.9 Favored 'General case' 0 C--N 1.312 -1.051 0 O-C-N 123.317 0.386 . . . . 0.0 111.446 -177.403 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 52.0 mt -107.69 112.57 40.69 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.906 -0.496 . . . . 0.0 109.745 174.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.578 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -118.64 120.37 37.24 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 174.397 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.61 109.63 0.26 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 113.48 0.919 . . . . 0.0 113.48 -165.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 132.44 -34.82 2.44 Favored Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.27 -1.332 . . . . 0.0 110.793 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 68.5 m80 -148.8 159.33 44.25 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.7 tt -102.09 119.03 49.81 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 172.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.578 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 61.7 m95 -99.81 134.73 42.28 Favored 'General case' 0 C--N 1.276 -2.596 0 CA-C-O 121.186 0.517 . . . . 0.0 110.581 -171.445 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.471 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.0 pt -100.22 131.92 46.8 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.131 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.847 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.15 127.04 9.05 Favored Glycine 0 N--CA 1.425 -2.099 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -178.078 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 27.4 p90 -151.36 166.64 30.39 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 120.976 0.417 . . . . 0.0 109.975 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -118.84 130.39 55.74 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.331 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -96.17 147.78 23.39 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.046 -178.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 29.8 p90 -46.96 -21.52 0.23 Allowed 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 126.246 1.818 . . . . 0.0 115.158 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -89.16 3.99 50.03 Favored 'General case' 0 CA--C 1.561 1.398 0 CA-C-O 121.665 0.745 . . . . 0.0 111.053 -177.579 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 91.59 16.92 51.13 Favored Glycine 0 CA--C 1.502 -0.748 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.135 177.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -96.06 124.08 39.93 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 120.991 0.424 . . . . 0.0 111.35 -176.322 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 30.3 tpt180 -82.91 109.09 16.73 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 105.127 -2.175 . . . . 0.0 105.127 172.397 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 20.1 t -118.81 140.19 43.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 C-N-CA 119.449 -0.901 . . . . 0.0 112.029 -171.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.503 ' HE2' ' SG ' ' A' ' 89' ' ' CYS . 66.8 m-85 -122.58 124.14 42.82 Favored 'General case' 0 N--CA 1.435 -1.219 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.205 174.664 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . 0.402 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 48.7 t -108.83 132.66 21.03 Favored Pre-proline 0 C--N 1.304 -1.372 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.358 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.74 -21.16 33.96 Favored 'Trans proline' 0 C--N 1.358 1.064 0 C-N-CA 123.092 2.528 . . . . 0.0 114.214 -176.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.317 33.2 m 45.85 -55.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.51 2.529 0 N-CA-C 118.67 2.841 . . . . 0.0 118.67 176.193 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . 0.406 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 34.2 ptt180 -153.6 149.11 27.26 Favored 'General case' 0 N--CA 1.441 -0.914 0 C-N-CA 122.966 0.507 . . . . 0.0 110.639 177.592 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.4 m -63.0 127.98 33.76 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 177.324 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.642 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 88.3 m -151.94 117.32 5.31 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.592 0.711 . . . . 0.0 111.363 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -114.35 144.84 42.62 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.121 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 141.41 -169.49 25.08 Favored Glycine 0 N--CA 1.429 -1.83 0 C-N-CA 119.769 -1.205 . . . . 0.0 111.454 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 15.4 m -136.68 142.23 38.23 Favored Pre-proline 0 C--N 1.298 -1.656 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_exo -43.92 127.46 6.61 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 123.784 2.989 . . . . 0.0 113.207 -178.235 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -96.21 -9.97 19.97 Favored 'Cis proline' 0 C--O 1.245 0.828 0 C-N-CA 124.195 -1.169 . . . . 0.0 114.12 1.384 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 57.9 t30 -72.67 100.86 2.91 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 121.998 0.904 . . . . 0.0 111.557 -172.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 33.4 p-80 -106.66 125.15 50.63 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.304 -1.316 . . . . 0.0 110.699 177.086 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.642 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 49.8 mm -85.66 107.96 14.62 Favored Pre-proline 0 C--N 1.306 -1.286 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 176.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_endo -84.89 123.8 2.86 Favored 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 122.723 2.282 . . . . 0.0 112.967 -177.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -98.74 -110.25 3.0 Favored Glycine 0 N--CA 1.433 -1.543 0 N-CA-C 111.374 -0.69 . . . . 0.0 111.374 177.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 48.1 t -94.79 122.38 46.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 -177.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.406 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.27 136.5 34.49 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.272 175.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.6 m-90 -102.04 16.07 27.15 Favored 'General case' 0 C--O 1.251 1.162 0 CA-C-O 121.581 0.705 . . . . 0.0 111.467 179.48 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -171.29 -171.57 36.6 Favored Glycine 0 N--CA 1.43 -1.74 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.064 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 59.1 t -111.51 125.41 68.83 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 123.508 0.723 . . . . 0.0 109.167 -177.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -93.58 135.12 35.17 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.015 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 96.0 mttt . . . . . 0 C--N 1.293 -1.856 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 179.067 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 15.1 m . . . . . 0 CA--C 1.546 0.824 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -84.13 88.6 7.2 Favored 'General case' 0 CA--C 1.5 -0.975 0 CA-C-O 121.428 0.632 . . . . 0.0 111.188 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.13 30.61 1.41 Allowed 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.062 -177.509 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -78.0 72.82 4.55 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.779 0.8 . . . . 0.0 110.491 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -143.21 35.01 1.34 Allowed 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 106.298 -1.741 . . . . 0.0 106.298 176.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -87.08 162.54 17.52 Favored 'General case' 0 N--CA 1.436 -1.133 0 CA-C-N 114.403 -1.271 . . . . 0.0 108.944 -175.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 75.2 mtm 82.42 -29.69 0.1 Allowed 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 125.268 1.427 . . . . 0.0 111.254 -178.208 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -76.79 118.5 19.46 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 169.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.2 ttmm -137.77 159.27 42.45 Favored 'General case' 0 C--N 1.284 -2.266 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 -176.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.97 82.43 0.23 Allowed Glycine 0 N--CA 1.442 -0.91 0 N-CA-C 110.471 -1.051 . . . . 0.0 110.471 175.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 22.5 m -93.72 -44.27 8.24 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 123.201 0.6 . . . . 0.0 110.233 -176.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.1 m -83.21 -28.6 29.14 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 176.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.9 p -125.29 85.47 2.41 Favored 'General case' 0 N--CA 1.427 -1.58 0 CA-C-O 121.785 0.802 . . . . 0.0 110.133 176.586 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 26.0 m -86.84 93.82 9.39 Favored 'General case' 0 N--CA 1.429 -1.525 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.221 -178.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 4.6 p -80.57 -49.31 11.47 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.179 178.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.8 p -78.38 67.25 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.038 0 CA-C-O 122.957 1.36 . . . . 0.0 112.343 -179.076 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.4 m -119.81 -17.66 6.37 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.069 0 CA-C-N 114.162 -1.381 . . . . 0.0 109.732 175.191 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 58.5 mtpt -121.17 87.54 2.77 Favored 'General case' 0 N--CA 1.434 -1.254 0 CA-C-N 115.078 -0.965 . . . . 0.0 109.05 178.559 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -126.74 -36.91 2.18 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 176.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 116.63 148.47 8.97 Favored Glycine 0 N--CA 1.413 -2.89 0 CA-C-N 114.392 -1.276 . . . . 0.0 110.978 178.092 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.15 134.71 34.61 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 120.547 -0.461 . . . . 0.0 109.993 177.415 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.1 m -70.68 -21.53 62.58 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.552 -175.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.5 m 67.92 23.97 8.16 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 123.987 0.915 . . . . 0.0 108.65 -177.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 21.2 t -147.22 93.68 2.28 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 -175.543 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -132.76 10.64 4.32 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.725 178.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 27.9 p 52.57 -171.58 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.301 1.44 . . . . 0.0 112.949 -177.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 21.7 p -104.82 118.44 56.29 Favored Pre-proline 0 C--N 1.295 -1.771 0 O-C-N 122.014 -0.429 . . . . 0.0 109.848 176.679 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -57.85 -35.0 99.02 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 122.334 2.023 . . . . 0.0 111.129 175.671 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 27.02 95.18 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 126.233 1.813 . . . . 0.0 114.295 172.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 24.8 m 86.87 -22.11 0.17 Allowed 'General case' 0 CA--C 1.557 1.245 0 C-N-CA 125.249 1.419 . . . . 0.0 110.274 -175.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.479 ' HB3' ' CD ' ' A' ' 32' ' ' PRO . 2.0 mpp_? -98.57 173.14 4.1 Favored Pre-proline 0 CA--C 1.561 1.377 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 170.624 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.479 ' CD ' ' HB3' ' A' ' 31' ' ' ARG . 9.9 Cg_exo -68.42 118.98 6.01 Favored 'Trans proline' 0 C--N 1.371 1.725 0 C-N-CA 122.522 2.148 . . . . 0.0 115.051 -170.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.2 p -111.3 85.57 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.362 0 CA-C-O 122.449 1.118 . . . . 0.0 108.88 174.171 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 36.6 m -146.78 138.67 24.57 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.203 -178.357 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.79 -67.32 0.34 Allowed Glycine 0 CA--C 1.49 -1.482 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 -179.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 14.7 m -76.02 -49.79 16.6 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 173.175 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . 0.507 ' CZ2' ' HD2' ' A' ' 47' ' ' LYS . 94.1 m95 -91.75 132.5 36.35 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 174.683 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -125.51 140.73 52.51 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 -179.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 59.8 tttp -89.63 118.04 28.95 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.192 0.52 . . . . 0.0 110.596 -177.509 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -89.85 152.24 21.36 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 175.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.7 tp60 -61.04 -13.68 18.3 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 123.745 0.818 . . . . 0.0 113.094 -173.675 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 62.9 m-85 -74.84 -9.05 58.18 Favored 'General case' 0 CA--C 1.542 0.649 0 CA-C-O 121.247 0.546 . . . . 0.0 109.838 176.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.77 20.17 54.47 Favored Glycine 0 CA--C 1.496 -1.116 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -176.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.447 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 22.1 m -105.81 129.08 54.06 Favored 'General case' 0 N--CA 1.408 -2.542 0 CA-C-N 114.13 -1.035 . . . . 0.0 108.679 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 81.0 m95 -92.48 132.07 37.1 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 175.344 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 31.8 p90 -130.69 147.74 52.4 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.991 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.507 ' HD2' ' CZ2' ' A' ' 37' ' ' TRP . 20.7 ptmt -125.1 141.99 40.07 Favored Pre-proline 0 C--N 1.294 -1.844 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.57 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -73.22 120.83 6.78 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 N-CA-C 108.699 -1.308 . . . . 0.0 108.699 172.403 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -168.12 121.53 0.9 Allowed 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 -178.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.436 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 19.8 t-20 -104.79 128.55 52.98 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.929 -173.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.528 ' HB2' ' CZ ' ' A' ' 85' ' ' TYR . . . -156.59 170.15 23.04 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 177.525 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 2.4 m -112.92 122.25 47.08 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.668 -174.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -95.82 124.24 39.75 Favored 'General case' 0 C--N 1.312 -1.062 0 O-C-N 121.969 -0.457 . . . . 0.0 110.582 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 38.2 t -110.56 112.59 41.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 176.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -68.34 137.03 54.29 Favored 'General case' 0 C--O 1.248 0.995 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -124.73 -57.63 0.17 Allowed Glycine 0 N--CA 1.424 -2.135 0 C-N-CA 118.934 -1.603 . . . . 0.0 115.654 -170.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -83.02 -53.46 5.8 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -170.058 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -142.62 154.68 63.32 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 119.942 -0.703 . . . . 0.0 111.082 -174.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -60.03 132.75 46.28 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 122.707 2.271 . . . . 0.0 110.213 176.251 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 41.8 mt -108.19 120.83 60.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -174.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.5 p -79.38 115.09 21.12 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.136 0 CA-C-O 121.753 0.787 . . . . 0.0 109.471 175.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 56.3 p -89.49 178.87 6.19 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 115.191 -0.913 . . . . 0.0 111.657 -173.104 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 84.6 mmt-85 -117.52 137.67 52.41 Favored 'General case' 0 N--CA 1.439 -0.978 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 176.203 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 72.3 mt -95.29 123.7 47.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.139 -176.247 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.87 -22.55 3.42 Favored Glycine 0 C--N 1.317 -0.505 0 N-CA-C 116.205 1.242 . . . . 0.0 116.205 171.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.3 m -152.32 140.61 13.54 Favored Pre-proline 0 C--N 1.306 -1.311 0 CA-C-N 118.322 1.061 . . . . 0.0 110.455 -177.208 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -90.05 118.89 0.76 Allowed 'Trans proline' 0 N--CA 1.433 -2.05 0 C-N-CA 121.03 1.154 . . . . 0.0 110.662 172.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.413 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 97.0 m-85 -169.04 166.99 10.86 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 104.134 -2.543 . . . . 0.0 104.134 179.076 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -79.22 -36.14 40.54 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 175.336 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.5 p-10 -96.06 19.99 10.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.336 -177.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.413 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -74.96 156.25 86.28 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 176.089 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -48.07 123.33 8.58 Favored 'Trans proline' 0 C--O 1.255 1.345 0 C-N-CA 123.385 2.723 . . . . 0.0 113.828 179.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 34.2 m -94.29 174.43 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.609 -1.178 . . . . 0.0 109.949 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.43 11.34 7.38 Favored Glycine 0 N--CA 1.439 -1.132 0 C-N-CA 120.17 -1.014 . . . . 0.0 112.909 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -119.78 130.13 8.31 Favored Glycine 0 N--CA 1.436 -1.324 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 174.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -128.36 130.16 47.31 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 118.024 0.912 . . . . 0.0 110.439 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 46.1 tp -101.16 110.31 60.95 Favored Pre-proline 0 C--N 1.3 -1.552 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.074 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -69.13 166.91 25.2 Favored 'Trans proline' 0 C--O 1.244 0.822 0 C-N-CA 122.57 2.18 . . . . 0.0 112.481 -177.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.43 141.08 43.24 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.468 -179.215 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.53 -23.78 32.3 Favored Glycine 0 C--O 1.244 0.761 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.05 128.22 35.13 Favored 'General case' 0 C--O 1.244 0.78 0 CA-C-O 121.13 0.49 . . . . 0.0 110.453 -178.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 39.9 m -111.88 121.58 45.44 Favored 'General case' 0 N--CA 1.416 -2.151 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.437 -178.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.1 mm -125.87 128.55 72.12 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 -178.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.9 p -83.92 133.2 29.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 175.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.528 ' CZ ' ' HB2' ' A' ' 51' ' ' ALA . 50.6 p90 -116.09 137.66 51.93 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.01 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -111.36 -10.5 14.22 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 122.232 1.015 . . . . 0.0 109.568 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -125.71 120.05 29.62 Favored 'General case' 0 N--CA 1.423 -1.804 0 CA-C-N 114.454 -1.248 . . . . 0.0 109.119 -176.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 45.0 t -106.58 130.51 58.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.447 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 62.1 m -129.08 153.18 47.89 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 120.882 0.372 . . . . 0.0 111.97 -174.41 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.3 mt -124.91 117.04 49.01 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 171.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.558 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -124.13 126.8 46.8 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 104.469 -2.419 . . . . 0.0 104.469 174.18 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.2 113.2 0.75 Allowed 'General case' 0 C--N 1.321 -0.645 0 O-C-N 124.789 1.306 . . . . 0.0 112.586 -168.704 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 131.68 -35.8 2.34 Favored Glycine 0 N--CA 1.432 -1.602 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.66 -176.606 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -154.19 168.41 26.63 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 122.418 -0.46 . . . . 0.0 110.257 -178.07 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.403 HG21 ' O ' ' A' ' 112' ' ' ARG . 15.4 tt -98.36 140.81 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 N-CA-C 103.724 -2.695 . . . . 0.0 103.724 168.159 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.558 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 49.8 m95 -125.15 147.83 48.85 Favored 'General case' 0 C--N 1.28 -2.447 0 CA-C-N 118.117 0.417 . . . . 0.0 110.308 -172.155 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 49.9 pt -110.49 131.31 61.93 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.022 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 172.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.55 121.1 7.05 Favored Glycine 0 N--CA 1.424 -2.113 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.324 -178.575 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -140.29 164.3 30.45 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-O 121.074 0.464 . . . . 0.0 110.688 178.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 31.0 t30 -120.74 127.02 51.6 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 178.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.55 172.32 11.73 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.064 0.459 . . . . 0.0 111.717 -176.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -60.47 -25.9 66.38 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.199 1.0 . . . . 0.0 112.603 -176.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 26.5 p-10 -92.78 -0.6 57.23 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.253 -177.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 91.67 9.62 62.59 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.481 178.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -78.55 122.3 25.71 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 11.2 tpt85 -88.18 98.29 11.48 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 16.5 t -103.86 139.91 23.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 CA-C-O 121.126 0.488 . . . . 0.0 111.066 -171.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -118.34 122.27 42.45 Favored 'General case' 0 N--CA 1.432 -1.367 0 CA-C-N 115.407 -0.815 . . . . 0.0 108.991 174.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.2 t -104.06 129.77 24.6 Favored Pre-proline 0 C--N 1.301 -1.541 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -178.511 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.98 -2.83 12.82 Favored 'Trans proline' 0 C--N 1.361 1.206 0 C-N-CA 123.329 2.686 . . . . 0.0 114.852 -177.195 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 28.3 m 29.59 -52.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.522 3.147 0 N-CA-C 120.116 3.376 . . . . 0.0 120.116 172.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . 0.403 ' O ' HG21 ' A' ' 95' ' ' ILE . 59.5 ttt180 -156.8 141.65 17.0 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 123.828 0.851 . . . . 0.0 109.23 -176.183 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 28.1 m -71.83 132.09 43.95 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 120.797 0.332 . . . . 0.0 110.183 177.756 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.434 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 86.1 m -151.47 143.52 23.92 Favored 'General case' 0 N--CA 1.437 -1.086 0 C-N-CA 123.729 0.812 . . . . 0.0 109.054 178.507 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 7.8 tt0 -134.26 133.78 41.19 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 178.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 156.25 -172.59 34.11 Favored Glycine 0 N--CA 1.437 -1.287 0 C-N-CA 119.925 -1.131 . . . . 0.0 112.096 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 31.0 m -129.68 148.51 69.74 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 75.4 Cg_exo -51.55 131.79 38.29 Favored 'Trans proline' 0 CA--C 1.545 1.063 0 C-N-CA 122.801 2.334 . . . . 0.0 113.125 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 6.4 Cg_endo -100.24 10.17 23.42 Favored 'Cis proline' 0 CA--C 1.544 1.005 0 C-N-CA 124.779 -0.925 . . . . 0.0 113.044 -3.235 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -93.55 102.31 14.51 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.793 0.806 . . . . 0.0 112.096 -174.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 39.3 p-80 -104.68 138.52 40.87 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.11 178.648 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.434 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 70.2 mt -92.68 110.37 44.87 Favored Pre-proline 0 C--N 1.305 -1.351 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 173.702 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -84.59 126.09 3.46 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 122.659 2.239 . . . . 0.0 113.942 -177.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -102.76 -138.34 9.95 Favored Glycine 0 N--CA 1.437 -1.28 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 176.374 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 60.4 t -73.85 127.83 35.92 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 C-N-CA 122.996 0.518 . . . . 0.0 111.801 -177.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.11 141.72 28.22 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.147 177.49 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.6 m0 -99.59 -4.89 30.07 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 119.59 -0.844 . . . . 0.0 111.615 177.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -160.61 -175.27 31.43 Favored Glycine 0 N--CA 1.43 -1.703 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -177.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 46.9 t -110.95 134.76 52.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 C-N-CA 122.963 0.505 . . . . 0.0 109.675 -174.084 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -101.03 110.92 23.0 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.6 tptt . . . . . 0 C--N 1.294 -1.84 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -177.786 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 37' ' ' TRP . . . . . 0.484 ' CZ3' HG13 ' A' ' 90' ' ' ILE . 60.3 m95 . . . . . 0 N--CA 1.444 -0.751 0 CA-C-O 120.901 0.382 . . . . 0.0 110.798 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 38.7 ttmt -114.45 151.18 33.6 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 61.7 tttm -93.26 144.74 25.02 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.513 0.673 . . . . 0.0 112.368 -175.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -107.91 156.12 19.54 Favored 'General case' 0 C--O 1.253 1.274 0 C-N-CA 125.182 1.393 . . . . 0.0 108.763 175.065 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 16.6 pm0 -62.08 -23.29 66.42 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.462 1.105 . . . . 0.0 113.183 -178.608 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -84.26 -3.26 58.1 Favored 'General case' 0 C--N 1.322 -0.6 0 O-C-N 121.819 -0.551 . . . . 0.0 111.4 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.9 -6.46 60.22 Favored Glycine 0 CA--C 1.5 -0.902 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 17.0 m -73.32 144.79 46.41 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 68.1 m95 -114.92 138.94 50.22 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 175.166 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -138.23 149.05 45.39 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 120.663 0.268 . . . . 0.0 111.676 -175.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.7 pttt -130.68 140.51 38.89 Favored Pre-proline 0 C--N 1.3 -1.567 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 176.373 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -75.2 121.99 6.83 Favored 'Trans proline' 0 C--O 1.254 1.309 0 C-N-CA 121.86 1.707 . . . . 0.0 109.354 172.533 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -166.24 122.33 1.27 Allowed 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -178.352 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.444 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 20.1 m120 -94.17 123.89 37.84 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.213 -178.886 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.43 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -149.39 175.09 11.76 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 176.848 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.424 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 11.8 m -115.91 148.62 39.83 Favored 'General case' 0 N--CA 1.419 -2.013 0 CA-C-O 121.349 0.595 . . . . 0.0 110.589 -174.573 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -131.46 122.67 26.63 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 175.4 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.3 t -104.11 112.68 38.58 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.242 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 176.618 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -75.12 138.5 42.1 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 120.124 -0.63 . . . . 0.0 110.17 -177.01 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -167.41 174.53 42.56 Favored Glycine 0 N--CA 1.423 -2.202 0 N-CA-C 107.913 -2.075 . . . . 0.0 107.913 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 36.8 t30 79.58 -45.6 0.33 Allowed 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 124.91 1.284 . . . . 0.0 110.209 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 4.0 pt20 -158.18 153.16 21.32 Favored Pre-proline 0 N--CA 1.413 -2.303 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.581 178.199 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -72.34 131.03 17.05 Favored 'Trans proline' 0 N--CA 1.444 -1.418 0 N-CA-C 107.418 -1.801 . . . . 0.0 107.418 167.029 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 49.2 mt -108.47 124.3 64.79 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 C-N-CA 120.3 -0.56 . . . . 0.0 109.745 -174.457 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.0 p -76.44 127.8 37.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 176.151 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 37.1 p -106.3 167.99 9.45 Favored 'General case' 0 N--CA 1.416 -2.157 0 CA-C-O 121.264 0.554 . . . . 0.0 111.41 -173.696 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 18.2 mmt180 -114.96 143.9 44.43 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 55.4 mt -111.93 134.63 53.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 C-N-CA 120.384 -0.527 . . . . 0.0 111.913 -175.249 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.09 -23.32 3.9 Favored Glycine 0 C--N 1.32 -0.329 0 N-CA-C 116.344 1.298 . . . . 0.0 116.344 171.826 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.8 m -155.87 137.1 9.36 Favored Pre-proline 0 C--N 1.301 -1.54 0 CA-C-N 118.228 1.014 . . . . 0.0 110.118 -179.1 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -89.86 121.44 0.99 Allowed 'Trans proline' 0 N--CA 1.444 -1.416 0 C-N-CA 122.24 1.96 . . . . 0.0 112.168 175.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -163.27 170.25 17.94 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 104.414 -2.439 . . . . 0.0 104.414 178.35 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -82.41 -26.08 33.11 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.255 0.55 . . . . 0.0 110.294 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -107.09 25.7 11.06 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 122.396 1.093 . . . . 0.0 108.498 178.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -68.64 157.57 88.0 Favored Pre-proline 0 C--N 1.318 -0.791 0 CA-C-N 115.186 -0.916 . . . . 0.0 111.336 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -53.96 133.47 55.0 Favored 'Trans proline' 0 C--N 1.361 1.205 0 C-N-CA 123.274 2.65 . . . . 0.0 113.623 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.7 m -99.22 176.23 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.012 0 C-N-CA 124.626 1.17 . . . . 0.0 110.662 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.59 4.53 10.67 Favored Glycine 0 CA--C 1.498 -0.972 0 C-N-CA 121.13 -0.557 . . . . 0.0 111.732 -178.66 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -122.12 124.48 5.76 Favored Glycine 0 N--CA 1.419 -2.434 0 N-CA-C 108.401 -1.88 . . . . 0.0 108.401 174.026 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -128.62 126.79 40.96 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 117.881 0.841 . . . . 0.0 109.668 176.326 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 49.4 tp -97.58 114.7 65.28 Favored Pre-proline 0 C--N 1.301 -1.511 0 C-N-CA 122.346 0.258 . . . . 0.0 110.337 -177.288 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -73.1 160.21 46.03 Favored 'Trans proline' 0 C--O 1.243 0.763 0 C-N-CA 122.348 2.032 . . . . 0.0 111.185 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.31 153.86 35.54 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.4 10.42 79.93 Favored Glycine 0 C--N 1.313 -0.738 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -178.446 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.16 126.41 38.25 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 60.1 m -96.82 108.78 21.52 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 177.093 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.6 mm -108.69 119.29 58.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.636 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.1 p -99.74 107.77 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.37 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 174.042 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.444 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 44.4 p90 -98.32 163.86 12.53 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.282 -174.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -125.38 -11.17 6.9 Favored 'General case' 0 C--N 1.318 -0.768 0 O-C-N 123.443 0.464 . . . . 0.0 111.538 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.433 ' HB2' ' NH2' ' A' ' 106' ' ' ARG . 31.1 tt0 -126.39 124.17 39.6 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -175.322 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 40.6 t -112.59 120.8 63.6 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.491 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.604 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 26.4 p -130.96 152.23 50.5 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 120.328 -0.549 . . . . 0.0 112.377 -176.671 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.484 HG13 ' CZ3' ' A' ' 37' ' ' TRP . 76.5 mt -112.74 113.64 44.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.169 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.049 177.314 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.518 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -112.1 113.66 26.06 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 103.363 -2.828 . . . . 0.0 103.363 169.102 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.6 109.76 0.28 Allowed 'General case' 0 C--O 1.241 0.635 0 O-C-N 124.722 1.264 . . . . 0.0 113.21 -164.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 137.4 -36.74 1.92 Allowed Glycine 0 N--CA 1.424 -2.118 0 CA-C-N 113.636 -1.62 . . . . 0.0 109.185 -176.328 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 52.9 m80 -149.02 165.33 31.97 Favored 'General case' 0 CA--C 1.5 -0.946 0 O-C-N 122.478 -0.424 . . . . 0.0 109.911 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.5 tt -103.24 135.84 38.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 N-CA-C 104.491 -2.411 . . . . 0.0 104.491 171.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.604 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 49.4 m95 -119.25 135.23 54.79 Favored 'General case' 0 C--N 1.275 -2.646 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 -173.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.492 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 47.0 pt -100.5 132.38 46.25 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 177.4 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.94 124.64 8.14 Favored Glycine 0 N--CA 1.425 -2.085 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -137.72 164.83 27.89 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 29.1 p-10 -117.54 137.5 52.54 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.982 0.42 . . . . 0.0 110.615 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.412 ' HB3' ' OD1' ' A' ' 105' ' ' ASN . . . -91.12 174.64 7.3 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.596 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -66.88 -12.08 58.12 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 121.263 0.554 . . . . 0.0 112.131 -177.876 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -81.01 -12.7 59.31 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.187 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 87.82 9.11 71.91 Favored Glycine 0 CA--C 1.505 -0.583 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.995 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.412 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 18.2 p-10 -91.86 147.58 22.87 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.126 0.489 . . . . 0.0 110.165 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ARG . . . . . 0.433 ' NH2' ' HB2' ' A' ' 87' ' ' GLU . 18.0 tpt180 -94.61 115.3 27.4 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -175.46 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 24.3 t -111.39 139.9 33.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -176.704 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.492 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 94.1 m-85 -118.47 132.32 56.24 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 123.641 0.776 . . . . 0.0 110.943 -178.52 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' CYS . . . . . 0.415 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 45.9 t -111.78 131.95 22.16 Favored Pre-proline 0 C--N 1.308 -1.201 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.363 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -70.69 -13.85 32.67 Favored 'Trans proline' 0 C--N 1.367 1.552 0 C-N-CA 123.311 2.674 . . . . 0.0 114.763 -176.674 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.31 35.9 m 38.86 -60.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.459 0 N-CA-C 119.072 2.99 . . . . 0.0 119.072 175.329 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 37.5 ptt180 -155.08 156.71 36.34 Favored 'General case' 0 C--O 1.248 0.977 0 O-C-N 121.894 -0.504 . . . . 0.0 109.717 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 25.3 m -64.54 136.78 57.39 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 174.687 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 65.3 m -149.67 128.05 12.19 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.727 0.775 . . . . 0.0 110.657 176.787 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -119.68 161.77 20.14 Favored 'General case' 0 C--N 1.286 -2.157 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.14 -167.13 12.85 Favored Glycine 0 C--N 1.286 -2.214 0 C-N-CA 118.918 -1.611 . . . . 0.0 112.284 177.157 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 24.6 m -140.91 147.33 47.66 Favored Pre-proline 0 C--N 1.306 -1.323 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.404 ' HB3' ' CG ' ' A' ' 37' ' ' TRP . 85.6 Cg_exo -48.63 136.1 27.18 Favored 'Trans proline' 0 CA--C 1.543 0.943 0 C-N-CA 123.24 2.627 . . . . 0.0 113.013 178.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -88.73 -19.72 15.55 Favored 'Cis proline' 0 CA--C 1.544 1.005 0 C-N-CA 123.779 -1.342 . . . . 0.0 113.176 -0.618 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 90.0 m-20 -77.34 102.2 6.66 Favored 'General case' 0 C--O 1.244 0.791 0 CA-C-O 122.244 1.021 . . . . 0.0 112.877 -172.79 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 32.4 p-80 -104.69 131.05 52.59 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 113.847 -1.524 . . . . 0.0 109.867 178.032 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.449 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 55.4 mt -96.66 108.6 43.7 Favored Pre-proline 0 C--N 1.286 -2.161 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -178.7 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -78.88 161.39 27.11 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.584 2.189 . . . . 0.0 112.521 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -134.74 -124.31 2.44 Favored Glycine 0 N--CA 1.437 -1.265 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 177.047 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.6 t -77.26 124.01 34.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 116.938 0.369 . . . . 0.0 110.795 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.5 151.32 19.44 Favored 'General case' 0 C--O 1.246 0.908 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.217 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.6 m-90 -124.98 29.64 6.09 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.93 178.501 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -169.4 -173.27 36.85 Favored Glycine 0 N--CA 1.434 -1.461 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 -179.458 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 47.4 t -114.63 115.28 49.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.164 0.507 . . . . 0.0 109.983 -178.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -83.72 130.19 34.95 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.007 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.424 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 1.6 tmtp? . . . . . 0 N--CA 1.421 -1.908 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 -176.083 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.3 m95 . . . . . 0 N--CA 1.432 -1.372 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.4 mptt -113.91 155.2 26.22 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 176.708 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -102.99 132.48 49.23 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.803 -0.759 . . . . 0.0 108.967 178.833 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.454 ' ND2' ' HB ' ' A' ' 44' ' ' THR . 38.7 p30 -86.5 178.19 7.17 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 175.222 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 -70.1 -23.12 63.0 Favored 'General case' 0 C--N 1.31 -1.134 0 CA-C-O 121.114 0.483 . . . . 0.0 111.144 -176.289 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.465 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 26.7 m-85 -74.87 -13.92 60.61 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.163 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.41 7.07 57.25 Favored Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.829 178.283 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.454 ' HB ' ' ND2' ' A' ' 40' ' ' ASN . 5.8 m -88.34 137.57 32.2 Favored 'General case' 0 N--CA 1.424 -1.755 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 92.2 m95 -96.44 122.29 39.17 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 176.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 54.4 p90 -123.58 152.34 41.97 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 120.869 0.366 . . . . 0.0 111.973 -174.536 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.0 ptmt -141.03 147.18 46.67 Favored Pre-proline 0 N--CA 1.433 -1.292 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 171.5 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -77.09 122.09 6.06 Favored 'Trans proline' 0 N--CA 1.445 -1.327 0 C-N-CA 121.492 1.461 . . . . 0.0 109.222 172.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.5 tp10 -153.35 125.74 8.09 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 -179.324 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.501 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 7.7 t30 -109.57 107.49 17.6 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.203 0.525 . . . . 0.0 111.098 -175.557 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.414 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -143.56 171.42 14.18 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.451 ' HB ' ' HB2' ' A' ' 131' ' ' LYS . 6.4 m -104.32 147.76 27.15 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -176.632 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -127.08 138.26 53.17 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 175.328 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.3 t -118.65 117.0 53.01 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 176.041 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.481 ' ND2' ' HA ' ' A' ' 79' ' ' ALA . 48.4 t30 -70.61 148.43 48.12 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.291 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -83.42 -132.7 2.05 Favored Glycine 0 N--CA 1.434 -1.471 0 N-CA-C 114.364 0.506 . . . . 0.0 114.364 -174.177 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -91.05 -4.32 56.45 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -171.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.4 ' HA ' ' HD3' ' A' ' 59' ' ' PRO . 0.0 OUTLIER -131.95 153.09 81.28 Favored Pre-proline 0 C--N 1.306 -1.285 0 C-N-CA 120.007 -0.677 . . . . 0.0 112.261 179.723 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 58' ' ' GLN . 7.4 Cg_exo -74.76 136.72 21.31 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.056 1.837 . . . . 0.0 111.079 176.857 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 61.0 mt -107.81 133.63 52.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -177.483 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.9 p -82.09 137.53 20.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 177.09 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 54.7 p -117.07 179.03 4.14 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.565 -172.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.425 ' NH1' HG12 ' A' ' 73' ' ' VAL . 47.2 mmt-85 -122.05 144.3 48.99 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.781 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 59.1 mt -106.35 125.99 62.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.868 -177.635 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.51 -22.64 1.68 Allowed Glycine 0 CA--C 1.527 0.812 0 N-CA-C 116.569 1.388 . . . . 0.0 116.569 171.515 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.5 m -145.68 134.17 10.86 Favored Pre-proline 0 C--N 1.3 -1.558 0 CA-C-N 118.562 1.181 . . . . 0.0 110.315 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -90.08 120.41 0.86 Allowed 'Trans proline' 0 N--CA 1.441 -1.614 0 C-N-CA 121.732 1.622 . . . . 0.0 111.624 174.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.587 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 93.1 m-85 -168.16 175.54 6.51 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 104.873 -2.269 . . . . 0.0 104.873 178.528 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -81.85 -45.3 15.7 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 176.647 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -94.04 25.93 3.48 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.108 -0.951 . . . . 0.0 111.151 -178.819 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.587 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.55 162.9 71.75 Favored Pre-proline 0 C--N 1.317 -0.835 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.468 178.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_exo -48.87 123.31 9.54 Favored 'Trans proline' 0 C--N 1.369 1.652 0 C-N-CA 123.537 2.825 . . . . 0.0 114.158 179.324 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.425 HG12 ' NH1' ' A' ' 63' ' ' ARG . 31.2 m -97.55 174.38 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.184 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.34 28.8 1.89 Allowed Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -150.94 126.61 2.16 Favored Glycine 0 N--CA 1.428 -1.896 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -127.39 136.79 52.35 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 57.2 tp -97.45 115.64 65.77 Favored Pre-proline 0 C--N 1.302 -1.463 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -59.24 152.67 58.4 Favored 'Trans proline' 0 C--O 1.245 0.856 0 C-N-CA 123.005 2.47 . . . . 0.0 112.609 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ALA . . . . . 0.481 ' HA ' ' ND2' ' A' ' 55' ' ' ASN . . . -73.42 139.97 46.22 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.13 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.74 -4.82 77.71 Favored Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 116.113 -0.494 . . . . 0.0 113.108 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.93 134.06 40.34 Favored 'General case' 0 N--CA 1.439 -1.018 0 CA-C-O 120.774 0.321 . . . . 0.0 110.893 -177.723 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 14.6 t -108.0 134.66 50.59 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 177.879 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 44.6 mm -132.05 140.14 48.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -177.223 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.5 p -103.96 113.41 40.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-O 121.965 0.888 . . . . 0.0 109.582 175.445 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.501 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 43.2 p90 -97.15 152.95 18.3 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.417 -175.019 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -119.77 4.28 11.04 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.657 0.741 . . . . 0.0 110.345 -178.652 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -142.06 132.96 25.83 Favored 'General case' 0 N--CA 1.426 -1.656 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.391 -175.421 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.8 t -124.68 128.27 73.31 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.452 ' HB2' HG22 ' A' ' 44' ' ' THR . 20.5 p -139.49 140.83 37.33 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-O 121.236 0.541 . . . . 0.0 111.421 -178.662 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.468 HG21 ' HA3' ' A' ' 116' ' ' GLY . 75.1 mt -101.03 114.87 41.51 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.731 179.488 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.586 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 50.0 tp60 -116.04 127.63 55.05 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 104.813 -2.292 . . . . 0.0 104.813 173.702 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.04 110.93 0.37 Allowed 'General case' 0 C--O 1.243 0.731 0 N-CA-C 113.275 0.842 . . . . 0.0 113.275 -167.338 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 124.23 -28.87 5.22 Favored Glycine 0 N--CA 1.438 -1.183 0 CA-C-N 114.498 -1.228 . . . . 0.0 112.729 179.151 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 74.8 m80 -151.12 169.9 20.74 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -176.342 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 19.0 tt -110.96 128.0 67.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.095 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 172.572 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.586 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 65.2 m95 -110.46 131.14 55.32 Favored 'General case' 0 C--N 1.274 -2.692 0 CA-C-O 120.966 0.412 . . . . 0.0 110.196 -173.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.505 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.5 pt -100.3 134.61 39.4 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.235 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.96 128.14 9.32 Favored Glycine 0 N--CA 1.428 -1.879 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 -178.607 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -151.38 163.93 37.85 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -97.77 116.81 30.72 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 174.461 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.09 178.25 6.5 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.999 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 46.5 p90 -47.49 -27.93 1.97 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 126.044 1.737 . . . . 0.0 113.858 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -99.27 2.42 45.54 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 112.222 0.453 . . . . 0.0 112.222 -175.751 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.85 0.67 81.07 Favored Glycine 0 C--N 1.32 -0.329 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.158 176.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -81.03 135.89 35.9 Favored 'General case' 0 C--N 1.306 -1.32 0 O-C-N 122.651 -0.323 . . . . 0.0 111.038 -178.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 4.1 tpp180 -75.29 102.24 4.99 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 173.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 67.6 t -108.27 143.87 17.89 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.029 0 CA-C-N 114.674 -1.148 . . . . 0.0 109.725 -174.033 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.505 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 96.5 m-85 -117.74 124.08 47.58 Favored 'General case' 0 N--CA 1.426 -1.647 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.273 178.671 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.8 t -104.13 133.71 20.08 Favored Pre-proline 0 C--N 1.298 -1.673 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -68.71 -22.88 36.76 Favored 'Trans proline' 0 C--N 1.359 1.115 0 C-N-CA 122.967 2.445 . . . . 0.0 113.472 -177.253 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.295 34.2 m 46.99 -53.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.207 0 N-CA-C 118.41 2.744 . . . . 0.0 118.41 175.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.526 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 38.9 ptt180 -158.93 156.77 30.11 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 122.832 0.453 . . . . 0.0 110.553 -178.298 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 2.6 p -72.83 136.99 45.46 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 175.745 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.429 ' SG ' ' HG3' ' A' ' 112' ' ' ARG . 96.1 m -154.37 133.04 12.16 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.838 0.352 . . . . 0.0 111.54 -178.827 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 29.9 mm-40 -97.11 113.38 24.95 Favored 'General case' 0 N--CA 1.427 -1.595 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 171.524 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.468 ' HA3' HG21 ' A' ' 90' ' ' ILE . . . -122.01 113.96 2.39 Favored Glycine 0 C--N 1.259 -3.697 0 C-N-CA 119.779 -1.201 . . . . 0.0 114.014 -173.577 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 7.0 m -125.97 97.14 35.91 Favored Pre-proline 0 C--N 1.293 -1.878 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 172.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 61.9 Cg_exo -42.84 130.77 5.66 Favored 'Trans proline' 0 C--N 1.357 0.994 0 C-N-CA 124.327 3.351 . . . . 0.0 114.774 -170.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 7.4 Cg_endo -92.71 8.0 59.8 Favored 'Cis proline' 0 CA--C 1.549 1.236 0 C-N-CA 124.412 -1.078 . . . . 0.0 113.046 1.243 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -74.93 102.03 4.64 Favored 'General case' 0 CA--C 1.508 -0.672 0 CA-C-O 121.563 0.697 . . . . 0.0 110.229 -175.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.422 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 37.4 p-80 -104.78 107.03 17.77 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.592 177.429 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.5 mt -100.2 100.44 11.77 Favored Pre-proline 0 C--N 1.318 -0.791 0 C-N-CA 122.703 0.401 . . . . 0.0 109.925 -177.166 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' PRO . . . . . 0.422 ' HD3' ' O ' ' A' ' 121' ' ' HIS . 2.9 Cg_endo -81.48 150.69 17.15 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 122.774 2.316 . . . . 0.0 113.265 -178.209 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.45 -116.13 3.3 Favored Glycine 0 N--CA 1.423 -2.228 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 175.022 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.3 t -97.39 124.45 50.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-O 120.801 0.334 . . . . 0.0 110.426 -176.179 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.526 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -95.02 146.88 23.96 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.708 177.445 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.7 m-90 -101.49 12.82 36.63 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 121.555 0.693 . . . . 0.0 109.246 177.283 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.74 179.24 37.24 Favored Glycine 0 N--CA 1.43 -1.705 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 49.4 t -112.08 137.79 43.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.398 -0.594 . . . . 0.0 109.398 -176.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -102.27 135.52 43.72 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-O 120.954 0.407 . . . . 0.0 110.11 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.451 ' HB2' ' HB ' ' A' ' 52' ' ' THR . 55.9 mtpt . . . . . 0 C--N 1.295 -1.776 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 47.8 m95 . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 109.13 -0.692 . . . . 0.0 109.13 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.407 ' O ' ' HA ' ' A' ' 45' ' ' TRP . 47.9 mmtm -113.32 149.94 33.24 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.601 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -101.52 122.05 43.1 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-O 121.123 0.487 . . . . 0.0 111.086 -175.445 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -88.62 155.14 19.79 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 175.027 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 47.6 tt0 -63.47 -20.51 65.65 Favored 'General case' 0 CA--C 1.546 0.815 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -175.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -75.64 5.2 6.41 Favored 'General case' 0 CA--C 1.542 0.665 0 CA-C-O 121.225 0.536 . . . . 0.0 110.994 176.684 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.07 22.67 70.75 Favored Glycine 0 CA--C 1.496 -1.121 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.424 HG22 ' HB2' ' A' ' 89' ' ' CYS . 48.0 m -105.42 128.03 53.31 Favored 'General case' 0 N--CA 1.416 -2.127 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 -179.213 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.531 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 84.5 m95 -95.34 120.84 36.27 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 177.643 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -121.87 150.64 41.65 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.824 0.345 . . . . 0.0 111.66 -175.04 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 52.0 pttt -135.57 135.48 22.2 Favored Pre-proline 0 C--N 1.299 -1.623 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 173.47 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -70.78 125.68 11.86 Favored 'Trans proline' 0 C--O 1.249 1.057 0 C-N-CA 121.764 1.643 . . . . 0.0 109.933 174.518 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -165.7 120.39 1.24 Allowed 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.541 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 25.7 t-20 -102.08 107.86 19.1 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.481 0.658 . . . . 0.0 111.114 -175.77 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -143.18 179.47 7.04 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.524 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 42.0 m -115.59 150.13 37.15 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.048 0.451 . . . . 0.0 110.641 -177.405 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 82.6 t80 -131.71 127.5 36.98 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 175.715 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.8 t -111.4 106.19 20.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.619 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -71.48 152.31 43.16 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -156.02 -41.14 0.02 OUTLIER Glycine 0 N--CA 1.435 -1.423 0 C-N-CA 118.589 -1.767 . . . . 0.0 115.16 -177.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -71.21 -49.02 47.84 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 117.406 0.603 . . . . 0.0 112.538 -172.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -146.86 153.64 46.35 Favored Pre-proline 0 C--N 1.305 -1.335 0 C-N-CA 119.979 -0.688 . . . . 0.0 110.385 -176.747 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_exo -65.66 123.18 11.03 Favored 'Trans proline' 0 C--O 1.248 1.019 0 C-N-CA 121.76 1.64 . . . . 0.0 108.411 170.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 55.1 mt -107.18 125.03 63.38 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 -173.542 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 9.9 p -76.52 119.93 25.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 43.2 p -95.43 151.46 19.27 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.236 -175.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -102.44 137.19 41.01 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -175.647 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.1 mt -106.0 135.12 45.5 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.922 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -171.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.66 -23.45 5.69 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 116.405 1.322 . . . . 0.0 116.405 170.56 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 51.3 m -157.63 142.19 11.86 Favored Pre-proline 0 C--N 1.307 -1.254 0 CA-C-N 118.102 0.951 . . . . 0.0 109.524 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -90.05 119.54 0.8 Allowed 'Trans proline' 0 N--CA 1.439 -1.695 0 C-N-CA 121.559 1.506 . . . . 0.0 111.193 175.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.405 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 57.5 m-85 -168.38 165.77 12.63 Favored 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 126.16 1.784 . . . . 0.0 106.321 -179.344 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 89.8 mt -85.25 -14.62 46.14 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 175.009 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -106.95 13.59 27.47 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.52 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.405 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.88 155.61 90.46 Favored Pre-proline 0 C--N 1.314 -0.973 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.021 -177.393 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -56.52 140.6 89.81 Favored 'Trans proline' 0 C--N 1.364 1.364 0 C-N-CA 123.6 2.867 . . . . 0.0 114.626 -178.079 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 33.3 m -97.81 175.63 0.79 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.747 0 C-N-CA 124.668 1.187 . . . . 0.0 110.609 178.11 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 121.0 -9.17 10.41 Favored Glycine 0 CA--C 1.496 -1.101 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 -178.698 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.89 126.97 9.07 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 108.198 -1.961 . . . . 0.0 108.198 172.402 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.9 t30 -128.26 125.3 38.61 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 118.057 0.929 . . . . 0.0 110.468 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 54.4 tp -96.84 108.5 43.62 Favored Pre-proline 0 C--N 1.296 -1.755 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.005 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -67.73 159.14 54.04 Favored 'Trans proline' 0 C--O 1.245 0.86 0 C-N-CA 122.389 2.06 . . . . 0.0 112.104 178.569 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.3 136.46 39.61 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.51 -2.38 64.93 Favored Glycine 0 C--N 1.31 -0.883 0 N-CA-C 111.664 -0.574 . . . . 0.0 111.664 -179.214 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.59 134.37 37.22 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-O 120.845 0.355 . . . . 0.0 111.711 -177.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 22.1 m -98.73 109.05 21.87 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.155 -0.93 . . . . 0.0 108.837 178.391 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 43.0 mm -110.78 135.35 50.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.45 -177.431 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.3 p -108.51 129.8 62.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 176.437 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.541 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 48.4 p90 -124.65 151.9 44.33 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -177.049 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.416 ' HA ' ' HA ' ' A' ' 50' ' ' ASN . 3.9 p30 -114.81 4.93 15.06 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 120.864 0.364 . . . . 0.0 110.537 -179.47 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -148.15 139.64 23.61 Favored 'General case' 0 N--CA 1.428 -1.562 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.383 -176.066 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 41.5 t -120.38 128.19 75.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 N-CA-C 105.725 -1.954 . . . . 0.0 105.725 175.514 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.424 ' HB2' HG22 ' A' ' 44' ' ' THR . 8.7 p -139.91 143.37 36.62 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -175.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 67.8 mt -105.66 117.24 51.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.094 0.473 . . . . 0.0 110.751 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.512 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 49.3 tp60 -115.66 113.52 23.64 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 103.021 -2.955 . . . . 0.0 103.021 168.154 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.59 115.88 1.4 Allowed 'General case' 0 CA--C 1.512 -0.512 0 O-C-N 124.458 1.099 . . . . 0.0 113.189 -165.433 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 133.02 -39.11 1.78 Allowed Glycine 0 N--CA 1.419 -2.459 0 CA-C-N 113.642 -1.617 . . . . 0.0 109.066 -176.493 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 64.4 m80 -148.16 161.15 42.03 Favored 'General case' 0 CA--C 1.506 -0.72 0 C-N-CA 122.921 0.488 . . . . 0.0 110.363 -179.511 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.454 ' O ' HG22 ' A' ' 111' ' ' VAL . 16.0 tt -106.75 121.44 59.47 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 175.201 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.512 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 52.9 m95 -104.77 138.25 41.33 Favored 'General case' 0 C--N 1.279 -2.469 0 CA-C-O 120.868 0.366 . . . . 0.0 110.881 -170.345 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.5 pt -100.34 132.51 45.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 175.757 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.14 116.07 5.45 Favored Glycine 0 N--CA 1.431 -1.67 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -178.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -136.08 175.25 9.77 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -115.29 127.42 55.44 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 177.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.28 -179.42 6.97 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.5 p90 -68.0 -20.39 65.02 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 118.488 0.585 . . . . 0.0 112.432 -176.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 59.3 t30 -73.7 -12.29 60.67 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-O 121.637 0.732 . . . . 0.0 109.532 175.548 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 92.26 -12.43 69.66 Favored Glycine 0 CA--C 1.501 -0.786 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.627 178.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -72.57 147.67 45.67 Favored 'General case' 0 C--O 1.253 1.245 0 C-N-CA 123.252 0.621 . . . . 0.0 109.841 -175.77 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.3 tpt180 -80.66 108.29 14.19 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 124.539 1.136 . . . . 0.0 108.414 -178.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 38.2 t -112.32 145.99 17.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 -176.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.463 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 91.9 m-85 -121.49 130.86 53.81 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.038 0.447 . . . . 0.0 110.671 -177.251 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' CYS . . . . . 0.464 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 52.5 t -109.11 130.49 22.67 Favored Pre-proline 0 C--N 1.304 -1.396 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 177.36 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -70.07 -14.15 34.76 Favored 'Trans proline' 0 C--O 1.21 -0.883 0 C-N-CA 122.962 2.442 . . . . 0.0 114.564 -177.194 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.454 HG22 ' O ' ' A' ' 95' ' ' ILE 0.295 21.5 m 43.29 -54.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.518 2.949 0 N-CA-C 118.431 2.752 . . . . 0.0 118.431 176.173 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.404 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 12.1 ptm180 -156.09 150.43 25.64 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 55.1 m -64.31 144.68 56.97 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 177.004 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.448 ' SG ' ' HB2' ' A' ' 121' ' ' HIS . 27.0 t -161.16 134.18 6.35 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-O 120.954 0.407 . . . . 0.0 110.738 -178.064 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -123.81 160.92 26.31 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 176.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.62 178.04 15.48 Favored Glycine 0 N--CA 1.423 -2.195 0 C-N-CA 119.055 -1.545 . . . . 0.0 113.455 174.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 16.5 m -128.39 128.12 23.64 Favored Pre-proline 0 C--N 1.3 -1.574 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.531 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 64.5 Cg_exo -48.46 139.63 22.54 Favored 'Trans proline' 0 C--O 1.237 0.459 0 C-N-CA 123.433 2.755 . . . . 0.0 113.788 -179.294 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -81.15 -18.71 24.29 Favored 'Cis proline' 0 C--O 1.246 0.91 0 C-N-CA 123.581 -1.424 . . . . 0.0 114.018 0.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -70.67 102.0 2.19 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 122.053 0.93 . . . . 0.0 112.665 -172.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.448 ' HB2' ' SG ' ' A' ' 114' ' ' CYS . 48.8 p-80 -104.64 130.35 52.67 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-N 114.65 -1.159 . . . . 0.0 110.188 178.74 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 60.9 mt -96.49 114.32 64.18 Favored Pre-proline 0 C--N 1.301 -1.524 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -75.88 162.27 35.08 Favored 'Trans proline' 0 C--O 1.245 0.862 0 C-N-CA 122.571 2.181 . . . . 0.0 113.181 -179.113 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.85 -164.31 11.0 Favored Glycine 0 N--CA 1.433 -1.535 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 177.805 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.1 t -52.84 115.97 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.818 0.847 . . . . 0.0 112.562 -176.032 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.404 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -93.85 148.85 21.75 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.248 177.434 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.9 m-90 -111.17 10.91 21.86 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-O 121.103 0.478 . . . . 0.0 111.252 178.498 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.5 -175.9 33.03 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.665 -178.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 54.7 t -111.33 138.98 37.53 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -176.205 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -101.22 147.49 26.21 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-O 120.597 0.237 . . . . 0.0 110.396 -178.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.2 mtpt . . . . . 0 C--O 1.26 1.621 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 175.087 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 93.1 m95 . . . . . 0 N--CA 1.437 -1.078 0 CA-C-O 121.158 0.504 . . . . 0.0 109.715 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -113.92 141.95 46.74 Favored 'General case' 0 C--N 1.286 -2.169 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 -177.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 66.1 tttm -100.2 144.51 29.13 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 119.681 -0.808 . . . . 0.0 110.138 -179.556 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 33.0 p30 -114.73 -179.18 3.55 Favored 'General case' 0 C--O 1.254 1.326 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.545 175.714 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -81.51 0.63 37.09 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -175.6 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -91.79 -0.77 57.55 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 121.846 0.832 . . . . 0.0 109.073 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.95 19.65 74.76 Favored Glycine 0 CA--C 1.5 -0.885 0 CA-C-N 115.235 -0.893 . . . . 0.0 111.191 -179.103 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.447 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 28.3 m -105.65 141.13 37.64 Favored 'General case' 0 N--CA 1.41 -2.458 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 -179.512 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.543 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 63.3 m95 -104.64 125.3 50.62 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 174.008 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -127.42 145.07 50.95 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-O 120.729 0.3 . . . . 0.0 110.614 -176.393 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.445 ' CG ' ' HB ' ' A' ' 88' ' ' VAL . 21.1 ptmt -124.86 132.78 24.37 Favored Pre-proline 0 C--N 1.294 -1.836 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 176.044 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -76.05 121.06 5.98 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 121.458 1.438 . . . . 0.0 109.555 174.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -166.71 120.91 1.07 Allowed 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.421 ' HA ' ' HA ' ' A' ' 86' ' ' ASP . 24.4 t-20 -95.43 120.2 35.25 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.091 -175.092 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.72 164.18 35.93 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 51.2 m -103.83 149.18 25.29 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.933 -177.415 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.5 t80 -126.42 134.13 51.08 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 177.257 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.8 t -114.2 118.11 57.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.923 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 49.9 t-20 -68.62 130.68 43.54 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -95.58 -68.29 1.01 Allowed Glycine 0 N--CA 1.421 -2.344 0 C-N-CA 120.005 -1.093 . . . . 0.0 114.253 -172.565 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -135.31 14.4 3.5 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -170.858 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.499 ' HB2' ' HB3' ' A' ' 127' ' ' TRP . 12.5 mm-40 -135.48 122.07 14.47 Favored Pre-proline 0 C--N 1.298 -1.642 0 C-N-CA 119.729 -0.788 . . . . 0.0 112.949 -177.802 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -67.22 120.66 7.74 Favored 'Trans proline' 0 N--CA 1.447 -1.209 0 N-CA-C 105.767 -2.436 . . . . 0.0 105.767 167.473 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.495 HG13 ' O ' ' A' ' 58' ' ' GLN . 49.4 mt -113.58 120.74 64.24 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.057 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.639 -171.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -73.84 122.78 27.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 176.391 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 44.8 p -102.42 170.35 8.11 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.884 -173.582 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -117.47 149.28 40.85 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 2.8 mp -111.58 133.19 58.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 121.082 0.468 . . . . 0.0 111.111 -178.283 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 84.29 -24.11 6.59 Favored Glycine 0 C--N 1.315 -0.615 0 N-CA-C 115.861 1.104 . . . . 0.0 115.861 171.573 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 65.5 m -160.46 146.67 11.67 Favored Pre-proline 0 C--N 1.311 -1.068 0 CA-C-N 118.216 1.008 . . . . 0.0 110.144 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.405 ' HG2' HG21 ' A' ' 44' ' ' THR . 58.9 Cg_endo -89.82 119.9 0.87 Allowed 'Trans proline' 0 N--CA 1.44 -1.638 0 C-N-CA 121.771 1.647 . . . . 0.0 111.732 175.221 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.458 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 88.2 m-85 -169.89 177.66 4.3 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 103.487 -2.782 . . . . 0.0 103.487 -179.082 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -89.95 -37.47 14.34 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 171.48 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -89.14 25.48 1.85 Allowed 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 114.751 -1.113 . . . . 0.0 111.138 -177.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.458 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -84.49 161.38 54.22 Favored Pre-proline 0 C--N 1.306 -1.309 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 178.486 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -47.66 135.12 21.98 Favored 'Trans proline' 0 C--N 1.364 1.35 0 C-N-CA 123.715 2.943 . . . . 0.0 114.722 -178.286 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 18.0 m -90.42 173.92 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 114.362 -1.29 . . . . 0.0 110.636 -178.372 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.86 28.53 2.04 Favored Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.535 177.716 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -151.08 128.59 2.64 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 120.001 -1.095 . . . . 0.0 112.567 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -128.12 127.76 43.61 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.751 -1.204 . . . . 0.0 107.751 173.253 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 55.0 tp -101.41 109.9 60.15 Favored Pre-proline 0 C--N 1.301 -1.509 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 178.151 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.22 154.06 51.54 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 122.46 2.107 . . . . 0.0 112.515 -178.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.53 141.48 51.9 Favored 'General case' 0 N--CA 1.438 -1.045 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.855 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.0 -7.13 67.14 Favored Glycine 0 N--CA 1.435 -1.412 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.618 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.04 136.56 34.45 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.902 0.351 . . . . 0.0 111.366 -178.278 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 47.6 m -103.77 112.9 26.05 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.308 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.7 mm -127.27 133.77 67.35 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -176.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 11.6 p -93.3 135.19 28.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.874 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.417 ' HA ' ' HB3' ' A' ' 99' ' ' TYR . 52.7 p90 -118.18 159.55 23.11 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -178.492 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.421 ' HA ' ' HA ' ' A' ' 50' ' ' ASN . 4.9 p-10 -130.12 -7.78 4.35 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 112.367 0.506 . . . . 0.0 112.367 -177.68 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.466 ' HG2' ' SG ' ' A' ' 89' ' ' CYS . 29.4 tt0 -131.36 120.83 23.67 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 -176.684 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.445 ' HB ' ' CG ' ' A' ' 47' ' ' LYS . 39.9 t -105.67 119.07 54.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.466 ' SG ' ' HG2' ' A' ' 87' ' ' GLU . 46.9 m -123.23 133.2 54.22 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -172.71 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 56.6 mt -97.7 113.86 33.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 CA-C-O 121.291 0.567 . . . . 0.0 109.942 173.752 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.507 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -121.42 134.04 55.09 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 172.145 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.62 117.05 1.84 Allowed 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 114.081 1.141 . . . . 0.0 114.081 -164.665 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 107.96 -22.61 27.33 Favored Glycine 0 N--CA 1.431 -1.681 0 CA-C-N 115.115 -0.948 . . . . 0.0 112.426 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' HIS . . . . . 0.438 ' HB2' ' NE1' ' A' ' 96' ' ' TRP . 57.9 m80 -144.45 169.22 18.36 Favored 'General case' 0 CA--C 1.509 -0.626 0 O-C-N 122.108 -0.642 . . . . 0.0 110.445 -176.575 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.6 tt -126.09 109.58 21.74 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.152 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 173.203 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.507 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 42.5 m95 -95.27 138.91 32.33 Favored 'General case' 0 C--N 1.279 -2.48 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.563 -167.486 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.453 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.8 pt -100.58 127.74 53.35 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 176.498 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.88 127.93 9.37 Favored Glycine 0 N--CA 1.421 -2.307 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.467 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' TYR . . . . . 0.417 ' HB3' ' HA ' ' A' ' 85' ' ' TYR . 41.3 p90 -142.63 150.46 40.3 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -102.08 119.15 38.33 Favored 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.411 ' HB3' ' OD1' ' A' ' 105' ' ' ASN . . . -87.19 168.12 13.51 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 120.954 0.407 . . . . 0.0 110.838 -177.472 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -52.88 -25.52 11.93 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.397 1.479 . . . . 0.0 112.897 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -83.69 -3.44 57.77 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.454 0.645 . . . . 0.0 110.497 -176.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.19 7.07 73.88 Favored Glycine 0 CA--C 1.501 -0.8 0 CA-C-O 121.422 0.456 . . . . 0.0 112.038 176.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.411 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 13.8 p-10 -94.66 130.21 41.24 Favored 'General case' 0 C--N 1.29 -1.991 0 C-N-CA 123.147 0.579 . . . . 0.0 111.008 -177.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 26.6 tpt180 -84.1 102.93 12.9 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 178.794 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.8 t -97.71 139.34 20.22 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -173.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.453 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 79.0 m-85 -119.69 122.55 41.72 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 123.336 0.654 . . . . 0.0 109.725 177.515 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' CYS . . . . . 0.424 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 48.6 t -111.38 130.87 22.62 Favored Pre-proline 0 C--N 1.305 -1.369 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.032 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.1 -27.41 41.98 Favored 'Trans proline' 0 C--N 1.355 0.884 0 C-N-CA 122.815 2.343 . . . . 0.0 114.112 -176.013 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.303 18.9 m 51.19 -42.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.505 0 N-CA-C 118.446 2.758 . . . . 0.0 118.446 176.81 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.53 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 37.9 ptt180 -161.5 165.08 29.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-O 121.112 0.482 . . . . 0.0 110.634 -179.409 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.5 m -75.93 139.72 41.74 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 176.205 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 49.5 t -155.97 128.01 7.51 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.47 0.652 . . . . 0.0 110.962 178.209 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' GLN . . . . . 0.457 ' HA ' ' OE1' ' A' ' 115' ' ' GLN . 7.9 mm-40 -121.69 162.45 20.72 Favored 'General case' 0 C--N 1.288 -2.106 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.493 177.718 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 124.58 -174.38 17.07 Favored Glycine 0 N--CA 1.418 -2.51 0 C-N-CA 119.947 -1.121 . . . . 0.0 112.021 177.297 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 18.9 m -131.87 133.22 23.82 Favored Pre-proline 0 C--N 1.3 -1.549 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.508 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.543 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 88.2 Cg_exo -48.74 137.13 27.34 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 123.332 2.688 . . . . 0.0 113.417 -178.444 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 11.7 Cg_endo -91.09 1.09 64.32 Favored 'Cis proline' 0 C--O 1.245 0.86 0 C-N-CA 123.584 -1.423 . . . . 0.0 113.079 1.541 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -80.7 100.18 8.58 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 121.76 0.791 . . . . 0.0 110.36 -173.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.436 ' HB2' ' SG ' ' A' ' 114' ' ' CYS . 47.1 p-80 -105.5 131.33 53.03 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 114.606 -1.179 . . . . 0.0 112.098 -177.442 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.456 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.1 mm -105.74 99.8 23.83 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 178.515 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -84.96 139.69 7.47 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.391 2.061 . . . . 0.0 112.29 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -102.39 -133.01 7.89 Favored Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 177.08 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 61.5 t -82.97 129.3 37.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 110.129 -0.322 . . . . 0.0 110.129 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.53 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -93.62 143.82 25.96 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.823 176.543 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' TRP . . . . . 0.499 ' HB3' ' HB2' ' A' ' 58' ' ' GLN . 4.8 m0 -101.99 12.59 36.66 Favored 'General case' 0 C--O 1.251 1.154 0 CA-C-O 122.031 0.92 . . . . 0.0 110.345 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.63 179.59 36.92 Favored Glycine 0 N--CA 1.426 -1.99 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.936 -179.568 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.5 t -113.54 134.97 54.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -177.012 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -87.62 122.1 30.89 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.136 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? . . . . . 0 C--N 1.291 -1.943 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.866 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 73.0 m95 . . . . . 0 N--CA 1.443 -0.822 0 CA-C-O 120.88 0.371 . . . . 0.0 110.296 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.464 ' HE3' ' HA ' ' A' ' 38' ' ' LYS . 0.0 OUTLIER -131.93 146.68 52.25 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 174.881 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -93.77 133.6 36.98 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 -178.142 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 33.3 p30 -96.84 176.81 5.85 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 175.326 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -77.22 1.75 17.56 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.515 0.674 . . . . 0.0 112.214 -175.768 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.7 m-85 -98.72 7.9 45.56 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.139 178.627 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.19 17.51 77.41 Favored Glycine 0 C--N 1.338 0.65 0 CA-C-N 115.128 -0.942 . . . . 0.0 112.32 177.14 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.45 HG21 ' HG2' ' A' ' 67' ' ' PRO . 5.3 m -105.01 141.9 35.76 Favored 'General case' 0 N--CA 1.42 -1.937 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -177.341 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.454 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 87.5 m95 -96.46 129.18 43.87 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.499 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.41 ' HA ' ' O ' ' A' ' 88' ' ' VAL . 51.8 p90 -125.89 150.28 48.04 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 123.199 0.312 . . . . 0.0 110.383 -178.944 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 14.1 ptmm? -135.66 148.06 63.98 Favored Pre-proline 0 C--N 1.303 -1.43 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 175.377 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -71.24 128.86 15.21 Favored 'Trans proline' 0 N--CA 1.444 -1.386 0 C-N-CA 121.27 1.313 . . . . 0.0 109.013 170.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.448 ' HB3' HG23 ' A' ' 88' ' ' VAL . 9.2 tp10 -162.64 120.18 2.04 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.505 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.526 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 6.6 t30 -105.87 113.48 27.06 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.684 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.413 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.55 175.62 12.57 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 89.0 m -118.9 133.19 56.0 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 120.253 -0.579 . . . . 0.0 112.32 -176.702 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -107.89 129.11 55.11 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 176.21 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.1 t -110.35 115.1 48.88 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 176.252 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -69.16 148.64 49.63 Favored 'General case' 0 C--N 1.309 -1.178 0 O-C-N 123.408 0.442 . . . . 0.0 110.466 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -81.58 -144.76 4.55 Favored Glycine 0 N--CA 1.43 -1.756 0 CA-C-N 115.998 -0.547 . . . . 0.0 113.84 -177.17 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 31.2 p-10 -85.65 12.22 9.23 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 -171.702 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.439 ' HA ' ' HD3' ' A' ' 59' ' ' PRO . 0.8 OUTLIER -142.4 143.46 27.04 Favored Pre-proline 0 C--N 1.301 -1.516 0 C-N-CA 120.592 -0.443 . . . . 0.0 112.065 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 58' ' ' GLN . 12.8 Cg_exo -71.98 131.75 18.69 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.138 1.892 . . . . 0.0 111.437 177.382 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -107.58 132.7 54.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.037 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.5 p -79.97 136.2 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 176.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 53.4 p -111.98 167.03 10.71 Favored 'General case' 0 C--N 1.287 -2.138 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.651 -175.682 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.415 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 21.7 mmt180 -114.68 137.14 52.26 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.7 mt -93.33 123.85 45.57 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 CA-C-N 115.396 -0.82 . . . . 0.0 113.156 -172.404 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.79 -23.19 3.75 Favored Glycine 0 C--O 1.237 0.291 0 N-CA-C 115.906 1.123 . . . . 0.0 115.906 172.468 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.408 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 50.7 m -151.7 144.53 16.96 Favored Pre-proline 0 C--N 1.306 -1.288 0 CA-C-N 118.53 1.165 . . . . 0.0 111.54 -177.004 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.45 ' HG2' HG21 ' A' ' 44' ' ' THR . 1.2 Cg_endo -89.35 120.95 1.06 Allowed 'Trans proline' 0 N--CA 1.448 -1.168 0 C-N-CA 122.457 2.105 . . . . 0.0 110.597 173.245 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.567 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 59.6 m-85 -168.53 170.43 9.66 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 126.355 1.862 . . . . 0.0 106.322 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 95.8 mt -82.51 -30.96 29.48 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 172.372 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 17.6 m120 -102.97 26.22 8.42 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.732 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.567 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -75.2 156.79 85.58 Favored Pre-proline 0 C--N 1.308 -1.198 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.397 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -50.7 131.44 33.47 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 123.651 2.901 . . . . 0.0 113.48 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 6.8 p -101.31 174.17 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 C-N-CA 124.051 0.94 . . . . 0.0 108.928 -176.365 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.44 -4.74 13.36 Favored Glycine 0 N--CA 1.443 -0.84 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.023 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -110.81 123.78 6.71 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 177.58 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -122.09 134.48 54.77 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 117.356 0.578 . . . . 0.0 110.139 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.5 tp -100.83 118.87 59.79 Favored Pre-proline 0 C--N 1.308 -1.217 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -66.62 160.06 47.96 Favored 'Trans proline' 0 C--O 1.243 0.764 0 C-N-CA 122.478 2.119 . . . . 0.0 112.709 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.56 136.65 47.56 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.666 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.64 1.49 90.53 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 121.423 -0.418 . . . . 0.0 113.365 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.59 127.09 31.05 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.179 0.514 . . . . 0.0 111.861 -177.867 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 46.2 m -96.97 109.0 21.84 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 177.78 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.3 mm -118.79 120.8 65.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.096 -174.744 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.6 p -89.06 127.46 41.77 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.134 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.526 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 48.5 p90 -116.43 154.55 30.11 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -178.509 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -120.31 4.93 10.74 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-O 121.469 0.652 . . . . 0.0 110.561 -179.008 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -147.45 140.7 25.24 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.713 -175.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.448 HG23 ' HB3' ' A' ' 49' ' ' GLU . 86.7 t -124.04 133.19 69.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 176.601 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.544 ' HG ' ' HE2' ' A' ' 108' ' ' TYR . 61.5 m -130.27 135.18 47.83 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 122.315 0.246 . . . . 0.0 111.369 -176.812 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.4 mt -103.03 111.84 34.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 176.199 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.1 tp-100 -115.69 145.1 43.05 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 105.448 -2.056 . . . . 0.0 105.448 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.37 104.81 0.08 Allowed 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -174.42 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 115.31 -30.89 6.48 Favored Glycine 0 N--CA 1.434 -1.456 0 CA-C-N 115.61 -0.723 . . . . 0.0 113.836 177.273 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 64.0 m80 -145.46 150.97 37.47 Favored 'General case' 0 CA--C 1.504 -0.827 0 CA-C-N 118.196 0.998 . . . . 0.0 110.743 -175.018 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.8 tt -106.41 111.78 36.78 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 176.75 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 47.9 m95 -95.87 148.43 22.62 Favored 'General case' 0 C--N 1.285 -2.233 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.424 -169.902 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.5 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.4 pt -107.34 139.23 29.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.411 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -106.49 121.46 6.65 Favored Glycine 0 N--CA 1.431 -1.675 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -135.65 167.96 20.15 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.667 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -102.42 131.06 49.32 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.891 179.088 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -83.51 175.52 9.73 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 173.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 29.9 p90 -53.37 -36.24 61.19 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -178.499 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 25.6 p-10 -88.63 1.91 54.15 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 120.68 0.276 . . . . 0.0 111.322 -178.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.11 5.79 72.58 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 121.306 -0.473 . . . . 0.0 112.009 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -67.94 129.7 40.71 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 22.9 tpt180 -82.68 107.7 15.5 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 -178.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 27.8 t -111.62 142.85 22.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -178.179 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.544 ' HE2' ' HG ' ' A' ' 89' ' ' CYS . 85.0 m-85 -117.63 131.35 56.67 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 120.963 0.411 . . . . 0.0 110.628 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 45.3 t -112.9 134.47 21.75 Favored Pre-proline 0 C--N 1.302 -1.483 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -68.16 -27.14 35.68 Favored 'Trans proline' 0 C--N 1.358 1.038 0 C-N-CA 122.626 2.217 . . . . 0.0 113.35 -177.317 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.29 21.9 m 52.52 -46.59 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.284 0 N-CA-C 117.968 2.581 . . . . 0.0 117.968 176.47 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.546 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 37.1 ptt180 -161.63 163.55 29.87 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 123.157 0.583 . . . . 0.0 110.068 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.8 t -81.69 141.51 33.54 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 175.087 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.9 t -156.18 127.78 7.24 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -109.17 139.12 44.51 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.052 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 142.49 177.91 17.98 Favored Glycine 0 N--CA 1.42 -2.393 0 C-N-CA 119.059 -1.543 . . . . 0.0 113.668 175.161 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 16.2 m -141.42 145.4 37.77 Favored Pre-proline 0 C--N 1.299 -1.593 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 178.69 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 83.8 Cg_exo -49.2 138.41 28.94 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 122.897 2.398 . . . . 0.0 112.922 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 60.0 Cg_endo -85.29 -16.04 29.78 Favored 'Cis proline' 0 C--O 1.25 1.118 0 C-N-CA 123.366 -1.514 . . . . 0.0 113.618 0.198 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -80.54 100.98 8.85 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -171.346 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -106.41 123.95 48.85 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 114.336 -1.302 . . . . 0.0 111.29 178.152 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 70.4 mt -95.46 108.19 37.82 Favored Pre-proline 0 C--N 1.319 -0.73 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.843 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -84.23 130.67 4.76 Favored 'Trans proline' 0 C--O 1.249 1.04 0 C-N-CA 122.37 2.047 . . . . 0.0 112.841 -179.059 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -115.35 -147.93 9.26 Favored Glycine 0 N--CA 1.435 -1.374 0 C-N-CA 120.562 -0.827 . . . . 0.0 112.017 178.595 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.6 t -57.63 116.13 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.823 0 C-N-CA 123.819 0.848 . . . . 0.0 112.047 -179.739 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.546 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.19 143.87 26.0 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.431 173.792 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.6 m-90 -104.51 19.74 19.78 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.635 0.731 . . . . 0.0 109.584 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -165.77 -175.74 36.54 Favored Glycine 0 N--CA 1.428 -1.882 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 179.487 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 60.8 t -112.88 141.59 28.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -177.756 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -107.14 122.15 45.93 Favored 'General case' 0 C--N 1.321 -0.653 0 O-C-N 123.231 0.332 . . . . 0.0 110.54 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt . . . . . 0 C--N 1.297 -1.676 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 177.994 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 48.3 m95 . . . . . 0 N--CA 1.435 -1.217 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -114.13 133.58 55.47 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -89.45 129.83 35.89 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 120.985 0.421 . . . . 0.0 111.201 -177.49 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 45.9 t-20 -99.83 160.0 14.64 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -65.26 -11.86 45.64 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.499 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -77.2 -5.57 49.7 Favored 'General case' 0 CA--C 1.541 0.633 0 CA-C-O 121.357 0.598 . . . . 0.0 109.996 176.655 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.26 1.83 83.7 Favored Glycine 0 CA--C 1.506 -0.492 0 N-CA-C 110.145 -1.182 . . . . 0.0 110.145 -177.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.424 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 9.2 m -89.42 141.01 28.94 Favored 'General case' 0 N--CA 1.415 -2.208 0 CA-C-N 113.86 -1.17 . . . . 0.0 109.299 -178.02 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.502 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 71.9 m95 -102.45 135.94 43.18 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 173.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.434 ' HA ' ' O ' ' A' ' 88' ' ' VAL . 32.0 p90 -137.4 155.47 49.33 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.702 -177.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -147.29 135.59 10.95 Favored Pre-proline 0 C--N 1.305 -1.364 0 CA-C-N 115.318 -0.855 . . . . 0.0 108.738 173.305 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -67.08 129.57 20.89 Favored 'Trans proline' 0 C--O 1.248 0.992 0 C-N-CA 122.264 1.976 . . . . 0.0 111.42 173.823 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -168.02 120.99 0.89 Allowed 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.061 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.567 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 15.9 m120 -88.57 109.5 20.13 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-O 120.906 0.384 . . . . 0.0 110.88 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.446 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -135.45 165.73 24.8 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 178.09 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.466 ' HB ' ' HG3' ' A' ' 131' ' ' LYS . 25.9 m -114.0 136.51 52.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-O 121.479 0.656 . . . . 0.0 111.964 -175.492 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 69.6 t80 -117.74 127.01 53.49 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 114.986 -1.007 . . . . 0.0 108.288 176.31 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 129' ' ' VAL . 46.0 t -105.41 105.6 18.97 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 178.301 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -76.42 121.51 23.16 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 178.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -149.63 -24.45 0.06 OUTLIER Glycine 0 C--N 1.309 -0.923 0 C-N-CA 118.325 -1.893 . . . . 0.0 114.654 -175.684 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -71.72 -53.14 14.45 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.172 0.511 . . . . 0.0 110.096 -177.012 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -156.21 159.83 31.2 Favored Pre-proline 0 C--N 1.312 -1.031 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.078 -176.165 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -67.77 131.67 24.8 Favored 'Trans proline' 0 C--O 1.248 0.991 0 C-N-CA 122.372 2.048 . . . . 0.0 110.135 173.521 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 47.4 mt -114.51 132.35 63.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -176.517 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.3 p -76.07 131.68 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 177.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 40.7 p -103.74 157.62 16.95 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.531 -177.047 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -110.78 143.88 40.63 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.3 mp -109.68 134.4 51.91 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 C-N-CA 120.531 -0.468 . . . . 0.0 111.22 -175.075 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.29 -22.74 1.99 Allowed Glycine 0 C--O 1.244 0.728 0 N-CA-C 117.157 1.623 . . . . 0.0 117.157 171.593 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.4 m -152.85 138.86 11.98 Favored Pre-proline 0 C--N 1.308 -1.197 0 CA-C-N 118.81 1.305 . . . . 0.0 111.462 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -89.75 120.49 0.94 Allowed 'Trans proline' 0 N--CA 1.441 -1.577 0 C-N-CA 121.992 1.795 . . . . 0.0 111.006 171.86 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.424 ' HA ' ' HG2' ' A' ' 91' ' ' GLN . 68.1 m-85 -166.58 166.33 16.21 Favored 'General case' 0 CA--C 1.493 -1.216 0 C-N-CA 126.63 1.972 . . . . 0.0 105.819 -178.812 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 86.3 mt -72.23 -41.28 67.03 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.436 0.636 . . . . 0.0 109.296 176.189 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 21.8 p-10 -97.47 25.63 5.55 Favored 'General case' 0 C--O 1.246 0.894 0 C-N-CA 124.477 1.111 . . . . 0.0 110.709 -177.578 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -65.84 153.32 91.51 Favored Pre-proline 0 C--O 1.249 1.077 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.627 -178.463 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -47.44 128.62 15.23 Favored 'Trans proline' 0 C--N 1.368 1.555 0 C-N-CA 124.205 3.27 . . . . 0.0 114.077 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.3 p -102.73 172.99 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.44 28.61 1.92 Allowed Glycine 0 N--CA 1.442 -0.903 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.649 -176.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -161.66 131.23 2.51 Favored Glycine 0 N--CA 1.433 -1.566 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 176.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -127.82 141.38 51.58 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 117.336 0.568 . . . . 0.0 110.272 -179.654 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 50.7 tp -100.96 113.26 65.78 Favored Pre-proline 0 C--N 1.301 -1.521 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.007 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -73.64 156.8 49.07 Favored 'Trans proline' 0 C--O 1.252 1.209 0 C-N-CA 122.405 2.07 . . . . 0.0 111.456 179.05 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.52 142.77 42.77 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 108.35 -22.46 26.8 Favored Glycine 0 N--CA 1.434 -1.475 0 N-CA-C 110.438 -1.065 . . . . 0.0 110.438 -176.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.5 126.77 30.56 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-O 121.349 0.595 . . . . 0.0 111.298 -178.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 17.0 m -98.67 110.77 23.31 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 177.613 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.1 mm -111.51 131.07 63.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.286 -173.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.6 p -108.67 112.48 40.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 CA-C-O 122.04 0.924 . . . . 0.0 109.074 175.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.567 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 46.9 p90 -97.45 149.32 22.28 Favored 'General case' 0 C--N 1.296 -1.744 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.363 -177.517 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -112.92 -9.9 13.58 Favored 'General case' 0 C--N 1.31 -1.139 0 O-C-N 123.804 0.69 . . . . 0.0 111.238 -176.144 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 46.3 tt0 -134.94 128.98 33.54 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -175.677 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 46' ' ' TYR . 13.8 t -107.89 126.71 64.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.424 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 62.5 m -128.94 139.02 52.3 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -177.135 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 46.9 mt -112.22 119.37 60.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 173.432 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.497 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -124.94 144.1 50.53 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 104.638 -2.356 . . . . 0.0 104.638 174.803 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -51.15 104.13 0.07 Allowed 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 113.353 0.871 . . . . 0.0 113.353 -172.129 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.45 -39.97 1.76 Allowed Glycine 0 N--CA 1.431 -1.642 0 CA-C-N 115.436 -0.802 . . . . 0.0 113.236 177.501 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 53.0 m80 -147.74 157.58 43.61 Favored 'General case' 0 CA--C 1.497 -1.091 0 O-C-N 122.083 -0.657 . . . . 0.0 110.602 -174.525 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.9 tt -96.78 128.28 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.714 0 N-CA-C 105.296 -2.112 . . . . 0.0 105.296 172.454 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.497 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 72.1 m95 -106.41 135.45 47.87 Favored 'General case' 0 C--N 1.266 -3.023 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -173.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.509 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.4 pt -100.38 126.38 53.97 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.894 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 177.637 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -100.29 124.23 8.18 Favored Glycine 0 N--CA 1.42 -2.422 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.173 -177.681 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -148.23 173.07 13.37 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 177.274 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -119.17 145.51 45.94 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 177.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.44 ' HB3' ' OD1' ' A' ' 105' ' ' ASN . . . -93.85 170.23 9.71 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.336 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -73.35 -9.8 59.07 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.141 0.496 . . . . 0.0 111.64 -176.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -72.63 -16.41 61.72 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 174.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 98.57 4.14 57.19 Favored Glycine 0 C--N 1.33 0.208 0 C-N-CA 121.062 -0.59 . . . . 0.0 111.964 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.44 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 23.5 p-10 -96.06 145.15 25.7 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 120.938 0.399 . . . . 0.0 110.968 -179.385 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 28.9 tpt180 -86.15 122.36 30.04 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 179.082 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 43.0 t -119.21 143.2 31.18 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.261 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 -173.592 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.509 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 86.3 m-85 -125.52 129.17 49.22 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 123.579 0.751 . . . . 0.0 110.134 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.4 t -109.3 135.06 20.29 Favored Pre-proline 0 C--N 1.299 -1.592 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 178.562 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -68.24 -23.24 39.2 Favored 'Trans proline' 0 C--N 1.365 1.416 0 C-N-CA 123.202 2.602 . . . . 0.0 114.38 -177.157 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.3 35.4 m 45.22 -53.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.286 0 N-CA-C 119.077 2.992 . . . . 0.0 119.077 176.054 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.442 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 33.2 ptt180 -158.7 152.87 23.86 Favored 'General case' 0 C--N 1.314 -0.964 0 O-C-N 121.718 -0.614 . . . . 0.0 110.47 -178.297 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.556 ' O ' ' HA ' ' A' ' 123' ' ' PRO . 13.7 m -63.88 127.48 31.58 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 174.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.41 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 99.6 m -152.92 118.76 5.39 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 123.477 0.711 . . . . 0.0 109.361 177.044 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 76.2 mt-30 -129.58 148.83 51.52 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.34 -167.86 30.82 Favored Glycine 0 N--CA 1.417 -2.602 0 C-N-CA 119.11 -1.519 . . . . 0.0 112.149 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 10.8 m -123.99 108.03 30.45 Favored Pre-proline 0 C--N 1.291 -1.971 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.502 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 60.6 Cg_exo -43.17 129.2 5.92 Favored 'Trans proline' 0 C--N 1.349 0.584 0 C-N-CA 124.004 3.136 . . . . 0.0 113.024 -175.608 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -90.53 10.77 60.32 Favored 'Cis proline' 0 C--O 1.242 0.694 0 C-N-CA 124.115 -1.202 . . . . 0.0 115.114 8.44 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -75.28 100.06 4.25 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 -179.046 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.431 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 45.8 p-80 -106.08 109.83 21.89 Favored 'General case' 0 C--N 1.289 -2.053 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.112 177.191 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.5 mt -94.82 105.21 17.49 Favored Pre-proline 0 C--N 1.299 -1.606 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.662 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' PRO . . . . . 0.556 ' HA ' ' O ' ' A' ' 113' ' ' THR . 72.8 Cg_endo -84.4 153.67 12.22 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.58 2.187 . . . . 0.0 113.121 -176.593 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -125.81 -97.53 1.09 Allowed Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 178.771 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 40.5 t -96.68 118.67 43.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -178.771 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.442 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.06 120.34 34.19 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.179 178.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.8 m-90 -101.5 58.02 0.85 Allowed 'General case' 0 C--N 1.31 -1.149 0 CA-C-O 120.661 0.267 . . . . 0.0 111.345 -179.19 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . 155.85 -169.78 33.59 Favored Glycine 0 CA--C 1.497 -1.082 0 C-N-CA 119.693 -1.241 . . . . 0.0 112.499 178.15 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 54' ' ' VAL . 97.9 t -111.94 128.68 68.38 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.671 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -112.07 136.87 50.89 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.152 -176.635 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.466 ' HG3' ' HB ' ' A' ' 52' ' ' THR . 18.1 ptpt . . . . . 0 N--CA 1.433 -1.315 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 175.028 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 92.1 m95 . . . . . 0 N--CA 1.436 -1.144 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -125.08 154.64 41.07 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.639 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -94.15 127.27 39.88 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 120.359 -0.536 . . . . 0.0 111.207 -176.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -84.48 151.28 24.72 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 174.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.9 pt20 -51.2 -27.45 8.92 Favored 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 123.739 0.816 . . . . 0.0 113.189 -178.286 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.437 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 50.2 m-85 -81.73 3.16 26.66 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -177.257 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.71 18.82 59.27 Favored Glycine 0 CA--C 1.5 -0.844 0 C-N-CA 120.333 -0.937 . . . . 0.0 111.628 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.524 HG22 ' HB2' ' A' ' 89' ' ' CYS . 12.3 m -105.21 132.98 50.73 Favored 'General case' 0 N--CA 1.416 -2.134 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 179.57 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -96.39 129.73 43.67 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 177.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -129.54 154.67 46.81 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.422 -175.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -135.76 145.91 54.96 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 173.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_exo -69.3 121.86 8.65 Favored 'Trans proline' 0 C--O 1.249 1.041 0 C-N-CA 121.737 1.625 . . . . 0.0 109.469 172.187 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.451 ' HB3' HG23 ' A' ' 88' ' ' VAL . 6.2 tp10 -150.18 120.9 7.53 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.446 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 3.0 t-20 -114.19 106.49 14.42 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.926 -0.71 . . . . 0.0 110.154 -175.617 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.89 -177.58 5.98 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.443 -178.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.468 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 13.3 m -104.68 150.12 24.98 Favored 'General case' 0 N--CA 1.429 -1.487 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -177.299 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -127.39 127.21 43.8 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 173.532 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.1 t -113.09 113.29 43.64 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.232 0 N-CA-C 106.795 -1.558 . . . . 0.0 106.795 176.145 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 53.2 t30 -64.76 152.57 42.27 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.639 -178.846 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -78.59 -146.3 3.12 Favored Glycine 0 N--CA 1.434 -1.434 0 CA-C-N 116.16 -0.473 . . . . 0.0 113.173 -177.547 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -86.97 7.54 27.07 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -173.458 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.453 ' HA ' ' HD3' ' A' ' 59' ' ' PRO . 0.3 OUTLIER -138.92 137.25 19.29 Favored Pre-proline 0 C--N 1.302 -1.484 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.209 -175.213 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 58' ' ' GLN . 26.6 Cg_exo -65.58 128.99 21.27 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.415 2.077 . . . . 0.0 110.757 176.761 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.2 mt -108.02 125.81 64.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -177.554 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.3 p -78.89 137.58 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.669 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 60.2 p -117.26 178.41 4.38 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.003 -172.472 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 33.9 mmt180 -116.81 146.59 42.77 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 60.7 mt -109.82 131.32 61.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.43 -175.28 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.2 -22.86 4.19 Favored Glycine 0 C--N 1.318 -0.42 0 N-CA-C 115.969 1.148 . . . . 0.0 115.969 171.666 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.409 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 39.1 m -153.61 140.77 13.24 Favored Pre-proline 0 C--N 1.298 -1.669 0 CA-C-N 117.875 0.837 . . . . 0.0 109.154 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.442 ' HG2' HG21 ' A' ' 44' ' ' THR . 12.5 Cg_endo -89.69 119.4 0.86 Allowed 'Trans proline' 0 N--CA 1.433 -2.036 0 C-N-CA 121.189 1.259 . . . . 0.0 110.347 173.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.661 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 82.4 m-85 -168.89 173.9 6.77 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 104.716 -2.328 . . . . 0.0 104.716 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -89.28 -34.25 16.66 Favored 'General case' 0 C--N 1.291 -1.969 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 176.344 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -97.87 22.49 9.16 Favored 'General case' 0 CA--C 1.548 0.904 0 CA-C-O 121.993 0.901 . . . . 0.0 109.803 -178.575 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.661 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -77.57 162.72 67.43 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.79 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -48.87 124.35 11.14 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 123.343 2.695 . . . . 0.0 113.559 178.742 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.0 p -97.83 173.73 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.195 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.367 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.62 -1.68 13.84 Favored Glycine 0 CA--C 1.502 -0.77 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.517 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -113.88 117.49 4.17 Favored Glycine 0 N--CA 1.429 -1.793 0 N-CA-C 108.849 -1.701 . . . . 0.0 108.849 174.36 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -126.8 128.14 46.12 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 117.737 0.769 . . . . 0.0 110.344 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 41.2 tp -96.55 119.76 63.39 Favored Pre-proline 0 C--N 1.309 -1.154 0 C-N-CA 123.282 0.633 . . . . 0.0 110.19 -175.652 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.02 165.08 25.09 Favored 'Trans proline' 0 CA--C 1.542 0.912 0 C-N-CA 122.805 2.337 . . . . 0.0 112.728 179.28 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.75 147.31 45.71 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.784 -177.605 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 69.52 5.91 52.34 Favored Glycine 0 N--CA 1.463 0.446 0 N-CA-C 114.247 0.459 . . . . 0.0 114.247 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.76 126.59 29.89 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-O 120.892 0.377 . . . . 0.0 111.417 -177.542 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 25.7 m -92.59 113.09 25.27 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 177.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.9 mm -122.55 138.97 50.89 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -176.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 p -103.47 129.33 55.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 175.125 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.446 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 32.2 p90 -117.71 150.56 38.87 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.591 -177.809 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -108.57 -12.36 14.99 Favored 'General case' 0 C--N 1.316 -0.856 0 O-C-N 123.473 0.483 . . . . 0.0 110.42 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -140.4 136.59 33.24 Favored 'General case' 0 N--CA 1.428 -1.54 0 C-N-CA 120.346 -0.542 . . . . 0.0 111.206 -172.379 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.451 HG23 ' HB3' ' A' ' 49' ' ' GLU . 71.4 t -118.62 127.85 75.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 176.211 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.524 ' HB2' HG22 ' A' ' 44' ' ' THR . 19.6 p -135.46 147.73 49.01 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 120.898 0.38 . . . . 0.0 111.613 -175.252 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.5 mt -109.5 113.81 45.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-O 121.225 0.536 . . . . 0.0 110.546 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.595 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -110.42 122.56 47.99 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 104.761 -2.311 . . . . 0.0 104.761 174.457 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -47.85 114.29 0.88 Allowed 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 121.845 0.831 . . . . 0.0 113.068 -165.293 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 120.58 -25.15 7.38 Favored Glycine 0 N--CA 1.429 -1.826 0 CA-C-N 114.1 -1.409 . . . . 0.0 112.42 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 75.8 m80 -152.05 170.11 20.72 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 15.9 tt -111.62 136.44 47.72 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.179 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 172.453 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.595 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 48.2 m95 -121.96 139.07 54.12 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -173.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.509 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 47.5 pt -100.52 136.02 33.86 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.92 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 175.266 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -105.03 119.46 6.21 Favored Glycine 0 N--CA 1.419 -2.459 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.478 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -136.83 152.83 50.71 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 120.408 -0.517 . . . . 0.0 109.954 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -86.25 127.38 34.75 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 174.116 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.27 163.33 17.79 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 27.7 p90 -54.81 -31.36 59.03 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -176.673 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -76.29 -14.44 60.11 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-O 121.055 0.455 . . . . 0.0 111.046 -179.227 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 108.92 -9.58 34.19 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 121.137 -0.554 . . . . 0.0 113.279 178.595 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -75.84 148.08 38.63 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-O 120.754 0.311 . . . . 0.0 111.226 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ARG . . . . . 0.437 HH11 ' HG2' ' A' ' 106' ' ' ARG . 0.5 OUTLIER -89.41 109.27 20.2 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 177.685 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 52.2 t -107.66 136.92 41.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.199 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -176.23 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.509 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 91.4 m-85 -116.33 126.0 52.91 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.4 t -105.44 131.85 21.39 Favored Pre-proline 0 C--N 1.301 -1.536 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -69.26 -11.4 31.39 Favored 'Trans proline' 0 C--N 1.364 1.375 0 C-N-CA 123.374 2.716 . . . . 0.0 113.794 -177.553 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.277 27.0 m 37.83 -63.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.148 0 N-CA-C 118.286 2.698 . . . . 0.0 118.286 174.579 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.524 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 34.9 ptt180 -153.06 149.79 28.48 Favored 'General case' 0 N--CA 1.429 -1.488 0 C-N-CA 122.872 0.469 . . . . 0.0 110.219 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 19.4 m -67.8 136.76 54.66 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 41.8 t -150.39 139.24 20.88 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -176.324 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 78.3 mm-40 -119.6 161.61 20.36 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 130.22 -171.75 20.45 Favored Glycine 0 N--CA 1.421 -2.363 0 C-N-CA 120.034 -1.079 . . . . 0.0 112.448 174.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.6 m -141.41 138.57 17.69 Favored Pre-proline 0 C--N 1.295 -1.787 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 90.6 Cg_exo -47.73 131.64 20.36 Favored 'Trans proline' 0 CA--C 1.539 0.736 0 C-N-CA 122.945 2.43 . . . . 0.0 112.786 -177.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 89.7 Cg_endo -96.65 7.5 40.89 Favored 'Cis proline' 0 CA--C 1.547 1.155 0 C-N-CA 124.492 -1.045 . . . . 0.0 113.884 1.19 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 44.4 t30 -76.27 102.39 5.83 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.636 0.732 . . . . 0.0 110.911 -175.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 -104.82 112.6 25.77 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 114.748 -1.115 . . . . 0.0 111.602 -178.372 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 59.3 mt -101.46 100.84 14.92 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.119 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -85.22 140.39 7.57 Favored 'Trans proline' 0 N--CA 1.452 -0.944 0 C-N-CA 122.87 2.38 . . . . 0.0 113.647 -177.707 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -110.66 -117.62 3.81 Favored Glycine 0 N--CA 1.436 -1.35 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 177.663 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 81.6 t -78.24 115.46 20.34 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 120.84 0.352 . . . . 0.0 110.861 -179.382 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.524 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.37 132.91 38.49 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.788 177.129 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.3 m-90 -102.35 8.07 40.36 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-O 121.488 0.661 . . . . 0.0 110.401 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.09 169.51 36.7 Favored Glycine 0 N--CA 1.431 -1.696 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 64.3 t -111.72 134.86 52.78 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 C-N-CA 122.895 0.478 . . . . 0.0 110.189 -175.628 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -97.68 132.62 43.16 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 178.124 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.468 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 48.7 tptt . . . . . 0 N--CA 1.413 -2.315 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -179.679 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 34.5 m95 . . . . . 0 N--CA 1.432 -1.333 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -113.35 150.56 32.43 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.417 ' HG2' ' O ' ' A' ' 40' ' ' ASN . 38.2 ttpt -110.15 136.2 49.75 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 118.376 -1.33 . . . . 0.0 111.528 -178.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.417 ' O ' ' HG2' ' A' ' 39' ' ' LYS . 45.9 t-20 -94.35 161.67 14.14 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 105.955 -1.869 . . . . 0.0 105.955 175.079 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 34.7 mt-30 -67.28 -13.31 61.87 Favored 'General case' 0 C--O 1.213 -0.836 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -173.784 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 47.9 m-85 -76.3 -1.24 25.67 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.352 0.596 . . . . 0.0 110.214 177.77 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.39 24.26 59.3 Favored Glycine 0 CA--C 1.494 -1.266 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.526 HG22 ' HB2' ' A' ' 89' ' ' CYS . 13.5 m -105.37 124.66 49.92 Favored 'General case' 0 N--CA 1.414 -2.231 0 CA-C-N 114.662 -0.769 . . . . 0.0 109.608 -178.503 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.551 ' CG ' ' HG3' ' A' ' 118' ' ' PRO . 84.1 m95 -93.3 131.11 38.74 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.18 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.41 ' HB3' ' HB3' ' A' ' 89' ' ' CYS . 54.2 p90 -132.75 151.85 51.89 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -175.196 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.434 ' HG3' ' HB ' ' A' ' 88' ' ' VAL . 16.8 ptmt -129.02 132.47 24.39 Favored Pre-proline 0 C--N 1.303 -1.443 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.664 175.637 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_exo -72.78 122.05 7.87 Favored 'Trans proline' 0 C--O 1.244 0.79 0 C-N-CA 121.835 1.69 . . . . 0.0 111.001 175.648 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -162.25 131.49 4.38 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 177.696 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.419 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 23.8 t-20 -110.03 123.46 49.71 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 120.699 -0.4 . . . . 0.0 110.182 -177.657 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -160.07 177.2 10.95 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -108.22 152.01 25.16 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 121.022 0.439 . . . . 0.0 112.126 -178.752 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.443 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 91.4 t80 -122.55 123.66 41.73 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 176.509 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 43.7 t -103.17 104.88 17.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 29.1 t30 -76.98 123.52 26.44 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 175.3 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -147.1 24.32 1.59 Allowed Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 118.973 -1.584 . . . . 0.0 113.308 -177.138 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -113.77 -50.71 2.82 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.256 179.088 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -158.22 164.96 19.65 Favored Pre-proline 0 C--N 1.315 -0.921 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.462 ' HB3' HD21 ' A' ' 76' ' ' ASN . 18.0 Cg_exo -69.27 125.87 12.93 Favored 'Trans proline' 0 C--O 1.254 1.301 0 N-CA-C 108.121 -1.531 . . . . 0.0 108.121 170.164 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 41.4 mt -108.12 130.17 61.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 110.127 -0.323 . . . . 0.0 110.127 -173.267 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 39.7 t -69.16 122.16 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.817 0 CA-C-O 121.968 0.889 . . . . 0.0 110.308 176.204 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -96.16 155.9 16.56 Favored 'General case' 0 N--CA 1.405 -2.689 0 CA-C-N 114.181 -1.372 . . . . 0.0 108.651 -176.242 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 15.6 mmt180 -112.24 141.64 45.7 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -178.272 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.2 mt -109.39 120.29 60.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 113.11 0.782 . . . . 0.0 113.11 -173.319 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.67 -22.51 27.49 Favored Glycine 0 C--O 1.236 0.249 0 N-CA-C 116.343 1.297 . . . . 0.0 116.343 170.549 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.7 m -155.01 140.26 12.28 Favored Pre-proline 0 C--N 1.307 -1.257 0 CA-C-N 118.502 1.151 . . . . 0.0 111.292 -178.27 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -89.93 119.96 0.86 Allowed 'Trans proline' 0 N--CA 1.437 -1.844 0 C-N-CA 121.716 1.611 . . . . 0.0 110.778 172.044 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -162.5 162.76 27.58 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 68.3 mt -80.1 -13.99 58.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 121.748 0.785 . . . . 0.0 109.434 177.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.4 p-10 -116.19 19.52 14.85 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.606 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.83 146.1 95.33 Favored Pre-proline 0 C--O 1.243 0.757 0 CA-C-N 115.386 -0.825 . . . . 0.0 112.201 -176.076 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -48.76 131.66 24.92 Favored 'Trans proline' 0 C--O 1.249 1.035 0 C-N-CA 124.104 3.203 . . . . 0.0 113.916 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.1 m -97.41 174.59 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 CA-C-N 114.552 -1.204 . . . . 0.0 110.483 -178.207 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.92 28.12 2.12 Favored Glycine 0 C--N 1.305 -1.192 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.021 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.81 132.67 4.1 Favored Glycine 0 N--CA 1.427 -1.924 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 176.125 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.462 HD21 ' HB3' ' A' ' 59' ' ' PRO . 8.3 t30 -128.35 125.77 39.38 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 117.597 0.699 . . . . 0.0 110.918 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 65.3 tp -88.26 111.69 44.86 Favored Pre-proline 0 N--CA 1.426 -1.634 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -63.43 152.4 80.26 Favored 'Trans proline' 0 C--O 1.251 1.146 0 C-N-CA 122.147 1.898 . . . . 0.0 112.553 -179.288 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.41 138.16 41.5 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.292 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.82 3.13 62.45 Favored Glycine 0 N--CA 1.441 -0.997 0 N-CA-C 111.434 -0.666 . . . . 0.0 111.434 -178.6 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.49 139.07 31.15 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-O 121.171 0.51 . . . . 0.0 111.188 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 39.0 m -113.53 113.55 25.27 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 177.627 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.1 mm -110.18 139.87 31.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -176.5 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.0 p -95.31 127.13 47.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 176.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.452 ' HA ' ' HB3' ' A' ' 99' ' ' TYR . 46.3 p90 -110.11 154.44 23.28 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.472 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -116.35 -9.09 11.57 Favored 'General case' 0 C--O 1.25 1.089 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.36 -177.805 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -144.84 131.69 20.18 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.876 -174.114 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.434 ' HB ' ' HG3' ' A' ' 47' ' ' LYS . 32.1 t -109.61 124.56 66.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 105.832 -1.914 . . . . 0.0 105.832 175.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.526 ' HB2' HG22 ' A' ' 44' ' ' THR . 24.6 p -137.5 148.49 46.06 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.871 -0.732 . . . . 0.0 112.624 -175.293 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 68.8 mt -111.4 124.15 67.9 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-O 121.061 0.458 . . . . 0.0 110.623 179.389 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.501 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -125.14 112.98 17.11 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 103.827 -2.657 . . . . 0.0 103.827 171.446 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.96 106.12 0.1 Allowed 'General case' 0 N--CA 1.479 0.983 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -164.737 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 141.63 -33.03 2.0 Favored Glycine 0 N--CA 1.439 -1.149 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -177.736 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 56.3 m80 -152.02 163.37 39.44 Favored 'General case' 0 CA--C 1.505 -0.786 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.278 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.3 tt -106.65 135.07 46.38 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 171.39 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.501 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 58.7 m95 -118.12 140.31 49.96 Favored 'General case' 0 C--N 1.28 -2.419 0 O-C-N 122.209 -0.307 . . . . 0.0 110.475 -171.118 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 48.1 pt -100.6 131.53 48.0 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 174.616 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.34 121.52 7.21 Favored Glycine 0 N--CA 1.417 -2.599 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' TYR . . . . . 0.452 ' HB3' ' HA ' ' A' ' 85' ' ' TYR . 39.0 p90 -132.17 146.58 52.12 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-O 121.466 0.651 . . . . 0.0 111.122 178.326 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -99.74 119.97 38.98 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.82 -1.082 . . . . 0.0 108.455 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.9 176.31 7.4 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.395 -177.183 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -66.0 -21.34 66.39 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.464 0.649 . . . . 0.0 112.019 -179.066 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -80.04 -14.52 58.48 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.985 177.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 84.62 5.59 86.53 Favored Glycine 0 C--O 1.24 0.475 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -174.48 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -80.79 132.98 35.56 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 27.2 tpt180 -88.48 104.89 17.23 Favored 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -178.082 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 15.5 t -107.12 142.75 19.13 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -175.328 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -125.61 127.1 45.81 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.088 0.471 . . . . 0.0 111.75 -178.184 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 52.8 t -107.51 135.4 19.73 Favored Pre-proline 0 C--N 1.307 -1.278 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.206 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -72.21 -12.63 27.93 Favored 'Trans proline' 0 C--N 1.36 1.156 0 C-N-CA 123.19 2.593 . . . . 0.0 114.503 -176.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.282 32.8 m 43.77 -56.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.516 2.827 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 175.548 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.527 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 38.2 ptt180 -159.98 151.05 19.29 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.03 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.2 t -73.42 143.14 46.86 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.659 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.9 t -155.26 136.98 14.35 Favored 'General case' 0 N--CA 1.421 -1.919 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -177.185 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -122.52 157.1 32.78 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 133.91 -163.83 24.47 Favored Glycine 0 N--CA 1.429 -1.815 0 C-N-CA 120.048 -1.072 . . . . 0.0 112.018 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 18.5 m -142.22 149.92 53.52 Favored Pre-proline 0 C--N 1.307 -1.272 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.551 ' HG3' ' CG ' ' A' ' 45' ' ' TRP . 33.3 Cg_endo -60.2 131.21 37.68 Favored 'Trans proline' 0 CA--C 1.541 0.843 0 C-N-CA 122.388 2.059 . . . . 0.0 112.412 -177.007 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 11.1 Cg_endo -99.59 8.81 26.2 Favored 'Cis proline' 0 C--O 1.251 1.154 0 C-N-CA 125.28 -0.717 . . . . 0.0 113.351 -0.454 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.1 t30 -75.04 100.63 4.24 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 122.106 0.955 . . . . 0.0 109.896 -177.324 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 48.3 p-80 -105.72 119.78 40.01 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 114.416 -1.266 . . . . 0.0 111.578 -177.381 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 62.1 mt -100.83 101.61 16.42 Favored Pre-proline 0 C--N 1.305 -1.35 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.565 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -85.06 130.45 4.08 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.732 2.288 . . . . 0.0 113.109 -177.71 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -103.87 -131.12 7.11 Favored Glycine 0 N--CA 1.433 -1.564 0 N-CA-C 111.199 -0.761 . . . . 0.0 111.199 177.752 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 48.8 t -68.05 120.03 14.77 Favored 'Isoleucine or valine' 0 C--O 1.252 1.195 0 C-N-CA 123.005 0.522 . . . . 0.0 111.003 -178.769 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.527 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -94.22 148.75 21.89 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.685 177.658 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.4 m-90 -116.2 8.28 14.32 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.399 0.619 . . . . 0.0 110.033 177.332 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.443 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -167.09 171.86 41.99 Favored Glycine 0 N--CA 1.431 -1.66 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 60.2 t -112.51 135.25 52.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 -177.457 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -85.8 121.99 29.23 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 176.148 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.284 -2.265 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 -175.599 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' TRP . . . . . 0.428 ' CZ3' HG13 ' A' ' 90' ' ' ILE . 30.4 m95 . . . . . 0 N--CA 1.442 -0.849 0 CA-C-O 120.717 0.294 . . . . 0.0 110.712 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -114.19 152.4 31.27 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 175.224 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -102.76 121.24 42.06 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.616 179.603 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.448 ' HB3' ' CE1' ' A' ' 46' ' ' TYR . 37.2 p30 -85.42 -178.29 6.67 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.774 -176.808 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -66.73 -16.67 64.4 Favored 'General case' 0 C--N 1.323 -0.575 0 C-N-CA 123.674 0.789 . . . . 0.0 113.037 -178.346 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 67.8 m-85 -93.77 2.69 56.18 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.449 0.643 . . . . 0.0 110.096 -177.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.8 25.56 66.91 Favored Glycine 0 N--CA 1.442 -0.942 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.457 HG22 ' HB2' ' A' ' 89' ' ' CYS . 12.8 m -105.26 141.21 37.19 Favored 'General case' 0 N--CA 1.425 -1.71 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -92.78 120.56 33.28 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 174.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.448 ' CE1' ' HB3' ' A' ' 40' ' ' ASN . 23.9 p90 -128.02 149.68 50.26 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 120.623 0.249 . . . . 0.0 110.611 -175.599 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.423 ' HE2' ' CZ2' ' A' ' 37' ' ' TRP . 52.2 pttt -139.33 140.4 25.75 Favored Pre-proline 0 C--N 1.295 -1.797 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 173.737 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_exo -71.23 127.23 13.18 Favored 'Trans proline' 0 C--O 1.255 1.36 0 C-N-CA 122.057 1.838 . . . . 0.0 110.314 174.691 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -164.78 120.85 1.46 Allowed 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -179.116 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.495 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 19.8 t-20 -103.02 109.54 21.12 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 120.962 0.41 . . . . 0.0 110.883 -174.647 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.452 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -145.28 172.35 13.27 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 14.1 m -107.68 134.76 50.19 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.939 0.4 . . . . 0.0 111.412 -173.486 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 72.9 t80 -112.36 122.46 47.77 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.567 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 39.0 t -108.23 103.77 16.01 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.866 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 178.645 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 30.2 t30 -76.4 131.61 39.21 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -144.68 2.52 1.25 Allowed Glycine 0 N--CA 1.432 -1.623 0 C-N-CA 119.307 -1.425 . . . . 0.0 113.546 -179.356 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -93.74 -52.06 4.63 Favored 'General case' 0 C--N 1.318 -0.789 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.826 -175.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 17.1 pt20 -159.25 171.64 7.12 Favored Pre-proline 0 C--N 1.314 -0.96 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -173.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.45 ' HB3' HD21 ' A' ' 76' ' ' ASN . 17.1 Cg_exo -69.0 122.11 8.99 Favored 'Trans proline' 0 N--CA 1.44 -1.655 0 N-CA-C 107.604 -1.729 . . . . 0.0 107.604 166.212 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 58.7 mt -107.84 123.32 63.19 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -175.337 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 25.9 m -79.93 139.42 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.366 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 175.32 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.5 p -118.36 178.94 4.26 Favored 'General case' 0 C--N 1.272 -2.781 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.918 -172.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.424 ' HG3' ' O ' ' A' ' 68' ' ' PHE . 82.0 mmt-85 -115.48 136.64 52.88 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 176.721 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 63.8 mt -97.24 121.29 47.61 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.64 -174.08 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 77.56 -16.87 5.89 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 116.034 1.173 . . . . 0.0 116.034 172.349 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.2 m -151.82 137.77 11.36 Favored Pre-proline 0 C--N 1.305 -1.336 0 CA-C-N 118.24 1.02 . . . . 0.0 110.204 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -89.93 119.19 0.8 Allowed 'Trans proline' 0 N--CA 1.434 -1.975 0 C-N-CA 121.163 1.242 . . . . 0.0 110.811 173.405 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.564 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 92.9 m-85 -169.55 168.73 9.14 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 178.6 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.96 -31.77 27.45 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 171.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -95.27 17.01 15.16 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.179 -0.918 . . . . 0.0 112.204 -178.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -79.0 162.75 63.43 Favored Pre-proline 0 C--N 1.311 -1.095 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -54.69 122.14 11.07 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 122.343 2.029 . . . . 0.0 112.438 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.413 HG22 ' H ' ' A' ' 74' ' ' GLY . 13.8 p -104.1 172.94 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.944 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.413 ' H ' HG22 ' A' ' 73' ' ' VAL . . . 120.33 -13.32 10.29 Favored Glycine 0 CA--C 1.502 -0.745 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 -179.067 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.46 108.83 3.08 Favored Glycine 0 N--CA 1.432 -1.597 0 N-CA-C 108.338 -1.905 . . . . 0.0 108.338 172.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.45 HD21 ' HB3' ' A' ' 59' ' ' PRO . 7.6 t30 -111.5 123.43 50.21 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 117.697 0.748 . . . . 0.0 110.339 -176.511 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 40.6 tp -98.83 114.27 65.27 Favored Pre-proline 0 C--N 1.302 -1.496 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -68.43 161.64 44.07 Favored 'Trans proline' 0 C--O 1.249 1.058 0 C-N-CA 122.236 1.957 . . . . 0.0 112.642 -178.409 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.41 139.42 42.32 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.83 5.82 58.41 Favored Glycine 0 N--CA 1.436 -1.352 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -85.86 128.84 34.92 Favored 'General case' 0 N--CA 1.432 -1.357 0 CA-C-O 121.033 0.444 . . . . 0.0 111.233 -178.754 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 37.0 m -103.91 110.25 22.31 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.1 mm -126.32 130.74 71.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 -175.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.9 p -88.69 133.93 29.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 176.246 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.495 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 40.1 p90 -109.98 151.17 27.47 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -124.67 -0.4 8.05 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 122.075 0.941 . . . . 0.0 110.391 -174.091 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -146.34 133.0 19.88 Favored 'General case' 0 N--CA 1.428 -1.526 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 -176.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 51.4 t -119.34 128.14 75.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.457 ' HB2' HG22 ' A' ' 44' ' ' THR . 23.5 p -141.51 145.46 35.21 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -176.314 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.428 HG13 ' CZ3' ' A' ' 37' ' ' TRP . 58.4 mt -107.16 117.04 52.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 175.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.507 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -118.12 117.59 29.59 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 103.327 -2.842 . . . . 0.0 103.327 171.211 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.47 110.44 0.34 Allowed 'General case' 0 C--N 1.315 -0.91 0 O-C-N 124.822 1.326 . . . . 0.0 112.876 -167.76 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 143.37 -42.86 1.05 Allowed Glycine 0 N--CA 1.42 -2.394 0 CA-C-N 113.582 -1.645 . . . . 0.0 109.345 -176.512 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' HIS . . . . . 0.439 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 73.7 m80 -153.4 165.93 34.26 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -179.256 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.5 tt -99.98 129.32 50.82 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 105.223 -2.14 . . . . 0.0 105.223 171.146 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.507 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 57.0 m95 -112.5 134.53 53.98 Favored 'General case' 0 C--N 1.274 -2.682 0 CA-C-O 120.997 0.427 . . . . 0.0 110.039 -172.029 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.547 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 44.8 pt -100.44 128.82 52.08 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 175.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -94.22 114.78 4.86 Favored Glycine 0 N--CA 1.416 -2.695 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 178.479 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 54.5 p90 -127.2 167.67 15.74 Favored 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 -178.616 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.1 m-80 -108.16 129.49 55.17 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.54 176.46 9.77 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.065 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -55.95 -27.16 51.2 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.961 0.905 . . . . 0.0 112.152 -178.555 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 32.9 p-10 -104.31 13.11 32.72 Favored 'General case' 0 C--N 1.322 -0.628 0 C-N-CA 123.241 0.616 . . . . 0.0 111.247 -175.56 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 77.88 21.78 70.54 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 121.089 -0.577 . . . . 0.0 113.28 177.417 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 50.2 t-20 -85.84 132.51 34.09 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 178.723 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -85.76 98.35 10.68 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 21.6 t -108.95 147.01 13.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 -175.322 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.547 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 94.7 m-85 -117.19 121.62 41.73 Favored 'General case' 0 C--N 1.314 -0.964 0 C-N-CA 122.494 0.317 . . . . 0.0 110.758 -178.072 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' CYS . . . . . 0.456 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 53.7 t -101.03 135.1 20.02 Favored Pre-proline 0 C--N 1.315 -0.902 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.05 -16.11 36.22 Favored 'Trans proline' 0 C--N 1.361 1.205 0 C-N-CA 123.322 2.681 . . . . 0.0 114.863 -176.583 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.308 33.0 m 42.21 -55.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.519 3.0 0 N-CA-C 118.837 2.903 . . . . 0.0 118.837 176.322 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.464 ' CZ ' ' HB2' ' A' ' 126' ' ' ALA . 8.2 ptp180 -153.97 148.98 26.76 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 123.868 0.867 . . . . 0.0 108.704 175.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.439 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 24.3 m -66.33 135.33 54.23 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 177.476 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 97.5 m -150.78 124.94 9.36 Favored 'General case' 0 CA--C 1.511 -0.524 0 CA-C-O 121.431 0.634 . . . . 0.0 112.467 -178.784 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -110.44 151.57 27.35 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 174.455 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.37 -171.25 22.64 Favored Glycine 0 C--N 1.3 -1.462 0 C-N-CA 118.251 -1.928 . . . . 0.0 114.092 177.17 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 64.9 t -137.44 127.67 15.69 Favored Pre-proline 0 C--N 1.309 -1.191 0 N-CA-C 105.947 -1.871 . . . . 0.0 105.947 -178.752 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 99.0 Cg_exo -46.36 137.18 14.72 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.371 2.714 . . . . 0.0 112.804 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 76.2 Cg_endo -86.61 -15.54 29.39 Favored 'Cis proline' 0 CA--C 1.542 0.877 0 C-N-CA 123.228 -1.572 . . . . 0.0 113.896 1.846 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -75.85 100.16 4.69 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 122.136 0.969 . . . . 0.0 111.645 -173.021 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 54.7 p-80 -106.34 138.53 42.35 Favored 'General case' 0 C--N 1.296 -1.717 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.808 176.109 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.0 mm -90.22 108.83 29.09 Favored Pre-proline 0 C--N 1.3 -1.565 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 176.33 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -84.66 123.91 2.98 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.457 2.105 . . . . 0.0 113.587 -176.761 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -95.25 -134.62 7.79 Favored Glycine 0 N--CA 1.436 -1.33 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 175.74 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 69.4 t -81.74 126.69 39.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 C-N-CA 122.982 0.513 . . . . 0.0 110.475 -179.418 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.464 ' HB2' ' CZ ' ' A' ' 112' ' ' ARG . . . -93.87 145.74 24.4 Favored 'General case' 0 CA--C 1.507 -0.689 0 O-C-N 123.75 0.657 . . . . 0.0 109.294 174.797 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.0 m-90 -110.33 18.3 20.0 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.344 0.592 . . . . 0.0 111.278 179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -166.57 -173.12 34.62 Favored Glycine 0 N--CA 1.432 -1.579 0 C-N-CA 120.045 -1.074 . . . . 0.0 112.173 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 48.7 t -110.98 131.11 63.1 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.674 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -103.54 120.44 40.87 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.299 -1.61 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 71.6 m95 . . . . . 0 CA--C 1.513 -0.476 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 53.2 tptt -120.31 153.9 35.76 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -95.94 125.44 40.49 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 118.917 -1.113 . . . . 0.0 110.458 -177.349 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.455 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 53.0 t30 -77.2 166.44 23.21 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.116 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 66.7 mm-40 -71.2 4.72 2.6 Favored 'General case' 0 C--N 1.312 -1.044 0 C-N-CA 123.548 0.739 . . . . 0.0 112.488 -174.214 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -104.5 -0.42 27.88 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.249 0.547 . . . . 0.0 110.493 175.574 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 91.51 -2.8 78.16 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.794 178.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.424 HG22 ' HB2' ' A' ' 89' ' ' CYS . 5.3 m -88.72 139.57 30.33 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 70.3 m95 -92.98 123.95 36.6 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.455 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 11.8 p90 -133.0 159.18 40.77 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.404 -174.86 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -147.96 142.29 16.42 Favored Pre-proline 0 C--N 1.297 -1.712 0 N-CA-C 106.031 -1.841 . . . . 0.0 106.031 172.114 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -72.4 134.38 22.54 Favored 'Trans proline' 0 N--CA 1.45 -1.073 0 C-N-CA 121.397 1.398 . . . . 0.0 110.475 174.185 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -150.94 121.4 7.38 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -101.84 106.14 17.08 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.55 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.78 176.56 11.66 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.477 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 24.0 m -113.58 151.03 32.21 Favored 'General case' 0 C--N 1.292 -1.904 0 CA-C-O 121.002 0.429 . . . . 0.0 111.163 -174.511 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.465 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 84.0 t80 -129.21 124.83 35.54 Favored 'General case' 0 N--CA 1.428 -1.526 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 174.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 33.6 t -108.54 110.04 30.55 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.11 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 62.5 t30 -77.07 130.4 37.36 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 177.839 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -122.58 -64.0 0.22 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 118.52 -1.8 . . . . 0.0 115.901 -173.135 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -68.71 -56.33 8.46 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 114.05 1.13 . . . . 0.0 114.05 -171.507 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 20.2 pt20 -134.39 157.88 76.45 Favored Pre-proline 0 C--N 1.292 -1.913 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.212 -170.245 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -68.5 138.28 41.7 Favored 'Trans proline' 0 N--CA 1.445 -1.325 0 C-N-CA 121.76 1.64 . . . . 0.0 109.071 170.182 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.7 mt -113.39 133.38 59.48 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -177.385 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 9.5 p -84.3 128.05 39.26 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.083 0 CA-C-O 121.42 0.629 . . . . 0.0 109.76 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' THR . . . . . 0.441 HG22 ' HA ' ' A' ' 109' ' ' CYS . 74.1 p -109.98 178.94 4.25 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.099 -173.488 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.57 ' HG2' ' CZ3' ' A' ' 96' ' ' TRP . 1.6 mmp_? -112.15 154.77 25.0 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 174.375 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 54.5 mt -119.26 126.1 75.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 120.759 -0.376 . . . . 0.0 111.045 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 85.08 -22.75 9.04 Favored Glycine 0 CA--C 1.519 0.337 0 N-CA-C 115.983 1.153 . . . . 0.0 115.983 171.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.1 m -153.99 142.65 14.49 Favored Pre-proline 0 C--N 1.309 -1.192 0 CA-C-N 118.276 1.038 . . . . 0.0 109.933 -178.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -90.63 119.14 0.67 Allowed 'Trans proline' 0 N--CA 1.443 -1.442 0 C-N-CA 121.806 1.67 . . . . 0.0 111.865 175.125 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.535 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 91.9 m-85 -168.9 168.94 10.06 Favored 'General case' 0 CA--C 1.49 -1.348 0 N-CA-C 104.584 -2.376 . . . . 0.0 104.584 179.216 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 85.2 mt -79.53 -37.86 35.57 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 171.569 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -88.84 12.09 16.12 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 114.32 -1.309 . . . . 0.0 112.101 -176.644 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.535 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.99 162.65 73.52 Favored Pre-proline 0 C--N 1.314 -0.966 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.561 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -46.94 123.18 7.03 Favored 'Trans proline' 0 C--N 1.367 1.518 0 C-N-CA 123.371 2.714 . . . . 0.0 113.797 -178.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.8 t -97.37 172.27 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.35 -30.03 5.94 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.84 126.98 10.02 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 178.011 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 -128.47 130.5 47.64 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 117.118 0.459 . . . . 0.0 110.505 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 64.0 tp -97.63 113.55 63.67 Favored Pre-proline 0 C--N 1.3 -1.561 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.508 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -66.76 155.65 69.54 Favored 'Trans proline' 0 C--O 1.247 0.947 0 C-N-CA 122.505 2.136 . . . . 0.0 112.421 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.96 142.61 41.92 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.899 -0.592 . . . . 0.0 109.695 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.35 -4.57 70.29 Favored Glycine 0 N--CA 1.447 -0.602 0 N-CA-C 111.774 -0.531 . . . . 0.0 111.774 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -82.47 126.75 32.59 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 121.215 0.531 . . . . 0.0 111.528 -177.085 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 24.0 m -95.09 114.26 26.05 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 176.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.9 mm -119.02 134.0 64.06 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 -176.123 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.4 p -99.26 135.43 34.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.597 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.55 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 16.5 p90 -109.38 160.61 16.03 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.943 -0.703 . . . . 0.0 112.164 -178.272 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -124.8 -37.23 2.49 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.878 -1.056 . . . . 0.0 111.105 -176.367 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -118.26 131.92 56.33 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -175.453 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.4 t -121.43 125.27 73.42 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 176.836 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.534 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 13.8 p -134.09 140.45 46.63 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -175.538 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 71.8 mt -101.2 115.45 42.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 109.128 -0.694 . . . . 0.0 109.128 178.459 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.482 ' HG2' ' HA ' ' A' ' 68' ' ' PHE . 6.2 tp-100 -118.59 144.68 45.95 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 105.493 -2.04 . . . . 0.0 105.493 175.492 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -57.0 104.23 0.15 Allowed 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -175.085 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.58 -38.05 2.07 Favored Glycine 0 N--CA 1.439 -1.15 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.688 177.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 46.2 m80 -152.99 153.23 32.5 Favored 'General case' 0 N--CA 1.478 0.932 0 O-C-N 122.118 -0.636 . . . . 0.0 110.06 -176.549 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 13.6 tt -97.16 117.75 42.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.57 ' CZ3' ' HG2' ' A' ' 63' ' ' ARG . 65.2 m95 -100.61 134.11 44.05 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-O 120.922 0.391 . . . . 0.0 110.86 -171.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.5 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.6 pt -100.5 125.35 54.32 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.869 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 174.588 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -99.06 125.72 8.66 Favored Glycine 0 N--CA 1.414 -2.805 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 38.5 p90 -138.58 172.72 12.46 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-O 120.81 0.338 . . . . 0.0 110.524 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.442 ' HA ' ' O ' ' A' ' 105' ' ' ASN . 1.7 p-10 -115.5 120.04 38.18 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.687 -178.471 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.55 ' HB3' ' HB2' ' A' ' 105' ' ' ASN . . . -90.46 -174.7 4.22 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.447 -179.754 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 45.1 p90 -45.84 -32.25 2.51 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 116.246 1.943 . . . . 0.0 116.246 -176.353 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -108.37 15.79 23.68 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.034 0.921 . . . . 0.0 109.899 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 81.05 22.28 61.4 Favored Glycine 0 C--N 1.315 -0.621 0 N-CA-C 110.214 -1.155 . . . . 0.0 110.214 -177.738 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.55 ' HB2' ' HB3' ' A' ' 101' ' ' ALA . 8.9 m120 -67.78 121.1 15.24 Favored 'General case' 0 CA--C 1.494 -1.193 0 CA-C-N 114.732 -0.734 . . . . 0.0 109.141 -178.277 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 21.2 tpt180 -86.16 95.75 9.68 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 178.435 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.9 t -102.95 142.23 17.33 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.3 -174.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.5 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 86.8 m-85 -118.96 116.19 25.94 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 123.642 0.589 . . . . 0.0 110.163 -179.277 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' CYS . . . . . 0.441 ' HA ' HG22 ' A' ' 62' ' ' THR . 46.3 t -99.94 133.89 21.33 Favored Pre-proline 0 C--N 1.304 -1.376 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -69.7 -23.57 30.9 Favored 'Trans proline' 0 C--N 1.358 1.027 0 C-N-CA 123.227 2.618 . . . . 0.0 113.679 -176.35 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.291 30.8 m 48.95 -53.56 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.164 0 N-CA-C 117.972 2.582 . . . . 0.0 117.972 177.551 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.417 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 21.0 ptt180 -159.22 150.59 20.22 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 123.782 0.833 . . . . 0.0 108.837 -178.513 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 71.2 m -69.74 137.82 52.29 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 175.329 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 46.6 t -153.91 129.16 9.73 Favored 'General case' 0 N--CA 1.41 -2.473 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -177.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 9.1 tp60 -96.72 146.0 25.28 Favored 'General case' 0 N--CA 1.408 -2.53 0 N-CA-C 103.285 -2.857 . . . . 0.0 103.285 172.288 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -167.07 142.12 7.36 Favored Glycine 0 N--CA 1.406 -3.31 0 C-N-CA 116.66 -2.686 . . . . 0.0 114.994 -177.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 6.2 m -131.59 97.47 19.22 Favored Pre-proline 0 C--N 1.279 -2.457 0 N-CA-C 104.501 -2.407 . . . . 0.0 104.501 171.052 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -48.31 139.68 21.6 Favored 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 123.456 2.771 . . . . 0.0 113.803 -170.012 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -85.97 6.74 63.45 Favored 'Cis proline' 0 CA--C 1.558 1.724 0 C-N-CA 124.288 -1.13 . . . . 0.0 114.051 0.071 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -70.46 102.64 2.25 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-O 121.541 0.686 . . . . 0.0 110.977 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 36.6 p-80 -105.3 117.25 33.53 Favored 'General case' 0 C--N 1.296 -1.717 0 CA-C-N 114.832 -1.077 . . . . 0.0 111.49 -178.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 53.1 mt -110.18 99.34 39.35 Favored Pre-proline 0 C--N 1.318 -0.782 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.53 141.73 8.98 Favored 'Trans proline' 0 C--O 1.247 0.931 0 C-N-CA 122.549 2.166 . . . . 0.0 112.683 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -106.84 -114.55 3.91 Favored Glycine 0 N--CA 1.433 -1.515 0 N-CA-C 110.616 -0.994 . . . . 0.0 110.616 176.585 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 85.8 t -88.97 127.17 41.88 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.065 0 CA-C-N 116.734 0.267 . . . . 0.0 110.43 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.417 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -94.16 143.05 26.72 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.306 177.208 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.1 m-90 -113.81 27.78 9.27 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 120.861 0.363 . . . . 0.0 110.551 179.118 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.465 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -169.92 -179.11 41.38 Favored Glycine 0 N--CA 1.429 -1.814 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 37.7 t -111.0 130.31 64.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -178.107 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -98.88 145.76 26.67 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-O 121.004 0.431 . . . . 0.0 110.792 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.477 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 88.1 tttt . . . . . 0 C--N 1.291 -1.967 0 N-CA-C 107.544 -1.28 . . . . 0.0 107.544 178.054 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 98.8 m95 . . . . . 0 N--CA 1.448 -0.562 0 CA-C-O 121.253 0.549 . . . . 0.0 109.962 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 7.1 tmtt? -120.56 139.15 53.36 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 105.461 -2.052 . . . . 0.0 105.461 -178.771 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -86.49 136.61 33.02 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.818 -0.753 . . . . 0.0 111.0 -175.392 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.402 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 45.3 t-20 -93.22 159.01 15.47 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 105.944 -1.873 . . . . 0.0 105.944 175.542 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -60.54 -22.28 63.46 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 123.467 0.707 . . . . 0.0 112.383 -174.614 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -79.13 2.34 21.2 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.865 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.11 10.72 80.05 Favored Glycine 0 CA--C 1.509 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.2 178.411 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.488 HG21 ' HG2' ' A' ' 67' ' ' PRO . 19.9 m -97.65 143.69 28.06 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 75.9 m95 -101.44 129.93 47.57 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.216 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.402 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 29.7 p90 -134.25 156.62 48.08 Favored 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.429 -177.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 49.2 pttt -135.96 132.23 19.24 Favored Pre-proline 0 C--N 1.293 -1.865 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 174.543 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -72.82 120.6 6.75 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 121.098 1.199 . . . . 0.0 109.007 174.126 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -154.45 130.14 10.01 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 -176.702 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -97.27 106.39 18.7 Favored 'General case' 0 C--N 1.307 -1.262 0 O-C-N 123.374 0.422 . . . . 0.0 109.963 -176.026 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.42 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -148.66 169.52 20.19 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 7.8 m -111.5 149.18 31.71 Favored 'General case' 0 C--N 1.298 -1.674 0 CA-C-O 120.981 0.42 . . . . 0.0 111.522 -173.172 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.4 t80 -130.58 131.36 44.96 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 174.291 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.424 HG22 HG23 ' A' ' 82' ' ' THR . 36.2 t -117.66 117.19 54.23 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 177.631 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -69.89 140.34 53.12 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -102.72 -73.97 1.0 Allowed Glycine 0 N--CA 1.432 -1.63 0 C-N-CA 120.306 -0.95 . . . . 0.0 114.75 -172.798 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -91.79 -69.13 0.75 Allowed 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 116.011 1.856 . . . . 0.0 116.011 -170.427 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -109.21 151.49 42.05 Favored Pre-proline 0 C--N 1.292 -1.914 0 O-C-N 121.828 -0.545 . . . . 0.0 111.192 -173.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.432 ' HA ' ' O ' ' A' ' 77' ' ' LEU . 50.0 Cg_exo -57.28 131.11 42.93 Favored 'Trans proline' 0 C--O 1.249 1.025 0 C-N-CA 122.171 1.914 . . . . 0.0 109.437 170.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -107.85 118.83 56.32 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -176.529 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 35.0 m -74.41 143.1 13.87 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.194 175.24 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 59.2 p -118.42 173.61 6.73 Favored 'General case' 0 C--N 1.277 -2.56 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.141 -173.724 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.466 ' HG3' ' O ' ' A' ' 68' ' ' PHE . 2.2 mmp_? -116.21 148.64 40.2 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.157 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 66.4 mt -112.21 131.26 64.15 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-O 120.62 0.248 . . . . 0.0 111.122 -177.303 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 85.98 -23.18 9.68 Favored Glycine 0 C--N 1.318 -0.423 0 N-CA-C 115.646 1.019 . . . . 0.0 115.646 171.267 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.0 m -157.87 142.23 11.67 Favored Pre-proline 0 C--N 1.296 -1.719 0 CA-C-N 117.51 0.655 . . . . 0.0 109.271 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.488 ' HG2' HG21 ' A' ' 44' ' ' THR . 60.9 Cg_endo -89.23 118.51 0.87 Allowed 'Trans proline' 0 N--CA 1.429 -2.306 0 C-N-CA 120.497 0.798 . . . . 0.0 110.089 172.276 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.489 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 90.8 m-85 -170.03 177.05 4.44 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 103.669 -2.715 . . . . 0.0 103.669 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -90.53 -37.81 13.62 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.411 0.624 . . . . 0.0 109.775 175.524 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -81.57 -2.33 49.62 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 114.772 -1.103 . . . . 0.0 111.035 -178.239 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.489 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -58.25 158.95 12.49 Favored Pre-proline 0 CA--C 1.547 0.828 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.547 -179.115 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_exo -47.11 134.73 18.9 Favored 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 123.823 3.015 . . . . 0.0 114.701 -178.289 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 26.6 m -90.63 173.53 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 CA-C-N 114.392 -1.276 . . . . 0.0 110.393 -178.644 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.44 6.22 12.04 Favored Glycine 0 C--N 1.314 -0.682 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.836 177.278 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -118.77 125.54 6.45 Favored Glycine 0 N--CA 1.432 -1.593 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.902 179.454 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -128.46 135.26 49.22 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 174.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.432 ' O ' ' HA ' ' A' ' 59' ' ' PRO . 53.9 tp -111.59 110.39 55.25 Favored Pre-proline 0 C--N 1.303 -1.422 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 176.523 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -67.47 166.14 24.78 Favored 'Trans proline' 0 CA--C 1.539 0.758 0 C-N-CA 122.699 2.266 . . . . 0.0 112.988 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.54 134.85 40.64 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.245 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.3 -10.81 73.56 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 121.236 -0.506 . . . . 0.0 112.298 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.76 129.38 39.56 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.902 0.382 . . . . 0.0 111.885 -176.816 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.424 HG23 HG22 ' A' ' 54' ' ' VAL . 52.9 m -104.98 117.02 32.96 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.121 179.545 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.0 mm -125.92 140.48 48.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -177.02 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.89 119.23 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-O 121.806 0.812 . . . . 0.0 108.864 175.362 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.42 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 39.4 p90 -97.37 148.4 23.2 Favored 'General case' 0 C--N 1.295 -1.799 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.929 -178.774 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -121.5 9.79 10.33 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 121.578 0.704 . . . . 0.0 110.231 -178.068 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -152.7 130.13 11.38 Favored 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -177.899 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 33.6 t -118.89 126.61 75.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 178.018 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.552 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 24.6 p -135.77 143.64 45.35 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.543 0.572 . . . . 0.0 112.543 -177.31 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 60.9 mt -102.32 116.83 46.7 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 CA-C-O 120.96 0.41 . . . . 0.0 110.003 177.695 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.582 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -124.27 121.77 35.94 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 174.117 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.89 107.95 0.16 Allowed 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 123.851 0.86 . . . . 0.0 113.14 -166.367 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 133.91 -33.97 2.46 Favored Glycine 0 N--CA 1.429 -1.81 0 CA-C-N 114.388 -1.278 . . . . 0.0 110.888 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -151.37 166.15 31.88 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -177.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 tt -107.71 119.13 56.78 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 171.211 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.582 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 55.4 m95 -100.77 134.11 44.23 Favored 'General case' 0 C--N 1.276 -2.612 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.9 -170.927 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.4 pt -100.12 133.7 42.2 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 176.272 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.13 121.97 7.21 Favored Glycine 0 N--CA 1.418 -2.564 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -126.13 147.04 49.7 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 176.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -93.96 112.85 24.75 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 -177.525 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.39 152.52 38.03 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -177.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -51.7 -30.12 20.95 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 124.313 1.045 . . . . 0.0 113.025 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -80.8 -5.52 57.33 Favored 'General case' 0 C--O 1.217 -0.644 0 CA-C-O 121.409 0.623 . . . . 0.0 110.829 -178.862 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 96.01 11.26 55.13 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.667 176.791 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -94.67 145.45 24.84 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.3 tpt180 -93.99 105.02 17.05 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 28.2 t -101.84 136.3 34.5 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -174.254 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.487 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 96.0 m-85 -116.09 126.04 53.2 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 123.419 0.688 . . . . 0.0 110.72 -178.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' CYS . . . . . 0.451 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 47.2 t -108.04 132.76 20.83 Favored Pre-proline 0 C--N 1.31 -1.123 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.143 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.06 -21.35 36.88 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 123.061 2.508 . . . . 0.0 114.683 -176.475 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.292 28.9 m 45.25 -53.71 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.914 0 N-CA-C 118.564 2.801 . . . . 0.0 118.564 176.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.453 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 28.8 ptt180 -154.67 142.05 19.61 Favored 'General case' 0 N--CA 1.44 -0.954 0 C-N-CA 123.826 0.851 . . . . 0.0 109.643 178.818 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 13.6 m -60.61 131.48 50.87 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.675 177.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.661 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 99.5 m -151.9 119.78 6.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.49 0.662 . . . . 0.0 112.091 -178.234 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -114.98 134.67 54.98 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 177.263 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 154.17 -175.97 32.2 Favored Glycine 0 CA--C 1.486 -1.768 0 C-N-CA 118.903 -1.618 . . . . 0.0 113.045 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.8 m -126.08 136.16 28.12 Favored Pre-proline 0 C--N 1.298 -1.644 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 179.37 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 92.5 Cg_exo -46.54 129.5 13.87 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 123.469 2.78 . . . . 0.0 113.332 -177.426 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 19.8 Cg_endo -96.18 -4.44 31.48 Favored 'Cis proline' 0 CA--C 1.542 0.908 0 C-N-CA 124.045 -1.231 . . . . 0.0 113.711 1.596 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -76.99 99.81 5.4 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-O 121.659 0.742 . . . . 0.0 110.868 -172.645 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 38.8 p-80 -106.99 132.79 52.53 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.334 176.813 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.661 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.6 mm -77.4 113.24 29.72 Favored Pre-proline 0 C--N 1.307 -1.262 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 174.302 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -84.55 124.42 3.13 Favored 'Trans proline' 0 N--CA 1.443 -1.457 0 C-N-CA 122.113 1.875 . . . . 0.0 112.528 -178.04 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.74 -139.19 9.85 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 176.691 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 58.4 t -80.62 123.43 37.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 -177.855 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.453 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -93.91 130.65 39.9 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 173.632 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.0 m-90 -95.66 12.63 29.12 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.635 0.731 . . . . 0.0 110.311 -178.434 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.03 -177.7 34.36 Favored Glycine 0 N--CA 1.421 -2.334 0 CA-C-N 115.196 -0.911 . . . . 0.0 111.298 -178.719 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 22.8 t -114.17 142.95 24.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -175.732 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -110.31 141.77 42.86 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.796 0.331 . . . . 0.0 111.289 -176.916 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? . . . . . 0 C--N 1.307 -1.27 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 172.534 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 95.5 m95 . . . . . 0 N--CA 1.43 -1.448 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -113.66 149.67 34.31 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.3 tttm -92.13 120.48 32.77 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 121.806 0.812 . . . . 0.0 111.158 -177.384 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 30.3 t-20 -84.5 147.87 26.83 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 176.813 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.0 tm0? -53.61 -28.66 33.77 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.209 1.004 . . . . 0.0 111.869 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.401 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 54.3 m-85 -74.0 -6.02 44.86 Favored 'General case' 0 CA--C 1.54 0.56 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -178.795 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.36 22.78 39.48 Favored Glycine 0 CA--C 1.495 -1.212 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -178.308 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.413 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 16.9 m -105.88 139.06 41.03 Favored 'General case' 0 N--CA 1.415 -2.222 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.175 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -102.59 133.25 47.9 Favored 'General case' 0 C--N 1.282 -2.366 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 175.664 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 35.9 p90 -138.94 158.97 43.23 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.436 -0.905 . . . . 0.0 112.286 -175.313 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.0 pttp -140.67 134.42 15.06 Favored Pre-proline 0 N--CA 1.431 -1.411 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 174.324 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -70.76 134.46 25.91 Favored 'Trans proline' 0 C--N 1.327 -0.597 0 C-N-CA 121.626 1.551 . . . . 0.0 110.566 177.726 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -163.62 121.09 1.83 Allowed 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.015 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.529 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 26.4 t-20 -95.35 106.06 18.07 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 177.376 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.473 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -144.03 168.83 19.06 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 -178.564 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.422 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 17.2 m -109.61 140.85 42.94 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.256 -174.769 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.469 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 91.7 t80 -120.9 133.65 55.29 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 176.717 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 81' ' ' ALA . 42.5 t -119.4 119.53 60.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.696 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.137 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -59.67 145.62 44.14 Favored 'General case' 0 C--O 1.246 0.916 0 O-C-N 123.518 0.511 . . . . 0.0 111.874 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -81.77 -122.34 0.63 Allowed Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.664 -0.698 . . . . 0.0 113.213 -178.481 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -95.88 -6.3 39.61 Favored 'General case' 0 C--N 1.315 -0.907 0 O-C-N 122.374 -0.486 . . . . 0.0 112.276 -175.427 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 9.5 pt20 -121.45 148.08 49.11 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.554 -178.62 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -72.37 135.59 24.81 Favored 'Trans proline' 0 N--CA 1.439 -1.722 0 C-N-CA 121.932 1.755 . . . . 0.0 107.813 168.333 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 57.8 mt -107.81 127.83 63.56 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -176.125 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.4 p -78.37 136.67 23.52 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.212 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 37.9 p -113.29 164.16 13.91 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 121.134 0.492 . . . . 0.0 112.043 -174.243 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.488 ' HE ' ' HA ' ' A' ' 63' ' ' ARG . 0.8 OUTLIER -109.63 147.01 33.81 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.392 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.0 mt -99.33 123.4 52.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 112.378 0.511 . . . . 0.0 112.378 -176.189 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 70.9 -22.27 0.58 Allowed Glycine 0 CA--C 1.521 0.41 0 N-CA-C 118.054 1.981 . . . . 0.0 118.054 170.705 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 41.6 m -140.73 136.16 16.18 Favored Pre-proline 0 C--N 1.298 -1.662 0 CA-C-N 119.074 1.437 . . . . 0.0 111.075 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -89.91 119.57 0.83 Allowed 'Trans proline' 0 N--CA 1.44 -1.661 0 C-N-CA 121.781 1.654 . . . . 0.0 110.484 172.51 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.422 ' HA ' ' HG2' ' A' ' 91' ' ' GLN . 55.3 m-85 -168.46 168.98 10.81 Favored 'General case' 0 CA--C 1.489 -1.367 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 -177.643 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.73 -8.77 53.89 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.536 0.684 . . . . 0.0 110.194 176.754 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 31.0 p30 -116.62 14.97 15.53 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.243 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.09 152.89 86.75 Favored Pre-proline 0 C--O 1.247 0.962 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.491 -175.229 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_exo -54.29 134.59 61.62 Favored 'Trans proline' 0 C--N 1.364 1.385 0 C-N-CA 123.66 2.907 . . . . 0.0 113.878 -179.064 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 32.3 m -90.1 174.42 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-N 114.564 -1.198 . . . . 0.0 110.234 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.36 28.75 1.9 Allowed Glycine 0 C--N 1.315 -0.611 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.851 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -148.06 127.99 2.74 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -128.12 127.14 42.48 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.608 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 26.1 tp -110.61 113.29 55.83 Favored Pre-proline 0 C--N 1.306 -1.325 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.695 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -62.21 162.31 23.73 Favored 'Trans proline' 0 N--CA 1.483 0.904 0 C-N-CA 123.461 2.774 . . . . 0.0 114.043 -176.067 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.96 144.67 48.81 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 178.456 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.73 11.15 85.61 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.478 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ALA . . . . . 0.41 ' O ' ' HA ' ' A' ' 54' ' ' VAL . . . -78.77 134.21 37.04 Favored 'General case' 0 N--CA 1.439 -1.01 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 178.724 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 42.1 m -104.47 108.84 20.46 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.745 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 45.5 mm -124.05 126.59 72.62 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-O 120.936 0.398 . . . . 0.0 110.518 -176.791 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 12.4 p -90.32 123.41 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.647 0 CA-C-O 121.486 0.66 . . . . 0.0 109.56 176.34 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.529 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 45.5 p90 -101.96 159.25 15.52 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.137 -178.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -118.29 -16.19 9.68 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 121.379 0.609 . . . . 0.0 111.786 -175.204 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -141.11 137.76 33.03 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.341 -175.836 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 67.6 t -112.28 125.76 69.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.74 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.413 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 57.9 m -127.24 142.5 51.46 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -175.86 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 55.0 mt -108.46 117.04 53.11 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 172.174 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.422 ' HG2' ' HA ' ' A' ' 68' ' ' PHE . 60.2 tp60 -113.97 121.33 43.58 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 103.107 -2.923 . . . . 0.0 103.107 170.171 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.17 104.07 0.06 Allowed 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 113.697 0.999 . . . . 0.0 113.697 -165.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 132.56 -36.36 2.19 Favored Glycine 0 N--CA 1.435 -1.411 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.15 -177.439 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 41.5 m80 -146.09 149.39 33.96 Favored 'General case' 0 CA--C 1.504 -0.81 0 O-C-N 122.293 -0.533 . . . . 0.0 111.621 -178.253 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.8 tt -97.86 138.11 23.56 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.913 0 N-CA-C 105.777 -1.934 . . . . 0.0 105.777 175.203 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -120.22 138.06 53.85 Favored 'General case' 0 C--N 1.283 -2.308 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 -174.35 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.1 pt -101.05 128.9 52.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 175.312 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.19 119.87 6.6 Favored Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 179.246 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 55.2 p90 -138.35 171.97 13.6 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -109.21 131.97 54.57 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.331 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -98.12 170.9 8.59 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.703 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 31.1 p90 -50.18 -24.02 2.56 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 115.516 1.672 . . . . 0.0 115.516 -176.537 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -86.03 -9.92 55.92 Favored 'General case' 0 C--N 1.315 -0.926 0 O-C-N 121.498 -0.751 . . . . 0.0 110.59 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.94 17.14 56.89 Favored Glycine 0 CA--C 1.499 -0.926 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -174.547 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 42.2 t30 -93.95 136.14 34.56 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 113.822 -1.189 . . . . 0.0 109.399 -175.622 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 -78.57 113.71 16.85 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 47.3 t -121.14 143.37 33.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 -175.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.446 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 92.6 m-85 -120.79 127.21 51.74 Favored 'General case' 0 C--O 1.242 0.698 0 C-N-CA 122.977 0.511 . . . . 0.0 110.977 -179.138 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 53.0 t -104.48 133.46 20.18 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 178.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.59 -10.81 27.31 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 123.409 2.739 . . . . 0.0 114.267 -176.341 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.279 35.5 m 38.71 -61.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 N-CA-C 118.706 2.854 . . . . 0.0 118.706 174.6 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.545 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 35.6 ptt180 -154.99 150.33 27.24 Favored 'General case' 0 N--CA 1.439 -0.982 0 C-N-CA 123.287 0.635 . . . . 0.0 109.997 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.459 ' O ' ' HA ' ' A' ' 123' ' ' PRO . 82.4 m -68.95 135.61 51.23 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.637 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 95.2 m -151.09 110.92 4.06 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 123.001 0.52 . . . . 0.0 110.868 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 23.3 mp0 -98.71 160.95 13.92 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 176.545 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 128.02 -167.05 20.42 Favored Glycine 0 CA--C 1.487 -1.667 0 C-N-CA 118.768 -1.682 . . . . 0.0 113.508 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 27.9 m -138.13 151.13 69.22 Favored Pre-proline 0 C--N 1.304 -1.38 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 53.6 Cg_exo -56.0 137.01 77.74 Favored 'Trans proline' 0 CA--C 1.54 0.775 0 C-N-CA 122.349 2.033 . . . . 0.0 112.992 -179.49 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 1.3 Cg_endo -92.11 -11.65 27.86 Favored 'Cis proline' 0 C--O 1.25 1.087 0 C-N-CA 124.098 -1.209 . . . . 0.0 113.06 -2.242 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -75.82 101.15 4.99 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-O 122.207 1.003 . . . . 0.0 112.168 -173.093 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.41 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 32.6 p-80 -105.44 132.71 51.28 Favored 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 114.194 -1.366 . . . . 0.0 110.537 177.669 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.637 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 3.1 mp -94.15 105.5 17.8 Favored Pre-proline 0 C--N 1.299 -1.591 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 179.412 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' PRO . . . . . 0.459 ' HA ' ' O ' ' A' ' 113' ' ' THR . 50.2 Cg_endo -84.31 143.18 9.93 Favored 'Trans proline' 0 N--CA 1.436 -1.864 0 C-N-CA 121.769 1.646 . . . . 0.0 112.813 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.7 -114.62 3.98 Favored Glycine 0 N--CA 1.426 -1.993 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 176.099 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 62.0 t -94.44 126.8 46.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.015 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.545 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.38 136.92 34.15 Favored 'General case' 0 N--CA 1.439 -1.015 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.349 175.199 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.0 m-90 -102.32 19.93 17.84 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.394 0.616 . . . . 0.0 110.939 -178.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.469 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -172.55 179.81 43.84 Favored Glycine 0 N--CA 1.427 -1.933 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.242 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 37.7 t -111.71 135.44 50.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -176.787 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -97.75 127.36 43.65 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.255 179.174 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 97.3 mttt . . . . . 0 C--N 1.29 -1.997 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 175.419 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 45.6 m95 . . . . . 0 N--CA 1.444 -0.729 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.8 mtpp -121.84 152.06 39.97 Favored 'General case' 0 C--N 1.309 -1.196 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 177.449 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 56.7 tttp -101.65 135.41 43.22 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 34.9 p30 -95.09 174.69 6.95 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -64.18 -22.31 66.89 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 122.924 0.49 . . . . 0.0 111.937 -178.263 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -82.43 -5.56 58.75 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.486 -178.324 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 95.34 -3.82 66.55 Favored Glycine 0 N--CA 1.439 -1.114 0 C-N-CA 121.151 -0.547 . . . . 0.0 112.615 176.492 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 7.1 m -84.58 141.08 30.94 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 122.706 0.402 . . . . 0.0 110.126 -176.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 98.2 m95 -92.52 135.87 33.7 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 174.344 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -137.97 159.13 42.83 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 120.84 0.352 . . . . 0.0 110.983 -177.676 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 58.7 pttt -141.97 152.32 61.64 Favored Pre-proline 0 C--N 1.301 -1.507 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 174.718 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -80.21 121.85 4.51 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.017 1.812 . . . . 0.0 110.572 175.673 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.42 ' HB3' HG23 ' A' ' 88' ' ' VAL . 38.2 tt0 -155.42 130.72 9.58 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.285 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.557 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 27.2 t-20 -117.95 115.31 24.65 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -177.078 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.526 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -154.49 178.29 10.23 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -179.086 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 28.5 m -103.35 131.14 50.67 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 121.066 0.46 . . . . 0.0 111.038 -176.225 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.426 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 79.8 t80 -107.08 121.95 45.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 173.403 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 41.4 t -106.65 102.25 13.66 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.045 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.668 -178.379 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 56.0 t30 -77.44 151.63 34.64 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 173.543 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -142.05 -71.8 0.03 OUTLIER Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.017 -1.563 . . . . 0.0 115.537 -176.195 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.402 ' OD1' ' HG3' ' A' ' 58' ' ' GLN . 26.7 p30 -72.1 -38.27 69.37 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 116.161 1.912 . . . . 0.0 116.161 -169.146 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.402 ' HG3' ' OD1' ' A' ' 57' ' ' ASN . 0.1 OUTLIER -138.54 161.4 58.98 Favored Pre-proline 0 C--N 1.296 -1.752 0 C-N-CA 120.494 -0.482 . . . . 0.0 112.123 -177.031 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -78.08 151.0 26.76 Favored 'Trans proline' 0 N--CA 1.439 -1.717 0 C-N-CA 121.722 1.614 . . . . 0.0 109.578 175.61 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.6 mt -125.04 126.22 70.77 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -178.388 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.6 p -82.21 117.75 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.218 0 CA-C-O 122.119 0.961 . . . . 0.0 109.527 176.166 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.3 p -91.28 173.62 7.82 Favored 'General case' 0 C--N 1.289 -2.065 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.333 -176.131 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 74.4 mmt-85 -111.25 145.72 38.24 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-O 121.285 0.564 . . . . 0.0 110.23 -178.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.3 mt -94.89 112.35 27.23 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 CA-C-N 115.203 -0.908 . . . . 0.0 112.717 -176.156 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.11 -23.13 1.16 Allowed Glycine 0 CA--C 1.518 0.279 0 N-CA-C 116.849 1.5 . . . . 0.0 116.849 171.166 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.451 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 18.1 m -137.11 135.96 20.36 Favored Pre-proline 0 C--N 1.301 -1.541 0 CA-C-N 118.329 1.064 . . . . 0.0 111.168 -175.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 66' ' ' SER . 9.6 Cg_endo -89.98 120.28 0.87 Allowed 'Trans proline' 0 N--CA 1.438 -1.745 0 C-N-CA 121.888 1.725 . . . . 0.0 111.525 173.681 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.549 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 92.9 m-85 -165.42 161.92 19.11 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 103.848 -2.649 . . . . 0.0 103.848 179.024 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 64.9 mt -72.85 -40.08 66.0 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.17 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -97.36 17.49 17.34 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.221 -0.9 . . . . 0.0 111.172 -178.41 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.549 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -60.68 161.69 14.04 Favored Pre-proline 0 N--CA 1.48 1.06 0 C-N-CA 122.959 0.504 . . . . 0.0 111.624 -179.078 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -57.11 130.71 41.06 Favored 'Trans proline' 0 C--N 1.366 1.5 0 C-N-CA 122.955 2.436 . . . . 0.0 113.185 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 22.2 m -102.92 175.75 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 C-N-CA 124.56 1.144 . . . . 0.0 110.874 -179.537 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.84 3.84 10.76 Favored Glycine 0 C--N 1.309 -0.919 0 C-N-CA 121.308 -0.473 . . . . 0.0 112.175 -178.678 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -110.18 94.3 0.79 Allowed Glycine 0 N--CA 1.434 -1.442 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 173.556 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -87.38 122.31 30.97 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.989 -0.713 . . . . 0.0 110.463 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.9 tp -96.78 113.33 62.64 Favored Pre-proline 0 C--N 1.304 -1.384 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.304 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.33 159.89 47.94 Favored 'Trans proline' 0 C--O 1.251 1.154 0 C-N-CA 122.591 2.194 . . . . 0.0 113.348 -176.648 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.28 124.86 25.97 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.889 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.09 -0.54 54.68 Favored Glycine 0 C--N 1.306 -1.106 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.18 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.36 126.52 29.88 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.299 0.571 . . . . 0.0 111.247 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 14.4 m -99.45 108.87 21.44 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 178.217 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.9 mm -119.16 128.56 75.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 120.723 0.296 . . . . 0.0 111.333 -173.192 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.2 p -87.98 128.97 39.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 173.765 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.557 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 21.1 p90 -104.01 157.98 16.73 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.955 -0.298 . . . . 0.0 111.472 -178.512 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -114.97 -23.6 9.01 Favored 'General case' 0 C--O 1.247 0.945 0 CA-C-O 121.665 0.745 . . . . 0.0 111.495 -176.796 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -141.52 137.42 32.03 Favored 'General case' 0 C--N 1.294 -1.807 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.911 -170.575 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.42 HG23 ' HB3' ' A' ' 49' ' ' GLU . 96.0 t -113.73 132.86 61.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.583 ' HG ' ' HE2' ' A' ' 108' ' ' TYR . 56.9 m -131.85 153.75 49.87 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 120.548 0.214 . . . . 0.0 111.235 -176.141 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 55.3 mt -122.12 119.71 59.26 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 173.554 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.48 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 6.2 tp-100 -122.58 146.31 47.54 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 176.743 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.71 104.76 0.07 Allowed 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -169.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 108.47 -19.75 31.02 Favored Glycine 0 N--CA 1.436 -1.322 0 CA-C-N 114.853 -1.067 . . . . 0.0 113.999 175.519 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -145.17 147.01 32.0 Favored 'General case' 0 C--N 1.316 -0.858 0 O-C-N 121.535 -0.979 . . . . 0.0 111.998 -176.673 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.468 HG23 HG23 ' A' ' 111' ' ' VAL . 14.7 tt -92.64 143.85 10.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 105.461 -2.052 . . . . 0.0 105.461 174.132 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.48 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 70.0 m95 -126.92 148.61 50.03 Favored 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 -175.46 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.8 pt -117.67 137.52 51.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 174.148 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -110.83 131.62 10.48 Favored Glycine 0 N--CA 1.421 -2.329 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -138.62 169.7 17.32 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 177.934 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 51.8 t-20 -106.56 114.64 28.88 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.32 162.62 28.25 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -178.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -57.54 -17.9 16.4 Favored 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 -177.024 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 7.3 t30 -79.23 -14.83 58.8 Favored 'General case' 0 CA--C 1.547 0.861 0 CA-C-O 121.18 0.514 . . . . 0.0 110.598 178.788 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 92.21 17.02 48.38 Favored Glycine 0 C--N 1.325 -0.079 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -174.9 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -97.49 142.89 28.78 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 114.648 -0.776 . . . . 0.0 110.68 -178.267 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 19.2 tpt180 -88.39 107.34 18.79 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 179.23 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 43.0 t -107.96 139.61 29.41 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -176.119 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.583 ' HE2' ' HG ' ' A' ' 89' ' ' CYS . 90.5 m-85 -117.5 128.34 54.89 Favored 'General case' 0 C--N 1.32 -0.695 0 O-C-N 123.331 0.395 . . . . 0.0 110.817 -179.317 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 41.9 t -104.7 133.29 20.25 Favored Pre-proline 0 C--N 1.3 -1.547 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.03 -9.49 25.74 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 123.135 2.557 . . . . 0.0 114.001 -177.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.468 HG23 HG23 ' A' ' 95' ' ' ILE 0.307 27.1 m 39.1 -63.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 N-CA-C 118.361 2.726 . . . . 0.0 118.361 175.133 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.547 ' HB2' ' O ' ' A' ' 125' ' ' VAL . 36.0 ptt180 -162.59 164.38 26.78 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-O 121.177 0.513 . . . . 0.0 111.468 177.357 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 58.4 m -75.37 134.72 40.9 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.265 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.477 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 89.6 m -154.58 124.26 6.59 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 123.787 0.835 . . . . 0.0 110.026 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -105.48 160.54 15.07 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 179.166 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 134.83 -176.24 20.08 Favored Glycine 0 C--N 1.292 -1.872 0 C-N-CA 118.262 -1.923 . . . . 0.0 114.209 175.272 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 76.7 t -127.37 121.33 22.45 Favored Pre-proline 0 C--N 1.298 -1.632 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 99.5 Cg_exo -43.76 136.25 6.97 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 124.043 3.162 . . . . 0.0 113.18 -178.182 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 0.9 OUTLIER -86.13 -11.17 42.48 Favored 'Cis proline' 0 C--O 1.25 1.103 0 C-N-CA 124.007 -1.247 . . . . 0.0 114.25 3.77 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -76.22 102.16 5.7 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.951 0.881 . . . . 0.0 112.19 -172.741 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -106.09 124.87 50.25 Favored 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 114.073 -1.421 . . . . 0.0 110.83 176.625 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 55.3 mt -93.74 109.43 41.23 Favored Pre-proline 0 C--N 1.295 -1.768 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.83 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -81.97 150.38 16.04 Favored 'Trans proline' 0 C--O 1.246 0.907 0 C-N-CA 122.485 2.123 . . . . 0.0 114.295 -175.654 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.33 -125.36 4.3 Favored Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 175.003 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.547 ' O ' ' HB2' ' A' ' 112' ' ' ARG . 60.3 t -79.09 133.68 29.44 Favored 'Isoleucine or valine' 0 C--O 1.244 0.805 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.447 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -93.22 132.94 36.93 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 123.268 0.627 . . . . 0.0 109.857 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 8.6 m0 -107.68 13.38 26.63 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.462 0.649 . . . . 0.0 109.995 178.826 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.426 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -173.58 170.69 43.85 Favored Glycine 0 N--CA 1.425 -2.089 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 179.569 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 73.3 t -111.41 129.57 66.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.981 0.391 . . . . 0.0 110.316 -176.635 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -94.4 129.58 41.07 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.079 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 28.0 ttpp . . . . . 0 N--CA 1.423 -1.817 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 -179.731 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 37' ' ' TRP . . . . . 0.41 ' CE2' ' HD3' ' A' ' 47' ' ' LYS . 66.2 m95 . . . . . 0 N--CA 1.433 -1.319 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.429 ' HD3' ' N ' ' A' ' 39' ' ' LYS . 12.4 tmtt? -135.18 137.89 43.13 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 177.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.429 ' N ' ' HD3' ' A' ' 38' ' ' LYS . 2.6 ttmp? -83.3 116.85 22.62 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.477 ' HB3' ' CE1' ' A' ' 46' ' ' TYR . 36.3 p30 -77.98 177.66 8.1 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 177.154 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -65.33 -7.41 13.36 Favored 'General case' 0 C--N 1.317 -0.819 0 C-N-CA 123.527 0.731 . . . . 0.0 112.525 -178.448 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.4 m-85 -102.25 4.27 39.08 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.497 0.665 . . . . 0.0 110.041 -178.514 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.44 16.15 79.85 Favored Glycine 0 N--CA 1.447 -0.591 0 CA-C-N 115.511 -0.768 . . . . 0.0 112.086 178.006 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 25.3 m -100.22 132.95 45.3 Favored 'General case' 0 N--CA 1.424 -1.743 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.042 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.407 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 75.1 m95 -87.93 125.31 34.44 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 176.477 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.477 ' CE1' ' HB3' ' A' ' 40' ' ' ASN . 50.9 p90 -130.31 151.52 50.73 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 121.184 -0.207 . . . . 0.0 111.156 -178.292 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.41 ' HD3' ' CE2' ' A' ' 37' ' ' TRP . 18.1 pttp -146.64 140.91 15.62 Favored Pre-proline 0 C--N 1.313 -0.985 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 173.104 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -79.61 120.96 4.51 Favored 'Trans proline' 0 C--O 1.244 0.8 0 C-N-CA 121.635 1.557 . . . . 0.0 112.559 -179.27 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.8 tt0 -158.14 125.21 4.97 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.063 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.404 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 26.0 t-20 -87.25 121.38 29.62 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.709 -175.789 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -150.27 169.52 21.17 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 19.9 m -116.14 143.41 45.53 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 -173.857 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -130.19 126.39 37.31 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 124.062 0.945 . . . . 0.0 108.964 175.622 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.1 t -111.41 109.01 26.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.671 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 37.9 t30 -77.09 131.27 38.28 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 175.428 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -156.91 83.27 0.15 Allowed Glycine 0 C--N 1.306 -1.103 0 C-N-CA 118.979 -1.581 . . . . 0.0 113.992 -176.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.473 ' HB3' ' OE1' ' A' ' 58' ' ' GLN . 40.3 t30 168.59 -67.86 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 125.269 1.427 . . . . 0.0 109.203 172.577 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.502 ' NE2' ' HB3' ' A' ' 127' ' ' TRP . 4.7 pm0 -111.89 152.24 44.08 Favored Pre-proline 0 C--N 1.304 -1.374 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.266 -175.244 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_exo -73.48 133.98 19.88 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.698 1.598 . . . . 0.0 108.051 170.046 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 61.1 mt -108.1 125.7 64.72 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -176.351 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.4 p -81.05 111.77 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.626 0 CA-C-O 122.066 0.936 . . . . 0.0 108.737 176.504 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 64.7 p -92.22 164.62 13.48 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.399 -176.556 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 17.2 mmt180 -105.41 135.49 46.7 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.635 -175.866 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.4 mt -98.9 125.56 52.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 N-CA-C 112.68 0.622 . . . . 0.0 112.68 -173.762 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.75 -21.87 1.52 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 116.388 1.315 . . . . 0.0 116.388 172.772 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.401 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 22.1 m -146.84 136.99 12.13 Favored Pre-proline 0 C--N 1.305 -1.335 0 CA-C-N 118.678 1.239 . . . . 0.0 111.063 -177.402 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 66' ' ' SER . 19.3 Cg_endo -90.3 120.43 0.82 Allowed 'Trans proline' 0 N--CA 1.437 -1.804 0 C-N-CA 121.925 1.75 . . . . 0.0 110.971 172.396 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.485 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 51.7 m-85 -167.03 171.45 11.07 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 179.685 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 69.4 mt -84.65 -28.46 26.42 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 107.481 -1.304 . . . . 0.0 107.481 172.418 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -96.68 19.78 11.88 Favored 'General case' 0 CA--C 1.549 0.936 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.294 179.524 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.485 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -71.21 155.28 93.24 Favored Pre-proline 0 C--N 1.315 -0.908 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.505 -176.645 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_exo -55.89 131.16 44.34 Favored 'Trans proline' 0 C--N 1.353 0.801 0 C-N-CA 123.404 2.736 . . . . 0.0 113.927 -179.726 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.3 m -97.54 174.62 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.259 178.059 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.66 -0.57 15.65 Favored Glycine 0 CA--C 1.496 -1.105 0 C-N-CA 120.071 -1.061 . . . . 0.0 112.235 178.529 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.43 96.23 0.87 Allowed Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 175.035 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -94.46 118.42 31.61 Favored 'General case' 0 C--N 1.288 -2.071 0 O-C-N 122.186 -0.596 . . . . 0.0 109.967 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 48.4 tp -90.69 117.75 68.18 Favored Pre-proline 0 C--N 1.306 -1.311 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.29 152.51 80.87 Favored 'Trans proline' 0 C--O 1.249 1.061 0 C-N-CA 122.289 1.992 . . . . 0.0 113.029 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.96 135.55 40.04 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 115.142 -0.935 . . . . 0.0 108.982 176.547 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.43 4.91 57.14 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.425 -179.568 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.28 130.48 38.99 Favored 'General case' 0 C--O 1.243 0.731 0 CA-C-O 121.151 0.501 . . . . 0.0 111.882 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.2 m -93.28 120.16 33.25 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.239 176.082 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.6 mm -119.94 118.63 57.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.884 -179.138 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 5.0 p -99.48 112.64 32.34 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 175.797 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.404 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 45.5 p90 -97.2 155.78 16.69 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.536 -173.17 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -115.54 -9.0 12.11 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -175.453 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -136.88 131.23 32.86 Favored 'General case' 0 C--N 1.309 -1.194 0 C-N-CA 120.531 -0.467 . . . . 0.0 109.755 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 24.2 t -102.02 129.4 53.42 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.752 ' HG ' ' HE2' ' A' ' 108' ' ' TYR . 43.9 m -134.88 145.93 48.73 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-N 117.84 0.291 . . . . 0.0 111.493 -176.406 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 65.1 mt -120.69 116.89 51.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 175.849 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.596 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -125.89 136.43 53.04 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 105.854 -1.906 . . . . 0.0 105.854 175.45 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.04 112.65 0.7 Allowed 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -171.132 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 125.43 -32.62 3.86 Favored Glycine 0 N--CA 1.437 -1.294 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.128 179.071 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 61.2 m80 -153.51 168.8 24.94 Favored 'General case' 0 N--CA 1.473 0.714 0 O-C-N 122.005 -0.703 . . . . 0.0 110.581 -176.451 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.9 tt -100.5 137.79 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.846 0 N-CA-C 103.449 -2.797 . . . . 0.0 103.449 167.457 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.596 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 69.5 m95 -118.73 136.76 53.78 Favored 'General case' 0 C--N 1.269 -2.913 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -173.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.449 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.3 pt -100.72 128.68 52.58 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.148 0 C-N-CA 119.896 -0.722 . . . . 0.0 109.43 177.592 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.33 118.83 6.25 Favored Glycine 0 N--CA 1.419 -2.458 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -142.83 168.68 19.14 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -114.72 138.08 51.15 Favored 'General case' 0 C--N 1.291 -1.967 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 176.322 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.98 -177.14 6.48 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.164 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -64.36 -21.67 66.7 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.319 0.581 . . . . 0.0 112.416 -177.69 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 48.8 t30 -77.74 -8.31 57.78 Favored 'General case' 0 CA--C 1.554 1.134 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.243 176.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 82.73 6.74 88.21 Favored Glycine 0 N--CA 1.461 0.354 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -177.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -82.87 133.38 35.13 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 124.067 0.947 . . . . 0.0 109.894 -176.764 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 16.3 tpp85 -75.29 119.37 19.3 Favored 'General case' 0 C--N 1.316 -0.858 0 O-C-N 123.849 0.718 . . . . 0.0 110.663 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.8 t -124.3 146.63 29.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.752 ' HE2' ' HG ' ' A' ' 89' ' ' CYS . 65.0 m-85 -119.39 131.71 55.71 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 123.477 0.711 . . . . 0.0 110.556 178.204 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 46.7 t -109.76 134.43 20.63 Favored Pre-proline 0 C--N 1.303 -1.454 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.687 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -68.7 -19.48 41.48 Favored 'Trans proline' 0 C--N 1.363 1.292 0 C-N-CA 123.135 2.556 . . . . 0.0 114.112 -177.722 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.296 30.6 m 44.79 -59.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.487 0 N-CA-C 118.394 2.738 . . . . 0.0 118.394 175.159 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.401 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 6.4 ptp180 -152.68 160.22 43.16 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.38 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.6 p -76.15 140.45 41.76 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.007 176.563 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 96.4 m -152.46 145.41 24.47 Favored 'General case' 0 CA--C 1.499 -1.019 0 CA-C-O 120.934 0.397 . . . . 0.0 111.177 -179.525 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -133.56 160.9 36.08 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.28 -1.748 . . . . 0.0 106.28 178.216 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.85 -173.44 21.83 Favored Glycine 0 C--N 1.3 -1.429 0 C-N-CA 118.596 -1.764 . . . . 0.0 113.939 175.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 21.1 m -138.24 123.88 12.51 Favored Pre-proline 0 C--N 1.311 -1.097 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.231 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.487 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 78.0 Cg_exo -46.53 128.43 12.69 Favored 'Trans proline' 0 CA--C 1.543 0.937 0 C-N-CA 123.521 2.814 . . . . 0.0 113.05 -178.62 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.487 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 91.7 Cg_endo -93.67 3.31 55.67 Favored 'Cis proline' 0 CA--C 1.551 1.373 0 N-CA-C 115.239 1.207 . . . . 0.0 115.239 5.698 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 53.9 t30 -78.71 102.27 7.98 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 122.199 1.0 . . . . 0.0 110.691 -176.359 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.429 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 35.6 p-80 -105.19 121.77 44.51 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-N 114.012 -1.449 . . . . 0.0 110.958 -177.454 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.4 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 58.3 mt -102.08 100.67 15.73 Favored Pre-proline 0 C--N 1.305 -1.36 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.094 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 121' ' ' HIS . 63.7 Cg_endo -85.7 135.14 4.86 Favored 'Trans proline' 0 CA--C 1.544 0.981 0 C-N-CA 122.872 2.381 . . . . 0.0 114.209 -177.821 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -112.11 -151.97 11.7 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 175.294 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 90.4 t -52.63 124.49 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.336 0 C-N-CA 123.938 0.895 . . . . 0.0 112.535 -178.768 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.401 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -93.77 143.7 26.09 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.871 175.29 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' TRP . . . . . 0.502 ' HB3' ' NE2' ' A' ' 58' ' ' GLN . 5.3 m-90 -105.47 17.24 24.21 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.327 0.584 . . . . 0.0 110.986 178.347 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -165.57 -170.43 30.5 Favored Glycine 0 N--CA 1.429 -1.804 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.171 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 98.8 t -111.23 133.04 58.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -178.171 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -104.43 127.6 52.14 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.4 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 14.7 tppt? . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' TRP . . . . . 0.525 ' CE2' ' HD2' ' A' ' 47' ' ' LYS . 86.2 m95 . . . . . 0 C--O 1.245 0.837 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 53.5 mtmt -135.49 148.92 49.38 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 175.596 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -88.08 125.86 34.8 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.57 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 55.1 t30 -93.78 169.36 10.36 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 123.687 0.795 . . . . 0.0 110.545 -176.618 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -47.66 -34.81 8.54 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.926 2.091 . . . . 0.0 113.005 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -88.21 7.55 31.39 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.113 0.482 . . . . 0.0 111.703 -175.274 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.87 -13.02 60.15 Favored Glycine 0 CA--C 1.507 -0.462 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.453 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 5.3 m -71.84 137.09 47.27 Favored 'General case' 0 N--CA 1.42 -1.965 0 C-N-CA 124.55 1.14 . . . . 0.0 110.413 -177.79 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.4 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 66.5 m95 -90.03 133.75 34.65 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 173.549 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.57 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 8.6 p90 -132.3 149.12 52.43 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.865 -177.589 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.525 ' HD2' ' CE2' ' A' ' 37' ' ' TRP . 21.9 ptmt -137.19 146.85 56.05 Favored Pre-proline 0 C--N 1.305 -1.328 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 175.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -77.02 121.85 5.99 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.057 1.838 . . . . 0.0 109.862 173.542 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -157.98 120.86 3.86 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -178.667 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.488 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 4.9 t30 -103.35 117.03 33.56 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 -177.009 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.422 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.93 -177.9 6.57 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.525 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 32.3 m -118.05 152.68 35.07 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 120.627 0.251 . . . . 0.0 110.577 -177.044 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.498 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 92.5 t80 -134.61 132.65 39.27 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 177.606 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.1 t -115.56 127.77 73.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.457 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -65.16 135.72 55.82 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.085 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -73.82 -90.91 0.15 Allowed Glycine 0 N--CA 1.44 -1.067 0 O-C-N 123.654 0.596 . . . . 0.0 113.804 -175.545 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -109.72 -47.03 3.41 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 114.097 1.147 . . . . 0.0 114.097 -174.528 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -116.95 152.25 48.44 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -174.107 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -57.13 137.46 81.93 Favored 'Trans proline' 0 C--O 1.242 0.699 0 C-N-CA 122.856 2.37 . . . . 0.0 112.106 178.434 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -108.98 125.85 66.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 -176.266 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 33.6 m -72.93 148.43 9.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 175.601 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 35.9 p -127.15 163.01 24.78 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 110.337 -0.245 . . . . 0.0 110.337 -175.89 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -110.18 141.85 42.53 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -178.523 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.7 mt -94.1 119.01 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.493 -175.561 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 72.18 -22.95 0.75 Allowed Glycine 0 CA--C 1.529 0.922 0 N-CA-C 117.273 1.669 . . . . 0.0 117.273 170.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.3 m -141.32 136.35 15.71 Favored Pre-proline 0 C--N 1.297 -1.69 0 CA-C-N 118.958 1.379 . . . . 0.0 110.862 -178.417 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -89.64 119.53 0.88 Allowed 'Trans proline' 0 N--CA 1.433 -2.055 0 C-N-CA 121.325 1.35 . . . . 0.0 110.47 172.531 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.458 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 72.0 m-85 -169.37 169.46 9.02 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 127.954 2.502 . . . . 0.0 104.61 -179.295 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -90.13 -17.87 26.86 Favored 'General case' 0 C--N 1.293 -1.879 0 CA-C-O 121.222 0.534 . . . . 0.0 110.75 175.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 27.8 p-10 -106.7 20.32 19.19 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.801 0.81 . . . . 0.0 109.665 177.303 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.458 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.59 156.4 90.18 Favored Pre-proline 0 C--O 1.25 1.101 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.734 179.022 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -54.58 122.97 12.52 Favored 'Trans proline' 0 C--N 1.357 1.024 0 C-N-CA 122.922 2.414 . . . . 0.0 112.372 -179.452 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.414 HG22 ' H ' ' A' ' 74' ' ' GLY . 8.5 p -103.45 174.24 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-N 114.916 -1.038 . . . . 0.0 108.235 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.414 ' H ' HG22 ' A' ' 73' ' ' VAL . . . 119.9 -6.43 12.26 Favored Glycine 0 CA--C 1.494 -1.258 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -178.383 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.23 131.55 10.62 Favored Glycine 0 N--CA 1.429 -1.773 0 N-CA-C 108.399 -1.88 . . . . 0.0 108.399 173.356 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.4 t-20 -126.98 141.38 51.81 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 118.113 0.956 . . . . 0.0 111.564 -177.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 51.5 tp -104.18 114.72 64.09 Favored Pre-proline 0 C--N 1.309 -1.171 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 176.09 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -62.7 160.42 32.76 Favored 'Trans proline' 0 C--O 1.243 0.75 0 C-N-CA 123.072 2.515 . . . . 0.0 112.81 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.67 137.49 46.06 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.327 -178.683 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.32 19.6 78.1 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.804 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -85.72 140.12 30.78 Favored 'General case' 0 C--N 1.317 -0.814 0 O-C-N 122.554 -0.38 . . . . 0.0 110.346 178.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 40.5 m -111.68 108.73 18.28 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.8 mm -116.52 136.51 53.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 122.889 0.475 . . . . 0.0 110.565 -175.743 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.4 p -102.92 128.24 55.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 174.46 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.488 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 42.5 p90 -117.63 157.74 25.88 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.559 -175.74 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -121.26 -5.99 9.39 Favored 'General case' 0 C--O 1.247 0.972 0 O-C-N 123.653 0.595 . . . . 0.0 111.261 -178.656 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -133.71 126.88 31.67 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -173.624 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.0 t -114.1 127.37 71.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 177.74 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.453 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 63.0 m -129.68 150.51 50.97 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 122.983 0.177 . . . . 0.0 111.469 -176.039 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 45.0 mt -121.28 117.29 52.3 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 172.526 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.409 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -111.39 144.46 40.56 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 104.261 -2.496 . . . . 0.0 104.261 173.185 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.8 104.07 0.07 Allowed 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -170.79 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 115.77 -23.94 10.58 Favored Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.471 -0.786 . . . . 0.0 113.677 178.304 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' HIS . . . . . 0.442 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 50.8 m80 -147.77 145.55 28.84 Favored 'General case' 0 CA--C 1.505 -0.786 0 O-C-N 121.559 -0.965 . . . . 0.0 112.204 -177.675 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.423 HG23 HG23 ' A' ' 111' ' ' VAL . 14.5 tt -93.9 139.01 19.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 105.552 -2.018 . . . . 0.0 105.552 173.692 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.409 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 74.5 m95 -124.02 139.01 54.36 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -174.563 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.448 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.3 pt -102.46 132.22 48.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 173.691 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.48 124.68 8.1 Favored Glycine 0 N--CA 1.425 -2.053 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -179.691 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -138.55 155.56 48.27 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 178.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -97.99 120.33 38.19 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 176.194 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.31 161.55 20.4 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -58.41 -14.09 6.9 Favored 'General case' 0 N--CA 1.483 1.212 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.245 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -77.62 -13.56 59.87 Favored 'General case' 0 CA--C 1.548 0.895 0 CA-C-O 121.5 0.667 . . . . 0.0 110.713 177.535 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 87.64 15.9 60.93 Favored Glycine 0 CA--C 1.497 -1.079 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -176.219 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 39.4 t-20 -97.1 132.82 42.51 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 114.239 -0.98 . . . . 0.0 109.226 -177.573 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 25.9 tpt180 -90.17 99.06 12.15 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 175.801 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 36.8 t -100.32 142.42 15.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.989 -173.485 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 81.5 m-85 -115.23 129.38 56.62 Favored 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 123.081 0.552 . . . . 0.0 110.223 178.23 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.1 t -108.32 133.45 20.56 Favored Pre-proline 0 C--N 1.306 -1.303 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.288 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.56 -10.06 24.8 Favored 'Trans proline' 0 C--N 1.364 1.344 0 C-N-CA 123.397 2.731 . . . . 0.0 114.729 -174.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.423 HG23 HG23 ' A' ' 95' ' ' ILE 0.293 27.2 m 38.19 -67.26 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 N-CA-C 118.026 2.602 . . . . 0.0 118.026 175.0 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.486 ' HE ' ' HB2' ' A' ' 126' ' ' ALA . 6.3 ptp85 -147.44 148.81 31.67 Favored 'General case' 0 N--CA 1.445 -0.7 0 C-N-CA 123.239 0.616 . . . . 0.0 109.603 176.078 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.442 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 66.8 m -67.95 133.98 50.0 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 176.386 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 86.3 m -151.34 103.82 3.03 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 122.886 0.474 . . . . 0.0 110.363 -179.173 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 45.8 mt-30 -88.85 141.14 28.75 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.193 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 139.7 178.04 16.31 Favored Glycine 0 N--CA 1.42 -2.386 0 C-N-CA 119.015 -1.564 . . . . 0.0 113.273 178.449 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 87.0 t -133.31 130.61 21.22 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 179.182 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.411 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 66.3 Cg_exo -43.46 132.51 7.1 Favored 'Trans proline' 0 CA--C 1.548 1.195 0 C-N-CA 123.44 2.76 . . . . 0.0 113.456 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.411 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 43.1 Cg_endo -89.31 -5.98 51.67 Favored 'Cis proline' 0 CA--C 1.541 0.826 0 C-N-CA 123.373 -1.511 . . . . 0.0 114.832 4.234 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -76.51 100.65 5.34 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-O 122.161 0.981 . . . . 0.0 112.409 -173.588 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 28.7 p-80 -105.43 126.57 52.27 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 113.845 -1.525 . . . . 0.0 111.007 178.509 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.564 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 60.7 mt -100.6 104.39 30.52 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 174.29 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -76.97 123.65 6.9 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.564 2.176 . . . . 0.0 113.171 -175.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -108.51 -141.86 9.76 Favored Glycine 0 N--CA 1.424 -2.12 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.586 177.242 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 67.0 t -75.21 122.28 28.57 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 C-N-CA 122.948 0.499 . . . . 0.0 111.996 -176.623 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.486 ' HB2' ' HE ' ' A' ' 112' ' ' ARG . . . -93.23 143.36 26.33 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.719 173.902 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.8 m-90 -106.03 14.61 27.61 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.951 0.881 . . . . 0.0 109.686 177.42 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.498 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -162.13 177.61 38.26 Favored Glycine 0 N--CA 1.407 -3.251 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.491 -179.426 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 57.5 t -111.52 118.82 58.45 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.192 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 -177.385 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 41.8 m-85 -78.74 132.77 37.08 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.271 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.525 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 53.9 tptt . . . . . 0 N--CA 1.404 -2.767 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 95.1 m95 . . . . . 0 C--O 1.237 0.418 0 CA-C-O 120.965 0.412 . . . . 0.0 110.419 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 8.3 tmtm? -118.44 133.46 55.85 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -81.67 128.74 34.28 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 120.91 0.386 . . . . 0.0 111.723 -176.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -96.67 166.08 11.83 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 176.136 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -51.65 -27.79 12.56 Favored 'General case' 0 N--CA 1.489 1.485 0 C-N-CA 125.184 1.394 . . . . 0.0 113.082 -176.897 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 69.0 m-85 -87.5 10.11 18.76 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 121.498 0.666 . . . . 0.0 111.535 -175.445 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.54 14.36 82.1 Favored Glycine 0 CA--C 1.5 -0.89 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 178.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.551 HG22 ' HB2' ' A' ' 89' ' ' CYS . 6.8 m -96.14 127.7 42.38 Favored 'General case' 0 N--CA 1.409 -2.517 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -177.334 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 71.8 m95 -95.31 120.99 36.5 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.092 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -120.14 148.69 43.32 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.106 -177.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.1 pttm -134.95 151.4 75.45 Favored Pre-proline 0 C--N 1.305 -1.342 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -71.88 132.51 20.1 Favored 'Trans proline' 0 N--CA 1.45 -1.043 0 C-N-CA 121.678 1.585 . . . . 0.0 111.471 175.523 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -159.16 120.61 3.34 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 176.098 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.442 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 3.7 t-20 -107.39 115.73 30.68 Favored 'General case' 0 C--N 1.295 -1.783 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.328 -175.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -160.94 178.63 9.2 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.241 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 17.4 m -116.82 151.98 35.38 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -178.539 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.4 t80 -124.95 127.96 47.86 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 175.767 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 46.6 t -112.27 112.69 41.57 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.037 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 55.3 t30 -65.72 136.25 56.01 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.2 -179.026 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -119.07 -83.19 0.84 Allowed Glycine 0 N--CA 1.43 -1.739 0 N-CA-C 115.77 1.068 . . . . 0.0 115.77 -170.572 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -79.07 -23.28 44.31 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 115.365 1.617 . . . . 0.0 115.365 -166.433 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.407 ' HA ' ' HD3' ' A' ' 59' ' ' PRO . 4.7 pp0? -152.79 150.1 23.72 Favored Pre-proline 0 C--N 1.311 -1.102 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.277 -178.833 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 58' ' ' GLN . 16.5 Cg_exo -68.37 131.24 22.82 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.369 2.046 . . . . 0.0 109.739 177.536 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 51.2 mt -106.81 127.52 62.28 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.828 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -171.79 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -81.5 138.03 20.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 178.08 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 50.9 p -110.51 170.11 8.3 Favored 'General case' 0 C--N 1.295 -1.791 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.751 -174.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -117.29 138.12 51.96 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.185 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.7 mt -99.09 125.68 52.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.889 -174.086 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.39 -22.93 3.58 Favored Glycine 0 N--CA 1.448 -0.534 0 N-CA-C 115.772 1.069 . . . . 0.0 115.772 172.504 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.5 m -152.3 138.1 11.5 Favored Pre-proline 0 C--N 1.297 -1.696 0 CA-C-N 118.074 0.937 . . . . 0.0 110.065 -177.694 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -89.84 120.87 0.95 Allowed 'Trans proline' 0 N--CA 1.44 -1.674 0 C-N-CA 121.64 1.56 . . . . 0.0 111.008 173.85 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.524 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 93.5 m-85 -168.58 166.24 12.03 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 127.246 2.218 . . . . 0.0 105.021 179.174 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 96.5 mt -82.01 -19.74 39.83 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-O 121.357 0.598 . . . . 0.0 109.994 175.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -111.02 19.69 18.21 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.294 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.524 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -73.38 156.88 88.69 Favored Pre-proline 0 C--O 1.249 1.05 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.573 -178.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -46.97 127.36 12.32 Favored 'Trans proline' 0 C--N 1.365 1.404 0 C-N-CA 123.754 2.969 . . . . 0.0 113.806 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 10.9 p -99.89 172.71 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-N 114.304 -1.316 . . . . 0.0 107.95 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.91 11.55 7.6 Favored Glycine 0 C--N 1.318 -0.469 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -177.478 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -137.1 121.11 2.25 Favored Glycine 0 N--CA 1.423 -2.228 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 175.768 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -126.17 141.54 51.89 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 117.519 0.66 . . . . 0.0 109.899 -178.266 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 27.4 tp -101.41 113.61 65.8 Favored Pre-proline 0 N--CA 1.429 -1.48 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.21 166.72 22.32 Favored 'Trans proline' 0 C--O 1.249 1.033 0 C-N-CA 122.272 1.981 . . . . 0.0 113.32 -177.597 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.15 128.64 36.32 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.225 179.243 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.99 -5.34 61.47 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.873 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.84 128.55 36.72 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.013 0.435 . . . . 0.0 111.22 -179.199 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 44.3 m -104.08 111.55 24.17 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.593 -179.574 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.6 mm -116.99 130.27 72.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.28 -176.314 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.2 p -99.11 139.34 21.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 174.71 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 46.2 p90 -135.3 158.16 45.08 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.802 -176.887 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -128.34 -0.39 5.69 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.589 177.426 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -129.64 127.8 41.32 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.06 -178.236 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.6 t -123.66 126.94 73.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.551 ' HB2' HG22 ' A' ' 44' ' ' THR . 27.2 p -135.84 148.46 48.68 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -174.24 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 68.8 mt -106.03 121.96 59.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.996 178.123 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.449 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -125.7 144.85 50.43 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 173.797 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -51.05 107.23 0.16 Allowed 'General case' 0 C--N 1.317 -0.805 0 O-C-N 123.51 0.506 . . . . 0.0 111.535 -177.3 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.7 -41.62 1.52 Allowed Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.117 178.694 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' HIS . . . . . 0.502 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 69.9 m80 -154.16 166.02 34.42 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 117.294 0.547 . . . . 0.0 110.915 -175.524 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.8 tt -105.26 110.15 30.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 173.549 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.524 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 45.2 m95 -96.74 142.66 28.5 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.784 -168.825 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.8 pt -100.2 134.22 40.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 174.786 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -101.96 124.63 8.27 Favored Glycine 0 N--CA 1.424 -2.158 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -149.72 169.92 19.93 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-O 121.018 0.437 . . . . 0.0 109.832 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -104.33 143.13 33.4 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.611 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -94.43 159.32 15.16 Favored 'General case' 0 C--N 1.291 -1.964 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 173.732 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -54.12 -21.92 9.83 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -179.064 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 11.4 t30 -92.59 7.31 43.87 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-O 121.973 0.892 . . . . 0.0 110.738 -177.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 83.02 13.41 77.53 Favored Glycine 0 C--N 1.321 -0.251 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.677 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 18.7 m120 -83.72 141.05 31.73 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.818 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 30.2 tpt180 -89.83 106.27 18.36 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 176.843 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.3 t -112.6 138.26 42.44 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 C-N-CA 119.895 -0.722 . . . . 0.0 110.512 -173.766 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.413 ' HE1' ' HG ' ' A' ' 89' ' ' CYS . 63.8 m-85 -117.17 126.8 53.36 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.452 -0.794 . . . . 0.0 110.002 176.643 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.7 t -109.07 130.63 22.5 Favored Pre-proline 0 C--N 1.304 -1.4 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.844 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -68.89 -22.26 36.49 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 122.819 2.346 . . . . 0.0 114.133 -176.423 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.298 34.4 m 49.3 -54.9 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.579 0 N-CA-C 117.771 2.508 . . . . 0.0 117.771 177.045 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -150.77 143.42 24.46 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 123.464 0.706 . . . . 0.0 109.67 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.502 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 69.1 m -71.61 127.87 33.96 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.732 178.443 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.511 ' SG ' ' HA ' ' A' ' 123' ' ' PRO . 94.5 m -149.49 140.51 22.93 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.06 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -125.12 153.99 42.14 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 105.788 -1.93 . . . . 0.0 105.788 178.855 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.84 -168.6 31.19 Favored Glycine 0 CA--C 1.483 -1.919 0 C-N-CA 118.633 -1.746 . . . . 0.0 112.275 178.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 65.6 t -138.82 121.52 10.63 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 179.134 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 88.5 Cg_exo -48.03 136.23 23.64 Favored 'Trans proline' 0 C--O 1.238 0.517 0 C-N-CA 123.175 2.583 . . . . 0.0 111.952 -179.501 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 90.8 Cg_endo -95.32 25.04 23.18 Favored 'Cis proline' 0 CA--C 1.548 1.193 0 C-N-CA 124.461 -1.058 . . . . 0.0 114.043 3.674 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -106.15 106.02 16.34 Favored 'General case' 0 C--N 1.315 -0.928 0 O-C-N 121.789 -0.57 . . . . 0.0 111.274 -178.383 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 25.2 p-80 -104.17 139.85 38.65 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.175 176.92 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 44.7 mm -104.02 107.4 56.9 Favored Pre-proline 0 C--N 1.293 -1.852 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' PRO . . . . . 0.511 ' HA ' ' SG ' ' A' ' 114' ' ' CYS . 86.0 Cg_endo -79.57 147.57 19.94 Favored 'Trans proline' 0 C--O 1.247 0.933 0 C-N-CA 122.623 2.215 . . . . 0.0 113.989 -175.733 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -131.49 -124.73 2.6 Favored Glycine 0 N--CA 1.428 -1.854 0 CA-C-N 115.415 -0.812 . . . . 0.0 111.266 176.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.0 t -85.62 121.37 37.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -175.424 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.38 151.23 19.55 Favored 'General case' 0 C--O 1.246 0.894 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.158 173.258 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' TRP . . . . . 0.421 ' HH2' ' HE2' ' A' ' 94' ' ' HIS . 5.5 m-90 -109.1 6.54 25.02 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 179.536 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -160.82 -171.74 27.18 Favored Glycine 0 N--CA 1.428 -1.899 0 C-N-CA 120.64 -0.79 . . . . 0.0 111.271 -178.153 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 44.0 t -111.7 131.97 61.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -174.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -91.9 137.46 32.34 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 176.747 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt . . . . . 0 C--N 1.288 -2.078 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.684 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 96.9 m95 . . . . . 0 N--CA 1.442 -0.841 0 CA-C-O 121.551 0.691 . . . . 0.0 111.791 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.6 tmtt? -130.3 140.98 50.63 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.334 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -85.84 146.16 26.88 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.396 0.617 . . . . 0.0 112.371 -173.049 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 48.2 t-20 -109.75 153.83 23.78 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 124.988 1.315 . . . . 0.0 107.622 178.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 48.2 tt0 -53.88 -26.5 25.18 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 125.443 1.497 . . . . 0.0 112.48 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -75.3 -7.91 55.23 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.359 0.6 . . . . 0.0 111.63 -179.609 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.02 -13.32 63.59 Favored Glycine 0 N--CA 1.437 -1.275 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 -178.38 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 7.3 m -68.63 147.98 51.12 Favored 'General case' 0 N--CA 1.421 -1.879 0 C-N-CA 124.954 1.301 . . . . 0.0 109.073 179.285 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.458 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 64.7 m95 -111.31 142.28 43.74 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 173.611 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -139.1 156.99 46.75 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-O 121.087 0.47 . . . . 0.0 111.531 -179.084 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -138.48 132.51 16.57 Favored Pre-proline 0 C--N 1.295 -1.779 0 CA-C-N 114.905 -1.043 . . . . 0.0 108.223 174.895 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.52 121.16 7.9 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 N-CA-C 108.752 -1.288 . . . . 0.0 108.752 173.633 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -168.03 124.9 1.09 Allowed 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -176.851 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -93.47 138.91 31.31 Favored 'General case' 0 CA--C 1.483 -1.61 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.341 -176.342 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.475 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -164.01 160.71 22.1 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 175.074 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.491 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 16.1 m -105.6 132.58 51.57 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.378 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -108.15 121.06 44.07 Favored 'General case' 0 N--CA 1.422 -1.825 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 175.883 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 42.5 t -107.19 119.25 56.49 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.078 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 176.805 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.428 ' ND2' HG12 ' A' ' 60' ' ' ILE . 46.4 t-20 -68.99 123.21 20.41 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.248 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -143.44 39.85 1.27 Allowed Glycine 0 N--CA 1.417 -2.624 0 C-N-CA 120.098 -1.048 . . . . 0.0 111.937 -176.902 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 20.7 t-20 -145.55 -66.73 0.31 Allowed 'General case' 0 C--N 1.31 -1.119 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.074 177.79 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -157.43 161.34 29.41 Favored Pre-proline 0 C--N 1.317 -0.806 0 CA-C-O 118.872 -0.585 . . . . 0.0 109.76 -178.708 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.24 137.88 81.38 Favored 'Trans proline' 0 C--N 1.357 0.994 0 C-N-CA 122.96 2.44 . . . . 0.0 112.279 -179.443 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.59 HG21 ' SG ' ' A' ' 109' ' ' CYS . 32.7 mm -106.95 140.55 24.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.996 -174.799 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.27 107.85 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.256 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 172.825 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 57.7 p -93.72 153.67 18.2 Favored 'General case' 0 C--N 1.294 -1.836 0 CA-C-N 115.067 -0.969 . . . . 0.0 110.37 -176.088 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -106.44 140.39 39.43 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -177.411 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.3 mp -105.53 125.14 60.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-O 121.282 0.563 . . . . 0.0 111.672 -175.679 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.32 -22.78 11.4 Favored Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 115.533 0.973 . . . . 0.0 115.533 172.431 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 41.9 m -152.91 136.67 10.19 Favored Pre-proline 0 C--N 1.305 -1.337 0 CA-C-N 118.12 0.96 . . . . 0.0 110.385 -178.076 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -90.04 119.61 0.81 Allowed 'Trans proline' 0 N--CA 1.439 -1.718 0 C-N-CA 121.434 1.422 . . . . 0.0 110.986 173.544 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.44 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 76.3 m-85 -169.41 175.09 5.66 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 105.151 -2.166 . . . . 0.0 105.151 -179.46 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -88.62 -29.74 19.74 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 172.686 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -92.32 20.39 6.15 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.784 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.44 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -80.56 159.38 69.63 Favored Pre-proline 0 C--N 1.309 -1.161 0 CA-C-O 119.644 -0.217 . . . . 0.0 110.733 -176.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -57.12 144.06 91.29 Favored 'Trans proline' 0 C--N 1.358 1.063 0 C-N-CA 123.405 2.737 . . . . 0.0 113.989 -177.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.7 m -101.81 174.53 1.04 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.062 0 C-N-CA 124.437 1.095 . . . . 0.0 110.458 -179.696 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.8 26.91 2.43 Favored Glycine 0 C--N 1.306 -1.118 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -179.255 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.88 109.63 0.59 Allowed Glycine 0 N--CA 1.423 -2.185 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -108.04 126.04 52.26 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-O 120.856 0.36 . . . . 0.0 110.102 178.787 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.49 ' HB3' ' HB ' ' A' ' 60' ' ' ILE . 33.1 tp -107.56 109.22 62.42 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 107.043 -1.466 . . . . 0.0 107.043 175.323 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -71.08 159.94 50.74 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.191 1.928 . . . . 0.0 112.195 -177.656 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.78 133.52 46.62 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 177.886 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.5 -10.52 56.31 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 121.046 -0.597 . . . . 0.0 111.971 -178.59 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.09 138.24 51.83 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.904 0.383 . . . . 0.0 110.682 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.7 m -117.89 110.17 17.42 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.259 -179.191 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.1 mm -120.89 120.3 61.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 CA-C-O 120.732 0.301 . . . . 0.0 110.62 -176.531 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 6.6 p -91.67 111.37 23.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-O 121.649 0.738 . . . . 0.0 109.404 175.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.475 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 46.6 p90 -97.12 168.6 10.35 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.963 -174.797 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -117.68 -17.59 9.87 Favored 'General case' 0 C--N 1.316 -0.857 0 O-C-N 123.858 0.724 . . . . 0.0 112.255 -176.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -135.66 133.92 38.66 Favored 'General case' 0 N--CA 1.432 -1.339 0 C-N-CA 119.891 -0.723 . . . . 0.0 110.905 -173.311 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.7 t -105.55 127.1 60.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 35.1 m -127.35 148.44 50.26 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 117.742 0.246 . . . . 0.0 110.927 -176.648 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 39.9 mt -119.14 120.18 63.09 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 CA-C-O 121.039 0.447 . . . . 0.0 109.964 172.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.501 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.2 tp-100 -122.51 118.58 28.62 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 103.514 -2.773 . . . . 0.0 103.514 172.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.45 107.3 0.12 Allowed 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 113.728 1.01 . . . . 0.0 113.728 -165.487 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 137.41 -31.4 2.52 Favored Glycine 0 N--CA 1.435 -1.391 0 CA-C-N 114.417 -1.265 . . . . 0.0 110.533 -179.252 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' HIS . . . . . 0.421 ' HA ' ' H ' ' A' ' 114' ' ' CYS . 73.0 m80 -151.13 163.97 37.57 Favored 'General case' 0 CA--C 1.483 -1.633 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.555 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.2 tt -103.9 133.92 46.57 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.742 0 N-CA-C 104.504 -2.406 . . . . 0.0 104.504 170.009 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.501 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 68.3 m95 -115.59 140.07 49.52 Favored 'General case' 0 C--N 1.27 -2.86 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -172.923 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.423 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.6 pt -100.98 130.02 51.0 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.315 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -101.27 120.4 6.86 Favored Glycine 0 N--CA 1.419 -2.464 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.163 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 44.4 p90 -142.83 144.47 32.54 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.071 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -101.93 126.13 48.77 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 175.451 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -93.45 167.84 11.45 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.238 -176.618 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 31.6 p90 -63.19 -2.21 1.29 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 113.859 1.059 . . . . 0.0 113.859 -178.361 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -88.09 -6.7 57.77 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 175.686 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 90.72 -0.47 76.94 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 111.808 -0.517 . . . . 0.0 111.808 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 21.2 p30 -96.36 147.67 23.57 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -177.046 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 9.7 tpp85 -92.13 111.56 23.16 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 175.128 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.5 t -111.99 143.58 21.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 -176.782 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.423 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 95.4 m-85 -119.33 129.28 54.78 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.027 0.441 . . . . 0.0 110.915 178.789 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' CYS . . . . . 0.59 ' SG ' HG21 ' A' ' 60' ' ' ILE . 43.1 t -110.56 127.97 26.1 Favored Pre-proline 0 C--N 1.302 -1.497 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.259 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -71.57 -5.63 17.46 Favored 'Trans proline' 0 C--N 1.359 1.123 0 C-N-CA 123.462 2.775 . . . . 0.0 115.243 -175.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.304 30.1 m 37.33 -59.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.515 2.775 0 N-CA-C 118.881 2.919 . . . . 0.0 118.881 175.26 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.464 ' CZ ' ' HB2' ' A' ' 126' ' ' ALA . 7.8 ptp180 -150.72 156.36 41.15 Favored 'General case' 0 C--O 1.248 0.994 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.485 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.2 m -67.27 132.63 48.11 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 176.442 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.421 ' H ' ' HA ' ' A' ' 94' ' ' HIS . 53.5 m -152.09 110.52 3.75 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.803 0.811 . . . . 0.0 111.449 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -102.93 143.72 32.14 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 106.119 -1.808 . . . . 0.0 106.119 178.144 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 147.71 -170.85 28.37 Favored Glycine 0 CA--C 1.489 -1.566 0 C-N-CA 118.207 -1.949 . . . . 0.0 113.488 178.879 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 84.7 t -134.67 123.27 16.11 Favored Pre-proline 0 C--N 1.304 -1.386 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 179.221 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 96.0 Cg_exo -45.86 135.53 13.76 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.76 2.974 . . . . 0.0 113.304 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 28.3 Cg_endo -95.1 17.82 37.08 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 C-N-CA 124.283 -1.132 . . . . 0.0 113.493 1.402 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -94.8 101.91 13.75 Favored 'General case' 0 C--N 1.312 -1.028 0 C-N-CA 120.491 -0.484 . . . . 0.0 110.405 -177.625 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 10.9 p-80 -104.63 138.99 40.14 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.902 177.843 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 50.6 mm -102.31 99.54 13.09 Favored Pre-proline 0 C--N 1.301 -1.502 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 172.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -84.52 147.61 11.14 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 122.82 2.347 . . . . 0.0 113.989 -174.634 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.07 -145.02 6.61 Favored Glycine 0 N--CA 1.419 -2.497 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.28 175.414 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.5 t -60.67 122.72 11.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 C-N-CA 123.727 0.811 . . . . 0.0 111.868 -177.26 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.464 ' HB2' ' CZ ' ' A' ' 112' ' ' ARG . . . -94.22 145.06 24.99 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.501 174.608 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.8 m-90 -105.59 18.69 21.79 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.341 0.591 . . . . 0.0 110.907 177.743 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -166.99 -165.89 25.16 Favored Glycine 0 N--CA 1.427 -1.933 0 C-N-CA 119.788 -1.196 . . . . 0.0 112.791 -179.727 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 48.7 t -124.03 139.12 51.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -178.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -105.09 134.41 48.24 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 177.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.298 -1.667 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 98.7 m95 . . . . . 0 CA--C 1.502 -0.904 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -140.41 145.53 37.15 Favored 'General case' 0 C--N 1.281 -2.406 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 179.571 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 24.5 ttmm -84.7 109.25 17.88 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-O 121.182 0.515 . . . . 0.0 109.83 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.47 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 44.2 t30 -78.35 168.5 19.73 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.655 -179.44 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -58.28 -12.11 3.37 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -174.524 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -91.84 2.26 56.63 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-O 121.195 0.521 . . . . 0.0 109.87 179.249 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.07 -12.51 57.84 Favored Glycine 0 C--N 1.33 0.205 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -178.522 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.479 HG21 ' HG2' ' A' ' 67' ' ' PRO . 14.6 m -76.56 140.57 41.14 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 124.638 1.175 . . . . 0.0 110.592 -176.316 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -90.8 131.97 36.14 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 175.667 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.47 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 11.0 p90 -136.88 159.43 41.89 Favored 'General case' 0 C--N 1.292 -1.915 0 C-N-CA 120.006 -0.677 . . . . 0.0 109.733 -179.541 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.7 pttm -155.09 141.33 13.04 Favored Pre-proline 0 N--CA 1.431 -1.394 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 170.621 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -71.23 122.46 8.73 Favored 'Trans proline' 0 C--O 1.247 0.941 0 C-N-CA 121.873 1.715 . . . . 0.0 110.593 175.517 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -154.71 120.95 5.3 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 -178.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.549 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 7.6 t30 -104.93 117.68 34.64 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.625 -172.747 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.458 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -151.69 173.57 14.54 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 179.674 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 31.1 m -113.58 129.78 56.5 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -176.125 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -107.98 131.69 54.29 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 176.341 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 52.4 t -113.94 112.89 42.14 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 175.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -71.19 139.87 50.3 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -76.89 -117.8 0.16 Allowed Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 114.865 0.706 . . . . 0.0 114.865 -173.119 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -109.98 10.49 24.23 Favored 'General case' 0 C--N 1.311 -1.08 0 O-C-N 122.303 -0.528 . . . . 0.0 112.016 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -131.38 138.53 32.97 Favored Pre-proline 0 C--N 1.299 -1.609 0 C-N-CA 120.805 -0.358 . . . . 0.0 110.286 -175.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -69.7 141.43 45.45 Favored 'Trans proline' 0 C--O 1.242 0.695 0 C-N-CA 121.898 1.732 . . . . 0.0 109.822 174.344 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 64.4 mt -121.04 125.15 73.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -178.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 29.1 m -80.97 140.05 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.172 0 CA-C-O 121.803 0.811 . . . . 0.0 109.19 175.436 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' THR . . . . . 0.438 HG22 ' HA ' ' A' ' 109' ' ' CYS . 37.3 p -124.24 164.16 20.13 Favored 'General case' 0 C--N 1.272 -2.796 0 CA-C-N 115.095 -0.957 . . . . 0.0 110.814 -171.412 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -107.81 143.58 36.18 Favored 'General case' 0 C--N 1.317 -0.804 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -177.087 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.5 mt -106.09 130.21 58.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-O 121.229 0.538 . . . . 0.0 112.128 -174.247 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.48 -23.05 5.8 Favored Glycine 0 CA--C 1.521 0.417 0 N-CA-C 116.207 1.243 . . . . 0.0 116.207 171.71 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 52.1 m -156.94 142.28 12.51 Favored Pre-proline 0 C--N 1.308 -1.202 0 CA-C-N 118.448 1.124 . . . . 0.0 110.077 179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.479 ' HG2' HG21 ' A' ' 44' ' ' THR . 90.8 Cg_endo -89.95 119.8 0.84 Allowed 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 121.581 1.521 . . . . 0.0 111.856 175.159 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.481 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 91.7 m-85 -168.78 164.18 11.91 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 104.764 -2.31 . . . . 0.0 104.764 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 81.0 mt -85.79 -17.84 34.65 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 173.297 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -95.38 -0.47 52.56 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.921 178.402 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.481 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -68.83 157.7 88.08 Favored Pre-proline 0 N--CA 1.472 0.654 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.256 -176.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -55.71 122.18 11.27 Favored 'Trans proline' 0 C--N 1.365 1.404 0 C-N-CA 122.951 2.434 . . . . 0.0 112.749 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.4 HG22 ' H ' ' A' ' 74' ' ' GLY . 7.3 p -98.95 173.38 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 179.094 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.4 ' H ' HG22 ' A' ' 73' ' ' VAL . . . 119.78 -3.37 13.29 Favored Glycine 0 C--N 1.308 -1.015 0 C-N-CA 120.319 -0.943 . . . . 0.0 111.565 -178.74 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.94 127.09 9.14 Favored Glycine 0 N--CA 1.432 -1.609 0 N-CA-C 107.932 -2.067 . . . . 0.0 107.932 172.059 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -116.82 140.6 49.25 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 118.292 1.046 . . . . 0.0 110.582 -177.822 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 48.6 tp -114.19 112.5 46.79 Favored Pre-proline 0 C--N 1.307 -1.273 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 177.409 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.41 164.3 34.72 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 122.344 2.03 . . . . 0.0 113.06 -178.709 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.86 139.79 45.28 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.471 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.98 -0.59 86.32 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 121.314 -0.47 . . . . 0.0 112.396 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -72.76 126.26 29.48 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 121.099 0.476 . . . . 0.0 110.865 -178.559 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 53.6 m -99.7 115.76 30.24 Favored 'General case' 0 N--CA 1.425 -1.677 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.018 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.4 mm -126.05 128.84 72.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 110.256 -0.275 . . . . 0.0 110.256 -175.756 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.6 p -93.46 123.3 45.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 175.15 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.549 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 40.9 p90 -107.37 145.23 33.16 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.899 -178.666 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -111.93 -15.75 13.26 Favored 'General case' 0 C--N 1.31 -1.143 0 O-C-N 124.002 0.814 . . . . 0.0 112.494 -175.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -136.58 138.51 41.3 Favored 'General case' 0 N--CA 1.437 -1.09 0 C-N-CA 120.21 -0.596 . . . . 0.0 109.758 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 61.5 t -114.84 132.02 65.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 69.6 m -127.47 135.32 50.24 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 120.743 0.306 . . . . 0.0 110.924 -177.773 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 65.6 mt -103.66 116.88 48.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 CA-C-O 121.296 0.569 . . . . 0.0 110.121 177.053 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.554 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 59.6 tp60 -124.96 118.96 27.42 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 103.981 -2.6 . . . . 0.0 103.981 175.806 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.14 106.19 0.1 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 -167.407 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 138.78 -41.17 1.38 Allowed Glycine 0 N--CA 1.421 -2.333 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.798 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 57.3 m80 -147.2 154.77 41.44 Favored 'General case' 0 CA--C 1.494 -1.181 0 O-C-N 122.142 -0.622 . . . . 0.0 110.206 -178.519 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.9 tt -96.98 125.77 49.9 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 175.234 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.554 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 68.2 m95 -105.03 133.97 48.91 Favored 'General case' 0 C--N 1.274 -2.683 0 CA-C-O 121.178 0.513 . . . . 0.0 110.355 -173.407 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.473 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 43.8 pt -100.12 120.84 50.1 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.323 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 175.486 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -94.77 114.15 4.76 Favored Glycine 0 N--CA 1.411 -2.97 0 N-CA-C 109.326 -1.509 . . . . 0.0 109.326 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -132.2 154.16 49.85 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -177.54 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -89.28 114.96 26.39 Favored 'General case' 0 C--N 1.272 -2.77 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 174.464 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.23 165.35 24.01 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-O 121.114 0.483 . . . . 0.0 110.846 -176.684 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.6 p90 -69.19 -2.79 11.33 Favored 'General case' 0 C--N 1.312 -1.034 0 C-N-CA 123.9 0.88 . . . . 0.0 112.162 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -95.45 -7.0 39.47 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.321 177.344 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 96.51 -7.8 66.14 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.907 -0.588 . . . . 0.0 113.665 176.062 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 15.3 p-10 -96.69 151.12 19.93 Favored 'General case' 0 C--N 1.296 -1.72 0 C-N-CA 122.972 0.509 . . . . 0.0 112.039 -178.244 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 14.5 tpp180 -84.29 108.47 17.17 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.067 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 25.8 t -110.94 146.62 15.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.022 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -176.525 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 88.2 m-85 -117.05 123.19 46.24 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' CYS . . . . . 0.438 ' HA ' HG22 ' A' ' 62' ' ' THR . 50.8 t -104.67 132.2 21.14 Favored Pre-proline 0 C--N 1.303 -1.424 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.361 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -69.84 -17.07 37.44 Favored 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 123.051 2.501 . . . . 0.0 114.372 -177.502 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.299 33.2 m 40.91 -58.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.52 3.032 0 N-CA-C 118.815 2.894 . . . . 0.0 118.815 175.872 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 33.3 ptt180 -153.96 150.6 28.49 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 123.577 0.751 . . . . 0.0 109.009 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 17.8 m -66.66 139.05 57.84 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.742 179.042 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.581 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 92.1 m -154.65 127.03 7.89 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 123.009 0.524 . . . . 0.0 111.17 179.573 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -125.83 122.49 36.3 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 177.655 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 168.84 175.03 37.96 Favored Glycine 0 N--CA 1.416 -2.696 0 C-N-CA 119.932 -1.128 . . . . 0.0 111.897 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 60.2 t -129.17 128.32 23.29 Favored Pre-proline 0 C--N 1.288 -2.076 0 N-CA-C 105.248 -2.13 . . . . 0.0 105.248 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -43.26 137.53 5.11 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 123.71 2.94 . . . . 0.0 113.027 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -81.88 -14.87 33.76 Favored 'Cis proline' 0 CA--C 1.553 1.467 0 C-N-CA 123.331 -1.529 . . . . 0.0 114.543 3.052 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -79.41 100.33 7.6 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.768 0.794 . . . . 0.0 112.952 -171.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 38.9 p-80 -106.99 112.73 25.83 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 114.869 -1.059 . . . . 0.0 111.164 175.628 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.581 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 49.4 mt -91.94 113.51 59.16 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 110.607 -0.146 . . . . 0.0 110.607 -178.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -84.48 164.75 12.54 Favored 'Trans proline' 0 C--O 1.246 0.918 0 C-N-CA 123.029 2.486 . . . . 0.0 113.36 -178.684 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.92 -130.96 2.92 Favored Glycine 0 N--CA 1.434 -1.473 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 176.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 80.7 t -73.81 122.3 26.62 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 C-N-CA 122.387 0.275 . . . . 0.0 111.287 -178.119 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.49 147.46 23.23 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.281 176.103 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.5 m0 -107.57 11.4 28.69 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.923 0.392 . . . . 0.0 111.792 179.213 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.66 -168.38 23.47 Favored Glycine 0 N--CA 1.436 -1.365 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.616 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 27.1 t -111.88 139.98 33.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -178.834 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 -118.32 123.16 44.67 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.426 0.155 . . . . 0.0 111.341 -175.463 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.1 pttm . . . . . 0 N--CA 1.433 -1.291 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 171.932 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.6 m95 . . . . . 0 N--CA 1.445 -0.707 0 CA-C-O 120.902 0.382 . . . . 0.0 110.956 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -113.64 156.14 24.23 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 175.063 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -101.4 126.2 48.14 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.559 -178.139 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.409 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 36.6 t-20 -89.39 164.57 14.82 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 -177.383 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -64.91 -15.14 61.67 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.309 1.043 . . . . 0.0 111.213 -176.164 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 46.0 m-85 -74.66 -18.02 60.6 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.916 177.4 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.12 -8.13 59.01 Favored Glycine 0 CA--C 1.507 -0.453 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -175.447 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 11.2 m -80.67 138.84 36.41 Favored 'General case' 0 N--CA 1.427 -1.611 0 C-N-CA 124.724 1.21 . . . . 0.0 110.703 -178.072 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.412 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 65.2 m95 -93.44 139.05 31.14 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 174.463 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.409 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 37.0 p90 -142.47 151.37 41.64 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 120.691 -0.403 . . . . 0.0 111.241 -178.455 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 pttm -144.18 151.48 51.91 Favored Pre-proline 0 C--O 1.25 1.081 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 173.222 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -73.5 122.12 7.64 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 121.952 1.768 . . . . 0.0 110.548 175.494 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -156.57 121.6 4.64 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.492 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 20.5 t-20 -101.55 115.71 31.12 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.146 -176.005 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.84 176.49 10.68 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.5 m -118.47 138.36 52.55 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 121.192 0.52 . . . . 0.0 111.978 -175.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 80.5 t80 -115.63 123.17 47.72 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 175.394 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 45.1 t -104.87 110.86 32.13 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 177.204 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.583 ' OD1' ' HA ' ' A' ' 79' ' ' ALA . 22.6 t-20 -66.15 128.09 34.72 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.318 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -136.5 -11.28 1.16 Allowed Glycine 0 N--CA 1.441 -0.993 0 C-N-CA 118.997 -1.573 . . . . 0.0 114.71 -176.787 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.496 ' OD1' ' HG3' ' A' ' 58' ' ' GLN . 15.5 t-20 -95.26 -74.51 0.55 Allowed 'General case' 0 C--N 1.319 -0.753 0 C-N-CA 119.073 -1.051 . . . . 0.0 110.876 -178.051 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.496 ' HG3' ' OD1' ' A' ' 57' ' ' ASN . 0.0 OUTLIER -141.14 167.4 17.44 Favored Pre-proline 0 C--N 1.305 -1.329 0 CA-C-O 118.948 -0.549 . . . . 0.0 110.471 -179.199 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -62.35 130.33 29.9 Favored 'Trans proline' 0 C--N 1.356 0.951 0 C-N-CA 121.824 1.683 . . . . 0.0 109.264 173.339 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 58.9 mt -107.13 125.03 63.3 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 C-N-CA 120.323 -0.551 . . . . 0.0 109.708 -173.641 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.7 p -82.66 119.4 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.83 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 176.839 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 75.6 p -95.86 178.96 5.26 Favored 'General case' 0 C--N 1.285 -2.209 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.131 -172.742 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.45 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 82.2 mmt-85 -118.35 139.93 50.61 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 175.809 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 67.4 mt -99.13 129.84 48.96 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 CA-C-O 121.451 0.643 . . . . 0.0 111.895 -175.584 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 77.11 -22.51 2.41 Favored Glycine 0 C--N 1.318 -0.426 0 N-CA-C 116.023 1.169 . . . . 0.0 116.023 173.028 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 16.5 m -147.22 138.24 13.0 Favored Pre-proline 0 C--N 1.303 -1.44 0 CA-C-N 117.981 0.89 . . . . 0.0 109.941 -176.324 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -89.73 118.62 0.79 Allowed 'Trans proline' 0 N--CA 1.433 -2.062 0 C-N-CA 120.776 0.984 . . . . 0.0 110.006 171.087 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.576 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 68.9 m-85 -169.06 178.35 4.49 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 104.27 -2.492 . . . . 0.0 104.27 -179.195 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -89.0 -40.12 13.22 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 174.805 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -96.84 25.46 5.26 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 121.942 0.877 . . . . 0.0 110.524 -177.648 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.576 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -75.61 159.74 80.83 Favored Pre-proline 0 C--N 1.307 -1.254 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.391 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_exo -47.4 123.03 7.36 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 122.98 2.454 . . . . 0.0 113.482 -179.002 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 6.4 t -98.52 172.6 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 -178.108 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.6 3.48 14.16 Favored Glycine 0 C--N 1.312 -0.77 0 C-N-CA 120.057 -1.068 . . . . 0.0 112.227 -179.212 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -115.51 111.77 2.52 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 175.607 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 38.6 t30 -107.49 130.13 54.88 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 117.318 0.559 . . . . 0.0 109.716 -178.829 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 46.8 tp -95.56 112.28 58.41 Favored Pre-proline 0 N--CA 1.431 -1.385 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 177.422 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -61.87 152.1 76.89 Favored 'Trans proline' 0 C--O 1.243 0.761 0 C-N-CA 122.471 2.114 . . . . 0.0 112.379 -177.119 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ALA . . . . . 0.583 ' HA ' ' OD1' ' A' ' 55' ' ' ASN . . . -68.18 134.52 50.62 Favored 'General case' 0 N--CA 1.436 -1.145 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.332 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.72 7.96 65.99 Favored Glycine 0 N--CA 1.436 -1.365 0 CA-C-N 115.417 -0.81 . . . . 0.0 112.623 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.33 132.75 37.55 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.116 0.484 . . . . 0.0 111.126 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 26.2 m -102.34 112.63 25.42 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.53 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 40.2 mm -115.65 121.8 68.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.836 -176.031 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.2 p -87.9 123.51 40.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 172.154 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.492 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 39.2 p90 -108.88 142.41 39.52 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -178.618 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -115.9 -10.96 11.58 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.719 0.771 . . . . 0.0 110.915 -174.167 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -131.65 134.42 45.95 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.662 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 50.3 t -117.87 133.11 65.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.329 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.503 ' SG ' ' HE2' ' A' ' 108' ' ' TYR . 67.1 m -132.02 140.4 48.9 Favored 'General case' 0 C--N 1.312 -1.051 0 O-C-N 123.317 0.386 . . . . 0.0 111.446 -177.403 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 52.0 mt -107.69 112.57 40.69 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.906 -0.496 . . . . 0.0 109.745 174.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.593 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -118.64 120.37 37.24 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 174.397 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.61 109.63 0.26 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 113.48 0.919 . . . . 0.0 113.48 -165.83 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 132.44 -34.82 2.44 Favored Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.27 -1.332 . . . . 0.0 110.793 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 68.5 m80 -148.8 159.33 44.25 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.7 tt -102.09 119.03 49.81 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 172.784 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.593 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 61.7 m95 -99.81 134.73 42.28 Favored 'General case' 0 C--N 1.276 -2.596 0 CA-C-O 121.186 0.517 . . . . 0.0 110.581 -171.445 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.483 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.0 pt -100.22 131.92 46.8 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.131 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.847 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.15 127.04 9.05 Favored Glycine 0 N--CA 1.425 -2.099 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -178.078 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 27.4 p90 -151.36 166.64 30.39 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 120.976 0.417 . . . . 0.0 109.975 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -118.84 130.39 55.74 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.331 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -96.17 147.78 23.39 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.046 -178.696 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 29.8 p90 -46.96 -21.52 0.23 Allowed 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 126.246 1.818 . . . . 0.0 115.158 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -89.16 3.99 50.03 Favored 'General case' 0 CA--C 1.561 1.398 0 CA-C-O 121.665 0.745 . . . . 0.0 111.053 -177.579 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 91.59 16.92 51.13 Favored Glycine 0 CA--C 1.502 -0.748 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.135 177.355 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -96.06 124.08 39.93 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 120.991 0.424 . . . . 0.0 111.35 -176.322 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 30.3 tpt180 -82.91 109.09 16.73 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 105.127 -2.175 . . . . 0.0 105.127 172.397 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 20.1 t -118.81 140.19 43.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 C-N-CA 119.449 -0.901 . . . . 0.0 112.029 -171.447 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.503 ' HE2' ' SG ' ' A' ' 89' ' ' CYS . 66.8 m-85 -122.58 124.14 42.82 Favored 'General case' 0 N--CA 1.435 -1.219 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.205 174.664 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' CYS . . . . . 0.418 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 48.7 t -108.83 132.66 21.03 Favored Pre-proline 0 C--N 1.304 -1.372 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.358 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.74 -21.16 33.96 Favored 'Trans proline' 0 C--N 1.358 1.064 0 C-N-CA 123.092 2.528 . . . . 0.0 114.214 -176.816 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.317 33.2 m 45.85 -55.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.51 2.529 0 N-CA-C 118.67 2.841 . . . . 0.0 118.67 176.193 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.447 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 34.2 ptt180 -153.6 149.11 27.26 Favored 'General case' 0 N--CA 1.441 -0.914 0 C-N-CA 122.966 0.507 . . . . 0.0 110.639 177.592 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.4 m -63.0 127.98 33.76 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 177.324 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.645 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 88.3 m -151.94 117.32 5.31 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.592 0.711 . . . . 0.0 111.363 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -114.35 144.84 42.62 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.121 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 141.41 -169.49 25.08 Favored Glycine 0 N--CA 1.429 -1.83 0 C-N-CA 119.769 -1.205 . . . . 0.0 111.454 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 15.4 m -136.68 142.23 38.23 Favored Pre-proline 0 C--N 1.298 -1.656 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 71.9 Cg_exo -43.92 127.46 6.61 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 123.784 2.989 . . . . 0.0 113.207 -178.235 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 11.2 Cg_endo -96.21 -9.97 19.97 Favored 'Cis proline' 0 C--O 1.245 0.828 0 C-N-CA 124.195 -1.169 . . . . 0.0 114.12 1.384 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 57.9 t30 -72.67 100.86 2.91 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 121.998 0.904 . . . . 0.0 111.557 -172.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 33.4 p-80 -106.66 125.15 50.63 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.304 -1.316 . . . . 0.0 110.699 177.086 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.645 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 49.8 mm -85.66 107.96 14.62 Favored Pre-proline 0 C--N 1.306 -1.286 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 176.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_endo -84.89 123.8 2.86 Favored 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 122.723 2.282 . . . . 0.0 112.967 -177.811 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -98.74 -110.25 3.0 Favored Glycine 0 N--CA 1.433 -1.543 0 N-CA-C 111.374 -0.69 . . . . 0.0 111.374 177.583 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 48.1 t -94.79 122.38 46.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 -177.831 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.447 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.27 136.5 34.49 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.272 175.757 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.6 m-90 -102.04 16.07 27.15 Favored 'General case' 0 C--O 1.251 1.162 0 CA-C-O 121.581 0.705 . . . . 0.0 111.467 179.48 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -171.29 -171.57 36.6 Favored Glycine 0 N--CA 1.43 -1.74 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.064 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 59.1 t -111.51 125.41 68.83 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 123.508 0.723 . . . . 0.0 109.167 -177.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -93.58 135.12 35.17 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.015 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 96.0 mttt . . . . . 0 C--N 1.293 -1.856 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 179.067 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 37' ' ' TRP . . . . . 0.524 ' CZ2' ' HD2' ' A' ' 47' ' ' LYS . 94.1 m95 . . . . . 0 N--CA 1.433 -1.293 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -125.51 140.73 52.51 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 -179.241 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 59.8 tttp -89.63 118.04 28.95 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.192 0.52 . . . . 0.0 110.596 -177.509 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -89.85 152.24 21.36 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 175.793 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.7 tp60 -61.04 -13.68 18.3 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 123.745 0.818 . . . . 0.0 113.094 -173.675 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 62.9 m-85 -74.84 -9.05 58.18 Favored 'General case' 0 CA--C 1.542 0.649 0 CA-C-O 121.247 0.546 . . . . 0.0 109.838 176.844 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.77 20.17 54.47 Favored Glycine 0 CA--C 1.496 -1.116 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -176.214 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 22.1 m -105.81 129.08 54.06 Favored 'General case' 0 N--CA 1.408 -2.542 0 CA-C-N 114.13 -1.035 . . . . 0.0 108.679 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 81.0 m95 -92.48 132.07 37.1 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 175.344 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 31.8 p90 -130.69 147.74 52.4 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.991 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.524 ' HD2' ' CZ2' ' A' ' 37' ' ' TRP . 20.7 ptmt -125.1 141.99 40.07 Favored Pre-proline 0 C--N 1.294 -1.844 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.57 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -73.22 120.83 6.78 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 N-CA-C 108.699 -1.308 . . . . 0.0 108.699 172.403 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -168.12 121.53 0.9 Allowed 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 -178.419 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 19.8 t-20 -104.79 128.55 52.98 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.929 -173.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.535 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -156.59 170.15 23.04 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 177.525 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.422 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 2.4 m -112.92 122.25 47.08 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.668 -174.923 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -95.82 124.24 39.75 Favored 'General case' 0 C--N 1.312 -1.062 0 O-C-N 121.969 -0.457 . . . . 0.0 110.582 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.439 HG22 HG23 ' A' ' 82' ' ' THR . 38.2 t -110.56 112.59 41.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 176.424 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -68.34 137.03 54.29 Favored 'General case' 0 C--O 1.248 0.995 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -124.73 -57.63 0.17 Allowed Glycine 0 N--CA 1.424 -2.135 0 C-N-CA 118.934 -1.603 . . . . 0.0 115.654 -170.699 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -83.02 -53.46 5.8 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -170.058 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -142.62 154.68 63.32 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 119.942 -0.703 . . . . 0.0 111.082 -174.822 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -60.03 132.75 46.28 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 122.707 2.271 . . . . 0.0 110.213 176.251 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 41.8 mt -108.19 120.83 60.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -174.738 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.5 p -79.38 115.09 21.12 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.136 0 CA-C-O 121.753 0.787 . . . . 0.0 109.471 175.643 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 56.3 p -89.49 178.87 6.19 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 115.191 -0.913 . . . . 0.0 111.657 -173.104 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 84.6 mmt-85 -117.52 137.67 52.41 Favored 'General case' 0 N--CA 1.439 -0.978 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 176.203 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 72.3 mt -95.29 123.7 47.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.139 -176.247 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.87 -22.55 3.42 Favored Glycine 0 C--N 1.317 -0.505 0 N-CA-C 116.205 1.242 . . . . 0.0 116.205 171.828 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.3 m -152.32 140.61 13.54 Favored Pre-proline 0 C--N 1.306 -1.311 0 CA-C-N 118.322 1.061 . . . . 0.0 110.455 -177.208 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -90.05 118.89 0.76 Allowed 'Trans proline' 0 N--CA 1.433 -2.05 0 C-N-CA 121.03 1.154 . . . . 0.0 110.662 172.632 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.543 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 97.0 m-85 -169.04 166.99 10.86 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 104.134 -2.543 . . . . 0.0 104.134 179.076 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -79.22 -36.14 40.54 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 175.336 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.5 p-10 -96.06 19.99 10.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.336 -177.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.543 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -74.96 156.25 86.28 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 176.089 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -48.07 123.33 8.58 Favored 'Trans proline' 0 C--O 1.255 1.345 0 C-N-CA 123.385 2.723 . . . . 0.0 113.828 179.754 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 34.2 m -94.29 174.43 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.609 -1.178 . . . . 0.0 109.949 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.43 11.34 7.38 Favored Glycine 0 N--CA 1.439 -1.132 0 C-N-CA 120.17 -1.014 . . . . 0.0 112.909 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -119.78 130.13 8.31 Favored Glycine 0 N--CA 1.436 -1.324 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 174.644 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -128.36 130.16 47.31 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 118.024 0.912 . . . . 0.0 110.439 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 46.1 tp -101.16 110.31 60.95 Favored Pre-proline 0 C--N 1.3 -1.552 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.074 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -69.13 166.91 25.2 Favored 'Trans proline' 0 C--O 1.244 0.822 0 C-N-CA 122.57 2.18 . . . . 0.0 112.481 -177.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.43 141.08 43.24 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.468 -179.215 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.53 -23.78 32.3 Favored Glycine 0 C--O 1.244 0.761 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.05 128.22 35.13 Favored 'General case' 0 C--O 1.244 0.78 0 CA-C-O 121.13 0.49 . . . . 0.0 110.453 -178.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.439 HG23 HG22 ' A' ' 54' ' ' VAL . 39.9 m -111.88 121.58 45.44 Favored 'General case' 0 N--CA 1.416 -2.151 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.437 -178.565 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.1 mm -125.87 128.55 72.12 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 -178.373 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 12.9 p -83.92 133.2 29.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 175.64 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.535 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 50.6 p90 -116.09 137.66 51.93 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.01 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -111.36 -10.5 14.22 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 122.232 1.015 . . . . 0.0 109.568 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.4 ' CD ' HH22 ' A' ' 106' ' ' ARG . 39.8 tt0 -125.71 120.05 29.62 Favored 'General case' 0 N--CA 1.423 -1.804 0 CA-C-N 114.454 -1.248 . . . . 0.0 109.119 -176.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 45.0 t -106.58 130.51 58.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.64 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.457 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 62.1 m -129.08 153.18 47.89 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 120.882 0.372 . . . . 0.0 111.97 -174.41 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.3 mt -124.91 117.04 49.01 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 171.863 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.563 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -124.13 126.8 46.8 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 104.469 -2.419 . . . . 0.0 104.469 174.18 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.2 113.2 0.75 Allowed 'General case' 0 C--N 1.321 -0.645 0 O-C-N 124.789 1.306 . . . . 0.0 112.586 -168.704 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 131.68 -35.8 2.34 Favored Glycine 0 N--CA 1.432 -1.602 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.66 -176.606 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -154.19 168.41 26.63 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 122.418 -0.46 . . . . 0.0 110.257 -178.07 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 112' ' ' ARG . 15.4 tt -98.36 140.81 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 N-CA-C 103.724 -2.695 . . . . 0.0 103.724 168.159 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' TRP . . . . . 0.563 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 49.8 m95 -125.15 147.83 48.85 Favored 'General case' 0 C--N 1.28 -2.447 0 CA-C-N 118.117 0.417 . . . . 0.0 110.308 -172.155 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 49.9 pt -110.49 131.31 61.93 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.022 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 172.876 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.55 121.1 7.05 Favored Glycine 0 N--CA 1.424 -2.113 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.324 -178.575 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -140.29 164.3 30.45 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-O 121.074 0.464 . . . . 0.0 110.688 178.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 31.0 t30 -120.74 127.02 51.6 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 178.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.55 172.32 11.73 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.064 0.459 . . . . 0.0 111.717 -176.698 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -60.47 -25.9 66.38 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.199 1.0 . . . . 0.0 112.603 -176.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 26.5 p-10 -92.78 -0.6 57.23 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.253 -177.843 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 91.67 9.62 62.59 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.481 178.656 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -78.55 122.3 25.71 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ARG . . . . . 0.4 HH22 ' CD ' ' A' ' 87' ' ' GLU . 11.2 tpt85 -88.18 98.29 11.48 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 -179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 16.5 t -103.86 139.91 23.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 CA-C-O 121.126 0.488 . . . . 0.0 111.066 -171.16 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -118.34 122.27 42.45 Favored 'General case' 0 N--CA 1.432 -1.367 0 CA-C-N 115.407 -0.815 . . . . 0.0 108.991 174.645 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.2 t -104.06 129.77 24.6 Favored Pre-proline 0 C--N 1.301 -1.541 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -178.511 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.98 -2.83 12.82 Favored 'Trans proline' 0 C--N 1.361 1.206 0 C-N-CA 123.329 2.686 . . . . 0.0 114.852 -177.195 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 28.3 m 29.59 -52.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.522 3.147 0 N-CA-C 120.116 3.376 . . . . 0.0 120.116 172.431 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.407 ' O ' HG22 ' A' ' 95' ' ' ILE . 59.5 ttt180 -156.8 141.65 17.0 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 123.828 0.851 . . . . 0.0 109.23 -176.183 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 28.1 m -71.83 132.09 43.95 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 120.797 0.332 . . . . 0.0 110.183 177.756 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 86.1 m -151.47 143.52 23.92 Favored 'General case' 0 N--CA 1.437 -1.086 0 C-N-CA 123.729 0.812 . . . . 0.0 109.054 178.507 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 51.3 tt0 -134.26 133.78 41.19 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 178.708 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 156.25 -172.59 34.11 Favored Glycine 0 N--CA 1.437 -1.287 0 C-N-CA 119.925 -1.131 . . . . 0.0 112.096 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 31.0 m -129.68 148.51 69.74 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 75.4 Cg_exo -51.55 131.79 38.29 Favored 'Trans proline' 0 CA--C 1.545 1.063 0 C-N-CA 122.801 2.334 . . . . 0.0 113.125 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 6.4 Cg_endo -100.24 10.17 23.42 Favored 'Cis proline' 0 CA--C 1.544 1.005 0 C-N-CA 124.779 -0.925 . . . . 0.0 113.044 -3.235 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -93.55 102.31 14.51 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.793 0.806 . . . . 0.0 112.096 -174.692 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 39.3 p-80 -104.68 138.52 40.87 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.11 178.648 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.447 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 70.2 mt -92.68 110.37 44.87 Favored Pre-proline 0 C--N 1.305 -1.351 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 173.702 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -84.59 126.09 3.46 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 122.659 2.239 . . . . 0.0 113.942 -177.42 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -102.76 -138.34 9.95 Favored Glycine 0 N--CA 1.437 -1.28 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 176.374 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 60.4 t -73.85 127.83 35.92 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 C-N-CA 122.996 0.518 . . . . 0.0 111.801 -177.236 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.11 141.72 28.22 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.147 177.49 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.6 m0 -99.59 -4.89 30.07 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 119.59 -0.844 . . . . 0.0 111.615 177.016 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -160.61 -175.27 31.43 Favored Glycine 0 N--CA 1.43 -1.703 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -177.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 46.9 t -110.95 134.76 52.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 C-N-CA 122.963 0.505 . . . . 0.0 109.675 -174.084 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -101.03 110.92 23.0 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.6 tptt . . . . . 0 C--N 1.294 -1.84 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -177.786 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 24.0 m . . . . . 0 N--CA 1.445 -0.709 0 CA-C-O 120.2 0.048 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -124.3 162.11 24.44 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.395 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -100.16 -60.67 1.48 Allowed 'General case' 0 N--CA 1.428 -1.564 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.662 -177.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.59 ' HA ' ' CE2' ' A' ' 6' ' ' TYR . 6.9 mtpm? -133.25 7.77 3.95 Favored 'General case' 0 C--O 1.246 0.871 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -177.199 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.448 ' ND2' ' H ' ' A' ' 18' ' ' LYS . 48.1 t-20 -88.0 82.46 7.21 Favored 'General case' 0 CA--C 1.504 -0.82 0 C-N-CA 118.832 -1.147 . . . . 0.0 108.954 175.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' TYR . . . . . 0.59 ' CE2' ' HA ' ' A' ' 4' ' ' LYS . 8.9 p90 -142.7 154.01 43.91 Favored 'General case' 0 N--CA 1.411 -2.392 0 CA-C-N 113.691 -1.595 . . . . 0.0 108.248 178.504 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' MET . . . . . 0.457 ' SD ' ' HB3' ' A' ' 9' ' ' LYS . 0.0 OUTLIER 179.04 89.16 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 104.864 -2.273 . . . . 0.0 104.864 177.671 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -87.13 92.07 8.93 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-O 121.312 0.577 . . . . 0.0 110.454 -176.242 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.457 ' HB3' ' SD ' ' A' ' 7' ' ' MET . 25.3 ttmm -178.5 160.9 1.29 Allowed 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 104.422 -2.436 . . . . 0.0 104.422 178.771 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -114.64 78.96 0.27 Allowed Glycine 0 N--CA 1.428 -1.894 0 C-N-CA 120.295 -0.955 . . . . 0.0 110.801 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 12.9 p -77.56 -39.12 46.9 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-O 120.934 0.397 . . . . 0.0 111.293 -177.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 75.4 m -159.34 -69.12 0.08 Allowed 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 123.476 0.711 . . . . 0.0 110.021 176.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.414 ' HB2' ' HB3' ' A' ' 92' ' ' ALA . 10.7 m -139.27 43.2 2.04 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 p -79.37 -179.11 6.6 Favored 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.017 -178.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 29.9 p 59.81 16.11 5.37 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -176.393 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 17.6 m -67.04 -41.52 87.36 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.781 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.036 177.021 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 45.8 t 59.67 94.19 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.88 0 N-CA-C 115.264 1.579 . . . . 0.0 115.264 173.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.448 ' H ' ' ND2' ' A' ' 5' ' ' ASN . 56.3 mtpt -135.19 96.17 3.44 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 173.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.423 ' HB2' ' HB2' ' A' ' 5' ' ' ASN . 17.5 t70 -170.37 155.8 5.35 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -177.702 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 143.88 -144.96 14.22 Favored Glycine 0 N--CA 1.41 -3.093 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 -178.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt 62.14 -88.78 0.03 OUTLIER 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.395 1.078 . . . . 0.0 110.944 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -158.18 73.79 0.68 Allowed 'General case' 0 C--N 1.31 -1.112 0 C-N-CA 124.187 0.995 . . . . 0.0 109.015 177.038 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.406 ' HB3' HG21 ' A' ' 33' ' ' VAL . 25.1 m -114.92 -32.14 5.86 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.289 -177.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 58.2 m -146.59 25.2 1.2 Allowed 'General case' 0 C--N 1.317 -0.83 0 O-C-N 121.957 -0.465 . . . . 0.0 110.455 177.662 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -64.03 -45.15 90.17 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-O 121.281 0.562 . . . . 0.0 110.54 -179.061 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 30.2 m -102.63 12.08 36.85 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.526 178.611 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 62.0 p 65.48 153.08 0.12 Allowed Pre-proline 0 CA--C 1.55 0.972 0 C-N-CA 126.805 2.042 . . . . 0.0 111.956 -175.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_exo -43.29 -49.36 7.44 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 123.721 2.947 . . . . 0.0 114.412 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 53.41 58.29 5.36 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 121.772 0.796 . . . . 0.0 110.006 -177.107 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.9 m 69.87 9.39 7.12 Favored 'General case' 0 CA--C 1.577 2.018 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.865 -177.227 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 21.5 tpp180 -139.68 77.14 28.37 Favored Pre-proline 0 CA--C 1.551 1.018 0 O-C-N 121.236 -0.915 . . . . 0.0 112.485 177.322 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.69 140.9 83.28 Favored 'Trans proline' 0 C--O 1.239 0.554 0 C-N-CA 122.198 1.932 . . . . 0.0 109.982 169.377 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.406 HG21 ' HB3' ' A' ' 23' ' ' SER . 22.8 m -84.84 4.95 2.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-O 121.4 0.619 . . . . 0.0 111.349 -177.135 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 3.7 p -84.81 -0.21 53.08 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.769 178.544 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 78.23 -135.42 15.94 Favored Glycine 0 N--CA 1.429 -1.779 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.729 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 10.0 m -91.27 10.09 28.7 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 123.203 0.601 . . . . 0.0 110.964 -177.451 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' TRP . . . . . 0.484 ' CZ3' HG13 ' A' ' 90' ' ' ILE . 60.3 m95 -89.16 140.16 29.75 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 120.901 0.382 . . . . 0.0 110.798 -176.501 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 38.7 ttmt -114.45 151.18 33.6 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 61.7 tttm -93.26 144.74 25.02 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.513 0.673 . . . . 0.0 112.368 -175.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -107.91 156.12 19.54 Favored 'General case' 0 C--O 1.253 1.274 0 C-N-CA 125.182 1.393 . . . . 0.0 108.763 175.065 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 16.6 pm0 -62.08 -23.29 66.42 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.462 1.105 . . . . 0.0 113.183 -178.608 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -84.26 -3.26 58.1 Favored 'General case' 0 C--N 1.322 -0.6 0 O-C-N 121.819 -0.551 . . . . 0.0 111.4 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.9 -6.46 60.22 Favored Glycine 0 CA--C 1.5 -0.902 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 17.0 m -73.32 144.79 46.41 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 68.1 m95 -114.92 138.94 50.22 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 175.166 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -138.23 149.05 45.39 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 120.663 0.268 . . . . 0.0 111.676 -175.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.7 pttt -130.68 140.51 38.89 Favored Pre-proline 0 C--N 1.3 -1.567 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 176.373 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -75.2 121.99 6.83 Favored 'Trans proline' 0 C--O 1.254 1.309 0 C-N-CA 121.86 1.707 . . . . 0.0 109.354 172.533 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -166.24 122.33 1.27 Allowed 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -178.352 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.444 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 20.1 m120 -94.17 123.89 37.84 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.213 -178.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.43 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -149.39 175.09 11.76 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 176.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.424 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 11.8 m -115.91 148.62 39.83 Favored 'General case' 0 N--CA 1.419 -2.013 0 CA-C-O 121.349 0.595 . . . . 0.0 110.589 -174.573 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -131.46 122.67 26.63 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 175.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.3 t -104.11 112.68 38.58 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.242 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 176.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -75.12 138.5 42.1 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 120.124 -0.63 . . . . 0.0 110.17 -177.01 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -167.41 174.53 42.56 Favored Glycine 0 N--CA 1.423 -2.202 0 N-CA-C 107.913 -2.075 . . . . 0.0 107.913 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 36.8 t30 79.58 -45.6 0.33 Allowed 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 124.91 1.284 . . . . 0.0 110.209 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 4.0 pt20 -158.18 153.16 21.32 Favored Pre-proline 0 N--CA 1.413 -2.303 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.581 178.199 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -72.34 131.03 17.05 Favored 'Trans proline' 0 N--CA 1.444 -1.418 0 N-CA-C 107.418 -1.801 . . . . 0.0 107.418 167.029 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 49.2 mt -108.47 124.3 64.79 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 C-N-CA 120.3 -0.56 . . . . 0.0 109.745 -174.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.0 p -76.44 127.8 37.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 176.151 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 37.1 p -106.3 167.99 9.45 Favored 'General case' 0 N--CA 1.416 -2.157 0 CA-C-O 121.264 0.554 . . . . 0.0 111.41 -173.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 18.2 mmt180 -114.96 143.9 44.43 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 55.4 mt -111.93 134.63 53.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 C-N-CA 120.384 -0.527 . . . . 0.0 111.913 -175.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.09 -23.32 3.9 Favored Glycine 0 C--N 1.32 -0.329 0 N-CA-C 116.344 1.298 . . . . 0.0 116.344 171.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.8 m -155.87 137.1 9.36 Favored Pre-proline 0 C--N 1.301 -1.54 0 CA-C-N 118.228 1.014 . . . . 0.0 110.118 -179.1 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -89.86 121.44 0.99 Allowed 'Trans proline' 0 N--CA 1.444 -1.416 0 C-N-CA 122.24 1.96 . . . . 0.0 112.168 175.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -163.27 170.25 17.94 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 104.414 -2.439 . . . . 0.0 104.414 178.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -82.41 -26.08 33.11 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.255 0.55 . . . . 0.0 110.294 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -107.09 25.7 11.06 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 122.396 1.093 . . . . 0.0 108.498 178.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -68.64 157.57 88.0 Favored Pre-proline 0 C--N 1.318 -0.791 0 CA-C-N 115.186 -0.916 . . . . 0.0 111.336 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -53.96 133.47 55.0 Favored 'Trans proline' 0 C--N 1.361 1.205 0 C-N-CA 123.274 2.65 . . . . 0.0 113.623 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.7 m -99.22 176.23 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.012 0 C-N-CA 124.626 1.17 . . . . 0.0 110.662 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.59 4.53 10.67 Favored Glycine 0 CA--C 1.498 -0.972 0 C-N-CA 121.13 -0.557 . . . . 0.0 111.732 -178.66 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -122.12 124.48 5.76 Favored Glycine 0 N--CA 1.419 -2.434 0 N-CA-C 108.401 -1.88 . . . . 0.0 108.401 174.026 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -128.62 126.79 40.96 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 117.881 0.841 . . . . 0.0 109.668 176.326 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 49.4 tp -97.58 114.7 65.28 Favored Pre-proline 0 C--N 1.301 -1.511 0 C-N-CA 122.346 0.258 . . . . 0.0 110.337 -177.288 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -73.1 160.21 46.03 Favored 'Trans proline' 0 C--O 1.243 0.763 0 C-N-CA 122.348 2.032 . . . . 0.0 111.185 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.31 153.86 35.54 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.4 10.42 79.93 Favored Glycine 0 C--N 1.313 -0.738 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -178.446 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.16 126.41 38.25 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 60.1 m -96.82 108.78 21.52 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 177.093 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.6 mm -108.69 119.29 58.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.636 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.1 p -99.74 107.77 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.37 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 174.042 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.444 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 44.4 p90 -98.32 163.86 12.53 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.282 -174.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -125.38 -11.17 6.9 Favored 'General case' 0 C--N 1.318 -0.768 0 O-C-N 123.443 0.464 . . . . 0.0 111.538 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.433 ' HB2' ' NH2' ' A' ' 106' ' ' ARG . 31.1 tt0 -126.39 124.17 39.6 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -175.322 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 40.6 t -112.59 120.8 63.6 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.491 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.604 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 26.4 p -130.96 152.23 50.5 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 120.328 -0.549 . . . . 0.0 112.377 -176.671 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.484 HG13 ' CZ3' ' A' ' 37' ' ' TRP . 76.5 mt -112.74 113.64 44.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.169 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.049 177.314 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.518 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -112.1 113.66 26.06 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 103.363 -2.828 . . . . 0.0 103.363 169.102 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.414 ' HB3' ' HB2' ' A' ' 13' ' ' SER . . . -48.6 109.76 0.28 Allowed 'General case' 0 C--O 1.241 0.635 0 O-C-N 124.722 1.264 . . . . 0.0 113.21 -164.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 137.4 -36.74 1.92 Allowed Glycine 0 N--CA 1.424 -2.118 0 CA-C-N 113.636 -1.62 . . . . 0.0 109.185 -176.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 52.9 m80 -149.02 165.33 31.97 Favored 'General case' 0 CA--C 1.5 -0.946 0 O-C-N 122.478 -0.424 . . . . 0.0 109.911 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.5 tt -103.24 135.84 38.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 N-CA-C 104.491 -2.411 . . . . 0.0 104.491 171.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.604 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 49.4 m95 -119.25 135.23 54.79 Favored 'General case' 0 C--N 1.275 -2.646 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 -173.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.492 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 47.0 pt -100.5 132.38 46.25 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 177.4 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.94 124.64 8.14 Favored Glycine 0 N--CA 1.425 -2.085 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -137.72 164.83 27.89 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 29.1 p-10 -117.54 137.5 52.54 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.982 0.42 . . . . 0.0 110.615 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.412 ' HB3' ' OD1' ' A' ' 105' ' ' ASN . . . -91.12 174.64 7.3 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.596 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -66.88 -12.08 58.12 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 121.263 0.554 . . . . 0.0 112.131 -177.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -81.01 -12.7 59.31 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.187 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 87.82 9.11 71.91 Favored Glycine 0 CA--C 1.505 -0.583 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.995 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.412 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 18.2 p-10 -91.86 147.58 22.87 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.126 0.489 . . . . 0.0 110.165 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ARG . . . . . 0.433 ' NH2' ' HB2' ' A' ' 87' ' ' GLU . 18.0 tpt180 -94.61 115.3 27.4 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -175.46 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 24.3 t -111.39 139.9 33.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -176.704 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.492 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 94.1 m-85 -118.47 132.32 56.24 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 123.641 0.776 . . . . 0.0 110.943 -178.52 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' CYS . . . . . 0.415 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 45.9 t -111.78 131.95 22.16 Favored Pre-proline 0 C--N 1.308 -1.201 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.363 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -70.69 -13.85 32.67 Favored 'Trans proline' 0 C--N 1.367 1.552 0 C-N-CA 123.311 2.674 . . . . 0.0 114.763 -176.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.31 35.9 m 38.86 -60.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.459 0 N-CA-C 119.072 2.99 . . . . 0.0 119.072 175.329 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 37.5 ptt180 -155.08 156.71 36.34 Favored 'General case' 0 C--O 1.248 0.977 0 O-C-N 121.894 -0.504 . . . . 0.0 109.717 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 25.3 m -64.54 136.78 57.39 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 174.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 65.3 m -149.67 128.05 12.19 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.727 0.775 . . . . 0.0 110.657 176.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -119.68 161.77 20.14 Favored 'General case' 0 C--N 1.286 -2.157 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.14 -167.13 12.85 Favored Glycine 0 C--N 1.286 -2.214 0 C-N-CA 118.918 -1.611 . . . . 0.0 112.284 177.157 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 24.6 m -140.91 147.33 47.66 Favored Pre-proline 0 C--N 1.306 -1.323 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.404 ' HB3' ' CG ' ' A' ' 37' ' ' TRP . 85.6 Cg_exo -48.63 136.1 27.18 Favored 'Trans proline' 0 CA--C 1.543 0.943 0 C-N-CA 123.24 2.627 . . . . 0.0 113.013 178.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -88.73 -19.72 15.55 Favored 'Cis proline' 0 CA--C 1.544 1.005 0 C-N-CA 123.779 -1.342 . . . . 0.0 113.176 -0.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 90.0 m-20 -77.34 102.2 6.66 Favored 'General case' 0 C--O 1.244 0.791 0 CA-C-O 122.244 1.021 . . . . 0.0 112.877 -172.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 32.4 p-80 -104.69 131.05 52.59 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 113.847 -1.524 . . . . 0.0 109.867 178.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.449 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 55.4 mt -96.66 108.6 43.7 Favored Pre-proline 0 C--N 1.286 -2.161 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -178.7 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -78.88 161.39 27.11 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.584 2.189 . . . . 0.0 112.521 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -134.74 -124.31 2.44 Favored Glycine 0 N--CA 1.437 -1.265 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 177.047 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.6 t -77.26 124.01 34.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 116.938 0.369 . . . . 0.0 110.795 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.5 151.32 19.44 Favored 'General case' 0 C--O 1.246 0.908 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.217 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.6 m-90 -124.98 29.64 6.09 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.93 178.501 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -169.4 -173.27 36.85 Favored Glycine 0 N--CA 1.434 -1.461 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 -179.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 47.4 t -114.63 115.28 49.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.164 0.507 . . . . 0.0 109.983 -178.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -83.72 130.19 34.95 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.007 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.424 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 1.6 tmtp? . . . . . 0 N--CA 1.421 -1.908 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 -176.083 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 22.2 t . . . . . 0 N--CA 1.449 -0.487 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -143.53 147.02 33.84 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 -177.546 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -158.64 89.47 0.96 Allowed 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -89.2 95.8 10.45 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.187 -179.48 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -101.19 109.33 21.18 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.59 0.709 . . . . 0.0 110.838 178.369 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -131.54 174.61 9.92 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 178.107 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 47.8 ttm 71.42 -43.23 0.56 Allowed 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 124.322 1.049 . . . . 0.0 112.571 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -64.45 155.12 33.69 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 123.685 0.794 . . . . 0.0 110.512 178.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.554 ' HD2' ' N ' ' A' ' 10' ' ' GLY . 0.5 OUTLIER -51.19 -28.68 11.89 Favored 'General case' 0 CA--C 1.547 0.839 0 N-CA-C 113.34 0.867 . . . . 0.0 113.34 177.671 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.554 ' N ' ' HD2' ' A' ' 9' ' ' LYS . . . 68.75 -113.5 5.3 Favored Glycine 0 N--CA 1.441 -0.989 0 N-CA-C 114.004 0.362 . . . . 0.0 114.004 174.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 15.8 p -71.24 98.6 1.75 Allowed 'General case' 0 N--CA 1.435 -1.195 0 CA-C-O 121.389 0.614 . . . . 0.0 111.216 -178.767 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 20.2 m -145.05 74.48 1.41 Allowed 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 177.432 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.4 m -87.47 -42.93 12.44 Favored 'General case' 0 N--CA 1.422 -1.85 0 CA-C-N 114.011 -1.449 . . . . 0.0 111.049 -174.164 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.8 m -82.81 3.97 27.28 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.768 0.794 . . . . 0.0 110.394 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 4.0 m -87.74 22.01 2.42 Favored 'General case' 0 CA--C 1.559 1.299 0 C-N-CA 124.296 1.038 . . . . 0.0 109.68 179.515 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.7 m -92.13 150.39 3.84 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 175.012 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 17.8 t 67.97 23.15 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.562 1.409 0 CA-C-O 123.621 1.677 . . . . 0.0 107.847 -175.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 52.5 tptt -77.27 -31.26 54.76 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 113.279 -1.782 . . . . 0.0 108.11 176.395 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -91.2 -167.25 1.76 Allowed 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 114.826 -1.079 . . . . 0.0 108.17 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 165.96 -47.04 0.27 Allowed Glycine 0 N--CA 1.43 -1.742 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 -178.294 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 58.4 tptt -93.68 104.07 16.19 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.097 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 32.2 p 54.97 79.84 0.14 Allowed 'General case' 0 C--O 1.243 0.718 0 C-N-CA 124.618 1.167 . . . . 0.0 112.977 -178.066 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 37.5 m -75.6 136.23 40.5 Favored 'General case' 0 N--CA 1.429 -1.504 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.956 -177.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.8 t 66.86 23.66 9.93 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.163 0.985 . . . . 0.0 110.017 -179.212 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.14 -45.07 87.99 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 176.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 19.7 m -103.08 94.98 5.83 Favored 'General case' 0 N--CA 1.414 -2.237 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 170.211 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 16.8 m -76.59 130.25 77.19 Favored Pre-proline 0 N--CA 1.431 -1.408 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.281 -174.59 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -69.46 91.72 0.48 Allowed 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 121.958 1.772 . . . . 0.0 110.416 173.582 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -136.89 -39.51 0.62 Allowed 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.968 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.9 m -87.9 -35.41 17.73 Favored 'General case' 0 N--CA 1.435 -1.192 0 CA-C-O 121.061 0.458 . . . . 0.0 110.153 -179.462 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -73.45 -56.91 2.89 Favored Pre-proline 0 CA--C 1.554 1.102 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 -175.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -61.61 103.07 0.26 Allowed 'Trans proline' 0 C--N 1.374 1.916 0 C-N-CA 121.724 1.616 . . . . 0.0 112.965 178.366 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.3 m -83.55 136.13 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 176.49 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 55.2 m 73.5 132.99 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.025 0 O-C-N 124.051 0.844 . . . . 0.0 110.119 -175.795 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 128.09 -38.18 2.14 Favored Glycine 0 CA--C 1.489 -1.535 0 N-CA-C 108.168 -1.973 . . . . 0.0 108.168 -174.525 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 2.9 p -70.15 -53.1 18.71 Favored 'General case' 0 N--CA 1.426 -1.658 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 172.42 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.3 m95 -87.04 133.22 33.61 Favored 'General case' 0 N--CA 1.432 -1.372 0 CA-C-N 114.051 -1.431 . . . . 0.0 107.725 173.324 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.4 mptt -113.91 155.2 26.22 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 176.708 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -102.99 132.48 49.23 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.803 -0.759 . . . . 0.0 108.967 178.833 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.454 ' ND2' ' HB ' ' A' ' 44' ' ' THR . 38.7 p30 -86.5 178.19 7.17 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 175.222 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 -70.1 -23.12 63.0 Favored 'General case' 0 C--N 1.31 -1.134 0 CA-C-O 121.114 0.483 . . . . 0.0 111.144 -176.289 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.465 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 26.7 m-85 -74.87 -13.92 60.61 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.163 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.41 7.07 57.25 Favored Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.829 178.283 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.454 ' HB ' ' ND2' ' A' ' 40' ' ' ASN . 5.8 m -88.34 137.57 32.2 Favored 'General case' 0 N--CA 1.424 -1.755 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 92.2 m95 -96.44 122.29 39.17 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 176.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 54.4 p90 -123.58 152.34 41.97 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 120.869 0.366 . . . . 0.0 111.973 -174.536 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.0 ptmt -141.03 147.18 46.67 Favored Pre-proline 0 N--CA 1.433 -1.292 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 171.5 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -77.09 122.09 6.06 Favored 'Trans proline' 0 N--CA 1.445 -1.327 0 C-N-CA 121.492 1.461 . . . . 0.0 109.222 172.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.5 tp10 -153.35 125.74 8.09 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 -179.324 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.501 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 7.7 t30 -109.57 107.49 17.6 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.203 0.525 . . . . 0.0 111.098 -175.557 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.414 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -143.56 171.42 14.18 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.451 ' HB ' ' HB2' ' A' ' 131' ' ' LYS . 6.4 m -104.32 147.76 27.15 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -176.632 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -127.08 138.26 53.17 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 175.328 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.3 t -118.65 117.0 53.01 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 176.041 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.481 ' ND2' ' HA ' ' A' ' 79' ' ' ALA . 48.4 t30 -70.61 148.43 48.12 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.291 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -83.42 -132.7 2.05 Favored Glycine 0 N--CA 1.434 -1.471 0 N-CA-C 114.364 0.506 . . . . 0.0 114.364 -174.177 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -91.05 -4.32 56.45 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -171.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.4 ' HA ' ' HD3' ' A' ' 59' ' ' PRO . 0.0 OUTLIER -131.95 153.09 81.28 Favored Pre-proline 0 C--N 1.306 -1.285 0 C-N-CA 120.007 -0.677 . . . . 0.0 112.261 179.723 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 58' ' ' GLN . 7.4 Cg_exo -74.76 136.72 21.31 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.056 1.837 . . . . 0.0 111.079 176.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 61.0 mt -107.81 133.63 52.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -177.483 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.9 p -82.09 137.53 20.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 177.09 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 54.7 p -117.07 179.03 4.14 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.565 -172.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.425 ' NH1' HG12 ' A' ' 73' ' ' VAL . 47.2 mmt-85 -122.05 144.3 48.99 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 59.1 mt -106.35 125.99 62.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.868 -177.635 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.51 -22.64 1.68 Allowed Glycine 0 CA--C 1.527 0.812 0 N-CA-C 116.569 1.388 . . . . 0.0 116.569 171.515 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.5 m -145.68 134.17 10.86 Favored Pre-proline 0 C--N 1.3 -1.558 0 CA-C-N 118.562 1.181 . . . . 0.0 110.315 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -90.08 120.41 0.86 Allowed 'Trans proline' 0 N--CA 1.441 -1.614 0 C-N-CA 121.732 1.622 . . . . 0.0 111.624 174.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.587 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 93.1 m-85 -168.16 175.54 6.51 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 104.873 -2.269 . . . . 0.0 104.873 178.528 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -81.85 -45.3 15.7 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 176.647 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -94.04 25.93 3.48 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.108 -0.951 . . . . 0.0 111.151 -178.819 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.587 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.55 162.9 71.75 Favored Pre-proline 0 C--N 1.317 -0.835 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.468 178.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_exo -48.87 123.31 9.54 Favored 'Trans proline' 0 C--N 1.369 1.652 0 C-N-CA 123.537 2.825 . . . . 0.0 114.158 179.324 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.425 HG12 ' NH1' ' A' ' 63' ' ' ARG . 31.2 m -97.55 174.38 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.184 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.34 28.8 1.89 Allowed Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -150.94 126.61 2.16 Favored Glycine 0 N--CA 1.428 -1.896 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -127.39 136.79 52.35 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 57.2 tp -97.45 115.64 65.77 Favored Pre-proline 0 C--N 1.302 -1.463 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -59.24 152.67 58.4 Favored 'Trans proline' 0 C--O 1.245 0.856 0 C-N-CA 123.005 2.47 . . . . 0.0 112.609 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.481 ' HA ' ' ND2' ' A' ' 55' ' ' ASN . . . -73.42 139.97 46.22 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.13 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.74 -4.82 77.71 Favored Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 116.113 -0.494 . . . . 0.0 113.108 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.93 134.06 40.34 Favored 'General case' 0 N--CA 1.439 -1.018 0 CA-C-O 120.774 0.321 . . . . 0.0 110.893 -177.723 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 14.6 t -108.0 134.66 50.59 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 177.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 44.6 mm -132.05 140.14 48.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -177.223 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.5 p -103.96 113.41 40.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-O 121.965 0.888 . . . . 0.0 109.582 175.445 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.501 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 43.2 p90 -97.15 152.95 18.3 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.417 -175.019 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -119.77 4.28 11.04 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.657 0.741 . . . . 0.0 110.345 -178.652 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -142.06 132.96 25.83 Favored 'General case' 0 N--CA 1.426 -1.656 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.391 -175.421 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.8 t -124.68 128.27 73.31 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.452 ' HB2' HG22 ' A' ' 44' ' ' THR . 20.5 p -139.49 140.83 37.33 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-O 121.236 0.541 . . . . 0.0 111.421 -178.662 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.468 HG21 ' HA3' ' A' ' 116' ' ' GLY . 75.1 mt -101.03 114.87 41.51 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.731 179.488 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.586 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 50.0 tp60 -116.04 127.63 55.05 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 104.813 -2.292 . . . . 0.0 104.813 173.702 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.04 110.93 0.37 Allowed 'General case' 0 C--O 1.243 0.731 0 N-CA-C 113.275 0.842 . . . . 0.0 113.275 -167.338 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 124.23 -28.87 5.22 Favored Glycine 0 N--CA 1.438 -1.183 0 CA-C-N 114.498 -1.228 . . . . 0.0 112.729 179.151 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 74.8 m80 -151.12 169.9 20.74 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -176.342 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 19.0 tt -110.96 128.0 67.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.095 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 172.572 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.586 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 65.2 m95 -110.46 131.14 55.32 Favored 'General case' 0 C--N 1.274 -2.692 0 CA-C-O 120.966 0.412 . . . . 0.0 110.196 -173.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.505 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.5 pt -100.3 134.61 39.4 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.235 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.96 128.14 9.32 Favored Glycine 0 N--CA 1.428 -1.879 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 -178.607 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -151.38 163.93 37.85 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -97.77 116.81 30.72 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 174.461 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.09 178.25 6.5 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.999 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 46.5 p90 -47.49 -27.93 1.97 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 126.044 1.737 . . . . 0.0 113.858 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -99.27 2.42 45.54 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 112.222 0.453 . . . . 0.0 112.222 -175.751 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.85 0.67 81.07 Favored Glycine 0 C--N 1.32 -0.329 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.158 176.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -81.03 135.89 35.9 Favored 'General case' 0 C--N 1.306 -1.32 0 O-C-N 122.651 -0.323 . . . . 0.0 111.038 -178.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 4.1 tpp180 -75.29 102.24 4.99 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 173.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 67.6 t -108.27 143.87 17.89 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.029 0 CA-C-N 114.674 -1.148 . . . . 0.0 109.725 -174.033 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.505 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 96.5 m-85 -117.74 124.08 47.58 Favored 'General case' 0 N--CA 1.426 -1.647 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.273 178.671 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.8 t -104.13 133.71 20.08 Favored Pre-proline 0 C--N 1.298 -1.673 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -68.71 -22.88 36.76 Favored 'Trans proline' 0 C--N 1.359 1.115 0 C-N-CA 122.967 2.445 . . . . 0.0 113.472 -177.253 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.295 34.2 m 46.99 -53.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.207 0 N-CA-C 118.41 2.744 . . . . 0.0 118.41 175.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.526 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 38.9 ptt180 -158.93 156.77 30.11 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 122.832 0.453 . . . . 0.0 110.553 -178.298 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 2.6 p -72.83 136.99 45.46 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 175.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.429 ' SG ' ' HG3' ' A' ' 112' ' ' ARG . 96.1 m -154.37 133.04 12.16 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.838 0.352 . . . . 0.0 111.54 -178.827 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 29.9 mm-40 -97.11 113.38 24.95 Favored 'General case' 0 N--CA 1.427 -1.595 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 171.524 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.468 ' HA3' HG21 ' A' ' 90' ' ' ILE . . . -122.01 113.96 2.39 Favored Glycine 0 C--N 1.259 -3.697 0 C-N-CA 119.779 -1.201 . . . . 0.0 114.014 -173.577 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 7.0 m -125.97 97.14 35.91 Favored Pre-proline 0 C--N 1.293 -1.878 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 172.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 61.9 Cg_exo -42.84 130.77 5.66 Favored 'Trans proline' 0 C--N 1.357 0.994 0 C-N-CA 124.327 3.351 . . . . 0.0 114.774 -170.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 7.4 Cg_endo -92.71 8.0 59.8 Favored 'Cis proline' 0 CA--C 1.549 1.236 0 C-N-CA 124.412 -1.078 . . . . 0.0 113.046 1.243 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -74.93 102.03 4.64 Favored 'General case' 0 CA--C 1.508 -0.672 0 CA-C-O 121.563 0.697 . . . . 0.0 110.229 -175.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.422 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 37.4 p-80 -104.78 107.03 17.77 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.592 177.429 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.5 mt -100.2 100.44 11.77 Favored Pre-proline 0 C--N 1.318 -0.791 0 C-N-CA 122.703 0.401 . . . . 0.0 109.925 -177.166 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.422 ' HD3' ' O ' ' A' ' 121' ' ' HIS . 2.9 Cg_endo -81.48 150.69 17.15 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 122.774 2.316 . . . . 0.0 113.265 -178.209 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.45 -116.13 3.3 Favored Glycine 0 N--CA 1.423 -2.228 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 175.022 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.3 t -97.39 124.45 50.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-O 120.801 0.334 . . . . 0.0 110.426 -176.179 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.526 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -95.02 146.88 23.96 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.708 177.445 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.7 m-90 -101.49 12.82 36.63 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 121.555 0.693 . . . . 0.0 109.246 177.283 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.74 179.24 37.24 Favored Glycine 0 N--CA 1.43 -1.705 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 49.4 t -112.08 137.79 43.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.398 -0.594 . . . . 0.0 109.398 -176.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -102.27 135.52 43.72 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-O 120.954 0.407 . . . . 0.0 110.11 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.451 ' HB2' ' HB ' ' A' ' 52' ' ' THR . 55.9 mtpt . . . . . 0 C--N 1.295 -1.776 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.241 0.655 0 CA-C-O 121.114 0.483 . . . . 0.0 111.048 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 56.3 t30 -84.53 -37.73 20.9 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 175.156 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.77 177.34 9.17 Favored 'General case' 0 N--CA 1.429 -1.516 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 177.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt 64.74 80.28 0.23 Allowed 'General case' 0 C--N 1.323 -0.544 0 O-C-N 124.249 0.968 . . . . 0.0 113.354 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -87.47 139.71 30.27 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.682 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 16.0 t80 -105.96 24.23 12.71 Favored 'General case' 0 CA--C 1.554 1.13 0 CA-C-O 121.45 0.643 . . . . 0.0 110.908 -174.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 24.6 ttt 79.42 -9.14 1.51 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 125.18 1.392 . . . . 0.0 113.131 174.157 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 17.2 t70 73.45 119.01 0.05 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 123.859 0.864 . . . . 0.0 109.27 -174.308 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 62.1 mttp 80.18 -43.58 0.25 Allowed 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 125.449 1.5 . . . . 0.0 110.666 -177.372 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.37 60.72 1.97 Allowed Glycine 0 N--CA 1.445 -0.755 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.609 177.262 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 27.3 p 54.24 88.51 0.04 OUTLIER 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 178.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.3 m -88.37 52.22 2.39 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 177.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.8 m -60.68 126.57 27.9 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.037 0.935 . . . . 0.0 111.975 -176.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.4 t -117.54 116.57 27.39 Favored 'General case' 0 N--CA 1.434 -1.251 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.275 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 60.0 m -56.18 -32.82 64.7 Favored 'General case' 0 CA--C 1.555 1.142 0 C-N-CA 124.795 1.238 . . . . 0.0 113.712 -175.595 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.7 p -75.56 -20.18 15.9 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.005 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -176.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.7 p -113.84 -39.71 3.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 C-N-CA 120.095 -0.642 . . . . 0.0 111.83 -178.79 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -106.2 99.07 8.67 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-O 121.718 0.771 . . . . 0.0 112.057 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -86.43 -25.11 25.42 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 114.7 -1.136 . . . . 0.0 108.144 173.46 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 129.25 -55.91 0.75 Allowed Glycine 0 N--CA 1.428 -1.857 0 CA-C-N 115.523 -0.762 . . . . 0.0 112.264 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -109.1 -10.49 15.0 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 121.007 0.432 . . . . 0.0 111.2 -174.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 14.6 m 82.84 84.13 0.03 OUTLIER 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 125.163 1.385 . . . . 0.0 111.406 178.717 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.0 t -127.75 -178.09 4.36 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 114.43 -1.259 . . . . 0.0 107.955 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 37.4 m 58.47 42.45 21.06 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 123.75 0.82 . . . . 0.0 111.734 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.23 -59.33 2.75 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.887 0.375 . . . . 0.0 111.312 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 19.5 m -82.9 -46.39 13.04 Favored 'General case' 0 C--O 1.25 1.12 0 CA-C-O 121.33 0.586 . . . . 0.0 109.662 -178.402 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.8 p -106.99 115.58 59.96 Favored Pre-proline 0 N--CA 1.421 -1.885 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.791 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -70.15 -18.56 35.09 Favored 'Trans proline' 0 CA--C 1.535 0.537 0 C-N-CA 121.651 1.568 . . . . 0.0 110.786 176.193 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 62.56 -87.52 0.02 OUTLIER 'General case' 0 C--O 1.24 0.595 0 C-N-CA 125.286 1.434 . . . . 0.0 112.895 175.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.7 m -92.53 -2.29 56.32 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.566 ' HD2' ' O ' ' A' ' 35' ' ' GLY . 39.2 ptt180 53.94 85.03 0.2 Allowed Pre-proline 0 N--CA 1.478 0.96 0 C-N-CA 125.76 1.624 . . . . 0.0 112.921 177.88 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_exo -43.46 -69.55 0.08 OUTLIER 'Trans proline' 0 C--N 1.362 1.243 0 C-N-CA 124.798 3.665 . . . . 0.0 116.219 -173.484 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 41.5 t -137.94 -61.63 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-O 121.308 0.575 . . . . 0.0 110.762 -174.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.6 m -81.56 41.84 0.65 Allowed 'General case' 0 CA--C 1.558 1.274 0 C-N-CA 123.862 0.865 . . . . 0.0 110.504 -175.301 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.566 ' O ' ' HD2' ' A' ' 31' ' ' ARG . . . -121.79 62.09 0.53 Allowed Glycine 0 N--CA 1.433 -1.521 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.486 -177.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 74.2 m -167.82 -68.23 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.062 0 C-N-CA 124.905 1.282 . . . . 0.0 108.509 177.289 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 47.8 m95 -92.39 152.68 19.6 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.13 -179.232 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.407 ' O ' ' HA ' ' A' ' 45' ' ' TRP . 47.9 mmtm -113.32 149.94 33.24 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.601 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -101.52 122.05 43.1 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-O 121.123 0.487 . . . . 0.0 111.086 -175.445 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -88.62 155.14 19.79 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 175.027 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 47.6 tt0 -63.47 -20.51 65.65 Favored 'General case' 0 CA--C 1.546 0.815 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -175.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -75.64 5.2 6.41 Favored 'General case' 0 CA--C 1.542 0.665 0 CA-C-O 121.225 0.536 . . . . 0.0 110.994 176.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.07 22.67 70.75 Favored Glycine 0 CA--C 1.496 -1.121 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.424 HG22 ' HB2' ' A' ' 89' ' ' CYS . 48.0 m -105.42 128.03 53.31 Favored 'General case' 0 N--CA 1.416 -2.127 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 -179.213 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.531 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 84.5 m95 -95.34 120.84 36.27 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 177.643 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -121.87 150.64 41.65 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.824 0.345 . . . . 0.0 111.66 -175.04 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 52.0 pttt -135.57 135.48 22.2 Favored Pre-proline 0 C--N 1.299 -1.623 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 173.47 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -70.78 125.68 11.86 Favored 'Trans proline' 0 C--O 1.249 1.057 0 C-N-CA 121.764 1.643 . . . . 0.0 109.933 174.518 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -165.7 120.39 1.24 Allowed 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.541 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 25.7 t-20 -102.08 107.86 19.1 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.481 0.658 . . . . 0.0 111.114 -175.77 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -143.18 179.47 7.04 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.524 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 42.0 m -115.59 150.13 37.15 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.048 0.451 . . . . 0.0 110.641 -177.405 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 82.6 t80 -131.71 127.5 36.98 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 175.715 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.8 t -111.4 106.19 20.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.619 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -71.48 152.31 43.16 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -156.02 -41.14 0.02 OUTLIER Glycine 0 N--CA 1.435 -1.423 0 C-N-CA 118.589 -1.767 . . . . 0.0 115.16 -177.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -71.21 -49.02 47.84 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 117.406 0.603 . . . . 0.0 112.538 -172.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -146.86 153.64 46.35 Favored Pre-proline 0 C--N 1.305 -1.335 0 C-N-CA 119.979 -0.688 . . . . 0.0 110.385 -176.747 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_exo -65.66 123.18 11.03 Favored 'Trans proline' 0 C--O 1.248 1.019 0 C-N-CA 121.76 1.64 . . . . 0.0 108.411 170.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 55.1 mt -107.18 125.03 63.38 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 -173.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 9.9 p -76.52 119.93 25.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 43.2 p -95.43 151.46 19.27 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.236 -175.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -102.44 137.19 41.01 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -175.647 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.1 mt -106.0 135.12 45.5 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.922 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -171.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.66 -23.45 5.69 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 116.405 1.322 . . . . 0.0 116.405 170.56 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 51.3 m -157.63 142.19 11.86 Favored Pre-proline 0 C--N 1.307 -1.254 0 CA-C-N 118.102 0.951 . . . . 0.0 109.524 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -90.05 119.54 0.8 Allowed 'Trans proline' 0 N--CA 1.439 -1.695 0 C-N-CA 121.559 1.506 . . . . 0.0 111.193 175.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.405 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 57.5 m-85 -168.38 165.77 12.63 Favored 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 126.16 1.784 . . . . 0.0 106.321 -179.344 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 89.8 mt -85.25 -14.62 46.14 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 175.009 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -106.95 13.59 27.47 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.52 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.405 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.88 155.61 90.46 Favored Pre-proline 0 C--N 1.314 -0.973 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.021 -177.393 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -56.52 140.6 89.81 Favored 'Trans proline' 0 C--N 1.364 1.364 0 C-N-CA 123.6 2.867 . . . . 0.0 114.626 -178.079 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 33.3 m -97.81 175.63 0.79 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.747 0 C-N-CA 124.668 1.187 . . . . 0.0 110.609 178.11 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 121.0 -9.17 10.41 Favored Glycine 0 CA--C 1.496 -1.101 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 -178.698 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.89 126.97 9.07 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 108.198 -1.961 . . . . 0.0 108.198 172.402 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.9 t30 -128.26 125.3 38.61 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 118.057 0.929 . . . . 0.0 110.468 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 54.4 tp -96.84 108.5 43.62 Favored Pre-proline 0 C--N 1.296 -1.755 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.005 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -67.73 159.14 54.04 Favored 'Trans proline' 0 C--O 1.245 0.86 0 C-N-CA 122.389 2.06 . . . . 0.0 112.104 178.569 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.3 136.46 39.61 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.51 -2.38 64.93 Favored Glycine 0 C--N 1.31 -0.883 0 N-CA-C 111.664 -0.574 . . . . 0.0 111.664 -179.214 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.59 134.37 37.22 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-O 120.845 0.355 . . . . 0.0 111.711 -177.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 22.1 m -98.73 109.05 21.87 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.155 -0.93 . . . . 0.0 108.837 178.391 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 43.0 mm -110.78 135.35 50.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.45 -177.431 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.3 p -108.51 129.8 62.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 176.437 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.541 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 48.4 p90 -124.65 151.9 44.33 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -177.049 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.416 ' HA ' ' HA ' ' A' ' 50' ' ' ASN . 3.9 p30 -114.81 4.93 15.06 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 120.864 0.364 . . . . 0.0 110.537 -179.47 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -148.15 139.64 23.61 Favored 'General case' 0 N--CA 1.428 -1.562 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.383 -176.066 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 41.5 t -120.38 128.19 75.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 N-CA-C 105.725 -1.954 . . . . 0.0 105.725 175.514 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.424 ' HB2' HG22 ' A' ' 44' ' ' THR . 8.7 p -139.91 143.37 36.62 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -175.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 67.8 mt -105.66 117.24 51.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.094 0.473 . . . . 0.0 110.751 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.512 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 49.3 tp60 -115.66 113.52 23.64 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 103.021 -2.955 . . . . 0.0 103.021 168.154 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.59 115.88 1.4 Allowed 'General case' 0 CA--C 1.512 -0.512 0 O-C-N 124.458 1.099 . . . . 0.0 113.189 -165.433 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 133.02 -39.11 1.78 Allowed Glycine 0 N--CA 1.419 -2.459 0 CA-C-N 113.642 -1.617 . . . . 0.0 109.066 -176.493 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 64.4 m80 -148.16 161.15 42.03 Favored 'General case' 0 CA--C 1.506 -0.72 0 C-N-CA 122.921 0.488 . . . . 0.0 110.363 -179.511 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.454 ' O ' HG22 ' A' ' 111' ' ' VAL . 16.0 tt -106.75 121.44 59.47 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 175.201 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.512 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 52.9 m95 -104.77 138.25 41.33 Favored 'General case' 0 C--N 1.279 -2.469 0 CA-C-O 120.868 0.366 . . . . 0.0 110.881 -170.345 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.5 pt -100.34 132.51 45.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 175.757 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.14 116.07 5.45 Favored Glycine 0 N--CA 1.431 -1.67 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -178.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -136.08 175.25 9.77 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -115.29 127.42 55.44 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 177.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.28 -179.42 6.97 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.5 p90 -68.0 -20.39 65.02 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 118.488 0.585 . . . . 0.0 112.432 -176.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 59.3 t30 -73.7 -12.29 60.67 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-O 121.637 0.732 . . . . 0.0 109.532 175.548 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 92.26 -12.43 69.66 Favored Glycine 0 CA--C 1.501 -0.786 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.627 178.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -72.57 147.67 45.67 Favored 'General case' 0 C--O 1.253 1.245 0 C-N-CA 123.252 0.621 . . . . 0.0 109.841 -175.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.3 tpt180 -80.66 108.29 14.19 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 124.539 1.136 . . . . 0.0 108.414 -178.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 38.2 t -112.32 145.99 17.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 -176.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.463 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 91.9 m-85 -121.49 130.86 53.81 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.038 0.447 . . . . 0.0 110.671 -177.251 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' CYS . . . . . 0.464 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 52.5 t -109.11 130.49 22.67 Favored Pre-proline 0 C--N 1.304 -1.396 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 177.36 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -70.07 -14.15 34.76 Favored 'Trans proline' 0 C--O 1.21 -0.883 0 C-N-CA 122.962 2.442 . . . . 0.0 114.564 -177.194 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.454 HG22 ' O ' ' A' ' 95' ' ' ILE 0.295 21.5 m 43.29 -54.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.518 2.949 0 N-CA-C 118.431 2.752 . . . . 0.0 118.431 176.173 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.404 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 12.1 ptm180 -156.09 150.43 25.64 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 55.1 m -64.31 144.68 56.97 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 177.004 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.448 ' SG ' ' HB2' ' A' ' 121' ' ' HIS . 27.0 t -161.16 134.18 6.35 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-O 120.954 0.407 . . . . 0.0 110.738 -178.064 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -123.81 160.92 26.31 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 176.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.62 178.04 15.48 Favored Glycine 0 N--CA 1.423 -2.195 0 C-N-CA 119.055 -1.545 . . . . 0.0 113.455 174.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 16.5 m -128.39 128.12 23.64 Favored Pre-proline 0 C--N 1.3 -1.574 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.531 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 64.5 Cg_exo -48.46 139.63 22.54 Favored 'Trans proline' 0 C--O 1.237 0.459 0 C-N-CA 123.433 2.755 . . . . 0.0 113.788 -179.294 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -81.15 -18.71 24.29 Favored 'Cis proline' 0 C--O 1.246 0.91 0 C-N-CA 123.581 -1.424 . . . . 0.0 114.018 0.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -70.67 102.0 2.19 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 122.053 0.93 . . . . 0.0 112.665 -172.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.448 ' HB2' ' SG ' ' A' ' 114' ' ' CYS . 48.8 p-80 -104.64 130.35 52.67 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-N 114.65 -1.159 . . . . 0.0 110.188 178.74 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 60.9 mt -96.49 114.32 64.18 Favored Pre-proline 0 C--N 1.301 -1.524 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -75.88 162.27 35.08 Favored 'Trans proline' 0 C--O 1.245 0.862 0 C-N-CA 122.571 2.181 . . . . 0.0 113.181 -179.113 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.85 -164.31 11.0 Favored Glycine 0 N--CA 1.433 -1.535 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 177.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.1 t -52.84 115.97 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.818 0.847 . . . . 0.0 112.562 -176.032 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.404 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -93.85 148.85 21.75 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.248 177.434 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.9 m-90 -111.17 10.91 21.86 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-O 121.103 0.478 . . . . 0.0 111.252 178.498 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.5 -175.9 33.03 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.665 -178.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 54.7 t -111.33 138.98 37.53 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -176.205 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -101.22 147.49 26.21 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-O 120.597 0.237 . . . . 0.0 110.396 -178.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.2 mtpt . . . . . 0 C--O 1.26 1.621 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 175.087 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 19.4 p . . . . . 0 N--CA 1.443 -0.79 0 CA-C-O 120.245 0.069 . . . . 0.0 111.061 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 24.2 t30 69.75 113.74 0.05 OUTLIER 'General case' 0 C--O 1.237 0.4 0 C-N-CA 124.151 0.98 . . . . 0.0 111.023 -177.341 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.77 2.19 27.23 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.223 -0.898 . . . . 0.0 112.165 -177.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt 78.18 -20.28 0.39 Allowed 'General case' 0 N--CA 1.494 1.727 0 C-N-CA 125.994 1.717 . . . . 0.0 111.586 177.316 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -146.77 128.56 15.3 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -130.17 71.72 1.46 Allowed 'General case' 0 C--N 1.308 -1.214 0 O-C-N 123.529 0.518 . . . . 0.0 110.022 177.267 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 49.6 tpp -152.31 95.46 2.05 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.902 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -97.09 79.89 2.9 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 175.438 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 tppp? -163.23 99.89 0.95 Allowed 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.491 -1.299 . . . . 0.0 107.491 -179.4 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -75.82 -2.68 71.35 Favored Glycine 0 C--N 1.313 -0.732 0 CA-C-N 115.491 -0.777 . . . . 0.0 113.691 -175.239 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 33.4 m -55.45 101.82 0.06 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.148 0.979 . . . . 0.0 111.151 178.594 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 31.0 m 62.44 19.15 10.94 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.808 0.843 . . . . 0.0 111.282 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 8.6 t -94.49 82.6 4.03 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-O 121.677 0.751 . . . . 0.0 109.15 -178.517 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.5 m -156.88 152.91 27.37 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 105.801 -1.926 . . . . 0.0 105.801 177.309 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.0 m -95.72 77.25 3.26 Favored 'General case' 0 C--N 1.294 -1.834 0 CA-C-O 121.738 0.78 . . . . 0.0 109.571 178.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 84.8 t -107.02 -53.09 6.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.769 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.8 t -90.4 125.69 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 178.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.499 ' N ' ' HD2' ' A' ' 18' ' ' LYS . 0.1 OUTLIER -94.13 92.58 7.36 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.161 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -82.0 140.08 34.16 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.713 -178.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.92 -15.02 68.77 Favored Glycine 0 C--N 1.317 -0.478 0 O-C-N 123.412 0.445 . . . . 0.0 113.184 -177.761 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.636 ' HE2' ' HA ' ' A' ' 21' ' ' LYS . 9.6 mmpt? 71.54 77.43 0.17 Allowed 'General case' 0 CA--C 1.509 -0.604 0 C-N-CA 124.783 1.233 . . . . 0.0 111.179 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 87.5 m -86.78 111.17 20.47 Favored 'General case' 0 N--CA 1.415 -2.21 0 CA-C-N 114.48 -1.236 . . . . 0.0 108.173 177.532 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.8 t -88.34 -169.63 2.64 Favored 'General case' 0 N--CA 1.417 -2.119 0 CA-C-N 114.98 -1.009 . . . . 0.0 109.567 -176.523 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.0 m -68.43 102.19 1.38 Allowed 'General case' 0 N--CA 1.423 -1.802 0 C-N-CA 123.858 0.863 . . . . 0.0 111.051 -178.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 67.59 86.15 0.13 Allowed 'General case' 0 C--O 1.243 0.73 0 C-N-CA 125.512 1.525 . . . . 0.0 113.977 176.129 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 19.7 m -73.16 133.73 44.17 Favored 'General case' 0 N--CA 1.435 -1.225 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 172.852 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 27.6 m 68.16 89.86 0.09 OUTLIER Pre-proline 0 CA--C 1.552 1.032 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -175.118 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_exo -63.09 -32.28 75.21 Favored 'Trans proline' 0 C--N 1.354 0.821 0 C-N-CA 123.0 2.467 . . . . 0.0 113.665 -175.76 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 60.26 -163.47 0.24 Allowed 'General case' 0 C--O 1.252 1.206 0 O-C-N 124.06 0.85 . . . . 0.0 109.009 -175.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 32.3 m -84.95 95.34 9.02 Favored 'General case' 0 N--CA 1.422 -1.834 0 CA-C-O 121.95 0.881 . . . . 0.0 109.357 175.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.535 ' H ' ' HD2' ' A' ' 32' ' ' PRO . 44.1 ttp180 -142.19 -52.23 0.02 OUTLIER Pre-proline 0 C--N 1.3 -1.565 0 CA-C-N 113.855 -1.521 . . . . 0.0 109.567 -179.428 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.535 ' HD2' ' H ' ' A' ' 31' ' ' ARG . 10.5 Cg_endo -57.49 125.95 20.4 Favored 'Trans proline' 0 C--N 1.386 2.521 0 N-CA-C 108.847 -1.251 . . . . 0.0 108.847 170.838 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 23.1 m -64.62 111.47 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 CA-C-O 121.76 0.791 . . . . 0.0 112.942 -175.054 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 19.0 p -96.59 25.98 4.77 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.113 -178.62 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -71.84 -66.33 2.15 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 121.186 -0.53 . . . . 0.0 112.011 -179.197 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 24.8 t -87.06 -47.07 9.22 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -86.93 122.65 31.08 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-N 115.586 -0.733 . . . . 0.0 109.715 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -113.92 141.95 46.74 Favored 'General case' 0 C--N 1.286 -2.169 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 -177.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 66.1 tttm -100.2 144.51 29.13 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 119.681 -0.808 . . . . 0.0 110.138 -179.556 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 33.0 p30 -114.73 -179.18 3.55 Favored 'General case' 0 C--O 1.254 1.326 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.545 175.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -81.51 0.63 37.09 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -175.6 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -91.79 -0.77 57.55 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 121.846 0.832 . . . . 0.0 109.073 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.95 19.65 74.76 Favored Glycine 0 CA--C 1.5 -0.885 0 CA-C-N 115.235 -0.893 . . . . 0.0 111.191 -179.103 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.447 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 28.3 m -105.65 141.13 37.64 Favored 'General case' 0 N--CA 1.41 -2.458 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 -179.512 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.543 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 63.3 m95 -104.64 125.3 50.62 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 174.008 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -127.42 145.07 50.95 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-O 120.729 0.3 . . . . 0.0 110.614 -176.393 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.445 ' CG ' ' HB ' ' A' ' 88' ' ' VAL . 21.1 ptmt -124.86 132.78 24.37 Favored Pre-proline 0 C--N 1.294 -1.836 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 176.044 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -76.05 121.06 5.98 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 121.458 1.438 . . . . 0.0 109.555 174.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -166.71 120.91 1.07 Allowed 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.421 ' HA ' ' HA ' ' A' ' 86' ' ' ASP . 24.4 t-20 -95.43 120.2 35.25 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.091 -175.092 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.72 164.18 35.93 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 51.2 m -103.83 149.18 25.29 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.933 -177.415 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.5 t80 -126.42 134.13 51.08 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 177.257 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.8 t -114.2 118.11 57.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.923 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 49.9 t-20 -68.62 130.68 43.54 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -95.58 -68.29 1.01 Allowed Glycine 0 N--CA 1.421 -2.344 0 C-N-CA 120.005 -1.093 . . . . 0.0 114.253 -172.565 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -135.31 14.4 3.5 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -170.858 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.499 ' HB2' ' HB3' ' A' ' 127' ' ' TRP . 12.5 mm-40 -135.48 122.07 14.47 Favored Pre-proline 0 C--N 1.298 -1.642 0 C-N-CA 119.729 -0.788 . . . . 0.0 112.949 -177.802 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -67.22 120.66 7.74 Favored 'Trans proline' 0 N--CA 1.447 -1.209 0 N-CA-C 105.767 -2.436 . . . . 0.0 105.767 167.473 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.495 HG13 ' O ' ' A' ' 58' ' ' GLN . 49.4 mt -113.58 120.74 64.24 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.057 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.639 -171.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -73.84 122.78 27.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 176.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 44.8 p -102.42 170.35 8.11 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.884 -173.582 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -117.47 149.28 40.85 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 2.8 mp -111.58 133.19 58.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 121.082 0.468 . . . . 0.0 111.111 -178.283 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 84.29 -24.11 6.59 Favored Glycine 0 C--N 1.315 -0.615 0 N-CA-C 115.861 1.104 . . . . 0.0 115.861 171.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 65.5 m -160.46 146.67 11.67 Favored Pre-proline 0 C--N 1.311 -1.068 0 CA-C-N 118.216 1.008 . . . . 0.0 110.144 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.405 ' HG2' HG21 ' A' ' 44' ' ' THR . 58.9 Cg_endo -89.82 119.9 0.87 Allowed 'Trans proline' 0 N--CA 1.44 -1.638 0 C-N-CA 121.771 1.647 . . . . 0.0 111.732 175.221 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.458 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 88.2 m-85 -169.89 177.66 4.3 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 103.487 -2.782 . . . . 0.0 103.487 -179.082 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -89.95 -37.47 14.34 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 171.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -89.14 25.48 1.85 Allowed 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 114.751 -1.113 . . . . 0.0 111.138 -177.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.458 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -84.49 161.38 54.22 Favored Pre-proline 0 C--N 1.306 -1.309 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 178.486 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -47.66 135.12 21.98 Favored 'Trans proline' 0 C--N 1.364 1.35 0 C-N-CA 123.715 2.943 . . . . 0.0 114.722 -178.286 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 18.0 m -90.42 173.92 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 114.362 -1.29 . . . . 0.0 110.636 -178.372 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.86 28.53 2.04 Favored Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.535 177.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -151.08 128.59 2.64 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 120.001 -1.095 . . . . 0.0 112.567 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -128.12 127.76 43.61 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.751 -1.204 . . . . 0.0 107.751 173.253 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 55.0 tp -101.41 109.9 60.15 Favored Pre-proline 0 C--N 1.301 -1.509 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 178.151 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.22 154.06 51.54 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 122.46 2.107 . . . . 0.0 112.515 -178.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.53 141.48 51.9 Favored 'General case' 0 N--CA 1.438 -1.045 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.855 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.0 -7.13 67.14 Favored Glycine 0 N--CA 1.435 -1.412 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.618 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.04 136.56 34.45 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.902 0.351 . . . . 0.0 111.366 -178.278 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 47.6 m -103.77 112.9 26.05 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.308 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.7 mm -127.27 133.77 67.35 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -176.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 11.6 p -93.3 135.19 28.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.417 ' HA ' ' HB3' ' A' ' 99' ' ' TYR . 52.7 p90 -118.18 159.55 23.11 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -178.492 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.421 ' HA ' ' HA ' ' A' ' 50' ' ' ASN . 4.9 p-10 -130.12 -7.78 4.35 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 112.367 0.506 . . . . 0.0 112.367 -177.68 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.466 ' HG2' ' SG ' ' A' ' 89' ' ' CYS . 29.4 tt0 -131.36 120.83 23.67 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 -176.684 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.445 ' HB ' ' CG ' ' A' ' 47' ' ' LYS . 39.9 t -105.67 119.07 54.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.466 ' SG ' ' HG2' ' A' ' 87' ' ' GLU . 46.9 m -123.23 133.2 54.22 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -172.71 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 56.6 mt -97.7 113.86 33.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 CA-C-O 121.291 0.567 . . . . 0.0 109.942 173.752 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.507 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -121.42 134.04 55.09 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 172.145 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.62 117.05 1.84 Allowed 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 114.081 1.141 . . . . 0.0 114.081 -164.665 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 107.96 -22.61 27.33 Favored Glycine 0 N--CA 1.431 -1.681 0 CA-C-N 115.115 -0.948 . . . . 0.0 112.426 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' HIS . . . . . 0.438 ' HB2' ' NE1' ' A' ' 96' ' ' TRP . 57.9 m80 -144.45 169.22 18.36 Favored 'General case' 0 CA--C 1.509 -0.626 0 O-C-N 122.108 -0.642 . . . . 0.0 110.445 -176.575 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.6 tt -126.09 109.58 21.74 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.152 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 173.203 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.507 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 42.5 m95 -95.27 138.91 32.33 Favored 'General case' 0 C--N 1.279 -2.48 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.563 -167.486 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.453 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.8 pt -100.58 127.74 53.35 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 176.498 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.88 127.93 9.37 Favored Glycine 0 N--CA 1.421 -2.307 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.467 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.417 ' HB3' ' HA ' ' A' ' 85' ' ' TYR . 41.3 p90 -142.63 150.46 40.3 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -102.08 119.15 38.33 Favored 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.411 ' HB3' ' OD1' ' A' ' 105' ' ' ASN . . . -87.19 168.12 13.51 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 120.954 0.407 . . . . 0.0 110.838 -177.472 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -52.88 -25.52 11.93 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.397 1.479 . . . . 0.0 112.897 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -83.69 -3.44 57.77 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.454 0.645 . . . . 0.0 110.497 -176.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.19 7.07 73.88 Favored Glycine 0 CA--C 1.501 -0.8 0 CA-C-O 121.422 0.456 . . . . 0.0 112.038 176.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.411 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 13.8 p-10 -94.66 130.21 41.24 Favored 'General case' 0 C--N 1.29 -1.991 0 C-N-CA 123.147 0.579 . . . . 0.0 111.008 -177.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 26.6 tpt180 -84.1 102.93 12.9 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 178.794 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.8 t -97.71 139.34 20.22 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -173.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.453 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 79.0 m-85 -119.69 122.55 41.72 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 123.336 0.654 . . . . 0.0 109.725 177.515 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' CYS . . . . . 0.424 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 48.6 t -111.38 130.87 22.62 Favored Pre-proline 0 C--N 1.305 -1.369 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.032 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.1 -27.41 41.98 Favored 'Trans proline' 0 C--N 1.355 0.884 0 C-N-CA 122.815 2.343 . . . . 0.0 114.112 -176.013 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.303 18.9 m 51.19 -42.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.505 0 N-CA-C 118.446 2.758 . . . . 0.0 118.446 176.81 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.53 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 37.9 ptt180 -161.5 165.08 29.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-O 121.112 0.482 . . . . 0.0 110.634 -179.409 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.5 m -75.93 139.72 41.74 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 176.205 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 49.5 t -155.97 128.01 7.51 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.47 0.652 . . . . 0.0 110.962 178.209 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' GLN . . . . . 0.457 ' HA ' ' OE1' ' A' ' 115' ' ' GLN . 7.9 mm-40 -121.69 162.45 20.72 Favored 'General case' 0 C--N 1.288 -2.106 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.493 177.718 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 124.58 -174.38 17.07 Favored Glycine 0 N--CA 1.418 -2.51 0 C-N-CA 119.947 -1.121 . . . . 0.0 112.021 177.297 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 18.9 m -131.87 133.22 23.82 Favored Pre-proline 0 C--N 1.3 -1.549 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.508 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.543 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 88.2 Cg_exo -48.74 137.13 27.34 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 123.332 2.688 . . . . 0.0 113.417 -178.444 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 11.7 Cg_endo -91.09 1.09 64.32 Favored 'Cis proline' 0 C--O 1.245 0.86 0 C-N-CA 123.584 -1.423 . . . . 0.0 113.079 1.541 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -80.7 100.18 8.58 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 121.76 0.791 . . . . 0.0 110.36 -173.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.436 ' HB2' ' SG ' ' A' ' 114' ' ' CYS . 47.1 p-80 -105.5 131.33 53.03 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 114.606 -1.179 . . . . 0.0 112.098 -177.442 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.456 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.1 mm -105.74 99.8 23.83 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 178.515 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -84.96 139.69 7.47 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.391 2.061 . . . . 0.0 112.29 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -102.39 -133.01 7.89 Favored Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 177.08 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 61.5 t -82.97 129.3 37.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 110.129 -0.322 . . . . 0.0 110.129 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.53 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -93.62 143.82 25.96 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.823 176.543 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' TRP . . . . . 0.499 ' HB3' ' HB2' ' A' ' 58' ' ' GLN . 4.8 m0 -101.99 12.59 36.66 Favored 'General case' 0 C--O 1.251 1.154 0 CA-C-O 122.031 0.92 . . . . 0.0 110.345 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.63 179.59 36.92 Favored Glycine 0 N--CA 1.426 -1.99 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.936 -179.568 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.5 t -113.54 134.97 54.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -177.012 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -87.62 122.1 30.89 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.136 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? . . . . . 0 C--N 1.291 -1.943 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.866 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 12.4 m . . . . . 0 N--CA 1.44 -0.946 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -142.83 107.65 4.88 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.121 -179.454 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.86 115.69 22.39 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 174.636 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 51.6 tptt -77.03 -8.53 57.58 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 120.855 0.359 . . . . 0.0 111.337 -174.284 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 72.14 -54.04 0.69 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 124.762 1.225 . . . . 0.0 112.962 177.448 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 70.37 -65.1 0.34 Allowed 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.848 1.659 . . . . 0.0 108.318 -175.468 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 23.8 ptt? -100.12 102.22 13.48 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 172.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -85.57 115.07 23.05 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -176.694 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.9 ptmm? -148.14 -4.57 0.47 Allowed 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 -175.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.05 -131.07 4.25 Favored Glycine 0 N--CA 1.439 -1.126 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.164 -178.141 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 38.0 m -99.91 82.83 2.63 Favored 'General case' 0 C--N 1.291 -1.935 0 CA-C-O 121.81 0.814 . . . . 0.0 111.155 -179.329 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.0 m -94.9 -10.56 30.83 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.175 -0.92 . . . . 0.0 108.603 174.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.0 m -70.29 145.53 51.22 Favored 'General case' 0 N--CA 1.439 -1.012 0 CA-C-N 115.253 -0.885 . . . . 0.0 108.972 176.379 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.9 t -159.44 173.0 16.89 Favored 'General case' 0 N--CA 1.424 -1.746 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 -178.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 5.8 m -78.33 79.99 4.75 Favored 'General case' 0 N--CA 1.428 -1.563 0 CA-C-O 121.876 0.846 . . . . 0.0 109.301 -178.606 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 50.2 t -88.29 101.85 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 CA-C-N 115.217 -0.901 . . . . 0.0 108.93 -179.221 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 30.6 m -78.7 144.28 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 60.9 mttp 66.15 24.72 10.81 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 124.244 1.017 . . . . 0.0 111.229 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -58.12 119.07 6.18 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 123.49 0.716 . . . . 0.0 111.406 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.87 166.15 28.11 Favored Glycine 0 CA--C 1.493 -1.297 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -178.01 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -76.57 86.74 3.26 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 118.093 0.947 . . . . 0.0 109.588 179.469 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.7 m -101.82 -57.22 2.11 Favored 'General case' 0 N--CA 1.423 -1.824 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.6 -176.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.0 m -82.76 131.73 35.19 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.271 -177.612 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.4 p -81.71 -15.12 55.45 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 122.013 0.911 . . . . 0.0 109.376 176.633 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -150.37 141.11 22.71 Favored 'General case' 0 N--CA 1.429 -1.52 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 175.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.412 ' O ' ' HD3' ' A' ' 28' ' ' PRO . 19.6 m -66.21 -30.64 71.14 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.092 0.472 . . . . 0.0 110.231 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 28.5 m -102.91 99.82 14.95 Favored Pre-proline 0 N--CA 1.423 -1.802 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 173.421 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.412 ' HD3' ' O ' ' A' ' 26' ' ' SER . 3.8 Cg_exo -75.89 66.32 6.77 Favored 'Trans proline' 0 C--O 1.243 0.727 0 C-N-CA 123.124 2.55 . . . . 0.0 111.494 -178.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.439 ' HA ' ' HA ' ' A' ' 33' ' ' VAL . . . -112.75 3.43 16.5 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 114.169 -1.378 . . . . 0.0 108.676 177.467 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.8 p -91.02 -78.34 0.39 Allowed 'General case' 0 N--CA 1.428 -1.57 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.565 -178.091 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.578 ' HB3' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -88.34 -61.97 0.23 Allowed Pre-proline 0 C--N 1.309 -1.183 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.936 -177.78 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.578 ' HD3' ' HB3' ' A' ' 31' ' ' ARG . 56.7 Cg_endo -89.5 46.92 0.93 Allowed 'Trans proline' 0 C--N 1.368 1.566 0 CA-C-N 121.092 1.426 . . . . 0.0 110.133 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.439 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 5.8 p -45.02 98.12 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.35 0.606 0 C-N-CA 124.642 1.177 . . . . 0.0 113.342 -176.352 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.3 p 156.13 -35.96 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 129.657 3.183 . . . . 0.0 106.316 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 136.42 -88.01 0.23 Allowed Glycine 0 N--CA 1.423 -2.178 0 N-CA-C 108.451 -1.859 . . . . 0.0 108.451 -177.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 49.4 m -157.61 28.43 0.28 Allowed 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.013 -1.476 . . . . 0.0 107.013 174.395 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 73.0 m95 -90.03 145.66 24.92 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.296 -174.157 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.464 ' HE3' ' HA ' ' A' ' 38' ' ' LYS . 0.0 OUTLIER -131.93 146.68 52.25 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 174.881 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -93.77 133.6 36.98 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 -178.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 33.3 p30 -96.84 176.81 5.85 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 175.326 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -77.22 1.75 17.56 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.515 0.674 . . . . 0.0 112.214 -175.768 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.7 m-85 -98.72 7.9 45.56 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.139 178.627 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.19 17.51 77.41 Favored Glycine 0 C--N 1.338 0.65 0 CA-C-N 115.128 -0.942 . . . . 0.0 112.32 177.14 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.45 HG21 ' HG2' ' A' ' 67' ' ' PRO . 5.3 m -105.01 141.9 35.76 Favored 'General case' 0 N--CA 1.42 -1.937 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -177.341 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.454 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 87.5 m95 -96.46 129.18 43.87 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.499 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.41 ' HA ' ' O ' ' A' ' 88' ' ' VAL . 51.8 p90 -125.89 150.28 48.04 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 123.199 0.312 . . . . 0.0 110.383 -178.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 14.1 ptmm? -135.66 148.06 63.98 Favored Pre-proline 0 C--N 1.303 -1.43 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 175.377 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -71.24 128.86 15.21 Favored 'Trans proline' 0 N--CA 1.444 -1.386 0 C-N-CA 121.27 1.313 . . . . 0.0 109.013 170.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.448 ' HB3' HG23 ' A' ' 88' ' ' VAL . 9.2 tp10 -162.64 120.18 2.04 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.505 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.526 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 6.6 t30 -105.87 113.48 27.06 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.684 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.413 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.55 175.62 12.57 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 89.0 m -118.9 133.19 56.0 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 120.253 -0.579 . . . . 0.0 112.32 -176.702 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -107.89 129.11 55.11 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 176.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.1 t -110.35 115.1 48.88 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 176.252 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -69.16 148.64 49.63 Favored 'General case' 0 C--N 1.309 -1.178 0 O-C-N 123.408 0.442 . . . . 0.0 110.466 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -81.58 -144.76 4.55 Favored Glycine 0 N--CA 1.43 -1.756 0 CA-C-N 115.998 -0.547 . . . . 0.0 113.84 -177.17 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 31.2 p-10 -85.65 12.22 9.23 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 -171.702 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.439 ' HA ' ' HD3' ' A' ' 59' ' ' PRO . 0.8 OUTLIER -142.4 143.46 27.04 Favored Pre-proline 0 C--N 1.301 -1.516 0 C-N-CA 120.592 -0.443 . . . . 0.0 112.065 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 58' ' ' GLN . 12.8 Cg_exo -71.98 131.75 18.69 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.138 1.892 . . . . 0.0 111.437 177.382 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -107.58 132.7 54.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.037 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.5 p -79.97 136.2 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 176.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 53.4 p -111.98 167.03 10.71 Favored 'General case' 0 C--N 1.287 -2.138 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.651 -175.682 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.415 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 21.7 mmt180 -114.68 137.14 52.26 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.7 mt -93.33 123.85 45.57 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 CA-C-N 115.396 -0.82 . . . . 0.0 113.156 -172.404 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.79 -23.19 3.75 Favored Glycine 0 C--O 1.237 0.291 0 N-CA-C 115.906 1.123 . . . . 0.0 115.906 172.468 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.408 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 50.7 m -151.7 144.53 16.96 Favored Pre-proline 0 C--N 1.306 -1.288 0 CA-C-N 118.53 1.165 . . . . 0.0 111.54 -177.004 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.45 ' HG2' HG21 ' A' ' 44' ' ' THR . 1.2 Cg_endo -89.35 120.95 1.06 Allowed 'Trans proline' 0 N--CA 1.448 -1.168 0 C-N-CA 122.457 2.105 . . . . 0.0 110.597 173.245 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.567 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 59.6 m-85 -168.53 170.43 9.66 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 126.355 1.862 . . . . 0.0 106.322 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 95.8 mt -82.51 -30.96 29.48 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 172.372 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 17.6 m120 -102.97 26.22 8.42 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.732 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.567 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -75.2 156.79 85.58 Favored Pre-proline 0 C--N 1.308 -1.198 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.397 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -50.7 131.44 33.47 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 123.651 2.901 . . . . 0.0 113.48 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 6.8 p -101.31 174.17 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 C-N-CA 124.051 0.94 . . . . 0.0 108.928 -176.365 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.44 -4.74 13.36 Favored Glycine 0 N--CA 1.443 -0.84 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.023 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -110.81 123.78 6.71 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 177.58 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -122.09 134.48 54.77 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 117.356 0.578 . . . . 0.0 110.139 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.5 tp -100.83 118.87 59.79 Favored Pre-proline 0 C--N 1.308 -1.217 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -66.62 160.06 47.96 Favored 'Trans proline' 0 C--O 1.243 0.764 0 C-N-CA 122.478 2.119 . . . . 0.0 112.709 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.56 136.65 47.56 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.666 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.64 1.49 90.53 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 121.423 -0.418 . . . . 0.0 113.365 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.59 127.09 31.05 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.179 0.514 . . . . 0.0 111.861 -177.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 46.2 m -96.97 109.0 21.84 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 177.78 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.3 mm -118.79 120.8 65.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.096 -174.744 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.6 p -89.06 127.46 41.77 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.134 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.526 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 48.5 p90 -116.43 154.55 30.11 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -178.509 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -120.31 4.93 10.74 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-O 121.469 0.652 . . . . 0.0 110.561 -179.008 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -147.45 140.7 25.24 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.713 -175.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.448 HG23 ' HB3' ' A' ' 49' ' ' GLU . 86.7 t -124.04 133.19 69.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 176.601 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.544 ' HG ' ' HE2' ' A' ' 108' ' ' TYR . 61.5 m -130.27 135.18 47.83 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 122.315 0.246 . . . . 0.0 111.369 -176.812 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.4 mt -103.03 111.84 34.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 176.199 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.1 tp-100 -115.69 145.1 43.05 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 105.448 -2.056 . . . . 0.0 105.448 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.37 104.81 0.08 Allowed 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -174.42 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 115.31 -30.89 6.48 Favored Glycine 0 N--CA 1.434 -1.456 0 CA-C-N 115.61 -0.723 . . . . 0.0 113.836 177.273 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 64.0 m80 -145.46 150.97 37.47 Favored 'General case' 0 CA--C 1.504 -0.827 0 CA-C-N 118.196 0.998 . . . . 0.0 110.743 -175.018 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.8 tt -106.41 111.78 36.78 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 176.75 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 47.9 m95 -95.87 148.43 22.62 Favored 'General case' 0 C--N 1.285 -2.233 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.424 -169.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.5 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.4 pt -107.34 139.23 29.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.411 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -106.49 121.46 6.65 Favored Glycine 0 N--CA 1.431 -1.675 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -135.65 167.96 20.15 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.667 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -102.42 131.06 49.32 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.891 179.088 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -83.51 175.52 9.73 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 173.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 29.9 p90 -53.37 -36.24 61.19 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -178.499 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 25.6 p-10 -88.63 1.91 54.15 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 120.68 0.276 . . . . 0.0 111.322 -178.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.11 5.79 72.58 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 121.306 -0.473 . . . . 0.0 112.009 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -67.94 129.7 40.71 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 22.9 tpt180 -82.68 107.7 15.5 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 -178.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 27.8 t -111.62 142.85 22.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -178.179 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.544 ' HE2' ' HG ' ' A' ' 89' ' ' CYS . 85.0 m-85 -117.63 131.35 56.67 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 120.963 0.411 . . . . 0.0 110.628 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 45.3 t -112.9 134.47 21.75 Favored Pre-proline 0 C--N 1.302 -1.483 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -68.16 -27.14 35.68 Favored 'Trans proline' 0 C--N 1.358 1.038 0 C-N-CA 122.626 2.217 . . . . 0.0 113.35 -177.317 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.29 21.9 m 52.52 -46.59 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.284 0 N-CA-C 117.968 2.581 . . . . 0.0 117.968 176.47 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.546 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 37.1 ptt180 -161.63 163.55 29.87 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 123.157 0.583 . . . . 0.0 110.068 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.8 t -81.69 141.51 33.54 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 175.087 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.9 t -156.18 127.78 7.24 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -109.17 139.12 44.51 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.052 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 142.49 177.91 17.98 Favored Glycine 0 N--CA 1.42 -2.393 0 C-N-CA 119.059 -1.543 . . . . 0.0 113.668 175.161 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 16.2 m -141.42 145.4 37.77 Favored Pre-proline 0 C--N 1.299 -1.593 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 178.69 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 83.8 Cg_exo -49.2 138.41 28.94 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 122.897 2.398 . . . . 0.0 112.922 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 60.0 Cg_endo -85.29 -16.04 29.78 Favored 'Cis proline' 0 C--O 1.25 1.118 0 C-N-CA 123.366 -1.514 . . . . 0.0 113.618 0.198 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -80.54 100.98 8.85 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -171.346 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -106.41 123.95 48.85 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 114.336 -1.302 . . . . 0.0 111.29 178.152 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 70.4 mt -95.46 108.19 37.82 Favored Pre-proline 0 C--N 1.319 -0.73 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -84.23 130.67 4.76 Favored 'Trans proline' 0 C--O 1.249 1.04 0 C-N-CA 122.37 2.047 . . . . 0.0 112.841 -179.059 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -115.35 -147.93 9.26 Favored Glycine 0 N--CA 1.435 -1.374 0 C-N-CA 120.562 -0.827 . . . . 0.0 112.017 178.595 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.6 t -57.63 116.13 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.823 0 C-N-CA 123.819 0.848 . . . . 0.0 112.047 -179.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.546 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.19 143.87 26.0 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.431 173.792 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.6 m-90 -104.51 19.74 19.78 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.635 0.731 . . . . 0.0 109.584 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -165.77 -175.74 36.54 Favored Glycine 0 N--CA 1.428 -1.882 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 179.487 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 60.8 t -112.88 141.59 28.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -177.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -107.14 122.15 45.93 Favored 'General case' 0 C--N 1.321 -0.653 0 O-C-N 123.231 0.332 . . . . 0.0 110.54 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt . . . . . 0 C--N 1.297 -1.676 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 177.994 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 26.0 m . . . . . 0 N--CA 1.439 -1.013 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -166.56 108.19 0.69 Allowed 'General case' 0 C--N 1.319 -0.732 0 C-N-CA 123.473 0.709 . . . . 0.0 109.408 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -123.05 152.26 41.17 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 176.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 41.9 tttm -82.26 124.51 30.0 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -178.143 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 45.5 t30 -90.23 122.46 33.17 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 176.475 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 84.0 m-85 74.56 124.39 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.942 1.297 . . . . 0.0 110.92 -175.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 94.8 mmm -93.9 75.31 4.2 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 121.51 0.671 . . . . 0.0 109.289 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 31.3 p-10 -104.44 -176.1 2.98 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.985 -178.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 11.9 mptt 67.19 27.53 8.42 Favored 'General case' 0 N--CA 1.489 1.523 0 C-N-CA 124.427 1.091 . . . . 0.0 108.969 -172.548 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -94.23 80.67 0.96 Allowed Glycine 0 N--CA 1.421 -2.313 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.709 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 6.2 m -49.03 104.55 0.06 Allowed 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 123.744 0.818 . . . . 0.0 109.966 178.103 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.7 m -87.54 20.85 2.73 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 112.905 0.706 . . . . 0.0 112.905 -172.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.3 m -76.43 151.71 36.43 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.611 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.2 m -83.76 -26.08 29.97 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 120.618 -0.433 . . . . 0.0 111.395 -178.075 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.5 m 72.3 -28.79 0.19 Allowed 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 124.622 1.169 . . . . 0.0 113.11 178.028 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 15.7 m -76.61 83.73 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-O 122.188 0.994 . . . . 0.0 110.838 175.543 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 30.2 m -102.18 -9.31 9.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.821 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 23.2 tptm -74.22 88.92 2.01 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-O 121.336 0.589 . . . . 0.0 109.861 -178.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -155.96 104.16 2.27 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-N 115.321 -0.854 . . . . 0.0 108.723 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -159.95 58.61 0.32 Allowed Glycine 0 N--CA 1.431 -1.64 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.02 91.44 0.68 Allowed 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 -178.27 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.7 p -140.0 94.2 2.73 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.877 -177.752 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.0 m -82.18 104.39 12.48 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.134 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 11.9 m -62.17 -35.28 78.32 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.503 0.668 . . . . 0.0 109.402 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -126.82 109.47 12.03 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 173.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.2 m -100.99 -72.09 0.69 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 16.9 p -142.9 118.06 6.49 Favored Pre-proline 0 C--N 1.302 -1.46 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -59.19 -44.28 35.29 Favored 'Trans proline' 0 C--O 1.243 0.726 0 C-N-CA 121.934 1.756 . . . . 0.0 109.67 173.318 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 63.31 -175.24 0.15 Allowed 'General case' 0 C--O 1.246 0.88 0 C-N-CA 124.886 1.275 . . . . 0.0 111.274 179.066 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -82.15 79.53 8.61 Favored 'General case' 0 N--CA 1.431 -1.391 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.528 ' HB3' ' HD3' ' A' ' 32' ' ' PRO . 1.5 tmt_? -147.57 -54.92 0.02 OUTLIER Pre-proline 0 C--N 1.308 -1.236 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.267 -179.028 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.528 ' HD3' ' HB3' ' A' ' 31' ' ' ARG . 3.5 Cg_exo -81.91 92.09 1.01 Allowed 'Trans proline' 0 C--N 1.369 1.63 0 CA-C-N 120.66 1.271 . . . . 0.0 109.546 175.519 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 93.2 t -73.85 108.41 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.019 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.627 ' HA ' ' O ' ' A' ' 118' ' ' PRO . 7.6 p -80.43 148.75 30.41 Favored 'General case' 0 N--CA 1.411 -2.383 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.879 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -99.6 -146.05 19.26 Favored Glycine 0 N--CA 1.43 -1.733 0 CA-C-N 115.294 -0.866 . . . . 0.0 112.858 -179.438 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 6.0 m -85.44 27.41 0.82 Allowed 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 124.261 1.025 . . . . 0.0 111.278 -175.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 48.3 m95 -91.96 153.22 19.61 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.752 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -114.13 133.58 55.47 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -89.45 129.83 35.89 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 120.985 0.421 . . . . 0.0 111.201 -177.49 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 45.9 t-20 -99.83 160.0 14.64 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -65.26 -11.86 45.64 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.499 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -77.2 -5.57 49.7 Favored 'General case' 0 CA--C 1.541 0.633 0 CA-C-O 121.357 0.598 . . . . 0.0 109.996 176.655 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.26 1.83 83.7 Favored Glycine 0 CA--C 1.506 -0.492 0 N-CA-C 110.145 -1.182 . . . . 0.0 110.145 -177.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.424 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 9.2 m -89.42 141.01 28.94 Favored 'General case' 0 N--CA 1.415 -2.208 0 CA-C-N 113.86 -1.17 . . . . 0.0 109.299 -178.02 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.502 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 71.9 m95 -102.45 135.94 43.18 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 173.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.434 ' HA ' ' O ' ' A' ' 88' ' ' VAL . 32.0 p90 -137.4 155.47 49.33 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.702 -177.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -147.29 135.59 10.95 Favored Pre-proline 0 C--N 1.305 -1.364 0 CA-C-N 115.318 -0.855 . . . . 0.0 108.738 173.305 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -67.08 129.57 20.89 Favored 'Trans proline' 0 C--O 1.248 0.992 0 C-N-CA 122.264 1.976 . . . . 0.0 111.42 173.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -168.02 120.99 0.89 Allowed 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.061 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.567 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 15.9 m120 -88.57 109.5 20.13 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-O 120.906 0.384 . . . . 0.0 110.88 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.446 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -135.45 165.73 24.8 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 178.09 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.466 ' HB ' ' HG3' ' A' ' 131' ' ' LYS . 25.9 m -114.0 136.51 52.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-O 121.479 0.656 . . . . 0.0 111.964 -175.492 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 69.6 t80 -117.74 127.01 53.49 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 114.986 -1.007 . . . . 0.0 108.288 176.31 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 129' ' ' VAL . 46.0 t -105.41 105.6 18.97 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 178.301 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -76.42 121.51 23.16 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 178.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -149.63 -24.45 0.06 OUTLIER Glycine 0 C--N 1.309 -0.923 0 C-N-CA 118.325 -1.893 . . . . 0.0 114.654 -175.684 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -71.72 -53.14 14.45 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.172 0.511 . . . . 0.0 110.096 -177.012 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -156.21 159.83 31.2 Favored Pre-proline 0 C--N 1.312 -1.031 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.078 -176.165 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -67.77 131.67 24.8 Favored 'Trans proline' 0 C--O 1.248 0.991 0 C-N-CA 122.372 2.048 . . . . 0.0 110.135 173.521 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 47.4 mt -114.51 132.35 63.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -176.517 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.3 p -76.07 131.68 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 177.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 40.7 p -103.74 157.62 16.95 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.531 -177.047 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -110.78 143.88 40.63 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.3 mp -109.68 134.4 51.91 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 C-N-CA 120.531 -0.468 . . . . 0.0 111.22 -175.075 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.29 -22.74 1.99 Allowed Glycine 0 C--O 1.244 0.728 0 N-CA-C 117.157 1.623 . . . . 0.0 117.157 171.593 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.4 m -152.85 138.86 11.98 Favored Pre-proline 0 C--N 1.308 -1.197 0 CA-C-N 118.81 1.305 . . . . 0.0 111.462 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -89.75 120.49 0.94 Allowed 'Trans proline' 0 N--CA 1.441 -1.577 0 C-N-CA 121.992 1.795 . . . . 0.0 111.006 171.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.424 ' HA ' ' HG2' ' A' ' 91' ' ' GLN . 68.1 m-85 -166.58 166.33 16.21 Favored 'General case' 0 CA--C 1.493 -1.216 0 C-N-CA 126.63 1.972 . . . . 0.0 105.819 -178.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 86.3 mt -72.23 -41.28 67.03 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.436 0.636 . . . . 0.0 109.296 176.189 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 21.8 p-10 -97.47 25.63 5.55 Favored 'General case' 0 C--O 1.246 0.894 0 C-N-CA 124.477 1.111 . . . . 0.0 110.709 -177.578 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -65.84 153.32 91.51 Favored Pre-proline 0 C--O 1.249 1.077 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.627 -178.463 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -47.44 128.62 15.23 Favored 'Trans proline' 0 C--N 1.368 1.555 0 C-N-CA 124.205 3.27 . . . . 0.0 114.077 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.3 p -102.73 172.99 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.44 28.61 1.92 Allowed Glycine 0 N--CA 1.442 -0.903 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.649 -176.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -161.66 131.23 2.51 Favored Glycine 0 N--CA 1.433 -1.566 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 176.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -127.82 141.38 51.58 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 117.336 0.568 . . . . 0.0 110.272 -179.654 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 50.7 tp -100.96 113.26 65.78 Favored Pre-proline 0 C--N 1.301 -1.521 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.007 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -73.64 156.8 49.07 Favored 'Trans proline' 0 C--O 1.252 1.209 0 C-N-CA 122.405 2.07 . . . . 0.0 111.456 179.05 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.52 142.77 42.77 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 108.35 -22.46 26.8 Favored Glycine 0 N--CA 1.434 -1.475 0 N-CA-C 110.438 -1.065 . . . . 0.0 110.438 -176.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.5 126.77 30.56 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-O 121.349 0.595 . . . . 0.0 111.298 -178.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 17.0 m -98.67 110.77 23.31 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 177.613 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.1 mm -111.51 131.07 63.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.286 -173.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.6 p -108.67 112.48 40.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 CA-C-O 122.04 0.924 . . . . 0.0 109.074 175.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.567 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 46.9 p90 -97.45 149.32 22.28 Favored 'General case' 0 C--N 1.296 -1.744 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.363 -177.517 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -112.92 -9.9 13.58 Favored 'General case' 0 C--N 1.31 -1.139 0 O-C-N 123.804 0.69 . . . . 0.0 111.238 -176.144 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 46.3 tt0 -134.94 128.98 33.54 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -175.677 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 46' ' ' TYR . 13.8 t -107.89 126.71 64.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.424 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 62.5 m -128.94 139.02 52.3 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -177.135 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 46.9 mt -112.22 119.37 60.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 173.432 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.497 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -124.94 144.1 50.53 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 104.638 -2.356 . . . . 0.0 104.638 174.803 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -51.15 104.13 0.07 Allowed 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 113.353 0.871 . . . . 0.0 113.353 -172.129 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.45 -39.97 1.76 Allowed Glycine 0 N--CA 1.431 -1.642 0 CA-C-N 115.436 -0.802 . . . . 0.0 113.236 177.501 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 53.0 m80 -147.74 157.58 43.61 Favored 'General case' 0 CA--C 1.497 -1.091 0 O-C-N 122.083 -0.657 . . . . 0.0 110.602 -174.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.9 tt -96.78 128.28 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.714 0 N-CA-C 105.296 -2.112 . . . . 0.0 105.296 172.454 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.497 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 72.1 m95 -106.41 135.45 47.87 Favored 'General case' 0 C--N 1.266 -3.023 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -173.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.509 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.4 pt -100.38 126.38 53.97 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.894 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 177.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -100.29 124.23 8.18 Favored Glycine 0 N--CA 1.42 -2.422 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.173 -177.681 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -148.23 173.07 13.37 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 177.274 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -119.17 145.51 45.94 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 177.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.44 ' HB3' ' OD1' ' A' ' 105' ' ' ASN . . . -93.85 170.23 9.71 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.336 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -73.35 -9.8 59.07 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.141 0.496 . . . . 0.0 111.64 -176.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -72.63 -16.41 61.72 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 174.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 98.57 4.14 57.19 Favored Glycine 0 C--N 1.33 0.208 0 C-N-CA 121.062 -0.59 . . . . 0.0 111.964 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.44 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 23.5 p-10 -96.06 145.15 25.7 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 120.938 0.399 . . . . 0.0 110.968 -179.385 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 28.9 tpt180 -86.15 122.36 30.04 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 179.082 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 43.0 t -119.21 143.2 31.18 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.261 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 -173.592 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.509 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 86.3 m-85 -125.52 129.17 49.22 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 123.579 0.751 . . . . 0.0 110.134 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.4 t -109.3 135.06 20.29 Favored Pre-proline 0 C--N 1.299 -1.592 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 178.562 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -68.24 -23.24 39.2 Favored 'Trans proline' 0 C--N 1.365 1.416 0 C-N-CA 123.202 2.602 . . . . 0.0 114.38 -177.157 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.3 35.4 m 45.22 -53.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.286 0 N-CA-C 119.077 2.992 . . . . 0.0 119.077 176.054 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.442 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 33.2 ptt180 -158.7 152.87 23.86 Favored 'General case' 0 C--N 1.314 -0.964 0 O-C-N 121.718 -0.614 . . . . 0.0 110.47 -178.297 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.556 ' O ' ' HA ' ' A' ' 123' ' ' PRO . 13.7 m -63.88 127.48 31.58 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 174.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.41 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 99.6 m -152.92 118.76 5.39 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 123.477 0.711 . . . . 0.0 109.361 177.044 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 76.2 mt-30 -129.58 148.83 51.52 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.34 -167.86 30.82 Favored Glycine 0 N--CA 1.417 -2.602 0 C-N-CA 119.11 -1.519 . . . . 0.0 112.149 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 10.8 m -123.99 108.03 30.45 Favored Pre-proline 0 C--N 1.291 -1.971 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.627 ' O ' ' HA ' ' A' ' 34' ' ' THR . 60.6 Cg_exo -43.17 129.2 5.92 Favored 'Trans proline' 0 C--N 1.349 0.584 0 C-N-CA 124.004 3.136 . . . . 0.0 113.024 -175.608 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -90.53 10.77 60.32 Favored 'Cis proline' 0 C--O 1.242 0.694 0 C-N-CA 124.115 -1.202 . . . . 0.0 115.114 8.44 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -75.28 100.06 4.25 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 -179.046 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.431 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 45.8 p-80 -106.08 109.83 21.89 Favored 'General case' 0 C--N 1.289 -2.053 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.112 177.191 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.5 mt -94.82 105.21 17.49 Favored Pre-proline 0 C--N 1.299 -1.606 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.662 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.556 ' HA ' ' O ' ' A' ' 113' ' ' THR . 72.8 Cg_endo -84.4 153.67 12.22 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.58 2.187 . . . . 0.0 113.121 -176.593 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -125.81 -97.53 1.09 Allowed Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 178.771 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 40.5 t -96.68 118.67 43.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -178.771 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.442 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.06 120.34 34.19 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.179 178.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.8 m-90 -101.5 58.02 0.85 Allowed 'General case' 0 C--N 1.31 -1.149 0 CA-C-O 120.661 0.267 . . . . 0.0 111.345 -179.19 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . 155.85 -169.78 33.59 Favored Glycine 0 CA--C 1.497 -1.082 0 C-N-CA 119.693 -1.241 . . . . 0.0 112.499 178.15 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 54' ' ' VAL . 97.9 t -111.94 128.68 68.38 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.671 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -112.07 136.87 50.89 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.152 -176.635 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.466 ' HG3' ' HB ' ' A' ' 52' ' ' THR . 18.1 ptpt . . . . . 0 N--CA 1.433 -1.315 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 175.028 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 20.0 m . . . . . 0 N--CA 1.443 -0.794 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -88.36 -34.62 17.53 Favored 'General case' 0 CA--C 1.497 -1.061 0 C-N-CA 120.925 -0.31 . . . . 0.0 110.251 178.421 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 65.37 173.1 0.22 Allowed 'General case' 0 C--O 1.241 0.646 0 C-N-CA 124.732 1.213 . . . . 0.0 111.36 -177.392 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -125.55 94.06 4.03 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -81.95 139.38 34.63 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 176.164 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 68.75 38.21 2.23 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 -173.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 23.1 ptp -57.15 121.8 10.92 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.904 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -112.0 -168.22 1.28 Allowed 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 120.118 -0.633 . . . . 0.0 109.477 -175.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.576 ' H ' ' HD3' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -132.42 -174.99 3.61 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -171.754 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.6 -97.68 0.55 Allowed Glycine 0 C--N 1.296 -1.659 0 C-N-CA 119.884 -1.15 . . . . 0.0 113.629 175.409 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 26.3 m -61.41 -49.99 74.63 Favored 'General case' 0 C--O 1.245 0.845 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 -174.673 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.0 m 70.03 -35.38 0.32 Allowed 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 124.728 1.211 . . . . 0.0 112.202 -177.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.8 t -76.27 110.55 10.88 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 176.515 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 43.7 m -77.92 -35.53 50.47 Favored 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 46.1 m -69.9 127.96 34.69 Favored 'General case' 0 C--O 1.251 1.15 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 174.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.6 m -75.92 121.03 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.761 0 CA-C-O 121.613 0.72 . . . . 0.0 111.264 -178.06 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 12.0 p -85.57 -25.72 6.62 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.398 -0.819 . . . . 0.0 112.165 -173.496 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 74.7 mmtt -72.08 -27.48 62.69 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.27 -179.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -70.66 108.9 4.6 Favored 'General case' 0 C--O 1.249 1.049 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.175 177.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -133.71 56.15 0.73 Allowed Glycine 0 N--CA 1.42 -2.371 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 17.6 pttm -74.32 112.78 10.82 Favored 'General case' 0 N--CA 1.436 -1.164 0 CA-C-O 121.568 0.699 . . . . 0.0 110.292 178.448 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.3 p -125.62 -174.27 3.03 Favored 'General case' 0 C--N 1.289 -2.027 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.152 -178.189 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 38.0 t -57.89 121.83 11.48 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.7 m -102.76 116.59 32.88 Favored 'General case' 0 N--CA 1.429 -1.498 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.294 -175.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -99.9 101.23 12.28 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.395 -177.724 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 17.5 m -93.04 -37.92 11.91 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.362 -1.348 . . . . 0.0 107.362 173.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.6 m 48.33 93.45 0.05 OUTLIER Pre-proline 0 CA--C 1.546 0.827 0 C-N-CA 126.523 1.929 . . . . 0.0 114.623 173.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -69.07 85.75 0.51 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.701 2.268 . . . . 0.0 110.928 174.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -90.56 -44.9 9.26 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 18.7 m -74.06 -41.17 62.15 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 175.832 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 11.2 mtp-105 74.4 141.04 0.08 OUTLIER Pre-proline 0 C--N 1.356 0.87 0 C-N-CA 125.964 1.706 . . . . 0.0 111.823 177.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_endo -68.32 -61.74 0.07 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.961 0 N-CA-C 107.741 -1.677 . . . . 0.0 107.741 169.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 91.3 t -153.71 -48.77 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 105.708 -1.96 . . . . 0.0 105.708 172.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.595 ' HB ' ' O ' ' A' ' 37' ' ' TRP . 7.1 p -76.04 95.91 3.7 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 113.939 -1.482 . . . . 0.0 112.691 -179.125 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -107.96 -41.32 1.57 Allowed Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 176.307 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 49.8 m -81.34 -42.33 20.71 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 174.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' TRP . . . . . 0.595 ' O ' ' HB ' ' A' ' 34' ' ' THR . 92.1 m95 -85.47 127.25 34.34 Favored 'General case' 0 N--CA 1.436 -1.144 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.949 178.444 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -125.08 154.64 41.07 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.639 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -94.15 127.27 39.88 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 120.359 -0.536 . . . . 0.0 111.207 -176.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -84.48 151.28 24.72 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 174.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.9 pt20 -51.2 -27.45 8.92 Favored 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 123.739 0.816 . . . . 0.0 113.189 -178.286 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.437 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 50.2 m-85 -81.73 3.16 26.66 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -177.257 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.71 18.82 59.27 Favored Glycine 0 CA--C 1.5 -0.844 0 C-N-CA 120.333 -0.937 . . . . 0.0 111.628 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.524 HG22 ' HB2' ' A' ' 89' ' ' CYS . 12.3 m -105.21 132.98 50.73 Favored 'General case' 0 N--CA 1.416 -2.134 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 179.57 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -96.39 129.73 43.67 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 177.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -129.54 154.67 46.81 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.422 -175.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -135.76 145.91 54.96 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 173.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_exo -69.3 121.86 8.65 Favored 'Trans proline' 0 C--O 1.249 1.041 0 C-N-CA 121.737 1.625 . . . . 0.0 109.469 172.187 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.451 ' HB3' HG23 ' A' ' 88' ' ' VAL . 6.2 tp10 -150.18 120.9 7.53 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.446 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 3.0 t-20 -114.19 106.49 14.42 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.926 -0.71 . . . . 0.0 110.154 -175.617 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.89 -177.58 5.98 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.443 -178.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.468 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 13.3 m -104.68 150.12 24.98 Favored 'General case' 0 N--CA 1.429 -1.487 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -177.299 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -127.39 127.21 43.8 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 173.532 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.1 t -113.09 113.29 43.64 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.232 0 N-CA-C 106.795 -1.558 . . . . 0.0 106.795 176.145 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 53.2 t30 -64.76 152.57 42.27 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.639 -178.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -78.59 -146.3 3.12 Favored Glycine 0 N--CA 1.434 -1.434 0 CA-C-N 116.16 -0.473 . . . . 0.0 113.173 -177.547 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -86.97 7.54 27.07 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -173.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.453 ' HA ' ' HD3' ' A' ' 59' ' ' PRO . 0.3 OUTLIER -138.92 137.25 19.29 Favored Pre-proline 0 C--N 1.302 -1.484 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.209 -175.213 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 58' ' ' GLN . 26.6 Cg_exo -65.58 128.99 21.27 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.415 2.077 . . . . 0.0 110.757 176.761 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.2 mt -108.02 125.81 64.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -177.554 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.3 p -78.89 137.58 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.669 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 60.2 p -117.26 178.41 4.38 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.003 -172.472 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 33.9 mmt180 -116.81 146.59 42.77 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 60.7 mt -109.82 131.32 61.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.43 -175.28 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.2 -22.86 4.19 Favored Glycine 0 C--N 1.318 -0.42 0 N-CA-C 115.969 1.148 . . . . 0.0 115.969 171.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.409 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 39.1 m -153.61 140.77 13.24 Favored Pre-proline 0 C--N 1.298 -1.669 0 CA-C-N 117.875 0.837 . . . . 0.0 109.154 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.442 ' HG2' HG21 ' A' ' 44' ' ' THR . 12.5 Cg_endo -89.69 119.4 0.86 Allowed 'Trans proline' 0 N--CA 1.433 -2.036 0 C-N-CA 121.189 1.259 . . . . 0.0 110.347 173.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.661 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 82.4 m-85 -168.89 173.9 6.77 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 104.716 -2.328 . . . . 0.0 104.716 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -89.28 -34.25 16.66 Favored 'General case' 0 C--N 1.291 -1.969 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 176.344 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -97.87 22.49 9.16 Favored 'General case' 0 CA--C 1.548 0.904 0 CA-C-O 121.993 0.901 . . . . 0.0 109.803 -178.575 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.661 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -77.57 162.72 67.43 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.79 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -48.87 124.35 11.14 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 123.343 2.695 . . . . 0.0 113.559 178.742 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.0 p -97.83 173.73 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.195 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.367 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.62 -1.68 13.84 Favored Glycine 0 CA--C 1.502 -0.77 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.517 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -113.88 117.49 4.17 Favored Glycine 0 N--CA 1.429 -1.793 0 N-CA-C 108.849 -1.701 . . . . 0.0 108.849 174.36 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -126.8 128.14 46.12 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 117.737 0.769 . . . . 0.0 110.344 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 41.2 tp -96.55 119.76 63.39 Favored Pre-proline 0 C--N 1.309 -1.154 0 C-N-CA 123.282 0.633 . . . . 0.0 110.19 -175.652 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.02 165.08 25.09 Favored 'Trans proline' 0 CA--C 1.542 0.912 0 C-N-CA 122.805 2.337 . . . . 0.0 112.728 179.28 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.75 147.31 45.71 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.784 -177.605 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 69.52 5.91 52.34 Favored Glycine 0 N--CA 1.463 0.446 0 N-CA-C 114.247 0.459 . . . . 0.0 114.247 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.76 126.59 29.89 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-O 120.892 0.377 . . . . 0.0 111.417 -177.542 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 25.7 m -92.59 113.09 25.27 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 177.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.9 mm -122.55 138.97 50.89 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -176.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 p -103.47 129.33 55.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 175.125 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.446 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 32.2 p90 -117.71 150.56 38.87 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.591 -177.809 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -108.57 -12.36 14.99 Favored 'General case' 0 C--N 1.316 -0.856 0 O-C-N 123.473 0.483 . . . . 0.0 110.42 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -140.4 136.59 33.24 Favored 'General case' 0 N--CA 1.428 -1.54 0 C-N-CA 120.346 -0.542 . . . . 0.0 111.206 -172.379 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.451 HG23 ' HB3' ' A' ' 49' ' ' GLU . 71.4 t -118.62 127.85 75.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 176.211 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.524 ' HB2' HG22 ' A' ' 44' ' ' THR . 19.6 p -135.46 147.73 49.01 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 120.898 0.38 . . . . 0.0 111.613 -175.252 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.5 mt -109.5 113.81 45.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-O 121.225 0.536 . . . . 0.0 110.546 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.595 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -110.42 122.56 47.99 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 104.761 -2.311 . . . . 0.0 104.761 174.457 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -47.85 114.29 0.88 Allowed 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 121.845 0.831 . . . . 0.0 113.068 -165.293 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 120.58 -25.15 7.38 Favored Glycine 0 N--CA 1.429 -1.826 0 CA-C-N 114.1 -1.409 . . . . 0.0 112.42 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 75.8 m80 -152.05 170.11 20.72 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 15.9 tt -111.62 136.44 47.72 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.179 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 172.453 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.595 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 48.2 m95 -121.96 139.07 54.12 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -173.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.509 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 47.5 pt -100.52 136.02 33.86 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.92 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 175.266 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -105.03 119.46 6.21 Favored Glycine 0 N--CA 1.419 -2.459 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.478 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -136.83 152.83 50.71 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 120.408 -0.517 . . . . 0.0 109.954 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -86.25 127.38 34.75 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 174.116 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.27 163.33 17.79 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 27.7 p90 -54.81 -31.36 59.03 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -176.673 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -76.29 -14.44 60.11 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-O 121.055 0.455 . . . . 0.0 111.046 -179.227 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 108.92 -9.58 34.19 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 121.137 -0.554 . . . . 0.0 113.279 178.595 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -75.84 148.08 38.63 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-O 120.754 0.311 . . . . 0.0 111.226 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ARG . . . . . 0.437 HH11 ' HG2' ' A' ' 106' ' ' ARG . 0.5 OUTLIER -89.41 109.27 20.2 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 177.685 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 52.2 t -107.66 136.92 41.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.199 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -176.23 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.509 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 91.4 m-85 -116.33 126.0 52.91 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.4 t -105.44 131.85 21.39 Favored Pre-proline 0 C--N 1.301 -1.536 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -69.26 -11.4 31.39 Favored 'Trans proline' 0 C--N 1.364 1.375 0 C-N-CA 123.374 2.716 . . . . 0.0 113.794 -177.553 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.277 27.0 m 37.83 -63.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.148 0 N-CA-C 118.286 2.698 . . . . 0.0 118.286 174.579 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.524 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 34.9 ptt180 -153.06 149.79 28.48 Favored 'General case' 0 N--CA 1.429 -1.488 0 C-N-CA 122.872 0.469 . . . . 0.0 110.219 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 19.4 m -67.8 136.76 54.66 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 41.8 t -150.39 139.24 20.88 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -176.324 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 78.3 mm-40 -119.6 161.61 20.36 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 130.22 -171.75 20.45 Favored Glycine 0 N--CA 1.421 -2.363 0 C-N-CA 120.034 -1.079 . . . . 0.0 112.448 174.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.6 m -141.41 138.57 17.69 Favored Pre-proline 0 C--N 1.295 -1.787 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 90.6 Cg_exo -47.73 131.64 20.36 Favored 'Trans proline' 0 CA--C 1.539 0.736 0 C-N-CA 122.945 2.43 . . . . 0.0 112.786 -177.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 89.7 Cg_endo -96.65 7.5 40.89 Favored 'Cis proline' 0 CA--C 1.547 1.155 0 C-N-CA 124.492 -1.045 . . . . 0.0 113.884 1.19 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 44.4 t30 -76.27 102.39 5.83 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.636 0.732 . . . . 0.0 110.911 -175.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 -104.82 112.6 25.77 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 114.748 -1.115 . . . . 0.0 111.602 -178.372 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 59.3 mt -101.46 100.84 14.92 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.119 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -85.22 140.39 7.57 Favored 'Trans proline' 0 N--CA 1.452 -0.944 0 C-N-CA 122.87 2.38 . . . . 0.0 113.647 -177.707 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -110.66 -117.62 3.81 Favored Glycine 0 N--CA 1.436 -1.35 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 177.663 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 81.6 t -78.24 115.46 20.34 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 120.84 0.352 . . . . 0.0 110.861 -179.382 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.524 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.37 132.91 38.49 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.788 177.129 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.3 m-90 -102.35 8.07 40.36 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-O 121.488 0.661 . . . . 0.0 110.401 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.09 169.51 36.7 Favored Glycine 0 N--CA 1.431 -1.696 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 64.3 t -111.72 134.86 52.78 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 C-N-CA 122.895 0.478 . . . . 0.0 110.189 -175.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -97.68 132.62 43.16 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 178.124 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.468 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 48.7 tptt . . . . . 0 N--CA 1.413 -2.315 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -179.679 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 17.3 m . . . . . 0 N--CA 1.439 -1.004 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 31.7 p-10 -150.93 16.6 0.76 Allowed 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 122.426 0.291 . . . . 0.0 110.475 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -59.67 -48.58 81.1 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 123.199 0.312 . . . . 0.0 110.166 -178.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 12.7 mptt -93.0 -46.69 7.35 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 174.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 56.0 t30 70.69 137.21 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.426 1.491 . . . . 0.0 112.731 176.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -90.65 124.25 34.92 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 171.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -134.66 147.2 50.09 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -177.418 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -129.04 43.42 3.15 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 174.121 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.412 ' HE3' ' HA ' ' A' ' 9' ' ' LYS . 1.9 tpmt? -61.73 128.32 35.65 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.887 -175.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 102.29 -24.49 30.9 Favored Glycine 0 C--N 1.317 -0.502 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 -177.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.8 m -126.62 26.06 6.34 Favored 'General case' 0 C--N 1.308 -1.204 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 178.238 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.8 m -77.06 87.46 3.56 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 114.872 -1.058 . . . . 0.0 111.916 -174.036 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 25.8 m -146.2 75.57 1.41 Allowed 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 175.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 13.1 m -73.51 -51.32 17.48 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.358 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 31.6 m -123.92 124.24 42.19 Favored 'General case' 0 N--CA 1.419 -2.009 0 CA-C-N 115.549 -0.751 . . . . 0.0 108.994 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 35.0 m -86.2 142.82 12.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 174.296 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.9 t -115.61 -64.3 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 C-N-CA 120.798 -0.361 . . . . 0.0 111.683 -174.635 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 34.7 mtmm 65.51 -74.53 0.05 Allowed 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 125.344 1.458 . . . . 0.0 109.673 -174.164 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -169.71 144.51 2.89 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 105.578 -2.008 . . . . 0.0 105.578 177.122 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -89.84 -33.17 9.25 Favored Glycine 0 C--N 1.291 -1.956 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.793 -174.098 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 59.14 66.04 1.1 Allowed 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 -173.172 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 13.2 p -79.03 -74.9 0.26 Allowed 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.22 -179.527 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 39.2 m -132.7 11.07 4.37 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-O 122.601 1.191 . . . . 0.0 108.076 173.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 44.5 m -117.88 134.93 54.45 Favored 'General case' 0 N--CA 1.419 -1.994 0 CA-C-N 113.778 -1.555 . . . . 0.0 107.755 178.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 76.4 -49.67 0.58 Allowed 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 125.737 1.615 . . . . 0.0 111.106 -175.694 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.3 t -168.6 174.45 6.74 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.424 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 67.9 m -139.17 96.59 8.92 Favored Pre-proline 0 C--N 1.303 -1.45 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 175.269 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -76.69 96.29 1.08 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.795 2.33 . . . . 0.0 112.607 -178.515 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -149.69 -41.88 0.14 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.609 179.002 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 m -89.51 -37.11 14.98 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.094 -178.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.553 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 15.6 mmm180 -70.32 -58.53 4.81 Favored Pre-proline 0 CA--C 1.543 0.703 0 C-N-CA 120.772 -0.371 . . . . 0.0 110.487 175.196 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.553 ' HD3' ' HB2' ' A' ' 31' ' ' ARG . 5.4 Cg_exo -84.08 80.02 2.49 Favored 'Trans proline' 0 C--N 1.365 1.411 0 N-CA-C 108.273 -1.472 . . . . 0.0 108.273 169.183 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 14.7 p -98.27 143.02 13.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.112 -173.314 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 8.9 m -75.37 98.92 3.97 Favored 'General case' 0 N--CA 1.431 -1.398 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.021 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 167.98 -26.5 0.14 Allowed Glycine 0 C--N 1.305 -1.183 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -177.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 6.8 m -66.37 -31.99 73.11 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.709 0.766 . . . . 0.0 109.022 174.691 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 34.5 m95 -92.0 145.93 24.14 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 114.741 -1.118 . . . . 0.0 108.231 177.142 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -113.35 150.56 32.43 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.417 ' HG2' ' O ' ' A' ' 40' ' ' ASN . 38.2 ttpt -110.15 136.2 49.75 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 118.376 -1.33 . . . . 0.0 111.528 -178.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.417 ' O ' ' HG2' ' A' ' 39' ' ' LYS . 45.9 t-20 -94.35 161.67 14.14 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 105.955 -1.869 . . . . 0.0 105.955 175.079 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 34.7 mt-30 -67.28 -13.31 61.87 Favored 'General case' 0 C--O 1.213 -0.836 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -173.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 47.9 m-85 -76.3 -1.24 25.67 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.352 0.596 . . . . 0.0 110.214 177.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.39 24.26 59.3 Favored Glycine 0 CA--C 1.494 -1.266 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.526 HG22 ' HB2' ' A' ' 89' ' ' CYS . 13.5 m -105.37 124.66 49.92 Favored 'General case' 0 N--CA 1.414 -2.231 0 CA-C-N 114.662 -0.769 . . . . 0.0 109.608 -178.503 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.551 ' CG ' ' HG3' ' A' ' 118' ' ' PRO . 84.1 m95 -93.3 131.11 38.74 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.18 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.41 ' HB3' ' HB3' ' A' ' 89' ' ' CYS . 54.2 p90 -132.75 151.85 51.89 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -175.196 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.434 ' HG3' ' HB ' ' A' ' 88' ' ' VAL . 16.8 ptmt -129.02 132.47 24.39 Favored Pre-proline 0 C--N 1.303 -1.443 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.664 175.637 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_exo -72.78 122.05 7.87 Favored 'Trans proline' 0 C--O 1.244 0.79 0 C-N-CA 121.835 1.69 . . . . 0.0 111.001 175.648 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -162.25 131.49 4.38 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 177.696 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.419 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 23.8 t-20 -110.03 123.46 49.71 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 120.699 -0.4 . . . . 0.0 110.182 -177.657 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -160.07 177.2 10.95 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -108.22 152.01 25.16 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 121.022 0.439 . . . . 0.0 112.126 -178.752 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.443 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 91.4 t80 -122.55 123.66 41.73 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 176.509 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 43.7 t -103.17 104.88 17.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 29.1 t30 -76.98 123.52 26.44 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 175.3 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -147.1 24.32 1.59 Allowed Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 118.973 -1.584 . . . . 0.0 113.308 -177.138 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -113.77 -50.71 2.82 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.256 179.088 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -158.22 164.96 19.65 Favored Pre-proline 0 C--N 1.315 -0.921 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.462 ' HB3' HD21 ' A' ' 76' ' ' ASN . 18.0 Cg_exo -69.27 125.87 12.93 Favored 'Trans proline' 0 C--O 1.254 1.301 0 N-CA-C 108.121 -1.531 . . . . 0.0 108.121 170.164 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 41.4 mt -108.12 130.17 61.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 110.127 -0.323 . . . . 0.0 110.127 -173.267 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 39.7 t -69.16 122.16 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.817 0 CA-C-O 121.968 0.889 . . . . 0.0 110.308 176.204 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -96.16 155.9 16.56 Favored 'General case' 0 N--CA 1.405 -2.689 0 CA-C-N 114.181 -1.372 . . . . 0.0 108.651 -176.242 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 15.6 mmt180 -112.24 141.64 45.7 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -178.272 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.2 mt -109.39 120.29 60.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 113.11 0.782 . . . . 0.0 113.11 -173.319 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.67 -22.51 27.49 Favored Glycine 0 C--O 1.236 0.249 0 N-CA-C 116.343 1.297 . . . . 0.0 116.343 170.549 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.7 m -155.01 140.26 12.28 Favored Pre-proline 0 C--N 1.307 -1.257 0 CA-C-N 118.502 1.151 . . . . 0.0 111.292 -178.27 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -89.93 119.96 0.86 Allowed 'Trans proline' 0 N--CA 1.437 -1.844 0 C-N-CA 121.716 1.611 . . . . 0.0 110.778 172.044 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -162.5 162.76 27.58 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 68.3 mt -80.1 -13.99 58.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 121.748 0.785 . . . . 0.0 109.434 177.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.4 p-10 -116.19 19.52 14.85 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.606 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.83 146.1 95.33 Favored Pre-proline 0 C--O 1.243 0.757 0 CA-C-N 115.386 -0.825 . . . . 0.0 112.201 -176.076 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -48.76 131.66 24.92 Favored 'Trans proline' 0 C--O 1.249 1.035 0 C-N-CA 124.104 3.203 . . . . 0.0 113.916 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.1 m -97.41 174.59 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 CA-C-N 114.552 -1.204 . . . . 0.0 110.483 -178.207 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.92 28.12 2.12 Favored Glycine 0 C--N 1.305 -1.192 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.021 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.81 132.67 4.1 Favored Glycine 0 N--CA 1.427 -1.924 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 176.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.462 HD21 ' HB3' ' A' ' 59' ' ' PRO . 8.3 t30 -128.35 125.77 39.38 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 117.597 0.699 . . . . 0.0 110.918 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 65.3 tp -88.26 111.69 44.86 Favored Pre-proline 0 N--CA 1.426 -1.634 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -63.43 152.4 80.26 Favored 'Trans proline' 0 C--O 1.251 1.146 0 C-N-CA 122.147 1.898 . . . . 0.0 112.553 -179.288 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.41 138.16 41.5 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.292 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.82 3.13 62.45 Favored Glycine 0 N--CA 1.441 -0.997 0 N-CA-C 111.434 -0.666 . . . . 0.0 111.434 -178.6 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.49 139.07 31.15 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-O 121.171 0.51 . . . . 0.0 111.188 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 39.0 m -113.53 113.55 25.27 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 177.627 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.1 mm -110.18 139.87 31.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -176.5 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.0 p -95.31 127.13 47.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 176.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.452 ' HA ' ' HB3' ' A' ' 99' ' ' TYR . 46.3 p90 -110.11 154.44 23.28 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.472 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -116.35 -9.09 11.57 Favored 'General case' 0 C--O 1.25 1.089 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.36 -177.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -144.84 131.69 20.18 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.876 -174.114 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.434 ' HB ' ' HG3' ' A' ' 47' ' ' LYS . 32.1 t -109.61 124.56 66.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 105.832 -1.914 . . . . 0.0 105.832 175.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.526 ' HB2' HG22 ' A' ' 44' ' ' THR . 24.6 p -137.5 148.49 46.06 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.871 -0.732 . . . . 0.0 112.624 -175.293 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 68.8 mt -111.4 124.15 67.9 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-O 121.061 0.458 . . . . 0.0 110.623 179.389 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.501 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -125.14 112.98 17.11 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 103.827 -2.657 . . . . 0.0 103.827 171.446 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.96 106.12 0.1 Allowed 'General case' 0 N--CA 1.479 0.983 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -164.737 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 141.63 -33.03 2.0 Favored Glycine 0 N--CA 1.439 -1.149 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -177.736 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 56.3 m80 -152.02 163.37 39.44 Favored 'General case' 0 CA--C 1.505 -0.786 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.278 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.3 tt -106.65 135.07 46.38 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 171.39 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.501 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 58.7 m95 -118.12 140.31 49.96 Favored 'General case' 0 C--N 1.28 -2.419 0 O-C-N 122.209 -0.307 . . . . 0.0 110.475 -171.118 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 48.1 pt -100.6 131.53 48.0 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 174.616 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.34 121.52 7.21 Favored Glycine 0 N--CA 1.417 -2.599 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.452 ' HB3' ' HA ' ' A' ' 85' ' ' TYR . 39.0 p90 -132.17 146.58 52.12 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-O 121.466 0.651 . . . . 0.0 111.122 178.326 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -99.74 119.97 38.98 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.82 -1.082 . . . . 0.0 108.455 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.9 176.31 7.4 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.395 -177.183 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -66.0 -21.34 66.39 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.464 0.649 . . . . 0.0 112.019 -179.066 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -80.04 -14.52 58.48 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.985 177.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 84.62 5.59 86.53 Favored Glycine 0 C--O 1.24 0.475 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -174.48 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -80.79 132.98 35.56 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 27.2 tpt180 -88.48 104.89 17.23 Favored 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -178.082 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 15.5 t -107.12 142.75 19.13 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -175.328 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -125.61 127.1 45.81 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.088 0.471 . . . . 0.0 111.75 -178.184 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 52.8 t -107.51 135.4 19.73 Favored Pre-proline 0 C--N 1.307 -1.278 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.206 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -72.21 -12.63 27.93 Favored 'Trans proline' 0 C--N 1.36 1.156 0 C-N-CA 123.19 2.593 . . . . 0.0 114.503 -176.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.282 32.8 m 43.77 -56.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.516 2.827 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 175.548 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.527 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 38.2 ptt180 -159.98 151.05 19.29 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.03 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.2 t -73.42 143.14 46.86 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.9 t -155.26 136.98 14.35 Favored 'General case' 0 N--CA 1.421 -1.919 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -177.185 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -122.52 157.1 32.78 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 133.91 -163.83 24.47 Favored Glycine 0 N--CA 1.429 -1.815 0 C-N-CA 120.048 -1.072 . . . . 0.0 112.018 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 18.5 m -142.22 149.92 53.52 Favored Pre-proline 0 C--N 1.307 -1.272 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.551 ' HG3' ' CG ' ' A' ' 45' ' ' TRP . 33.3 Cg_endo -60.2 131.21 37.68 Favored 'Trans proline' 0 CA--C 1.541 0.843 0 C-N-CA 122.388 2.059 . . . . 0.0 112.412 -177.007 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 11.1 Cg_endo -99.59 8.81 26.2 Favored 'Cis proline' 0 C--O 1.251 1.154 0 C-N-CA 125.28 -0.717 . . . . 0.0 113.351 -0.454 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.1 t30 -75.04 100.63 4.24 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 122.106 0.955 . . . . 0.0 109.896 -177.324 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 48.3 p-80 -105.72 119.78 40.01 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 114.416 -1.266 . . . . 0.0 111.578 -177.381 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 62.1 mt -100.83 101.61 16.42 Favored Pre-proline 0 C--N 1.305 -1.35 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.565 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -85.06 130.45 4.08 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.732 2.288 . . . . 0.0 113.109 -177.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -103.87 -131.12 7.11 Favored Glycine 0 N--CA 1.433 -1.564 0 N-CA-C 111.199 -0.761 . . . . 0.0 111.199 177.752 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 48.8 t -68.05 120.03 14.77 Favored 'Isoleucine or valine' 0 C--O 1.252 1.195 0 C-N-CA 123.005 0.522 . . . . 0.0 111.003 -178.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.527 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -94.22 148.75 21.89 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.685 177.658 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.4 m-90 -116.2 8.28 14.32 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.399 0.619 . . . . 0.0 110.033 177.332 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.443 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -167.09 171.86 41.99 Favored Glycine 0 N--CA 1.431 -1.66 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 60.2 t -112.51 135.25 52.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 -177.457 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -85.8 121.99 29.23 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 176.148 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.284 -2.265 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 -175.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.444 -0.767 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -70.11 -46.27 65.18 Favored 'General case' 0 CA--C 1.502 -0.876 0 CA-C-O 121.308 0.575 . . . . 0.0 110.415 -179.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -94.3 120.0 33.91 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 175.508 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -115.42 133.28 56.18 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-O 121.081 0.467 . . . . 0.0 111.085 -176.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -157.01 97.65 1.69 Allowed 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 175.448 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -62.72 -49.7 74.01 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.131 -0.94 . . . . 0.0 111.267 -174.199 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 69.9 mtm -97.64 92.24 5.8 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 177.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -118.13 93.27 4.07 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.738 -174.694 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 31.2 mmtp 64.32 9.7 5.07 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 124.344 1.058 . . . . 0.0 112.392 173.336 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -81.83 68.29 3.51 Favored Glycine 0 N--CA 1.438 -1.221 0 N-CA-C 115.753 1.061 . . . . 0.0 115.753 -170.429 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 12.5 p -70.8 96.12 1.21 Allowed 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 171.007 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.7 m -64.73 -54.87 24.66 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 113.469 0.914 . . . . 0.0 113.469 -172.378 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.5 m -124.19 147.94 47.63 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -176.571 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.5 m -87.34 90.06 8.23 Favored 'General case' 0 N--CA 1.418 -2.057 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.595 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.6 t -77.95 -22.04 50.1 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 122.617 1.198 . . . . 0.0 107.835 177.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p -134.73 129.65 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.479 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 172.333 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 9.1 m -79.23 84.79 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 CA-C-O 122.283 1.039 . . . . 0.0 111.516 -178.013 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 22.5 ttmm -65.58 116.39 6.78 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 113.757 -1.565 . . . . 0.0 110.386 -177.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -121.52 114.33 21.08 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.011 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 164.75 -32.07 0.25 Allowed Glycine 0 N--CA 1.432 -1.608 0 C-N-CA 120.464 -0.874 . . . . 0.0 112.393 -179.294 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 60.9 tttm -89.7 65.31 6.81 Favored 'General case' 0 C--O 1.245 0.838 0 CA-C-O 121.818 0.818 . . . . 0.0 110.734 -178.222 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 94.0 m -163.97 104.82 0.9 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 124.857 1.263 . . . . 0.0 107.992 177.432 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.1 m -81.82 113.37 19.72 Favored 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 177.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 5.5 m -56.11 -45.18 79.55 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 124.176 0.99 . . . . 0.0 112.726 -174.391 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -143.79 105.25 4.28 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.213 0.53 . . . . 0.0 110.624 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 17.1 m -113.22 -32.19 6.38 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.954 177.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.5 p -78.44 121.57 83.91 Favored Pre-proline 0 N--CA 1.434 -1.266 0 CA-C-N 115.496 -0.775 . . . . 0.0 112.386 -176.612 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_exo -67.23 -25.4 42.99 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 122.913 2.409 . . . . 0.0 112.247 174.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 64.73 -163.33 0.26 Allowed 'General case' 0 C--O 1.248 0.999 0 C-N-CA 124.077 0.951 . . . . 0.0 109.581 -177.033 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.9 p -81.45 66.17 6.88 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.801 0.81 . . . . 0.0 111.184 179.263 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.519 ' H ' ' HD2' ' A' ' 32' ' ' PRO . 40.1 ttm180 -120.69 -53.44 0.04 OUTLIER Pre-proline 0 C--N 1.305 -1.354 0 CA-C-N 114.937 -1.029 . . . . 0.0 112.909 -177.09 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.519 ' HD2' ' H ' ' A' ' 31' ' ' ARG . 37.4 Cg_endo -70.23 98.52 0.74 Allowed 'Trans proline' 0 C--N 1.375 1.942 0 CA-C-N 120.643 1.265 . . . . 0.0 110.062 173.193 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 54.6 t -123.1 111.99 31.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 CA-C-O 121.085 0.469 . . . . 0.0 112.015 -173.31 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 15.0 t -115.79 0.97 13.33 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 170.101 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 81.89 -150.16 29.03 Favored Glycine 0 N--CA 1.426 -1.978 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.665 -178.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 3.3 p -93.12 19.19 8.23 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 123.792 0.837 . . . . 0.0 111.054 -179.26 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' TRP . . . . . 0.428 ' CZ3' HG13 ' A' ' 90' ' ' ILE . 30.4 m95 -91.67 141.37 28.77 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.712 -175.404 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -114.19 152.4 31.27 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 175.224 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -102.76 121.24 42.06 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.616 179.603 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.448 ' HB3' ' CE1' ' A' ' 46' ' ' TYR . 37.2 p30 -85.42 -178.29 6.67 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.774 -176.808 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -66.73 -16.67 64.4 Favored 'General case' 0 C--N 1.323 -0.575 0 C-N-CA 123.674 0.789 . . . . 0.0 113.037 -178.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 67.8 m-85 -93.77 2.69 56.18 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.449 0.643 . . . . 0.0 110.096 -177.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.8 25.56 66.91 Favored Glycine 0 N--CA 1.442 -0.942 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.457 HG22 ' HB2' ' A' ' 89' ' ' CYS . 12.8 m -105.26 141.21 37.19 Favored 'General case' 0 N--CA 1.425 -1.71 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -92.78 120.56 33.28 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 174.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.448 ' CE1' ' HB3' ' A' ' 40' ' ' ASN . 23.9 p90 -128.02 149.68 50.26 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 120.623 0.249 . . . . 0.0 110.611 -175.599 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.423 ' HE2' ' CZ2' ' A' ' 37' ' ' TRP . 52.2 pttt -139.33 140.4 25.75 Favored Pre-proline 0 C--N 1.295 -1.797 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 173.737 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_exo -71.23 127.23 13.18 Favored 'Trans proline' 0 C--O 1.255 1.36 0 C-N-CA 122.057 1.838 . . . . 0.0 110.314 174.691 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -164.78 120.85 1.46 Allowed 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -179.116 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.495 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 19.8 t-20 -103.02 109.54 21.12 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 120.962 0.41 . . . . 0.0 110.883 -174.647 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.452 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -145.28 172.35 13.27 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 14.1 m -107.68 134.76 50.19 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.939 0.4 . . . . 0.0 111.412 -173.486 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 72.9 t80 -112.36 122.46 47.77 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.567 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 39.0 t -108.23 103.77 16.01 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.866 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 178.645 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 30.2 t30 -76.4 131.61 39.21 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -144.68 2.52 1.25 Allowed Glycine 0 N--CA 1.432 -1.623 0 C-N-CA 119.307 -1.425 . . . . 0.0 113.546 -179.356 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -93.74 -52.06 4.63 Favored 'General case' 0 C--N 1.318 -0.789 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.826 -175.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 17.1 pt20 -159.25 171.64 7.12 Favored Pre-proline 0 C--N 1.314 -0.96 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -173.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.45 ' HB3' HD21 ' A' ' 76' ' ' ASN . 17.1 Cg_exo -69.0 122.11 8.99 Favored 'Trans proline' 0 N--CA 1.44 -1.655 0 N-CA-C 107.604 -1.729 . . . . 0.0 107.604 166.212 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 58.7 mt -107.84 123.32 63.19 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -175.337 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 25.9 m -79.93 139.42 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.366 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 175.32 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.5 p -118.36 178.94 4.26 Favored 'General case' 0 C--N 1.272 -2.781 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.918 -172.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.424 ' HG3' ' O ' ' A' ' 68' ' ' PHE . 82.0 mmt-85 -115.48 136.64 52.88 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 176.721 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 63.8 mt -97.24 121.29 47.61 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.64 -174.08 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 77.56 -16.87 5.89 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 116.034 1.173 . . . . 0.0 116.034 172.349 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.2 m -151.82 137.77 11.36 Favored Pre-proline 0 C--N 1.305 -1.336 0 CA-C-N 118.24 1.02 . . . . 0.0 110.204 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -89.93 119.19 0.8 Allowed 'Trans proline' 0 N--CA 1.434 -1.975 0 C-N-CA 121.163 1.242 . . . . 0.0 110.811 173.405 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.564 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 92.9 m-85 -169.55 168.73 9.14 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 178.6 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.96 -31.77 27.45 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 171.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -95.27 17.01 15.16 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.179 -0.918 . . . . 0.0 112.204 -178.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -79.0 162.75 63.43 Favored Pre-proline 0 C--N 1.311 -1.095 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -54.69 122.14 11.07 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 122.343 2.029 . . . . 0.0 112.438 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.413 HG22 ' H ' ' A' ' 74' ' ' GLY . 13.8 p -104.1 172.94 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.944 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.413 ' H ' HG22 ' A' ' 73' ' ' VAL . . . 120.33 -13.32 10.29 Favored Glycine 0 CA--C 1.502 -0.745 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 -179.067 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.46 108.83 3.08 Favored Glycine 0 N--CA 1.432 -1.597 0 N-CA-C 108.338 -1.905 . . . . 0.0 108.338 172.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.45 HD21 ' HB3' ' A' ' 59' ' ' PRO . 7.6 t30 -111.5 123.43 50.21 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 117.697 0.748 . . . . 0.0 110.339 -176.511 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 40.6 tp -98.83 114.27 65.27 Favored Pre-proline 0 C--N 1.302 -1.496 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -68.43 161.64 44.07 Favored 'Trans proline' 0 C--O 1.249 1.058 0 C-N-CA 122.236 1.957 . . . . 0.0 112.642 -178.409 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.41 139.42 42.32 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.83 5.82 58.41 Favored Glycine 0 N--CA 1.436 -1.352 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -85.86 128.84 34.92 Favored 'General case' 0 N--CA 1.432 -1.357 0 CA-C-O 121.033 0.444 . . . . 0.0 111.233 -178.754 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 37.0 m -103.91 110.25 22.31 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.1 mm -126.32 130.74 71.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 -175.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.9 p -88.69 133.93 29.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 176.246 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.495 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 40.1 p90 -109.98 151.17 27.47 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -124.67 -0.4 8.05 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 122.075 0.941 . . . . 0.0 110.391 -174.091 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -146.34 133.0 19.88 Favored 'General case' 0 N--CA 1.428 -1.526 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 -176.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 51.4 t -119.34 128.14 75.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.457 ' HB2' HG22 ' A' ' 44' ' ' THR . 23.5 p -141.51 145.46 35.21 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -176.314 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.428 HG13 ' CZ3' ' A' ' 37' ' ' TRP . 58.4 mt -107.16 117.04 52.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 175.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.507 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -118.12 117.59 29.59 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 103.327 -2.842 . . . . 0.0 103.327 171.211 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.47 110.44 0.34 Allowed 'General case' 0 C--N 1.315 -0.91 0 O-C-N 124.822 1.326 . . . . 0.0 112.876 -167.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 143.37 -42.86 1.05 Allowed Glycine 0 N--CA 1.42 -2.394 0 CA-C-N 113.582 -1.645 . . . . 0.0 109.345 -176.512 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' HIS . . . . . 0.439 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 73.7 m80 -153.4 165.93 34.26 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -179.256 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.5 tt -99.98 129.32 50.82 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 105.223 -2.14 . . . . 0.0 105.223 171.146 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.507 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 57.0 m95 -112.5 134.53 53.98 Favored 'General case' 0 C--N 1.274 -2.682 0 CA-C-O 120.997 0.427 . . . . 0.0 110.039 -172.029 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.547 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 44.8 pt -100.44 128.82 52.08 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 175.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -94.22 114.78 4.86 Favored Glycine 0 N--CA 1.416 -2.695 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 178.479 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 54.5 p90 -127.2 167.67 15.74 Favored 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 -178.616 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.1 m-80 -108.16 129.49 55.17 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.54 176.46 9.77 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.065 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -55.95 -27.16 51.2 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.961 0.905 . . . . 0.0 112.152 -178.555 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 32.9 p-10 -104.31 13.11 32.72 Favored 'General case' 0 C--N 1.322 -0.628 0 C-N-CA 123.241 0.616 . . . . 0.0 111.247 -175.56 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 77.88 21.78 70.54 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 121.089 -0.577 . . . . 0.0 113.28 177.417 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 50.2 t-20 -85.84 132.51 34.09 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 178.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -85.76 98.35 10.68 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 21.6 t -108.95 147.01 13.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 -175.322 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.547 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 94.7 m-85 -117.19 121.62 41.73 Favored 'General case' 0 C--N 1.314 -0.964 0 C-N-CA 122.494 0.317 . . . . 0.0 110.758 -178.072 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' CYS . . . . . 0.456 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 53.7 t -101.03 135.1 20.02 Favored Pre-proline 0 C--N 1.315 -0.902 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.05 -16.11 36.22 Favored 'Trans proline' 0 C--N 1.361 1.205 0 C-N-CA 123.322 2.681 . . . . 0.0 114.863 -176.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.308 33.0 m 42.21 -55.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.519 3.0 0 N-CA-C 118.837 2.903 . . . . 0.0 118.837 176.322 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.464 ' CZ ' ' HB2' ' A' ' 126' ' ' ALA . 8.2 ptp180 -153.97 148.98 26.76 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 123.868 0.867 . . . . 0.0 108.704 175.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.439 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 24.3 m -66.33 135.33 54.23 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 177.476 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 97.5 m -150.78 124.94 9.36 Favored 'General case' 0 CA--C 1.511 -0.524 0 CA-C-O 121.431 0.634 . . . . 0.0 112.467 -178.784 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -110.44 151.57 27.35 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 174.455 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.37 -171.25 22.64 Favored Glycine 0 C--N 1.3 -1.462 0 C-N-CA 118.251 -1.928 . . . . 0.0 114.092 177.17 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 64.9 t -137.44 127.67 15.69 Favored Pre-proline 0 C--N 1.309 -1.191 0 N-CA-C 105.947 -1.871 . . . . 0.0 105.947 -178.752 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 99.0 Cg_exo -46.36 137.18 14.72 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.371 2.714 . . . . 0.0 112.804 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 76.2 Cg_endo -86.61 -15.54 29.39 Favored 'Cis proline' 0 CA--C 1.542 0.877 0 C-N-CA 123.228 -1.572 . . . . 0.0 113.896 1.846 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -75.85 100.16 4.69 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 122.136 0.969 . . . . 0.0 111.645 -173.021 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 54.7 p-80 -106.34 138.53 42.35 Favored 'General case' 0 C--N 1.296 -1.717 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.808 176.109 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.0 mm -90.22 108.83 29.09 Favored Pre-proline 0 C--N 1.3 -1.565 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 176.33 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -84.66 123.91 2.98 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.457 2.105 . . . . 0.0 113.587 -176.761 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -95.25 -134.62 7.79 Favored Glycine 0 N--CA 1.436 -1.33 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 175.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 69.4 t -81.74 126.69 39.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 C-N-CA 122.982 0.513 . . . . 0.0 110.475 -179.418 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.464 ' HB2' ' CZ ' ' A' ' 112' ' ' ARG . . . -93.87 145.74 24.4 Favored 'General case' 0 CA--C 1.507 -0.689 0 O-C-N 123.75 0.657 . . . . 0.0 109.294 174.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.0 m-90 -110.33 18.3 20.0 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.344 0.592 . . . . 0.0 111.278 179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -166.57 -173.12 34.62 Favored Glycine 0 N--CA 1.432 -1.579 0 C-N-CA 120.045 -1.074 . . . . 0.0 112.173 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 48.7 t -110.98 131.11 63.1 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.674 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -103.54 120.44 40.87 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.299 -1.61 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 17.6 m . . . . . 0 N--CA 1.444 -0.767 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -85.5 79.96 9.24 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 177.557 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -162.67 115.77 1.67 Allowed 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.853 -177.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -93.44 124.37 37.39 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 173.029 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 7.9 t30 70.44 85.36 0.13 Allowed 'General case' 0 CA--C 1.508 -0.646 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 -169.014 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -74.82 89.1 2.31 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.084 -174.24 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 52.6 ttm -143.08 74.69 1.45 Allowed 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 172.294 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -165.26 73.77 0.21 Allowed 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 114.324 -1.307 . . . . 0.0 108.89 -178.68 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.3 ttmp? 173.78 122.65 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 125.09 1.356 . . . . 0.0 108.851 177.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -119.12 160.73 14.07 Favored Glycine 0 N--CA 1.421 -2.32 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 176.735 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 20.1 m -115.36 71.46 0.77 Allowed 'General case' 0 N--CA 1.419 -2.024 0 CA-C-O 121.915 0.864 . . . . 0.0 109.839 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 20.2 m -89.31 -15.83 32.53 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.298 177.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 34.9 t -120.82 121.18 37.59 Favored 'General case' 0 N--CA 1.423 -1.809 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 177.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.3 m -77.59 109.28 11.42 Favored 'General case' 0 N--CA 1.432 -1.339 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 175.232 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 31.8 m 76.64 160.12 0.22 Allowed 'General case' 0 CA--C 1.566 1.589 0 O-C-N 124.44 1.088 . . . . 0.0 108.234 -175.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 34.1 m -68.46 -20.31 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 O-C-N 121.378 -0.827 . . . . 0.0 111.137 -179.31 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.9 t 66.01 83.01 0.06 OUTLIER 'Isoleucine or valine' 0 C--O 1.247 0.954 0 C-N-CA 124.287 1.035 . . . . 0.0 109.599 -179.523 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 2.7 tmtp? -80.74 84.54 6.26 Favored 'General case' 0 N--CA 1.428 -1.532 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 178.488 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -167.15 141.69 3.88 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 -177.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -82.07 -78.37 1.01 Allowed Glycine 0 N--CA 1.43 -1.754 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 177.304 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 3.1 tppp? -153.08 75.36 1.07 Allowed 'General case' 0 N--CA 1.422 -1.836 0 CA-C-O 121.313 0.578 . . . . 0.0 109.804 177.051 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 31.7 m -97.6 -20.09 17.9 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-O 121.798 0.809 . . . . 0.0 109.169 176.655 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 34.0 t -82.33 102.58 11.31 Favored 'General case' 0 N--CA 1.425 -1.678 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.419 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 65.3 m -87.72 120.88 29.48 Favored 'General case' 0 N--CA 1.428 -1.527 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 173.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 70.25 -83.9 0.03 OUTLIER 'General case' 0 C--O 1.225 -0.198 0 C-N-CA 124.708 1.203 . . . . 0.0 110.349 -175.609 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 33.8 t -156.49 140.96 16.76 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.2 p -111.2 97.19 34.22 Favored Pre-proline 0 C--N 1.296 -1.728 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -61.39 -80.42 0.01 OUTLIER 'Trans proline' 0 N--CA 1.448 -1.183 0 C-N-CA 122.358 2.038 . . . . 0.0 113.384 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 52.71 26.3 4.36 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.366 0.666 . . . . 0.0 111.756 -178.454 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 m 65.85 16.47 10.49 Favored 'General case' 0 CA--C 1.57 1.748 0 C-N-CA 124.11 0.964 . . . . 0.0 111.349 -177.537 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.552 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 26.2 mtp180 -72.46 -46.93 10.1 Favored Pre-proline 0 CA--C 1.546 0.82 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 175.207 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.552 ' HD3' ' HB2' ' A' ' 31' ' ' ARG . 1.2 Cg_endo -91.81 136.87 1.81 Allowed 'Trans proline' 0 N--CA 1.439 -1.679 0 C-N-CA 121.805 1.67 . . . . 0.0 108.129 163.189 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.422 HG13 HG23 ' A' ' 34' ' ' THR . 7.3 p -74.54 -41.44 48.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.886 -0.725 . . . . 0.0 111.338 -179.177 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.422 HG23 HG13 ' A' ' 33' ' ' VAL . 22.5 p -88.73 74.43 8.35 Favored 'General case' 0 N--CA 1.429 -1.514 0 CA-C-O 121.202 0.525 . . . . 0.0 111.574 -177.159 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 66.49 -116.96 8.85 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.123 179.241 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.6 m -106.91 4.59 27.47 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-O 120.894 0.378 . . . . 0.0 110.438 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -91.95 130.53 37.68 Favored 'General case' 0 CA--C 1.513 -0.476 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.047 -177.492 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 53.2 tptt -120.31 153.9 35.76 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -95.94 125.44 40.49 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 118.917 -1.113 . . . . 0.0 110.458 -177.349 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.455 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 53.0 t30 -77.2 166.44 23.21 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.116 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 66.7 mm-40 -71.2 4.72 2.6 Favored 'General case' 0 C--N 1.312 -1.044 0 C-N-CA 123.548 0.739 . . . . 0.0 112.488 -174.214 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -104.5 -0.42 27.88 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.249 0.547 . . . . 0.0 110.493 175.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 91.51 -2.8 78.16 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.794 178.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.424 HG22 ' HB2' ' A' ' 89' ' ' CYS . 5.3 m -88.72 139.57 30.33 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 70.3 m95 -92.98 123.95 36.6 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.455 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 11.8 p90 -133.0 159.18 40.77 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.404 -174.86 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -147.96 142.29 16.42 Favored Pre-proline 0 C--N 1.297 -1.712 0 N-CA-C 106.031 -1.841 . . . . 0.0 106.031 172.114 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -72.4 134.38 22.54 Favored 'Trans proline' 0 N--CA 1.45 -1.073 0 C-N-CA 121.397 1.398 . . . . 0.0 110.475 174.185 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -150.94 121.4 7.38 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -101.84 106.14 17.08 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.55 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.78 176.56 11.66 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.477 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 24.0 m -113.58 151.03 32.21 Favored 'General case' 0 C--N 1.292 -1.904 0 CA-C-O 121.002 0.429 . . . . 0.0 111.163 -174.511 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.465 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 84.0 t80 -129.21 124.83 35.54 Favored 'General case' 0 N--CA 1.428 -1.526 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 174.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 33.6 t -108.54 110.04 30.55 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.11 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 62.5 t30 -77.07 130.4 37.36 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 177.839 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -122.58 -64.0 0.22 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 118.52 -1.8 . . . . 0.0 115.901 -173.135 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -68.71 -56.33 8.46 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 114.05 1.13 . . . . 0.0 114.05 -171.507 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 20.2 pt20 -134.39 157.88 76.45 Favored Pre-proline 0 C--N 1.292 -1.913 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.212 -170.245 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -68.5 138.28 41.7 Favored 'Trans proline' 0 N--CA 1.445 -1.325 0 C-N-CA 121.76 1.64 . . . . 0.0 109.071 170.182 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.7 mt -113.39 133.38 59.48 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -177.385 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 9.5 p -84.3 128.05 39.26 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.083 0 CA-C-O 121.42 0.629 . . . . 0.0 109.76 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' THR . . . . . 0.441 HG22 ' HA ' ' A' ' 109' ' ' CYS . 74.1 p -109.98 178.94 4.25 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.099 -173.488 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.57 ' HG2' ' CZ3' ' A' ' 96' ' ' TRP . 1.6 mmp_? -112.15 154.77 25.0 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 174.375 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 54.5 mt -119.26 126.1 75.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 120.759 -0.376 . . . . 0.0 111.045 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 85.08 -22.75 9.04 Favored Glycine 0 CA--C 1.519 0.337 0 N-CA-C 115.983 1.153 . . . . 0.0 115.983 171.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.1 m -153.99 142.65 14.49 Favored Pre-proline 0 C--N 1.309 -1.192 0 CA-C-N 118.276 1.038 . . . . 0.0 109.933 -178.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -90.63 119.14 0.67 Allowed 'Trans proline' 0 N--CA 1.443 -1.442 0 C-N-CA 121.806 1.67 . . . . 0.0 111.865 175.125 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.535 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 91.9 m-85 -168.9 168.94 10.06 Favored 'General case' 0 CA--C 1.49 -1.348 0 N-CA-C 104.584 -2.376 . . . . 0.0 104.584 179.216 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 85.2 mt -79.53 -37.86 35.57 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 171.569 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -88.84 12.09 16.12 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 114.32 -1.309 . . . . 0.0 112.101 -176.644 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.535 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.99 162.65 73.52 Favored Pre-proline 0 C--N 1.314 -0.966 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.561 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -46.94 123.18 7.03 Favored 'Trans proline' 0 C--N 1.367 1.518 0 C-N-CA 123.371 2.714 . . . . 0.0 113.797 -178.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.8 t -97.37 172.27 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.35 -30.03 5.94 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.84 126.98 10.02 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 178.011 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 -128.47 130.5 47.64 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 117.118 0.459 . . . . 0.0 110.505 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 64.0 tp -97.63 113.55 63.67 Favored Pre-proline 0 C--N 1.3 -1.561 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.508 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -66.76 155.65 69.54 Favored 'Trans proline' 0 C--O 1.247 0.947 0 C-N-CA 122.505 2.136 . . . . 0.0 112.421 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.96 142.61 41.92 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.899 -0.592 . . . . 0.0 109.695 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.35 -4.57 70.29 Favored Glycine 0 N--CA 1.447 -0.602 0 N-CA-C 111.774 -0.531 . . . . 0.0 111.774 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -82.47 126.75 32.59 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 121.215 0.531 . . . . 0.0 111.528 -177.085 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 24.0 m -95.09 114.26 26.05 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 176.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.9 mm -119.02 134.0 64.06 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 -176.123 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.4 p -99.26 135.43 34.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.597 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.55 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 16.5 p90 -109.38 160.61 16.03 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.943 -0.703 . . . . 0.0 112.164 -178.272 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -124.8 -37.23 2.49 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.878 -1.056 . . . . 0.0 111.105 -176.367 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -118.26 131.92 56.33 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -175.453 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.4 t -121.43 125.27 73.42 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 176.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.534 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 13.8 p -134.09 140.45 46.63 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -175.538 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 71.8 mt -101.2 115.45 42.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 109.128 -0.694 . . . . 0.0 109.128 178.459 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.482 ' HG2' ' HA ' ' A' ' 68' ' ' PHE . 6.2 tp-100 -118.59 144.68 45.95 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 105.493 -2.04 . . . . 0.0 105.493 175.492 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -57.0 104.23 0.15 Allowed 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -175.085 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.58 -38.05 2.07 Favored Glycine 0 N--CA 1.439 -1.15 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.688 177.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 46.2 m80 -152.99 153.23 32.5 Favored 'General case' 0 N--CA 1.478 0.932 0 O-C-N 122.118 -0.636 . . . . 0.0 110.06 -176.549 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 13.6 tt -97.16 117.75 42.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.57 ' CZ3' ' HG2' ' A' ' 63' ' ' ARG . 65.2 m95 -100.61 134.11 44.05 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-O 120.922 0.391 . . . . 0.0 110.86 -171.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.5 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.6 pt -100.5 125.35 54.32 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.869 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 174.588 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -99.06 125.72 8.66 Favored Glycine 0 N--CA 1.414 -2.805 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 38.5 p90 -138.58 172.72 12.46 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-O 120.81 0.338 . . . . 0.0 110.524 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.442 ' HA ' ' O ' ' A' ' 105' ' ' ASN . 1.7 p-10 -115.5 120.04 38.18 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.687 -178.471 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.55 ' HB3' ' HB2' ' A' ' 105' ' ' ASN . . . -90.46 -174.7 4.22 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.447 -179.754 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 45.1 p90 -45.84 -32.25 2.51 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 116.246 1.943 . . . . 0.0 116.246 -176.353 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -108.37 15.79 23.68 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.034 0.921 . . . . 0.0 109.899 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 81.05 22.28 61.4 Favored Glycine 0 C--N 1.315 -0.621 0 N-CA-C 110.214 -1.155 . . . . 0.0 110.214 -177.738 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.55 ' HB2' ' HB3' ' A' ' 101' ' ' ALA . 8.9 m120 -67.78 121.1 15.24 Favored 'General case' 0 CA--C 1.494 -1.193 0 CA-C-N 114.732 -0.734 . . . . 0.0 109.141 -178.277 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 21.2 tpt180 -86.16 95.75 9.68 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 178.435 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.9 t -102.95 142.23 17.33 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.3 -174.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.5 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 86.8 m-85 -118.96 116.19 25.94 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 123.642 0.589 . . . . 0.0 110.163 -179.277 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' CYS . . . . . 0.441 ' HA ' HG22 ' A' ' 62' ' ' THR . 46.3 t -99.94 133.89 21.33 Favored Pre-proline 0 C--N 1.304 -1.376 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -69.7 -23.57 30.9 Favored 'Trans proline' 0 C--N 1.358 1.027 0 C-N-CA 123.227 2.618 . . . . 0.0 113.679 -176.35 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.291 30.8 m 48.95 -53.56 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.164 0 N-CA-C 117.972 2.582 . . . . 0.0 117.972 177.551 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.417 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 21.0 ptt180 -159.22 150.59 20.22 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 123.782 0.833 . . . . 0.0 108.837 -178.513 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 71.2 m -69.74 137.82 52.29 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 175.329 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 46.6 t -153.91 129.16 9.73 Favored 'General case' 0 N--CA 1.41 -2.473 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -177.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 9.1 tp60 -96.72 146.0 25.28 Favored 'General case' 0 N--CA 1.408 -2.53 0 N-CA-C 103.285 -2.857 . . . . 0.0 103.285 172.288 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -167.07 142.12 7.36 Favored Glycine 0 N--CA 1.406 -3.31 0 C-N-CA 116.66 -2.686 . . . . 0.0 114.994 -177.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 6.2 m -131.59 97.47 19.22 Favored Pre-proline 0 C--N 1.279 -2.457 0 N-CA-C 104.501 -2.407 . . . . 0.0 104.501 171.052 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -48.31 139.68 21.6 Favored 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 123.456 2.771 . . . . 0.0 113.803 -170.012 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -85.97 6.74 63.45 Favored 'Cis proline' 0 CA--C 1.558 1.724 0 C-N-CA 124.288 -1.13 . . . . 0.0 114.051 0.071 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -70.46 102.64 2.25 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-O 121.541 0.686 . . . . 0.0 110.977 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 36.6 p-80 -105.3 117.25 33.53 Favored 'General case' 0 C--N 1.296 -1.717 0 CA-C-N 114.832 -1.077 . . . . 0.0 111.49 -178.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 53.1 mt -110.18 99.34 39.35 Favored Pre-proline 0 C--N 1.318 -0.782 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.53 141.73 8.98 Favored 'Trans proline' 0 C--O 1.247 0.931 0 C-N-CA 122.549 2.166 . . . . 0.0 112.683 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -106.84 -114.55 3.91 Favored Glycine 0 N--CA 1.433 -1.515 0 N-CA-C 110.616 -0.994 . . . . 0.0 110.616 176.585 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 85.8 t -88.97 127.17 41.88 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.065 0 CA-C-N 116.734 0.267 . . . . 0.0 110.43 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.417 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -94.16 143.05 26.72 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.306 177.208 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.1 m-90 -113.81 27.78 9.27 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 120.861 0.363 . . . . 0.0 110.551 179.118 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.465 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -169.92 -179.11 41.38 Favored Glycine 0 N--CA 1.429 -1.814 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 37.7 t -111.0 130.31 64.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -178.107 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -98.88 145.76 26.67 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-O 121.004 0.431 . . . . 0.0 110.792 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.477 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 88.1 tttt . . . . . 0 C--N 1.291 -1.967 0 N-CA-C 107.544 -1.28 . . . . 0.0 107.544 178.054 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 24.4 m . . . . . 0 N--CA 1.444 -0.755 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 43.6 t-20 -106.62 139.25 41.37 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 174.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.469 ' HA ' ' O ' ' A' ' 7' ' ' MET . . . -155.74 -153.53 0.44 Allowed 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 121.061 -0.255 . . . . 0.0 111.072 -171.139 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 81.33 -69.08 0.09 Allowed 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 126.561 1.944 . . . . 0.0 110.753 179.819 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -89.09 -70.26 0.66 Allowed 'General case' 0 C--N 1.324 -0.535 0 C-N-CA 119.47 -0.892 . . . . 0.0 111.55 -177.172 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 23.3 p90 -87.71 68.01 9.34 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -175.259 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' MET . . . . . 0.469 ' O ' ' HA ' ' A' ' 3' ' ' ALA . 58.0 mtm 60.61 -158.62 0.32 Allowed 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 114.446 -1.252 . . . . 0.0 110.066 177.833 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -117.59 110.59 18.11 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 175.401 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.9 tppp? -95.67 105.39 17.38 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.32 56.97 2.41 Favored Glycine 0 C--O 1.245 0.817 0 N-CA-C 116.233 1.253 . . . . 0.0 116.233 -171.386 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 10.1 t -166.12 151.0 8.21 Favored 'General case' 0 N--CA 1.42 -1.945 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 175.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.1 m 72.76 132.36 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 124.751 1.22 . . . . 0.0 113.505 176.409 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.6 p -79.64 -18.33 51.72 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.386 177.347 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.5 m 74.74 86.91 0.09 Allowed 'General case' 0 N--CA 1.447 -0.604 0 C-N-CA 125.485 1.514 . . . . 0.0 111.278 177.6 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 49.3 m -94.92 104.14 16.02 Favored 'General case' 0 N--CA 1.417 -2.105 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.947 -178.218 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 28.9 t -114.72 78.59 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 104.852 -2.277 . . . . 0.0 104.852 171.137 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.7 t 68.22 -81.62 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 C-N-CA 124.734 1.214 . . . . 0.0 108.67 -169.7 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -162.24 -77.4 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 124.973 1.309 . . . . 0.0 108.625 177.33 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -159.74 146.29 16.24 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 105.68 -1.97 . . . . 0.0 105.68 -177.41 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -163.71 -104.0 0.18 Allowed Glycine 0 C--N 1.291 -1.938 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.08 24.47 1.54 Allowed 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.762 0.792 . . . . 0.0 111.06 177.774 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -70.42 -18.26 63.01 Favored 'General case' 0 N--CA 1.437 -1.122 0 C-N-CA 125.076 1.35 . . . . 0.0 110.263 176.544 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 38.0 t -150.12 147.01 27.24 Favored 'General case' 0 N--CA 1.413 -2.291 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.626 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.4 t -89.54 167.33 13.05 Favored 'General case' 0 C--O 1.265 1.88 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 173.243 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 58.15 37.41 26.33 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-O 121.987 0.899 . . . . 0.0 108.775 -175.757 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.513 ' O ' ' HD3' ' A' ' 28' ' ' PRO . 6.5 p -71.65 -1.97 15.59 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.262 -1.335 . . . . 0.0 114.026 -173.46 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.8 p -113.29 78.94 3.57 Favored Pre-proline 0 N--CA 1.434 -1.265 0 CA-C-O 120.828 0.347 . . . . 0.0 110.968 177.416 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.513 ' HD3' ' O ' ' A' ' 26' ' ' SER . 3.7 Cg_endo -88.36 2.77 6.16 Favored 'Trans proline' 0 C--N 1.36 1.173 0 C-N-CA 122.565 2.176 . . . . 0.0 112.092 -176.678 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -68.22 110.38 4.01 Favored 'General case' 0 N--CA 1.439 -1.005 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.776 -178.903 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . 0.276 73.4 p 66.78 -9.07 0.37 Allowed 'General case' 0 CA--C 1.549 0.936 0 N-CA-C 116.264 1.95 . . . . 0.0 116.264 176.855 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.57 ' HB2' ' HD3' ' A' ' 32' ' ' PRO 0.251 9.9 mpt_? -77.42 -66.89 0.29 Allowed Pre-proline 0 CA--C 1.54 0.58 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.265 177.144 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.57 ' HD3' ' HB2' ' A' ' 31' ' ' ARG . 2.4 Cg_endo -84.68 162.1 12.37 Favored 'Trans proline' 0 N--CA 1.437 -1.814 0 N-CA-C 107.439 -1.793 . . . . 0.0 107.439 167.34 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 t -84.2 73.05 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 C-N-CA 119.251 -0.979 . . . . 0.0 109.896 179.602 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 20.5 p -147.62 90.27 1.84 Allowed 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 125.145 1.378 . . . . 0.0 108.423 177.378 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.26 -66.47 2.02 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.813 -0.708 . . . . 0.0 111.472 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 35.8 t -123.45 -4.1 8.32 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 122.773 -0.251 . . . . 0.0 110.732 178.379 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 98.8 m95 -71.97 116.42 12.34 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 121.253 0.549 . . . . 0.0 109.962 179.15 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 7.1 tmtt? -120.56 139.15 53.36 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 105.461 -2.052 . . . . 0.0 105.461 -178.771 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -86.49 136.61 33.02 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.818 -0.753 . . . . 0.0 111.0 -175.392 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.402 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 45.3 t-20 -93.22 159.01 15.47 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 105.944 -1.873 . . . . 0.0 105.944 175.542 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -60.54 -22.28 63.46 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 123.467 0.707 . . . . 0.0 112.383 -174.614 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -79.13 2.34 21.2 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.865 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.11 10.72 80.05 Favored Glycine 0 CA--C 1.509 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.2 178.411 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.488 HG21 ' HG2' ' A' ' 67' ' ' PRO . 19.9 m -97.65 143.69 28.06 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 75.9 m95 -101.44 129.93 47.57 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.216 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.402 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 29.7 p90 -134.25 156.62 48.08 Favored 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.429 -177.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 49.2 pttt -135.96 132.23 19.24 Favored Pre-proline 0 C--N 1.293 -1.865 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 174.543 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -72.82 120.6 6.75 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 121.098 1.199 . . . . 0.0 109.007 174.126 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -154.45 130.14 10.01 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 -176.702 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -97.27 106.39 18.7 Favored 'General case' 0 C--N 1.307 -1.262 0 O-C-N 123.374 0.422 . . . . 0.0 109.963 -176.026 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.42 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -148.66 169.52 20.19 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 7.8 m -111.5 149.18 31.71 Favored 'General case' 0 C--N 1.298 -1.674 0 CA-C-O 120.981 0.42 . . . . 0.0 111.522 -173.172 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.4 t80 -130.58 131.36 44.96 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 174.291 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.424 HG22 HG23 ' A' ' 82' ' ' THR . 36.2 t -117.66 117.19 54.23 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 177.631 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -69.89 140.34 53.12 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -102.72 -73.97 1.0 Allowed Glycine 0 N--CA 1.432 -1.63 0 C-N-CA 120.306 -0.95 . . . . 0.0 114.75 -172.798 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -91.79 -69.13 0.75 Allowed 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 116.011 1.856 . . . . 0.0 116.011 -170.427 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -109.21 151.49 42.05 Favored Pre-proline 0 C--N 1.292 -1.914 0 O-C-N 121.828 -0.545 . . . . 0.0 111.192 -173.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.432 ' HA ' ' O ' ' A' ' 77' ' ' LEU . 50.0 Cg_exo -57.28 131.11 42.93 Favored 'Trans proline' 0 C--O 1.249 1.025 0 C-N-CA 122.171 1.914 . . . . 0.0 109.437 170.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -107.85 118.83 56.32 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -176.529 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 35.0 m -74.41 143.1 13.87 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.194 175.24 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 59.2 p -118.42 173.61 6.73 Favored 'General case' 0 C--N 1.277 -2.56 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.141 -173.724 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.466 ' HG3' ' O ' ' A' ' 68' ' ' PHE . 2.2 mmp_? -116.21 148.64 40.2 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.157 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 66.4 mt -112.21 131.26 64.15 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-O 120.62 0.248 . . . . 0.0 111.122 -177.303 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 85.98 -23.18 9.68 Favored Glycine 0 C--N 1.318 -0.423 0 N-CA-C 115.646 1.019 . . . . 0.0 115.646 171.267 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.0 m -157.87 142.23 11.67 Favored Pre-proline 0 C--N 1.296 -1.719 0 CA-C-N 117.51 0.655 . . . . 0.0 109.271 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.488 ' HG2' HG21 ' A' ' 44' ' ' THR . 60.9 Cg_endo -89.23 118.51 0.87 Allowed 'Trans proline' 0 N--CA 1.429 -2.306 0 C-N-CA 120.497 0.798 . . . . 0.0 110.089 172.276 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.489 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 90.8 m-85 -170.03 177.05 4.44 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 103.669 -2.715 . . . . 0.0 103.669 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -90.53 -37.81 13.62 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.411 0.624 . . . . 0.0 109.775 175.524 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -81.57 -2.33 49.62 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 114.772 -1.103 . . . . 0.0 111.035 -178.239 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.489 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -58.25 158.95 12.49 Favored Pre-proline 0 CA--C 1.547 0.828 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.547 -179.115 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_exo -47.11 134.73 18.9 Favored 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 123.823 3.015 . . . . 0.0 114.701 -178.289 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 26.6 m -90.63 173.53 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 CA-C-N 114.392 -1.276 . . . . 0.0 110.393 -178.644 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.44 6.22 12.04 Favored Glycine 0 C--N 1.314 -0.682 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.836 177.278 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -118.77 125.54 6.45 Favored Glycine 0 N--CA 1.432 -1.593 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.902 179.454 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -128.46 135.26 49.22 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 174.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.432 ' O ' ' HA ' ' A' ' 59' ' ' PRO . 53.9 tp -111.59 110.39 55.25 Favored Pre-proline 0 C--N 1.303 -1.422 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 176.523 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -67.47 166.14 24.78 Favored 'Trans proline' 0 CA--C 1.539 0.758 0 C-N-CA 122.699 2.266 . . . . 0.0 112.988 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.54 134.85 40.64 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.245 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.3 -10.81 73.56 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 121.236 -0.506 . . . . 0.0 112.298 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.76 129.38 39.56 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.902 0.382 . . . . 0.0 111.885 -176.816 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.424 HG23 HG22 ' A' ' 54' ' ' VAL . 52.9 m -104.98 117.02 32.96 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.121 179.545 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.0 mm -125.92 140.48 48.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -177.02 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.89 119.23 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-O 121.806 0.812 . . . . 0.0 108.864 175.362 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.42 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 39.4 p90 -97.37 148.4 23.2 Favored 'General case' 0 C--N 1.295 -1.799 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.929 -178.774 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -121.5 9.79 10.33 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 121.578 0.704 . . . . 0.0 110.231 -178.068 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -152.7 130.13 11.38 Favored 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -177.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 33.6 t -118.89 126.61 75.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 178.018 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.552 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 24.6 p -135.77 143.64 45.35 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.543 0.572 . . . . 0.0 112.543 -177.31 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 60.9 mt -102.32 116.83 46.7 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 CA-C-O 120.96 0.41 . . . . 0.0 110.003 177.695 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.582 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -124.27 121.77 35.94 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 174.117 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.89 107.95 0.16 Allowed 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 123.851 0.86 . . . . 0.0 113.14 -166.367 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 133.91 -33.97 2.46 Favored Glycine 0 N--CA 1.429 -1.81 0 CA-C-N 114.388 -1.278 . . . . 0.0 110.888 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -151.37 166.15 31.88 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -177.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 tt -107.71 119.13 56.78 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 171.211 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.582 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 55.4 m95 -100.77 134.11 44.23 Favored 'General case' 0 C--N 1.276 -2.612 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.9 -170.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.4 pt -100.12 133.7 42.2 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 176.272 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.13 121.97 7.21 Favored Glycine 0 N--CA 1.418 -2.564 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -126.13 147.04 49.7 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 176.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -93.96 112.85 24.75 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 -177.525 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.39 152.52 38.03 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -177.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -51.7 -30.12 20.95 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 124.313 1.045 . . . . 0.0 113.025 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -80.8 -5.52 57.33 Favored 'General case' 0 C--O 1.217 -0.644 0 CA-C-O 121.409 0.623 . . . . 0.0 110.829 -178.862 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 96.01 11.26 55.13 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.667 176.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -94.67 145.45 24.84 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.3 tpt180 -93.99 105.02 17.05 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 28.2 t -101.84 136.3 34.5 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -174.254 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.487 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 96.0 m-85 -116.09 126.04 53.2 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 123.419 0.688 . . . . 0.0 110.72 -178.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' CYS . . . . . 0.451 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 47.2 t -108.04 132.76 20.83 Favored Pre-proline 0 C--N 1.31 -1.123 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.143 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.06 -21.35 36.88 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 123.061 2.508 . . . . 0.0 114.683 -176.475 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.292 28.9 m 45.25 -53.71 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.914 0 N-CA-C 118.564 2.801 . . . . 0.0 118.564 176.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.453 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 28.8 ptt180 -154.67 142.05 19.61 Favored 'General case' 0 N--CA 1.44 -0.954 0 C-N-CA 123.826 0.851 . . . . 0.0 109.643 178.818 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 13.6 m -60.61 131.48 50.87 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.675 177.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.661 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 99.5 m -151.9 119.78 6.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.49 0.662 . . . . 0.0 112.091 -178.234 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -114.98 134.67 54.98 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 177.263 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 154.17 -175.97 32.2 Favored Glycine 0 CA--C 1.486 -1.768 0 C-N-CA 118.903 -1.618 . . . . 0.0 113.045 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.8 m -126.08 136.16 28.12 Favored Pre-proline 0 C--N 1.298 -1.644 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 179.37 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 92.5 Cg_exo -46.54 129.5 13.87 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 123.469 2.78 . . . . 0.0 113.332 -177.426 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 19.8 Cg_endo -96.18 -4.44 31.48 Favored 'Cis proline' 0 CA--C 1.542 0.908 0 C-N-CA 124.045 -1.231 . . . . 0.0 113.711 1.596 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -76.99 99.81 5.4 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-O 121.659 0.742 . . . . 0.0 110.868 -172.645 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 38.8 p-80 -106.99 132.79 52.53 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.334 176.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.661 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.6 mm -77.4 113.24 29.72 Favored Pre-proline 0 C--N 1.307 -1.262 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 174.302 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -84.55 124.42 3.13 Favored 'Trans proline' 0 N--CA 1.443 -1.457 0 C-N-CA 122.113 1.875 . . . . 0.0 112.528 -178.04 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.74 -139.19 9.85 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 176.691 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 58.4 t -80.62 123.43 37.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 -177.855 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.453 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -93.91 130.65 39.9 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 173.632 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.0 m-90 -95.66 12.63 29.12 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.635 0.731 . . . . 0.0 110.311 -178.434 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.03 -177.7 34.36 Favored Glycine 0 N--CA 1.421 -2.334 0 CA-C-N 115.196 -0.911 . . . . 0.0 111.298 -178.719 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 22.8 t -114.17 142.95 24.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -175.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -110.31 141.77 42.86 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.796 0.331 . . . . 0.0 111.289 -176.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? . . . . . 0 C--N 1.307 -1.27 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 172.534 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 N--CA 1.45 -0.462 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -94.87 83.82 4.07 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 172.137 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -70.68 131.95 44.68 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.63 -1.168 . . . . 0.0 110.43 -175.766 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 21.8 pttm -76.37 121.1 22.53 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 177.613 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 30.4 t30 69.76 89.97 0.1 Allowed 'General case' 0 C--N 1.313 -1.014 0 C-N-CA 123.941 0.897 . . . . 0.0 112.399 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -122.03 145.31 48.26 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 172.255 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 14.4 tpt 59.09 74.03 0.46 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.194 0.934 . . . . 0.0 108.737 -170.24 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -52.56 -58.04 8.04 Favored 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 114.514 -1.221 . . . . 0.0 112.815 -175.349 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.1 tttm 58.4 84.75 0.1 Allowed 'General case' 0 C--O 1.245 0.818 0 O-C-N 124.097 0.873 . . . . 0.0 110.645 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -156.09 37.25 0.6 Allowed Glycine 0 CA--C 1.489 -1.549 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -178.587 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 30.0 m -67.73 -43.52 79.75 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -178.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 20.3 m -86.01 91.37 8.38 Favored 'General case' 0 N--CA 1.427 -1.614 0 CA-C-O 121.43 0.633 . . . . 0.0 110.448 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 23.4 m -108.59 -41.85 4.7 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 175.326 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 13.8 m -91.21 85.84 5.98 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 177.879 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 88.3 m -155.63 128.86 8.22 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 -178.547 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 28.3 m -94.35 160.05 2.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 5.6 p -65.23 -47.85 85.78 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 CA-C-O 121.147 0.499 . . . . 0.0 109.942 178.107 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 49.9 tttm -165.81 147.97 7.31 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 178.543 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -140.34 -67.76 0.42 Allowed 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 175.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.87 -28.21 8.92 Favored Glycine 0 C--N 1.308 -0.973 0 C-N-CA 120.934 -0.65 . . . . 0.0 113.681 176.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 2.1 mppt? -88.85 -39.61 13.72 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 117.561 0.681 . . . . 0.0 109.871 -176.628 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 27.6 m -65.75 107.51 1.8 Allowed 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.195 -178.318 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.5 m -78.27 -12.97 60.04 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.558 -178.214 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.8 m -72.2 114.64 10.54 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.16 -179.401 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.11 99.55 9.27 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 176.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 14.2 m -51.4 138.28 21.94 Favored 'General case' 0 C--O 1.25 1.117 0 C-N-CA 124.024 0.93 . . . . 0.0 111.693 -178.191 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 27.6 p 52.69 68.91 2.67 Favored Pre-proline 0 CA--C 1.539 0.525 0 C-N-CA 124.69 1.196 . . . . 0.0 111.768 -175.148 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_exo -69.32 88.21 0.49 Allowed 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.13 2.553 . . . . 0.0 113.783 -174.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -111.1 -64.57 1.26 Allowed 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 174.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 p -65.0 -26.78 68.43 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 -176.72 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.448 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 8.9 mpt_? -77.69 -59.24 0.83 Allowed Pre-proline 0 C--N 1.318 -0.782 0 N-CA-C 113.167 0.802 . . . . 0.0 113.167 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.448 ' HD3' ' HB2' ' A' ' 31' ' ' ARG . 16.9 Cg_exo -71.43 -33.59 10.75 Favored 'Trans proline' 0 C--N 1.37 1.707 0 C-N-CA 121.489 1.459 . . . . 0.0 112.932 178.703 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 76.4 t -94.21 98.5 8.21 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 CA-C-O 121.717 0.77 . . . . 0.0 110.898 -177.23 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 46.5 m -149.3 95.69 2.4 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 176.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -117.32 -95.35 1.82 Allowed Glycine 0 N--CA 1.437 -1.268 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.447 -178.249 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 27.9 m -70.94 -35.73 72.33 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 179.235 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 95.5 m95 -86.07 120.49 27.5 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 175.807 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -113.66 149.67 34.31 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.3 tttm -92.13 120.48 32.77 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 121.806 0.812 . . . . 0.0 111.158 -177.384 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 30.3 t-20 -84.5 147.87 26.83 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 176.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.0 tm0? -53.61 -28.66 33.77 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.209 1.004 . . . . 0.0 111.869 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.401 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 54.3 m-85 -74.0 -6.02 44.86 Favored 'General case' 0 CA--C 1.54 0.56 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -178.795 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.36 22.78 39.48 Favored Glycine 0 CA--C 1.495 -1.212 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -178.308 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.413 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 16.9 m -105.88 139.06 41.03 Favored 'General case' 0 N--CA 1.415 -2.222 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.175 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -102.59 133.25 47.9 Favored 'General case' 0 C--N 1.282 -2.366 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 175.664 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 35.9 p90 -138.94 158.97 43.23 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.436 -0.905 . . . . 0.0 112.286 -175.313 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.0 pttp -140.67 134.42 15.06 Favored Pre-proline 0 N--CA 1.431 -1.411 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 174.324 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -70.76 134.46 25.91 Favored 'Trans proline' 0 C--N 1.327 -0.597 0 C-N-CA 121.626 1.551 . . . . 0.0 110.566 177.726 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -163.62 121.09 1.83 Allowed 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.015 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.529 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 26.4 t-20 -95.35 106.06 18.07 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 177.376 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.473 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -144.03 168.83 19.06 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 -178.564 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.422 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 17.2 m -109.61 140.85 42.94 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.256 -174.769 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.469 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 91.7 t80 -120.9 133.65 55.29 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 176.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 81' ' ' ALA . 42.5 t -119.4 119.53 60.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.696 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.137 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -59.67 145.62 44.14 Favored 'General case' 0 C--O 1.246 0.916 0 O-C-N 123.518 0.511 . . . . 0.0 111.874 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -81.77 -122.34 0.63 Allowed Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.664 -0.698 . . . . 0.0 113.213 -178.481 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -95.88 -6.3 39.61 Favored 'General case' 0 C--N 1.315 -0.907 0 O-C-N 122.374 -0.486 . . . . 0.0 112.276 -175.427 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 9.5 pt20 -121.45 148.08 49.11 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.554 -178.62 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -72.37 135.59 24.81 Favored 'Trans proline' 0 N--CA 1.439 -1.722 0 C-N-CA 121.932 1.755 . . . . 0.0 107.813 168.333 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 57.8 mt -107.81 127.83 63.56 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -176.125 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.4 p -78.37 136.67 23.52 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.212 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 37.9 p -113.29 164.16 13.91 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 121.134 0.492 . . . . 0.0 112.043 -174.243 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.488 ' HE ' ' HA ' ' A' ' 63' ' ' ARG . 0.8 OUTLIER -109.63 147.01 33.81 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.392 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.0 mt -99.33 123.4 52.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 112.378 0.511 . . . . 0.0 112.378 -176.189 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 70.9 -22.27 0.58 Allowed Glycine 0 CA--C 1.521 0.41 0 N-CA-C 118.054 1.981 . . . . 0.0 118.054 170.705 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 41.6 m -140.73 136.16 16.18 Favored Pre-proline 0 C--N 1.298 -1.662 0 CA-C-N 119.074 1.437 . . . . 0.0 111.075 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -89.91 119.57 0.83 Allowed 'Trans proline' 0 N--CA 1.44 -1.661 0 C-N-CA 121.781 1.654 . . . . 0.0 110.484 172.51 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.422 ' HA ' ' HG2' ' A' ' 91' ' ' GLN . 55.3 m-85 -168.46 168.98 10.81 Favored 'General case' 0 CA--C 1.489 -1.367 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 -177.643 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.73 -8.77 53.89 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.536 0.684 . . . . 0.0 110.194 176.754 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 31.0 p30 -116.62 14.97 15.53 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.243 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.09 152.89 86.75 Favored Pre-proline 0 C--O 1.247 0.962 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.491 -175.229 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_exo -54.29 134.59 61.62 Favored 'Trans proline' 0 C--N 1.364 1.385 0 C-N-CA 123.66 2.907 . . . . 0.0 113.878 -179.064 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 32.3 m -90.1 174.42 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-N 114.564 -1.198 . . . . 0.0 110.234 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.36 28.75 1.9 Allowed Glycine 0 C--N 1.315 -0.611 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.851 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -148.06 127.99 2.74 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -128.12 127.14 42.48 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.608 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 26.1 tp -110.61 113.29 55.83 Favored Pre-proline 0 C--N 1.306 -1.325 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.695 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -62.21 162.31 23.73 Favored 'Trans proline' 0 N--CA 1.483 0.904 0 C-N-CA 123.461 2.774 . . . . 0.0 114.043 -176.067 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.96 144.67 48.81 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 178.456 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.73 11.15 85.61 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.478 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.41 ' O ' ' HA ' ' A' ' 54' ' ' VAL . . . -78.77 134.21 37.04 Favored 'General case' 0 N--CA 1.439 -1.01 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 178.724 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 42.1 m -104.47 108.84 20.46 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.745 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 45.5 mm -124.05 126.59 72.62 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-O 120.936 0.398 . . . . 0.0 110.518 -176.791 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 12.4 p -90.32 123.41 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.647 0 CA-C-O 121.486 0.66 . . . . 0.0 109.56 176.34 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.529 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 45.5 p90 -101.96 159.25 15.52 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.137 -178.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -118.29 -16.19 9.68 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 121.379 0.609 . . . . 0.0 111.786 -175.204 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -141.11 137.76 33.03 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.341 -175.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 67.6 t -112.28 125.76 69.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.74 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.413 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 57.9 m -127.24 142.5 51.46 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -175.86 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 55.0 mt -108.46 117.04 53.11 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 172.174 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.422 ' HG2' ' HA ' ' A' ' 68' ' ' PHE . 60.2 tp60 -113.97 121.33 43.58 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 103.107 -2.923 . . . . 0.0 103.107 170.171 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.17 104.07 0.06 Allowed 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 113.697 0.999 . . . . 0.0 113.697 -165.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 132.56 -36.36 2.19 Favored Glycine 0 N--CA 1.435 -1.411 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.15 -177.439 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 41.5 m80 -146.09 149.39 33.96 Favored 'General case' 0 CA--C 1.504 -0.81 0 O-C-N 122.293 -0.533 . . . . 0.0 111.621 -178.253 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.8 tt -97.86 138.11 23.56 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.913 0 N-CA-C 105.777 -1.934 . . . . 0.0 105.777 175.203 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -120.22 138.06 53.85 Favored 'General case' 0 C--N 1.283 -2.308 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 -174.35 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.1 pt -101.05 128.9 52.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 175.312 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.19 119.87 6.6 Favored Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 179.246 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 55.2 p90 -138.35 171.97 13.6 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -109.21 131.97 54.57 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.331 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -98.12 170.9 8.59 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.703 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 31.1 p90 -50.18 -24.02 2.56 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 115.516 1.672 . . . . 0.0 115.516 -176.537 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -86.03 -9.92 55.92 Favored 'General case' 0 C--N 1.315 -0.926 0 O-C-N 121.498 -0.751 . . . . 0.0 110.59 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.94 17.14 56.89 Favored Glycine 0 CA--C 1.499 -0.926 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -174.547 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 42.2 t30 -93.95 136.14 34.56 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 113.822 -1.189 . . . . 0.0 109.399 -175.622 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 -78.57 113.71 16.85 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 47.3 t -121.14 143.37 33.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 -175.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.446 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 92.6 m-85 -120.79 127.21 51.74 Favored 'General case' 0 C--O 1.242 0.698 0 C-N-CA 122.977 0.511 . . . . 0.0 110.977 -179.138 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 53.0 t -104.48 133.46 20.18 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 178.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.59 -10.81 27.31 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 123.409 2.739 . . . . 0.0 114.267 -176.341 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.279 35.5 m 38.71 -61.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 N-CA-C 118.706 2.854 . . . . 0.0 118.706 174.6 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.545 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 35.6 ptt180 -154.99 150.33 27.24 Favored 'General case' 0 N--CA 1.439 -0.982 0 C-N-CA 123.287 0.635 . . . . 0.0 109.997 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.459 ' O ' ' HA ' ' A' ' 123' ' ' PRO . 82.4 m -68.95 135.61 51.23 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.637 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 95.2 m -151.09 110.92 4.06 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 123.001 0.52 . . . . 0.0 110.868 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 23.3 mp0 -98.71 160.95 13.92 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 176.545 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 128.02 -167.05 20.42 Favored Glycine 0 CA--C 1.487 -1.667 0 C-N-CA 118.768 -1.682 . . . . 0.0 113.508 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 27.9 m -138.13 151.13 69.22 Favored Pre-proline 0 C--N 1.304 -1.38 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 53.6 Cg_exo -56.0 137.01 77.74 Favored 'Trans proline' 0 CA--C 1.54 0.775 0 C-N-CA 122.349 2.033 . . . . 0.0 112.992 -179.49 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 1.3 Cg_endo -92.11 -11.65 27.86 Favored 'Cis proline' 0 C--O 1.25 1.087 0 C-N-CA 124.098 -1.209 . . . . 0.0 113.06 -2.242 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -75.82 101.15 4.99 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-O 122.207 1.003 . . . . 0.0 112.168 -173.093 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.41 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 32.6 p-80 -105.44 132.71 51.28 Favored 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 114.194 -1.366 . . . . 0.0 110.537 177.669 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.637 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 3.1 mp -94.15 105.5 17.8 Favored Pre-proline 0 C--N 1.299 -1.591 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 179.412 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.459 ' HA ' ' O ' ' A' ' 113' ' ' THR . 50.2 Cg_endo -84.31 143.18 9.93 Favored 'Trans proline' 0 N--CA 1.436 -1.864 0 C-N-CA 121.769 1.646 . . . . 0.0 112.813 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.7 -114.62 3.98 Favored Glycine 0 N--CA 1.426 -1.993 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 176.099 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 62.0 t -94.44 126.8 46.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.015 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.545 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.38 136.92 34.15 Favored 'General case' 0 N--CA 1.439 -1.015 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.349 175.199 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.0 m-90 -102.32 19.93 17.84 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.394 0.616 . . . . 0.0 110.939 -178.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.469 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -172.55 179.81 43.84 Favored Glycine 0 N--CA 1.427 -1.933 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.242 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 37.7 t -111.71 135.44 50.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -176.787 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -97.75 127.36 43.65 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.255 179.174 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 97.3 mttt . . . . . 0 C--N 1.29 -1.997 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 175.419 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 35.1 t . . . . . 0 N--CA 1.444 -0.739 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 16.0 m120 -87.39 110.27 20.15 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-O 120.651 0.263 . . . . 0.0 110.732 -178.044 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.22 65.69 8.37 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 176.591 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 65.7 tttp -118.98 -17.26 9.08 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 114.603 -1.18 . . . . 0.0 110.586 -176.535 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 31.3 p30 -84.75 -6.64 59.36 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.901 -177.353 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 70.29 1.17 3.47 Favored 'General case' 0 C--O 1.246 0.909 0 C-N-CA 124.365 1.066 . . . . 0.0 112.54 178.666 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 28.6 mmt -87.21 72.74 9.86 Favored 'General case' 0 N--CA 1.425 -1.702 0 CA-C-O 121.674 0.75 . . . . 0.0 109.935 -177.355 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -147.0 -39.09 0.2 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 114.326 -1.307 . . . . 0.0 107.529 173.318 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.2 tppp? -82.21 -59.88 2.4 Favored 'General case' 0 C--O 1.242 0.675 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 173.023 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -81.04 80.84 1.67 Allowed Glycine 0 N--CA 1.433 -1.561 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 176.382 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 34.3 m -145.03 133.84 22.32 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.8 p -76.95 114.8 16.14 Favored 'General case' 0 N--CA 1.42 -1.925 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 177.036 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 44.1 t -115.18 105.03 12.43 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -178.627 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 54.5 m 63.84 24.65 13.81 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 123.999 0.92 . . . . 0.0 110.561 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 5.6 m -95.97 71.35 2.92 Favored 'General case' 0 N--CA 1.424 -1.745 0 CA-C-O 121.825 0.822 . . . . 0.0 110.881 -175.747 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.6 m -113.06 23.99 4.7 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 177.544 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 9.2 p -62.07 133.04 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 CA-C-N 113.068 -1.878 . . . . 0.0 112.779 -175.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 28.1 tptp -100.78 116.87 33.7 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 106.155 -1.794 . . . . 0.0 106.155 171.12 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -56.58 110.25 0.75 Allowed 'General case' 0 C--O 1.239 0.508 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 176.42 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -80.31 144.91 26.23 Favored Glycine 0 N--CA 1.427 -1.915 0 CA-C-N 115.76 -0.655 . . . . 0.0 113.87 -171.088 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 61.1 tttm -72.58 107.93 5.35 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 177.25 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 8.5 m -130.55 154.49 47.76 Favored 'General case' 0 C--N 1.288 -2.085 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -174.456 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 30.2 m -80.94 131.94 35.37 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 173.337 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.3 m -47.39 116.42 1.42 Allowed 'General case' 0 C--O 1.243 0.763 0 C-N-CA 124.109 0.964 . . . . 0.0 111.838 -177.635 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -100.79 -163.88 1.06 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.135 -175.595 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 41.6 m 71.63 78.48 0.16 Allowed 'General case' 0 C--O 1.246 0.876 0 C-N-CA 124.187 0.995 . . . . 0.0 112.427 178.574 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.1 p -72.69 126.18 90.85 Favored Pre-proline 0 N--CA 1.42 -1.946 0 CA-C-N 114.567 -1.197 . . . . 0.0 108.461 175.024 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -44.88 -49.14 10.0 Favored 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 123.858 3.039 . . . . 0.0 113.623 -178.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 59.97 28.1 17.57 Favored 'General case' 0 C--O 1.246 0.896 0 O-C-N 124.203 0.939 . . . . 0.0 110.836 178.812 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.0 m 60.86 80.15 0.22 Allowed 'General case' 0 N--CA 1.438 -1.05 0 C-N-CA 124.74 1.216 . . . . 0.0 109.924 -176.454 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.411 ' HB3' ' HD3' ' A' ' 32' ' ' PRO . 41.0 ttm180 -153.81 -58.09 0.02 OUTLIER Pre-proline 0 CA--C 1.552 1.057 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.01 -177.176 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.411 ' HD3' ' HB3' ' A' ' 31' ' ' ARG . 57.8 Cg_endo -78.07 87.86 1.49 Allowed 'Trans proline' 0 C--N 1.377 2.061 0 N-CA-C 108.961 -1.207 . . . . 0.0 108.961 169.638 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -112.31 175.16 2.06 Favored 'Isoleucine or valine' 0 C--O 1.261 1.675 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.047 -175.142 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.2 m -74.18 70.76 1.63 Allowed 'General case' 0 N--CA 1.434 -1.255 0 CA-C-O 121.556 0.693 . . . . 0.0 109.771 178.008 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -119.31 -18.96 4.38 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 177.64 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 5.5 m -94.66 -21.9 18.5 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 121.706 0.765 . . . . 0.0 109.927 179.258 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 45.6 m95 -92.14 147.54 22.86 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.431 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.8 mtpp -121.84 152.06 39.97 Favored 'General case' 0 C--N 1.309 -1.196 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 177.449 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 56.7 tttp -101.65 135.41 43.22 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 34.9 p30 -95.09 174.69 6.95 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -64.18 -22.31 66.89 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 122.924 0.49 . . . . 0.0 111.937 -178.263 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -82.43 -5.56 58.75 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.486 -178.324 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 95.34 -3.82 66.55 Favored Glycine 0 N--CA 1.439 -1.114 0 C-N-CA 121.151 -0.547 . . . . 0.0 112.615 176.492 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 7.1 m -84.58 141.08 30.94 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 122.706 0.402 . . . . 0.0 110.126 -176.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 98.2 m95 -92.52 135.87 33.7 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 174.344 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -137.97 159.13 42.83 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 120.84 0.352 . . . . 0.0 110.983 -177.676 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 58.7 pttt -141.97 152.32 61.64 Favored Pre-proline 0 C--N 1.301 -1.507 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 174.718 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -80.21 121.85 4.51 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.017 1.812 . . . . 0.0 110.572 175.673 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.42 ' HB3' HG23 ' A' ' 88' ' ' VAL . 38.2 tt0 -155.42 130.72 9.58 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.285 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.557 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 27.2 t-20 -117.95 115.31 24.65 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -177.078 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.526 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -154.49 178.29 10.23 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -179.086 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 28.5 m -103.35 131.14 50.67 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 121.066 0.46 . . . . 0.0 111.038 -176.225 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.426 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 79.8 t80 -107.08 121.95 45.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 173.403 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 41.4 t -106.65 102.25 13.66 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.045 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.668 -178.379 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 56.0 t30 -77.44 151.63 34.64 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 173.543 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -142.05 -71.8 0.03 OUTLIER Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.017 -1.563 . . . . 0.0 115.537 -176.195 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.402 ' OD1' ' HG3' ' A' ' 58' ' ' GLN . 26.7 p30 -72.1 -38.27 69.37 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 116.161 1.912 . . . . 0.0 116.161 -169.146 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.402 ' HG3' ' OD1' ' A' ' 57' ' ' ASN . 0.1 OUTLIER -138.54 161.4 58.98 Favored Pre-proline 0 C--N 1.296 -1.752 0 C-N-CA 120.494 -0.482 . . . . 0.0 112.123 -177.031 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -78.08 151.0 26.76 Favored 'Trans proline' 0 N--CA 1.439 -1.717 0 C-N-CA 121.722 1.614 . . . . 0.0 109.578 175.61 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.6 mt -125.04 126.22 70.77 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -178.388 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.6 p -82.21 117.75 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.218 0 CA-C-O 122.119 0.961 . . . . 0.0 109.527 176.166 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.3 p -91.28 173.62 7.82 Favored 'General case' 0 C--N 1.289 -2.065 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.333 -176.131 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 74.4 mmt-85 -111.25 145.72 38.24 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-O 121.285 0.564 . . . . 0.0 110.23 -178.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.3 mt -94.89 112.35 27.23 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 CA-C-N 115.203 -0.908 . . . . 0.0 112.717 -176.156 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.11 -23.13 1.16 Allowed Glycine 0 CA--C 1.518 0.279 0 N-CA-C 116.849 1.5 . . . . 0.0 116.849 171.166 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.451 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 18.1 m -137.11 135.96 20.36 Favored Pre-proline 0 C--N 1.301 -1.541 0 CA-C-N 118.329 1.064 . . . . 0.0 111.168 -175.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 66' ' ' SER . 9.6 Cg_endo -89.98 120.28 0.87 Allowed 'Trans proline' 0 N--CA 1.438 -1.745 0 C-N-CA 121.888 1.725 . . . . 0.0 111.525 173.681 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.549 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 92.9 m-85 -165.42 161.92 19.11 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 103.848 -2.649 . . . . 0.0 103.848 179.024 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 64.9 mt -72.85 -40.08 66.0 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.17 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -97.36 17.49 17.34 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.221 -0.9 . . . . 0.0 111.172 -178.41 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.549 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -60.68 161.69 14.04 Favored Pre-proline 0 N--CA 1.48 1.06 0 C-N-CA 122.959 0.504 . . . . 0.0 111.624 -179.078 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -57.11 130.71 41.06 Favored 'Trans proline' 0 C--N 1.366 1.5 0 C-N-CA 122.955 2.436 . . . . 0.0 113.185 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 22.2 m -102.92 175.75 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 C-N-CA 124.56 1.144 . . . . 0.0 110.874 -179.537 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.84 3.84 10.76 Favored Glycine 0 C--N 1.309 -0.919 0 C-N-CA 121.308 -0.473 . . . . 0.0 112.175 -178.678 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -110.18 94.3 0.79 Allowed Glycine 0 N--CA 1.434 -1.442 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 173.556 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -87.38 122.31 30.97 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.989 -0.713 . . . . 0.0 110.463 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.9 tp -96.78 113.33 62.64 Favored Pre-proline 0 C--N 1.304 -1.384 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.304 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.33 159.89 47.94 Favored 'Trans proline' 0 C--O 1.251 1.154 0 C-N-CA 122.591 2.194 . . . . 0.0 113.348 -176.648 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.28 124.86 25.97 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.889 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.09 -0.54 54.68 Favored Glycine 0 C--N 1.306 -1.106 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.18 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.36 126.52 29.88 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.299 0.571 . . . . 0.0 111.247 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 14.4 m -99.45 108.87 21.44 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 178.217 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.9 mm -119.16 128.56 75.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 120.723 0.296 . . . . 0.0 111.333 -173.192 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.2 p -87.98 128.97 39.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 173.765 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.557 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 21.1 p90 -104.01 157.98 16.73 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.955 -0.298 . . . . 0.0 111.472 -178.512 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -114.97 -23.6 9.01 Favored 'General case' 0 C--O 1.247 0.945 0 CA-C-O 121.665 0.745 . . . . 0.0 111.495 -176.796 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -141.52 137.42 32.03 Favored 'General case' 0 C--N 1.294 -1.807 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.911 -170.575 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.42 HG23 ' HB3' ' A' ' 49' ' ' GLU . 96.0 t -113.73 132.86 61.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.583 ' HG ' ' HE2' ' A' ' 108' ' ' TYR . 56.9 m -131.85 153.75 49.87 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 120.548 0.214 . . . . 0.0 111.235 -176.141 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 55.3 mt -122.12 119.71 59.26 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 173.554 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.48 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 6.2 tp-100 -122.58 146.31 47.54 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 176.743 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.71 104.76 0.07 Allowed 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -169.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 108.47 -19.75 31.02 Favored Glycine 0 N--CA 1.436 -1.322 0 CA-C-N 114.853 -1.067 . . . . 0.0 113.999 175.519 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -145.17 147.01 32.0 Favored 'General case' 0 C--N 1.316 -0.858 0 O-C-N 121.535 -0.979 . . . . 0.0 111.998 -176.673 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.468 HG23 HG23 ' A' ' 111' ' ' VAL . 14.7 tt -92.64 143.85 10.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 105.461 -2.052 . . . . 0.0 105.461 174.132 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.48 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 70.0 m95 -126.92 148.61 50.03 Favored 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 -175.46 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.8 pt -117.67 137.52 51.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 174.148 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -110.83 131.62 10.48 Favored Glycine 0 N--CA 1.421 -2.329 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -138.62 169.7 17.32 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 177.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 51.8 t-20 -106.56 114.64 28.88 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.32 162.62 28.25 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -178.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -57.54 -17.9 16.4 Favored 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 -177.024 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 7.3 t30 -79.23 -14.83 58.8 Favored 'General case' 0 CA--C 1.547 0.861 0 CA-C-O 121.18 0.514 . . . . 0.0 110.598 178.788 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 92.21 17.02 48.38 Favored Glycine 0 C--N 1.325 -0.079 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -174.9 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -97.49 142.89 28.78 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 114.648 -0.776 . . . . 0.0 110.68 -178.267 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 19.2 tpt180 -88.39 107.34 18.79 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 179.23 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 43.0 t -107.96 139.61 29.41 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -176.119 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.583 ' HE2' ' HG ' ' A' ' 89' ' ' CYS . 90.5 m-85 -117.5 128.34 54.89 Favored 'General case' 0 C--N 1.32 -0.695 0 O-C-N 123.331 0.395 . . . . 0.0 110.817 -179.317 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 41.9 t -104.7 133.29 20.25 Favored Pre-proline 0 C--N 1.3 -1.547 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.03 -9.49 25.74 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 123.135 2.557 . . . . 0.0 114.001 -177.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.468 HG23 HG23 ' A' ' 95' ' ' ILE 0.307 27.1 m 39.1 -63.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 N-CA-C 118.361 2.726 . . . . 0.0 118.361 175.133 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.547 ' HB2' ' O ' ' A' ' 125' ' ' VAL . 36.0 ptt180 -162.59 164.38 26.78 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-O 121.177 0.513 . . . . 0.0 111.468 177.357 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 58.4 m -75.37 134.72 40.9 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.265 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.477 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 89.6 m -154.58 124.26 6.59 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 123.787 0.835 . . . . 0.0 110.026 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -105.48 160.54 15.07 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 179.166 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 134.83 -176.24 20.08 Favored Glycine 0 C--N 1.292 -1.872 0 C-N-CA 118.262 -1.923 . . . . 0.0 114.209 175.272 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 76.7 t -127.37 121.33 22.45 Favored Pre-proline 0 C--N 1.298 -1.632 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 99.5 Cg_exo -43.76 136.25 6.97 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 124.043 3.162 . . . . 0.0 113.18 -178.182 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 0.9 OUTLIER -86.13 -11.17 42.48 Favored 'Cis proline' 0 C--O 1.25 1.103 0 C-N-CA 124.007 -1.247 . . . . 0.0 114.25 3.77 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -76.22 102.16 5.7 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.951 0.881 . . . . 0.0 112.19 -172.741 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -106.09 124.87 50.25 Favored 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 114.073 -1.421 . . . . 0.0 110.83 176.625 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 55.3 mt -93.74 109.43 41.23 Favored Pre-proline 0 C--N 1.295 -1.768 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.83 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -81.97 150.38 16.04 Favored 'Trans proline' 0 C--O 1.246 0.907 0 C-N-CA 122.485 2.123 . . . . 0.0 114.295 -175.654 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.33 -125.36 4.3 Favored Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 175.003 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.547 ' O ' ' HB2' ' A' ' 112' ' ' ARG . 60.3 t -79.09 133.68 29.44 Favored 'Isoleucine or valine' 0 C--O 1.244 0.805 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.447 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -93.22 132.94 36.93 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 123.268 0.627 . . . . 0.0 109.857 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 8.6 m0 -107.68 13.38 26.63 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.462 0.649 . . . . 0.0 109.995 178.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.426 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -173.58 170.69 43.85 Favored Glycine 0 N--CA 1.425 -2.089 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 179.569 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 73.3 t -111.41 129.57 66.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.981 0.391 . . . . 0.0 110.316 -176.635 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -94.4 129.58 41.07 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.079 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 28.0 ttpp . . . . . 0 N--CA 1.423 -1.817 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 -179.731 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 26.3 m . . . . . 0 N--CA 1.44 -0.935 0 CA-C-O 121.076 0.465 . . . . 0.0 110.908 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -78.5 108.19 11.69 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 176.047 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 75.03 153.56 0.14 Allowed 'General case' 0 C--O 1.253 1.239 0 C-N-CA 125.228 1.411 . . . . 0.0 111.08 -173.833 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 23.4 tptm -70.67 120.12 15.82 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.53 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -87.0 84.79 7.26 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.341 0.591 . . . . 0.0 111.926 -177.023 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 20.7 m-85 -165.04 113.06 1.02 Allowed 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 126.218 1.807 . . . . 0.0 108.917 177.469 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 94.9 mmm -81.79 91.8 6.55 Favored 'General case' 0 C--N 1.311 -1.091 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 173.573 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -62.85 144.41 56.64 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -177.123 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . 0.314 0.4 OUTLIER -79.36 81.73 5.58 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -174.227 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.48 62.51 0.54 Allowed Glycine 0 N--CA 1.414 -2.821 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 171.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 5.4 t -78.27 78.38 4.75 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-O 122.606 1.193 . . . . 0.0 111.595 -175.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.7 m -140.1 81.09 1.8 Allowed 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 175.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.431 ' HB2' HG22 ' A' ' 16' ' ' VAL . 5.4 m -67.62 124.91 24.58 Favored 'General case' 0 N--CA 1.435 -1.201 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.376 -178.439 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.8 m -71.68 67.83 0.58 Allowed 'General case' 0 C--N 1.314 -0.953 0 C-N-CA 123.547 0.739 . . . . 0.0 111.369 -177.272 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 46.5 m -170.62 -42.45 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 126.207 1.803 . . . . 0.0 106.872 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.431 HG22 ' HB2' ' A' ' 13' ' ' SER . 12.9 m -93.31 159.8 2.75 Favored 'Isoleucine or valine' 0 C--O 1.245 0.848 0 CA-C-N 115.067 -0.97 . . . . 0.0 111.373 -173.048 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 50.1 t -108.25 134.92 48.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 176.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -89.74 -68.28 0.79 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.719 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -171.62 151.93 3.05 Favored 'General case' 0 C--O 1.248 1.004 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.1 61.23 3.81 Favored Glycine 0 N--CA 1.443 -0.871 0 N-CA-C 111.196 -0.762 . . . . 0.0 111.196 177.614 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -84.93 -34.03 22.58 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.412 ' HB ' ' O ' ' A' ' 25' ' ' ALA . 2.5 p -77.98 79.85 4.43 Favored 'General case' 0 N--CA 1.419 -1.987 0 CA-C-O 122.086 0.946 . . . . 0.0 111.977 -178.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 20.7 p -97.32 -34.05 11.21 Favored 'General case' 0 N--CA 1.424 -1.74 0 CA-C-N 114.57 -1.196 . . . . 0.0 109.834 179.533 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.3 m -84.38 -24.3 29.74 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 175.753 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.412 ' O ' ' HB ' ' A' ' 22' ' ' THR . . . -103.25 92.73 4.64 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 175.303 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 16.8 m -60.66 103.67 0.27 Allowed 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.42 -176.363 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.8 m -85.31 120.99 73.81 Favored Pre-proline 0 N--CA 1.427 -1.597 0 CA-C-N 115.217 -0.901 . . . . 0.0 108.772 -179.224 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -61.88 -53.97 1.82 Allowed 'Trans proline' 0 C--N 1.357 1.02 0 C-N-CA 121.869 1.713 . . . . 0.0 111.572 179.103 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 59.3 -85.17 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 124.756 1.222 . . . . 0.0 112.144 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.4 t -85.63 -19.99 30.15 Favored 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 176.397 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -76.34 165.73 50.56 Favored Pre-proline 0 C--O 1.241 0.639 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 174.729 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -69.91 101.84 0.98 Allowed 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 122.319 2.012 . . . . 0.0 112.857 -173.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 48.6 t -70.72 -69.92 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.855 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 173.011 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 29.8 m 63.92 -48.43 0.27 Allowed 'General case' 0 CA--C 1.561 1.386 0 C-N-CA 125.433 1.493 . . . . 0.0 114.342 174.556 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -67.74 78.17 0.2 Allowed Glycine 0 C--N 1.337 0.625 0 C-N-CA 124.0 0.809 . . . . 0.0 111.838 178.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 47.6 m -168.09 -39.53 0.02 OUTLIER 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 103.941 -2.614 . . . . 0.0 103.941 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' TRP . . . . . 0.41 ' CE2' ' HD3' ' A' ' 47' ' ' LYS . 66.2 m95 -90.54 150.21 21.85 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.788 176.31 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.429 ' HD3' ' N ' ' A' ' 39' ' ' LYS . 12.4 tmtt? -135.18 137.89 43.13 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 177.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.429 ' N ' ' HD3' ' A' ' 38' ' ' LYS . 2.6 ttmp? -83.3 116.85 22.62 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.477 ' HB3' ' CE1' ' A' ' 46' ' ' TYR . 36.3 p30 -77.98 177.66 8.1 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 177.154 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -65.33 -7.41 13.36 Favored 'General case' 0 C--N 1.317 -0.819 0 C-N-CA 123.527 0.731 . . . . 0.0 112.525 -178.448 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.4 m-85 -102.25 4.27 39.08 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.497 0.665 . . . . 0.0 110.041 -178.514 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.44 16.15 79.85 Favored Glycine 0 N--CA 1.447 -0.591 0 CA-C-N 115.511 -0.768 . . . . 0.0 112.086 178.006 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 25.3 m -100.22 132.95 45.3 Favored 'General case' 0 N--CA 1.424 -1.743 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.042 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.407 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 75.1 m95 -87.93 125.31 34.44 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 176.477 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.477 ' CE1' ' HB3' ' A' ' 40' ' ' ASN . 50.9 p90 -130.31 151.52 50.73 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 121.184 -0.207 . . . . 0.0 111.156 -178.292 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.41 ' HD3' ' CE2' ' A' ' 37' ' ' TRP . 18.1 pttp -146.64 140.91 15.62 Favored Pre-proline 0 C--N 1.313 -0.985 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 173.104 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -79.61 120.96 4.51 Favored 'Trans proline' 0 C--O 1.244 0.8 0 C-N-CA 121.635 1.557 . . . . 0.0 112.559 -179.27 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.8 tt0 -158.14 125.21 4.97 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.063 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.404 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 26.0 t-20 -87.25 121.38 29.62 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.709 -175.789 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -150.27 169.52 21.17 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 19.9 m -116.14 143.41 45.53 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 -173.857 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -130.19 126.39 37.31 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 124.062 0.945 . . . . 0.0 108.964 175.622 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.1 t -111.41 109.01 26.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.671 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 37.9 t30 -77.09 131.27 38.28 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 175.428 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -156.91 83.27 0.15 Allowed Glycine 0 C--N 1.306 -1.103 0 C-N-CA 118.979 -1.581 . . . . 0.0 113.992 -176.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.473 ' HB3' ' OE1' ' A' ' 58' ' ' GLN . 40.3 t30 168.59 -67.86 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 125.269 1.427 . . . . 0.0 109.203 172.577 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.502 ' NE2' ' HB3' ' A' ' 127' ' ' TRP . 4.7 pm0 -111.89 152.24 44.08 Favored Pre-proline 0 C--N 1.304 -1.374 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.266 -175.244 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_exo -73.48 133.98 19.88 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.698 1.598 . . . . 0.0 108.051 170.046 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 61.1 mt -108.1 125.7 64.72 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -176.351 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.4 p -81.05 111.77 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.626 0 CA-C-O 122.066 0.936 . . . . 0.0 108.737 176.504 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 64.7 p -92.22 164.62 13.48 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.399 -176.556 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 17.2 mmt180 -105.41 135.49 46.7 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.635 -175.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.4 mt -98.9 125.56 52.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 N-CA-C 112.68 0.622 . . . . 0.0 112.68 -173.762 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.75 -21.87 1.52 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 116.388 1.315 . . . . 0.0 116.388 172.772 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.401 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 22.1 m -146.84 136.99 12.13 Favored Pre-proline 0 C--N 1.305 -1.335 0 CA-C-N 118.678 1.239 . . . . 0.0 111.063 -177.402 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 66' ' ' SER . 19.3 Cg_endo -90.3 120.43 0.82 Allowed 'Trans proline' 0 N--CA 1.437 -1.804 0 C-N-CA 121.925 1.75 . . . . 0.0 110.971 172.396 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.485 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 51.7 m-85 -167.03 171.45 11.07 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 179.685 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 69.4 mt -84.65 -28.46 26.42 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 107.481 -1.304 . . . . 0.0 107.481 172.418 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -96.68 19.78 11.88 Favored 'General case' 0 CA--C 1.549 0.936 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.294 179.524 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.485 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -71.21 155.28 93.24 Favored Pre-proline 0 C--N 1.315 -0.908 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.505 -176.645 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_exo -55.89 131.16 44.34 Favored 'Trans proline' 0 C--N 1.353 0.801 0 C-N-CA 123.404 2.736 . . . . 0.0 113.927 -179.726 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.3 m -97.54 174.62 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.259 178.059 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.66 -0.57 15.65 Favored Glycine 0 CA--C 1.496 -1.105 0 C-N-CA 120.071 -1.061 . . . . 0.0 112.235 178.529 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.43 96.23 0.87 Allowed Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 175.035 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -94.46 118.42 31.61 Favored 'General case' 0 C--N 1.288 -2.071 0 O-C-N 122.186 -0.596 . . . . 0.0 109.967 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 48.4 tp -90.69 117.75 68.18 Favored Pre-proline 0 C--N 1.306 -1.311 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.29 152.51 80.87 Favored 'Trans proline' 0 C--O 1.249 1.061 0 C-N-CA 122.289 1.992 . . . . 0.0 113.029 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.96 135.55 40.04 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 115.142 -0.935 . . . . 0.0 108.982 176.547 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.43 4.91 57.14 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.425 -179.568 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.28 130.48 38.99 Favored 'General case' 0 C--O 1.243 0.731 0 CA-C-O 121.151 0.501 . . . . 0.0 111.882 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.2 m -93.28 120.16 33.25 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.239 176.082 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.6 mm -119.94 118.63 57.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.884 -179.138 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 5.0 p -99.48 112.64 32.34 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 175.797 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.404 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 45.5 p90 -97.2 155.78 16.69 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.536 -173.17 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -115.54 -9.0 12.11 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -175.453 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -136.88 131.23 32.86 Favored 'General case' 0 C--N 1.309 -1.194 0 C-N-CA 120.531 -0.467 . . . . 0.0 109.755 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 24.2 t -102.02 129.4 53.42 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.752 ' HG ' ' HE2' ' A' ' 108' ' ' TYR . 43.9 m -134.88 145.93 48.73 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-N 117.84 0.291 . . . . 0.0 111.493 -176.406 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 65.1 mt -120.69 116.89 51.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 175.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.596 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -125.89 136.43 53.04 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 105.854 -1.906 . . . . 0.0 105.854 175.45 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.04 112.65 0.7 Allowed 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -171.132 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 125.43 -32.62 3.86 Favored Glycine 0 N--CA 1.437 -1.294 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.128 179.071 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 61.2 m80 -153.51 168.8 24.94 Favored 'General case' 0 N--CA 1.473 0.714 0 O-C-N 122.005 -0.703 . . . . 0.0 110.581 -176.451 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.9 tt -100.5 137.79 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.846 0 N-CA-C 103.449 -2.797 . . . . 0.0 103.449 167.457 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.596 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 69.5 m95 -118.73 136.76 53.78 Favored 'General case' 0 C--N 1.269 -2.913 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -173.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.449 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.3 pt -100.72 128.68 52.58 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.148 0 C-N-CA 119.896 -0.722 . . . . 0.0 109.43 177.592 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.33 118.83 6.25 Favored Glycine 0 N--CA 1.419 -2.458 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -142.83 168.68 19.14 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -114.72 138.08 51.15 Favored 'General case' 0 C--N 1.291 -1.967 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 176.322 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.98 -177.14 6.48 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.164 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -64.36 -21.67 66.7 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.319 0.581 . . . . 0.0 112.416 -177.69 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 48.8 t30 -77.74 -8.31 57.78 Favored 'General case' 0 CA--C 1.554 1.134 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.243 176.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 82.73 6.74 88.21 Favored Glycine 0 N--CA 1.461 0.354 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -177.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -82.87 133.38 35.13 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 124.067 0.947 . . . . 0.0 109.894 -176.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 16.3 tpp85 -75.29 119.37 19.3 Favored 'General case' 0 C--N 1.316 -0.858 0 O-C-N 123.849 0.718 . . . . 0.0 110.663 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.8 t -124.3 146.63 29.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.752 ' HE2' ' HG ' ' A' ' 89' ' ' CYS . 65.0 m-85 -119.39 131.71 55.71 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 123.477 0.711 . . . . 0.0 110.556 178.204 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 46.7 t -109.76 134.43 20.63 Favored Pre-proline 0 C--N 1.303 -1.454 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -68.7 -19.48 41.48 Favored 'Trans proline' 0 C--N 1.363 1.292 0 C-N-CA 123.135 2.556 . . . . 0.0 114.112 -177.722 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.296 30.6 m 44.79 -59.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.487 0 N-CA-C 118.394 2.738 . . . . 0.0 118.394 175.159 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.401 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 6.4 ptp180 -152.68 160.22 43.16 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.38 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.6 p -76.15 140.45 41.76 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.007 176.563 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 96.4 m -152.46 145.41 24.47 Favored 'General case' 0 CA--C 1.499 -1.019 0 CA-C-O 120.934 0.397 . . . . 0.0 111.177 -179.525 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -133.56 160.9 36.08 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.28 -1.748 . . . . 0.0 106.28 178.216 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.85 -173.44 21.83 Favored Glycine 0 C--N 1.3 -1.429 0 C-N-CA 118.596 -1.764 . . . . 0.0 113.939 175.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 21.1 m -138.24 123.88 12.51 Favored Pre-proline 0 C--N 1.311 -1.097 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.231 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.487 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 78.0 Cg_exo -46.53 128.43 12.69 Favored 'Trans proline' 0 CA--C 1.543 0.937 0 C-N-CA 123.521 2.814 . . . . 0.0 113.05 -178.62 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.487 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 91.7 Cg_endo -93.67 3.31 55.67 Favored 'Cis proline' 0 CA--C 1.551 1.373 0 N-CA-C 115.239 1.207 . . . . 0.0 115.239 5.698 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 53.9 t30 -78.71 102.27 7.98 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 122.199 1.0 . . . . 0.0 110.691 -176.359 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.429 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 35.6 p-80 -105.19 121.77 44.51 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-N 114.012 -1.449 . . . . 0.0 110.958 -177.454 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.4 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 58.3 mt -102.08 100.67 15.73 Favored Pre-proline 0 C--N 1.305 -1.36 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.094 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 121' ' ' HIS . 63.7 Cg_endo -85.7 135.14 4.86 Favored 'Trans proline' 0 CA--C 1.544 0.981 0 C-N-CA 122.872 2.381 . . . . 0.0 114.209 -177.821 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -112.11 -151.97 11.7 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 175.294 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 90.4 t -52.63 124.49 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.336 0 C-N-CA 123.938 0.895 . . . . 0.0 112.535 -178.768 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.401 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -93.77 143.7 26.09 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.871 175.29 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' TRP . . . . . 0.502 ' HB3' ' NE2' ' A' ' 58' ' ' GLN . 5.3 m-90 -105.47 17.24 24.21 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.327 0.584 . . . . 0.0 110.986 178.347 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -165.57 -170.43 30.5 Favored Glycine 0 N--CA 1.429 -1.804 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.171 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 98.8 t -111.23 133.04 58.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -178.171 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -104.43 127.6 52.14 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.4 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 14.7 tppt? . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 42.8 m . . . . . 0 CA--C 1.539 0.546 0 N-CA-C 108.798 -0.815 . . . . 0.0 108.798 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -80.51 -80.17 0.14 Allowed 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 112.957 0.725 . . . . 0.0 112.957 -176.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -124.25 19.11 9.04 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 120.856 0.36 . . . . 0.0 110.938 -174.401 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 60.6 tttm 64.34 12.64 7.4 Favored 'General case' 0 CA--C 1.557 1.233 0 C-N-CA 123.978 0.911 . . . . 0.0 111.92 177.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -91.41 85.22 5.72 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.639 0.733 . . . . 0.0 109.491 179.537 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -133.86 24.45 3.96 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 107.278 -1.378 . . . . 0.0 107.278 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 48.3 ttm -139.8 141.71 36.74 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 113.902 -1.499 . . . . 0.0 107.386 -179.507 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -96.5 157.39 15.92 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 178.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.5 pttm -126.24 72.05 1.29 Allowed 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.24 1.019 . . . . 0.0 111.254 176.229 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 80.66 -80.99 1.62 Allowed Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.473 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 6.3 t -124.94 104.2 8.45 Favored 'General case' 0 N--CA 1.418 -2.066 0 CA-C-O 122.348 1.07 . . . . 0.0 109.537 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.5 m -126.17 93.36 3.79 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 106.519 -1.66 . . . . 0.0 106.519 176.46 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.0 m -47.32 -36.16 9.0 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 115.21 1.559 . . . . 0.0 115.21 -171.185 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.1 m -78.35 -46.95 18.74 Favored 'General case' 0 C--N 1.31 -1.125 0 C-N-CA 120.051 -0.66 . . . . 0.0 110.696 178.61 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 21.9 m -67.34 -32.81 74.01 Favored 'General case' 0 CA--C 1.547 0.855 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -177.505 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 17.6 m -82.64 -5.48 9.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 O-C-N 122.291 -0.255 . . . . 0.0 110.945 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.0 t 60.63 74.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.243 0.749 0 C-N-CA 124.604 1.161 . . . . 0.0 110.001 -177.527 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 75.46 116.08 0.06 Allowed 'General case' 0 C--O 1.236 0.367 0 CA-C-N 114.191 -1.368 . . . . 0.0 112.059 -178.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -109.76 148.94 30.54 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.168 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -110.24 0.15 29.73 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 119.901 -1.142 . . . . 0.0 112.909 -177.716 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 34.8 mtmm -90.23 -51.04 5.65 Favored 'General case' 0 C--N 1.312 -1.027 0 O-C-N 122.296 -0.532 . . . . 0.0 111.395 -177.303 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 13.3 t -118.75 114.04 22.07 Favored 'General case' 0 N--CA 1.428 -1.547 0 CA-C-O 122.234 1.016 . . . . 0.0 110.677 179.4 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.8 p -129.58 165.39 21.82 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 114.726 -1.124 . . . . 0.0 110.169 -175.683 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.3 m -68.79 123.28 20.51 Favored 'General case' 0 C--O 1.252 1.199 0 C-N-CA 122.221 0.208 . . . . 0.0 110.648 -178.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 57.81 26.58 13.36 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 124.808 1.243 . . . . 0.0 111.871 177.615 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 28.0 m 65.79 -78.26 0.04 OUTLIER 'General case' 0 C--O 1.245 0.864 0 C-N-CA 124.344 1.058 . . . . 0.0 110.69 -175.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.9 t -155.28 87.3 3.24 Favored Pre-proline 0 N--CA 1.434 -1.273 0 N-CA-C 114.498 1.296 . . . . 0.0 114.498 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -97.88 4.2 1.39 Allowed 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 122.926 2.417 . . . . 0.0 108.477 164.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 52.93 -97.34 0.06 Allowed 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 126.066 1.746 . . . . 0.0 111.317 -174.305 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.6 m -143.71 25.01 1.67 Allowed 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 177.355 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 38.6 ttt180 -60.76 -55.31 46.05 Favored Pre-proline 0 C--N 1.346 0.445 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.618 178.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -78.81 92.25 1.15 Allowed 'Trans proline' 0 N--CA 1.441 -1.559 0 CA-C-N 120.192 1.104 . . . . 0.0 109.402 169.489 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 13.7 p -66.63 -41.9 88.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.961 0.41 . . . . 0.0 111.205 -176.307 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.7 t -108.17 -26.3 10.66 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 121.369 0.604 . . . . 0.0 110.36 178.696 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.78 128.47 6.03 Favored Glycine 0 N--CA 1.433 -1.551 0 C-N-CA 120.99 -0.624 . . . . 0.0 111.593 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 10.5 t 75.29 -40.58 0.43 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.43 1.492 . . . . 0.0 111.952 177.175 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' TRP . . . . . 0.525 ' CE2' ' HD2' ' A' ' 47' ' ' LYS . 86.2 m95 -70.28 138.4 51.54 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 177.824 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 53.5 mtmt -135.49 148.92 49.38 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 175.596 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -88.08 125.86 34.8 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.57 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 55.1 t30 -93.78 169.36 10.36 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 123.687 0.795 . . . . 0.0 110.545 -176.618 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -47.66 -34.81 8.54 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.926 2.091 . . . . 0.0 113.005 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -88.21 7.55 31.39 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.113 0.482 . . . . 0.0 111.703 -175.274 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.87 -13.02 60.15 Favored Glycine 0 CA--C 1.507 -0.462 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.453 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 5.3 m -71.84 137.09 47.27 Favored 'General case' 0 N--CA 1.42 -1.965 0 C-N-CA 124.55 1.14 . . . . 0.0 110.413 -177.79 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.4 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 66.5 m95 -90.03 133.75 34.65 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 173.549 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.57 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 8.6 p90 -132.3 149.12 52.43 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.865 -177.589 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.525 ' HD2' ' CE2' ' A' ' 37' ' ' TRP . 21.9 ptmt -137.19 146.85 56.05 Favored Pre-proline 0 C--N 1.305 -1.328 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 175.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -77.02 121.85 5.99 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.057 1.838 . . . . 0.0 109.862 173.542 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -157.98 120.86 3.86 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -178.667 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.488 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 4.9 t30 -103.35 117.03 33.56 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 -177.009 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.422 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.93 -177.9 6.57 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.525 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 32.3 m -118.05 152.68 35.07 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 120.627 0.251 . . . . 0.0 110.577 -177.044 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.498 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 92.5 t80 -134.61 132.65 39.27 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 177.606 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.1 t -115.56 127.77 73.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.457 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -65.16 135.72 55.82 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.085 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -73.82 -90.91 0.15 Allowed Glycine 0 N--CA 1.44 -1.067 0 O-C-N 123.654 0.596 . . . . 0.0 113.804 -175.545 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -109.72 -47.03 3.41 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 114.097 1.147 . . . . 0.0 114.097 -174.528 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -116.95 152.25 48.44 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -174.107 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -57.13 137.46 81.93 Favored 'Trans proline' 0 C--O 1.242 0.699 0 C-N-CA 122.856 2.37 . . . . 0.0 112.106 178.434 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -108.98 125.85 66.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 -176.266 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 33.6 m -72.93 148.43 9.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 175.601 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 35.9 p -127.15 163.01 24.78 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 110.337 -0.245 . . . . 0.0 110.337 -175.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -110.18 141.85 42.53 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -178.523 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.7 mt -94.1 119.01 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.493 -175.561 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 72.18 -22.95 0.75 Allowed Glycine 0 CA--C 1.529 0.922 0 N-CA-C 117.273 1.669 . . . . 0.0 117.273 170.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.3 m -141.32 136.35 15.71 Favored Pre-proline 0 C--N 1.297 -1.69 0 CA-C-N 118.958 1.379 . . . . 0.0 110.862 -178.417 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -89.64 119.53 0.88 Allowed 'Trans proline' 0 N--CA 1.433 -2.055 0 C-N-CA 121.325 1.35 . . . . 0.0 110.47 172.531 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.458 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 72.0 m-85 -169.37 169.46 9.02 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 127.954 2.502 . . . . 0.0 104.61 -179.295 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -90.13 -17.87 26.86 Favored 'General case' 0 C--N 1.293 -1.879 0 CA-C-O 121.222 0.534 . . . . 0.0 110.75 175.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 27.8 p-10 -106.7 20.32 19.19 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.801 0.81 . . . . 0.0 109.665 177.303 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.458 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.59 156.4 90.18 Favored Pre-proline 0 C--O 1.25 1.101 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.734 179.022 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -54.58 122.97 12.52 Favored 'Trans proline' 0 C--N 1.357 1.024 0 C-N-CA 122.922 2.414 . . . . 0.0 112.372 -179.452 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.414 HG22 ' H ' ' A' ' 74' ' ' GLY . 8.5 p -103.45 174.24 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-N 114.916 -1.038 . . . . 0.0 108.235 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.414 ' H ' HG22 ' A' ' 73' ' ' VAL . . . 119.9 -6.43 12.26 Favored Glycine 0 CA--C 1.494 -1.258 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -178.383 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.23 131.55 10.62 Favored Glycine 0 N--CA 1.429 -1.773 0 N-CA-C 108.399 -1.88 . . . . 0.0 108.399 173.356 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.4 t-20 -126.98 141.38 51.81 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 118.113 0.956 . . . . 0.0 111.564 -177.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 51.5 tp -104.18 114.72 64.09 Favored Pre-proline 0 C--N 1.309 -1.171 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 176.09 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -62.7 160.42 32.76 Favored 'Trans proline' 0 C--O 1.243 0.75 0 C-N-CA 123.072 2.515 . . . . 0.0 112.81 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.67 137.49 46.06 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.327 -178.683 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.32 19.6 78.1 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.804 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -85.72 140.12 30.78 Favored 'General case' 0 C--N 1.317 -0.814 0 O-C-N 122.554 -0.38 . . . . 0.0 110.346 178.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 40.5 m -111.68 108.73 18.28 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.8 mm -116.52 136.51 53.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 122.889 0.475 . . . . 0.0 110.565 -175.743 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.4 p -102.92 128.24 55.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 174.46 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.488 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 42.5 p90 -117.63 157.74 25.88 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.559 -175.74 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -121.26 -5.99 9.39 Favored 'General case' 0 C--O 1.247 0.972 0 O-C-N 123.653 0.595 . . . . 0.0 111.261 -178.656 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -133.71 126.88 31.67 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -173.624 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.0 t -114.1 127.37 71.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 177.74 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.453 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 63.0 m -129.68 150.51 50.97 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 122.983 0.177 . . . . 0.0 111.469 -176.039 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 45.0 mt -121.28 117.29 52.3 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 172.526 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.409 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -111.39 144.46 40.56 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 104.261 -2.496 . . . . 0.0 104.261 173.185 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.8 104.07 0.07 Allowed 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -170.79 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 115.77 -23.94 10.58 Favored Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.471 -0.786 . . . . 0.0 113.677 178.304 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' HIS . . . . . 0.442 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 50.8 m80 -147.77 145.55 28.84 Favored 'General case' 0 CA--C 1.505 -0.786 0 O-C-N 121.559 -0.965 . . . . 0.0 112.204 -177.675 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.423 HG23 HG23 ' A' ' 111' ' ' VAL . 14.5 tt -93.9 139.01 19.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 105.552 -2.018 . . . . 0.0 105.552 173.692 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.409 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 74.5 m95 -124.02 139.01 54.36 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -174.563 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.448 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.3 pt -102.46 132.22 48.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 173.691 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.48 124.68 8.1 Favored Glycine 0 N--CA 1.425 -2.053 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -179.691 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -138.55 155.56 48.27 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 178.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -97.99 120.33 38.19 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 176.194 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.31 161.55 20.4 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -58.41 -14.09 6.9 Favored 'General case' 0 N--CA 1.483 1.212 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.245 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -77.62 -13.56 59.87 Favored 'General case' 0 CA--C 1.548 0.895 0 CA-C-O 121.5 0.667 . . . . 0.0 110.713 177.535 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 87.64 15.9 60.93 Favored Glycine 0 CA--C 1.497 -1.079 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -176.219 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 39.4 t-20 -97.1 132.82 42.51 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 114.239 -0.98 . . . . 0.0 109.226 -177.573 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 25.9 tpt180 -90.17 99.06 12.15 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 175.801 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 36.8 t -100.32 142.42 15.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.989 -173.485 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 81.5 m-85 -115.23 129.38 56.62 Favored 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 123.081 0.552 . . . . 0.0 110.223 178.23 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.1 t -108.32 133.45 20.56 Favored Pre-proline 0 C--N 1.306 -1.303 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.288 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.56 -10.06 24.8 Favored 'Trans proline' 0 C--N 1.364 1.344 0 C-N-CA 123.397 2.731 . . . . 0.0 114.729 -174.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.423 HG23 HG23 ' A' ' 95' ' ' ILE 0.293 27.2 m 38.19 -67.26 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 N-CA-C 118.026 2.602 . . . . 0.0 118.026 175.0 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.486 ' HE ' ' HB2' ' A' ' 126' ' ' ALA . 6.3 ptp85 -147.44 148.81 31.67 Favored 'General case' 0 N--CA 1.445 -0.7 0 C-N-CA 123.239 0.616 . . . . 0.0 109.603 176.078 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.442 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 66.8 m -67.95 133.98 50.0 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 176.386 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 86.3 m -151.34 103.82 3.03 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 122.886 0.474 . . . . 0.0 110.363 -179.173 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 45.8 mt-30 -88.85 141.14 28.75 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.193 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 139.7 178.04 16.31 Favored Glycine 0 N--CA 1.42 -2.386 0 C-N-CA 119.015 -1.564 . . . . 0.0 113.273 178.449 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 87.0 t -133.31 130.61 21.22 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 179.182 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.411 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 66.3 Cg_exo -43.46 132.51 7.1 Favored 'Trans proline' 0 CA--C 1.548 1.195 0 C-N-CA 123.44 2.76 . . . . 0.0 113.456 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.411 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 43.1 Cg_endo -89.31 -5.98 51.67 Favored 'Cis proline' 0 CA--C 1.541 0.826 0 C-N-CA 123.373 -1.511 . . . . 0.0 114.832 4.234 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -76.51 100.65 5.34 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-O 122.161 0.981 . . . . 0.0 112.409 -173.588 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 28.7 p-80 -105.43 126.57 52.27 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 113.845 -1.525 . . . . 0.0 111.007 178.509 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.564 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 60.7 mt -100.6 104.39 30.52 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 174.29 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -76.97 123.65 6.9 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.564 2.176 . . . . 0.0 113.171 -175.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -108.51 -141.86 9.76 Favored Glycine 0 N--CA 1.424 -2.12 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.586 177.242 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 67.0 t -75.21 122.28 28.57 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 C-N-CA 122.948 0.499 . . . . 0.0 111.996 -176.623 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.486 ' HB2' ' HE ' ' A' ' 112' ' ' ARG . . . -93.23 143.36 26.33 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.719 173.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.8 m-90 -106.03 14.61 27.61 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.951 0.881 . . . . 0.0 109.686 177.42 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.498 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -162.13 177.61 38.26 Favored Glycine 0 N--CA 1.407 -3.251 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.491 -179.426 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 57.5 t -111.52 118.82 58.45 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.192 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 -177.385 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 41.8 m-85 -78.74 132.77 37.08 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.271 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.525 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 53.9 tptt . . . . . 0 N--CA 1.404 -2.767 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 19.4 m . . . . . 0 N--CA 1.446 -0.669 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 54.3 t30 -87.31 -75.01 0.42 Allowed 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.336 -176.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -98.34 -28.56 13.6 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-O 121.436 0.636 . . . . 0.0 110.865 -175.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -92.52 79.48 4.9 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 121.673 0.749 . . . . 0.0 109.503 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 42.0 t30 -166.63 138.48 3.55 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 106.584 -1.635 . . . . 0.0 106.584 178.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -130.05 137.03 50.02 Favored 'General case' 0 C--N 1.295 -1.784 0 C-N-CA 120.592 -0.443 . . . . 0.0 111.358 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 84.9 mtp -81.23 -38.27 27.22 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 174.228 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 37.0 t70 51.05 81.5 0.07 Allowed 'General case' 0 CA--C 1.516 -0.36 0 C-N-CA 125.46 1.504 . . . . 0.0 113.553 177.455 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 27.6 mmtp -145.2 86.94 1.79 Allowed 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.814 174.682 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.47 -35.09 18.04 Favored Glycine 0 N--CA 1.434 -1.455 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 175.415 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.4 m -91.35 102.65 15.34 Favored 'General case' 0 N--CA 1.427 -1.613 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.377 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.8 p -72.55 -42.44 64.67 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 122.149 0.976 . . . . 0.0 109.702 178.303 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 4.5 p -146.8 136.39 22.98 Favored 'General case' 0 N--CA 1.422 -1.828 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.227 178.47 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.8 p -103.59 104.61 14.69 Favored 'General case' 0 C--N 1.309 -1.152 0 N-CA-C 114.573 1.323 . . . . 0.0 114.573 -173.046 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 12.9 m 60.17 31.03 20.37 Favored 'General case' 0 CA--C 1.564 1.507 0 C-N-CA 124.383 1.073 . . . . 0.0 112.443 172.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.1 p -86.88 86.13 2.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 O-C-N 120.916 -1.115 . . . . 0.0 110.401 179.358 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.9 m -96.27 -12.81 8.34 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.473 178.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.507 ' HA ' ' HE2' ' A' ' 18' ' ' LYS . 0.2 OUTLIER -149.21 139.02 21.9 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 -179.255 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -92.22 24.35 3.39 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 122.792 0.437 . . . . 0.0 109.867 178.643 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.419 ' HA2' ' HB3' ' A' ' 25' ' ' ALA . . . -80.95 49.13 3.9 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -179.585 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 56.2 mtpt -140.31 -170.09 2.9 Favored 'General case' 0 C--N 1.288 -2.067 0 N-CA-C 105.804 -1.925 . . . . 0.0 105.804 -175.813 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.3 m -75.41 88.36 2.61 Favored 'General case' 0 N--CA 1.428 -1.554 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 174.787 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 55.0 m -157.99 -50.27 0.07 Allowed 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.178 -177.487 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.8 t -158.87 -41.29 0.06 Allowed 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 120.032 -0.667 . . . . 0.0 111.908 -178.372 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.419 ' HB3' ' HA2' ' A' ' 20' ' ' GLY . . . -62.1 -36.72 82.57 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 113.699 1.0 . . . . 0.0 113.699 -175.662 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 19.8 m -81.07 108.64 14.91 Favored 'General case' 0 C--O 1.248 1.015 0 CA-C-O 121.238 0.542 . . . . 0.0 111.121 -178.822 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.4 p -82.99 150.67 62.11 Favored Pre-proline 0 N--CA 1.436 -1.149 0 CA-C-N 115.298 -0.865 . . . . 0.0 111.618 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -75.57 85.64 1.57 Allowed 'Trans proline' 0 N--CA 1.451 -1.024 0 C-N-CA 122.791 2.327 . . . . 0.0 113.626 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -89.67 -14.26 35.2 Favored 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 170.812 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.421 ' O ' ' HD2' ' A' ' 32' ' ' PRO . 10.1 t -174.39 -172.69 0.7 Allowed 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 103.65 -2.722 . . . . 0.0 103.65 179.412 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.419 ' HB2' ' HD3' ' A' ' 32' ' ' PRO 0.349 10.5 mmt180 86.5 -91.02 0.0 OUTLIER Pre-proline 0 CA--C 1.565 1.521 0 C-N-CA 125.294 1.437 . . . . 0.0 113.667 -179.881 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.421 ' HD2' ' O ' ' A' ' 30' ' ' THR . 98.0 Cg_endo -82.84 33.66 0.53 Allowed 'Trans proline' 0 C--N 1.384 2.435 0 CA-C-N 123.104 2.144 . . . . 0.0 112.133 -178.555 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.2 m -80.68 4.18 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.718 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 12.0 p -73.15 -37.99 66.39 Favored 'General case' 0 N--CA 1.423 -1.819 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.443 176.402 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 56.07 -95.72 0.04 OUTLIER Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.319 -0.855 . . . . 0.0 114.261 175.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 21.8 t -77.58 -23.3 49.98 Favored 'General case' 0 C--N 1.311 -1.089 0 C-N-CA 123.603 0.761 . . . . 0.0 109.923 -178.048 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -77.74 117.23 18.93 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.965 0.412 . . . . 0.0 110.419 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 8.3 tmtm? -118.44 133.46 55.85 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -81.67 128.74 34.28 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 120.91 0.386 . . . . 0.0 111.723 -176.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -96.67 166.08 11.83 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 176.136 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -51.65 -27.79 12.56 Favored 'General case' 0 N--CA 1.489 1.485 0 C-N-CA 125.184 1.394 . . . . 0.0 113.082 -176.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 69.0 m-85 -87.5 10.11 18.76 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 121.498 0.666 . . . . 0.0 111.535 -175.445 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.54 14.36 82.1 Favored Glycine 0 CA--C 1.5 -0.89 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 178.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.551 HG22 ' HB2' ' A' ' 89' ' ' CYS . 6.8 m -96.14 127.7 42.38 Favored 'General case' 0 N--CA 1.409 -2.517 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -177.334 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 71.8 m95 -95.31 120.99 36.5 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.092 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -120.14 148.69 43.32 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.106 -177.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.1 pttm -134.95 151.4 75.45 Favored Pre-proline 0 C--N 1.305 -1.342 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -71.88 132.51 20.1 Favored 'Trans proline' 0 N--CA 1.45 -1.043 0 C-N-CA 121.678 1.585 . . . . 0.0 111.471 175.523 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -159.16 120.61 3.34 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 176.098 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.442 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 3.7 t-20 -107.39 115.73 30.68 Favored 'General case' 0 C--N 1.295 -1.783 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.328 -175.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -160.94 178.63 9.2 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.241 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 17.4 m -116.82 151.98 35.38 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -178.539 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.4 t80 -124.95 127.96 47.86 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 175.767 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 46.6 t -112.27 112.69 41.57 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.037 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 55.3 t30 -65.72 136.25 56.01 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.2 -179.026 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -119.07 -83.19 0.84 Allowed Glycine 0 N--CA 1.43 -1.739 0 N-CA-C 115.77 1.068 . . . . 0.0 115.77 -170.572 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -79.07 -23.28 44.31 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 115.365 1.617 . . . . 0.0 115.365 -166.433 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.407 ' HA ' ' HD3' ' A' ' 59' ' ' PRO . 4.7 pp0? -152.79 150.1 23.72 Favored Pre-proline 0 C--N 1.311 -1.102 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.277 -178.833 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 58' ' ' GLN . 16.5 Cg_exo -68.37 131.24 22.82 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.369 2.046 . . . . 0.0 109.739 177.536 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 51.2 mt -106.81 127.52 62.28 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.828 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -171.79 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -81.5 138.03 20.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 178.08 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 50.9 p -110.51 170.11 8.3 Favored 'General case' 0 C--N 1.295 -1.791 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.751 -174.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -117.29 138.12 51.96 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.185 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.7 mt -99.09 125.68 52.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.889 -174.086 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.39 -22.93 3.58 Favored Glycine 0 N--CA 1.448 -0.534 0 N-CA-C 115.772 1.069 . . . . 0.0 115.772 172.504 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.5 m -152.3 138.1 11.5 Favored Pre-proline 0 C--N 1.297 -1.696 0 CA-C-N 118.074 0.937 . . . . 0.0 110.065 -177.694 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -89.84 120.87 0.95 Allowed 'Trans proline' 0 N--CA 1.44 -1.674 0 C-N-CA 121.64 1.56 . . . . 0.0 111.008 173.85 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.524 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 93.5 m-85 -168.58 166.24 12.03 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 127.246 2.218 . . . . 0.0 105.021 179.174 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 96.5 mt -82.01 -19.74 39.83 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-O 121.357 0.598 . . . . 0.0 109.994 175.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -111.02 19.69 18.21 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.294 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.524 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -73.38 156.88 88.69 Favored Pre-proline 0 C--O 1.249 1.05 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.573 -178.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -46.97 127.36 12.32 Favored 'Trans proline' 0 C--N 1.365 1.404 0 C-N-CA 123.754 2.969 . . . . 0.0 113.806 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 10.9 p -99.89 172.71 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-N 114.304 -1.316 . . . . 0.0 107.95 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.91 11.55 7.6 Favored Glycine 0 C--N 1.318 -0.469 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -177.478 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -137.1 121.11 2.25 Favored Glycine 0 N--CA 1.423 -2.228 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 175.768 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -126.17 141.54 51.89 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 117.519 0.66 . . . . 0.0 109.899 -178.266 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 27.4 tp -101.41 113.61 65.8 Favored Pre-proline 0 N--CA 1.429 -1.48 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.21 166.72 22.32 Favored 'Trans proline' 0 C--O 1.249 1.033 0 C-N-CA 122.272 1.981 . . . . 0.0 113.32 -177.597 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.15 128.64 36.32 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.225 179.243 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.99 -5.34 61.47 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.873 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.84 128.55 36.72 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.013 0.435 . . . . 0.0 111.22 -179.199 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 44.3 m -104.08 111.55 24.17 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.593 -179.574 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.6 mm -116.99 130.27 72.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.28 -176.314 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.2 p -99.11 139.34 21.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 174.71 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 46.2 p90 -135.3 158.16 45.08 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.802 -176.887 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -128.34 -0.39 5.69 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.589 177.426 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -129.64 127.8 41.32 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.06 -178.236 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.6 t -123.66 126.94 73.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.551 ' HB2' HG22 ' A' ' 44' ' ' THR . 27.2 p -135.84 148.46 48.68 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -174.24 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 68.8 mt -106.03 121.96 59.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.996 178.123 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.449 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -125.7 144.85 50.43 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 173.797 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -51.05 107.23 0.16 Allowed 'General case' 0 C--N 1.317 -0.805 0 O-C-N 123.51 0.506 . . . . 0.0 111.535 -177.3 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.7 -41.62 1.52 Allowed Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.117 178.694 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' HIS . . . . . 0.502 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 69.9 m80 -154.16 166.02 34.42 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 117.294 0.547 . . . . 0.0 110.915 -175.524 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.8 tt -105.26 110.15 30.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 173.549 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.524 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 45.2 m95 -96.74 142.66 28.5 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.784 -168.825 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.8 pt -100.2 134.22 40.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 174.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -101.96 124.63 8.27 Favored Glycine 0 N--CA 1.424 -2.158 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -149.72 169.92 19.93 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-O 121.018 0.437 . . . . 0.0 109.832 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -104.33 143.13 33.4 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.611 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -94.43 159.32 15.16 Favored 'General case' 0 C--N 1.291 -1.964 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 173.732 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -54.12 -21.92 9.83 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -179.064 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 11.4 t30 -92.59 7.31 43.87 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-O 121.973 0.892 . . . . 0.0 110.738 -177.743 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 83.02 13.41 77.53 Favored Glycine 0 C--N 1.321 -0.251 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.677 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 18.7 m120 -83.72 141.05 31.73 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.818 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 30.2 tpt180 -89.83 106.27 18.36 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 176.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.3 t -112.6 138.26 42.44 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 C-N-CA 119.895 -0.722 . . . . 0.0 110.512 -173.766 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.413 ' HE1' ' HG ' ' A' ' 89' ' ' CYS . 63.8 m-85 -117.17 126.8 53.36 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.452 -0.794 . . . . 0.0 110.002 176.643 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.7 t -109.07 130.63 22.5 Favored Pre-proline 0 C--N 1.304 -1.4 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.844 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -68.89 -22.26 36.49 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 122.819 2.346 . . . . 0.0 114.133 -176.423 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.298 34.4 m 49.3 -54.9 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.579 0 N-CA-C 117.771 2.508 . . . . 0.0 117.771 177.045 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -150.77 143.42 24.46 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 123.464 0.706 . . . . 0.0 109.67 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.502 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 69.1 m -71.61 127.87 33.96 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.732 178.443 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.511 ' SG ' ' HA ' ' A' ' 123' ' ' PRO . 94.5 m -149.49 140.51 22.93 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.06 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -125.12 153.99 42.14 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 105.788 -1.93 . . . . 0.0 105.788 178.855 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.84 -168.6 31.19 Favored Glycine 0 CA--C 1.483 -1.919 0 C-N-CA 118.633 -1.746 . . . . 0.0 112.275 178.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 65.6 t -138.82 121.52 10.63 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 179.134 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 88.5 Cg_exo -48.03 136.23 23.64 Favored 'Trans proline' 0 C--O 1.238 0.517 0 C-N-CA 123.175 2.583 . . . . 0.0 111.952 -179.501 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 90.8 Cg_endo -95.32 25.04 23.18 Favored 'Cis proline' 0 CA--C 1.548 1.193 0 C-N-CA 124.461 -1.058 . . . . 0.0 114.043 3.674 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -106.15 106.02 16.34 Favored 'General case' 0 C--N 1.315 -0.928 0 O-C-N 121.789 -0.57 . . . . 0.0 111.274 -178.383 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 25.2 p-80 -104.17 139.85 38.65 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.175 176.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 44.7 mm -104.02 107.4 56.9 Favored Pre-proline 0 C--N 1.293 -1.852 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.511 ' HA ' ' SG ' ' A' ' 114' ' ' CYS . 86.0 Cg_endo -79.57 147.57 19.94 Favored 'Trans proline' 0 C--O 1.247 0.933 0 C-N-CA 122.623 2.215 . . . . 0.0 113.989 -175.733 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -131.49 -124.73 2.6 Favored Glycine 0 N--CA 1.428 -1.854 0 CA-C-N 115.415 -0.812 . . . . 0.0 111.266 176.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.0 t -85.62 121.37 37.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -175.424 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.38 151.23 19.55 Favored 'General case' 0 C--O 1.246 0.894 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.158 173.258 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' TRP . . . . . 0.421 ' HH2' ' HE2' ' A' ' 94' ' ' HIS . 5.5 m-90 -109.1 6.54 25.02 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 179.536 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -160.82 -171.74 27.18 Favored Glycine 0 N--CA 1.428 -1.899 0 C-N-CA 120.64 -0.79 . . . . 0.0 111.271 -178.153 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 44.0 t -111.7 131.97 61.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -174.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -91.9 137.46 32.34 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 176.747 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt . . . . . 0 C--N 1.288 -2.078 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.684 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 14.6 m . . . . . 0 N--CA 1.438 -1.067 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 60.8 t30 -62.6 -40.97 98.62 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.349 0.595 . . . . 0.0 109.446 178.134 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -128.47 117.95 22.24 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.665 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 34.0 mmtp 66.22 178.24 0.21 Allowed 'General case' 0 C--O 1.242 0.663 0 CA-C-O 122.134 0.969 . . . . 0.0 112.961 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 29.1 p-10 -142.03 16.27 2.1 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 174.415 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 53.3 t80 -141.36 116.67 10.08 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 114.146 -1.388 . . . . 0.0 108.794 -173.201 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 53.0 ttm -103.64 132.99 49.4 Favored 'General case' 0 C--N 1.293 -1.868 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 175.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -67.12 -30.06 69.96 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 120.411 -0.516 . . . . 0.0 110.894 -178.334 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -91.3 96.61 10.64 Favored 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 174.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -127.86 54.81 0.77 Allowed Glycine 0 N--CA 1.43 -1.712 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -178.638 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 89.4 m -146.58 106.66 4.0 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.48 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.1 m -66.48 104.23 1.21 Allowed 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 173.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.1 m -65.25 107.26 1.54 Allowed 'General case' 0 N--CA 1.435 -1.178 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.427 -173.452 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 42.4 m 69.96 -18.9 0.21 Allowed 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 125.303 1.441 . . . . 0.0 114.263 177.256 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.5 m -84.11 97.59 9.42 Favored 'General case' 0 N--CA 1.434 -1.23 0 CA-C-O 120.923 0.392 . . . . 0.0 110.581 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 31.6 m -125.46 -37.39 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.884 178.034 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.0 m -143.18 164.34 16.06 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -178.606 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.6 tttp -110.38 76.76 1.0 Allowed 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 106.062 -1.829 . . . . 0.0 106.062 173.351 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -76.72 -35.51 57.77 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 113.555 -1.657 . . . . 0.0 113.92 -170.583 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -101.63 145.48 16.8 Favored Glycine 0 N--CA 1.436 -1.35 0 C-N-CA 119.867 -1.159 . . . . 0.0 115.838 -171.089 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.4 tttm 59.58 64.76 1.26 Allowed 'General case' 0 C--O 1.245 0.822 0 C-N-CA 126.055 1.742 . . . . 0.0 111.944 174.413 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 23.6 m -116.18 -2.83 12.09 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-N 114.376 -1.284 . . . . 0.0 108.468 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 88.7 p 62.29 -87.61 0.02 OUTLIER 'General case' 0 C--O 1.236 0.369 0 C-N-CA 126.609 1.964 . . . . 0.0 110.166 -173.048 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 49.2 m -161.7 -70.04 0.06 Allowed 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 123.731 0.812 . . . . 0.0 109.244 175.471 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 174.92 -164.38 0.03 OUTLIER 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 -177.353 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.3 p -70.6 -12.52 61.62 Favored 'General case' 0 CA--C 1.548 0.896 0 CA-C-O 121.521 0.677 . . . . 0.0 111.194 175.774 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 21.5 m -108.33 99.47 32.52 Favored Pre-proline 0 N--CA 1.436 -1.139 0 N-CA-C 106.189 -1.782 . . . . 0.0 106.189 171.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -90.66 -26.03 0.36 Allowed 'Trans proline' 0 N--CA 1.452 -0.92 0 N-CA-C 117.228 1.972 . . . . 0.0 117.228 -172.471 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 64.6 36.11 8.69 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -173.305 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 m 60.72 83.9 0.14 Allowed 'General case' 0 CA--C 1.549 0.917 0 CA-C-N 114.151 -1.386 . . . . 0.0 111.818 -178.028 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -132.12 -64.89 0.02 OUTLIER Pre-proline 0 CA--C 1.544 0.713 0 N-CA-C 112.818 0.673 . . . . 0.0 112.818 -178.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.26 -20.3 32.65 Favored 'Trans proline' 0 C--N 1.373 1.833 0 CA-C-N 120.692 1.283 . . . . 0.0 111.431 177.305 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.4 t 73.42 68.68 0.06 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-O 123.143 1.449 . . . . 0.0 109.925 -178.43 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.0 p -102.41 80.07 1.9 Allowed 'General case' 0 N--CA 1.408 -2.548 0 CA-C-N 113.382 -1.736 . . . . 0.0 109.742 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -87.8 -53.53 2.7 Favored Glycine 0 N--CA 1.43 -1.751 0 CA-C-N 115.298 -0.865 . . . . 0.0 111.127 -178.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.7 m -89.55 -28.56 19.51 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 178.624 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -78.35 127.38 32.13 Favored 'General case' 0 N--CA 1.442 -0.841 0 CA-C-O 121.551 0.691 . . . . 0.0 111.791 -177.072 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.6 tmtt? -130.3 140.98 50.63 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.334 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -85.84 146.16 26.88 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.396 0.617 . . . . 0.0 112.371 -173.049 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 48.2 t-20 -109.75 153.83 23.78 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 124.988 1.315 . . . . 0.0 107.622 178.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 48.2 tt0 -53.88 -26.5 25.18 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 125.443 1.497 . . . . 0.0 112.48 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -75.3 -7.91 55.23 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.359 0.6 . . . . 0.0 111.63 -179.609 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.02 -13.32 63.59 Favored Glycine 0 N--CA 1.437 -1.275 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 -178.38 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 7.3 m -68.63 147.98 51.12 Favored 'General case' 0 N--CA 1.421 -1.879 0 C-N-CA 124.954 1.301 . . . . 0.0 109.073 179.285 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.458 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 64.7 m95 -111.31 142.28 43.74 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 173.611 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -139.1 156.99 46.75 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-O 121.087 0.47 . . . . 0.0 111.531 -179.084 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -138.48 132.51 16.57 Favored Pre-proline 0 C--N 1.295 -1.779 0 CA-C-N 114.905 -1.043 . . . . 0.0 108.223 174.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.52 121.16 7.9 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 N-CA-C 108.752 -1.288 . . . . 0.0 108.752 173.633 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -168.03 124.9 1.09 Allowed 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -176.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -93.47 138.91 31.31 Favored 'General case' 0 CA--C 1.483 -1.61 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.341 -176.342 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.475 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -164.01 160.71 22.1 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 175.074 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.491 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 16.1 m -105.6 132.58 51.57 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.378 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -108.15 121.06 44.07 Favored 'General case' 0 N--CA 1.422 -1.825 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 175.883 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 42.5 t -107.19 119.25 56.49 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.078 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 176.805 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.428 ' ND2' HG12 ' A' ' 60' ' ' ILE . 46.4 t-20 -68.99 123.21 20.41 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.248 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -143.44 39.85 1.27 Allowed Glycine 0 N--CA 1.417 -2.624 0 C-N-CA 120.098 -1.048 . . . . 0.0 111.937 -176.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 20.7 t-20 -145.55 -66.73 0.31 Allowed 'General case' 0 C--N 1.31 -1.119 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.074 177.79 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -157.43 161.34 29.41 Favored Pre-proline 0 C--N 1.317 -0.806 0 CA-C-O 118.872 -0.585 . . . . 0.0 109.76 -178.708 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.24 137.88 81.38 Favored 'Trans proline' 0 C--N 1.357 0.994 0 C-N-CA 122.96 2.44 . . . . 0.0 112.279 -179.443 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.59 HG21 ' SG ' ' A' ' 109' ' ' CYS . 32.7 mm -106.95 140.55 24.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.996 -174.799 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.27 107.85 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.256 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 172.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 57.7 p -93.72 153.67 18.2 Favored 'General case' 0 C--N 1.294 -1.836 0 CA-C-N 115.067 -0.969 . . . . 0.0 110.37 -176.088 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -106.44 140.39 39.43 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -177.411 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.3 mp -105.53 125.14 60.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-O 121.282 0.563 . . . . 0.0 111.672 -175.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.32 -22.78 11.4 Favored Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 115.533 0.973 . . . . 0.0 115.533 172.431 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 41.9 m -152.91 136.67 10.19 Favored Pre-proline 0 C--N 1.305 -1.337 0 CA-C-N 118.12 0.96 . . . . 0.0 110.385 -178.076 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -90.04 119.61 0.81 Allowed 'Trans proline' 0 N--CA 1.439 -1.718 0 C-N-CA 121.434 1.422 . . . . 0.0 110.986 173.544 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.44 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 76.3 m-85 -169.41 175.09 5.66 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 105.151 -2.166 . . . . 0.0 105.151 -179.46 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -88.62 -29.74 19.74 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 172.686 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -92.32 20.39 6.15 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.784 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.44 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -80.56 159.38 69.63 Favored Pre-proline 0 C--N 1.309 -1.161 0 CA-C-O 119.644 -0.217 . . . . 0.0 110.733 -176.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -57.12 144.06 91.29 Favored 'Trans proline' 0 C--N 1.358 1.063 0 C-N-CA 123.405 2.737 . . . . 0.0 113.989 -177.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.7 m -101.81 174.53 1.04 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.062 0 C-N-CA 124.437 1.095 . . . . 0.0 110.458 -179.696 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.8 26.91 2.43 Favored Glycine 0 C--N 1.306 -1.118 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -179.255 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.88 109.63 0.59 Allowed Glycine 0 N--CA 1.423 -2.185 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -108.04 126.04 52.26 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-O 120.856 0.36 . . . . 0.0 110.102 178.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.49 ' HB3' ' HB ' ' A' ' 60' ' ' ILE . 33.1 tp -107.56 109.22 62.42 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 107.043 -1.466 . . . . 0.0 107.043 175.323 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -71.08 159.94 50.74 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.191 1.928 . . . . 0.0 112.195 -177.656 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.78 133.52 46.62 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 177.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.5 -10.52 56.31 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 121.046 -0.597 . . . . 0.0 111.971 -178.59 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.09 138.24 51.83 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.904 0.383 . . . . 0.0 110.682 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.7 m -117.89 110.17 17.42 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.259 -179.191 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.1 mm -120.89 120.3 61.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 CA-C-O 120.732 0.301 . . . . 0.0 110.62 -176.531 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 6.6 p -91.67 111.37 23.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-O 121.649 0.738 . . . . 0.0 109.404 175.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.475 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 46.6 p90 -97.12 168.6 10.35 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.963 -174.797 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -117.68 -17.59 9.87 Favored 'General case' 0 C--N 1.316 -0.857 0 O-C-N 123.858 0.724 . . . . 0.0 112.255 -176.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -135.66 133.92 38.66 Favored 'General case' 0 N--CA 1.432 -1.339 0 C-N-CA 119.891 -0.723 . . . . 0.0 110.905 -173.311 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.7 t -105.55 127.1 60.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 35.1 m -127.35 148.44 50.26 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 117.742 0.246 . . . . 0.0 110.927 -176.648 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 39.9 mt -119.14 120.18 63.09 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 CA-C-O 121.039 0.447 . . . . 0.0 109.964 172.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.501 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.2 tp-100 -122.51 118.58 28.62 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 103.514 -2.773 . . . . 0.0 103.514 172.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.45 107.3 0.12 Allowed 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 113.728 1.01 . . . . 0.0 113.728 -165.487 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 137.41 -31.4 2.52 Favored Glycine 0 N--CA 1.435 -1.391 0 CA-C-N 114.417 -1.265 . . . . 0.0 110.533 -179.252 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' HIS . . . . . 0.421 ' HA ' ' H ' ' A' ' 114' ' ' CYS . 73.0 m80 -151.13 163.97 37.57 Favored 'General case' 0 CA--C 1.483 -1.633 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.555 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.2 tt -103.9 133.92 46.57 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.742 0 N-CA-C 104.504 -2.406 . . . . 0.0 104.504 170.009 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.501 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 68.3 m95 -115.59 140.07 49.52 Favored 'General case' 0 C--N 1.27 -2.86 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -172.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.423 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.6 pt -100.98 130.02 51.0 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.315 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -101.27 120.4 6.86 Favored Glycine 0 N--CA 1.419 -2.464 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.163 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 44.4 p90 -142.83 144.47 32.54 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.071 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -101.93 126.13 48.77 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 175.451 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -93.45 167.84 11.45 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.238 -176.618 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 31.6 p90 -63.19 -2.21 1.29 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 113.859 1.059 . . . . 0.0 113.859 -178.361 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -88.09 -6.7 57.77 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 175.686 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 90.72 -0.47 76.94 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 111.808 -0.517 . . . . 0.0 111.808 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 21.2 p30 -96.36 147.67 23.57 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -177.046 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 9.7 tpp85 -92.13 111.56 23.16 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 175.128 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.5 t -111.99 143.58 21.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 -176.782 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.423 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 95.4 m-85 -119.33 129.28 54.78 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.027 0.441 . . . . 0.0 110.915 178.789 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' CYS . . . . . 0.59 ' SG ' HG21 ' A' ' 60' ' ' ILE . 43.1 t -110.56 127.97 26.1 Favored Pre-proline 0 C--N 1.302 -1.497 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.259 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -71.57 -5.63 17.46 Favored 'Trans proline' 0 C--N 1.359 1.123 0 C-N-CA 123.462 2.775 . . . . 0.0 115.243 -175.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.304 30.1 m 37.33 -59.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.515 2.775 0 N-CA-C 118.881 2.919 . . . . 0.0 118.881 175.26 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.464 ' CZ ' ' HB2' ' A' ' 126' ' ' ALA . 7.8 ptp180 -150.72 156.36 41.15 Favored 'General case' 0 C--O 1.248 0.994 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.485 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.2 m -67.27 132.63 48.11 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 176.442 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.421 ' H ' ' HA ' ' A' ' 94' ' ' HIS . 53.5 m -152.09 110.52 3.75 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.803 0.811 . . . . 0.0 111.449 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -102.93 143.72 32.14 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 106.119 -1.808 . . . . 0.0 106.119 178.144 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 147.71 -170.85 28.37 Favored Glycine 0 CA--C 1.489 -1.566 0 C-N-CA 118.207 -1.949 . . . . 0.0 113.488 178.879 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 84.7 t -134.67 123.27 16.11 Favored Pre-proline 0 C--N 1.304 -1.386 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 179.221 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 96.0 Cg_exo -45.86 135.53 13.76 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.76 2.974 . . . . 0.0 113.304 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 28.3 Cg_endo -95.1 17.82 37.08 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 C-N-CA 124.283 -1.132 . . . . 0.0 113.493 1.402 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -94.8 101.91 13.75 Favored 'General case' 0 C--N 1.312 -1.028 0 C-N-CA 120.491 -0.484 . . . . 0.0 110.405 -177.625 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 10.9 p-80 -104.63 138.99 40.14 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.902 177.843 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 50.6 mm -102.31 99.54 13.09 Favored Pre-proline 0 C--N 1.301 -1.502 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 172.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -84.52 147.61 11.14 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 122.82 2.347 . . . . 0.0 113.989 -174.634 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.07 -145.02 6.61 Favored Glycine 0 N--CA 1.419 -2.497 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.28 175.414 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.5 t -60.67 122.72 11.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 C-N-CA 123.727 0.811 . . . . 0.0 111.868 -177.26 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.464 ' HB2' ' CZ ' ' A' ' 112' ' ' ARG . . . -94.22 145.06 24.99 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.501 174.608 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.8 m-90 -105.59 18.69 21.79 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.341 0.591 . . . . 0.0 110.907 177.743 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -166.99 -165.89 25.16 Favored Glycine 0 N--CA 1.427 -1.933 0 C-N-CA 119.788 -1.196 . . . . 0.0 112.791 -179.727 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 48.7 t -124.03 139.12 51.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -178.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -105.09 134.41 48.24 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 177.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.298 -1.667 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 42.6 t . . . . . 0 CA--C 1.514 -0.412 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.458 ' O ' ' HD2' ' A' ' 6' ' ' TYR . 3.4 m-20 -75.55 -44.01 45.62 Favored 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -179.172 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 56.0 -74.01 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 125.47 1.508 . . . . 0.0 114.25 175.554 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -142.49 -73.3 0.3 Allowed 'General case' 0 N--CA 1.431 -1.414 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -129.2 94.83 3.89 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.38 0.609 . . . . 0.0 111.876 -177.468 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' TYR . . . . . 0.458 ' HD2' ' O ' ' A' ' 2' ' ' ASN . 97.2 m-85 -137.69 74.99 1.5 Allowed 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 104.21 -2.515 . . . . 0.0 104.21 168.165 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 66.6 mtt -108.26 15.2 24.3 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 114.444 -1.253 . . . . 0.0 113.257 -167.9 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -68.36 99.24 0.91 Allowed 'General case' 0 C--O 1.247 0.923 0 CA-C-O 121.372 0.606 . . . . 0.0 111.187 177.1 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.8 tptt -79.66 127.48 32.22 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 178.213 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.43 -21.51 12.84 Favored Glycine 0 N--CA 1.435 -1.375 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -177.256 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 23.6 p 55.03 74.08 0.38 Allowed 'General case' 0 C--O 1.24 0.558 0 C-N-CA 125.092 1.357 . . . . 0.0 113.611 -178.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.2 m -77.54 125.84 29.97 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.503 -1.226 . . . . 0.0 108.287 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 41.4 m -148.62 143.8 26.79 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 73.5 m 66.56 -172.22 0.19 Allowed 'General case' 0 C--O 1.242 0.687 0 C-N-CA 124.521 1.128 . . . . 0.0 112.695 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.0 m -78.66 87.72 4.58 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-O 121.421 0.629 . . . . 0.0 111.026 -177.317 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 31.4 m -118.76 145.23 25.09 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 174.422 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.4 p -87.0 -34.08 7.34 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.167 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.842 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt 60.05 69.48 0.7 Allowed 'General case' 0 C--O 1.242 0.669 0 N-CA-C 106.016 -1.846 . . . . 0.0 106.016 -172.254 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -69.28 107.42 3.26 Favored 'General case' 0 CA--C 1.505 -0.756 0 CA-C-N 114.109 -1.405 . . . . 0.0 110.808 -171.578 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.93 -128.48 7.55 Favored Glycine 0 N--CA 1.422 -2.273 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -177.755 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -138.53 -62.22 0.57 Allowed 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.219 0.533 . . . . 0.0 110.346 178.037 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.412 ' HB ' ' HB2' ' A' ' 25' ' ' ALA . 44.7 m -84.73 130.01 34.75 Favored 'General case' 0 N--CA 1.425 -1.683 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.628 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.3 m -65.74 127.75 33.21 Favored 'General case' 0 C--O 1.248 1.004 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.085 -177.517 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.1 m 61.12 33.93 19.23 Favored 'General case' 0 C--O 1.239 0.51 0 C-N-CA 124.236 1.015 . . . . 0.0 111.457 177.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.412 ' HB2' ' HB ' ' A' ' 22' ' ' THR . . . -67.75 -42.13 82.29 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 176.534 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 22.5 t -113.17 161.11 17.54 Favored 'General case' 0 N--CA 1.411 -2.382 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 173.472 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 43.5 p 53.94 62.71 8.62 Favored Pre-proline 0 CA--C 1.557 1.215 0 C-N-CA 123.631 0.772 . . . . 0.0 112.148 -175.593 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -80.99 98.53 1.05 Allowed 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 122.453 2.102 . . . . 0.0 112.401 -178.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -102.95 -63.9 1.12 Allowed 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 176.035 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 m -79.6 30.86 0.24 Allowed 'General case' 0 CA--C 1.561 1.372 0 C-N-CA 124.027 0.931 . . . . 0.0 111.319 -176.756 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.412 ' H ' ' HD2' ' A' ' 32' ' ' PRO . 12.4 mmt180 -124.03 -63.16 0.03 OUTLIER Pre-proline 0 C--N 1.312 -1.045 0 O-C-N 121.428 -0.795 . . . . 0.0 110.618 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.412 ' HD2' ' H ' ' A' ' 31' ' ' ARG . 53.9 Cg_endo -68.62 -11.26 31.42 Favored 'Trans proline' 0 C--N 1.385 2.451 0 C-N-CA 122.197 1.932 . . . . 0.0 113.967 178.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 96.7 t -68.29 -49.56 65.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 174.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.7 p -94.26 60.14 2.69 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 114.753 -1.112 . . . . 0.0 109.501 178.023 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -78.58 90.81 1.15 Allowed Glycine 0 CA--C 1.495 -1.158 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.392 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 46.5 m 75.58 -39.87 0.4 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.252 1.421 . . . . 0.0 111.084 -176.294 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 98.7 m95 -70.35 125.01 25.58 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 175.498 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -140.41 145.53 37.15 Favored 'General case' 0 C--N 1.281 -2.406 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 179.571 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 24.5 ttmm -84.7 109.25 17.88 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-O 121.182 0.515 . . . . 0.0 109.83 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.47 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 44.2 t30 -78.35 168.5 19.73 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.655 -179.44 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -58.28 -12.11 3.37 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -174.524 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -91.84 2.26 56.63 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-O 121.195 0.521 . . . . 0.0 109.87 179.249 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.07 -12.51 57.84 Favored Glycine 0 C--N 1.33 0.205 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -178.522 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.479 HG21 ' HG2' ' A' ' 67' ' ' PRO . 14.6 m -76.56 140.57 41.14 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 124.638 1.175 . . . . 0.0 110.592 -176.316 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -90.8 131.97 36.14 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 175.667 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.47 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 11.0 p90 -136.88 159.43 41.89 Favored 'General case' 0 C--N 1.292 -1.915 0 C-N-CA 120.006 -0.677 . . . . 0.0 109.733 -179.541 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.7 pttm -155.09 141.33 13.04 Favored Pre-proline 0 N--CA 1.431 -1.394 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 170.621 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -71.23 122.46 8.73 Favored 'Trans proline' 0 C--O 1.247 0.941 0 C-N-CA 121.873 1.715 . . . . 0.0 110.593 175.517 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -154.71 120.95 5.3 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 -178.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.549 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 7.6 t30 -104.93 117.68 34.64 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.625 -172.747 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.458 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -151.69 173.57 14.54 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 179.674 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 31.1 m -113.58 129.78 56.5 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -176.125 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -107.98 131.69 54.29 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 176.341 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 52.4 t -113.94 112.89 42.14 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 175.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -71.19 139.87 50.3 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -76.89 -117.8 0.16 Allowed Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 114.865 0.706 . . . . 0.0 114.865 -173.119 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -109.98 10.49 24.23 Favored 'General case' 0 C--N 1.311 -1.08 0 O-C-N 122.303 -0.528 . . . . 0.0 112.016 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -131.38 138.53 32.97 Favored Pre-proline 0 C--N 1.299 -1.609 0 C-N-CA 120.805 -0.358 . . . . 0.0 110.286 -175.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -69.7 141.43 45.45 Favored 'Trans proline' 0 C--O 1.242 0.695 0 C-N-CA 121.898 1.732 . . . . 0.0 109.822 174.344 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 64.4 mt -121.04 125.15 73.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -178.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 29.1 m -80.97 140.05 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.172 0 CA-C-O 121.803 0.811 . . . . 0.0 109.19 175.436 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' THR . . . . . 0.438 HG22 ' HA ' ' A' ' 109' ' ' CYS . 37.3 p -124.24 164.16 20.13 Favored 'General case' 0 C--N 1.272 -2.796 0 CA-C-N 115.095 -0.957 . . . . 0.0 110.814 -171.412 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -107.81 143.58 36.18 Favored 'General case' 0 C--N 1.317 -0.804 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -177.087 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.5 mt -106.09 130.21 58.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-O 121.229 0.538 . . . . 0.0 112.128 -174.247 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.48 -23.05 5.8 Favored Glycine 0 CA--C 1.521 0.417 0 N-CA-C 116.207 1.243 . . . . 0.0 116.207 171.71 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 52.1 m -156.94 142.28 12.51 Favored Pre-proline 0 C--N 1.308 -1.202 0 CA-C-N 118.448 1.124 . . . . 0.0 110.077 179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.479 ' HG2' HG21 ' A' ' 44' ' ' THR . 90.8 Cg_endo -89.95 119.8 0.84 Allowed 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 121.581 1.521 . . . . 0.0 111.856 175.159 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.481 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 91.7 m-85 -168.78 164.18 11.91 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 104.764 -2.31 . . . . 0.0 104.764 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 81.0 mt -85.79 -17.84 34.65 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 173.297 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -95.38 -0.47 52.56 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.921 178.402 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.481 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -68.83 157.7 88.08 Favored Pre-proline 0 N--CA 1.472 0.654 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.256 -176.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -55.71 122.18 11.27 Favored 'Trans proline' 0 C--N 1.365 1.404 0 C-N-CA 122.951 2.434 . . . . 0.0 112.749 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.4 HG22 ' H ' ' A' ' 74' ' ' GLY . 7.3 p -98.95 173.38 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 179.094 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.4 ' H ' HG22 ' A' ' 73' ' ' VAL . . . 119.78 -3.37 13.29 Favored Glycine 0 C--N 1.308 -1.015 0 C-N-CA 120.319 -0.943 . . . . 0.0 111.565 -178.74 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.94 127.09 9.14 Favored Glycine 0 N--CA 1.432 -1.609 0 N-CA-C 107.932 -2.067 . . . . 0.0 107.932 172.059 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -116.82 140.6 49.25 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 118.292 1.046 . . . . 0.0 110.582 -177.822 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 48.6 tp -114.19 112.5 46.79 Favored Pre-proline 0 C--N 1.307 -1.273 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 177.409 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.41 164.3 34.72 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 122.344 2.03 . . . . 0.0 113.06 -178.709 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.86 139.79 45.28 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.471 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.98 -0.59 86.32 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 121.314 -0.47 . . . . 0.0 112.396 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -72.76 126.26 29.48 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 121.099 0.476 . . . . 0.0 110.865 -178.559 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 53.6 m -99.7 115.76 30.24 Favored 'General case' 0 N--CA 1.425 -1.677 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.018 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.4 mm -126.05 128.84 72.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 110.256 -0.275 . . . . 0.0 110.256 -175.756 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.6 p -93.46 123.3 45.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 175.15 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.549 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 40.9 p90 -107.37 145.23 33.16 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.899 -178.666 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -111.93 -15.75 13.26 Favored 'General case' 0 C--N 1.31 -1.143 0 O-C-N 124.002 0.814 . . . . 0.0 112.494 -175.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -136.58 138.51 41.3 Favored 'General case' 0 N--CA 1.437 -1.09 0 C-N-CA 120.21 -0.596 . . . . 0.0 109.758 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 61.5 t -114.84 132.02 65.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 69.6 m -127.47 135.32 50.24 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 120.743 0.306 . . . . 0.0 110.924 -177.773 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 65.6 mt -103.66 116.88 48.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 CA-C-O 121.296 0.569 . . . . 0.0 110.121 177.053 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.554 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 59.6 tp60 -124.96 118.96 27.42 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 103.981 -2.6 . . . . 0.0 103.981 175.806 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.14 106.19 0.1 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 -167.407 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 138.78 -41.17 1.38 Allowed Glycine 0 N--CA 1.421 -2.333 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.798 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 57.3 m80 -147.2 154.77 41.44 Favored 'General case' 0 CA--C 1.494 -1.181 0 O-C-N 122.142 -0.622 . . . . 0.0 110.206 -178.519 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.9 tt -96.98 125.77 49.9 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 175.234 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.554 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 68.2 m95 -105.03 133.97 48.91 Favored 'General case' 0 C--N 1.274 -2.683 0 CA-C-O 121.178 0.513 . . . . 0.0 110.355 -173.407 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.473 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 43.8 pt -100.12 120.84 50.1 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.323 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 175.486 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -94.77 114.15 4.76 Favored Glycine 0 N--CA 1.411 -2.97 0 N-CA-C 109.326 -1.509 . . . . 0.0 109.326 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -132.2 154.16 49.85 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -177.54 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -89.28 114.96 26.39 Favored 'General case' 0 C--N 1.272 -2.77 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 174.464 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.23 165.35 24.01 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-O 121.114 0.483 . . . . 0.0 110.846 -176.684 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.6 p90 -69.19 -2.79 11.33 Favored 'General case' 0 C--N 1.312 -1.034 0 C-N-CA 123.9 0.88 . . . . 0.0 112.162 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -95.45 -7.0 39.47 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.321 177.344 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 96.51 -7.8 66.14 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.907 -0.588 . . . . 0.0 113.665 176.062 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 15.3 p-10 -96.69 151.12 19.93 Favored 'General case' 0 C--N 1.296 -1.72 0 C-N-CA 122.972 0.509 . . . . 0.0 112.039 -178.244 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 14.5 tpp180 -84.29 108.47 17.17 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.067 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 25.8 t -110.94 146.62 15.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.022 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -176.525 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 88.2 m-85 -117.05 123.19 46.24 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' CYS . . . . . 0.438 ' HA ' HG22 ' A' ' 62' ' ' THR . 50.8 t -104.67 132.2 21.14 Favored Pre-proline 0 C--N 1.303 -1.424 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.361 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -69.84 -17.07 37.44 Favored 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 123.051 2.501 . . . . 0.0 114.372 -177.502 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.299 33.2 m 40.91 -58.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.52 3.032 0 N-CA-C 118.815 2.894 . . . . 0.0 118.815 175.872 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 33.3 ptt180 -153.96 150.6 28.49 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 123.577 0.751 . . . . 0.0 109.009 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 17.8 m -66.66 139.05 57.84 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.742 179.042 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.581 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 92.1 m -154.65 127.03 7.89 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 123.009 0.524 . . . . 0.0 111.17 179.573 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -125.83 122.49 36.3 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 177.655 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 168.84 175.03 37.96 Favored Glycine 0 N--CA 1.416 -2.696 0 C-N-CA 119.932 -1.128 . . . . 0.0 111.897 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 60.2 t -129.17 128.32 23.29 Favored Pre-proline 0 C--N 1.288 -2.076 0 N-CA-C 105.248 -2.13 . . . . 0.0 105.248 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -43.26 137.53 5.11 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 123.71 2.94 . . . . 0.0 113.027 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -81.88 -14.87 33.76 Favored 'Cis proline' 0 CA--C 1.553 1.467 0 C-N-CA 123.331 -1.529 . . . . 0.0 114.543 3.052 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -79.41 100.33 7.6 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.768 0.794 . . . . 0.0 112.952 -171.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 38.9 p-80 -106.99 112.73 25.83 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 114.869 -1.059 . . . . 0.0 111.164 175.628 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.581 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 49.4 mt -91.94 113.51 59.16 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 110.607 -0.146 . . . . 0.0 110.607 -178.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -84.48 164.75 12.54 Favored 'Trans proline' 0 C--O 1.246 0.918 0 C-N-CA 123.029 2.486 . . . . 0.0 113.36 -178.684 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.92 -130.96 2.92 Favored Glycine 0 N--CA 1.434 -1.473 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 176.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 80.7 t -73.81 122.3 26.62 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 C-N-CA 122.387 0.275 . . . . 0.0 111.287 -178.119 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.49 147.46 23.23 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.281 176.103 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.5 m0 -107.57 11.4 28.69 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.923 0.392 . . . . 0.0 111.792 179.213 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.66 -168.38 23.47 Favored Glycine 0 N--CA 1.436 -1.365 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.616 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 27.1 t -111.88 139.98 33.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -178.834 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 -118.32 123.16 44.67 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.426 0.155 . . . . 0.0 111.341 -175.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.1 pttm . . . . . 0 N--CA 1.433 -1.291 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 171.932 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 13.3 m . . . . . 0 N--CA 1.443 -0.793 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -67.63 -48.11 67.69 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 174.833 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -89.44 95.79 10.43 Favored 'General case' 0 N--CA 1.427 -1.62 0 N-CA-C 107.767 -1.198 . . . . 0.0 107.767 175.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 59.2 mttm -71.61 -39.23 70.6 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 -178.434 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.686 ' HB3' ' HA ' ' A' ' 8' ' ' ASP . 85.1 m-20 -122.35 132.61 54.47 Favored 'General case' 0 N--CA 1.426 -1.656 0 N-CA-C 106.314 -1.735 . . . . 0.0 106.314 172.293 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 35.5 t80 -88.0 -51.36 5.86 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 120.795 0.331 . . . . 0.0 110.617 -176.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 1.6 pmm? -105.59 -7.58 18.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.125 0.488 . . . . 0.0 109.88 177.493 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.686 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . 25.0 t70 75.49 92.17 0.07 Allowed 'General case' 0 CA--C 1.498 -1.047 0 C-N-CA 125.437 1.495 . . . . 0.0 112.053 -178.825 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.6 tmtm? -125.93 116.51 21.61 Favored 'General case' 0 N--CA 1.427 -1.588 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 147.27 -72.02 0.32 Allowed Glycine 0 N--CA 1.436 -1.321 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.31 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 6.8 t -163.23 135.9 5.43 Favored 'General case' 0 N--CA 1.428 -1.548 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.3 m -97.99 3.15 49.52 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 178.781 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.2 m 64.77 89.27 0.1 Allowed 'General case' 0 C--N 1.347 0.485 0 C-N-CA 124.901 1.28 . . . . 0.0 110.528 -177.561 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.4 m -140.91 108.36 5.56 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.637 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.9 m -77.17 109.66 11.21 Favored 'General case' 0 N--CA 1.427 -1.581 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.313 -178.754 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 33.7 m -92.73 -4.26 10.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -175.63 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 7.1 p -76.23 78.66 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.068 0 CA-C-O 122.935 1.35 . . . . 0.0 110.914 176.733 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 53.7 pttt -163.99 120.27 1.65 Allowed 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 113.504 -1.68 . . . . 0.0 108.358 -178.704 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -170.21 176.26 4.63 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -178.814 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 126.71 141.63 5.48 Favored Glycine 0 N--CA 1.434 -1.472 0 C-N-CA 120.426 -0.892 . . . . 0.0 112.131 176.542 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.486 ' HD3' ' H ' ' A' ' 21' ' ' LYS . 0.0 OUTLIER -67.25 112.5 4.55 Favored 'General case' 0 C--O 1.249 1.07 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 176.232 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 27.4 m 72.06 117.76 0.05 OUTLIER 'General case' 0 CA--C 1.547 0.856 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -171.537 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 12.8 m -53.95 -46.96 71.75 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 113.58 0.955 . . . . 0.0 113.58 -174.043 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.8 t -140.42 140.82 35.52 Favored 'General case' 0 N--CA 1.421 -1.903 0 C-N-CA 120.424 -0.51 . . . . 0.0 109.808 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.14 103.07 4.45 Favored 'General case' 0 N--CA 1.431 -1.395 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.158 177.376 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 12.7 m -89.67 114.1 25.68 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.317 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 23.9 m -121.26 94.73 48.74 Favored Pre-proline 0 C--N 1.303 -1.448 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.652 -179.024 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.535 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 2.0 Cg_endo -89.1 -77.18 0.0 OUTLIER 'Trans proline' 0 N--CA 1.434 -1.979 0 C-N-CA 122.002 1.801 . . . . 0.0 112.97 173.866 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 65.63 -72.26 0.08 Allowed 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 124.81 1.244 . . . . 0.0 109.242 -175.456 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 32.1 m -103.28 -49.48 3.72 Favored 'General case' 0 N--CA 1.423 -1.788 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 173.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 64.1 mtp180 -145.62 127.36 7.73 Favored Pre-proline 0 N--CA 1.467 0.423 0 C-N-CA 123.901 0.88 . . . . 0.0 109.14 -179.808 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.535 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 12.9 Cg_endo -57.19 90.91 0.05 OUTLIER 'Trans proline' 0 C--N 1.362 1.251 0 C-N-CA 123.243 2.628 . . . . 0.0 113.54 175.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.6 m -73.31 -27.49 24.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.76 0.79 . . . . 0.0 109.112 178.55 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 20.1 p -134.28 134.4 41.87 Favored 'General case' 0 N--CA 1.413 -2.282 0 CA-C-N 114.214 -1.357 . . . . 0.0 107.546 174.247 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -118.74 -136.21 5.36 Favored Glycine 0 C--N 1.3 -1.459 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 11.1 m -85.77 1.03 51.23 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 121.541 0.686 . . . . 0.0 109.467 177.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.6 m95 -75.12 127.76 33.95 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.956 -178.585 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -113.64 156.14 24.23 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 175.063 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -101.4 126.2 48.14 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.559 -178.139 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.409 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 36.6 t-20 -89.39 164.57 14.82 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 -177.383 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -64.91 -15.14 61.67 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.309 1.043 . . . . 0.0 111.213 -176.164 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 46.0 m-85 -74.66 -18.02 60.6 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.916 177.4 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.12 -8.13 59.01 Favored Glycine 0 CA--C 1.507 -0.453 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -175.447 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 11.2 m -80.67 138.84 36.41 Favored 'General case' 0 N--CA 1.427 -1.611 0 C-N-CA 124.724 1.21 . . . . 0.0 110.703 -178.072 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.412 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 65.2 m95 -93.44 139.05 31.14 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 174.463 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.409 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 37.0 p90 -142.47 151.37 41.64 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 120.691 -0.403 . . . . 0.0 111.241 -178.455 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 pttm -144.18 151.48 51.91 Favored Pre-proline 0 C--O 1.25 1.081 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 173.222 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -73.5 122.12 7.64 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 121.952 1.768 . . . . 0.0 110.548 175.494 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -156.57 121.6 4.64 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.492 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 20.5 t-20 -101.55 115.71 31.12 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.146 -176.005 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.84 176.49 10.68 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.5 m -118.47 138.36 52.55 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 121.192 0.52 . . . . 0.0 111.978 -175.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 80.5 t80 -115.63 123.17 47.72 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 175.394 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 45.1 t -104.87 110.86 32.13 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 177.204 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.583 ' OD1' ' HA ' ' A' ' 79' ' ' ALA . 22.6 t-20 -66.15 128.09 34.72 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.318 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -136.5 -11.28 1.16 Allowed Glycine 0 N--CA 1.441 -0.993 0 C-N-CA 118.997 -1.573 . . . . 0.0 114.71 -176.787 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.496 ' OD1' ' HG3' ' A' ' 58' ' ' GLN . 15.5 t-20 -95.26 -74.51 0.55 Allowed 'General case' 0 C--N 1.319 -0.753 0 C-N-CA 119.073 -1.051 . . . . 0.0 110.876 -178.051 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.496 ' HG3' ' OD1' ' A' ' 57' ' ' ASN . 0.0 OUTLIER -141.14 167.4 17.44 Favored Pre-proline 0 C--N 1.305 -1.329 0 CA-C-O 118.948 -0.549 . . . . 0.0 110.471 -179.199 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -62.35 130.33 29.9 Favored 'Trans proline' 0 C--N 1.356 0.951 0 C-N-CA 121.824 1.683 . . . . 0.0 109.264 173.339 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 58.9 mt -107.13 125.03 63.3 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 C-N-CA 120.323 -0.551 . . . . 0.0 109.708 -173.641 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.7 p -82.66 119.4 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.83 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 176.839 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 75.6 p -95.86 178.96 5.26 Favored 'General case' 0 C--N 1.285 -2.209 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.131 -172.742 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.45 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 82.2 mmt-85 -118.35 139.93 50.61 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 175.809 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 67.4 mt -99.13 129.84 48.96 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 CA-C-O 121.451 0.643 . . . . 0.0 111.895 -175.584 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 77.11 -22.51 2.41 Favored Glycine 0 C--N 1.318 -0.426 0 N-CA-C 116.023 1.169 . . . . 0.0 116.023 173.028 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 16.5 m -147.22 138.24 13.0 Favored Pre-proline 0 C--N 1.303 -1.44 0 CA-C-N 117.981 0.89 . . . . 0.0 109.941 -176.324 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -89.73 118.62 0.79 Allowed 'Trans proline' 0 N--CA 1.433 -2.062 0 C-N-CA 120.776 0.984 . . . . 0.0 110.006 171.087 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.576 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 68.9 m-85 -169.06 178.35 4.49 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 104.27 -2.492 . . . . 0.0 104.27 -179.195 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -89.0 -40.12 13.22 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 174.805 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -96.84 25.46 5.26 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 121.942 0.877 . . . . 0.0 110.524 -177.648 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.576 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -75.61 159.74 80.83 Favored Pre-proline 0 C--N 1.307 -1.254 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.391 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_exo -47.4 123.03 7.36 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 122.98 2.454 . . . . 0.0 113.482 -179.002 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 6.4 t -98.52 172.6 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 -178.108 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.6 3.48 14.16 Favored Glycine 0 C--N 1.312 -0.77 0 C-N-CA 120.057 -1.068 . . . . 0.0 112.227 -179.212 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -115.51 111.77 2.52 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 175.607 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 38.6 t30 -107.49 130.13 54.88 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 117.318 0.559 . . . . 0.0 109.716 -178.829 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 46.8 tp -95.56 112.28 58.41 Favored Pre-proline 0 N--CA 1.431 -1.385 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 177.422 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -61.87 152.1 76.89 Favored 'Trans proline' 0 C--O 1.243 0.761 0 C-N-CA 122.471 2.114 . . . . 0.0 112.379 -177.119 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.583 ' HA ' ' OD1' ' A' ' 55' ' ' ASN . . . -68.18 134.52 50.62 Favored 'General case' 0 N--CA 1.436 -1.145 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.332 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.72 7.96 65.99 Favored Glycine 0 N--CA 1.436 -1.365 0 CA-C-N 115.417 -0.81 . . . . 0.0 112.623 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.33 132.75 37.55 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.116 0.484 . . . . 0.0 111.126 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 26.2 m -102.34 112.63 25.42 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.53 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 40.2 mm -115.65 121.8 68.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.836 -176.031 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.2 p -87.9 123.51 40.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 172.154 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.492 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 39.2 p90 -108.88 142.41 39.52 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -178.618 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -115.9 -10.96 11.58 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.719 0.771 . . . . 0.0 110.915 -174.167 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -131.65 134.42 45.95 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.662 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 50.3 t -117.87 133.11 65.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.329 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.503 ' SG ' ' HE2' ' A' ' 108' ' ' TYR . 67.1 m -132.02 140.4 48.9 Favored 'General case' 0 C--N 1.312 -1.051 0 O-C-N 123.317 0.386 . . . . 0.0 111.446 -177.403 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 52.0 mt -107.69 112.57 40.69 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.906 -0.496 . . . . 0.0 109.745 174.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.593 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -118.64 120.37 37.24 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 174.397 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.61 109.63 0.26 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 113.48 0.919 . . . . 0.0 113.48 -165.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 132.44 -34.82 2.44 Favored Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.27 -1.332 . . . . 0.0 110.793 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 68.5 m80 -148.8 159.33 44.25 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.7 tt -102.09 119.03 49.81 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 172.784 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.593 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 61.7 m95 -99.81 134.73 42.28 Favored 'General case' 0 C--N 1.276 -2.596 0 CA-C-O 121.186 0.517 . . . . 0.0 110.581 -171.445 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.483 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.0 pt -100.22 131.92 46.8 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.131 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.847 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.15 127.04 9.05 Favored Glycine 0 N--CA 1.425 -2.099 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -178.078 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 27.4 p90 -151.36 166.64 30.39 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 120.976 0.417 . . . . 0.0 109.975 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -118.84 130.39 55.74 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.331 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -96.17 147.78 23.39 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.046 -178.696 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 29.8 p90 -46.96 -21.52 0.23 Allowed 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 126.246 1.818 . . . . 0.0 115.158 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -89.16 3.99 50.03 Favored 'General case' 0 CA--C 1.561 1.398 0 CA-C-O 121.665 0.745 . . . . 0.0 111.053 -177.579 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 91.59 16.92 51.13 Favored Glycine 0 CA--C 1.502 -0.748 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.135 177.355 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -96.06 124.08 39.93 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 120.991 0.424 . . . . 0.0 111.35 -176.322 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 30.3 tpt180 -82.91 109.09 16.73 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 105.127 -2.175 . . . . 0.0 105.127 172.397 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 20.1 t -118.81 140.19 43.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 C-N-CA 119.449 -0.901 . . . . 0.0 112.029 -171.447 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.503 ' HE2' ' SG ' ' A' ' 89' ' ' CYS . 66.8 m-85 -122.58 124.14 42.82 Favored 'General case' 0 N--CA 1.435 -1.219 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.205 174.664 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' CYS . . . . . 0.418 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 48.7 t -108.83 132.66 21.03 Favored Pre-proline 0 C--N 1.304 -1.372 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.358 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.74 -21.16 33.96 Favored 'Trans proline' 0 C--N 1.358 1.064 0 C-N-CA 123.092 2.528 . . . . 0.0 114.214 -176.816 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.317 33.2 m 45.85 -55.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.51 2.529 0 N-CA-C 118.67 2.841 . . . . 0.0 118.67 176.193 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.447 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 34.2 ptt180 -153.6 149.11 27.26 Favored 'General case' 0 N--CA 1.441 -0.914 0 C-N-CA 122.966 0.507 . . . . 0.0 110.639 177.592 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.4 m -63.0 127.98 33.76 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 177.324 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.645 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 88.3 m -151.94 117.32 5.31 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.592 0.711 . . . . 0.0 111.363 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -114.35 144.84 42.62 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.121 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 141.41 -169.49 25.08 Favored Glycine 0 N--CA 1.429 -1.83 0 C-N-CA 119.769 -1.205 . . . . 0.0 111.454 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 15.4 m -136.68 142.23 38.23 Favored Pre-proline 0 C--N 1.298 -1.656 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 71.9 Cg_exo -43.92 127.46 6.61 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 123.784 2.989 . . . . 0.0 113.207 -178.235 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 11.2 Cg_endo -96.21 -9.97 19.97 Favored 'Cis proline' 0 C--O 1.245 0.828 0 C-N-CA 124.195 -1.169 . . . . 0.0 114.12 1.384 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 57.9 t30 -72.67 100.86 2.91 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 121.998 0.904 . . . . 0.0 111.557 -172.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 33.4 p-80 -106.66 125.15 50.63 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.304 -1.316 . . . . 0.0 110.699 177.086 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.645 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 49.8 mm -85.66 107.96 14.62 Favored Pre-proline 0 C--N 1.306 -1.286 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 176.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_endo -84.89 123.8 2.86 Favored 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 122.723 2.282 . . . . 0.0 112.967 -177.811 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -98.74 -110.25 3.0 Favored Glycine 0 N--CA 1.433 -1.543 0 N-CA-C 111.374 -0.69 . . . . 0.0 111.374 177.583 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 48.1 t -94.79 122.38 46.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 -177.831 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.447 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.27 136.5 34.49 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.272 175.757 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.6 m-90 -102.04 16.07 27.15 Favored 'General case' 0 C--O 1.251 1.162 0 CA-C-O 121.581 0.705 . . . . 0.0 111.467 179.48 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -171.29 -171.57 36.6 Favored Glycine 0 N--CA 1.43 -1.74 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.064 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 59.1 t -111.51 125.41 68.83 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 123.508 0.723 . . . . 0.0 109.167 -177.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -93.58 135.12 35.17 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.015 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 96.0 mttt . . . . . 0 C--N 1.293 -1.856 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 179.067 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 15.1 m . . . . . 0 CA--C 1.546 0.824 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -84.13 88.6 7.2 Favored 'General case' 0 CA--C 1.5 -0.975 0 CA-C-O 121.428 0.632 . . . . 0.0 111.188 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.13 30.61 1.41 Allowed 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.062 -177.509 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -78.0 72.82 4.55 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.779 0.8 . . . . 0.0 110.491 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -143.21 35.01 1.34 Allowed 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 106.298 -1.741 . . . . 0.0 106.298 176.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -87.08 162.54 17.52 Favored 'General case' 0 N--CA 1.436 -1.133 0 CA-C-N 114.403 -1.271 . . . . 0.0 108.944 -175.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 75.2 mtm 82.42 -29.69 0.1 Allowed 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 125.268 1.427 . . . . 0.0 111.254 -178.208 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -76.79 118.5 19.46 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 169.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.2 ttmm -137.77 159.27 42.45 Favored 'General case' 0 C--N 1.284 -2.266 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 -176.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.97 82.43 0.23 Allowed Glycine 0 N--CA 1.442 -0.91 0 N-CA-C 110.471 -1.051 . . . . 0.0 110.471 175.593 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 22.5 m -93.72 -44.27 8.24 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 123.201 0.6 . . . . 0.0 110.233 -176.926 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.1 m -83.21 -28.6 29.14 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 176.523 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.9 p -125.29 85.47 2.41 Favored 'General case' 0 N--CA 1.427 -1.58 0 CA-C-O 121.785 0.802 . . . . 0.0 110.133 176.586 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 26.0 m -86.84 93.82 9.39 Favored 'General case' 0 N--CA 1.429 -1.525 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.221 -178.817 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 4.6 p -80.57 -49.31 11.47 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.179 178.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.8 p -78.38 67.25 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.038 0 CA-C-O 122.957 1.36 . . . . 0.0 112.343 -179.076 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.4 m -119.81 -17.66 6.37 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.069 0 CA-C-N 114.162 -1.381 . . . . 0.0 109.732 175.191 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 58.5 mtpt -121.17 87.54 2.77 Favored 'General case' 0 N--CA 1.434 -1.254 0 CA-C-N 115.078 -0.965 . . . . 0.0 109.05 178.559 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -126.74 -36.91 2.18 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 176.746 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 116.63 148.47 8.97 Favored Glycine 0 N--CA 1.413 -2.89 0 CA-C-N 114.392 -1.276 . . . . 0.0 110.978 178.092 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.15 134.71 34.61 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 120.547 -0.461 . . . . 0.0 109.993 177.415 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.1 m -70.68 -21.53 62.58 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.552 -175.717 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.5 m 67.92 23.97 8.16 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 123.987 0.915 . . . . 0.0 108.65 -177.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 21.2 t -147.22 93.68 2.28 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 -175.543 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -132.76 10.64 4.32 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.725 178.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 27.9 p 52.57 -171.58 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.301 1.44 . . . . 0.0 112.949 -177.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 21.7 p -104.82 118.44 56.29 Favored Pre-proline 0 C--N 1.295 -1.771 0 O-C-N 122.014 -0.429 . . . . 0.0 109.848 176.679 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -57.85 -35.0 99.02 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 122.334 2.023 . . . . 0.0 111.129 175.671 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 27.02 95.18 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 126.233 1.813 . . . . 0.0 114.295 172.224 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 24.8 m 86.87 -22.11 0.17 Allowed 'General case' 0 CA--C 1.557 1.245 0 C-N-CA 125.249 1.419 . . . . 0.0 110.274 -175.768 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.495 ' HB3' ' CD ' ' A' ' 32' ' ' PRO . 2.0 mpp_? -98.57 173.14 4.1 Favored Pre-proline 0 CA--C 1.561 1.377 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 170.624 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.495 ' CD ' ' HB3' ' A' ' 31' ' ' ARG . 9.9 Cg_exo -68.42 118.98 6.01 Favored 'Trans proline' 0 C--N 1.371 1.725 0 C-N-CA 122.522 2.148 . . . . 0.0 115.051 -170.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.2 p -111.3 85.57 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.362 0 CA-C-O 122.449 1.118 . . . . 0.0 108.88 174.171 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 36.6 m -146.78 138.67 24.57 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.203 -178.357 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.79 -67.32 0.34 Allowed Glycine 0 CA--C 1.49 -1.482 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 -179.594 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 14.7 m -76.02 -49.79 16.6 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 173.175 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' TRP . . . . . 0.524 ' CZ2' ' HD2' ' A' ' 47' ' ' LYS . 94.1 m95 -91.75 132.5 36.35 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 174.683 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -125.51 140.73 52.51 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 -179.241 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 59.8 tttp -89.63 118.04 28.95 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.192 0.52 . . . . 0.0 110.596 -177.509 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -89.85 152.24 21.36 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 175.793 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.7 tp60 -61.04 -13.68 18.3 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 123.745 0.818 . . . . 0.0 113.094 -173.675 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 62.9 m-85 -74.84 -9.05 58.18 Favored 'General case' 0 CA--C 1.542 0.649 0 CA-C-O 121.247 0.546 . . . . 0.0 109.838 176.844 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.77 20.17 54.47 Favored Glycine 0 CA--C 1.496 -1.116 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -176.214 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 22.1 m -105.81 129.08 54.06 Favored 'General case' 0 N--CA 1.408 -2.542 0 CA-C-N 114.13 -1.035 . . . . 0.0 108.679 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 81.0 m95 -92.48 132.07 37.1 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 175.344 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 31.8 p90 -130.69 147.74 52.4 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.991 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.524 ' HD2' ' CZ2' ' A' ' 37' ' ' TRP . 20.7 ptmt -125.1 141.99 40.07 Favored Pre-proline 0 C--N 1.294 -1.844 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.57 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -73.22 120.83 6.78 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 N-CA-C 108.699 -1.308 . . . . 0.0 108.699 172.403 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -168.12 121.53 0.9 Allowed 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 -178.419 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 19.8 t-20 -104.79 128.55 52.98 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.929 -173.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.535 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -156.59 170.15 23.04 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 177.525 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.422 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 2.4 m -112.92 122.25 47.08 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.668 -174.923 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -95.82 124.24 39.75 Favored 'General case' 0 C--N 1.312 -1.062 0 O-C-N 121.969 -0.457 . . . . 0.0 110.582 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.439 HG22 HG23 ' A' ' 82' ' ' THR . 38.2 t -110.56 112.59 41.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 176.424 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -68.34 137.03 54.29 Favored 'General case' 0 C--O 1.248 0.995 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -124.73 -57.63 0.17 Allowed Glycine 0 N--CA 1.424 -2.135 0 C-N-CA 118.934 -1.603 . . . . 0.0 115.654 -170.699 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -83.02 -53.46 5.8 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -170.058 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -142.62 154.68 63.32 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 119.942 -0.703 . . . . 0.0 111.082 -174.822 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -60.03 132.75 46.28 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 122.707 2.271 . . . . 0.0 110.213 176.251 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 41.8 mt -108.19 120.83 60.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -174.738 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.5 p -79.38 115.09 21.12 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.136 0 CA-C-O 121.753 0.787 . . . . 0.0 109.471 175.643 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 56.3 p -89.49 178.87 6.19 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 115.191 -0.913 . . . . 0.0 111.657 -173.104 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 84.6 mmt-85 -117.52 137.67 52.41 Favored 'General case' 0 N--CA 1.439 -0.978 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 176.203 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 72.3 mt -95.29 123.7 47.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.139 -176.247 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.87 -22.55 3.42 Favored Glycine 0 C--N 1.317 -0.505 0 N-CA-C 116.205 1.242 . . . . 0.0 116.205 171.828 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.3 m -152.32 140.61 13.54 Favored Pre-proline 0 C--N 1.306 -1.311 0 CA-C-N 118.322 1.061 . . . . 0.0 110.455 -177.208 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -90.05 118.89 0.76 Allowed 'Trans proline' 0 N--CA 1.433 -2.05 0 C-N-CA 121.03 1.154 . . . . 0.0 110.662 172.632 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.543 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 97.0 m-85 -169.04 166.99 10.86 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 104.134 -2.543 . . . . 0.0 104.134 179.076 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -79.22 -36.14 40.54 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 175.336 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.5 p-10 -96.06 19.99 10.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.336 -177.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.543 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -74.96 156.25 86.28 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 176.089 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -48.07 123.33 8.58 Favored 'Trans proline' 0 C--O 1.255 1.345 0 C-N-CA 123.385 2.723 . . . . 0.0 113.828 179.754 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 34.2 m -94.29 174.43 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.609 -1.178 . . . . 0.0 109.949 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.43 11.34 7.38 Favored Glycine 0 N--CA 1.439 -1.132 0 C-N-CA 120.17 -1.014 . . . . 0.0 112.909 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -119.78 130.13 8.31 Favored Glycine 0 N--CA 1.436 -1.324 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 174.644 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -128.36 130.16 47.31 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 118.024 0.912 . . . . 0.0 110.439 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 46.1 tp -101.16 110.31 60.95 Favored Pre-proline 0 C--N 1.3 -1.552 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.074 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -69.13 166.91 25.2 Favored 'Trans proline' 0 C--O 1.244 0.822 0 C-N-CA 122.57 2.18 . . . . 0.0 112.481 -177.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.43 141.08 43.24 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.468 -179.215 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.53 -23.78 32.3 Favored Glycine 0 C--O 1.244 0.761 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.05 128.22 35.13 Favored 'General case' 0 C--O 1.244 0.78 0 CA-C-O 121.13 0.49 . . . . 0.0 110.453 -178.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.439 HG23 HG22 ' A' ' 54' ' ' VAL . 39.9 m -111.88 121.58 45.44 Favored 'General case' 0 N--CA 1.416 -2.151 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.437 -178.565 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.1 mm -125.87 128.55 72.12 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 -178.373 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 12.9 p -83.92 133.2 29.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 175.64 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.535 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 50.6 p90 -116.09 137.66 51.93 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.01 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -111.36 -10.5 14.22 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 122.232 1.015 . . . . 0.0 109.568 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.4 ' CD ' HH22 ' A' ' 106' ' ' ARG . 39.8 tt0 -125.71 120.05 29.62 Favored 'General case' 0 N--CA 1.423 -1.804 0 CA-C-N 114.454 -1.248 . . . . 0.0 109.119 -176.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 45.0 t -106.58 130.51 58.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.64 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.457 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 62.1 m -129.08 153.18 47.89 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 120.882 0.372 . . . . 0.0 111.97 -174.41 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.3 mt -124.91 117.04 49.01 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 171.863 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.563 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -124.13 126.8 46.8 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 104.469 -2.419 . . . . 0.0 104.469 174.18 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.2 113.2 0.75 Allowed 'General case' 0 C--N 1.321 -0.645 0 O-C-N 124.789 1.306 . . . . 0.0 112.586 -168.704 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 131.68 -35.8 2.34 Favored Glycine 0 N--CA 1.432 -1.602 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.66 -176.606 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -154.19 168.41 26.63 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 122.418 -0.46 . . . . 0.0 110.257 -178.07 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 112' ' ' ARG . 15.4 tt -98.36 140.81 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 N-CA-C 103.724 -2.695 . . . . 0.0 103.724 168.159 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.563 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 49.8 m95 -125.15 147.83 48.85 Favored 'General case' 0 C--N 1.28 -2.447 0 CA-C-N 118.117 0.417 . . . . 0.0 110.308 -172.155 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 49.9 pt -110.49 131.31 61.93 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.022 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 172.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.55 121.1 7.05 Favored Glycine 0 N--CA 1.424 -2.113 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.324 -178.575 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -140.29 164.3 30.45 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-O 121.074 0.464 . . . . 0.0 110.688 178.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 31.0 t30 -120.74 127.02 51.6 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 178.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.55 172.32 11.73 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.064 0.459 . . . . 0.0 111.717 -176.698 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -60.47 -25.9 66.38 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.199 1.0 . . . . 0.0 112.603 -176.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 26.5 p-10 -92.78 -0.6 57.23 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.253 -177.843 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 91.67 9.62 62.59 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.481 178.656 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -78.55 122.3 25.71 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ARG . . . . . 0.4 HH22 ' CD ' ' A' ' 87' ' ' GLU . 11.2 tpt85 -88.18 98.29 11.48 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 -179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 16.5 t -103.86 139.91 23.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 CA-C-O 121.126 0.488 . . . . 0.0 111.066 -171.16 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -118.34 122.27 42.45 Favored 'General case' 0 N--CA 1.432 -1.367 0 CA-C-N 115.407 -0.815 . . . . 0.0 108.991 174.645 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.2 t -104.06 129.77 24.6 Favored Pre-proline 0 C--N 1.301 -1.541 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -178.511 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.98 -2.83 12.82 Favored 'Trans proline' 0 C--N 1.361 1.206 0 C-N-CA 123.329 2.686 . . . . 0.0 114.852 -177.195 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 28.3 m 29.59 -52.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.522 3.147 0 N-CA-C 120.116 3.376 . . . . 0.0 120.116 172.431 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.407 ' O ' HG22 ' A' ' 95' ' ' ILE . 59.5 ttt180 -156.8 141.65 17.0 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 123.828 0.851 . . . . 0.0 109.23 -176.183 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 28.1 m -71.83 132.09 43.95 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 120.797 0.332 . . . . 0.0 110.183 177.756 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 86.1 m -151.47 143.52 23.92 Favored 'General case' 0 N--CA 1.437 -1.086 0 C-N-CA 123.729 0.812 . . . . 0.0 109.054 178.507 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 51.3 tt0 -134.26 133.78 41.19 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 178.708 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 156.25 -172.59 34.11 Favored Glycine 0 N--CA 1.437 -1.287 0 C-N-CA 119.925 -1.131 . . . . 0.0 112.096 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 31.0 m -129.68 148.51 69.74 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 75.4 Cg_exo -51.55 131.79 38.29 Favored 'Trans proline' 0 CA--C 1.545 1.063 0 C-N-CA 122.801 2.334 . . . . 0.0 113.125 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 6.4 Cg_endo -100.24 10.17 23.42 Favored 'Cis proline' 0 CA--C 1.544 1.005 0 C-N-CA 124.779 -0.925 . . . . 0.0 113.044 -3.235 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -93.55 102.31 14.51 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.793 0.806 . . . . 0.0 112.096 -174.692 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 39.3 p-80 -104.68 138.52 40.87 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.11 178.648 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.447 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 70.2 mt -92.68 110.37 44.87 Favored Pre-proline 0 C--N 1.305 -1.351 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 173.702 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -84.59 126.09 3.46 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 122.659 2.239 . . . . 0.0 113.942 -177.42 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -102.76 -138.34 9.95 Favored Glycine 0 N--CA 1.437 -1.28 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 176.374 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 60.4 t -73.85 127.83 35.92 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 C-N-CA 122.996 0.518 . . . . 0.0 111.801 -177.236 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.11 141.72 28.22 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.147 177.49 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.6 m0 -99.59 -4.89 30.07 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 119.59 -0.844 . . . . 0.0 111.615 177.016 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -160.61 -175.27 31.43 Favored Glycine 0 N--CA 1.43 -1.703 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -177.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 46.9 t -110.95 134.76 52.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 C-N-CA 122.963 0.505 . . . . 0.0 109.675 -174.084 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -101.03 110.92 23.0 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.6 tptt . . . . . 0 C--N 1.294 -1.84 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -177.786 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . 0.484 ' CZ3' HG13 ' A' ' 90' ' ' ILE . 60.3 m95 . . . . . 0 N--CA 1.444 -0.751 0 CA-C-O 120.901 0.382 . . . . 0.0 110.798 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 38.7 ttmt -114.45 151.18 33.6 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 61.7 tttm -93.26 144.74 25.02 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.513 0.673 . . . . 0.0 112.368 -175.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -107.91 156.12 19.54 Favored 'General case' 0 C--O 1.253 1.274 0 C-N-CA 125.182 1.393 . . . . 0.0 108.763 175.065 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 16.6 pm0 -62.08 -23.29 66.42 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.462 1.105 . . . . 0.0 113.183 -178.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -84.26 -3.26 58.1 Favored 'General case' 0 C--N 1.322 -0.6 0 O-C-N 121.819 -0.551 . . . . 0.0 111.4 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.9 -6.46 60.22 Favored Glycine 0 CA--C 1.5 -0.902 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 17.0 m -73.32 144.79 46.41 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 68.1 m95 -114.92 138.94 50.22 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 175.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -138.23 149.05 45.39 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 120.663 0.268 . . . . 0.0 111.676 -175.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.7 pttt -130.68 140.51 38.89 Favored Pre-proline 0 C--N 1.3 -1.567 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 176.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -75.2 121.99 6.83 Favored 'Trans proline' 0 C--O 1.254 1.309 0 C-N-CA 121.86 1.707 . . . . 0.0 109.354 172.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -166.24 122.33 1.27 Allowed 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -178.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.444 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 20.1 m120 -94.17 123.89 37.84 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.213 -178.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.43 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -149.39 175.09 11.76 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 176.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.424 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 11.8 m -115.91 148.62 39.83 Favored 'General case' 0 N--CA 1.419 -2.013 0 CA-C-O 121.349 0.595 . . . . 0.0 110.589 -174.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -131.46 122.67 26.63 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 175.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.3 t -104.11 112.68 38.58 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.242 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 176.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -75.12 138.5 42.1 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 120.124 -0.63 . . . . 0.0 110.17 -177.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -167.41 174.53 42.56 Favored Glycine 0 N--CA 1.423 -2.202 0 N-CA-C 107.913 -2.075 . . . . 0.0 107.913 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 36.8 t30 79.58 -45.6 0.33 Allowed 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 124.91 1.284 . . . . 0.0 110.209 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.492 HE21 HG12 ' A' ' 60' ' ' ILE . 10.8 pt20 -158.18 153.16 21.32 Favored Pre-proline 0 N--CA 1.413 -2.303 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.581 178.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -72.34 131.03 17.05 Favored 'Trans proline' 0 N--CA 1.444 -1.418 0 N-CA-C 107.418 -1.801 . . . . 0.0 107.418 167.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.492 HG12 HE21 ' A' ' 58' ' ' GLN . 49.2 mt -108.47 124.3 64.79 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 C-N-CA 120.3 -0.56 . . . . 0.0 109.745 -174.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.0 p -76.44 127.8 37.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 176.151 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 37.1 p -106.3 167.99 9.45 Favored 'General case' 0 N--CA 1.416 -2.157 0 CA-C-O 121.264 0.554 . . . . 0.0 111.41 -173.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 18.2 mmt180 -114.96 143.9 44.43 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 55.4 mt -111.93 134.63 53.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 C-N-CA 120.384 -0.527 . . . . 0.0 111.913 -175.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.09 -23.32 3.9 Favored Glycine 0 C--N 1.32 -0.329 0 N-CA-C 116.344 1.298 . . . . 0.0 116.344 171.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.8 m -155.87 137.1 9.36 Favored Pre-proline 0 C--N 1.301 -1.54 0 CA-C-N 118.228 1.014 . . . . 0.0 110.118 -179.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -89.86 121.44 0.99 Allowed 'Trans proline' 0 N--CA 1.444 -1.416 0 C-N-CA 122.24 1.96 . . . . 0.0 112.168 175.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -163.27 170.25 17.94 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 104.414 -2.439 . . . . 0.0 104.414 178.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -82.41 -26.08 33.11 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.255 0.55 . . . . 0.0 110.294 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -107.09 25.7 11.06 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 122.396 1.093 . . . . 0.0 108.498 178.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -68.64 157.57 88.0 Favored Pre-proline 0 C--N 1.318 -0.791 0 CA-C-N 115.186 -0.916 . . . . 0.0 111.336 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -53.96 133.47 55.0 Favored 'Trans proline' 0 C--N 1.361 1.205 0 C-N-CA 123.274 2.65 . . . . 0.0 113.623 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.7 m -99.22 176.23 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.012 0 C-N-CA 124.626 1.17 . . . . 0.0 110.662 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.59 4.53 10.67 Favored Glycine 0 CA--C 1.498 -0.972 0 C-N-CA 121.13 -0.557 . . . . 0.0 111.732 -178.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -122.12 124.48 5.76 Favored Glycine 0 N--CA 1.419 -2.434 0 N-CA-C 108.401 -1.88 . . . . 0.0 108.401 174.026 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -128.62 126.79 40.96 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 117.881 0.841 . . . . 0.0 109.668 176.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 49.4 tp -97.58 114.7 65.28 Favored Pre-proline 0 C--N 1.301 -1.511 0 C-N-CA 122.346 0.258 . . . . 0.0 110.337 -177.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -73.1 160.21 46.03 Favored 'Trans proline' 0 C--O 1.243 0.763 0 C-N-CA 122.348 2.032 . . . . 0.0 111.185 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.31 153.86 35.54 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.4 10.42 79.93 Favored Glycine 0 C--N 1.313 -0.738 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -178.446 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.16 126.41 38.25 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 60.1 m -96.82 108.78 21.52 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 177.093 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.6 mm -108.69 119.29 58.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.636 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.1 p -99.74 107.77 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.37 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 174.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.444 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 44.4 p90 -98.32 163.86 12.53 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.282 -174.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -125.38 -11.17 6.9 Favored 'General case' 0 C--N 1.318 -0.768 0 O-C-N 123.443 0.464 . . . . 0.0 111.538 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.433 ' HB2' ' NH2' ' A' ' 106' ' ' ARG . 31.1 tt0 -126.39 124.17 39.6 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -175.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 40.6 t -112.59 120.8 63.6 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.491 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.604 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 26.4 p -130.96 152.23 50.5 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 120.328 -0.549 . . . . 0.0 112.377 -176.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.484 HG13 ' CZ3' ' A' ' 37' ' ' TRP . 76.5 mt -112.74 113.64 44.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.169 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.049 177.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.518 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -112.1 113.66 26.06 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 103.363 -2.828 . . . . 0.0 103.363 169.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.6 109.76 0.28 Allowed 'General case' 0 C--O 1.241 0.635 0 O-C-N 124.722 1.264 . . . . 0.0 113.21 -164.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 137.4 -36.74 1.92 Allowed Glycine 0 N--CA 1.424 -2.118 0 CA-C-N 113.636 -1.62 . . . . 0.0 109.185 -176.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 52.9 m80 -149.02 165.33 31.97 Favored 'General case' 0 CA--C 1.5 -0.946 0 O-C-N 122.478 -0.424 . . . . 0.0 109.911 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.5 tt -103.24 135.84 38.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 N-CA-C 104.491 -2.411 . . . . 0.0 104.491 171.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.604 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 49.4 m95 -119.25 135.23 54.79 Favored 'General case' 0 C--N 1.275 -2.646 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 -173.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.492 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 47.0 pt -100.5 132.38 46.25 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 177.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.94 124.64 8.14 Favored Glycine 0 N--CA 1.425 -2.085 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -137.72 164.83 27.89 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 29.1 p-10 -117.54 137.5 52.54 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.982 0.42 . . . . 0.0 110.615 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.412 ' HB3' ' OD1' ' A' ' 105' ' ' ASN . . . -91.12 174.64 7.3 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -66.88 -12.08 58.12 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 121.263 0.554 . . . . 0.0 112.131 -177.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -81.01 -12.7 59.31 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 87.82 9.11 71.91 Favored Glycine 0 CA--C 1.505 -0.583 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.995 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.412 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 18.2 p-10 -91.86 147.58 22.87 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.126 0.489 . . . . 0.0 110.165 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . 0.433 ' NH2' ' HB2' ' A' ' 87' ' ' GLU . 18.0 tpt180 -94.61 115.3 27.4 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -175.46 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 24.3 t -111.39 139.9 33.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -176.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.492 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 94.1 m-85 -118.47 132.32 56.24 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 123.641 0.776 . . . . 0.0 110.943 -178.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . 0.415 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 45.9 t -111.78 131.95 22.16 Favored Pre-proline 0 C--N 1.308 -1.201 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.363 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -70.69 -13.85 32.67 Favored 'Trans proline' 0 C--N 1.367 1.552 0 C-N-CA 123.311 2.674 . . . . 0.0 114.763 -176.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.31 35.9 m 38.86 -60.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.459 0 N-CA-C 119.072 2.99 . . . . 0.0 119.072 175.329 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 37.5 ptt180 -155.08 156.71 36.34 Favored 'General case' 0 C--O 1.248 0.977 0 O-C-N 121.894 -0.504 . . . . 0.0 109.717 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 25.3 m -64.54 136.78 57.39 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 174.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 65.3 m -149.67 128.05 12.19 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.727 0.775 . . . . 0.0 110.657 176.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -119.68 161.77 20.14 Favored 'General case' 0 C--N 1.286 -2.157 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.14 -167.13 12.85 Favored Glycine 0 C--N 1.286 -2.214 0 C-N-CA 118.918 -1.611 . . . . 0.0 112.284 177.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 24.6 m -140.91 147.33 47.66 Favored Pre-proline 0 C--N 1.306 -1.323 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.404 ' HB3' ' CG ' ' A' ' 37' ' ' TRP . 85.6 Cg_exo -48.63 136.1 27.18 Favored 'Trans proline' 0 CA--C 1.543 0.943 0 C-N-CA 123.24 2.627 . . . . 0.0 113.013 178.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -88.73 -19.72 15.55 Favored 'Cis proline' 0 CA--C 1.544 1.005 0 C-N-CA 123.779 -1.342 . . . . 0.0 113.176 -0.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 90.0 m-20 -77.34 102.2 6.66 Favored 'General case' 0 C--O 1.244 0.791 0 CA-C-O 122.244 1.021 . . . . 0.0 112.877 -172.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 32.4 p-80 -104.69 131.05 52.59 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 113.847 -1.524 . . . . 0.0 109.867 178.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.449 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 55.4 mt -96.66 108.6 43.7 Favored Pre-proline 0 C--N 1.286 -2.161 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -178.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -78.88 161.39 27.11 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.584 2.189 . . . . 0.0 112.521 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -134.74 -124.31 2.44 Favored Glycine 0 N--CA 1.437 -1.265 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 177.047 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.6 t -77.26 124.01 34.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 116.938 0.369 . . . . 0.0 110.795 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.5 151.32 19.44 Favored 'General case' 0 C--O 1.246 0.908 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.217 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.6 m-90 -124.98 29.64 6.09 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.93 178.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -169.4 -173.27 36.85 Favored Glycine 0 N--CA 1.434 -1.461 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 -179.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 47.4 t -114.63 115.28 49.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.164 0.507 . . . . 0.0 109.983 -178.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -83.72 130.19 34.95 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.007 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.424 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 1.6 tmtp? . . . . . 0 N--CA 1.421 -1.908 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 -176.083 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.3 m95 . . . . . 0 N--CA 1.432 -1.372 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.4 mptt -113.91 155.2 26.22 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 176.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -102.99 132.48 49.23 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.803 -0.759 . . . . 0.0 108.967 178.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.454 ' ND2' ' HB ' ' A' ' 44' ' ' THR . 38.7 p30 -86.5 178.19 7.17 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 175.222 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 -70.1 -23.12 63.0 Favored 'General case' 0 C--N 1.31 -1.134 0 CA-C-O 121.114 0.483 . . . . 0.0 111.144 -176.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.465 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 26.7 m-85 -74.87 -13.92 60.61 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.163 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.41 7.07 57.25 Favored Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.829 178.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.454 ' HB ' ' ND2' ' A' ' 40' ' ' ASN . 5.8 m -88.34 137.57 32.2 Favored 'General case' 0 N--CA 1.424 -1.755 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 92.2 m95 -96.44 122.29 39.17 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 176.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 54.4 p90 -123.58 152.34 41.97 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 120.869 0.366 . . . . 0.0 111.973 -174.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.0 ptmt -141.03 147.18 46.67 Favored Pre-proline 0 N--CA 1.433 -1.292 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 171.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -77.09 122.09 6.06 Favored 'Trans proline' 0 N--CA 1.445 -1.327 0 C-N-CA 121.492 1.461 . . . . 0.0 109.222 172.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.5 tp10 -153.35 125.74 8.09 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 -179.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.501 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 7.7 t30 -109.57 107.49 17.6 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.203 0.525 . . . . 0.0 111.098 -175.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.414 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -143.56 171.42 14.18 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.451 ' HB ' ' HB2' ' A' ' 131' ' ' LYS . 6.4 m -104.32 147.76 27.15 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -176.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -127.08 138.26 53.17 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 175.328 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.3 t -118.65 117.0 53.01 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 176.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.481 ' ND2' ' HA ' ' A' ' 79' ' ' ALA . 48.4 t30 -70.61 148.43 48.12 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.291 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -83.42 -132.7 2.05 Favored Glycine 0 N--CA 1.434 -1.471 0 N-CA-C 114.364 0.506 . . . . 0.0 114.364 -174.177 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -91.05 -4.32 56.45 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -171.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.4 ' HA ' ' HD3' ' A' ' 59' ' ' PRO . 0.8 OUTLIER -131.95 153.09 81.28 Favored Pre-proline 0 C--N 1.306 -1.285 0 C-N-CA 120.007 -0.677 . . . . 0.0 112.261 179.723 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.517 ' HB3' HD21 ' A' ' 76' ' ' ASN . 7.4 Cg_exo -74.76 136.72 21.31 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.056 1.837 . . . . 0.0 111.079 176.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 61.0 mt -107.81 133.63 52.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -177.483 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.9 p -82.09 137.53 20.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 177.09 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 54.7 p -117.07 179.03 4.14 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.565 -172.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.425 ' NH1' HG12 ' A' ' 73' ' ' VAL . 47.2 mmt-85 -122.05 144.3 48.99 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 59.1 mt -106.35 125.99 62.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.868 -177.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.51 -22.64 1.68 Allowed Glycine 0 CA--C 1.527 0.812 0 N-CA-C 116.569 1.388 . . . . 0.0 116.569 171.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.5 m -145.68 134.17 10.86 Favored Pre-proline 0 C--N 1.3 -1.558 0 CA-C-N 118.562 1.181 . . . . 0.0 110.315 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -90.08 120.41 0.86 Allowed 'Trans proline' 0 N--CA 1.441 -1.614 0 C-N-CA 121.732 1.622 . . . . 0.0 111.624 174.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.587 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 93.1 m-85 -168.16 175.54 6.51 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 104.873 -2.269 . . . . 0.0 104.873 178.528 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -81.85 -45.3 15.7 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 176.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -94.04 25.93 3.48 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.108 -0.951 . . . . 0.0 111.151 -178.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.587 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.55 162.9 71.75 Favored Pre-proline 0 C--N 1.317 -0.835 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.468 178.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_exo -48.87 123.31 9.54 Favored 'Trans proline' 0 C--N 1.369 1.652 0 C-N-CA 123.537 2.825 . . . . 0.0 114.158 179.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.425 HG12 ' NH1' ' A' ' 63' ' ' ARG . 31.2 m -97.55 174.38 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.184 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.34 28.8 1.89 Allowed Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -150.94 126.61 2.16 Favored Glycine 0 N--CA 1.428 -1.896 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.517 HD21 ' HB3' ' A' ' 59' ' ' PRO . 8.0 t30 -127.39 136.79 52.35 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 57.2 tp -97.45 115.64 65.77 Favored Pre-proline 0 C--N 1.302 -1.463 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -59.24 152.67 58.4 Favored 'Trans proline' 0 C--O 1.245 0.856 0 C-N-CA 123.005 2.47 . . . . 0.0 112.609 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . 0.481 ' HA ' ' ND2' ' A' ' 55' ' ' ASN . . . -73.42 139.97 46.22 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.13 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.74 -4.82 77.71 Favored Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 116.113 -0.494 . . . . 0.0 113.108 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.93 134.06 40.34 Favored 'General case' 0 N--CA 1.439 -1.018 0 CA-C-O 120.774 0.321 . . . . 0.0 110.893 -177.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 14.6 t -108.0 134.66 50.59 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 177.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 44.6 mm -132.05 140.14 48.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -177.223 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.5 p -103.96 113.41 40.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-O 121.965 0.888 . . . . 0.0 109.582 175.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.501 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 43.2 p90 -97.15 152.95 18.3 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.417 -175.019 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -119.77 4.28 11.04 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.657 0.741 . . . . 0.0 110.345 -178.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -142.06 132.96 25.83 Favored 'General case' 0 N--CA 1.426 -1.656 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.391 -175.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.8 t -124.68 128.27 73.31 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.452 ' HB2' HG22 ' A' ' 44' ' ' THR . 20.5 p -139.49 140.83 37.33 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-O 121.236 0.541 . . . . 0.0 111.421 -178.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.468 HG21 ' HA3' ' A' ' 116' ' ' GLY . 75.1 mt -101.03 114.87 41.51 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.731 179.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.586 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 50.0 tp60 -116.04 127.63 55.05 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 104.813 -2.292 . . . . 0.0 104.813 173.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.04 110.93 0.37 Allowed 'General case' 0 C--O 1.243 0.731 0 N-CA-C 113.275 0.842 . . . . 0.0 113.275 -167.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 124.23 -28.87 5.22 Favored Glycine 0 N--CA 1.438 -1.183 0 CA-C-N 114.498 -1.228 . . . . 0.0 112.729 179.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 74.8 m80 -151.12 169.9 20.74 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -176.342 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 19.0 tt -110.96 128.0 67.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.095 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 172.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.586 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 65.2 m95 -110.46 131.14 55.32 Favored 'General case' 0 C--N 1.274 -2.692 0 CA-C-O 120.966 0.412 . . . . 0.0 110.196 -173.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.505 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.5 pt -100.3 134.61 39.4 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.96 128.14 9.32 Favored Glycine 0 N--CA 1.428 -1.879 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 -178.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -151.38 163.93 37.85 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -97.77 116.81 30.72 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 174.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.09 178.25 6.5 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.999 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 46.5 p90 -47.49 -27.93 1.97 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 126.044 1.737 . . . . 0.0 113.858 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -99.27 2.42 45.54 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 112.222 0.453 . . . . 0.0 112.222 -175.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.85 0.67 81.07 Favored Glycine 0 C--N 1.32 -0.329 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.158 176.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -81.03 135.89 35.9 Favored 'General case' 0 C--N 1.306 -1.32 0 O-C-N 122.651 -0.323 . . . . 0.0 111.038 -178.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 4.1 tpp180 -75.29 102.24 4.99 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 173.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 67.6 t -108.27 143.87 17.89 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.029 0 CA-C-N 114.674 -1.148 . . . . 0.0 109.725 -174.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.505 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 96.5 m-85 -117.74 124.08 47.58 Favored 'General case' 0 N--CA 1.426 -1.647 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.273 178.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.8 t -104.13 133.71 20.08 Favored Pre-proline 0 C--N 1.298 -1.673 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -68.71 -22.88 36.76 Favored 'Trans proline' 0 C--N 1.359 1.115 0 C-N-CA 122.967 2.445 . . . . 0.0 113.472 -177.253 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.295 34.2 m 46.99 -53.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.207 0 N-CA-C 118.41 2.744 . . . . 0.0 118.41 175.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.526 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 38.9 ptt180 -158.93 156.77 30.11 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 122.832 0.453 . . . . 0.0 110.553 -178.298 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 2.6 p -72.83 136.99 45.46 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 175.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.429 ' SG ' ' HG3' ' A' ' 112' ' ' ARG . 96.1 m -154.37 133.04 12.16 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.838 0.352 . . . . 0.0 111.54 -178.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 29.9 mm-40 -97.11 113.38 24.95 Favored 'General case' 0 N--CA 1.427 -1.595 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 171.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.468 ' HA3' HG21 ' A' ' 90' ' ' ILE . . . -122.01 113.96 2.39 Favored Glycine 0 C--N 1.259 -3.697 0 C-N-CA 119.779 -1.201 . . . . 0.0 114.014 -173.577 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 7.0 m -125.97 97.14 35.91 Favored Pre-proline 0 C--N 1.293 -1.878 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 172.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 61.9 Cg_exo -42.84 130.77 5.66 Favored 'Trans proline' 0 C--N 1.357 0.994 0 C-N-CA 124.327 3.351 . . . . 0.0 114.774 -170.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 7.4 Cg_endo -92.71 8.0 59.8 Favored 'Cis proline' 0 CA--C 1.549 1.236 0 C-N-CA 124.412 -1.078 . . . . 0.0 113.046 1.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -74.93 102.03 4.64 Favored 'General case' 0 CA--C 1.508 -0.672 0 CA-C-O 121.563 0.697 . . . . 0.0 110.229 -175.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.422 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 37.4 p-80 -104.78 107.03 17.77 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.592 177.429 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.5 mt -100.2 100.44 11.77 Favored Pre-proline 0 C--N 1.318 -0.791 0 C-N-CA 122.703 0.401 . . . . 0.0 109.925 -177.166 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . 0.422 ' HD3' ' O ' ' A' ' 121' ' ' HIS . 2.9 Cg_endo -81.48 150.69 17.15 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 122.774 2.316 . . . . 0.0 113.265 -178.209 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.45 -116.13 3.3 Favored Glycine 0 N--CA 1.423 -2.228 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 175.022 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.3 t -97.39 124.45 50.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-O 120.801 0.334 . . . . 0.0 110.426 -176.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.526 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -95.02 146.88 23.96 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.708 177.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.7 m-90 -101.49 12.82 36.63 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 121.555 0.693 . . . . 0.0 109.246 177.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.74 179.24 37.24 Favored Glycine 0 N--CA 1.43 -1.705 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 49.4 t -112.08 137.79 43.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.398 -0.594 . . . . 0.0 109.398 -176.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -102.27 135.52 43.72 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-O 120.954 0.407 . . . . 0.0 110.11 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.451 ' HB2' ' HB ' ' A' ' 52' ' ' THR . 55.9 mtpt . . . . . 0 C--N 1.295 -1.776 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 47.8 m95 . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 109.13 -0.692 . . . . 0.0 109.13 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.407 ' O ' ' HA ' ' A' ' 45' ' ' TRP . 47.9 mmtm -113.32 149.94 33.24 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.601 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -101.52 122.05 43.1 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-O 121.123 0.487 . . . . 0.0 111.086 -175.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -88.62 155.14 19.79 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 175.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -63.47 -20.51 65.65 Favored 'General case' 0 CA--C 1.546 0.815 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -175.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -75.64 5.2 6.41 Favored 'General case' 0 CA--C 1.542 0.665 0 CA-C-O 121.225 0.536 . . . . 0.0 110.994 176.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.07 22.67 70.75 Favored Glycine 0 CA--C 1.496 -1.121 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.424 HG22 ' HB2' ' A' ' 89' ' ' CYS . 48.0 m -105.42 128.03 53.31 Favored 'General case' 0 N--CA 1.416 -2.127 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 -179.213 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.531 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 84.5 m95 -95.34 120.84 36.27 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 177.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -121.87 150.64 41.65 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.824 0.345 . . . . 0.0 111.66 -175.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 52.0 pttt -135.57 135.48 22.2 Favored Pre-proline 0 C--N 1.299 -1.623 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 173.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -70.78 125.68 11.86 Favored 'Trans proline' 0 C--O 1.249 1.057 0 C-N-CA 121.764 1.643 . . . . 0.0 109.933 174.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -165.7 120.39 1.24 Allowed 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.541 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 25.7 t-20 -102.08 107.86 19.1 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.481 0.658 . . . . 0.0 111.114 -175.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -143.18 179.47 7.04 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.524 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 42.0 m -115.59 150.13 37.15 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.048 0.451 . . . . 0.0 110.641 -177.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 82.6 t80 -131.71 127.5 36.98 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 175.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.8 t -111.4 106.19 20.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -71.48 152.31 43.16 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -156.02 -41.14 0.02 OUTLIER Glycine 0 N--CA 1.435 -1.423 0 C-N-CA 118.589 -1.767 . . . . 0.0 115.16 -177.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 45.0 t30 -71.21 -49.02 47.84 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 117.406 0.603 . . . . 0.0 112.538 -172.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -146.86 153.64 46.35 Favored Pre-proline 0 C--N 1.305 -1.335 0 C-N-CA 119.979 -0.688 . . . . 0.0 110.385 -176.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_exo -65.66 123.18 11.03 Favored 'Trans proline' 0 C--O 1.248 1.019 0 C-N-CA 121.76 1.64 . . . . 0.0 108.411 170.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 55.1 mt -107.18 125.03 63.38 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 -173.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 9.9 p -76.52 119.93 25.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 43.2 p -95.43 151.46 19.27 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.236 -175.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -102.44 137.19 41.01 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -175.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.1 mt -106.0 135.12 45.5 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.922 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -171.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.66 -23.45 5.69 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 116.405 1.322 . . . . 0.0 116.405 170.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 51.3 m -157.63 142.19 11.86 Favored Pre-proline 0 C--N 1.307 -1.254 0 CA-C-N 118.102 0.951 . . . . 0.0 109.524 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -90.05 119.54 0.8 Allowed 'Trans proline' 0 N--CA 1.439 -1.695 0 C-N-CA 121.559 1.506 . . . . 0.0 111.193 175.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.405 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 57.5 m-85 -168.38 165.77 12.63 Favored 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 126.16 1.784 . . . . 0.0 106.321 -179.344 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 89.8 mt -85.25 -14.62 46.14 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 175.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -106.95 13.59 27.47 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.52 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.405 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.88 155.61 90.46 Favored Pre-proline 0 C--N 1.314 -0.973 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.021 -177.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -56.52 140.6 89.81 Favored 'Trans proline' 0 C--N 1.364 1.364 0 C-N-CA 123.6 2.867 . . . . 0.0 114.626 -178.079 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 33.3 m -97.81 175.63 0.79 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.747 0 C-N-CA 124.668 1.187 . . . . 0.0 110.609 178.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 121.0 -9.17 10.41 Favored Glycine 0 CA--C 1.496 -1.101 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 -178.698 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.89 126.97 9.07 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 108.198 -1.961 . . . . 0.0 108.198 172.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.9 t30 -128.26 125.3 38.61 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 118.057 0.929 . . . . 0.0 110.468 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 54.4 tp -96.84 108.5 43.62 Favored Pre-proline 0 C--N 1.296 -1.755 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.005 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -67.73 159.14 54.04 Favored 'Trans proline' 0 C--O 1.245 0.86 0 C-N-CA 122.389 2.06 . . . . 0.0 112.104 178.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.3 136.46 39.61 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.51 -2.38 64.93 Favored Glycine 0 C--N 1.31 -0.883 0 N-CA-C 111.664 -0.574 . . . . 0.0 111.664 -179.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.59 134.37 37.22 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-O 120.845 0.355 . . . . 0.0 111.711 -177.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 22.1 m -98.73 109.05 21.87 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.155 -0.93 . . . . 0.0 108.837 178.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 43.0 mm -110.78 135.35 50.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.45 -177.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.3 p -108.51 129.8 62.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 176.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.541 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 48.4 p90 -124.65 151.9 44.33 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -177.049 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.416 ' HA ' ' HA ' ' A' ' 50' ' ' ASN . 3.9 p30 -114.81 4.93 15.06 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 120.864 0.364 . . . . 0.0 110.537 -179.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -148.15 139.64 23.61 Favored 'General case' 0 N--CA 1.428 -1.562 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.383 -176.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 41.5 t -120.38 128.19 75.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 N-CA-C 105.725 -1.954 . . . . 0.0 105.725 175.514 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.424 ' HB2' HG22 ' A' ' 44' ' ' THR . 8.7 p -139.91 143.37 36.62 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -175.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 67.8 mt -105.66 117.24 51.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.094 0.473 . . . . 0.0 110.751 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.512 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 6.1 tp-100 -115.66 113.52 23.64 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 103.021 -2.955 . . . . 0.0 103.021 168.154 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.59 115.88 1.4 Allowed 'General case' 0 CA--C 1.512 -0.512 0 O-C-N 124.458 1.099 . . . . 0.0 113.189 -165.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 133.02 -39.11 1.78 Allowed Glycine 0 N--CA 1.419 -2.459 0 CA-C-N 113.642 -1.617 . . . . 0.0 109.066 -176.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 64.4 m80 -148.16 161.15 42.03 Favored 'General case' 0 CA--C 1.506 -0.72 0 C-N-CA 122.921 0.488 . . . . 0.0 110.363 -179.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.454 ' O ' HG22 ' A' ' 111' ' ' VAL . 16.0 tt -106.75 121.44 59.47 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 175.201 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.512 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 52.9 m95 -104.77 138.25 41.33 Favored 'General case' 0 C--N 1.279 -2.469 0 CA-C-O 120.868 0.366 . . . . 0.0 110.881 -170.345 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.5 pt -100.34 132.51 45.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 175.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.14 116.07 5.45 Favored Glycine 0 N--CA 1.431 -1.67 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -178.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -136.08 175.25 9.77 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -115.29 127.42 55.44 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 177.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.28 -179.42 6.97 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.5 p90 -68.0 -20.39 65.02 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 118.488 0.585 . . . . 0.0 112.432 -176.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 59.3 t30 -73.7 -12.29 60.67 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-O 121.637 0.732 . . . . 0.0 109.532 175.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 92.26 -12.43 69.66 Favored Glycine 0 CA--C 1.501 -0.786 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.627 178.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -72.57 147.67 45.67 Favored 'General case' 0 C--O 1.253 1.245 0 C-N-CA 123.252 0.621 . . . . 0.0 109.841 -175.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.3 tpt180 -80.66 108.29 14.19 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 124.539 1.136 . . . . 0.0 108.414 -178.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 38.2 t -112.32 145.99 17.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 -176.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.463 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 91.9 m-85 -121.49 130.86 53.81 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.038 0.447 . . . . 0.0 110.671 -177.251 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . 0.464 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 52.5 t -109.11 130.49 22.67 Favored Pre-proline 0 C--N 1.304 -1.396 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 177.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -70.07 -14.15 34.76 Favored 'Trans proline' 0 C--O 1.21 -0.883 0 C-N-CA 122.962 2.442 . . . . 0.0 114.564 -177.194 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.454 HG22 ' O ' ' A' ' 95' ' ' ILE 0.295 21.5 m 43.29 -54.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.518 2.949 0 N-CA-C 118.431 2.752 . . . . 0.0 118.431 176.173 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.404 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 12.1 ptm180 -156.09 150.43 25.64 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 55.1 m -64.31 144.68 56.97 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 177.004 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.448 ' SG ' ' HB2' ' A' ' 121' ' ' HIS . 27.0 t -161.16 134.18 6.35 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-O 120.954 0.407 . . . . 0.0 110.738 -178.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -123.81 160.92 26.31 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 176.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.62 178.04 15.48 Favored Glycine 0 N--CA 1.423 -2.195 0 C-N-CA 119.055 -1.545 . . . . 0.0 113.455 174.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 16.5 m -128.39 128.12 23.64 Favored Pre-proline 0 C--N 1.3 -1.574 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.531 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 64.5 Cg_exo -48.46 139.63 22.54 Favored 'Trans proline' 0 C--O 1.237 0.459 0 C-N-CA 123.433 2.755 . . . . 0.0 113.788 -179.294 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -81.15 -18.71 24.29 Favored 'Cis proline' 0 C--O 1.246 0.91 0 C-N-CA 123.581 -1.424 . . . . 0.0 114.018 0.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -70.67 102.0 2.19 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 122.053 0.93 . . . . 0.0 112.665 -172.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.448 ' HB2' ' SG ' ' A' ' 114' ' ' CYS . 48.8 p-80 -104.64 130.35 52.67 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-N 114.65 -1.159 . . . . 0.0 110.188 178.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 60.9 mt -96.49 114.32 64.18 Favored Pre-proline 0 C--N 1.301 -1.524 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -75.88 162.27 35.08 Favored 'Trans proline' 0 C--O 1.245 0.862 0 C-N-CA 122.571 2.181 . . . . 0.0 113.181 -179.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.85 -164.31 11.0 Favored Glycine 0 N--CA 1.433 -1.535 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 177.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.1 t -52.84 115.97 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.818 0.847 . . . . 0.0 112.562 -176.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.404 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -93.85 148.85 21.75 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.248 177.434 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.9 m-90 -111.17 10.91 21.86 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-O 121.103 0.478 . . . . 0.0 111.252 178.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.5 -175.9 33.03 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.665 -178.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 54.7 t -111.33 138.98 37.53 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -176.205 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -101.22 147.49 26.21 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-O 120.597 0.237 . . . . 0.0 110.396 -178.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.2 mtpt . . . . . 0 C--O 1.26 1.621 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 175.087 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 93.1 m95 . . . . . 0 N--CA 1.437 -1.078 0 CA-C-O 121.158 0.504 . . . . 0.0 109.715 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -113.92 141.95 46.74 Favored 'General case' 0 C--N 1.286 -2.169 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 -177.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 66.1 tttm -100.2 144.51 29.13 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 119.681 -0.808 . . . . 0.0 110.138 -179.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 33.0 p30 -114.73 -179.18 3.55 Favored 'General case' 0 C--O 1.254 1.326 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.545 175.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -81.51 0.63 37.09 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -175.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -91.79 -0.77 57.55 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 121.846 0.832 . . . . 0.0 109.073 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.95 19.65 74.76 Favored Glycine 0 CA--C 1.5 -0.885 0 CA-C-N 115.235 -0.893 . . . . 0.0 111.191 -179.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.447 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 28.3 m -105.65 141.13 37.64 Favored 'General case' 0 N--CA 1.41 -2.458 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 -179.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.543 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 63.3 m95 -104.64 125.3 50.62 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 174.008 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -127.42 145.07 50.95 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-O 120.729 0.3 . . . . 0.0 110.614 -176.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.445 ' CG ' ' HB ' ' A' ' 88' ' ' VAL . 21.1 ptmt -124.86 132.78 24.37 Favored Pre-proline 0 C--N 1.294 -1.836 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 176.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -76.05 121.06 5.98 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 121.458 1.438 . . . . 0.0 109.555 174.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -166.71 120.91 1.07 Allowed 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.421 ' HA ' ' HA ' ' A' ' 86' ' ' ASP . 24.4 t-20 -95.43 120.2 35.25 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.091 -175.092 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.72 164.18 35.93 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 51.2 m -103.83 149.18 25.29 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.933 -177.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.5 t80 -126.42 134.13 51.08 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 177.257 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.8 t -114.2 118.11 57.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.923 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 49.9 t-20 -68.62 130.68 43.54 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -95.58 -68.29 1.01 Allowed Glycine 0 N--CA 1.421 -2.344 0 C-N-CA 120.005 -1.093 . . . . 0.0 114.253 -172.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -135.31 14.4 3.5 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -170.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.499 ' HB2' ' HB3' ' A' ' 127' ' ' TRP . 0.0 OUTLIER -135.48 122.07 14.47 Favored Pre-proline 0 C--N 1.298 -1.642 0 C-N-CA 119.729 -0.788 . . . . 0.0 112.949 -177.802 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -67.22 120.66 7.74 Favored 'Trans proline' 0 N--CA 1.447 -1.209 0 N-CA-C 105.767 -2.436 . . . . 0.0 105.767 167.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.495 HG13 ' O ' ' A' ' 58' ' ' GLN . 49.4 mt -113.58 120.74 64.24 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.057 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.639 -171.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -73.84 122.78 27.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 176.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 44.8 p -102.42 170.35 8.11 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.884 -173.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -117.47 149.28 40.85 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 2.8 mp -111.58 133.19 58.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 121.082 0.468 . . . . 0.0 111.111 -178.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 84.29 -24.11 6.59 Favored Glycine 0 C--N 1.315 -0.615 0 N-CA-C 115.861 1.104 . . . . 0.0 115.861 171.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 65.5 m -160.46 146.67 11.67 Favored Pre-proline 0 C--N 1.311 -1.068 0 CA-C-N 118.216 1.008 . . . . 0.0 110.144 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.405 ' HG2' HG21 ' A' ' 44' ' ' THR . 58.9 Cg_endo -89.82 119.9 0.87 Allowed 'Trans proline' 0 N--CA 1.44 -1.638 0 C-N-CA 121.771 1.647 . . . . 0.0 111.732 175.221 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.458 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 88.2 m-85 -169.89 177.66 4.3 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 103.487 -2.782 . . . . 0.0 103.487 -179.082 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -89.95 -37.47 14.34 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 171.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -89.14 25.48 1.85 Allowed 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 114.751 -1.113 . . . . 0.0 111.138 -177.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.458 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -84.49 161.38 54.22 Favored Pre-proline 0 C--N 1.306 -1.309 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 178.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -47.66 135.12 21.98 Favored 'Trans proline' 0 C--N 1.364 1.35 0 C-N-CA 123.715 2.943 . . . . 0.0 114.722 -178.286 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 18.0 m -90.42 173.92 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 114.362 -1.29 . . . . 0.0 110.636 -178.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.86 28.53 2.04 Favored Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.535 177.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -151.08 128.59 2.64 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 120.001 -1.095 . . . . 0.0 112.567 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -128.12 127.76 43.61 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.751 -1.204 . . . . 0.0 107.751 173.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 55.0 tp -101.41 109.9 60.15 Favored Pre-proline 0 C--N 1.301 -1.509 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 178.151 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.22 154.06 51.54 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 122.46 2.107 . . . . 0.0 112.515 -178.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.53 141.48 51.9 Favored 'General case' 0 N--CA 1.438 -1.045 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.855 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.0 -7.13 67.14 Favored Glycine 0 N--CA 1.435 -1.412 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.618 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.04 136.56 34.45 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.902 0.351 . . . . 0.0 111.366 -178.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 47.6 m -103.77 112.9 26.05 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.7 mm -127.27 133.77 67.35 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -176.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 11.6 p -93.3 135.19 28.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.417 ' HA ' ' HB3' ' A' ' 99' ' ' TYR . 52.7 p90 -118.18 159.55 23.11 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -178.492 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.421 ' HA ' ' HA ' ' A' ' 50' ' ' ASN . 4.9 p-10 -130.12 -7.78 4.35 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 112.367 0.506 . . . . 0.0 112.367 -177.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.466 ' HG2' ' SG ' ' A' ' 89' ' ' CYS . 29.4 tt0 -131.36 120.83 23.67 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 -176.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.445 ' HB ' ' CG ' ' A' ' 47' ' ' LYS . 39.9 t -105.67 119.07 54.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.466 ' SG ' ' HG2' ' A' ' 87' ' ' GLU . 46.9 m -123.23 133.2 54.22 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -172.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 56.6 mt -97.7 113.86 33.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 CA-C-O 121.291 0.567 . . . . 0.0 109.942 173.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.507 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -121.42 134.04 55.09 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 172.145 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.62 117.05 1.84 Allowed 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 114.081 1.141 . . . . 0.0 114.081 -164.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 107.96 -22.61 27.33 Favored Glycine 0 N--CA 1.431 -1.681 0 CA-C-N 115.115 -0.948 . . . . 0.0 112.426 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . 0.438 ' HB2' ' NE1' ' A' ' 96' ' ' TRP . 57.9 m80 -144.45 169.22 18.36 Favored 'General case' 0 CA--C 1.509 -0.626 0 O-C-N 122.108 -0.642 . . . . 0.0 110.445 -176.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.6 tt -126.09 109.58 21.74 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.152 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 173.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.507 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 42.5 m95 -95.27 138.91 32.33 Favored 'General case' 0 C--N 1.279 -2.48 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.563 -167.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.453 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.8 pt -100.58 127.74 53.35 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 176.498 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.88 127.93 9.37 Favored Glycine 0 N--CA 1.421 -2.307 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . 0.417 ' HB3' ' HA ' ' A' ' 85' ' ' TYR . 41.3 p90 -142.63 150.46 40.3 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -102.08 119.15 38.33 Favored 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.411 ' HB3' ' OD1' ' A' ' 105' ' ' ASN . . . -87.19 168.12 13.51 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 120.954 0.407 . . . . 0.0 110.838 -177.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -52.88 -25.52 11.93 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.397 1.479 . . . . 0.0 112.897 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -83.69 -3.44 57.77 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.454 0.645 . . . . 0.0 110.497 -176.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.19 7.07 73.88 Favored Glycine 0 CA--C 1.501 -0.8 0 CA-C-O 121.422 0.456 . . . . 0.0 112.038 176.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.411 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 13.8 p-10 -94.66 130.21 41.24 Favored 'General case' 0 C--N 1.29 -1.991 0 C-N-CA 123.147 0.579 . . . . 0.0 111.008 -177.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 26.6 tpt180 -84.1 102.93 12.9 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 178.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.8 t -97.71 139.34 20.22 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -173.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.453 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 79.0 m-85 -119.69 122.55 41.72 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 123.336 0.654 . . . . 0.0 109.725 177.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . 0.424 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 48.6 t -111.38 130.87 22.62 Favored Pre-proline 0 C--N 1.305 -1.369 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.032 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.1 -27.41 41.98 Favored 'Trans proline' 0 C--N 1.355 0.884 0 C-N-CA 122.815 2.343 . . . . 0.0 114.112 -176.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.303 18.9 m 51.19 -42.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.505 0 N-CA-C 118.446 2.758 . . . . 0.0 118.446 176.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.53 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 37.9 ptt180 -161.5 165.08 29.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-O 121.112 0.482 . . . . 0.0 110.634 -179.409 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.5 m -75.93 139.72 41.74 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 176.205 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 49.5 t -155.97 128.01 7.51 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.47 0.652 . . . . 0.0 110.962 178.209 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . 0.457 ' HA ' ' OE1' ' A' ' 115' ' ' GLN . 7.9 mm-40 -121.69 162.45 20.72 Favored 'General case' 0 C--N 1.288 -2.106 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.493 177.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 124.58 -174.38 17.07 Favored Glycine 0 N--CA 1.418 -2.51 0 C-N-CA 119.947 -1.121 . . . . 0.0 112.021 177.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 18.9 m -131.87 133.22 23.82 Favored Pre-proline 0 C--N 1.3 -1.549 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.508 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.543 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 88.2 Cg_exo -48.74 137.13 27.34 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 123.332 2.688 . . . . 0.0 113.417 -178.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 11.7 Cg_endo -91.09 1.09 64.32 Favored 'Cis proline' 0 C--O 1.245 0.86 0 C-N-CA 123.584 -1.423 . . . . 0.0 113.079 1.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -80.7 100.18 8.58 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 121.76 0.791 . . . . 0.0 110.36 -173.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.436 ' HB2' ' SG ' ' A' ' 114' ' ' CYS . 47.1 p-80 -105.5 131.33 53.03 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 114.606 -1.179 . . . . 0.0 112.098 -177.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.456 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.1 mm -105.74 99.8 23.83 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 178.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -84.96 139.69 7.47 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.391 2.061 . . . . 0.0 112.29 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -102.39 -133.01 7.89 Favored Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 177.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 61.5 t -82.97 129.3 37.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 110.129 -0.322 . . . . 0.0 110.129 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.53 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -93.62 143.82 25.96 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.823 176.543 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . 0.499 ' HB3' ' HB2' ' A' ' 58' ' ' GLN . 4.8 m0 -101.99 12.59 36.66 Favored 'General case' 0 C--O 1.251 1.154 0 CA-C-O 122.031 0.92 . . . . 0.0 110.345 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.63 179.59 36.92 Favored Glycine 0 N--CA 1.426 -1.99 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.936 -179.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.5 t -113.54 134.97 54.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -177.012 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -87.62 122.1 30.89 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? . . . . . 0 C--N 1.291 -1.943 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.866 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 73.0 m95 . . . . . 0 N--CA 1.443 -0.822 0 CA-C-O 120.88 0.371 . . . . 0.0 110.296 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.464 ' HE3' ' HA ' ' A' ' 38' ' ' LYS . 0.0 OUTLIER -131.93 146.68 52.25 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 174.881 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -93.77 133.6 36.98 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 -178.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 33.3 p30 -96.84 176.81 5.85 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 175.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -77.22 1.75 17.56 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.515 0.674 . . . . 0.0 112.214 -175.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.7 m-85 -98.72 7.9 45.56 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.139 178.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.19 17.51 77.41 Favored Glycine 0 C--N 1.338 0.65 0 CA-C-N 115.128 -0.942 . . . . 0.0 112.32 177.14 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.45 HG21 ' HG2' ' A' ' 67' ' ' PRO . 5.3 m -105.01 141.9 35.76 Favored 'General case' 0 N--CA 1.42 -1.937 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -177.341 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.454 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 87.5 m95 -96.46 129.18 43.87 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.41 ' HA ' ' O ' ' A' ' 88' ' ' VAL . 51.8 p90 -125.89 150.28 48.04 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 123.199 0.312 . . . . 0.0 110.383 -178.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 14.1 ptmm? -135.66 148.06 63.98 Favored Pre-proline 0 C--N 1.303 -1.43 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 175.377 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -71.24 128.86 15.21 Favored 'Trans proline' 0 N--CA 1.444 -1.386 0 C-N-CA 121.27 1.313 . . . . 0.0 109.013 170.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.448 ' HB3' HG23 ' A' ' 88' ' ' VAL . 9.2 tp10 -162.64 120.18 2.04 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.526 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 6.6 t30 -105.87 113.48 27.06 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.684 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.413 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.55 175.62 12.57 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 89.0 m -118.9 133.19 56.0 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 120.253 -0.579 . . . . 0.0 112.32 -176.702 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -107.89 129.11 55.11 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 176.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.1 t -110.35 115.1 48.88 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 176.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -69.16 148.64 49.63 Favored 'General case' 0 C--N 1.309 -1.178 0 O-C-N 123.408 0.442 . . . . 0.0 110.466 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -81.58 -144.76 4.55 Favored Glycine 0 N--CA 1.43 -1.756 0 CA-C-N 115.998 -0.547 . . . . 0.0 113.84 -177.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 31.2 p-10 -85.65 12.22 9.23 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 -171.702 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.439 ' HA ' ' HD3' ' A' ' 59' ' ' PRO . 0.8 OUTLIER -142.4 143.46 27.04 Favored Pre-proline 0 C--N 1.301 -1.516 0 C-N-CA 120.592 -0.443 . . . . 0.0 112.065 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 58' ' ' GLN . 12.8 Cg_exo -71.98 131.75 18.69 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.138 1.892 . . . . 0.0 111.437 177.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -107.58 132.7 54.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.037 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.5 p -79.97 136.2 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 176.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 53.4 p -111.98 167.03 10.71 Favored 'General case' 0 C--N 1.287 -2.138 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.651 -175.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.415 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 21.7 mmt180 -114.68 137.14 52.26 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.7 mt -93.33 123.85 45.57 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 CA-C-N 115.396 -0.82 . . . . 0.0 113.156 -172.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.79 -23.19 3.75 Favored Glycine 0 C--O 1.237 0.291 0 N-CA-C 115.906 1.123 . . . . 0.0 115.906 172.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.408 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 50.7 m -151.7 144.53 16.96 Favored Pre-proline 0 C--N 1.306 -1.288 0 CA-C-N 118.53 1.165 . . . . 0.0 111.54 -177.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.45 ' HG2' HG21 ' A' ' 44' ' ' THR . 1.2 Cg_endo -89.35 120.95 1.06 Allowed 'Trans proline' 0 N--CA 1.448 -1.168 0 C-N-CA 122.457 2.105 . . . . 0.0 110.597 173.245 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.567 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 59.6 m-85 -168.53 170.43 9.66 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 126.355 1.862 . . . . 0.0 106.322 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 95.8 mt -82.51 -30.96 29.48 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 172.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 17.6 m120 -102.97 26.22 8.42 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.732 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.567 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -75.2 156.79 85.58 Favored Pre-proline 0 C--N 1.308 -1.198 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.397 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -50.7 131.44 33.47 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 123.651 2.901 . . . . 0.0 113.48 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 6.8 p -101.31 174.17 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 C-N-CA 124.051 0.94 . . . . 0.0 108.928 -176.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.44 -4.74 13.36 Favored Glycine 0 N--CA 1.443 -0.84 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.023 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -110.81 123.78 6.71 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 177.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -122.09 134.48 54.77 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 117.356 0.578 . . . . 0.0 110.139 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.5 tp -100.83 118.87 59.79 Favored Pre-proline 0 C--N 1.308 -1.217 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -66.62 160.06 47.96 Favored 'Trans proline' 0 C--O 1.243 0.764 0 C-N-CA 122.478 2.119 . . . . 0.0 112.709 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.56 136.65 47.56 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.666 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.64 1.49 90.53 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 121.423 -0.418 . . . . 0.0 113.365 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.59 127.09 31.05 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.179 0.514 . . . . 0.0 111.861 -177.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 46.2 m -96.97 109.0 21.84 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 177.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.3 mm -118.79 120.8 65.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.096 -174.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.6 p -89.06 127.46 41.77 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.134 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.526 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 48.5 p90 -116.43 154.55 30.11 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -178.509 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -120.31 4.93 10.74 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-O 121.469 0.652 . . . . 0.0 110.561 -179.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -147.45 140.7 25.24 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.713 -175.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.448 HG23 ' HB3' ' A' ' 49' ' ' GLU . 86.7 t -124.04 133.19 69.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 176.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.544 ' HG ' ' HE2' ' A' ' 108' ' ' TYR . 61.5 m -130.27 135.18 47.83 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 122.315 0.246 . . . . 0.0 111.369 -176.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.4 mt -103.03 111.84 34.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 176.199 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.1 tp-100 -115.69 145.1 43.05 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 105.448 -2.056 . . . . 0.0 105.448 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.37 104.81 0.08 Allowed 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -174.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 115.31 -30.89 6.48 Favored Glycine 0 N--CA 1.434 -1.456 0 CA-C-N 115.61 -0.723 . . . . 0.0 113.836 177.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 64.0 m80 -145.46 150.97 37.47 Favored 'General case' 0 CA--C 1.504 -0.827 0 CA-C-N 118.196 0.998 . . . . 0.0 110.743 -175.018 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.8 tt -106.41 111.78 36.78 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 176.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 47.9 m95 -95.87 148.43 22.62 Favored 'General case' 0 C--N 1.285 -2.233 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.424 -169.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.5 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.4 pt -107.34 139.23 29.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.411 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -106.49 121.46 6.65 Favored Glycine 0 N--CA 1.431 -1.675 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -135.65 167.96 20.15 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.667 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -102.42 131.06 49.32 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.891 179.088 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -83.51 175.52 9.73 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 173.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 29.9 p90 -53.37 -36.24 61.19 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -178.499 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 25.6 p-10 -88.63 1.91 54.15 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 120.68 0.276 . . . . 0.0 111.322 -178.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.11 5.79 72.58 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 121.306 -0.473 . . . . 0.0 112.009 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 60.8 t30 -67.94 129.7 40.71 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 22.9 tpt180 -82.68 107.7 15.5 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 -178.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 27.8 t -111.62 142.85 22.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -178.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.544 ' HE2' ' HG ' ' A' ' 89' ' ' CYS . 85.0 m-85 -117.63 131.35 56.67 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 120.963 0.411 . . . . 0.0 110.628 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 45.3 t -112.9 134.47 21.75 Favored Pre-proline 0 C--N 1.302 -1.483 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -68.16 -27.14 35.68 Favored 'Trans proline' 0 C--N 1.358 1.038 0 C-N-CA 122.626 2.217 . . . . 0.0 113.35 -177.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.29 21.9 m 52.52 -46.59 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.284 0 N-CA-C 117.968 2.581 . . . . 0.0 117.968 176.47 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.546 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 37.1 ptt180 -161.63 163.55 29.87 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 123.157 0.583 . . . . 0.0 110.068 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.8 t -81.69 141.51 33.54 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 175.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.9 t -156.18 127.78 7.24 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -109.17 139.12 44.51 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 142.49 177.91 17.98 Favored Glycine 0 N--CA 1.42 -2.393 0 C-N-CA 119.059 -1.543 . . . . 0.0 113.668 175.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 16.2 m -141.42 145.4 37.77 Favored Pre-proline 0 C--N 1.299 -1.593 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 178.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 83.8 Cg_exo -49.2 138.41 28.94 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 122.897 2.398 . . . . 0.0 112.922 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 60.0 Cg_endo -85.29 -16.04 29.78 Favored 'Cis proline' 0 C--O 1.25 1.118 0 C-N-CA 123.366 -1.514 . . . . 0.0 113.618 0.198 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -80.54 100.98 8.85 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -171.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -106.41 123.95 48.85 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 114.336 -1.302 . . . . 0.0 111.29 178.152 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 70.4 mt -95.46 108.19 37.82 Favored Pre-proline 0 C--N 1.319 -0.73 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -84.23 130.67 4.76 Favored 'Trans proline' 0 C--O 1.249 1.04 0 C-N-CA 122.37 2.047 . . . . 0.0 112.841 -179.059 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -115.35 -147.93 9.26 Favored Glycine 0 N--CA 1.435 -1.374 0 C-N-CA 120.562 -0.827 . . . . 0.0 112.017 178.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.6 t -57.63 116.13 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.823 0 C-N-CA 123.819 0.848 . . . . 0.0 112.047 -179.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.546 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.19 143.87 26.0 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.431 173.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.6 m-90 -104.51 19.74 19.78 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.635 0.731 . . . . 0.0 109.584 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -165.77 -175.74 36.54 Favored Glycine 0 N--CA 1.428 -1.882 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 179.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 60.8 t -112.88 141.59 28.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -177.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -107.14 122.15 45.93 Favored 'General case' 0 C--N 1.321 -0.653 0 O-C-N 123.231 0.332 . . . . 0.0 110.54 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt . . . . . 0 C--N 1.297 -1.676 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 177.994 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 48.3 m95 . . . . . 0 N--CA 1.435 -1.217 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -114.13 133.58 55.47 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -89.45 129.83 35.89 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 120.985 0.421 . . . . 0.0 111.201 -177.49 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 45.9 t-20 -99.83 160.0 14.64 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -65.26 -11.86 45.64 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -77.2 -5.57 49.7 Favored 'General case' 0 CA--C 1.541 0.633 0 CA-C-O 121.357 0.598 . . . . 0.0 109.996 176.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.26 1.83 83.7 Favored Glycine 0 CA--C 1.506 -0.492 0 N-CA-C 110.145 -1.182 . . . . 0.0 110.145 -177.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.424 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 9.2 m -89.42 141.01 28.94 Favored 'General case' 0 N--CA 1.415 -2.208 0 CA-C-N 113.86 -1.17 . . . . 0.0 109.299 -178.02 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.502 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 71.9 m95 -102.45 135.94 43.18 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 173.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.434 ' HA ' ' O ' ' A' ' 88' ' ' VAL . 32.0 p90 -137.4 155.47 49.33 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.702 -177.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -147.29 135.59 10.95 Favored Pre-proline 0 C--N 1.305 -1.364 0 CA-C-N 115.318 -0.855 . . . . 0.0 108.738 173.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -67.08 129.57 20.89 Favored 'Trans proline' 0 C--O 1.248 0.992 0 C-N-CA 122.264 1.976 . . . . 0.0 111.42 173.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -168.02 120.99 0.89 Allowed 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.567 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 15.9 m120 -88.57 109.5 20.13 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-O 120.906 0.384 . . . . 0.0 110.88 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.446 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -135.45 165.73 24.8 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 178.09 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.466 ' HB ' ' HG3' ' A' ' 131' ' ' LYS . 25.9 m -114.0 136.51 52.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-O 121.479 0.656 . . . . 0.0 111.964 -175.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 69.6 t80 -117.74 127.01 53.49 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 114.986 -1.007 . . . . 0.0 108.288 176.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 129' ' ' VAL . 46.0 t -105.41 105.6 18.97 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 178.301 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -76.42 121.51 23.16 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 178.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -149.63 -24.45 0.06 OUTLIER Glycine 0 C--N 1.309 -0.923 0 C-N-CA 118.325 -1.893 . . . . 0.0 114.654 -175.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -71.72 -53.14 14.45 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.172 0.511 . . . . 0.0 110.096 -177.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -156.21 159.83 31.2 Favored Pre-proline 0 C--N 1.312 -1.031 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.078 -176.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -67.77 131.67 24.8 Favored 'Trans proline' 0 C--O 1.248 0.991 0 C-N-CA 122.372 2.048 . . . . 0.0 110.135 173.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 47.4 mt -114.51 132.35 63.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -176.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.3 p -76.07 131.68 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 177.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 40.7 p -103.74 157.62 16.95 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.531 -177.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -110.78 143.88 40.63 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.3 mp -109.68 134.4 51.91 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 C-N-CA 120.531 -0.468 . . . . 0.0 111.22 -175.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.29 -22.74 1.99 Allowed Glycine 0 C--O 1.244 0.728 0 N-CA-C 117.157 1.623 . . . . 0.0 117.157 171.593 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.4 m -152.85 138.86 11.98 Favored Pre-proline 0 C--N 1.308 -1.197 0 CA-C-N 118.81 1.305 . . . . 0.0 111.462 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -89.75 120.49 0.94 Allowed 'Trans proline' 0 N--CA 1.441 -1.577 0 C-N-CA 121.992 1.795 . . . . 0.0 111.006 171.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.424 ' HA ' ' HG2' ' A' ' 91' ' ' GLN . 68.1 m-85 -166.58 166.33 16.21 Favored 'General case' 0 CA--C 1.493 -1.216 0 C-N-CA 126.63 1.972 . . . . 0.0 105.819 -178.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 86.3 mt -72.23 -41.28 67.03 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.436 0.636 . . . . 0.0 109.296 176.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 21.8 p-10 -97.47 25.63 5.55 Favored 'General case' 0 C--O 1.246 0.894 0 C-N-CA 124.477 1.111 . . . . 0.0 110.709 -177.578 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -65.84 153.32 91.51 Favored Pre-proline 0 C--O 1.249 1.077 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.627 -178.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -47.44 128.62 15.23 Favored 'Trans proline' 0 C--N 1.368 1.555 0 C-N-CA 124.205 3.27 . . . . 0.0 114.077 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.3 p -102.73 172.99 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.44 28.61 1.92 Allowed Glycine 0 N--CA 1.442 -0.903 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.649 -176.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -161.66 131.23 2.51 Favored Glycine 0 N--CA 1.433 -1.566 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 176.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -127.82 141.38 51.58 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 117.336 0.568 . . . . 0.0 110.272 -179.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 50.7 tp -100.96 113.26 65.78 Favored Pre-proline 0 C--N 1.301 -1.521 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.007 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -73.64 156.8 49.07 Favored 'Trans proline' 0 C--O 1.252 1.209 0 C-N-CA 122.405 2.07 . . . . 0.0 111.456 179.05 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.52 142.77 42.77 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 108.35 -22.46 26.8 Favored Glycine 0 N--CA 1.434 -1.475 0 N-CA-C 110.438 -1.065 . . . . 0.0 110.438 -176.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.5 126.77 30.56 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-O 121.349 0.595 . . . . 0.0 111.298 -178.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 17.0 m -98.67 110.77 23.31 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 177.613 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.1 mm -111.51 131.07 63.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.286 -173.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.6 p -108.67 112.48 40.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 CA-C-O 122.04 0.924 . . . . 0.0 109.074 175.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.567 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 46.9 p90 -97.45 149.32 22.28 Favored 'General case' 0 C--N 1.296 -1.744 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.363 -177.517 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -112.92 -9.9 13.58 Favored 'General case' 0 C--N 1.31 -1.139 0 O-C-N 123.804 0.69 . . . . 0.0 111.238 -176.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 46.3 tt0 -134.94 128.98 33.54 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -175.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 46' ' ' TYR . 13.8 t -107.89 126.71 64.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.424 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 62.5 m -128.94 139.02 52.3 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -177.135 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 46.9 mt -112.22 119.37 60.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 173.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.497 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -124.94 144.1 50.53 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 104.638 -2.356 . . . . 0.0 104.638 174.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -51.15 104.13 0.07 Allowed 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 113.353 0.871 . . . . 0.0 113.353 -172.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.45 -39.97 1.76 Allowed Glycine 0 N--CA 1.431 -1.642 0 CA-C-N 115.436 -0.802 . . . . 0.0 113.236 177.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 53.0 m80 -147.74 157.58 43.61 Favored 'General case' 0 CA--C 1.497 -1.091 0 O-C-N 122.083 -0.657 . . . . 0.0 110.602 -174.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.9 tt -96.78 128.28 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.714 0 N-CA-C 105.296 -2.112 . . . . 0.0 105.296 172.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.497 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 72.1 m95 -106.41 135.45 47.87 Favored 'General case' 0 C--N 1.266 -3.023 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -173.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.509 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.4 pt -100.38 126.38 53.97 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.894 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 177.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -100.29 124.23 8.18 Favored Glycine 0 N--CA 1.42 -2.422 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.173 -177.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -148.23 173.07 13.37 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 177.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -119.17 145.51 45.94 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 177.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.44 ' HB3' ' OD1' ' A' ' 105' ' ' ASN . . . -93.85 170.23 9.71 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -73.35 -9.8 59.07 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.141 0.496 . . . . 0.0 111.64 -176.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -72.63 -16.41 61.72 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 174.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 98.57 4.14 57.19 Favored Glycine 0 C--N 1.33 0.208 0 C-N-CA 121.062 -0.59 . . . . 0.0 111.964 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.44 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 23.5 p-10 -96.06 145.15 25.7 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 120.938 0.399 . . . . 0.0 110.968 -179.385 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 28.9 tpt180 -86.15 122.36 30.04 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 179.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 43.0 t -119.21 143.2 31.18 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.261 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 -173.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.509 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 86.3 m-85 -125.52 129.17 49.22 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 123.579 0.751 . . . . 0.0 110.134 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.4 t -109.3 135.06 20.29 Favored Pre-proline 0 C--N 1.299 -1.592 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 178.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -68.24 -23.24 39.2 Favored 'Trans proline' 0 C--N 1.365 1.416 0 C-N-CA 123.202 2.602 . . . . 0.0 114.38 -177.157 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.3 35.4 m 45.22 -53.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.286 0 N-CA-C 119.077 2.992 . . . . 0.0 119.077 176.054 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.442 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 33.2 ptt180 -158.7 152.87 23.86 Favored 'General case' 0 C--N 1.314 -0.964 0 O-C-N 121.718 -0.614 . . . . 0.0 110.47 -178.297 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.556 ' O ' ' HA ' ' A' ' 123' ' ' PRO . 13.7 m -63.88 127.48 31.58 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 174.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.41 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 99.6 m -152.92 118.76 5.39 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 123.477 0.711 . . . . 0.0 109.361 177.044 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 26.7 mt-30 -129.58 148.83 51.52 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.34 -167.86 30.82 Favored Glycine 0 N--CA 1.417 -2.602 0 C-N-CA 119.11 -1.519 . . . . 0.0 112.149 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 10.8 m -123.99 108.03 30.45 Favored Pre-proline 0 C--N 1.291 -1.971 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.502 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 60.6 Cg_exo -43.17 129.2 5.92 Favored 'Trans proline' 0 C--N 1.349 0.584 0 C-N-CA 124.004 3.136 . . . . 0.0 113.024 -175.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -90.53 10.77 60.32 Favored 'Cis proline' 0 C--O 1.242 0.694 0 C-N-CA 124.115 -1.202 . . . . 0.0 115.114 8.44 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -75.28 100.06 4.25 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 -179.046 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.431 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 45.8 p-80 -106.08 109.83 21.89 Favored 'General case' 0 C--N 1.289 -2.053 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.112 177.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.5 mt -94.82 105.21 17.49 Favored Pre-proline 0 C--N 1.299 -1.606 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . 0.556 ' HA ' ' O ' ' A' ' 113' ' ' THR . 72.8 Cg_endo -84.4 153.67 12.22 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.58 2.187 . . . . 0.0 113.121 -176.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -125.81 -97.53 1.09 Allowed Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 178.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 40.5 t -96.68 118.67 43.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -178.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.442 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.06 120.34 34.19 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.179 178.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.8 m-90 -101.5 58.02 0.85 Allowed 'General case' 0 C--N 1.31 -1.149 0 CA-C-O 120.661 0.267 . . . . 0.0 111.345 -179.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . 155.85 -169.78 33.59 Favored Glycine 0 CA--C 1.497 -1.082 0 C-N-CA 119.693 -1.241 . . . . 0.0 112.499 178.15 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 54' ' ' VAL . 97.9 t -111.94 128.68 68.38 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -112.07 136.87 50.89 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.152 -176.635 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.466 ' HG3' ' HB ' ' A' ' 52' ' ' THR . 18.1 ptpt . . . . . 0 N--CA 1.433 -1.315 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 175.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 92.1 m95 . . . . . 0 N--CA 1.436 -1.144 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -125.08 154.64 41.07 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.639 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -94.15 127.27 39.88 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 120.359 -0.536 . . . . 0.0 111.207 -176.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -84.48 151.28 24.72 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 174.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.9 pt20 -51.2 -27.45 8.92 Favored 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 123.739 0.816 . . . . 0.0 113.189 -178.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.437 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 50.2 m-85 -81.73 3.16 26.66 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -177.257 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.71 18.82 59.27 Favored Glycine 0 CA--C 1.5 -0.844 0 C-N-CA 120.333 -0.937 . . . . 0.0 111.628 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.524 HG22 ' HB2' ' A' ' 89' ' ' CYS . 12.3 m -105.21 132.98 50.73 Favored 'General case' 0 N--CA 1.416 -2.134 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 179.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -96.39 129.73 43.67 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 177.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -129.54 154.67 46.81 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.422 -175.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -135.76 145.91 54.96 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 173.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_exo -69.3 121.86 8.65 Favored 'Trans proline' 0 C--O 1.249 1.041 0 C-N-CA 121.737 1.625 . . . . 0.0 109.469 172.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.451 ' HB3' HG23 ' A' ' 88' ' ' VAL . 6.2 tp10 -150.18 120.9 7.53 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.446 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 3.0 t-20 -114.19 106.49 14.42 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.926 -0.71 . . . . 0.0 110.154 -175.617 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.89 -177.58 5.98 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.443 -178.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.468 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 13.3 m -104.68 150.12 24.98 Favored 'General case' 0 N--CA 1.429 -1.487 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -177.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -127.39 127.21 43.8 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 173.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.1 t -113.09 113.29 43.64 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.232 0 N-CA-C 106.795 -1.558 . . . . 0.0 106.795 176.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 53.2 t30 -64.76 152.57 42.27 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.639 -178.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -78.59 -146.3 3.12 Favored Glycine 0 N--CA 1.434 -1.434 0 CA-C-N 116.16 -0.473 . . . . 0.0 113.173 -177.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -86.97 7.54 27.07 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -173.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.453 ' HA ' ' HD3' ' A' ' 59' ' ' PRO . 0.3 OUTLIER -138.92 137.25 19.29 Favored Pre-proline 0 C--N 1.302 -1.484 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.209 -175.213 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 58' ' ' GLN . 26.6 Cg_exo -65.58 128.99 21.27 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.415 2.077 . . . . 0.0 110.757 176.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.2 mt -108.02 125.81 64.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -177.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.3 p -78.89 137.58 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.669 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 60.2 p -117.26 178.41 4.38 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.003 -172.472 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 33.9 mmt180 -116.81 146.59 42.77 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 60.7 mt -109.82 131.32 61.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.43 -175.28 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.2 -22.86 4.19 Favored Glycine 0 C--N 1.318 -0.42 0 N-CA-C 115.969 1.148 . . . . 0.0 115.969 171.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.409 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 39.1 m -153.61 140.77 13.24 Favored Pre-proline 0 C--N 1.298 -1.669 0 CA-C-N 117.875 0.837 . . . . 0.0 109.154 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.442 ' HG2' HG21 ' A' ' 44' ' ' THR . 12.5 Cg_endo -89.69 119.4 0.86 Allowed 'Trans proline' 0 N--CA 1.433 -2.036 0 C-N-CA 121.189 1.259 . . . . 0.0 110.347 173.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.661 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 82.4 m-85 -168.89 173.9 6.77 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 104.716 -2.328 . . . . 0.0 104.716 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -89.28 -34.25 16.66 Favored 'General case' 0 C--N 1.291 -1.969 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 176.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -97.87 22.49 9.16 Favored 'General case' 0 CA--C 1.548 0.904 0 CA-C-O 121.993 0.901 . . . . 0.0 109.803 -178.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.661 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -77.57 162.72 67.43 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.79 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -48.87 124.35 11.14 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 123.343 2.695 . . . . 0.0 113.559 178.742 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.0 p -97.83 173.73 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.195 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.367 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.62 -1.68 13.84 Favored Glycine 0 CA--C 1.502 -0.77 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.517 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -113.88 117.49 4.17 Favored Glycine 0 N--CA 1.429 -1.793 0 N-CA-C 108.849 -1.701 . . . . 0.0 108.849 174.36 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -126.8 128.14 46.12 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 117.737 0.769 . . . . 0.0 110.344 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 41.2 tp -96.55 119.76 63.39 Favored Pre-proline 0 C--N 1.309 -1.154 0 C-N-CA 123.282 0.633 . . . . 0.0 110.19 -175.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.02 165.08 25.09 Favored 'Trans proline' 0 CA--C 1.542 0.912 0 C-N-CA 122.805 2.337 . . . . 0.0 112.728 179.28 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.75 147.31 45.71 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.784 -177.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 69.52 5.91 52.34 Favored Glycine 0 N--CA 1.463 0.446 0 N-CA-C 114.247 0.459 . . . . 0.0 114.247 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.76 126.59 29.89 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-O 120.892 0.377 . . . . 0.0 111.417 -177.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 25.7 m -92.59 113.09 25.27 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 177.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.9 mm -122.55 138.97 50.89 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -176.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 p -103.47 129.33 55.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 175.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.446 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 32.2 p90 -117.71 150.56 38.87 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.591 -177.809 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -108.57 -12.36 14.99 Favored 'General case' 0 C--N 1.316 -0.856 0 O-C-N 123.473 0.483 . . . . 0.0 110.42 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -140.4 136.59 33.24 Favored 'General case' 0 N--CA 1.428 -1.54 0 C-N-CA 120.346 -0.542 . . . . 0.0 111.206 -172.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.451 HG23 ' HB3' ' A' ' 49' ' ' GLU . 71.4 t -118.62 127.85 75.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 176.211 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.524 ' HB2' HG22 ' A' ' 44' ' ' THR . 19.6 p -135.46 147.73 49.01 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 120.898 0.38 . . . . 0.0 111.613 -175.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.5 mt -109.5 113.81 45.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-O 121.225 0.536 . . . . 0.0 110.546 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.595 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -110.42 122.56 47.99 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 104.761 -2.311 . . . . 0.0 104.761 174.457 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -47.85 114.29 0.88 Allowed 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 121.845 0.831 . . . . 0.0 113.068 -165.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 120.58 -25.15 7.38 Favored Glycine 0 N--CA 1.429 -1.826 0 CA-C-N 114.1 -1.409 . . . . 0.0 112.42 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 75.8 m80 -152.05 170.11 20.72 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 15.9 tt -111.62 136.44 47.72 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.179 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 172.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.595 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 48.2 m95 -121.96 139.07 54.12 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -173.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.509 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 47.5 pt -100.52 136.02 33.86 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.92 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 175.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -105.03 119.46 6.21 Favored Glycine 0 N--CA 1.419 -2.459 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -136.83 152.83 50.71 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 120.408 -0.517 . . . . 0.0 109.954 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -86.25 127.38 34.75 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 174.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.27 163.33 17.79 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 27.7 p90 -54.81 -31.36 59.03 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -176.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -76.29 -14.44 60.11 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-O 121.055 0.455 . . . . 0.0 111.046 -179.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 108.92 -9.58 34.19 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 121.137 -0.554 . . . . 0.0 113.279 178.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -75.84 148.08 38.63 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-O 120.754 0.311 . . . . 0.0 111.226 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . 0.437 HH11 ' HG2' ' A' ' 106' ' ' ARG . 0.5 OUTLIER -89.41 109.27 20.2 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 177.685 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 52.2 t -107.66 136.92 41.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.199 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -176.23 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.509 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 91.4 m-85 -116.33 126.0 52.91 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.4 t -105.44 131.85 21.39 Favored Pre-proline 0 C--N 1.301 -1.536 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -69.26 -11.4 31.39 Favored 'Trans proline' 0 C--N 1.364 1.375 0 C-N-CA 123.374 2.716 . . . . 0.0 113.794 -177.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.277 27.0 m 37.83 -63.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.148 0 N-CA-C 118.286 2.698 . . . . 0.0 118.286 174.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.524 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 34.9 ptt180 -153.06 149.79 28.48 Favored 'General case' 0 N--CA 1.429 -1.488 0 C-N-CA 122.872 0.469 . . . . 0.0 110.219 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 19.4 m -67.8 136.76 54.66 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 41.8 t -150.39 139.24 20.88 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -176.324 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 78.3 mm-40 -119.6 161.61 20.36 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 130.22 -171.75 20.45 Favored Glycine 0 N--CA 1.421 -2.363 0 C-N-CA 120.034 -1.079 . . . . 0.0 112.448 174.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.6 m -141.41 138.57 17.69 Favored Pre-proline 0 C--N 1.295 -1.787 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 90.6 Cg_exo -47.73 131.64 20.36 Favored 'Trans proline' 0 CA--C 1.539 0.736 0 C-N-CA 122.945 2.43 . . . . 0.0 112.786 -177.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 89.7 Cg_endo -96.65 7.5 40.89 Favored 'Cis proline' 0 CA--C 1.547 1.155 0 C-N-CA 124.492 -1.045 . . . . 0.0 113.884 1.19 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 44.4 t30 -76.27 102.39 5.83 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.636 0.732 . . . . 0.0 110.911 -175.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 -104.82 112.6 25.77 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 114.748 -1.115 . . . . 0.0 111.602 -178.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 59.3 mt -101.46 100.84 14.92 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -85.22 140.39 7.57 Favored 'Trans proline' 0 N--CA 1.452 -0.944 0 C-N-CA 122.87 2.38 . . . . 0.0 113.647 -177.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -110.66 -117.62 3.81 Favored Glycine 0 N--CA 1.436 -1.35 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 177.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 81.6 t -78.24 115.46 20.34 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 120.84 0.352 . . . . 0.0 110.861 -179.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.524 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.37 132.91 38.49 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.788 177.129 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.3 m-90 -102.35 8.07 40.36 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-O 121.488 0.661 . . . . 0.0 110.401 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.09 169.51 36.7 Favored Glycine 0 N--CA 1.431 -1.696 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 64.3 t -111.72 134.86 52.78 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 C-N-CA 122.895 0.478 . . . . 0.0 110.189 -175.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -97.68 132.62 43.16 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 178.124 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.468 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 48.7 tptt . . . . . 0 N--CA 1.413 -2.315 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -179.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 34.5 m95 . . . . . 0 N--CA 1.432 -1.333 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -113.35 150.56 32.43 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.417 ' HG2' ' O ' ' A' ' 40' ' ' ASN . 38.2 ttpt -110.15 136.2 49.75 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 118.376 -1.33 . . . . 0.0 111.528 -178.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.417 ' O ' ' HG2' ' A' ' 39' ' ' LYS . 45.9 t-20 -94.35 161.67 14.14 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 105.955 -1.869 . . . . 0.0 105.955 175.079 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 34.7 mt-30 -67.28 -13.31 61.87 Favored 'General case' 0 C--O 1.213 -0.836 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -173.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 47.9 m-85 -76.3 -1.24 25.67 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.352 0.596 . . . . 0.0 110.214 177.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.39 24.26 59.3 Favored Glycine 0 CA--C 1.494 -1.266 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.526 HG22 ' HB2' ' A' ' 89' ' ' CYS . 13.5 m -105.37 124.66 49.92 Favored 'General case' 0 N--CA 1.414 -2.231 0 CA-C-N 114.662 -0.769 . . . . 0.0 109.608 -178.503 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.551 ' CG ' ' HG3' ' A' ' 118' ' ' PRO . 84.1 m95 -93.3 131.11 38.74 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.18 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.41 ' HB3' ' HB3' ' A' ' 89' ' ' CYS . 54.2 p90 -132.75 151.85 51.89 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -175.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.434 ' HG3' ' HB ' ' A' ' 88' ' ' VAL . 16.8 ptmt -129.02 132.47 24.39 Favored Pre-proline 0 C--N 1.303 -1.443 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.664 175.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_exo -72.78 122.05 7.87 Favored 'Trans proline' 0 C--O 1.244 0.79 0 C-N-CA 121.835 1.69 . . . . 0.0 111.001 175.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -162.25 131.49 4.38 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 177.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.419 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 23.8 t-20 -110.03 123.46 49.71 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 120.699 -0.4 . . . . 0.0 110.182 -177.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -160.07 177.2 10.95 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -108.22 152.01 25.16 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 121.022 0.439 . . . . 0.0 112.126 -178.752 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.443 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 91.4 t80 -122.55 123.66 41.73 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 176.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 43.7 t -103.17 104.88 17.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 29.1 t30 -76.98 123.52 26.44 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 175.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -147.1 24.32 1.59 Allowed Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 118.973 -1.584 . . . . 0.0 113.308 -177.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -113.77 -50.71 2.82 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.256 179.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -158.22 164.96 19.65 Favored Pre-proline 0 C--N 1.315 -0.921 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.462 ' HB3' HD21 ' A' ' 76' ' ' ASN . 18.0 Cg_exo -69.27 125.87 12.93 Favored 'Trans proline' 0 C--O 1.254 1.301 0 N-CA-C 108.121 -1.531 . . . . 0.0 108.121 170.164 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 41.4 mt -108.12 130.17 61.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 110.127 -0.323 . . . . 0.0 110.127 -173.267 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 39.7 t -69.16 122.16 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.817 0 CA-C-O 121.968 0.889 . . . . 0.0 110.308 176.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -96.16 155.9 16.56 Favored 'General case' 0 N--CA 1.405 -2.689 0 CA-C-N 114.181 -1.372 . . . . 0.0 108.651 -176.242 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 15.6 mmt180 -112.24 141.64 45.7 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -178.272 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.2 mt -109.39 120.29 60.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 113.11 0.782 . . . . 0.0 113.11 -173.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.67 -22.51 27.49 Favored Glycine 0 C--O 1.236 0.249 0 N-CA-C 116.343 1.297 . . . . 0.0 116.343 170.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.7 m -155.01 140.26 12.28 Favored Pre-proline 0 C--N 1.307 -1.257 0 CA-C-N 118.502 1.151 . . . . 0.0 111.292 -178.27 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -89.93 119.96 0.86 Allowed 'Trans proline' 0 N--CA 1.437 -1.844 0 C-N-CA 121.716 1.611 . . . . 0.0 110.778 172.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -162.5 162.76 27.58 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 68.3 mt -80.1 -13.99 58.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 121.748 0.785 . . . . 0.0 109.434 177.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.4 p-10 -116.19 19.52 14.85 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.606 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.83 146.1 95.33 Favored Pre-proline 0 C--O 1.243 0.757 0 CA-C-N 115.386 -0.825 . . . . 0.0 112.201 -176.076 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -48.76 131.66 24.92 Favored 'Trans proline' 0 C--O 1.249 1.035 0 C-N-CA 124.104 3.203 . . . . 0.0 113.916 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.1 m -97.41 174.59 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 CA-C-N 114.552 -1.204 . . . . 0.0 110.483 -178.207 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.92 28.12 2.12 Favored Glycine 0 C--N 1.305 -1.192 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.021 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.81 132.67 4.1 Favored Glycine 0 N--CA 1.427 -1.924 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 176.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.462 HD21 ' HB3' ' A' ' 59' ' ' PRO . 8.3 t30 -128.35 125.77 39.38 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 117.597 0.699 . . . . 0.0 110.918 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 65.3 tp -88.26 111.69 44.86 Favored Pre-proline 0 N--CA 1.426 -1.634 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -63.43 152.4 80.26 Favored 'Trans proline' 0 C--O 1.251 1.146 0 C-N-CA 122.147 1.898 . . . . 0.0 112.553 -179.288 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.41 138.16 41.5 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.292 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.82 3.13 62.45 Favored Glycine 0 N--CA 1.441 -0.997 0 N-CA-C 111.434 -0.666 . . . . 0.0 111.434 -178.6 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.49 139.07 31.15 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-O 121.171 0.51 . . . . 0.0 111.188 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 39.0 m -113.53 113.55 25.27 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 177.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.1 mm -110.18 139.87 31.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -176.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.0 p -95.31 127.13 47.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 176.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.452 ' HA ' ' HB3' ' A' ' 99' ' ' TYR . 46.3 p90 -110.11 154.44 23.28 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.472 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -116.35 -9.09 11.57 Favored 'General case' 0 C--O 1.25 1.089 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.36 -177.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -144.84 131.69 20.18 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.876 -174.114 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.434 ' HB ' ' HG3' ' A' ' 47' ' ' LYS . 32.1 t -109.61 124.56 66.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 105.832 -1.914 . . . . 0.0 105.832 175.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.526 ' HB2' HG22 ' A' ' 44' ' ' THR . 24.6 p -137.5 148.49 46.06 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.871 -0.732 . . . . 0.0 112.624 -175.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 68.8 mt -111.4 124.15 67.9 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-O 121.061 0.458 . . . . 0.0 110.623 179.389 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.501 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -125.14 112.98 17.11 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 103.827 -2.657 . . . . 0.0 103.827 171.446 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.96 106.12 0.1 Allowed 'General case' 0 N--CA 1.479 0.983 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -164.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 141.63 -33.03 2.0 Favored Glycine 0 N--CA 1.439 -1.149 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -177.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 56.3 m80 -152.02 163.37 39.44 Favored 'General case' 0 CA--C 1.505 -0.786 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.3 tt -106.65 135.07 46.38 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 171.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.501 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 58.7 m95 -118.12 140.31 49.96 Favored 'General case' 0 C--N 1.28 -2.419 0 O-C-N 122.209 -0.307 . . . . 0.0 110.475 -171.118 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 48.1 pt -100.6 131.53 48.0 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 174.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.34 121.52 7.21 Favored Glycine 0 N--CA 1.417 -2.599 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . 0.452 ' HB3' ' HA ' ' A' ' 85' ' ' TYR . 39.0 p90 -132.17 146.58 52.12 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-O 121.466 0.651 . . . . 0.0 111.122 178.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -99.74 119.97 38.98 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.82 -1.082 . . . . 0.0 108.455 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.9 176.31 7.4 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.395 -177.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -66.0 -21.34 66.39 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.464 0.649 . . . . 0.0 112.019 -179.066 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -80.04 -14.52 58.48 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.985 177.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 84.62 5.59 86.53 Favored Glycine 0 C--O 1.24 0.475 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -174.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -80.79 132.98 35.56 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 27.2 tpt180 -88.48 104.89 17.23 Favored 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -178.082 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 15.5 t -107.12 142.75 19.13 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -175.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -125.61 127.1 45.81 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.088 0.471 . . . . 0.0 111.75 -178.184 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 52.8 t -107.51 135.4 19.73 Favored Pre-proline 0 C--N 1.307 -1.278 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -72.21 -12.63 27.93 Favored 'Trans proline' 0 C--N 1.36 1.156 0 C-N-CA 123.19 2.593 . . . . 0.0 114.503 -176.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.282 32.8 m 43.77 -56.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.516 2.827 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 175.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.527 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 38.2 ptt180 -159.98 151.05 19.29 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.03 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.2 t -73.42 143.14 46.86 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.9 t -155.26 136.98 14.35 Favored 'General case' 0 N--CA 1.421 -1.919 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -177.185 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 21.6 mt-30 -122.52 157.1 32.78 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 133.91 -163.83 24.47 Favored Glycine 0 N--CA 1.429 -1.815 0 C-N-CA 120.048 -1.072 . . . . 0.0 112.018 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 18.5 m -142.22 149.92 53.52 Favored Pre-proline 0 C--N 1.307 -1.272 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.551 ' HG3' ' CG ' ' A' ' 45' ' ' TRP . 33.3 Cg_endo -60.2 131.21 37.68 Favored 'Trans proline' 0 CA--C 1.541 0.843 0 C-N-CA 122.388 2.059 . . . . 0.0 112.412 -177.007 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 11.1 Cg_endo -99.59 8.81 26.2 Favored 'Cis proline' 0 C--O 1.251 1.154 0 C-N-CA 125.28 -0.717 . . . . 0.0 113.351 -0.454 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.1 t30 -75.04 100.63 4.24 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 122.106 0.955 . . . . 0.0 109.896 -177.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 48.3 p-80 -105.72 119.78 40.01 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 114.416 -1.266 . . . . 0.0 111.578 -177.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 62.1 mt -100.83 101.61 16.42 Favored Pre-proline 0 C--N 1.305 -1.35 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -85.06 130.45 4.08 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.732 2.288 . . . . 0.0 113.109 -177.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -103.87 -131.12 7.11 Favored Glycine 0 N--CA 1.433 -1.564 0 N-CA-C 111.199 -0.761 . . . . 0.0 111.199 177.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 48.8 t -68.05 120.03 14.77 Favored 'Isoleucine or valine' 0 C--O 1.252 1.195 0 C-N-CA 123.005 0.522 . . . . 0.0 111.003 -178.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.527 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -94.22 148.75 21.89 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.685 177.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.4 m-90 -116.2 8.28 14.32 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.399 0.619 . . . . 0.0 110.033 177.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.443 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -167.09 171.86 41.99 Favored Glycine 0 N--CA 1.431 -1.66 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 60.2 t -112.51 135.25 52.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 -177.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -85.8 121.99 29.23 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 176.148 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.284 -2.265 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 -175.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . 0.428 ' CZ3' HG13 ' A' ' 90' ' ' ILE . 30.4 m95 . . . . . 0 N--CA 1.442 -0.849 0 CA-C-O 120.717 0.294 . . . . 0.0 110.712 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -114.19 152.4 31.27 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 175.224 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -102.76 121.24 42.06 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.616 179.603 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.448 ' HB3' ' CE1' ' A' ' 46' ' ' TYR . 37.2 p30 -85.42 -178.29 6.67 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.774 -176.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -66.73 -16.67 64.4 Favored 'General case' 0 C--N 1.323 -0.575 0 C-N-CA 123.674 0.789 . . . . 0.0 113.037 -178.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 67.8 m-85 -93.77 2.69 56.18 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.449 0.643 . . . . 0.0 110.096 -177.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.8 25.56 66.91 Favored Glycine 0 N--CA 1.442 -0.942 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.457 HG22 ' HB2' ' A' ' 89' ' ' CYS . 12.8 m -105.26 141.21 37.19 Favored 'General case' 0 N--CA 1.425 -1.71 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -92.78 120.56 33.28 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 174.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.448 ' CE1' ' HB3' ' A' ' 40' ' ' ASN . 23.9 p90 -128.02 149.68 50.26 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 120.623 0.249 . . . . 0.0 110.611 -175.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.423 ' HE2' ' CZ2' ' A' ' 37' ' ' TRP . 52.2 pttt -139.33 140.4 25.75 Favored Pre-proline 0 C--N 1.295 -1.797 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 173.737 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_exo -71.23 127.23 13.18 Favored 'Trans proline' 0 C--O 1.255 1.36 0 C-N-CA 122.057 1.838 . . . . 0.0 110.314 174.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -164.78 120.85 1.46 Allowed 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -179.116 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.495 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 19.8 t-20 -103.02 109.54 21.12 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 120.962 0.41 . . . . 0.0 110.883 -174.647 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.452 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -145.28 172.35 13.27 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 14.1 m -107.68 134.76 50.19 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.939 0.4 . . . . 0.0 111.412 -173.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 72.9 t80 -112.36 122.46 47.77 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 39.0 t -108.23 103.77 16.01 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.866 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 178.645 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 30.2 t30 -76.4 131.61 39.21 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -144.68 2.52 1.25 Allowed Glycine 0 N--CA 1.432 -1.623 0 C-N-CA 119.307 -1.425 . . . . 0.0 113.546 -179.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -93.74 -52.06 4.63 Favored 'General case' 0 C--N 1.318 -0.789 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.826 -175.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 17.1 pt20 -159.25 171.64 7.12 Favored Pre-proline 0 C--N 1.314 -0.96 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -173.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.45 ' HB3' HD21 ' A' ' 76' ' ' ASN . 17.1 Cg_exo -69.0 122.11 8.99 Favored 'Trans proline' 0 N--CA 1.44 -1.655 0 N-CA-C 107.604 -1.729 . . . . 0.0 107.604 166.212 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 58.7 mt -107.84 123.32 63.19 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -175.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 25.9 m -79.93 139.42 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.366 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 175.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.5 p -118.36 178.94 4.26 Favored 'General case' 0 C--N 1.272 -2.781 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.918 -172.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.424 ' HG3' ' O ' ' A' ' 68' ' ' PHE . 82.0 mmt-85 -115.48 136.64 52.88 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 176.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 63.8 mt -97.24 121.29 47.61 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.64 -174.08 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 77.56 -16.87 5.89 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 116.034 1.173 . . . . 0.0 116.034 172.349 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.2 m -151.82 137.77 11.36 Favored Pre-proline 0 C--N 1.305 -1.336 0 CA-C-N 118.24 1.02 . . . . 0.0 110.204 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -89.93 119.19 0.8 Allowed 'Trans proline' 0 N--CA 1.434 -1.975 0 C-N-CA 121.163 1.242 . . . . 0.0 110.811 173.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.564 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 92.9 m-85 -169.55 168.73 9.14 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 178.6 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.96 -31.77 27.45 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 171.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -95.27 17.01 15.16 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.179 -0.918 . . . . 0.0 112.204 -178.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -79.0 162.75 63.43 Favored Pre-proline 0 C--N 1.311 -1.095 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -54.69 122.14 11.07 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 122.343 2.029 . . . . 0.0 112.438 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.413 HG22 ' H ' ' A' ' 74' ' ' GLY . 13.8 p -104.1 172.94 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.944 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.413 ' H ' HG22 ' A' ' 73' ' ' VAL . . . 120.33 -13.32 10.29 Favored Glycine 0 CA--C 1.502 -0.745 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 -179.067 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.46 108.83 3.08 Favored Glycine 0 N--CA 1.432 -1.597 0 N-CA-C 108.338 -1.905 . . . . 0.0 108.338 172.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.45 HD21 ' HB3' ' A' ' 59' ' ' PRO . 7.6 t30 -111.5 123.43 50.21 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 117.697 0.748 . . . . 0.0 110.339 -176.511 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 40.6 tp -98.83 114.27 65.27 Favored Pre-proline 0 C--N 1.302 -1.496 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -68.43 161.64 44.07 Favored 'Trans proline' 0 C--O 1.249 1.058 0 C-N-CA 122.236 1.957 . . . . 0.0 112.642 -178.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.41 139.42 42.32 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.83 5.82 58.41 Favored Glycine 0 N--CA 1.436 -1.352 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -85.86 128.84 34.92 Favored 'General case' 0 N--CA 1.432 -1.357 0 CA-C-O 121.033 0.444 . . . . 0.0 111.233 -178.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 37.0 m -103.91 110.25 22.31 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.1 mm -126.32 130.74 71.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 -175.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.9 p -88.69 133.93 29.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 176.246 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.495 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 40.1 p90 -109.98 151.17 27.47 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -124.67 -0.4 8.05 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 122.075 0.941 . . . . 0.0 110.391 -174.091 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -146.34 133.0 19.88 Favored 'General case' 0 N--CA 1.428 -1.526 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 -176.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 51.4 t -119.34 128.14 75.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.457 ' HB2' HG22 ' A' ' 44' ' ' THR . 23.5 p -141.51 145.46 35.21 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -176.314 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.428 HG13 ' CZ3' ' A' ' 37' ' ' TRP . 58.4 mt -107.16 117.04 52.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 175.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.507 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -118.12 117.59 29.59 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 103.327 -2.842 . . . . 0.0 103.327 171.211 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.47 110.44 0.34 Allowed 'General case' 0 C--N 1.315 -0.91 0 O-C-N 124.822 1.326 . . . . 0.0 112.876 -167.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 143.37 -42.86 1.05 Allowed Glycine 0 N--CA 1.42 -2.394 0 CA-C-N 113.582 -1.645 . . . . 0.0 109.345 -176.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . 0.439 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 73.7 m80 -153.4 165.93 34.26 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -179.256 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.5 tt -99.98 129.32 50.82 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 105.223 -2.14 . . . . 0.0 105.223 171.146 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.507 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 57.0 m95 -112.5 134.53 53.98 Favored 'General case' 0 C--N 1.274 -2.682 0 CA-C-O 120.997 0.427 . . . . 0.0 110.039 -172.029 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.547 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 44.8 pt -100.44 128.82 52.08 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 175.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -94.22 114.78 4.86 Favored Glycine 0 N--CA 1.416 -2.695 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 178.479 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 54.5 p90 -127.2 167.67 15.74 Favored 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 -178.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.1 m-80 -108.16 129.49 55.17 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.54 176.46 9.77 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -55.95 -27.16 51.2 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.961 0.905 . . . . 0.0 112.152 -178.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 32.9 p-10 -104.31 13.11 32.72 Favored 'General case' 0 C--N 1.322 -0.628 0 C-N-CA 123.241 0.616 . . . . 0.0 111.247 -175.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 77.88 21.78 70.54 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 121.089 -0.577 . . . . 0.0 113.28 177.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 50.2 t-20 -85.84 132.51 34.09 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 178.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -85.76 98.35 10.68 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 21.6 t -108.95 147.01 13.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 -175.322 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.547 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 94.7 m-85 -117.19 121.62 41.73 Favored 'General case' 0 C--N 1.314 -0.964 0 C-N-CA 122.494 0.317 . . . . 0.0 110.758 -178.072 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . 0.456 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 53.7 t -101.03 135.1 20.02 Favored Pre-proline 0 C--N 1.315 -0.902 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.05 -16.11 36.22 Favored 'Trans proline' 0 C--N 1.361 1.205 0 C-N-CA 123.322 2.681 . . . . 0.0 114.863 -176.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.308 33.0 m 42.21 -55.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.519 3.0 0 N-CA-C 118.837 2.903 . . . . 0.0 118.837 176.322 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.464 ' CZ ' ' HB2' ' A' ' 126' ' ' ALA . 8.2 ptp180 -153.97 148.98 26.76 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 123.868 0.867 . . . . 0.0 108.704 175.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.439 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 24.3 m -66.33 135.33 54.23 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 177.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 97.5 m -150.78 124.94 9.36 Favored 'General case' 0 CA--C 1.511 -0.524 0 CA-C-O 121.431 0.634 . . . . 0.0 112.467 -178.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -110.44 151.57 27.35 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 174.455 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.37 -171.25 22.64 Favored Glycine 0 C--N 1.3 -1.462 0 C-N-CA 118.251 -1.928 . . . . 0.0 114.092 177.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 64.9 t -137.44 127.67 15.69 Favored Pre-proline 0 C--N 1.309 -1.191 0 N-CA-C 105.947 -1.871 . . . . 0.0 105.947 -178.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 99.0 Cg_exo -46.36 137.18 14.72 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.371 2.714 . . . . 0.0 112.804 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 76.2 Cg_endo -86.61 -15.54 29.39 Favored 'Cis proline' 0 CA--C 1.542 0.877 0 C-N-CA 123.228 -1.572 . . . . 0.0 113.896 1.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -75.85 100.16 4.69 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 122.136 0.969 . . . . 0.0 111.645 -173.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 54.7 p-80 -106.34 138.53 42.35 Favored 'General case' 0 C--N 1.296 -1.717 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.808 176.109 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.0 mm -90.22 108.83 29.09 Favored Pre-proline 0 C--N 1.3 -1.565 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 176.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -84.66 123.91 2.98 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.457 2.105 . . . . 0.0 113.587 -176.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -95.25 -134.62 7.79 Favored Glycine 0 N--CA 1.436 -1.33 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 175.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 69.4 t -81.74 126.69 39.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 C-N-CA 122.982 0.513 . . . . 0.0 110.475 -179.418 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.464 ' HB2' ' CZ ' ' A' ' 112' ' ' ARG . . . -93.87 145.74 24.4 Favored 'General case' 0 CA--C 1.507 -0.689 0 O-C-N 123.75 0.657 . . . . 0.0 109.294 174.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.0 m-90 -110.33 18.3 20.0 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.344 0.592 . . . . 0.0 111.278 179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -166.57 -173.12 34.62 Favored Glycine 0 N--CA 1.432 -1.579 0 C-N-CA 120.045 -1.074 . . . . 0.0 112.173 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 48.7 t -110.98 131.11 63.1 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -103.54 120.44 40.87 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.299 -1.61 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 71.6 m95 . . . . . 0 CA--C 1.513 -0.476 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 53.2 tptt -120.31 153.9 35.76 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -95.94 125.44 40.49 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 118.917 -1.113 . . . . 0.0 110.458 -177.349 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.455 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 53.0 t30 -77.2 166.44 23.21 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.116 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 66.7 mm-40 -71.2 4.72 2.6 Favored 'General case' 0 C--N 1.312 -1.044 0 C-N-CA 123.548 0.739 . . . . 0.0 112.488 -174.214 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -104.5 -0.42 27.88 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.249 0.547 . . . . 0.0 110.493 175.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 91.51 -2.8 78.16 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.794 178.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.424 HG22 ' HB2' ' A' ' 89' ' ' CYS . 5.3 m -88.72 139.57 30.33 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 70.3 m95 -92.98 123.95 36.6 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.455 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 11.8 p90 -133.0 159.18 40.77 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.404 -174.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -147.96 142.29 16.42 Favored Pre-proline 0 C--N 1.297 -1.712 0 N-CA-C 106.031 -1.841 . . . . 0.0 106.031 172.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -72.4 134.38 22.54 Favored 'Trans proline' 0 N--CA 1.45 -1.073 0 C-N-CA 121.397 1.398 . . . . 0.0 110.475 174.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -150.94 121.4 7.38 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -101.84 106.14 17.08 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.55 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.78 176.56 11.66 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.477 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 24.0 m -113.58 151.03 32.21 Favored 'General case' 0 C--N 1.292 -1.904 0 CA-C-O 121.002 0.429 . . . . 0.0 111.163 -174.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.465 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 84.0 t80 -129.21 124.83 35.54 Favored 'General case' 0 N--CA 1.428 -1.526 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 174.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 33.6 t -108.54 110.04 30.55 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.11 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 62.5 t30 -77.07 130.4 37.36 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 177.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -122.58 -64.0 0.22 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 118.52 -1.8 . . . . 0.0 115.901 -173.135 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -68.71 -56.33 8.46 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 114.05 1.13 . . . . 0.0 114.05 -171.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 20.2 pt20 -134.39 157.88 76.45 Favored Pre-proline 0 C--N 1.292 -1.913 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.212 -170.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.4 ' HB3' HD21 ' A' ' 76' ' ' ASN . 19.7 Cg_exo -68.5 138.28 41.7 Favored 'Trans proline' 0 N--CA 1.445 -1.325 0 C-N-CA 121.76 1.64 . . . . 0.0 109.071 170.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.7 mt -113.39 133.38 59.48 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -177.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 9.5 p -84.3 128.05 39.26 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.083 0 CA-C-O 121.42 0.629 . . . . 0.0 109.76 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . 0.441 HG22 ' HA ' ' A' ' 109' ' ' CYS . 74.1 p -109.98 178.94 4.25 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.099 -173.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.57 ' HG2' ' CZ3' ' A' ' 96' ' ' TRP . 1.6 mmp_? -112.15 154.77 25.0 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 174.375 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 54.5 mt -119.26 126.1 75.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 120.759 -0.376 . . . . 0.0 111.045 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 85.08 -22.75 9.04 Favored Glycine 0 CA--C 1.519 0.337 0 N-CA-C 115.983 1.153 . . . . 0.0 115.983 171.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.1 m -153.99 142.65 14.49 Favored Pre-proline 0 C--N 1.309 -1.192 0 CA-C-N 118.276 1.038 . . . . 0.0 109.933 -178.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -90.63 119.14 0.67 Allowed 'Trans proline' 0 N--CA 1.443 -1.442 0 C-N-CA 121.806 1.67 . . . . 0.0 111.865 175.125 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.535 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 91.9 m-85 -168.9 168.94 10.06 Favored 'General case' 0 CA--C 1.49 -1.348 0 N-CA-C 104.584 -2.376 . . . . 0.0 104.584 179.216 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 85.2 mt -79.53 -37.86 35.57 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 171.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -88.84 12.09 16.12 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 114.32 -1.309 . . . . 0.0 112.101 -176.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.535 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.99 162.65 73.52 Favored Pre-proline 0 C--N 1.314 -0.966 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.561 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -46.94 123.18 7.03 Favored 'Trans proline' 0 C--N 1.367 1.518 0 C-N-CA 123.371 2.714 . . . . 0.0 113.797 -178.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.8 t -97.37 172.27 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.35 -30.03 5.94 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.84 126.98 10.02 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 178.011 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.4 HD21 ' HB3' ' A' ' 59' ' ' PRO . 9.3 t30 -128.47 130.5 47.64 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 117.118 0.459 . . . . 0.0 110.505 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 64.0 tp -97.63 113.55 63.67 Favored Pre-proline 0 C--N 1.3 -1.561 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -66.76 155.65 69.54 Favored 'Trans proline' 0 C--O 1.247 0.947 0 C-N-CA 122.505 2.136 . . . . 0.0 112.421 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.96 142.61 41.92 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.899 -0.592 . . . . 0.0 109.695 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.35 -4.57 70.29 Favored Glycine 0 N--CA 1.447 -0.602 0 N-CA-C 111.774 -0.531 . . . . 0.0 111.774 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -82.47 126.75 32.59 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 121.215 0.531 . . . . 0.0 111.528 -177.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 24.0 m -95.09 114.26 26.05 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 176.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.9 mm -119.02 134.0 64.06 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 -176.123 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.4 p -99.26 135.43 34.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.55 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 16.5 p90 -109.38 160.61 16.03 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.943 -0.703 . . . . 0.0 112.164 -178.272 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -124.8 -37.23 2.49 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.878 -1.056 . . . . 0.0 111.105 -176.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -118.26 131.92 56.33 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -175.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.4 t -121.43 125.27 73.42 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 176.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.534 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 13.8 p -134.09 140.45 46.63 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -175.538 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 71.8 mt -101.2 115.45 42.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 109.128 -0.694 . . . . 0.0 109.128 178.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.482 ' HG2' ' HA ' ' A' ' 68' ' ' PHE . 6.2 tp-100 -118.59 144.68 45.95 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 105.493 -2.04 . . . . 0.0 105.493 175.492 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -57.0 104.23 0.15 Allowed 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -175.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.58 -38.05 2.07 Favored Glycine 0 N--CA 1.439 -1.15 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.688 177.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 46.2 m80 -152.99 153.23 32.5 Favored 'General case' 0 N--CA 1.478 0.932 0 O-C-N 122.118 -0.636 . . . . 0.0 110.06 -176.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 13.6 tt -97.16 117.75 42.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.57 ' CZ3' ' HG2' ' A' ' 63' ' ' ARG . 65.2 m95 -100.61 134.11 44.05 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-O 120.922 0.391 . . . . 0.0 110.86 -171.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.5 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.6 pt -100.5 125.35 54.32 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.869 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 174.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -99.06 125.72 8.66 Favored Glycine 0 N--CA 1.414 -2.805 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 38.5 p90 -138.58 172.72 12.46 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-O 120.81 0.338 . . . . 0.0 110.524 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.442 ' HA ' ' O ' ' A' ' 105' ' ' ASN . 1.7 p-10 -115.5 120.04 38.18 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.687 -178.471 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.55 ' HB3' ' HB2' ' A' ' 105' ' ' ASN . . . -90.46 -174.7 4.22 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.447 -179.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 45.1 p90 -45.84 -32.25 2.51 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 116.246 1.943 . . . . 0.0 116.246 -176.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -108.37 15.79 23.68 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.034 0.921 . . . . 0.0 109.899 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 81.05 22.28 61.4 Favored Glycine 0 C--N 1.315 -0.621 0 N-CA-C 110.214 -1.155 . . . . 0.0 110.214 -177.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.55 ' HB2' ' HB3' ' A' ' 101' ' ' ALA . 8.9 m120 -67.78 121.1 15.24 Favored 'General case' 0 CA--C 1.494 -1.193 0 CA-C-N 114.732 -0.734 . . . . 0.0 109.141 -178.277 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 21.2 tpt180 -86.16 95.75 9.68 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 178.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.9 t -102.95 142.23 17.33 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.3 -174.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.5 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 86.8 m-85 -118.96 116.19 25.94 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 123.642 0.589 . . . . 0.0 110.163 -179.277 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . 0.441 ' HA ' HG22 ' A' ' 62' ' ' THR . 46.3 t -99.94 133.89 21.33 Favored Pre-proline 0 C--N 1.304 -1.376 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -69.7 -23.57 30.9 Favored 'Trans proline' 0 C--N 1.358 1.027 0 C-N-CA 123.227 2.618 . . . . 0.0 113.679 -176.35 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.291 30.8 m 48.95 -53.56 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.164 0 N-CA-C 117.972 2.582 . . . . 0.0 117.972 177.551 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.417 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 21.0 ptt180 -159.22 150.59 20.22 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 123.782 0.833 . . . . 0.0 108.837 -178.513 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 71.2 m -69.74 137.82 52.29 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 175.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 46.6 t -153.91 129.16 9.73 Favored 'General case' 0 N--CA 1.41 -2.473 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -177.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . 0.603 ' HA ' HE21 ' A' ' 115' ' ' GLN . 0.1 OUTLIER -96.72 146.0 25.28 Favored 'General case' 0 N--CA 1.408 -2.53 0 N-CA-C 103.285 -2.857 . . . . 0.0 103.285 172.288 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -167.07 142.12 7.36 Favored Glycine 0 N--CA 1.406 -3.31 0 C-N-CA 116.66 -2.686 . . . . 0.0 114.994 -177.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 6.2 m -131.59 97.47 19.22 Favored Pre-proline 0 C--N 1.279 -2.457 0 N-CA-C 104.501 -2.407 . . . . 0.0 104.501 171.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -48.31 139.68 21.6 Favored 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 123.456 2.771 . . . . 0.0 113.803 -170.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -85.97 6.74 63.45 Favored 'Cis proline' 0 CA--C 1.558 1.724 0 C-N-CA 124.288 -1.13 . . . . 0.0 114.051 0.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -70.46 102.64 2.25 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-O 121.541 0.686 . . . . 0.0 110.977 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 36.6 p-80 -105.3 117.25 33.53 Favored 'General case' 0 C--N 1.296 -1.717 0 CA-C-N 114.832 -1.077 . . . . 0.0 111.49 -178.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 53.1 mt -110.18 99.34 39.35 Favored Pre-proline 0 C--N 1.318 -0.782 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.53 141.73 8.98 Favored 'Trans proline' 0 C--O 1.247 0.931 0 C-N-CA 122.549 2.166 . . . . 0.0 112.683 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -106.84 -114.55 3.91 Favored Glycine 0 N--CA 1.433 -1.515 0 N-CA-C 110.616 -0.994 . . . . 0.0 110.616 176.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 85.8 t -88.97 127.17 41.88 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.065 0 CA-C-N 116.734 0.267 . . . . 0.0 110.43 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.417 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -94.16 143.05 26.72 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.306 177.208 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.1 m-90 -113.81 27.78 9.27 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 120.861 0.363 . . . . 0.0 110.551 179.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.465 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -169.92 -179.11 41.38 Favored Glycine 0 N--CA 1.429 -1.814 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 37.7 t -111.0 130.31 64.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -178.107 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -98.88 145.76 26.67 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-O 121.004 0.431 . . . . 0.0 110.792 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.477 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 88.1 tttt . . . . . 0 C--N 1.291 -1.967 0 N-CA-C 107.544 -1.28 . . . . 0.0 107.544 178.054 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 98.8 m95 . . . . . 0 N--CA 1.448 -0.562 0 CA-C-O 121.253 0.549 . . . . 0.0 109.962 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 7.1 tmtt? -120.56 139.15 53.36 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 105.461 -2.052 . . . . 0.0 105.461 -178.771 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -86.49 136.61 33.02 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.818 -0.753 . . . . 0.0 111.0 -175.392 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.402 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 45.3 t-20 -93.22 159.01 15.47 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 105.944 -1.873 . . . . 0.0 105.944 175.542 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -60.54 -22.28 63.46 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 123.467 0.707 . . . . 0.0 112.383 -174.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -79.13 2.34 21.2 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.865 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.11 10.72 80.05 Favored Glycine 0 CA--C 1.509 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.2 178.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.488 HG21 ' HG2' ' A' ' 67' ' ' PRO . 19.9 m -97.65 143.69 28.06 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 75.9 m95 -101.44 129.93 47.57 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.402 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 29.7 p90 -134.25 156.62 48.08 Favored 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.429 -177.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 49.2 pttt -135.96 132.23 19.24 Favored Pre-proline 0 C--N 1.293 -1.865 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 174.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -72.82 120.6 6.75 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 121.098 1.199 . . . . 0.0 109.007 174.126 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -154.45 130.14 10.01 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 -176.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -97.27 106.39 18.7 Favored 'General case' 0 C--N 1.307 -1.262 0 O-C-N 123.374 0.422 . . . . 0.0 109.963 -176.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.42 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -148.66 169.52 20.19 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 7.8 m -111.5 149.18 31.71 Favored 'General case' 0 C--N 1.298 -1.674 0 CA-C-O 120.981 0.42 . . . . 0.0 111.522 -173.172 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.4 t80 -130.58 131.36 44.96 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 174.291 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.424 HG22 HG23 ' A' ' 82' ' ' THR . 36.2 t -117.66 117.19 54.23 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 177.631 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -69.89 140.34 53.12 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -102.72 -73.97 1.0 Allowed Glycine 0 N--CA 1.432 -1.63 0 C-N-CA 120.306 -0.95 . . . . 0.0 114.75 -172.798 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -91.79 -69.13 0.75 Allowed 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 116.011 1.856 . . . . 0.0 116.011 -170.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -109.21 151.49 42.05 Favored Pre-proline 0 C--N 1.292 -1.914 0 O-C-N 121.828 -0.545 . . . . 0.0 111.192 -173.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.432 ' HA ' ' O ' ' A' ' 77' ' ' LEU . 50.0 Cg_exo -57.28 131.11 42.93 Favored 'Trans proline' 0 C--O 1.249 1.025 0 C-N-CA 122.171 1.914 . . . . 0.0 109.437 170.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -107.85 118.83 56.32 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -176.529 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 35.0 m -74.41 143.1 13.87 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.194 175.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 59.2 p -118.42 173.61 6.73 Favored 'General case' 0 C--N 1.277 -2.56 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.141 -173.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.466 ' HG3' ' O ' ' A' ' 68' ' ' PHE . 2.2 mmp_? -116.21 148.64 40.2 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.157 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 66.4 mt -112.21 131.26 64.15 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-O 120.62 0.248 . . . . 0.0 111.122 -177.303 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 85.98 -23.18 9.68 Favored Glycine 0 C--N 1.318 -0.423 0 N-CA-C 115.646 1.019 . . . . 0.0 115.646 171.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.0 m -157.87 142.23 11.67 Favored Pre-proline 0 C--N 1.296 -1.719 0 CA-C-N 117.51 0.655 . . . . 0.0 109.271 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.488 ' HG2' HG21 ' A' ' 44' ' ' THR . 60.9 Cg_endo -89.23 118.51 0.87 Allowed 'Trans proline' 0 N--CA 1.429 -2.306 0 C-N-CA 120.497 0.798 . . . . 0.0 110.089 172.276 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.489 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 90.8 m-85 -170.03 177.05 4.44 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 103.669 -2.715 . . . . 0.0 103.669 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -90.53 -37.81 13.62 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.411 0.624 . . . . 0.0 109.775 175.524 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -81.57 -2.33 49.62 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 114.772 -1.103 . . . . 0.0 111.035 -178.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.489 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -58.25 158.95 12.49 Favored Pre-proline 0 CA--C 1.547 0.828 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.547 -179.115 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_exo -47.11 134.73 18.9 Favored 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 123.823 3.015 . . . . 0.0 114.701 -178.289 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 26.6 m -90.63 173.53 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 CA-C-N 114.392 -1.276 . . . . 0.0 110.393 -178.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.44 6.22 12.04 Favored Glycine 0 C--N 1.314 -0.682 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.836 177.278 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -118.77 125.54 6.45 Favored Glycine 0 N--CA 1.432 -1.593 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.902 179.454 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -128.46 135.26 49.22 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 174.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.432 ' O ' ' HA ' ' A' ' 59' ' ' PRO . 53.9 tp -111.59 110.39 55.25 Favored Pre-proline 0 C--N 1.303 -1.422 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 176.523 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -67.47 166.14 24.78 Favored 'Trans proline' 0 CA--C 1.539 0.758 0 C-N-CA 122.699 2.266 . . . . 0.0 112.988 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.54 134.85 40.64 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.245 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.3 -10.81 73.56 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 121.236 -0.506 . . . . 0.0 112.298 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.76 129.38 39.56 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.902 0.382 . . . . 0.0 111.885 -176.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.424 HG23 HG22 ' A' ' 54' ' ' VAL . 52.9 m -104.98 117.02 32.96 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.121 179.545 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.0 mm -125.92 140.48 48.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -177.02 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.89 119.23 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-O 121.806 0.812 . . . . 0.0 108.864 175.362 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.42 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 39.4 p90 -97.37 148.4 23.2 Favored 'General case' 0 C--N 1.295 -1.799 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.929 -178.774 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -121.5 9.79 10.33 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 121.578 0.704 . . . . 0.0 110.231 -178.068 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -152.7 130.13 11.38 Favored 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -177.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 33.6 t -118.89 126.61 75.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 178.018 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.552 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 24.6 p -135.77 143.64 45.35 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.543 0.572 . . . . 0.0 112.543 -177.31 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 60.9 mt -102.32 116.83 46.7 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 CA-C-O 120.96 0.41 . . . . 0.0 110.003 177.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.582 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -124.27 121.77 35.94 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 174.117 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.89 107.95 0.16 Allowed 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 123.851 0.86 . . . . 0.0 113.14 -166.367 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 133.91 -33.97 2.46 Favored Glycine 0 N--CA 1.429 -1.81 0 CA-C-N 114.388 -1.278 . . . . 0.0 110.888 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -151.37 166.15 31.88 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -177.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 tt -107.71 119.13 56.78 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 171.211 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.582 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 55.4 m95 -100.77 134.11 44.23 Favored 'General case' 0 C--N 1.276 -2.612 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.9 -170.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.4 pt -100.12 133.7 42.2 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 176.272 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.13 121.97 7.21 Favored Glycine 0 N--CA 1.418 -2.564 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -126.13 147.04 49.7 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 176.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -93.96 112.85 24.75 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 -177.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.39 152.52 38.03 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -177.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -51.7 -30.12 20.95 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 124.313 1.045 . . . . 0.0 113.025 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -80.8 -5.52 57.33 Favored 'General case' 0 C--O 1.217 -0.644 0 CA-C-O 121.409 0.623 . . . . 0.0 110.829 -178.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 96.01 11.26 55.13 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.667 176.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -94.67 145.45 24.84 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.3 tpt180 -93.99 105.02 17.05 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 28.2 t -101.84 136.3 34.5 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -174.254 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.487 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 96.0 m-85 -116.09 126.04 53.2 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 123.419 0.688 . . . . 0.0 110.72 -178.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . 0.451 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 47.2 t -108.04 132.76 20.83 Favored Pre-proline 0 C--N 1.31 -1.123 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.143 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.06 -21.35 36.88 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 123.061 2.508 . . . . 0.0 114.683 -176.475 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.292 28.9 m 45.25 -53.71 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.914 0 N-CA-C 118.564 2.801 . . . . 0.0 118.564 176.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.453 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 28.8 ptt180 -154.67 142.05 19.61 Favored 'General case' 0 N--CA 1.44 -0.954 0 C-N-CA 123.826 0.851 . . . . 0.0 109.643 178.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 13.6 m -60.61 131.48 50.87 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.675 177.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.661 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 99.5 m -151.9 119.78 6.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.49 0.662 . . . . 0.0 112.091 -178.234 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -114.98 134.67 54.98 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 177.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 154.17 -175.97 32.2 Favored Glycine 0 CA--C 1.486 -1.768 0 C-N-CA 118.903 -1.618 . . . . 0.0 113.045 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.8 m -126.08 136.16 28.12 Favored Pre-proline 0 C--N 1.298 -1.644 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 179.37 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 92.5 Cg_exo -46.54 129.5 13.87 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 123.469 2.78 . . . . 0.0 113.332 -177.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 19.8 Cg_endo -96.18 -4.44 31.48 Favored 'Cis proline' 0 CA--C 1.542 0.908 0 C-N-CA 124.045 -1.231 . . . . 0.0 113.711 1.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -76.99 99.81 5.4 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-O 121.659 0.742 . . . . 0.0 110.868 -172.645 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 38.8 p-80 -106.99 132.79 52.53 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.334 176.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.661 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.6 mm -77.4 113.24 29.72 Favored Pre-proline 0 C--N 1.307 -1.262 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 174.302 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -84.55 124.42 3.13 Favored 'Trans proline' 0 N--CA 1.443 -1.457 0 C-N-CA 122.113 1.875 . . . . 0.0 112.528 -178.04 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.74 -139.19 9.85 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 176.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 58.4 t -80.62 123.43 37.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 -177.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.453 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -93.91 130.65 39.9 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 173.632 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.0 m-90 -95.66 12.63 29.12 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.635 0.731 . . . . 0.0 110.311 -178.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.03 -177.7 34.36 Favored Glycine 0 N--CA 1.421 -2.334 0 CA-C-N 115.196 -0.911 . . . . 0.0 111.298 -178.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 22.8 t -114.17 142.95 24.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -175.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -110.31 141.77 42.86 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.796 0.331 . . . . 0.0 111.289 -176.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? . . . . . 0 C--N 1.307 -1.27 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 172.534 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 95.5 m95 . . . . . 0 N--CA 1.43 -1.448 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -113.66 149.67 34.31 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.3 tttm -92.13 120.48 32.77 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 121.806 0.812 . . . . 0.0 111.158 -177.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 30.3 t-20 -84.5 147.87 26.83 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 176.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.0 tm0? -53.61 -28.66 33.77 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.209 1.004 . . . . 0.0 111.869 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.401 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 54.3 m-85 -74.0 -6.02 44.86 Favored 'General case' 0 CA--C 1.54 0.56 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -178.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.36 22.78 39.48 Favored Glycine 0 CA--C 1.495 -1.212 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -178.308 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.413 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 16.9 m -105.88 139.06 41.03 Favored 'General case' 0 N--CA 1.415 -2.222 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.175 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -102.59 133.25 47.9 Favored 'General case' 0 C--N 1.282 -2.366 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 175.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 35.9 p90 -138.94 158.97 43.23 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.436 -0.905 . . . . 0.0 112.286 -175.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.0 pttp -140.67 134.42 15.06 Favored Pre-proline 0 N--CA 1.431 -1.411 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 174.324 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -70.76 134.46 25.91 Favored 'Trans proline' 0 C--N 1.327 -0.597 0 C-N-CA 121.626 1.551 . . . . 0.0 110.566 177.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -163.62 121.09 1.83 Allowed 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.529 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 26.4 t-20 -95.35 106.06 18.07 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 177.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.473 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -144.03 168.83 19.06 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 -178.564 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.422 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 17.2 m -109.61 140.85 42.94 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.256 -174.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.469 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 91.7 t80 -120.9 133.65 55.29 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 176.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 81' ' ' ALA . 42.5 t -119.4 119.53 60.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.696 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.137 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -59.67 145.62 44.14 Favored 'General case' 0 C--O 1.246 0.916 0 O-C-N 123.518 0.511 . . . . 0.0 111.874 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -81.77 -122.34 0.63 Allowed Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.664 -0.698 . . . . 0.0 113.213 -178.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -95.88 -6.3 39.61 Favored 'General case' 0 C--N 1.315 -0.907 0 O-C-N 122.374 -0.486 . . . . 0.0 112.276 -175.427 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 9.5 pt20 -121.45 148.08 49.11 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.554 -178.62 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -72.37 135.59 24.81 Favored 'Trans proline' 0 N--CA 1.439 -1.722 0 C-N-CA 121.932 1.755 . . . . 0.0 107.813 168.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 57.8 mt -107.81 127.83 63.56 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -176.125 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.4 p -78.37 136.67 23.52 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.212 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 37.9 p -113.29 164.16 13.91 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 121.134 0.492 . . . . 0.0 112.043 -174.243 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.488 ' HE ' ' HA ' ' A' ' 63' ' ' ARG . 0.8 OUTLIER -109.63 147.01 33.81 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.392 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.0 mt -99.33 123.4 52.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 112.378 0.511 . . . . 0.0 112.378 -176.189 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 70.9 -22.27 0.58 Allowed Glycine 0 CA--C 1.521 0.41 0 N-CA-C 118.054 1.981 . . . . 0.0 118.054 170.705 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 41.6 m -140.73 136.16 16.18 Favored Pre-proline 0 C--N 1.298 -1.662 0 CA-C-N 119.074 1.437 . . . . 0.0 111.075 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -89.91 119.57 0.83 Allowed 'Trans proline' 0 N--CA 1.44 -1.661 0 C-N-CA 121.781 1.654 . . . . 0.0 110.484 172.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.422 ' HA ' ' HG2' ' A' ' 91' ' ' GLN . 55.3 m-85 -168.46 168.98 10.81 Favored 'General case' 0 CA--C 1.489 -1.367 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 -177.643 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.73 -8.77 53.89 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.536 0.684 . . . . 0.0 110.194 176.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 31.0 p30 -116.62 14.97 15.53 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.243 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.09 152.89 86.75 Favored Pre-proline 0 C--O 1.247 0.962 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.491 -175.229 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_exo -54.29 134.59 61.62 Favored 'Trans proline' 0 C--N 1.364 1.385 0 C-N-CA 123.66 2.907 . . . . 0.0 113.878 -179.064 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 32.3 m -90.1 174.42 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-N 114.564 -1.198 . . . . 0.0 110.234 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.36 28.75 1.9 Allowed Glycine 0 C--N 1.315 -0.611 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.851 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -148.06 127.99 2.74 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -128.12 127.14 42.48 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 26.1 tp -110.61 113.29 55.83 Favored Pre-proline 0 C--N 1.306 -1.325 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.695 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -62.21 162.31 23.73 Favored 'Trans proline' 0 N--CA 1.483 0.904 0 C-N-CA 123.461 2.774 . . . . 0.0 114.043 -176.067 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.96 144.67 48.81 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 178.456 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.73 11.15 85.61 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.478 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . 0.41 ' O ' ' HA ' ' A' ' 54' ' ' VAL . . . -78.77 134.21 37.04 Favored 'General case' 0 N--CA 1.439 -1.01 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 178.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 42.1 m -104.47 108.84 20.46 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 45.5 mm -124.05 126.59 72.62 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-O 120.936 0.398 . . . . 0.0 110.518 -176.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 12.4 p -90.32 123.41 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.647 0 CA-C-O 121.486 0.66 . . . . 0.0 109.56 176.34 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.529 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 45.5 p90 -101.96 159.25 15.52 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.137 -178.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -118.29 -16.19 9.68 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 121.379 0.609 . . . . 0.0 111.786 -175.204 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -141.11 137.76 33.03 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.341 -175.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 67.6 t -112.28 125.76 69.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.74 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.413 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 57.9 m -127.24 142.5 51.46 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -175.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 55.0 mt -108.46 117.04 53.11 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 172.174 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.422 ' HG2' ' HA ' ' A' ' 68' ' ' PHE . 7.7 tp-100 -113.97 121.33 43.58 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 103.107 -2.923 . . . . 0.0 103.107 170.171 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.17 104.07 0.06 Allowed 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 113.697 0.999 . . . . 0.0 113.697 -165.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 132.56 -36.36 2.19 Favored Glycine 0 N--CA 1.435 -1.411 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.15 -177.439 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 41.5 m80 -146.09 149.39 33.96 Favored 'General case' 0 CA--C 1.504 -0.81 0 O-C-N 122.293 -0.533 . . . . 0.0 111.621 -178.253 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.8 tt -97.86 138.11 23.56 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.913 0 N-CA-C 105.777 -1.934 . . . . 0.0 105.777 175.203 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -120.22 138.06 53.85 Favored 'General case' 0 C--N 1.283 -2.308 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 -174.35 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.1 pt -101.05 128.9 52.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 175.312 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.19 119.87 6.6 Favored Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 179.246 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 55.2 p90 -138.35 171.97 13.6 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -109.21 131.97 54.57 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.331 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -98.12 170.9 8.59 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.703 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 31.1 p90 -50.18 -24.02 2.56 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 115.516 1.672 . . . . 0.0 115.516 -176.537 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -86.03 -9.92 55.92 Favored 'General case' 0 C--N 1.315 -0.926 0 O-C-N 121.498 -0.751 . . . . 0.0 110.59 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.94 17.14 56.89 Favored Glycine 0 CA--C 1.499 -0.926 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -174.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 42.2 t30 -93.95 136.14 34.56 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 113.822 -1.189 . . . . 0.0 109.399 -175.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 -78.57 113.71 16.85 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 47.3 t -121.14 143.37 33.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 -175.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.446 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 92.6 m-85 -120.79 127.21 51.74 Favored 'General case' 0 C--O 1.242 0.698 0 C-N-CA 122.977 0.511 . . . . 0.0 110.977 -179.138 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 53.0 t -104.48 133.46 20.18 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 178.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.59 -10.81 27.31 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 123.409 2.739 . . . . 0.0 114.267 -176.341 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.279 35.5 m 38.71 -61.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 N-CA-C 118.706 2.854 . . . . 0.0 118.706 174.6 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.545 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 35.6 ptt180 -154.99 150.33 27.24 Favored 'General case' 0 N--CA 1.439 -0.982 0 C-N-CA 123.287 0.635 . . . . 0.0 109.997 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.459 ' O ' ' HA ' ' A' ' 123' ' ' PRO . 82.4 m -68.95 135.61 51.23 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.637 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 95.2 m -151.09 110.92 4.06 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 123.001 0.52 . . . . 0.0 110.868 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 23.3 mp0 -98.71 160.95 13.92 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 176.545 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 128.02 -167.05 20.42 Favored Glycine 0 CA--C 1.487 -1.667 0 C-N-CA 118.768 -1.682 . . . . 0.0 113.508 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 27.9 m -138.13 151.13 69.22 Favored Pre-proline 0 C--N 1.304 -1.38 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 53.6 Cg_exo -56.0 137.01 77.74 Favored 'Trans proline' 0 CA--C 1.54 0.775 0 C-N-CA 122.349 2.033 . . . . 0.0 112.992 -179.49 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 1.3 Cg_endo -92.11 -11.65 27.86 Favored 'Cis proline' 0 C--O 1.25 1.087 0 C-N-CA 124.098 -1.209 . . . . 0.0 113.06 -2.242 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -75.82 101.15 4.99 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-O 122.207 1.003 . . . . 0.0 112.168 -173.093 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.41 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 32.6 p-80 -105.44 132.71 51.28 Favored 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 114.194 -1.366 . . . . 0.0 110.537 177.669 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.637 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 3.1 mp -94.15 105.5 17.8 Favored Pre-proline 0 C--N 1.299 -1.591 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 179.412 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . 0.459 ' HA ' ' O ' ' A' ' 113' ' ' THR . 50.2 Cg_endo -84.31 143.18 9.93 Favored 'Trans proline' 0 N--CA 1.436 -1.864 0 C-N-CA 121.769 1.646 . . . . 0.0 112.813 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.7 -114.62 3.98 Favored Glycine 0 N--CA 1.426 -1.993 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 176.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 62.0 t -94.44 126.8 46.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.545 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.38 136.92 34.15 Favored 'General case' 0 N--CA 1.439 -1.015 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.349 175.199 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.0 m-90 -102.32 19.93 17.84 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.394 0.616 . . . . 0.0 110.939 -178.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.469 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -172.55 179.81 43.84 Favored Glycine 0 N--CA 1.427 -1.933 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.242 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 37.7 t -111.71 135.44 50.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -176.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -97.75 127.36 43.65 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.255 179.174 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 97.3 mttt . . . . . 0 C--N 1.29 -1.997 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 175.419 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 45.6 m95 . . . . . 0 N--CA 1.444 -0.729 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.8 mtpp -121.84 152.06 39.97 Favored 'General case' 0 C--N 1.309 -1.196 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 177.449 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 56.7 tttp -101.65 135.41 43.22 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 34.9 p30 -95.09 174.69 6.95 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -64.18 -22.31 66.89 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 122.924 0.49 . . . . 0.0 111.937 -178.263 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -82.43 -5.56 58.75 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.486 -178.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 95.34 -3.82 66.55 Favored Glycine 0 N--CA 1.439 -1.114 0 C-N-CA 121.151 -0.547 . . . . 0.0 112.615 176.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 7.1 m -84.58 141.08 30.94 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 122.706 0.402 . . . . 0.0 110.126 -176.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 98.2 m95 -92.52 135.87 33.7 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 174.344 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -137.97 159.13 42.83 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 120.84 0.352 . . . . 0.0 110.983 -177.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 58.7 pttt -141.97 152.32 61.64 Favored Pre-proline 0 C--N 1.301 -1.507 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 174.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -80.21 121.85 4.51 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.017 1.812 . . . . 0.0 110.572 175.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.42 ' HB3' HG23 ' A' ' 88' ' ' VAL . 38.2 tt0 -155.42 130.72 9.58 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.285 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.557 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 27.2 t-20 -117.95 115.31 24.65 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -177.078 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.526 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -154.49 178.29 10.23 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -179.086 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 28.5 m -103.35 131.14 50.67 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 121.066 0.46 . . . . 0.0 111.038 -176.225 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.426 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 79.8 t80 -107.08 121.95 45.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 173.403 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 41.4 t -106.65 102.25 13.66 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.045 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.668 -178.379 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 56.0 t30 -77.44 151.63 34.64 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 173.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -142.05 -71.8 0.03 OUTLIER Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.017 -1.563 . . . . 0.0 115.537 -176.195 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.402 ' OD1' ' HG3' ' A' ' 58' ' ' GLN . 26.7 p30 -72.1 -38.27 69.37 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 116.161 1.912 . . . . 0.0 116.161 -169.146 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.402 ' HG3' ' OD1' ' A' ' 57' ' ' ASN . 0.1 OUTLIER -138.54 161.4 58.98 Favored Pre-proline 0 C--N 1.296 -1.752 0 C-N-CA 120.494 -0.482 . . . . 0.0 112.123 -177.031 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -78.08 151.0 26.76 Favored 'Trans proline' 0 N--CA 1.439 -1.717 0 C-N-CA 121.722 1.614 . . . . 0.0 109.578 175.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.6 mt -125.04 126.22 70.77 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -178.388 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.6 p -82.21 117.75 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.218 0 CA-C-O 122.119 0.961 . . . . 0.0 109.527 176.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.3 p -91.28 173.62 7.82 Favored 'General case' 0 C--N 1.289 -2.065 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.333 -176.131 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 74.4 mmt-85 -111.25 145.72 38.24 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-O 121.285 0.564 . . . . 0.0 110.23 -178.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.494 HG23 HD21 ' A' ' 105' ' ' ASN . 76.3 mt -94.89 112.35 27.23 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 CA-C-N 115.203 -0.908 . . . . 0.0 112.717 -176.156 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.11 -23.13 1.16 Allowed Glycine 0 CA--C 1.518 0.279 0 N-CA-C 116.849 1.5 . . . . 0.0 116.849 171.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.451 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 18.1 m -137.11 135.96 20.36 Favored Pre-proline 0 C--N 1.301 -1.541 0 CA-C-N 118.329 1.064 . . . . 0.0 111.168 -175.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 66' ' ' SER . 9.6 Cg_endo -89.98 120.28 0.87 Allowed 'Trans proline' 0 N--CA 1.438 -1.745 0 C-N-CA 121.888 1.725 . . . . 0.0 111.525 173.681 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.549 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 92.9 m-85 -165.42 161.92 19.11 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 103.848 -2.649 . . . . 0.0 103.848 179.024 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 64.9 mt -72.85 -40.08 66.0 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.17 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -97.36 17.49 17.34 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.221 -0.9 . . . . 0.0 111.172 -178.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.549 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -60.68 161.69 14.04 Favored Pre-proline 0 N--CA 1.48 1.06 0 C-N-CA 122.959 0.504 . . . . 0.0 111.624 -179.078 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -57.11 130.71 41.06 Favored 'Trans proline' 0 C--N 1.366 1.5 0 C-N-CA 122.955 2.436 . . . . 0.0 113.185 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 22.2 m -102.92 175.75 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 C-N-CA 124.56 1.144 . . . . 0.0 110.874 -179.537 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.84 3.84 10.76 Favored Glycine 0 C--N 1.309 -0.919 0 C-N-CA 121.308 -0.473 . . . . 0.0 112.175 -178.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -110.18 94.3 0.79 Allowed Glycine 0 N--CA 1.434 -1.442 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 173.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -87.38 122.31 30.97 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.989 -0.713 . . . . 0.0 110.463 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.9 tp -96.78 113.33 62.64 Favored Pre-proline 0 C--N 1.304 -1.384 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.33 159.89 47.94 Favored 'Trans proline' 0 C--O 1.251 1.154 0 C-N-CA 122.591 2.194 . . . . 0.0 113.348 -176.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.28 124.86 25.97 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.889 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.09 -0.54 54.68 Favored Glycine 0 C--N 1.306 -1.106 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.18 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.36 126.52 29.88 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.299 0.571 . . . . 0.0 111.247 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 14.4 m -99.45 108.87 21.44 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 178.217 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.9 mm -119.16 128.56 75.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 120.723 0.296 . . . . 0.0 111.333 -173.192 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.2 p -87.98 128.97 39.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 173.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.557 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 21.1 p90 -104.01 157.98 16.73 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.955 -0.298 . . . . 0.0 111.472 -178.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -114.97 -23.6 9.01 Favored 'General case' 0 C--O 1.247 0.945 0 CA-C-O 121.665 0.745 . . . . 0.0 111.495 -176.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -141.52 137.42 32.03 Favored 'General case' 0 C--N 1.294 -1.807 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.911 -170.575 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.42 HG23 ' HB3' ' A' ' 49' ' ' GLU . 96.0 t -113.73 132.86 61.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.583 ' HG ' ' HE2' ' A' ' 108' ' ' TYR . 56.9 m -131.85 153.75 49.87 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 120.548 0.214 . . . . 0.0 111.235 -176.141 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 55.3 mt -122.12 119.71 59.26 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 173.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.48 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 6.2 tp-100 -122.58 146.31 47.54 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 176.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.71 104.76 0.07 Allowed 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -169.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 108.47 -19.75 31.02 Favored Glycine 0 N--CA 1.436 -1.322 0 CA-C-N 114.853 -1.067 . . . . 0.0 113.999 175.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -145.17 147.01 32.0 Favored 'General case' 0 C--N 1.316 -0.858 0 O-C-N 121.535 -0.979 . . . . 0.0 111.998 -176.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.468 HG23 HG23 ' A' ' 111' ' ' VAL . 14.7 tt -92.64 143.85 10.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 105.461 -2.052 . . . . 0.0 105.461 174.132 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.48 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 70.0 m95 -126.92 148.61 50.03 Favored 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 -175.46 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.8 pt -117.67 137.52 51.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 174.148 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -110.83 131.62 10.48 Favored Glycine 0 N--CA 1.421 -2.329 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -138.62 169.7 17.32 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 177.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 51.8 t-20 -106.56 114.64 28.88 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.32 162.62 28.25 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -178.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -57.54 -17.9 16.4 Favored 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 -177.024 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 7.3 t30 -79.23 -14.83 58.8 Favored 'General case' 0 CA--C 1.547 0.861 0 CA-C-O 121.18 0.514 . . . . 0.0 110.598 178.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 92.21 17.02 48.38 Favored Glycine 0 C--N 1.325 -0.079 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -174.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.494 HD21 HG23 ' A' ' 64' ' ' ILE . 38.1 t30 -97.49 142.89 28.78 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 114.648 -0.776 . . . . 0.0 110.68 -178.267 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 19.2 tpt180 -88.39 107.34 18.79 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 179.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 43.0 t -107.96 139.61 29.41 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -176.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.583 ' HE2' ' HG ' ' A' ' 89' ' ' CYS . 90.5 m-85 -117.5 128.34 54.89 Favored 'General case' 0 C--N 1.32 -0.695 0 O-C-N 123.331 0.395 . . . . 0.0 110.817 -179.317 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 41.9 t -104.7 133.29 20.25 Favored Pre-proline 0 C--N 1.3 -1.547 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.03 -9.49 25.74 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 123.135 2.557 . . . . 0.0 114.001 -177.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.468 HG23 HG23 ' A' ' 95' ' ' ILE 0.307 27.1 m 39.1 -63.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 N-CA-C 118.361 2.726 . . . . 0.0 118.361 175.133 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.547 ' HB2' ' O ' ' A' ' 125' ' ' VAL . 36.0 ptt180 -162.59 164.38 26.78 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-O 121.177 0.513 . . . . 0.0 111.468 177.357 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 58.4 m -75.37 134.72 40.9 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.265 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.477 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 89.6 m -154.58 124.26 6.59 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 123.787 0.835 . . . . 0.0 110.026 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -105.48 160.54 15.07 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 179.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 134.83 -176.24 20.08 Favored Glycine 0 C--N 1.292 -1.872 0 C-N-CA 118.262 -1.923 . . . . 0.0 114.209 175.272 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 76.7 t -127.37 121.33 22.45 Favored Pre-proline 0 C--N 1.298 -1.632 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 99.5 Cg_exo -43.76 136.25 6.97 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 124.043 3.162 . . . . 0.0 113.18 -178.182 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 0.9 OUTLIER -86.13 -11.17 42.48 Favored 'Cis proline' 0 C--O 1.25 1.103 0 C-N-CA 124.007 -1.247 . . . . 0.0 114.25 3.77 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -76.22 102.16 5.7 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.951 0.881 . . . . 0.0 112.19 -172.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -106.09 124.87 50.25 Favored 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 114.073 -1.421 . . . . 0.0 110.83 176.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 55.3 mt -93.74 109.43 41.23 Favored Pre-proline 0 C--N 1.295 -1.768 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.83 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -81.97 150.38 16.04 Favored 'Trans proline' 0 C--O 1.246 0.907 0 C-N-CA 122.485 2.123 . . . . 0.0 114.295 -175.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.33 -125.36 4.3 Favored Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 175.003 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.547 ' O ' ' HB2' ' A' ' 112' ' ' ARG . 60.3 t -79.09 133.68 29.44 Favored 'Isoleucine or valine' 0 C--O 1.244 0.805 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.447 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -93.22 132.94 36.93 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 123.268 0.627 . . . . 0.0 109.857 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 8.6 m0 -107.68 13.38 26.63 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.462 0.649 . . . . 0.0 109.995 178.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.426 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -173.58 170.69 43.85 Favored Glycine 0 N--CA 1.425 -2.089 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 179.569 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 73.3 t -111.41 129.57 66.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.981 0.391 . . . . 0.0 110.316 -176.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -94.4 129.58 41.07 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.079 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 28.0 ttpp . . . . . 0 N--CA 1.423 -1.817 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 -179.731 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . 0.41 ' CE2' ' HD3' ' A' ' 47' ' ' LYS . 66.2 m95 . . . . . 0 N--CA 1.433 -1.319 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.429 ' HD3' ' N ' ' A' ' 39' ' ' LYS . 12.4 tmtt? -135.18 137.89 43.13 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 177.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.429 ' N ' ' HD3' ' A' ' 38' ' ' LYS . 2.6 ttmp? -83.3 116.85 22.62 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.477 ' HB3' ' CE1' ' A' ' 46' ' ' TYR . 36.3 p30 -77.98 177.66 8.1 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 177.154 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -65.33 -7.41 13.36 Favored 'General case' 0 C--N 1.317 -0.819 0 C-N-CA 123.527 0.731 . . . . 0.0 112.525 -178.448 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.4 m-85 -102.25 4.27 39.08 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.497 0.665 . . . . 0.0 110.041 -178.514 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.44 16.15 79.85 Favored Glycine 0 N--CA 1.447 -0.591 0 CA-C-N 115.511 -0.768 . . . . 0.0 112.086 178.006 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 25.3 m -100.22 132.95 45.3 Favored 'General case' 0 N--CA 1.424 -1.743 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.042 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.407 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 75.1 m95 -87.93 125.31 34.44 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 176.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.477 ' CE1' ' HB3' ' A' ' 40' ' ' ASN . 50.9 p90 -130.31 151.52 50.73 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 121.184 -0.207 . . . . 0.0 111.156 -178.292 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.41 ' HD3' ' CE2' ' A' ' 37' ' ' TRP . 18.1 pttp -146.64 140.91 15.62 Favored Pre-proline 0 C--N 1.313 -0.985 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 173.104 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -79.61 120.96 4.51 Favored 'Trans proline' 0 C--O 1.244 0.8 0 C-N-CA 121.635 1.557 . . . . 0.0 112.559 -179.27 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.8 tt0 -158.14 125.21 4.97 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.063 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.404 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 26.0 t-20 -87.25 121.38 29.62 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.709 -175.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -150.27 169.52 21.17 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 19.9 m -116.14 143.41 45.53 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 -173.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -130.19 126.39 37.31 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 124.062 0.945 . . . . 0.0 108.964 175.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.1 t -111.41 109.01 26.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.671 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 37.9 t30 -77.09 131.27 38.28 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 175.428 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -156.91 83.27 0.15 Allowed Glycine 0 C--N 1.306 -1.103 0 C-N-CA 118.979 -1.581 . . . . 0.0 113.992 -176.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.473 ' HB3' ' OE1' ' A' ' 58' ' ' GLN . 40.3 t30 168.59 -67.86 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 125.269 1.427 . . . . 0.0 109.203 172.577 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.502 ' NE2' ' HB3' ' A' ' 127' ' ' TRP . 4.7 pm0 -111.89 152.24 44.08 Favored Pre-proline 0 C--N 1.304 -1.374 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.266 -175.244 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_exo -73.48 133.98 19.88 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.698 1.598 . . . . 0.0 108.051 170.046 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 61.1 mt -108.1 125.7 64.72 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -176.351 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.4 p -81.05 111.77 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.626 0 CA-C-O 122.066 0.936 . . . . 0.0 108.737 176.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 64.7 p -92.22 164.62 13.48 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.399 -176.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 17.2 mmt180 -105.41 135.49 46.7 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.635 -175.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.4 mt -98.9 125.56 52.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 N-CA-C 112.68 0.622 . . . . 0.0 112.68 -173.762 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.75 -21.87 1.52 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 116.388 1.315 . . . . 0.0 116.388 172.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.401 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 22.1 m -146.84 136.99 12.13 Favored Pre-proline 0 C--N 1.305 -1.335 0 CA-C-N 118.678 1.239 . . . . 0.0 111.063 -177.402 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 66' ' ' SER . 19.3 Cg_endo -90.3 120.43 0.82 Allowed 'Trans proline' 0 N--CA 1.437 -1.804 0 C-N-CA 121.925 1.75 . . . . 0.0 110.971 172.396 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.485 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 51.7 m-85 -167.03 171.45 11.07 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 179.685 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 69.4 mt -84.65 -28.46 26.42 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 107.481 -1.304 . . . . 0.0 107.481 172.418 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -96.68 19.78 11.88 Favored 'General case' 0 CA--C 1.549 0.936 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.294 179.524 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.485 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -71.21 155.28 93.24 Favored Pre-proline 0 C--N 1.315 -0.908 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.505 -176.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_exo -55.89 131.16 44.34 Favored 'Trans proline' 0 C--N 1.353 0.801 0 C-N-CA 123.404 2.736 . . . . 0.0 113.927 -179.726 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.3 m -97.54 174.62 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.259 178.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.66 -0.57 15.65 Favored Glycine 0 CA--C 1.496 -1.105 0 C-N-CA 120.071 -1.061 . . . . 0.0 112.235 178.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.43 96.23 0.87 Allowed Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 175.035 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -94.46 118.42 31.61 Favored 'General case' 0 C--N 1.288 -2.071 0 O-C-N 122.186 -0.596 . . . . 0.0 109.967 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 48.4 tp -90.69 117.75 68.18 Favored Pre-proline 0 C--N 1.306 -1.311 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.29 152.51 80.87 Favored 'Trans proline' 0 C--O 1.249 1.061 0 C-N-CA 122.289 1.992 . . . . 0.0 113.029 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.96 135.55 40.04 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 115.142 -0.935 . . . . 0.0 108.982 176.547 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.43 4.91 57.14 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.425 -179.568 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.28 130.48 38.99 Favored 'General case' 0 C--O 1.243 0.731 0 CA-C-O 121.151 0.501 . . . . 0.0 111.882 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.2 m -93.28 120.16 33.25 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.239 176.082 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.6 mm -119.94 118.63 57.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.884 -179.138 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 5.0 p -99.48 112.64 32.34 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 175.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.404 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 45.5 p90 -97.2 155.78 16.69 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.536 -173.17 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -115.54 -9.0 12.11 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -175.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -136.88 131.23 32.86 Favored 'General case' 0 C--N 1.309 -1.194 0 C-N-CA 120.531 -0.467 . . . . 0.0 109.755 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 24.2 t -102.02 129.4 53.42 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.752 ' HG ' ' HE2' ' A' ' 108' ' ' TYR . 43.9 m -134.88 145.93 48.73 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-N 117.84 0.291 . . . . 0.0 111.493 -176.406 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 65.1 mt -120.69 116.89 51.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 175.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.596 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -125.89 136.43 53.04 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 105.854 -1.906 . . . . 0.0 105.854 175.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.04 112.65 0.7 Allowed 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -171.132 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 125.43 -32.62 3.86 Favored Glycine 0 N--CA 1.437 -1.294 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.128 179.071 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 61.2 m80 -153.51 168.8 24.94 Favored 'General case' 0 N--CA 1.473 0.714 0 O-C-N 122.005 -0.703 . . . . 0.0 110.581 -176.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.9 tt -100.5 137.79 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.846 0 N-CA-C 103.449 -2.797 . . . . 0.0 103.449 167.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.596 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 69.5 m95 -118.73 136.76 53.78 Favored 'General case' 0 C--N 1.269 -2.913 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -173.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.449 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.3 pt -100.72 128.68 52.58 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.148 0 C-N-CA 119.896 -0.722 . . . . 0.0 109.43 177.592 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.33 118.83 6.25 Favored Glycine 0 N--CA 1.419 -2.458 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -142.83 168.68 19.14 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -114.72 138.08 51.15 Favored 'General case' 0 C--N 1.291 -1.967 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 176.322 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.98 -177.14 6.48 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.164 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -64.36 -21.67 66.7 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.319 0.581 . . . . 0.0 112.416 -177.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 48.8 t30 -77.74 -8.31 57.78 Favored 'General case' 0 CA--C 1.554 1.134 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.243 176.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 82.73 6.74 88.21 Favored Glycine 0 N--CA 1.461 0.354 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -177.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 43.3 t30 -82.87 133.38 35.13 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 124.067 0.947 . . . . 0.0 109.894 -176.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 16.3 tpp85 -75.29 119.37 19.3 Favored 'General case' 0 C--N 1.316 -0.858 0 O-C-N 123.849 0.718 . . . . 0.0 110.663 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.8 t -124.3 146.63 29.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.752 ' HE2' ' HG ' ' A' ' 89' ' ' CYS . 65.0 m-85 -119.39 131.71 55.71 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 123.477 0.711 . . . . 0.0 110.556 178.204 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 46.7 t -109.76 134.43 20.63 Favored Pre-proline 0 C--N 1.303 -1.454 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -68.7 -19.48 41.48 Favored 'Trans proline' 0 C--N 1.363 1.292 0 C-N-CA 123.135 2.556 . . . . 0.0 114.112 -177.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.296 30.6 m 44.79 -59.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.487 0 N-CA-C 118.394 2.738 . . . . 0.0 118.394 175.159 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.401 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 6.4 ptp180 -152.68 160.22 43.16 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.38 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.6 p -76.15 140.45 41.76 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.007 176.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 96.4 m -152.46 145.41 24.47 Favored 'General case' 0 CA--C 1.499 -1.019 0 CA-C-O 120.934 0.397 . . . . 0.0 111.177 -179.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -133.56 160.9 36.08 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.28 -1.748 . . . . 0.0 106.28 178.216 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.85 -173.44 21.83 Favored Glycine 0 C--N 1.3 -1.429 0 C-N-CA 118.596 -1.764 . . . . 0.0 113.939 175.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 21.1 m -138.24 123.88 12.51 Favored Pre-proline 0 C--N 1.311 -1.097 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.231 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.487 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 78.0 Cg_exo -46.53 128.43 12.69 Favored 'Trans proline' 0 CA--C 1.543 0.937 0 C-N-CA 123.521 2.814 . . . . 0.0 113.05 -178.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.487 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 91.7 Cg_endo -93.67 3.31 55.67 Favored 'Cis proline' 0 CA--C 1.551 1.373 0 N-CA-C 115.239 1.207 . . . . 0.0 115.239 5.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -78.71 102.27 7.98 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 122.199 1.0 . . . . 0.0 110.691 -176.359 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.429 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 35.6 p-80 -105.19 121.77 44.51 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-N 114.012 -1.449 . . . . 0.0 110.958 -177.454 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.4 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 58.3 mt -102.08 100.67 15.73 Favored Pre-proline 0 C--N 1.305 -1.36 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.094 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 121' ' ' HIS . 63.7 Cg_endo -85.7 135.14 4.86 Favored 'Trans proline' 0 CA--C 1.544 0.981 0 C-N-CA 122.872 2.381 . . . . 0.0 114.209 -177.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -112.11 -151.97 11.7 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 175.294 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 90.4 t -52.63 124.49 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.336 0 C-N-CA 123.938 0.895 . . . . 0.0 112.535 -178.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.401 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -93.77 143.7 26.09 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.871 175.29 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . 0.502 ' HB3' ' NE2' ' A' ' 58' ' ' GLN . 5.3 m-90 -105.47 17.24 24.21 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.327 0.584 . . . . 0.0 110.986 178.347 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -165.57 -170.43 30.5 Favored Glycine 0 N--CA 1.429 -1.804 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.171 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 98.8 t -111.23 133.04 58.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -178.171 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -104.43 127.6 52.14 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.4 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 14.7 tppt? . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . 0.525 ' CE2' ' HD2' ' A' ' 47' ' ' LYS . 86.2 m95 . . . . . 0 C--O 1.245 0.837 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 53.5 mtmt -135.49 148.92 49.38 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 175.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -88.08 125.86 34.8 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.57 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 55.1 t30 -93.78 169.36 10.36 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 123.687 0.795 . . . . 0.0 110.545 -176.618 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -47.66 -34.81 8.54 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.926 2.091 . . . . 0.0 113.005 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -88.21 7.55 31.39 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.113 0.482 . . . . 0.0 111.703 -175.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.87 -13.02 60.15 Favored Glycine 0 CA--C 1.507 -0.462 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.453 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 5.3 m -71.84 137.09 47.27 Favored 'General case' 0 N--CA 1.42 -1.965 0 C-N-CA 124.55 1.14 . . . . 0.0 110.413 -177.79 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.4 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 66.5 m95 -90.03 133.75 34.65 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 173.549 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.57 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 8.6 p90 -132.3 149.12 52.43 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.865 -177.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.525 ' HD2' ' CE2' ' A' ' 37' ' ' TRP . 21.9 ptmt -137.19 146.85 56.05 Favored Pre-proline 0 C--N 1.305 -1.328 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 175.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -77.02 121.85 5.99 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.057 1.838 . . . . 0.0 109.862 173.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -157.98 120.86 3.86 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -178.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.488 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 4.9 t30 -103.35 117.03 33.56 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 -177.009 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.422 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.93 -177.9 6.57 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.525 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 32.3 m -118.05 152.68 35.07 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 120.627 0.251 . . . . 0.0 110.577 -177.044 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.498 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 92.5 t80 -134.61 132.65 39.27 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 177.606 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.1 t -115.56 127.77 73.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.457 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -65.16 135.72 55.82 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.085 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -73.82 -90.91 0.15 Allowed Glycine 0 N--CA 1.44 -1.067 0 O-C-N 123.654 0.596 . . . . 0.0 113.804 -175.545 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -109.72 -47.03 3.41 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 114.097 1.147 . . . . 0.0 114.097 -174.528 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -116.95 152.25 48.44 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -174.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.47 ' HB3' HD21 ' A' ' 76' ' ' ASN . 51.9 Cg_exo -57.13 137.46 81.93 Favored 'Trans proline' 0 C--O 1.242 0.699 0 C-N-CA 122.856 2.37 . . . . 0.0 112.106 178.434 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -108.98 125.85 66.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 -176.266 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 33.6 m -72.93 148.43 9.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 175.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 35.9 p -127.15 163.01 24.78 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 110.337 -0.245 . . . . 0.0 110.337 -175.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -110.18 141.85 42.53 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -178.523 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.7 mt -94.1 119.01 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.493 -175.561 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 72.18 -22.95 0.75 Allowed Glycine 0 CA--C 1.529 0.922 0 N-CA-C 117.273 1.669 . . . . 0.0 117.273 170.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.3 m -141.32 136.35 15.71 Favored Pre-proline 0 C--N 1.297 -1.69 0 CA-C-N 118.958 1.379 . . . . 0.0 110.862 -178.417 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -89.64 119.53 0.88 Allowed 'Trans proline' 0 N--CA 1.433 -2.055 0 C-N-CA 121.325 1.35 . . . . 0.0 110.47 172.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.458 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 72.0 m-85 -169.37 169.46 9.02 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 127.954 2.502 . . . . 0.0 104.61 -179.295 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -90.13 -17.87 26.86 Favored 'General case' 0 C--N 1.293 -1.879 0 CA-C-O 121.222 0.534 . . . . 0.0 110.75 175.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 27.8 p-10 -106.7 20.32 19.19 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.801 0.81 . . . . 0.0 109.665 177.303 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.458 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.59 156.4 90.18 Favored Pre-proline 0 C--O 1.25 1.101 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.734 179.022 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -54.58 122.97 12.52 Favored 'Trans proline' 0 C--N 1.357 1.024 0 C-N-CA 122.922 2.414 . . . . 0.0 112.372 -179.452 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.414 HG22 ' H ' ' A' ' 74' ' ' GLY . 8.5 p -103.45 174.24 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-N 114.916 -1.038 . . . . 0.0 108.235 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.414 ' H ' HG22 ' A' ' 73' ' ' VAL . . . 119.9 -6.43 12.26 Favored Glycine 0 CA--C 1.494 -1.258 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -178.383 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.23 131.55 10.62 Favored Glycine 0 N--CA 1.429 -1.773 0 N-CA-C 108.399 -1.88 . . . . 0.0 108.399 173.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.47 HD21 ' HB3' ' A' ' 59' ' ' PRO . 9.2 t30 -126.98 141.38 51.81 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 118.113 0.956 . . . . 0.0 111.564 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 51.5 tp -104.18 114.72 64.09 Favored Pre-proline 0 C--N 1.309 -1.171 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 176.09 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -62.7 160.42 32.76 Favored 'Trans proline' 0 C--O 1.243 0.75 0 C-N-CA 123.072 2.515 . . . . 0.0 112.81 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.67 137.49 46.06 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.327 -178.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.32 19.6 78.1 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.804 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -85.72 140.12 30.78 Favored 'General case' 0 C--N 1.317 -0.814 0 O-C-N 122.554 -0.38 . . . . 0.0 110.346 178.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 40.5 m -111.68 108.73 18.28 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.8 mm -116.52 136.51 53.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 122.889 0.475 . . . . 0.0 110.565 -175.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.4 p -102.92 128.24 55.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 174.46 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.488 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 42.5 p90 -117.63 157.74 25.88 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.559 -175.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -121.26 -5.99 9.39 Favored 'General case' 0 C--O 1.247 0.972 0 O-C-N 123.653 0.595 . . . . 0.0 111.261 -178.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -133.71 126.88 31.67 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -173.624 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.0 t -114.1 127.37 71.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 177.74 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.453 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 63.0 m -129.68 150.51 50.97 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 122.983 0.177 . . . . 0.0 111.469 -176.039 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 45.0 mt -121.28 117.29 52.3 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 172.526 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.409 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -111.39 144.46 40.56 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 104.261 -2.496 . . . . 0.0 104.261 173.185 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.8 104.07 0.07 Allowed 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -170.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 115.77 -23.94 10.58 Favored Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.471 -0.786 . . . . 0.0 113.677 178.304 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . 0.442 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 50.8 m80 -147.77 145.55 28.84 Favored 'General case' 0 CA--C 1.505 -0.786 0 O-C-N 121.559 -0.965 . . . . 0.0 112.204 -177.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.423 HG23 HG23 ' A' ' 111' ' ' VAL . 14.5 tt -93.9 139.01 19.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 105.552 -2.018 . . . . 0.0 105.552 173.692 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.409 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 74.5 m95 -124.02 139.01 54.36 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -174.563 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.448 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.3 pt -102.46 132.22 48.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 173.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.48 124.68 8.1 Favored Glycine 0 N--CA 1.425 -2.053 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -179.691 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -138.55 155.56 48.27 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 178.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -97.99 120.33 38.19 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 176.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.31 161.55 20.4 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -58.41 -14.09 6.9 Favored 'General case' 0 N--CA 1.483 1.212 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.245 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -77.62 -13.56 59.87 Favored 'General case' 0 CA--C 1.548 0.895 0 CA-C-O 121.5 0.667 . . . . 0.0 110.713 177.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 87.64 15.9 60.93 Favored Glycine 0 CA--C 1.497 -1.079 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -176.219 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 39.4 t-20 -97.1 132.82 42.51 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 114.239 -0.98 . . . . 0.0 109.226 -177.573 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 25.9 tpt180 -90.17 99.06 12.15 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 175.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 36.8 t -100.32 142.42 15.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.989 -173.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 81.5 m-85 -115.23 129.38 56.62 Favored 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 123.081 0.552 . . . . 0.0 110.223 178.23 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.1 t -108.32 133.45 20.56 Favored Pre-proline 0 C--N 1.306 -1.303 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.288 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.56 -10.06 24.8 Favored 'Trans proline' 0 C--N 1.364 1.344 0 C-N-CA 123.397 2.731 . . . . 0.0 114.729 -174.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.423 HG23 HG23 ' A' ' 95' ' ' ILE 0.293 27.2 m 38.19 -67.26 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 N-CA-C 118.026 2.602 . . . . 0.0 118.026 175.0 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.486 ' HE ' ' HB2' ' A' ' 126' ' ' ALA . 6.3 ptp85 -147.44 148.81 31.67 Favored 'General case' 0 N--CA 1.445 -0.7 0 C-N-CA 123.239 0.616 . . . . 0.0 109.603 176.078 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.442 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 66.8 m -67.95 133.98 50.0 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 176.386 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 86.3 m -151.34 103.82 3.03 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 122.886 0.474 . . . . 0.0 110.363 -179.173 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 45.8 mt-30 -88.85 141.14 28.75 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.193 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 139.7 178.04 16.31 Favored Glycine 0 N--CA 1.42 -2.386 0 C-N-CA 119.015 -1.564 . . . . 0.0 113.273 178.449 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 87.0 t -133.31 130.61 21.22 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 179.182 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.411 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 66.3 Cg_exo -43.46 132.51 7.1 Favored 'Trans proline' 0 CA--C 1.548 1.195 0 C-N-CA 123.44 2.76 . . . . 0.0 113.456 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.411 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 43.1 Cg_endo -89.31 -5.98 51.67 Favored 'Cis proline' 0 CA--C 1.541 0.826 0 C-N-CA 123.373 -1.511 . . . . 0.0 114.832 4.234 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -76.51 100.65 5.34 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-O 122.161 0.981 . . . . 0.0 112.409 -173.588 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 28.7 p-80 -105.43 126.57 52.27 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 113.845 -1.525 . . . . 0.0 111.007 178.509 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.564 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 60.7 mt -100.6 104.39 30.52 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 174.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -76.97 123.65 6.9 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.564 2.176 . . . . 0.0 113.171 -175.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -108.51 -141.86 9.76 Favored Glycine 0 N--CA 1.424 -2.12 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.586 177.242 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 67.0 t -75.21 122.28 28.57 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 C-N-CA 122.948 0.499 . . . . 0.0 111.996 -176.623 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.486 ' HB2' ' HE ' ' A' ' 112' ' ' ARG . . . -93.23 143.36 26.33 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.719 173.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.8 m-90 -106.03 14.61 27.61 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.951 0.881 . . . . 0.0 109.686 177.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.498 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -162.13 177.61 38.26 Favored Glycine 0 N--CA 1.407 -3.251 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.491 -179.426 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 57.5 t -111.52 118.82 58.45 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.192 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 -177.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 41.8 m-85 -78.74 132.77 37.08 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.525 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 53.9 tptt . . . . . 0 N--CA 1.404 -2.767 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 95.1 m95 . . . . . 0 C--O 1.237 0.418 0 CA-C-O 120.965 0.412 . . . . 0.0 110.419 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 8.3 tmtm? -118.44 133.46 55.85 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -81.67 128.74 34.28 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 120.91 0.386 . . . . 0.0 111.723 -176.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -96.67 166.08 11.83 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 176.136 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -51.65 -27.79 12.56 Favored 'General case' 0 N--CA 1.489 1.485 0 C-N-CA 125.184 1.394 . . . . 0.0 113.082 -176.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 69.0 m-85 -87.5 10.11 18.76 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 121.498 0.666 . . . . 0.0 111.535 -175.445 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.54 14.36 82.1 Favored Glycine 0 CA--C 1.5 -0.89 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 178.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.551 HG22 ' HB2' ' A' ' 89' ' ' CYS . 6.8 m -96.14 127.7 42.38 Favored 'General case' 0 N--CA 1.409 -2.517 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -177.334 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 71.8 m95 -95.31 120.99 36.5 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.092 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -120.14 148.69 43.32 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.106 -177.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.1 pttm -134.95 151.4 75.45 Favored Pre-proline 0 C--N 1.305 -1.342 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -71.88 132.51 20.1 Favored 'Trans proline' 0 N--CA 1.45 -1.043 0 C-N-CA 121.678 1.585 . . . . 0.0 111.471 175.523 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -159.16 120.61 3.34 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 176.098 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.442 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 3.7 t-20 -107.39 115.73 30.68 Favored 'General case' 0 C--N 1.295 -1.783 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.328 -175.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -160.94 178.63 9.2 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.241 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 17.4 m -116.82 151.98 35.38 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -178.539 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.4 t80 -124.95 127.96 47.86 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 175.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 46.6 t -112.27 112.69 41.57 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.037 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 55.3 t30 -65.72 136.25 56.01 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.2 -179.026 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -119.07 -83.19 0.84 Allowed Glycine 0 N--CA 1.43 -1.739 0 N-CA-C 115.77 1.068 . . . . 0.0 115.77 -170.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -79.07 -23.28 44.31 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 115.365 1.617 . . . . 0.0 115.365 -166.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.439 HE21 ' HB2' ' A' ' 58' ' ' GLN . 0.0 OUTLIER -152.79 150.1 23.72 Favored Pre-proline 0 C--N 1.311 -1.102 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.277 -178.833 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 58' ' ' GLN . 16.5 Cg_exo -68.37 131.24 22.82 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.369 2.046 . . . . 0.0 109.739 177.536 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 51.2 mt -106.81 127.52 62.28 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.828 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -171.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -81.5 138.03 20.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 178.08 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 50.9 p -110.51 170.11 8.3 Favored 'General case' 0 C--N 1.295 -1.791 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.751 -174.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -117.29 138.12 51.96 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.185 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.7 mt -99.09 125.68 52.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.889 -174.086 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.39 -22.93 3.58 Favored Glycine 0 N--CA 1.448 -0.534 0 N-CA-C 115.772 1.069 . . . . 0.0 115.772 172.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.5 m -152.3 138.1 11.5 Favored Pre-proline 0 C--N 1.297 -1.696 0 CA-C-N 118.074 0.937 . . . . 0.0 110.065 -177.694 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -89.84 120.87 0.95 Allowed 'Trans proline' 0 N--CA 1.44 -1.674 0 C-N-CA 121.64 1.56 . . . . 0.0 111.008 173.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.524 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 93.5 m-85 -168.58 166.24 12.03 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 127.246 2.218 . . . . 0.0 105.021 179.174 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 96.5 mt -82.01 -19.74 39.83 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-O 121.357 0.598 . . . . 0.0 109.994 175.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -111.02 19.69 18.21 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.294 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.524 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -73.38 156.88 88.69 Favored Pre-proline 0 C--O 1.249 1.05 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.573 -178.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -46.97 127.36 12.32 Favored 'Trans proline' 0 C--N 1.365 1.404 0 C-N-CA 123.754 2.969 . . . . 0.0 113.806 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 10.9 p -99.89 172.71 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-N 114.304 -1.316 . . . . 0.0 107.95 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.91 11.55 7.6 Favored Glycine 0 C--N 1.318 -0.469 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -177.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -137.1 121.11 2.25 Favored Glycine 0 N--CA 1.423 -2.228 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 175.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -126.17 141.54 51.89 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 117.519 0.66 . . . . 0.0 109.899 -178.266 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 27.4 tp -101.41 113.61 65.8 Favored Pre-proline 0 N--CA 1.429 -1.48 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.21 166.72 22.32 Favored 'Trans proline' 0 C--O 1.249 1.033 0 C-N-CA 122.272 1.981 . . . . 0.0 113.32 -177.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.15 128.64 36.32 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.225 179.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.99 -5.34 61.47 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.873 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.84 128.55 36.72 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.013 0.435 . . . . 0.0 111.22 -179.199 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 44.3 m -104.08 111.55 24.17 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.593 -179.574 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.6 mm -116.99 130.27 72.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.28 -176.314 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.2 p -99.11 139.34 21.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 174.71 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 46.2 p90 -135.3 158.16 45.08 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.802 -176.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -128.34 -0.39 5.69 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.589 177.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -129.64 127.8 41.32 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.06 -178.236 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.6 t -123.66 126.94 73.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.551 ' HB2' HG22 ' A' ' 44' ' ' THR . 27.2 p -135.84 148.46 48.68 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -174.24 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 68.8 mt -106.03 121.96 59.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.996 178.123 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.449 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -125.7 144.85 50.43 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 173.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -51.05 107.23 0.16 Allowed 'General case' 0 C--N 1.317 -0.805 0 O-C-N 123.51 0.506 . . . . 0.0 111.535 -177.3 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.7 -41.62 1.52 Allowed Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.117 178.694 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . 0.502 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 69.9 m80 -154.16 166.02 34.42 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 117.294 0.547 . . . . 0.0 110.915 -175.524 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.8 tt -105.26 110.15 30.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 173.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.524 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 45.2 m95 -96.74 142.66 28.5 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.784 -168.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.8 pt -100.2 134.22 40.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 174.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -101.96 124.63 8.27 Favored Glycine 0 N--CA 1.424 -2.158 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -149.72 169.92 19.93 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-O 121.018 0.437 . . . . 0.0 109.832 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -104.33 143.13 33.4 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.611 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -94.43 159.32 15.16 Favored 'General case' 0 C--N 1.291 -1.964 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 173.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -54.12 -21.92 9.83 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -179.064 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 11.4 t30 -92.59 7.31 43.87 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-O 121.973 0.892 . . . . 0.0 110.738 -177.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 83.02 13.41 77.53 Favored Glycine 0 C--N 1.321 -0.251 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.677 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 18.7 m120 -83.72 141.05 31.73 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.818 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 30.2 tpt180 -89.83 106.27 18.36 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 176.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.3 t -112.6 138.26 42.44 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 C-N-CA 119.895 -0.722 . . . . 0.0 110.512 -173.766 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.413 ' HE1' ' HG ' ' A' ' 89' ' ' CYS . 63.8 m-85 -117.17 126.8 53.36 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.452 -0.794 . . . . 0.0 110.002 176.643 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.7 t -109.07 130.63 22.5 Favored Pre-proline 0 C--N 1.304 -1.4 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -68.89 -22.26 36.49 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 122.819 2.346 . . . . 0.0 114.133 -176.423 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.298 34.4 m 49.3 -54.9 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.579 0 N-CA-C 117.771 2.508 . . . . 0.0 117.771 177.045 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -150.77 143.42 24.46 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 123.464 0.706 . . . . 0.0 109.67 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.502 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 69.1 m -71.61 127.87 33.96 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.732 178.443 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.511 ' SG ' ' HA ' ' A' ' 123' ' ' PRO . 94.5 m -149.49 140.51 22.93 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.06 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -125.12 153.99 42.14 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 105.788 -1.93 . . . . 0.0 105.788 178.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.84 -168.6 31.19 Favored Glycine 0 CA--C 1.483 -1.919 0 C-N-CA 118.633 -1.746 . . . . 0.0 112.275 178.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 65.6 t -138.82 121.52 10.63 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 179.134 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 88.5 Cg_exo -48.03 136.23 23.64 Favored 'Trans proline' 0 C--O 1.238 0.517 0 C-N-CA 123.175 2.583 . . . . 0.0 111.952 -179.501 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 90.8 Cg_endo -95.32 25.04 23.18 Favored 'Cis proline' 0 CA--C 1.548 1.193 0 C-N-CA 124.461 -1.058 . . . . 0.0 114.043 3.674 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -106.15 106.02 16.34 Favored 'General case' 0 C--N 1.315 -0.928 0 O-C-N 121.789 -0.57 . . . . 0.0 111.274 -178.383 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 25.2 p-80 -104.17 139.85 38.65 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.175 176.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 44.7 mm -104.02 107.4 56.9 Favored Pre-proline 0 C--N 1.293 -1.852 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . 0.511 ' HA ' ' SG ' ' A' ' 114' ' ' CYS . 86.0 Cg_endo -79.57 147.57 19.94 Favored 'Trans proline' 0 C--O 1.247 0.933 0 C-N-CA 122.623 2.215 . . . . 0.0 113.989 -175.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -131.49 -124.73 2.6 Favored Glycine 0 N--CA 1.428 -1.854 0 CA-C-N 115.415 -0.812 . . . . 0.0 111.266 176.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.0 t -85.62 121.37 37.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -175.424 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.38 151.23 19.55 Favored 'General case' 0 C--O 1.246 0.894 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.158 173.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . 0.421 ' HH2' ' HE2' ' A' ' 94' ' ' HIS . 5.5 m-90 -109.1 6.54 25.02 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 179.536 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -160.82 -171.74 27.18 Favored Glycine 0 N--CA 1.428 -1.899 0 C-N-CA 120.64 -0.79 . . . . 0.0 111.271 -178.153 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 44.0 t -111.7 131.97 61.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -174.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -91.9 137.46 32.34 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 176.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt . . . . . 0 C--N 1.288 -2.078 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.684 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 96.9 m95 . . . . . 0 N--CA 1.442 -0.841 0 CA-C-O 121.551 0.691 . . . . 0.0 111.791 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.6 tmtt? -130.3 140.98 50.63 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.334 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -85.84 146.16 26.88 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.396 0.617 . . . . 0.0 112.371 -173.049 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 48.2 t-20 -109.75 153.83 23.78 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 124.988 1.315 . . . . 0.0 107.622 178.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 7.9 tt0 -53.88 -26.5 25.18 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 125.443 1.497 . . . . 0.0 112.48 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -75.3 -7.91 55.23 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.359 0.6 . . . . 0.0 111.63 -179.609 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.02 -13.32 63.59 Favored Glycine 0 N--CA 1.437 -1.275 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 -178.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 7.3 m -68.63 147.98 51.12 Favored 'General case' 0 N--CA 1.421 -1.879 0 C-N-CA 124.954 1.301 . . . . 0.0 109.073 179.285 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.458 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 64.7 m95 -111.31 142.28 43.74 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 173.611 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -139.1 156.99 46.75 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-O 121.087 0.47 . . . . 0.0 111.531 -179.084 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -138.48 132.51 16.57 Favored Pre-proline 0 C--N 1.295 -1.779 0 CA-C-N 114.905 -1.043 . . . . 0.0 108.223 174.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.52 121.16 7.9 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 N-CA-C 108.752 -1.288 . . . . 0.0 108.752 173.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -168.03 124.9 1.09 Allowed 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -176.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -93.47 138.91 31.31 Favored 'General case' 0 CA--C 1.483 -1.61 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.341 -176.342 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.475 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -164.01 160.71 22.1 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 175.074 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.491 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 16.1 m -105.6 132.58 51.57 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.378 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -108.15 121.06 44.07 Favored 'General case' 0 N--CA 1.422 -1.825 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 175.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 42.5 t -107.19 119.25 56.49 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.078 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 176.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.428 ' ND2' HG12 ' A' ' 60' ' ' ILE . 46.4 t-20 -68.99 123.21 20.41 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.248 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -143.44 39.85 1.27 Allowed Glycine 0 N--CA 1.417 -2.624 0 C-N-CA 120.098 -1.048 . . . . 0.0 111.937 -176.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 20.7 t-20 -145.55 -66.73 0.31 Allowed 'General case' 0 C--N 1.31 -1.119 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.074 177.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -157.43 161.34 29.41 Favored Pre-proline 0 C--N 1.317 -0.806 0 CA-C-O 118.872 -0.585 . . . . 0.0 109.76 -178.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.24 137.88 81.38 Favored 'Trans proline' 0 C--N 1.357 0.994 0 C-N-CA 122.96 2.44 . . . . 0.0 112.279 -179.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.59 HG21 ' SG ' ' A' ' 109' ' ' CYS . 32.7 mm -106.95 140.55 24.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.996 -174.799 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.27 107.85 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.256 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 172.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 57.7 p -93.72 153.67 18.2 Favored 'General case' 0 C--N 1.294 -1.836 0 CA-C-N 115.067 -0.969 . . . . 0.0 110.37 -176.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -106.44 140.39 39.43 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -177.411 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.3 mp -105.53 125.14 60.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-O 121.282 0.563 . . . . 0.0 111.672 -175.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.32 -22.78 11.4 Favored Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 115.533 0.973 . . . . 0.0 115.533 172.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 41.9 m -152.91 136.67 10.19 Favored Pre-proline 0 C--N 1.305 -1.337 0 CA-C-N 118.12 0.96 . . . . 0.0 110.385 -178.076 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -90.04 119.61 0.81 Allowed 'Trans proline' 0 N--CA 1.439 -1.718 0 C-N-CA 121.434 1.422 . . . . 0.0 110.986 173.544 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.44 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 76.3 m-85 -169.41 175.09 5.66 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 105.151 -2.166 . . . . 0.0 105.151 -179.46 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -88.62 -29.74 19.74 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 172.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -92.32 20.39 6.15 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.784 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.44 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -80.56 159.38 69.63 Favored Pre-proline 0 C--N 1.309 -1.161 0 CA-C-O 119.644 -0.217 . . . . 0.0 110.733 -176.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -57.12 144.06 91.29 Favored 'Trans proline' 0 C--N 1.358 1.063 0 C-N-CA 123.405 2.737 . . . . 0.0 113.989 -177.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.7 m -101.81 174.53 1.04 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.062 0 C-N-CA 124.437 1.095 . . . . 0.0 110.458 -179.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.8 26.91 2.43 Favored Glycine 0 C--N 1.306 -1.118 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -179.255 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.88 109.63 0.59 Allowed Glycine 0 N--CA 1.423 -2.185 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -108.04 126.04 52.26 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-O 120.856 0.36 . . . . 0.0 110.102 178.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.49 ' HB3' ' HB ' ' A' ' 60' ' ' ILE . 33.1 tp -107.56 109.22 62.42 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 107.043 -1.466 . . . . 0.0 107.043 175.323 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -71.08 159.94 50.74 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.191 1.928 . . . . 0.0 112.195 -177.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.78 133.52 46.62 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 177.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.5 -10.52 56.31 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 121.046 -0.597 . . . . 0.0 111.971 -178.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.09 138.24 51.83 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.904 0.383 . . . . 0.0 110.682 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.7 m -117.89 110.17 17.42 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.259 -179.191 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.1 mm -120.89 120.3 61.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 CA-C-O 120.732 0.301 . . . . 0.0 110.62 -176.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 6.6 p -91.67 111.37 23.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-O 121.649 0.738 . . . . 0.0 109.404 175.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.475 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 46.6 p90 -97.12 168.6 10.35 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.963 -174.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -117.68 -17.59 9.87 Favored 'General case' 0 C--N 1.316 -0.857 0 O-C-N 123.858 0.724 . . . . 0.0 112.255 -176.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -135.66 133.92 38.66 Favored 'General case' 0 N--CA 1.432 -1.339 0 C-N-CA 119.891 -0.723 . . . . 0.0 110.905 -173.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.7 t -105.55 127.1 60.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 35.1 m -127.35 148.44 50.26 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 117.742 0.246 . . . . 0.0 110.927 -176.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 39.9 mt -119.14 120.18 63.09 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 CA-C-O 121.039 0.447 . . . . 0.0 109.964 172.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.501 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.2 tp-100 -122.51 118.58 28.62 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 103.514 -2.773 . . . . 0.0 103.514 172.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.45 107.3 0.12 Allowed 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 113.728 1.01 . . . . 0.0 113.728 -165.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 137.41 -31.4 2.52 Favored Glycine 0 N--CA 1.435 -1.391 0 CA-C-N 114.417 -1.265 . . . . 0.0 110.533 -179.252 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . 0.421 ' HA ' ' H ' ' A' ' 114' ' ' CYS . 73.0 m80 -151.13 163.97 37.57 Favored 'General case' 0 CA--C 1.483 -1.633 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.555 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.2 tt -103.9 133.92 46.57 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.742 0 N-CA-C 104.504 -2.406 . . . . 0.0 104.504 170.009 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.501 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 68.3 m95 -115.59 140.07 49.52 Favored 'General case' 0 C--N 1.27 -2.86 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -172.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.423 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.6 pt -100.98 130.02 51.0 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.315 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -101.27 120.4 6.86 Favored Glycine 0 N--CA 1.419 -2.464 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.163 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 44.4 p90 -142.83 144.47 32.54 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -101.93 126.13 48.77 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 175.451 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -93.45 167.84 11.45 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.238 -176.618 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 31.6 p90 -63.19 -2.21 1.29 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 113.859 1.059 . . . . 0.0 113.859 -178.361 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -88.09 -6.7 57.77 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 175.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 90.72 -0.47 76.94 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 111.808 -0.517 . . . . 0.0 111.808 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 21.2 p30 -96.36 147.67 23.57 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -177.046 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 9.7 tpp85 -92.13 111.56 23.16 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 175.128 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.5 t -111.99 143.58 21.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 -176.782 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.423 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 95.4 m-85 -119.33 129.28 54.78 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.027 0.441 . . . . 0.0 110.915 178.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . 0.59 ' SG ' HG21 ' A' ' 60' ' ' ILE . 43.1 t -110.56 127.97 26.1 Favored Pre-proline 0 C--N 1.302 -1.497 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -71.57 -5.63 17.46 Favored 'Trans proline' 0 C--N 1.359 1.123 0 C-N-CA 123.462 2.775 . . . . 0.0 115.243 -175.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.304 30.1 m 37.33 -59.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.515 2.775 0 N-CA-C 118.881 2.919 . . . . 0.0 118.881 175.26 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.464 ' CZ ' ' HB2' ' A' ' 126' ' ' ALA . 7.8 ptp180 -150.72 156.36 41.15 Favored 'General case' 0 C--O 1.248 0.994 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.485 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.2 m -67.27 132.63 48.11 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 176.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.421 ' H ' ' HA ' ' A' ' 94' ' ' HIS . 53.5 m -152.09 110.52 3.75 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.803 0.811 . . . . 0.0 111.449 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -102.93 143.72 32.14 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 106.119 -1.808 . . . . 0.0 106.119 178.144 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 147.71 -170.85 28.37 Favored Glycine 0 CA--C 1.489 -1.566 0 C-N-CA 118.207 -1.949 . . . . 0.0 113.488 178.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 84.7 t -134.67 123.27 16.11 Favored Pre-proline 0 C--N 1.304 -1.386 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 179.221 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 96.0 Cg_exo -45.86 135.53 13.76 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.76 2.974 . . . . 0.0 113.304 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 28.3 Cg_endo -95.1 17.82 37.08 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 C-N-CA 124.283 -1.132 . . . . 0.0 113.493 1.402 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -94.8 101.91 13.75 Favored 'General case' 0 C--N 1.312 -1.028 0 C-N-CA 120.491 -0.484 . . . . 0.0 110.405 -177.625 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 10.9 p-80 -104.63 138.99 40.14 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.902 177.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 50.6 mm -102.31 99.54 13.09 Favored Pre-proline 0 C--N 1.301 -1.502 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 172.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -84.52 147.61 11.14 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 122.82 2.347 . . . . 0.0 113.989 -174.634 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.07 -145.02 6.61 Favored Glycine 0 N--CA 1.419 -2.497 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.28 175.414 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.5 t -60.67 122.72 11.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 C-N-CA 123.727 0.811 . . . . 0.0 111.868 -177.26 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.464 ' HB2' ' CZ ' ' A' ' 112' ' ' ARG . . . -94.22 145.06 24.99 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.501 174.608 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.8 m-90 -105.59 18.69 21.79 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.341 0.591 . . . . 0.0 110.907 177.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -166.99 -165.89 25.16 Favored Glycine 0 N--CA 1.427 -1.933 0 C-N-CA 119.788 -1.196 . . . . 0.0 112.791 -179.727 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 48.7 t -124.03 139.12 51.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -178.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -105.09 134.41 48.24 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 177.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.298 -1.667 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 98.7 m95 . . . . . 0 CA--C 1.502 -0.904 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -140.41 145.53 37.15 Favored 'General case' 0 C--N 1.281 -2.406 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 179.571 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 24.5 ttmm -84.7 109.25 17.88 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-O 121.182 0.515 . . . . 0.0 109.83 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.47 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 44.2 t30 -78.35 168.5 19.73 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.655 -179.44 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -58.28 -12.11 3.37 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -174.524 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -91.84 2.26 56.63 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-O 121.195 0.521 . . . . 0.0 109.87 179.249 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.07 -12.51 57.84 Favored Glycine 0 C--N 1.33 0.205 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -178.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.479 HG21 ' HG2' ' A' ' 67' ' ' PRO . 14.6 m -76.56 140.57 41.14 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 124.638 1.175 . . . . 0.0 110.592 -176.316 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -90.8 131.97 36.14 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 175.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.47 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 11.0 p90 -136.88 159.43 41.89 Favored 'General case' 0 C--N 1.292 -1.915 0 C-N-CA 120.006 -0.677 . . . . 0.0 109.733 -179.541 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.7 pttm -155.09 141.33 13.04 Favored Pre-proline 0 N--CA 1.431 -1.394 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 170.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -71.23 122.46 8.73 Favored 'Trans proline' 0 C--O 1.247 0.941 0 C-N-CA 121.873 1.715 . . . . 0.0 110.593 175.517 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -154.71 120.95 5.3 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 -178.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.549 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 7.6 t30 -104.93 117.68 34.64 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.625 -172.747 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.458 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -151.69 173.57 14.54 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 179.674 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 31.1 m -113.58 129.78 56.5 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -176.125 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -107.98 131.69 54.29 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 176.341 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 52.4 t -113.94 112.89 42.14 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 175.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -71.19 139.87 50.3 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -76.89 -117.8 0.16 Allowed Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 114.865 0.706 . . . . 0.0 114.865 -173.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -109.98 10.49 24.23 Favored 'General case' 0 C--N 1.311 -1.08 0 O-C-N 122.303 -0.528 . . . . 0.0 112.016 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -131.38 138.53 32.97 Favored Pre-proline 0 C--N 1.299 -1.609 0 C-N-CA 120.805 -0.358 . . . . 0.0 110.286 -175.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -69.7 141.43 45.45 Favored 'Trans proline' 0 C--O 1.242 0.695 0 C-N-CA 121.898 1.732 . . . . 0.0 109.822 174.344 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 64.4 mt -121.04 125.15 73.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -178.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 29.1 m -80.97 140.05 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.172 0 CA-C-O 121.803 0.811 . . . . 0.0 109.19 175.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . 0.438 HG22 ' HA ' ' A' ' 109' ' ' CYS . 37.3 p -124.24 164.16 20.13 Favored 'General case' 0 C--N 1.272 -2.796 0 CA-C-N 115.095 -0.957 . . . . 0.0 110.814 -171.412 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -107.81 143.58 36.18 Favored 'General case' 0 C--N 1.317 -0.804 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -177.087 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.5 mt -106.09 130.21 58.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-O 121.229 0.538 . . . . 0.0 112.128 -174.247 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.48 -23.05 5.8 Favored Glycine 0 CA--C 1.521 0.417 0 N-CA-C 116.207 1.243 . . . . 0.0 116.207 171.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 52.1 m -156.94 142.28 12.51 Favored Pre-proline 0 C--N 1.308 -1.202 0 CA-C-N 118.448 1.124 . . . . 0.0 110.077 179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.479 ' HG2' HG21 ' A' ' 44' ' ' THR . 90.8 Cg_endo -89.95 119.8 0.84 Allowed 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 121.581 1.521 . . . . 0.0 111.856 175.159 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.481 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 91.7 m-85 -168.78 164.18 11.91 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 104.764 -2.31 . . . . 0.0 104.764 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 81.0 mt -85.79 -17.84 34.65 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 173.297 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -95.38 -0.47 52.56 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.921 178.402 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.481 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -68.83 157.7 88.08 Favored Pre-proline 0 N--CA 1.472 0.654 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.256 -176.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -55.71 122.18 11.27 Favored 'Trans proline' 0 C--N 1.365 1.404 0 C-N-CA 122.951 2.434 . . . . 0.0 112.749 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.4 HG22 ' H ' ' A' ' 74' ' ' GLY . 7.3 p -98.95 173.38 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 179.094 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.4 ' H ' HG22 ' A' ' 73' ' ' VAL . . . 119.78 -3.37 13.29 Favored Glycine 0 C--N 1.308 -1.015 0 C-N-CA 120.319 -0.943 . . . . 0.0 111.565 -178.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.94 127.09 9.14 Favored Glycine 0 N--CA 1.432 -1.609 0 N-CA-C 107.932 -2.067 . . . . 0.0 107.932 172.059 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -116.82 140.6 49.25 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 118.292 1.046 . . . . 0.0 110.582 -177.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 48.6 tp -114.19 112.5 46.79 Favored Pre-proline 0 C--N 1.307 -1.273 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 177.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.41 164.3 34.72 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 122.344 2.03 . . . . 0.0 113.06 -178.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.86 139.79 45.28 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.471 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.98 -0.59 86.32 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 121.314 -0.47 . . . . 0.0 112.396 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -72.76 126.26 29.48 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 121.099 0.476 . . . . 0.0 110.865 -178.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 53.6 m -99.7 115.76 30.24 Favored 'General case' 0 N--CA 1.425 -1.677 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.018 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.4 mm -126.05 128.84 72.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 110.256 -0.275 . . . . 0.0 110.256 -175.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.6 p -93.46 123.3 45.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 175.15 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.549 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 40.9 p90 -107.37 145.23 33.16 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.899 -178.666 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -111.93 -15.75 13.26 Favored 'General case' 0 C--N 1.31 -1.143 0 O-C-N 124.002 0.814 . . . . 0.0 112.494 -175.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -136.58 138.51 41.3 Favored 'General case' 0 N--CA 1.437 -1.09 0 C-N-CA 120.21 -0.596 . . . . 0.0 109.758 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 61.5 t -114.84 132.02 65.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 69.6 m -127.47 135.32 50.24 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 120.743 0.306 . . . . 0.0 110.924 -177.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 65.6 mt -103.66 116.88 48.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 CA-C-O 121.296 0.569 . . . . 0.0 110.121 177.053 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.554 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 7.5 tp-100 -124.96 118.96 27.42 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 103.981 -2.6 . . . . 0.0 103.981 175.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.14 106.19 0.1 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 -167.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 138.78 -41.17 1.38 Allowed Glycine 0 N--CA 1.421 -2.333 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.798 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 57.3 m80 -147.2 154.77 41.44 Favored 'General case' 0 CA--C 1.494 -1.181 0 O-C-N 122.142 -0.622 . . . . 0.0 110.206 -178.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.9 tt -96.98 125.77 49.9 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 175.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.554 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 68.2 m95 -105.03 133.97 48.91 Favored 'General case' 0 C--N 1.274 -2.683 0 CA-C-O 121.178 0.513 . . . . 0.0 110.355 -173.407 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.473 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 43.8 pt -100.12 120.84 50.1 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.323 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 175.486 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -94.77 114.15 4.76 Favored Glycine 0 N--CA 1.411 -2.97 0 N-CA-C 109.326 -1.509 . . . . 0.0 109.326 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -132.2 154.16 49.85 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -177.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -89.28 114.96 26.39 Favored 'General case' 0 C--N 1.272 -2.77 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 174.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.23 165.35 24.01 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-O 121.114 0.483 . . . . 0.0 110.846 -176.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.6 p90 -69.19 -2.79 11.33 Favored 'General case' 0 C--N 1.312 -1.034 0 C-N-CA 123.9 0.88 . . . . 0.0 112.162 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -95.45 -7.0 39.47 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.321 177.344 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 96.51 -7.8 66.14 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.907 -0.588 . . . . 0.0 113.665 176.062 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 15.3 p-10 -96.69 151.12 19.93 Favored 'General case' 0 C--N 1.296 -1.72 0 C-N-CA 122.972 0.509 . . . . 0.0 112.039 -178.244 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 14.5 tpp180 -84.29 108.47 17.17 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.067 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 25.8 t -110.94 146.62 15.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.022 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -176.525 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 88.2 m-85 -117.05 123.19 46.24 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . 0.438 ' HA ' HG22 ' A' ' 62' ' ' THR . 50.8 t -104.67 132.2 21.14 Favored Pre-proline 0 C--N 1.303 -1.424 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.361 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -69.84 -17.07 37.44 Favored 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 123.051 2.501 . . . . 0.0 114.372 -177.502 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.299 33.2 m 40.91 -58.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.52 3.032 0 N-CA-C 118.815 2.894 . . . . 0.0 118.815 175.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 33.3 ptt180 -153.96 150.6 28.49 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 123.577 0.751 . . . . 0.0 109.009 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 17.8 m -66.66 139.05 57.84 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.742 179.042 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.581 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 92.1 m -154.65 127.03 7.89 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 123.009 0.524 . . . . 0.0 111.17 179.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -125.83 122.49 36.3 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 177.655 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 168.84 175.03 37.96 Favored Glycine 0 N--CA 1.416 -2.696 0 C-N-CA 119.932 -1.128 . . . . 0.0 111.897 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 60.2 t -129.17 128.32 23.29 Favored Pre-proline 0 C--N 1.288 -2.076 0 N-CA-C 105.248 -2.13 . . . . 0.0 105.248 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -43.26 137.53 5.11 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 123.71 2.94 . . . . 0.0 113.027 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -81.88 -14.87 33.76 Favored 'Cis proline' 0 CA--C 1.553 1.467 0 C-N-CA 123.331 -1.529 . . . . 0.0 114.543 3.052 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -79.41 100.33 7.6 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.768 0.794 . . . . 0.0 112.952 -171.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 38.9 p-80 -106.99 112.73 25.83 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 114.869 -1.059 . . . . 0.0 111.164 175.628 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.581 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 49.4 mt -91.94 113.51 59.16 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 110.607 -0.146 . . . . 0.0 110.607 -178.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -84.48 164.75 12.54 Favored 'Trans proline' 0 C--O 1.246 0.918 0 C-N-CA 123.029 2.486 . . . . 0.0 113.36 -178.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.92 -130.96 2.92 Favored Glycine 0 N--CA 1.434 -1.473 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 176.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 80.7 t -73.81 122.3 26.62 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 C-N-CA 122.387 0.275 . . . . 0.0 111.287 -178.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.49 147.46 23.23 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.281 176.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.5 m0 -107.57 11.4 28.69 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.923 0.392 . . . . 0.0 111.792 179.213 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.66 -168.38 23.47 Favored Glycine 0 N--CA 1.436 -1.365 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.616 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 27.1 t -111.88 139.98 33.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -178.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 -118.32 123.16 44.67 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.426 0.155 . . . . 0.0 111.341 -175.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.1 pttm . . . . . 0 N--CA 1.433 -1.291 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 171.932 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.6 m95 . . . . . 0 N--CA 1.445 -0.707 0 CA-C-O 120.902 0.382 . . . . 0.0 110.956 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -113.64 156.14 24.23 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 175.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -101.4 126.2 48.14 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.559 -178.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.409 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 36.6 t-20 -89.39 164.57 14.82 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 -177.383 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -64.91 -15.14 61.67 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.309 1.043 . . . . 0.0 111.213 -176.164 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 46.0 m-85 -74.66 -18.02 60.6 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.916 177.4 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.12 -8.13 59.01 Favored Glycine 0 CA--C 1.507 -0.453 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -175.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 11.2 m -80.67 138.84 36.41 Favored 'General case' 0 N--CA 1.427 -1.611 0 C-N-CA 124.724 1.21 . . . . 0.0 110.703 -178.072 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.412 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 65.2 m95 -93.44 139.05 31.14 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 174.463 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.409 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 37.0 p90 -142.47 151.37 41.64 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 120.691 -0.403 . . . . 0.0 111.241 -178.455 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 pttm -144.18 151.48 51.91 Favored Pre-proline 0 C--O 1.25 1.081 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 173.222 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -73.5 122.12 7.64 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 121.952 1.768 . . . . 0.0 110.548 175.494 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -156.57 121.6 4.64 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.492 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 20.5 t-20 -101.55 115.71 31.12 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.146 -176.005 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.84 176.49 10.68 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.5 m -118.47 138.36 52.55 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 121.192 0.52 . . . . 0.0 111.978 -175.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 80.5 t80 -115.63 123.17 47.72 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 175.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 45.1 t -104.87 110.86 32.13 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 177.204 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.583 ' OD1' ' HA ' ' A' ' 79' ' ' ALA . 22.6 t-20 -66.15 128.09 34.72 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.318 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -136.5 -11.28 1.16 Allowed Glycine 0 N--CA 1.441 -0.993 0 C-N-CA 118.997 -1.573 . . . . 0.0 114.71 -176.787 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.496 ' OD1' ' HG3' ' A' ' 58' ' ' GLN . 15.5 t-20 -95.26 -74.51 0.55 Allowed 'General case' 0 C--N 1.319 -0.753 0 C-N-CA 119.073 -1.051 . . . . 0.0 110.876 -178.051 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.496 ' HG3' ' OD1' ' A' ' 57' ' ' ASN . 0.0 OUTLIER -141.14 167.4 17.44 Favored Pre-proline 0 C--N 1.305 -1.329 0 CA-C-O 118.948 -0.549 . . . . 0.0 110.471 -179.199 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -62.35 130.33 29.9 Favored 'Trans proline' 0 C--N 1.356 0.951 0 C-N-CA 121.824 1.683 . . . . 0.0 109.264 173.339 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 58.9 mt -107.13 125.03 63.3 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 C-N-CA 120.323 -0.551 . . . . 0.0 109.708 -173.641 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.7 p -82.66 119.4 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.83 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 176.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 75.6 p -95.86 178.96 5.26 Favored 'General case' 0 C--N 1.285 -2.209 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.131 -172.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.45 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 82.2 mmt-85 -118.35 139.93 50.61 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 175.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 67.4 mt -99.13 129.84 48.96 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 CA-C-O 121.451 0.643 . . . . 0.0 111.895 -175.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 77.11 -22.51 2.41 Favored Glycine 0 C--N 1.318 -0.426 0 N-CA-C 116.023 1.169 . . . . 0.0 116.023 173.028 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 16.5 m -147.22 138.24 13.0 Favored Pre-proline 0 C--N 1.303 -1.44 0 CA-C-N 117.981 0.89 . . . . 0.0 109.941 -176.324 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -89.73 118.62 0.79 Allowed 'Trans proline' 0 N--CA 1.433 -2.062 0 C-N-CA 120.776 0.984 . . . . 0.0 110.006 171.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.576 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 68.9 m-85 -169.06 178.35 4.49 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 104.27 -2.492 . . . . 0.0 104.27 -179.195 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -89.0 -40.12 13.22 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 174.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -96.84 25.46 5.26 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 121.942 0.877 . . . . 0.0 110.524 -177.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.576 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -75.61 159.74 80.83 Favored Pre-proline 0 C--N 1.307 -1.254 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.391 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_exo -47.4 123.03 7.36 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 122.98 2.454 . . . . 0.0 113.482 -179.002 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 6.4 t -98.52 172.6 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 -178.108 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.6 3.48 14.16 Favored Glycine 0 C--N 1.312 -0.77 0 C-N-CA 120.057 -1.068 . . . . 0.0 112.227 -179.212 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -115.51 111.77 2.52 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 175.607 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 38.6 t30 -107.49 130.13 54.88 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 117.318 0.559 . . . . 0.0 109.716 -178.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 46.8 tp -95.56 112.28 58.41 Favored Pre-proline 0 N--CA 1.431 -1.385 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 177.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -61.87 152.1 76.89 Favored 'Trans proline' 0 C--O 1.243 0.761 0 C-N-CA 122.471 2.114 . . . . 0.0 112.379 -177.119 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . 0.583 ' HA ' ' OD1' ' A' ' 55' ' ' ASN . . . -68.18 134.52 50.62 Favored 'General case' 0 N--CA 1.436 -1.145 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.332 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.72 7.96 65.99 Favored Glycine 0 N--CA 1.436 -1.365 0 CA-C-N 115.417 -0.81 . . . . 0.0 112.623 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.33 132.75 37.55 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.116 0.484 . . . . 0.0 111.126 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 26.2 m -102.34 112.63 25.42 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 40.2 mm -115.65 121.8 68.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.836 -176.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.2 p -87.9 123.51 40.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 172.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.492 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 39.2 p90 -108.88 142.41 39.52 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -178.618 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -115.9 -10.96 11.58 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.719 0.771 . . . . 0.0 110.915 -174.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -131.65 134.42 45.95 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 50.3 t -117.87 133.11 65.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.329 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.503 ' SG ' ' HE2' ' A' ' 108' ' ' TYR . 67.1 m -132.02 140.4 48.9 Favored 'General case' 0 C--N 1.312 -1.051 0 O-C-N 123.317 0.386 . . . . 0.0 111.446 -177.403 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 52.0 mt -107.69 112.57 40.69 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.906 -0.496 . . . . 0.0 109.745 174.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.593 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -118.64 120.37 37.24 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 174.397 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.61 109.63 0.26 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 113.48 0.919 . . . . 0.0 113.48 -165.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 132.44 -34.82 2.44 Favored Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.27 -1.332 . . . . 0.0 110.793 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 68.5 m80 -148.8 159.33 44.25 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.7 tt -102.09 119.03 49.81 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 172.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.593 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 61.7 m95 -99.81 134.73 42.28 Favored 'General case' 0 C--N 1.276 -2.596 0 CA-C-O 121.186 0.517 . . . . 0.0 110.581 -171.445 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.483 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.0 pt -100.22 131.92 46.8 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.131 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.15 127.04 9.05 Favored Glycine 0 N--CA 1.425 -2.099 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -178.078 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 27.4 p90 -151.36 166.64 30.39 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 120.976 0.417 . . . . 0.0 109.975 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -118.84 130.39 55.74 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.331 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -96.17 147.78 23.39 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.046 -178.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 29.8 p90 -46.96 -21.52 0.23 Allowed 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 126.246 1.818 . . . . 0.0 115.158 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -89.16 3.99 50.03 Favored 'General case' 0 CA--C 1.561 1.398 0 CA-C-O 121.665 0.745 . . . . 0.0 111.053 -177.579 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 91.59 16.92 51.13 Favored Glycine 0 CA--C 1.502 -0.748 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.135 177.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -96.06 124.08 39.93 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 120.991 0.424 . . . . 0.0 111.35 -176.322 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 30.3 tpt180 -82.91 109.09 16.73 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 105.127 -2.175 . . . . 0.0 105.127 172.397 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 20.1 t -118.81 140.19 43.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 C-N-CA 119.449 -0.901 . . . . 0.0 112.029 -171.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.503 ' HE2' ' SG ' ' A' ' 89' ' ' CYS . 66.8 m-85 -122.58 124.14 42.82 Favored 'General case' 0 N--CA 1.435 -1.219 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.205 174.664 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . 0.418 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 48.7 t -108.83 132.66 21.03 Favored Pre-proline 0 C--N 1.304 -1.372 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.358 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.74 -21.16 33.96 Favored 'Trans proline' 0 C--N 1.358 1.064 0 C-N-CA 123.092 2.528 . . . . 0.0 114.214 -176.816 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.317 33.2 m 45.85 -55.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.51 2.529 0 N-CA-C 118.67 2.841 . . . . 0.0 118.67 176.193 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.447 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 34.2 ptt180 -153.6 149.11 27.26 Favored 'General case' 0 N--CA 1.441 -0.914 0 C-N-CA 122.966 0.507 . . . . 0.0 110.639 177.592 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.4 m -63.0 127.98 33.76 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 177.324 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.645 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 88.3 m -151.94 117.32 5.31 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.592 0.711 . . . . 0.0 111.363 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -114.35 144.84 42.62 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.121 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 141.41 -169.49 25.08 Favored Glycine 0 N--CA 1.429 -1.83 0 C-N-CA 119.769 -1.205 . . . . 0.0 111.454 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 15.4 m -136.68 142.23 38.23 Favored Pre-proline 0 C--N 1.298 -1.656 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 71.9 Cg_exo -43.92 127.46 6.61 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 123.784 2.989 . . . . 0.0 113.207 -178.235 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 11.2 Cg_endo -96.21 -9.97 19.97 Favored 'Cis proline' 0 C--O 1.245 0.828 0 C-N-CA 124.195 -1.169 . . . . 0.0 114.12 1.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 57.9 t30 -72.67 100.86 2.91 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 121.998 0.904 . . . . 0.0 111.557 -172.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 33.4 p-80 -106.66 125.15 50.63 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.304 -1.316 . . . . 0.0 110.699 177.086 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.645 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 49.8 mm -85.66 107.96 14.62 Favored Pre-proline 0 C--N 1.306 -1.286 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 176.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_endo -84.89 123.8 2.86 Favored 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 122.723 2.282 . . . . 0.0 112.967 -177.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -98.74 -110.25 3.0 Favored Glycine 0 N--CA 1.433 -1.543 0 N-CA-C 111.374 -0.69 . . . . 0.0 111.374 177.583 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 48.1 t -94.79 122.38 46.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 -177.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.447 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.27 136.5 34.49 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.272 175.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.6 m-90 -102.04 16.07 27.15 Favored 'General case' 0 C--O 1.251 1.162 0 CA-C-O 121.581 0.705 . . . . 0.0 111.467 179.48 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -171.29 -171.57 36.6 Favored Glycine 0 N--CA 1.43 -1.74 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.064 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 59.1 t -111.51 125.41 68.83 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 123.508 0.723 . . . . 0.0 109.167 -177.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -93.58 135.12 35.17 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.015 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 96.0 mttt . . . . . 0 C--N 1.293 -1.856 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 179.067 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . 0.524 ' CZ2' ' HD2' ' A' ' 47' ' ' LYS . 94.1 m95 . . . . . 0 N--CA 1.433 -1.293 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -125.51 140.73 52.51 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 -179.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 59.8 tttp -89.63 118.04 28.95 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.192 0.52 . . . . 0.0 110.596 -177.509 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -89.85 152.24 21.36 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 175.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.7 tp60 -61.04 -13.68 18.3 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 123.745 0.818 . . . . 0.0 113.094 -173.675 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 62.9 m-85 -74.84 -9.05 58.18 Favored 'General case' 0 CA--C 1.542 0.649 0 CA-C-O 121.247 0.546 . . . . 0.0 109.838 176.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.77 20.17 54.47 Favored Glycine 0 CA--C 1.496 -1.116 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -176.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 22.1 m -105.81 129.08 54.06 Favored 'General case' 0 N--CA 1.408 -2.542 0 CA-C-N 114.13 -1.035 . . . . 0.0 108.679 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 81.0 m95 -92.48 132.07 37.1 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 175.344 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 31.8 p90 -130.69 147.74 52.4 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.991 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.524 ' HD2' ' CZ2' ' A' ' 37' ' ' TRP . 20.7 ptmt -125.1 141.99 40.07 Favored Pre-proline 0 C--N 1.294 -1.844 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.57 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -73.22 120.83 6.78 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 N-CA-C 108.699 -1.308 . . . . 0.0 108.699 172.403 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -168.12 121.53 0.9 Allowed 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 -178.419 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 19.8 t-20 -104.79 128.55 52.98 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.929 -173.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.535 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -156.59 170.15 23.04 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 177.525 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.422 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 2.4 m -112.92 122.25 47.08 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.668 -174.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -95.82 124.24 39.75 Favored 'General case' 0 C--N 1.312 -1.062 0 O-C-N 121.969 -0.457 . . . . 0.0 110.582 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.439 HG22 HG23 ' A' ' 82' ' ' THR . 38.2 t -110.56 112.59 41.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 176.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -68.34 137.03 54.29 Favored 'General case' 0 C--O 1.248 0.995 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -124.73 -57.63 0.17 Allowed Glycine 0 N--CA 1.424 -2.135 0 C-N-CA 118.934 -1.603 . . . . 0.0 115.654 -170.699 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -83.02 -53.46 5.8 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -170.058 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -142.62 154.68 63.32 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 119.942 -0.703 . . . . 0.0 111.082 -174.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -60.03 132.75 46.28 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 122.707 2.271 . . . . 0.0 110.213 176.251 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 41.8 mt -108.19 120.83 60.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -174.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.5 p -79.38 115.09 21.12 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.136 0 CA-C-O 121.753 0.787 . . . . 0.0 109.471 175.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 56.3 p -89.49 178.87 6.19 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 115.191 -0.913 . . . . 0.0 111.657 -173.104 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 84.6 mmt-85 -117.52 137.67 52.41 Favored 'General case' 0 N--CA 1.439 -0.978 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 176.203 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 72.3 mt -95.29 123.7 47.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.139 -176.247 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.87 -22.55 3.42 Favored Glycine 0 C--N 1.317 -0.505 0 N-CA-C 116.205 1.242 . . . . 0.0 116.205 171.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.3 m -152.32 140.61 13.54 Favored Pre-proline 0 C--N 1.306 -1.311 0 CA-C-N 118.322 1.061 . . . . 0.0 110.455 -177.208 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -90.05 118.89 0.76 Allowed 'Trans proline' 0 N--CA 1.433 -2.05 0 C-N-CA 121.03 1.154 . . . . 0.0 110.662 172.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.543 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 97.0 m-85 -169.04 166.99 10.86 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 104.134 -2.543 . . . . 0.0 104.134 179.076 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -79.22 -36.14 40.54 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 175.336 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.5 p-10 -96.06 19.99 10.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.336 -177.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.543 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -74.96 156.25 86.28 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 176.089 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -48.07 123.33 8.58 Favored 'Trans proline' 0 C--O 1.255 1.345 0 C-N-CA 123.385 2.723 . . . . 0.0 113.828 179.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 34.2 m -94.29 174.43 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.609 -1.178 . . . . 0.0 109.949 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.43 11.34 7.38 Favored Glycine 0 N--CA 1.439 -1.132 0 C-N-CA 120.17 -1.014 . . . . 0.0 112.909 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -119.78 130.13 8.31 Favored Glycine 0 N--CA 1.436 -1.324 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 174.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -128.36 130.16 47.31 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 118.024 0.912 . . . . 0.0 110.439 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 46.1 tp -101.16 110.31 60.95 Favored Pre-proline 0 C--N 1.3 -1.552 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.074 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -69.13 166.91 25.2 Favored 'Trans proline' 0 C--O 1.244 0.822 0 C-N-CA 122.57 2.18 . . . . 0.0 112.481 -177.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.43 141.08 43.24 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.468 -179.215 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.53 -23.78 32.3 Favored Glycine 0 C--O 1.244 0.761 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.05 128.22 35.13 Favored 'General case' 0 C--O 1.244 0.78 0 CA-C-O 121.13 0.49 . . . . 0.0 110.453 -178.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.439 HG23 HG22 ' A' ' 54' ' ' VAL . 39.9 m -111.88 121.58 45.44 Favored 'General case' 0 N--CA 1.416 -2.151 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.437 -178.565 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.1 mm -125.87 128.55 72.12 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 -178.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 12.9 p -83.92 133.2 29.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 175.64 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.535 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 50.6 p90 -116.09 137.66 51.93 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.01 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -111.36 -10.5 14.22 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 122.232 1.015 . . . . 0.0 109.568 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.4 ' CD ' HH22 ' A' ' 106' ' ' ARG . 39.8 tt0 -125.71 120.05 29.62 Favored 'General case' 0 N--CA 1.423 -1.804 0 CA-C-N 114.454 -1.248 . . . . 0.0 109.119 -176.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 45.0 t -106.58 130.51 58.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.64 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.457 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 62.1 m -129.08 153.18 47.89 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 120.882 0.372 . . . . 0.0 111.97 -174.41 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.3 mt -124.91 117.04 49.01 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 171.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.563 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -124.13 126.8 46.8 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 104.469 -2.419 . . . . 0.0 104.469 174.18 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.2 113.2 0.75 Allowed 'General case' 0 C--N 1.321 -0.645 0 O-C-N 124.789 1.306 . . . . 0.0 112.586 -168.704 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 131.68 -35.8 2.34 Favored Glycine 0 N--CA 1.432 -1.602 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.66 -176.606 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -154.19 168.41 26.63 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 122.418 -0.46 . . . . 0.0 110.257 -178.07 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 112' ' ' ARG . 15.4 tt -98.36 140.81 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 N-CA-C 103.724 -2.695 . . . . 0.0 103.724 168.159 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . 0.563 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 49.8 m95 -125.15 147.83 48.85 Favored 'General case' 0 C--N 1.28 -2.447 0 CA-C-N 118.117 0.417 . . . . 0.0 110.308 -172.155 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 49.9 pt -110.49 131.31 61.93 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.022 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 172.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.55 121.1 7.05 Favored Glycine 0 N--CA 1.424 -2.113 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.324 -178.575 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -140.29 164.3 30.45 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-O 121.074 0.464 . . . . 0.0 110.688 178.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 31.0 t30 -120.74 127.02 51.6 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 178.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.55 172.32 11.73 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.064 0.459 . . . . 0.0 111.717 -176.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -60.47 -25.9 66.38 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.199 1.0 . . . . 0.0 112.603 -176.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 26.5 p-10 -92.78 -0.6 57.23 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.253 -177.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 91.67 9.62 62.59 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.481 178.656 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -78.55 122.3 25.71 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . 0.4 HH22 ' CD ' ' A' ' 87' ' ' GLU . 11.2 tpt85 -88.18 98.29 11.48 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 -179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 16.5 t -103.86 139.91 23.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 CA-C-O 121.126 0.488 . . . . 0.0 111.066 -171.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -118.34 122.27 42.45 Favored 'General case' 0 N--CA 1.432 -1.367 0 CA-C-N 115.407 -0.815 . . . . 0.0 108.991 174.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.2 t -104.06 129.77 24.6 Favored Pre-proline 0 C--N 1.301 -1.541 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -178.511 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.98 -2.83 12.82 Favored 'Trans proline' 0 C--N 1.361 1.206 0 C-N-CA 123.329 2.686 . . . . 0.0 114.852 -177.195 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 28.3 m 29.59 -52.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.522 3.147 0 N-CA-C 120.116 3.376 . . . . 0.0 120.116 172.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.407 ' O ' HG22 ' A' ' 95' ' ' ILE . 59.5 ttt180 -156.8 141.65 17.0 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 123.828 0.851 . . . . 0.0 109.23 -176.183 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 28.1 m -71.83 132.09 43.95 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 120.797 0.332 . . . . 0.0 110.183 177.756 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 86.1 m -151.47 143.52 23.92 Favored 'General case' 0 N--CA 1.437 -1.086 0 C-N-CA 123.729 0.812 . . . . 0.0 109.054 178.507 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 7.8 tt0 -134.26 133.78 41.19 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 178.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 156.25 -172.59 34.11 Favored Glycine 0 N--CA 1.437 -1.287 0 C-N-CA 119.925 -1.131 . . . . 0.0 112.096 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 31.0 m -129.68 148.51 69.74 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 75.4 Cg_exo -51.55 131.79 38.29 Favored 'Trans proline' 0 CA--C 1.545 1.063 0 C-N-CA 122.801 2.334 . . . . 0.0 113.125 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 6.4 Cg_endo -100.24 10.17 23.42 Favored 'Cis proline' 0 CA--C 1.544 1.005 0 C-N-CA 124.779 -0.925 . . . . 0.0 113.044 -3.235 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -93.55 102.31 14.51 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.793 0.806 . . . . 0.0 112.096 -174.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 39.3 p-80 -104.68 138.52 40.87 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.11 178.648 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.447 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 70.2 mt -92.68 110.37 44.87 Favored Pre-proline 0 C--N 1.305 -1.351 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 173.702 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -84.59 126.09 3.46 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 122.659 2.239 . . . . 0.0 113.942 -177.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -102.76 -138.34 9.95 Favored Glycine 0 N--CA 1.437 -1.28 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 176.374 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 60.4 t -73.85 127.83 35.92 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 C-N-CA 122.996 0.518 . . . . 0.0 111.801 -177.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.11 141.72 28.22 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.147 177.49 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.6 m0 -99.59 -4.89 30.07 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 119.59 -0.844 . . . . 0.0 111.615 177.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -160.61 -175.27 31.43 Favored Glycine 0 N--CA 1.43 -1.703 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -177.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 46.9 t -110.95 134.76 52.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 C-N-CA 122.963 0.505 . . . . 0.0 109.675 -174.084 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -101.03 110.92 23.0 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.6 tptt . . . . . 0 C--N 1.294 -1.84 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -177.786 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 24.0 m . . . . . 0 N--CA 1.445 -0.709 0 CA-C-O 120.2 0.048 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -124.3 162.11 24.44 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.395 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -100.16 -60.67 1.48 Allowed 'General case' 0 N--CA 1.428 -1.564 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.662 -177.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.59 ' HA ' ' CE2' ' A' ' 6' ' ' TYR . 6.9 mtpm? -133.25 7.77 3.95 Favored 'General case' 0 C--O 1.246 0.871 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -177.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.448 ' ND2' ' H ' ' A' ' 18' ' ' LYS . 48.1 t-20 -88.0 82.46 7.21 Favored 'General case' 0 CA--C 1.504 -0.82 0 C-N-CA 118.832 -1.147 . . . . 0.0 108.954 175.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . 0.59 ' CE2' ' HA ' ' A' ' 4' ' ' LYS . 8.9 p90 -142.7 154.01 43.91 Favored 'General case' 0 N--CA 1.411 -2.392 0 CA-C-N 113.691 -1.595 . . . . 0.0 108.248 178.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . 0.457 ' SD ' ' HB3' ' A' ' 9' ' ' LYS . 0.0 OUTLIER 179.04 89.16 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 104.864 -2.273 . . . . 0.0 104.864 177.671 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -87.13 92.07 8.93 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-O 121.312 0.577 . . . . 0.0 110.454 -176.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.457 ' HB3' ' SD ' ' A' ' 7' ' ' MET . 25.3 ttmm -178.5 160.9 1.29 Allowed 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 104.422 -2.436 . . . . 0.0 104.422 178.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -114.64 78.96 0.27 Allowed Glycine 0 N--CA 1.428 -1.894 0 C-N-CA 120.295 -0.955 . . . . 0.0 110.801 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 12.9 p -77.56 -39.12 46.9 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-O 120.934 0.397 . . . . 0.0 111.293 -177.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 75.4 m -159.34 -69.12 0.08 Allowed 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 123.476 0.711 . . . . 0.0 110.021 176.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.414 ' HB2' ' HB3' ' A' ' 92' ' ' ALA . 10.7 m -139.27 43.2 2.04 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 p -79.37 -179.11 6.6 Favored 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.017 -178.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 29.9 p 59.81 16.11 5.37 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -176.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 17.6 m -67.04 -41.52 87.36 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.781 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.036 177.021 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 45.8 t 59.67 94.19 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.88 0 N-CA-C 115.264 1.579 . . . . 0.0 115.264 173.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.448 ' H ' ' ND2' ' A' ' 5' ' ' ASN . 56.3 mtpt -135.19 96.17 3.44 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 173.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.423 ' HB2' ' HB2' ' A' ' 5' ' ' ASN . 17.5 t70 -170.37 155.8 5.35 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -177.702 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 143.88 -144.96 14.22 Favored Glycine 0 N--CA 1.41 -3.093 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 -178.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt 62.14 -88.78 0.03 OUTLIER 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.395 1.078 . . . . 0.0 110.944 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -158.18 73.79 0.68 Allowed 'General case' 0 C--N 1.31 -1.112 0 C-N-CA 124.187 0.995 . . . . 0.0 109.015 177.038 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.406 ' HB3' HG21 ' A' ' 33' ' ' VAL . 25.1 m -114.92 -32.14 5.86 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.289 -177.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 58.2 m -146.59 25.2 1.2 Allowed 'General case' 0 C--N 1.317 -0.83 0 O-C-N 121.957 -0.465 . . . . 0.0 110.455 177.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -64.03 -45.15 90.17 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-O 121.281 0.562 . . . . 0.0 110.54 -179.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 30.2 m -102.63 12.08 36.85 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.526 178.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 62.0 p 65.48 153.08 0.12 Allowed Pre-proline 0 CA--C 1.55 0.972 0 C-N-CA 126.805 2.042 . . . . 0.0 111.956 -175.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_exo -43.29 -49.36 7.44 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 123.721 2.947 . . . . 0.0 114.412 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 53.41 58.29 5.36 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 121.772 0.796 . . . . 0.0 110.006 -177.107 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.9 m 69.87 9.39 7.12 Favored 'General case' 0 CA--C 1.577 2.018 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.865 -177.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 21.5 tpp180 -139.68 77.14 28.37 Favored Pre-proline 0 CA--C 1.551 1.018 0 O-C-N 121.236 -0.915 . . . . 0.0 112.485 177.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.69 140.9 83.28 Favored 'Trans proline' 0 C--O 1.239 0.554 0 C-N-CA 122.198 1.932 . . . . 0.0 109.982 169.377 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.406 HG21 ' HB3' ' A' ' 23' ' ' SER . 22.8 m -84.84 4.95 2.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-O 121.4 0.619 . . . . 0.0 111.349 -177.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 3.7 p -84.81 -0.21 53.08 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.769 178.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 78.23 -135.42 15.94 Favored Glycine 0 N--CA 1.429 -1.779 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.729 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 10.0 m -91.27 10.09 28.7 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 123.203 0.601 . . . . 0.0 110.964 -177.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . 0.484 ' CZ3' HG13 ' A' ' 90' ' ' ILE . 60.3 m95 -89.16 140.16 29.75 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 120.901 0.382 . . . . 0.0 110.798 -176.501 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 38.7 ttmt -114.45 151.18 33.6 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 61.7 tttm -93.26 144.74 25.02 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.513 0.673 . . . . 0.0 112.368 -175.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -107.91 156.12 19.54 Favored 'General case' 0 C--O 1.253 1.274 0 C-N-CA 125.182 1.393 . . . . 0.0 108.763 175.065 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 16.6 pm0 -62.08 -23.29 66.42 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.462 1.105 . . . . 0.0 113.183 -178.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -84.26 -3.26 58.1 Favored 'General case' 0 C--N 1.322 -0.6 0 O-C-N 121.819 -0.551 . . . . 0.0 111.4 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.9 -6.46 60.22 Favored Glycine 0 CA--C 1.5 -0.902 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 17.0 m -73.32 144.79 46.41 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 68.1 m95 -114.92 138.94 50.22 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 175.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -138.23 149.05 45.39 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 120.663 0.268 . . . . 0.0 111.676 -175.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.7 pttt -130.68 140.51 38.89 Favored Pre-proline 0 C--N 1.3 -1.567 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 176.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -75.2 121.99 6.83 Favored 'Trans proline' 0 C--O 1.254 1.309 0 C-N-CA 121.86 1.707 . . . . 0.0 109.354 172.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -166.24 122.33 1.27 Allowed 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -178.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.444 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 20.1 m120 -94.17 123.89 37.84 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.213 -178.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.43 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -149.39 175.09 11.76 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 176.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.424 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 11.8 m -115.91 148.62 39.83 Favored 'General case' 0 N--CA 1.419 -2.013 0 CA-C-O 121.349 0.595 . . . . 0.0 110.589 -174.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -131.46 122.67 26.63 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 175.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.3 t -104.11 112.68 38.58 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.242 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 176.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -75.12 138.5 42.1 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 120.124 -0.63 . . . . 0.0 110.17 -177.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -167.41 174.53 42.56 Favored Glycine 0 N--CA 1.423 -2.202 0 N-CA-C 107.913 -2.075 . . . . 0.0 107.913 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 36.8 t30 79.58 -45.6 0.33 Allowed 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 124.91 1.284 . . . . 0.0 110.209 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.492 HE21 HG12 ' A' ' 60' ' ' ILE . 10.8 pt20 -158.18 153.16 21.32 Favored Pre-proline 0 N--CA 1.413 -2.303 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.581 178.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -72.34 131.03 17.05 Favored 'Trans proline' 0 N--CA 1.444 -1.418 0 N-CA-C 107.418 -1.801 . . . . 0.0 107.418 167.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.492 HG12 HE21 ' A' ' 58' ' ' GLN . 49.2 mt -108.47 124.3 64.79 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 C-N-CA 120.3 -0.56 . . . . 0.0 109.745 -174.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.0 p -76.44 127.8 37.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 176.151 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 37.1 p -106.3 167.99 9.45 Favored 'General case' 0 N--CA 1.416 -2.157 0 CA-C-O 121.264 0.554 . . . . 0.0 111.41 -173.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 18.2 mmt180 -114.96 143.9 44.43 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 55.4 mt -111.93 134.63 53.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 C-N-CA 120.384 -0.527 . . . . 0.0 111.913 -175.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.09 -23.32 3.9 Favored Glycine 0 C--N 1.32 -0.329 0 N-CA-C 116.344 1.298 . . . . 0.0 116.344 171.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.8 m -155.87 137.1 9.36 Favored Pre-proline 0 C--N 1.301 -1.54 0 CA-C-N 118.228 1.014 . . . . 0.0 110.118 -179.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -89.86 121.44 0.99 Allowed 'Trans proline' 0 N--CA 1.444 -1.416 0 C-N-CA 122.24 1.96 . . . . 0.0 112.168 175.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -163.27 170.25 17.94 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 104.414 -2.439 . . . . 0.0 104.414 178.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -82.41 -26.08 33.11 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.255 0.55 . . . . 0.0 110.294 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -107.09 25.7 11.06 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 122.396 1.093 . . . . 0.0 108.498 178.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -68.64 157.57 88.0 Favored Pre-proline 0 C--N 1.318 -0.791 0 CA-C-N 115.186 -0.916 . . . . 0.0 111.336 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -53.96 133.47 55.0 Favored 'Trans proline' 0 C--N 1.361 1.205 0 C-N-CA 123.274 2.65 . . . . 0.0 113.623 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.7 m -99.22 176.23 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.012 0 C-N-CA 124.626 1.17 . . . . 0.0 110.662 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.59 4.53 10.67 Favored Glycine 0 CA--C 1.498 -0.972 0 C-N-CA 121.13 -0.557 . . . . 0.0 111.732 -178.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -122.12 124.48 5.76 Favored Glycine 0 N--CA 1.419 -2.434 0 N-CA-C 108.401 -1.88 . . . . 0.0 108.401 174.026 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -128.62 126.79 40.96 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 117.881 0.841 . . . . 0.0 109.668 176.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 49.4 tp -97.58 114.7 65.28 Favored Pre-proline 0 C--N 1.301 -1.511 0 C-N-CA 122.346 0.258 . . . . 0.0 110.337 -177.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -73.1 160.21 46.03 Favored 'Trans proline' 0 C--O 1.243 0.763 0 C-N-CA 122.348 2.032 . . . . 0.0 111.185 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.31 153.86 35.54 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.4 10.42 79.93 Favored Glycine 0 C--N 1.313 -0.738 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -178.446 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.16 126.41 38.25 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 60.1 m -96.82 108.78 21.52 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 177.093 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.6 mm -108.69 119.29 58.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.636 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.1 p -99.74 107.77 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.37 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 174.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.444 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 44.4 p90 -98.32 163.86 12.53 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.282 -174.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -125.38 -11.17 6.9 Favored 'General case' 0 C--N 1.318 -0.768 0 O-C-N 123.443 0.464 . . . . 0.0 111.538 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.433 ' HB2' ' NH2' ' A' ' 106' ' ' ARG . 31.1 tt0 -126.39 124.17 39.6 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -175.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 40.6 t -112.59 120.8 63.6 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.491 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.604 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 26.4 p -130.96 152.23 50.5 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 120.328 -0.549 . . . . 0.0 112.377 -176.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.484 HG13 ' CZ3' ' A' ' 37' ' ' TRP . 76.5 mt -112.74 113.64 44.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.169 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.049 177.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.518 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -112.1 113.66 26.06 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 103.363 -2.828 . . . . 0.0 103.363 169.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.414 ' HB3' ' HB2' ' A' ' 13' ' ' SER . . . -48.6 109.76 0.28 Allowed 'General case' 0 C--O 1.241 0.635 0 O-C-N 124.722 1.264 . . . . 0.0 113.21 -164.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 137.4 -36.74 1.92 Allowed Glycine 0 N--CA 1.424 -2.118 0 CA-C-N 113.636 -1.62 . . . . 0.0 109.185 -176.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 52.9 m80 -149.02 165.33 31.97 Favored 'General case' 0 CA--C 1.5 -0.946 0 O-C-N 122.478 -0.424 . . . . 0.0 109.911 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.5 tt -103.24 135.84 38.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 N-CA-C 104.491 -2.411 . . . . 0.0 104.491 171.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.604 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 49.4 m95 -119.25 135.23 54.79 Favored 'General case' 0 C--N 1.275 -2.646 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 -173.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.492 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 47.0 pt -100.5 132.38 46.25 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 177.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.94 124.64 8.14 Favored Glycine 0 N--CA 1.425 -2.085 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -137.72 164.83 27.89 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 29.1 p-10 -117.54 137.5 52.54 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.982 0.42 . . . . 0.0 110.615 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.412 ' HB3' ' OD1' ' A' ' 105' ' ' ASN . . . -91.12 174.64 7.3 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -66.88 -12.08 58.12 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 121.263 0.554 . . . . 0.0 112.131 -177.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -81.01 -12.7 59.31 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 87.82 9.11 71.91 Favored Glycine 0 CA--C 1.505 -0.583 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.995 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.412 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 18.2 p-10 -91.86 147.58 22.87 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.126 0.489 . . . . 0.0 110.165 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . 0.433 ' NH2' ' HB2' ' A' ' 87' ' ' GLU . 18.0 tpt180 -94.61 115.3 27.4 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -175.46 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 24.3 t -111.39 139.9 33.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -176.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.492 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 94.1 m-85 -118.47 132.32 56.24 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 123.641 0.776 . . . . 0.0 110.943 -178.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . 0.415 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 45.9 t -111.78 131.95 22.16 Favored Pre-proline 0 C--N 1.308 -1.201 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.363 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -70.69 -13.85 32.67 Favored 'Trans proline' 0 C--N 1.367 1.552 0 C-N-CA 123.311 2.674 . . . . 0.0 114.763 -176.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.31 35.9 m 38.86 -60.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.459 0 N-CA-C 119.072 2.99 . . . . 0.0 119.072 175.329 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 37.5 ptt180 -155.08 156.71 36.34 Favored 'General case' 0 C--O 1.248 0.977 0 O-C-N 121.894 -0.504 . . . . 0.0 109.717 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 25.3 m -64.54 136.78 57.39 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 174.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 65.3 m -149.67 128.05 12.19 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.727 0.775 . . . . 0.0 110.657 176.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -119.68 161.77 20.14 Favored 'General case' 0 C--N 1.286 -2.157 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.14 -167.13 12.85 Favored Glycine 0 C--N 1.286 -2.214 0 C-N-CA 118.918 -1.611 . . . . 0.0 112.284 177.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 24.6 m -140.91 147.33 47.66 Favored Pre-proline 0 C--N 1.306 -1.323 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.404 ' HB3' ' CG ' ' A' ' 37' ' ' TRP . 85.6 Cg_exo -48.63 136.1 27.18 Favored 'Trans proline' 0 CA--C 1.543 0.943 0 C-N-CA 123.24 2.627 . . . . 0.0 113.013 178.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -88.73 -19.72 15.55 Favored 'Cis proline' 0 CA--C 1.544 1.005 0 C-N-CA 123.779 -1.342 . . . . 0.0 113.176 -0.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 90.0 m-20 -77.34 102.2 6.66 Favored 'General case' 0 C--O 1.244 0.791 0 CA-C-O 122.244 1.021 . . . . 0.0 112.877 -172.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 32.4 p-80 -104.69 131.05 52.59 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 113.847 -1.524 . . . . 0.0 109.867 178.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.449 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 55.4 mt -96.66 108.6 43.7 Favored Pre-proline 0 C--N 1.286 -2.161 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -178.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -78.88 161.39 27.11 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.584 2.189 . . . . 0.0 112.521 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -134.74 -124.31 2.44 Favored Glycine 0 N--CA 1.437 -1.265 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 177.047 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.6 t -77.26 124.01 34.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 116.938 0.369 . . . . 0.0 110.795 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.5 151.32 19.44 Favored 'General case' 0 C--O 1.246 0.908 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.217 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.6 m-90 -124.98 29.64 6.09 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.93 178.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -169.4 -173.27 36.85 Favored Glycine 0 N--CA 1.434 -1.461 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 -179.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 47.4 t -114.63 115.28 49.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.164 0.507 . . . . 0.0 109.983 -178.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -83.72 130.19 34.95 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.007 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.424 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 1.6 tmtp? . . . . . 0 N--CA 1.421 -1.908 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 -176.083 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 22.2 t . . . . . 0 N--CA 1.449 -0.487 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -143.53 147.02 33.84 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 -177.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -158.64 89.47 0.96 Allowed 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -89.2 95.8 10.45 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.187 -179.48 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -101.19 109.33 21.18 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.59 0.709 . . . . 0.0 110.838 178.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -131.54 174.61 9.92 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 178.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 47.8 ttm 71.42 -43.23 0.56 Allowed 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 124.322 1.049 . . . . 0.0 112.571 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -64.45 155.12 33.69 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 123.685 0.794 . . . . 0.0 110.512 178.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.554 ' HD2' ' N ' ' A' ' 10' ' ' GLY . 0.5 OUTLIER -51.19 -28.68 11.89 Favored 'General case' 0 CA--C 1.547 0.839 0 N-CA-C 113.34 0.867 . . . . 0.0 113.34 177.671 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.554 ' N ' ' HD2' ' A' ' 9' ' ' LYS . . . 68.75 -113.5 5.3 Favored Glycine 0 N--CA 1.441 -0.989 0 N-CA-C 114.004 0.362 . . . . 0.0 114.004 174.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 15.8 p -71.24 98.6 1.75 Allowed 'General case' 0 N--CA 1.435 -1.195 0 CA-C-O 121.389 0.614 . . . . 0.0 111.216 -178.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 20.2 m -145.05 74.48 1.41 Allowed 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 177.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.4 m -87.47 -42.93 12.44 Favored 'General case' 0 N--CA 1.422 -1.85 0 CA-C-N 114.011 -1.449 . . . . 0.0 111.049 -174.164 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.8 m -82.81 3.97 27.28 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.768 0.794 . . . . 0.0 110.394 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 4.0 m -87.74 22.01 2.42 Favored 'General case' 0 CA--C 1.559 1.299 0 C-N-CA 124.296 1.038 . . . . 0.0 109.68 179.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.7 m -92.13 150.39 3.84 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 175.012 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 17.8 t 67.97 23.15 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.562 1.409 0 CA-C-O 123.621 1.677 . . . . 0.0 107.847 -175.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 52.5 tptt -77.27 -31.26 54.76 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 113.279 -1.782 . . . . 0.0 108.11 176.395 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -91.2 -167.25 1.76 Allowed 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 114.826 -1.079 . . . . 0.0 108.17 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 165.96 -47.04 0.27 Allowed Glycine 0 N--CA 1.43 -1.742 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 -178.294 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 58.4 tptt -93.68 104.07 16.19 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.097 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 32.2 p 54.97 79.84 0.14 Allowed 'General case' 0 C--O 1.243 0.718 0 C-N-CA 124.618 1.167 . . . . 0.0 112.977 -178.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 37.5 m -75.6 136.23 40.5 Favored 'General case' 0 N--CA 1.429 -1.504 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.956 -177.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.8 t 66.86 23.66 9.93 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.163 0.985 . . . . 0.0 110.017 -179.212 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.14 -45.07 87.99 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 176.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 19.7 m -103.08 94.98 5.83 Favored 'General case' 0 N--CA 1.414 -2.237 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 170.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 16.8 m -76.59 130.25 77.19 Favored Pre-proline 0 N--CA 1.431 -1.408 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.281 -174.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -69.46 91.72 0.48 Allowed 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 121.958 1.772 . . . . 0.0 110.416 173.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -136.89 -39.51 0.62 Allowed 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.968 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.9 m -87.9 -35.41 17.73 Favored 'General case' 0 N--CA 1.435 -1.192 0 CA-C-O 121.061 0.458 . . . . 0.0 110.153 -179.462 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -73.45 -56.91 2.89 Favored Pre-proline 0 CA--C 1.554 1.102 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 -175.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -61.61 103.07 0.26 Allowed 'Trans proline' 0 C--N 1.374 1.916 0 C-N-CA 121.724 1.616 . . . . 0.0 112.965 178.366 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.3 m -83.55 136.13 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 176.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 55.2 m 73.5 132.99 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.025 0 O-C-N 124.051 0.844 . . . . 0.0 110.119 -175.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 128.09 -38.18 2.14 Favored Glycine 0 CA--C 1.489 -1.535 0 N-CA-C 108.168 -1.973 . . . . 0.0 108.168 -174.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 2.9 p -70.15 -53.1 18.71 Favored 'General case' 0 N--CA 1.426 -1.658 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 172.42 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.3 m95 -87.04 133.22 33.61 Favored 'General case' 0 N--CA 1.432 -1.372 0 CA-C-N 114.051 -1.431 . . . . 0.0 107.725 173.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.4 mptt -113.91 155.2 26.22 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 176.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -102.99 132.48 49.23 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.803 -0.759 . . . . 0.0 108.967 178.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.454 ' ND2' ' HB ' ' A' ' 44' ' ' THR . 38.7 p30 -86.5 178.19 7.17 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 175.222 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 -70.1 -23.12 63.0 Favored 'General case' 0 C--N 1.31 -1.134 0 CA-C-O 121.114 0.483 . . . . 0.0 111.144 -176.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.465 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 26.7 m-85 -74.87 -13.92 60.61 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.163 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.41 7.07 57.25 Favored Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.829 178.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.454 ' HB ' ' ND2' ' A' ' 40' ' ' ASN . 5.8 m -88.34 137.57 32.2 Favored 'General case' 0 N--CA 1.424 -1.755 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 92.2 m95 -96.44 122.29 39.17 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 176.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 54.4 p90 -123.58 152.34 41.97 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 120.869 0.366 . . . . 0.0 111.973 -174.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.0 ptmt -141.03 147.18 46.67 Favored Pre-proline 0 N--CA 1.433 -1.292 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 171.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -77.09 122.09 6.06 Favored 'Trans proline' 0 N--CA 1.445 -1.327 0 C-N-CA 121.492 1.461 . . . . 0.0 109.222 172.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.5 tp10 -153.35 125.74 8.09 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 -179.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.501 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 7.7 t30 -109.57 107.49 17.6 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.203 0.525 . . . . 0.0 111.098 -175.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.414 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -143.56 171.42 14.18 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.451 ' HB ' ' HB2' ' A' ' 131' ' ' LYS . 6.4 m -104.32 147.76 27.15 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -176.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -127.08 138.26 53.17 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 175.328 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.3 t -118.65 117.0 53.01 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 176.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.481 ' ND2' ' HA ' ' A' ' 79' ' ' ALA . 48.4 t30 -70.61 148.43 48.12 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.291 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -83.42 -132.7 2.05 Favored Glycine 0 N--CA 1.434 -1.471 0 N-CA-C 114.364 0.506 . . . . 0.0 114.364 -174.177 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -91.05 -4.32 56.45 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -171.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.4 ' HA ' ' HD3' ' A' ' 59' ' ' PRO . 0.8 OUTLIER -131.95 153.09 81.28 Favored Pre-proline 0 C--N 1.306 -1.285 0 C-N-CA 120.007 -0.677 . . . . 0.0 112.261 179.723 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.517 ' HB3' HD21 ' A' ' 76' ' ' ASN . 7.4 Cg_exo -74.76 136.72 21.31 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.056 1.837 . . . . 0.0 111.079 176.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 61.0 mt -107.81 133.63 52.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -177.483 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.9 p -82.09 137.53 20.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 177.09 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 54.7 p -117.07 179.03 4.14 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.565 -172.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.425 ' NH1' HG12 ' A' ' 73' ' ' VAL . 47.2 mmt-85 -122.05 144.3 48.99 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 59.1 mt -106.35 125.99 62.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.868 -177.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.51 -22.64 1.68 Allowed Glycine 0 CA--C 1.527 0.812 0 N-CA-C 116.569 1.388 . . . . 0.0 116.569 171.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.5 m -145.68 134.17 10.86 Favored Pre-proline 0 C--N 1.3 -1.558 0 CA-C-N 118.562 1.181 . . . . 0.0 110.315 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -90.08 120.41 0.86 Allowed 'Trans proline' 0 N--CA 1.441 -1.614 0 C-N-CA 121.732 1.622 . . . . 0.0 111.624 174.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.587 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 93.1 m-85 -168.16 175.54 6.51 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 104.873 -2.269 . . . . 0.0 104.873 178.528 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -81.85 -45.3 15.7 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 176.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -94.04 25.93 3.48 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.108 -0.951 . . . . 0.0 111.151 -178.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.587 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.55 162.9 71.75 Favored Pre-proline 0 C--N 1.317 -0.835 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.468 178.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_exo -48.87 123.31 9.54 Favored 'Trans proline' 0 C--N 1.369 1.652 0 C-N-CA 123.537 2.825 . . . . 0.0 114.158 179.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.425 HG12 ' NH1' ' A' ' 63' ' ' ARG . 31.2 m -97.55 174.38 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.184 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.34 28.8 1.89 Allowed Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -150.94 126.61 2.16 Favored Glycine 0 N--CA 1.428 -1.896 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.517 HD21 ' HB3' ' A' ' 59' ' ' PRO . 8.0 t30 -127.39 136.79 52.35 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 57.2 tp -97.45 115.64 65.77 Favored Pre-proline 0 C--N 1.302 -1.463 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -59.24 152.67 58.4 Favored 'Trans proline' 0 C--O 1.245 0.856 0 C-N-CA 123.005 2.47 . . . . 0.0 112.609 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.481 ' HA ' ' ND2' ' A' ' 55' ' ' ASN . . . -73.42 139.97 46.22 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.13 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.74 -4.82 77.71 Favored Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 116.113 -0.494 . . . . 0.0 113.108 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.93 134.06 40.34 Favored 'General case' 0 N--CA 1.439 -1.018 0 CA-C-O 120.774 0.321 . . . . 0.0 110.893 -177.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 14.6 t -108.0 134.66 50.59 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 177.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 44.6 mm -132.05 140.14 48.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -177.223 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.5 p -103.96 113.41 40.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-O 121.965 0.888 . . . . 0.0 109.582 175.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.501 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 43.2 p90 -97.15 152.95 18.3 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.417 -175.019 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -119.77 4.28 11.04 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.657 0.741 . . . . 0.0 110.345 -178.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -142.06 132.96 25.83 Favored 'General case' 0 N--CA 1.426 -1.656 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.391 -175.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.8 t -124.68 128.27 73.31 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.452 ' HB2' HG22 ' A' ' 44' ' ' THR . 20.5 p -139.49 140.83 37.33 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-O 121.236 0.541 . . . . 0.0 111.421 -178.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.468 HG21 ' HA3' ' A' ' 116' ' ' GLY . 75.1 mt -101.03 114.87 41.51 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.731 179.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.586 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 50.0 tp60 -116.04 127.63 55.05 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 104.813 -2.292 . . . . 0.0 104.813 173.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.04 110.93 0.37 Allowed 'General case' 0 C--O 1.243 0.731 0 N-CA-C 113.275 0.842 . . . . 0.0 113.275 -167.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 124.23 -28.87 5.22 Favored Glycine 0 N--CA 1.438 -1.183 0 CA-C-N 114.498 -1.228 . . . . 0.0 112.729 179.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 74.8 m80 -151.12 169.9 20.74 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -176.342 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 19.0 tt -110.96 128.0 67.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.095 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 172.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.586 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 65.2 m95 -110.46 131.14 55.32 Favored 'General case' 0 C--N 1.274 -2.692 0 CA-C-O 120.966 0.412 . . . . 0.0 110.196 -173.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.505 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.5 pt -100.3 134.61 39.4 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.96 128.14 9.32 Favored Glycine 0 N--CA 1.428 -1.879 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 -178.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -151.38 163.93 37.85 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -97.77 116.81 30.72 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 174.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -76.09 178.25 6.5 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.999 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 46.5 p90 -47.49 -27.93 1.97 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 126.044 1.737 . . . . 0.0 113.858 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -99.27 2.42 45.54 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 112.222 0.453 . . . . 0.0 112.222 -175.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.85 0.67 81.07 Favored Glycine 0 C--N 1.32 -0.329 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.158 176.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -81.03 135.89 35.9 Favored 'General case' 0 C--N 1.306 -1.32 0 O-C-N 122.651 -0.323 . . . . 0.0 111.038 -178.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 4.1 tpp180 -75.29 102.24 4.99 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 173.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 67.6 t -108.27 143.87 17.89 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.029 0 CA-C-N 114.674 -1.148 . . . . 0.0 109.725 -174.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.505 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 96.5 m-85 -117.74 124.08 47.58 Favored 'General case' 0 N--CA 1.426 -1.647 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.273 178.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.8 t -104.13 133.71 20.08 Favored Pre-proline 0 C--N 1.298 -1.673 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -68.71 -22.88 36.76 Favored 'Trans proline' 0 C--N 1.359 1.115 0 C-N-CA 122.967 2.445 . . . . 0.0 113.472 -177.253 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.295 34.2 m 46.99 -53.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.207 0 N-CA-C 118.41 2.744 . . . . 0.0 118.41 175.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.526 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 38.9 ptt180 -158.93 156.77 30.11 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 122.832 0.453 . . . . 0.0 110.553 -178.298 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 2.6 p -72.83 136.99 45.46 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 175.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.429 ' SG ' ' HG3' ' A' ' 112' ' ' ARG . 96.1 m -154.37 133.04 12.16 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.838 0.352 . . . . 0.0 111.54 -178.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 29.9 mm-40 -97.11 113.38 24.95 Favored 'General case' 0 N--CA 1.427 -1.595 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 171.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.468 ' HA3' HG21 ' A' ' 90' ' ' ILE . . . -122.01 113.96 2.39 Favored Glycine 0 C--N 1.259 -3.697 0 C-N-CA 119.779 -1.201 . . . . 0.0 114.014 -173.577 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 7.0 m -125.97 97.14 35.91 Favored Pre-proline 0 C--N 1.293 -1.878 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 172.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 61.9 Cg_exo -42.84 130.77 5.66 Favored 'Trans proline' 0 C--N 1.357 0.994 0 C-N-CA 124.327 3.351 . . . . 0.0 114.774 -170.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 7.4 Cg_endo -92.71 8.0 59.8 Favored 'Cis proline' 0 CA--C 1.549 1.236 0 C-N-CA 124.412 -1.078 . . . . 0.0 113.046 1.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -74.93 102.03 4.64 Favored 'General case' 0 CA--C 1.508 -0.672 0 CA-C-O 121.563 0.697 . . . . 0.0 110.229 -175.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.422 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 37.4 p-80 -104.78 107.03 17.77 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.592 177.429 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.5 mt -100.2 100.44 11.77 Favored Pre-proline 0 C--N 1.318 -0.791 0 C-N-CA 122.703 0.401 . . . . 0.0 109.925 -177.166 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.422 ' HD3' ' O ' ' A' ' 121' ' ' HIS . 2.9 Cg_endo -81.48 150.69 17.15 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 122.774 2.316 . . . . 0.0 113.265 -178.209 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.45 -116.13 3.3 Favored Glycine 0 N--CA 1.423 -2.228 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 175.022 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.3 t -97.39 124.45 50.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-O 120.801 0.334 . . . . 0.0 110.426 -176.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.526 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -95.02 146.88 23.96 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.708 177.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.7 m-90 -101.49 12.82 36.63 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 121.555 0.693 . . . . 0.0 109.246 177.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.74 179.24 37.24 Favored Glycine 0 N--CA 1.43 -1.705 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 49.4 t -112.08 137.79 43.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.398 -0.594 . . . . 0.0 109.398 -176.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -102.27 135.52 43.72 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-O 120.954 0.407 . . . . 0.0 110.11 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.451 ' HB2' ' HB ' ' A' ' 52' ' ' THR . 55.9 mtpt . . . . . 0 C--N 1.295 -1.776 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.241 0.655 0 CA-C-O 121.114 0.483 . . . . 0.0 111.048 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 56.3 t30 -84.53 -37.73 20.9 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 175.156 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.77 177.34 9.17 Favored 'General case' 0 N--CA 1.429 -1.516 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 177.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt 64.74 80.28 0.23 Allowed 'General case' 0 C--N 1.323 -0.544 0 O-C-N 124.249 0.968 . . . . 0.0 113.354 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -87.47 139.71 30.27 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.682 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 16.0 t80 -105.96 24.23 12.71 Favored 'General case' 0 CA--C 1.554 1.13 0 CA-C-O 121.45 0.643 . . . . 0.0 110.908 -174.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 24.6 ttt 79.42 -9.14 1.51 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 125.18 1.392 . . . . 0.0 113.131 174.157 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 17.2 t70 73.45 119.01 0.05 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 123.859 0.864 . . . . 0.0 109.27 -174.308 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 62.1 mttp 80.18 -43.58 0.25 Allowed 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 125.449 1.5 . . . . 0.0 110.666 -177.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.37 60.72 1.97 Allowed Glycine 0 N--CA 1.445 -0.755 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.609 177.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 27.3 p 54.24 88.51 0.04 OUTLIER 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 178.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.3 m -88.37 52.22 2.39 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 177.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.8 m -60.68 126.57 27.9 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.037 0.935 . . . . 0.0 111.975 -176.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.4 t -117.54 116.57 27.39 Favored 'General case' 0 N--CA 1.434 -1.251 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 60.0 m -56.18 -32.82 64.7 Favored 'General case' 0 CA--C 1.555 1.142 0 C-N-CA 124.795 1.238 . . . . 0.0 113.712 -175.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.7 p -75.56 -20.18 15.9 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.005 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -176.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.7 p -113.84 -39.71 3.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 C-N-CA 120.095 -0.642 . . . . 0.0 111.83 -178.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -106.2 99.07 8.67 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-O 121.718 0.771 . . . . 0.0 112.057 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -86.43 -25.11 25.42 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 114.7 -1.136 . . . . 0.0 108.144 173.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 129.25 -55.91 0.75 Allowed Glycine 0 N--CA 1.428 -1.857 0 CA-C-N 115.523 -0.762 . . . . 0.0 112.264 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -109.1 -10.49 15.0 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 121.007 0.432 . . . . 0.0 111.2 -174.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 14.6 m 82.84 84.13 0.03 OUTLIER 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 125.163 1.385 . . . . 0.0 111.406 178.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.0 t -127.75 -178.09 4.36 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 114.43 -1.259 . . . . 0.0 107.955 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 37.4 m 58.47 42.45 21.06 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 123.75 0.82 . . . . 0.0 111.734 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.23 -59.33 2.75 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.887 0.375 . . . . 0.0 111.312 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 19.5 m -82.9 -46.39 13.04 Favored 'General case' 0 C--O 1.25 1.12 0 CA-C-O 121.33 0.586 . . . . 0.0 109.662 -178.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.8 p -106.99 115.58 59.96 Favored Pre-proline 0 N--CA 1.421 -1.885 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.791 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -70.15 -18.56 35.09 Favored 'Trans proline' 0 CA--C 1.535 0.537 0 C-N-CA 121.651 1.568 . . . . 0.0 110.786 176.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 62.56 -87.52 0.02 OUTLIER 'General case' 0 C--O 1.24 0.595 0 C-N-CA 125.286 1.434 . . . . 0.0 112.895 175.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.7 m -92.53 -2.29 56.32 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.566 ' HD2' ' O ' ' A' ' 35' ' ' GLY . 39.2 ptt180 53.94 85.03 0.2 Allowed Pre-proline 0 N--CA 1.478 0.96 0 C-N-CA 125.76 1.624 . . . . 0.0 112.921 177.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_exo -43.46 -69.55 0.08 OUTLIER 'Trans proline' 0 C--N 1.362 1.243 0 C-N-CA 124.798 3.665 . . . . 0.0 116.219 -173.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 41.5 t -137.94 -61.63 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-O 121.308 0.575 . . . . 0.0 110.762 -174.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.6 m -81.56 41.84 0.65 Allowed 'General case' 0 CA--C 1.558 1.274 0 C-N-CA 123.862 0.865 . . . . 0.0 110.504 -175.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.566 ' O ' ' HD2' ' A' ' 31' ' ' ARG . . . -121.79 62.09 0.53 Allowed Glycine 0 N--CA 1.433 -1.521 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.486 -177.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 74.2 m -167.82 -68.23 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.062 0 C-N-CA 124.905 1.282 . . . . 0.0 108.509 177.289 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 47.8 m95 -92.39 152.68 19.6 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.13 -179.232 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.407 ' O ' ' HA ' ' A' ' 45' ' ' TRP . 47.9 mmtm -113.32 149.94 33.24 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.601 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -101.52 122.05 43.1 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-O 121.123 0.487 . . . . 0.0 111.086 -175.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -88.62 155.14 19.79 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 175.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -63.47 -20.51 65.65 Favored 'General case' 0 CA--C 1.546 0.815 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -175.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -75.64 5.2 6.41 Favored 'General case' 0 CA--C 1.542 0.665 0 CA-C-O 121.225 0.536 . . . . 0.0 110.994 176.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.07 22.67 70.75 Favored Glycine 0 CA--C 1.496 -1.121 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.424 HG22 ' HB2' ' A' ' 89' ' ' CYS . 48.0 m -105.42 128.03 53.31 Favored 'General case' 0 N--CA 1.416 -2.127 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 -179.213 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.531 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 84.5 m95 -95.34 120.84 36.27 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 177.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -121.87 150.64 41.65 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.824 0.345 . . . . 0.0 111.66 -175.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 52.0 pttt -135.57 135.48 22.2 Favored Pre-proline 0 C--N 1.299 -1.623 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 173.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -70.78 125.68 11.86 Favored 'Trans proline' 0 C--O 1.249 1.057 0 C-N-CA 121.764 1.643 . . . . 0.0 109.933 174.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -165.7 120.39 1.24 Allowed 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.541 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 25.7 t-20 -102.08 107.86 19.1 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.481 0.658 . . . . 0.0 111.114 -175.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -143.18 179.47 7.04 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.524 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 42.0 m -115.59 150.13 37.15 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.048 0.451 . . . . 0.0 110.641 -177.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 82.6 t80 -131.71 127.5 36.98 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 175.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.8 t -111.4 106.19 20.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -71.48 152.31 43.16 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -156.02 -41.14 0.02 OUTLIER Glycine 0 N--CA 1.435 -1.423 0 C-N-CA 118.589 -1.767 . . . . 0.0 115.16 -177.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 45.0 t30 -71.21 -49.02 47.84 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 117.406 0.603 . . . . 0.0 112.538 -172.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -146.86 153.64 46.35 Favored Pre-proline 0 C--N 1.305 -1.335 0 C-N-CA 119.979 -0.688 . . . . 0.0 110.385 -176.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_exo -65.66 123.18 11.03 Favored 'Trans proline' 0 C--O 1.248 1.019 0 C-N-CA 121.76 1.64 . . . . 0.0 108.411 170.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 55.1 mt -107.18 125.03 63.38 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 -173.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 9.9 p -76.52 119.93 25.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 43.2 p -95.43 151.46 19.27 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.236 -175.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -102.44 137.19 41.01 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -175.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.1 mt -106.0 135.12 45.5 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.922 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -171.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.66 -23.45 5.69 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 116.405 1.322 . . . . 0.0 116.405 170.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 51.3 m -157.63 142.19 11.86 Favored Pre-proline 0 C--N 1.307 -1.254 0 CA-C-N 118.102 0.951 . . . . 0.0 109.524 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -90.05 119.54 0.8 Allowed 'Trans proline' 0 N--CA 1.439 -1.695 0 C-N-CA 121.559 1.506 . . . . 0.0 111.193 175.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.405 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 57.5 m-85 -168.38 165.77 12.63 Favored 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 126.16 1.784 . . . . 0.0 106.321 -179.344 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 89.8 mt -85.25 -14.62 46.14 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 175.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -106.95 13.59 27.47 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.52 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.405 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.88 155.61 90.46 Favored Pre-proline 0 C--N 1.314 -0.973 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.021 -177.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -56.52 140.6 89.81 Favored 'Trans proline' 0 C--N 1.364 1.364 0 C-N-CA 123.6 2.867 . . . . 0.0 114.626 -178.079 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 33.3 m -97.81 175.63 0.79 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.747 0 C-N-CA 124.668 1.187 . . . . 0.0 110.609 178.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 121.0 -9.17 10.41 Favored Glycine 0 CA--C 1.496 -1.101 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 -178.698 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.89 126.97 9.07 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 108.198 -1.961 . . . . 0.0 108.198 172.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.9 t30 -128.26 125.3 38.61 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 118.057 0.929 . . . . 0.0 110.468 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 54.4 tp -96.84 108.5 43.62 Favored Pre-proline 0 C--N 1.296 -1.755 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.005 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -67.73 159.14 54.04 Favored 'Trans proline' 0 C--O 1.245 0.86 0 C-N-CA 122.389 2.06 . . . . 0.0 112.104 178.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.3 136.46 39.61 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.51 -2.38 64.93 Favored Glycine 0 C--N 1.31 -0.883 0 N-CA-C 111.664 -0.574 . . . . 0.0 111.664 -179.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.59 134.37 37.22 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-O 120.845 0.355 . . . . 0.0 111.711 -177.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 22.1 m -98.73 109.05 21.87 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.155 -0.93 . . . . 0.0 108.837 178.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 43.0 mm -110.78 135.35 50.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.45 -177.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.3 p -108.51 129.8 62.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 176.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.541 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 48.4 p90 -124.65 151.9 44.33 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -177.049 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.416 ' HA ' ' HA ' ' A' ' 50' ' ' ASN . 3.9 p30 -114.81 4.93 15.06 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 120.864 0.364 . . . . 0.0 110.537 -179.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -148.15 139.64 23.61 Favored 'General case' 0 N--CA 1.428 -1.562 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.383 -176.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 41.5 t -120.38 128.19 75.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 N-CA-C 105.725 -1.954 . . . . 0.0 105.725 175.514 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.424 ' HB2' HG22 ' A' ' 44' ' ' THR . 8.7 p -139.91 143.37 36.62 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -175.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 67.8 mt -105.66 117.24 51.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.094 0.473 . . . . 0.0 110.751 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.512 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 6.1 tp-100 -115.66 113.52 23.64 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 103.021 -2.955 . . . . 0.0 103.021 168.154 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.59 115.88 1.4 Allowed 'General case' 0 CA--C 1.512 -0.512 0 O-C-N 124.458 1.099 . . . . 0.0 113.189 -165.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 133.02 -39.11 1.78 Allowed Glycine 0 N--CA 1.419 -2.459 0 CA-C-N 113.642 -1.617 . . . . 0.0 109.066 -176.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 64.4 m80 -148.16 161.15 42.03 Favored 'General case' 0 CA--C 1.506 -0.72 0 C-N-CA 122.921 0.488 . . . . 0.0 110.363 -179.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.454 ' O ' HG22 ' A' ' 111' ' ' VAL . 16.0 tt -106.75 121.44 59.47 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 175.201 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.512 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 52.9 m95 -104.77 138.25 41.33 Favored 'General case' 0 C--N 1.279 -2.469 0 CA-C-O 120.868 0.366 . . . . 0.0 110.881 -170.345 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.5 pt -100.34 132.51 45.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 175.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.14 116.07 5.45 Favored Glycine 0 N--CA 1.431 -1.67 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -178.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -136.08 175.25 9.77 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -115.29 127.42 55.44 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 177.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.28 -179.42 6.97 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.5 p90 -68.0 -20.39 65.02 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 118.488 0.585 . . . . 0.0 112.432 -176.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 59.3 t30 -73.7 -12.29 60.67 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-O 121.637 0.732 . . . . 0.0 109.532 175.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 92.26 -12.43 69.66 Favored Glycine 0 CA--C 1.501 -0.786 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.627 178.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -72.57 147.67 45.67 Favored 'General case' 0 C--O 1.253 1.245 0 C-N-CA 123.252 0.621 . . . . 0.0 109.841 -175.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.3 tpt180 -80.66 108.29 14.19 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 124.539 1.136 . . . . 0.0 108.414 -178.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 38.2 t -112.32 145.99 17.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 -176.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.463 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 91.9 m-85 -121.49 130.86 53.81 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.038 0.447 . . . . 0.0 110.671 -177.251 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . 0.464 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 52.5 t -109.11 130.49 22.67 Favored Pre-proline 0 C--N 1.304 -1.396 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 177.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -70.07 -14.15 34.76 Favored 'Trans proline' 0 C--O 1.21 -0.883 0 C-N-CA 122.962 2.442 . . . . 0.0 114.564 -177.194 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.454 HG22 ' O ' ' A' ' 95' ' ' ILE 0.295 21.5 m 43.29 -54.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.518 2.949 0 N-CA-C 118.431 2.752 . . . . 0.0 118.431 176.173 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.404 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 12.1 ptm180 -156.09 150.43 25.64 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 55.1 m -64.31 144.68 56.97 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 177.004 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.448 ' SG ' ' HB2' ' A' ' 121' ' ' HIS . 27.0 t -161.16 134.18 6.35 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-O 120.954 0.407 . . . . 0.0 110.738 -178.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -123.81 160.92 26.31 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 176.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.62 178.04 15.48 Favored Glycine 0 N--CA 1.423 -2.195 0 C-N-CA 119.055 -1.545 . . . . 0.0 113.455 174.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 16.5 m -128.39 128.12 23.64 Favored Pre-proline 0 C--N 1.3 -1.574 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.531 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 64.5 Cg_exo -48.46 139.63 22.54 Favored 'Trans proline' 0 C--O 1.237 0.459 0 C-N-CA 123.433 2.755 . . . . 0.0 113.788 -179.294 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -81.15 -18.71 24.29 Favored 'Cis proline' 0 C--O 1.246 0.91 0 C-N-CA 123.581 -1.424 . . . . 0.0 114.018 0.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -70.67 102.0 2.19 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 122.053 0.93 . . . . 0.0 112.665 -172.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.448 ' HB2' ' SG ' ' A' ' 114' ' ' CYS . 48.8 p-80 -104.64 130.35 52.67 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-N 114.65 -1.159 . . . . 0.0 110.188 178.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 60.9 mt -96.49 114.32 64.18 Favored Pre-proline 0 C--N 1.301 -1.524 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -75.88 162.27 35.08 Favored 'Trans proline' 0 C--O 1.245 0.862 0 C-N-CA 122.571 2.181 . . . . 0.0 113.181 -179.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.85 -164.31 11.0 Favored Glycine 0 N--CA 1.433 -1.535 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 177.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 59.1 t -52.84 115.97 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.818 0.847 . . . . 0.0 112.562 -176.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.404 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -93.85 148.85 21.75 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.248 177.434 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.9 m-90 -111.17 10.91 21.86 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-O 121.103 0.478 . . . . 0.0 111.252 178.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.5 -175.9 33.03 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.665 -178.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 54.7 t -111.33 138.98 37.53 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -176.205 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -101.22 147.49 26.21 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-O 120.597 0.237 . . . . 0.0 110.396 -178.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.2 mtpt . . . . . 0 C--O 1.26 1.621 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 175.087 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 19.4 p . . . . . 0 N--CA 1.443 -0.79 0 CA-C-O 120.245 0.069 . . . . 0.0 111.061 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 24.2 t30 69.75 113.74 0.05 OUTLIER 'General case' 0 C--O 1.237 0.4 0 C-N-CA 124.151 0.98 . . . . 0.0 111.023 -177.341 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.77 2.19 27.23 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.223 -0.898 . . . . 0.0 112.165 -177.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt 78.18 -20.28 0.39 Allowed 'General case' 0 N--CA 1.494 1.727 0 C-N-CA 125.994 1.717 . . . . 0.0 111.586 177.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -146.77 128.56 15.3 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -130.17 71.72 1.46 Allowed 'General case' 0 C--N 1.308 -1.214 0 O-C-N 123.529 0.518 . . . . 0.0 110.022 177.267 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 49.6 tpp -152.31 95.46 2.05 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.902 178.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -97.09 79.89 2.9 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 175.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 tppp? -163.23 99.89 0.95 Allowed 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.491 -1.299 . . . . 0.0 107.491 -179.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -75.82 -2.68 71.35 Favored Glycine 0 C--N 1.313 -0.732 0 CA-C-N 115.491 -0.777 . . . . 0.0 113.691 -175.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 33.4 m -55.45 101.82 0.06 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.148 0.979 . . . . 0.0 111.151 178.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 31.0 m 62.44 19.15 10.94 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.808 0.843 . . . . 0.0 111.282 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 8.6 t -94.49 82.6 4.03 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-O 121.677 0.751 . . . . 0.0 109.15 -178.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.5 m -156.88 152.91 27.37 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 105.801 -1.926 . . . . 0.0 105.801 177.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.0 m -95.72 77.25 3.26 Favored 'General case' 0 C--N 1.294 -1.834 0 CA-C-O 121.738 0.78 . . . . 0.0 109.571 178.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 84.8 t -107.02 -53.09 6.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.769 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.8 t -90.4 125.69 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 178.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.499 ' N ' ' HD2' ' A' ' 18' ' ' LYS . 0.1 OUTLIER -94.13 92.58 7.36 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.161 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -82.0 140.08 34.16 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.713 -178.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.92 -15.02 68.77 Favored Glycine 0 C--N 1.317 -0.478 0 O-C-N 123.412 0.445 . . . . 0.0 113.184 -177.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.636 ' HE2' ' HA ' ' A' ' 21' ' ' LYS . 9.6 mmpt? 71.54 77.43 0.17 Allowed 'General case' 0 CA--C 1.509 -0.604 0 C-N-CA 124.783 1.233 . . . . 0.0 111.179 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 87.5 m -86.78 111.17 20.47 Favored 'General case' 0 N--CA 1.415 -2.21 0 CA-C-N 114.48 -1.236 . . . . 0.0 108.173 177.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.8 t -88.34 -169.63 2.64 Favored 'General case' 0 N--CA 1.417 -2.119 0 CA-C-N 114.98 -1.009 . . . . 0.0 109.567 -176.523 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.0 m -68.43 102.19 1.38 Allowed 'General case' 0 N--CA 1.423 -1.802 0 C-N-CA 123.858 0.863 . . . . 0.0 111.051 -178.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 67.59 86.15 0.13 Allowed 'General case' 0 C--O 1.243 0.73 0 C-N-CA 125.512 1.525 . . . . 0.0 113.977 176.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 19.7 m -73.16 133.73 44.17 Favored 'General case' 0 N--CA 1.435 -1.225 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 172.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 27.6 m 68.16 89.86 0.09 OUTLIER Pre-proline 0 CA--C 1.552 1.032 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -175.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_exo -63.09 -32.28 75.21 Favored 'Trans proline' 0 C--N 1.354 0.821 0 C-N-CA 123.0 2.467 . . . . 0.0 113.665 -175.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 60.26 -163.47 0.24 Allowed 'General case' 0 C--O 1.252 1.206 0 O-C-N 124.06 0.85 . . . . 0.0 109.009 -175.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 32.3 m -84.95 95.34 9.02 Favored 'General case' 0 N--CA 1.422 -1.834 0 CA-C-O 121.95 0.881 . . . . 0.0 109.357 175.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.535 ' H ' ' HD2' ' A' ' 32' ' ' PRO . 44.1 ttp180 -142.19 -52.23 0.02 OUTLIER Pre-proline 0 C--N 1.3 -1.565 0 CA-C-N 113.855 -1.521 . . . . 0.0 109.567 -179.428 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.535 ' HD2' ' H ' ' A' ' 31' ' ' ARG . 10.5 Cg_endo -57.49 125.95 20.4 Favored 'Trans proline' 0 C--N 1.386 2.521 0 N-CA-C 108.847 -1.251 . . . . 0.0 108.847 170.838 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 23.1 m -64.62 111.47 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 CA-C-O 121.76 0.791 . . . . 0.0 112.942 -175.054 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 19.0 p -96.59 25.98 4.77 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.113 -178.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -71.84 -66.33 2.15 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 121.186 -0.53 . . . . 0.0 112.011 -179.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 24.8 t -87.06 -47.07 9.22 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -86.93 122.65 31.08 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-N 115.586 -0.733 . . . . 0.0 109.715 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -113.92 141.95 46.74 Favored 'General case' 0 C--N 1.286 -2.169 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 -177.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 66.1 tttm -100.2 144.51 29.13 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 119.681 -0.808 . . . . 0.0 110.138 -179.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 33.0 p30 -114.73 -179.18 3.55 Favored 'General case' 0 C--O 1.254 1.326 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.545 175.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -81.51 0.63 37.09 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -175.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -91.79 -0.77 57.55 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 121.846 0.832 . . . . 0.0 109.073 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.95 19.65 74.76 Favored Glycine 0 CA--C 1.5 -0.885 0 CA-C-N 115.235 -0.893 . . . . 0.0 111.191 -179.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.447 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 28.3 m -105.65 141.13 37.64 Favored 'General case' 0 N--CA 1.41 -2.458 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 -179.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.543 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 63.3 m95 -104.64 125.3 50.62 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 174.008 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -127.42 145.07 50.95 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-O 120.729 0.3 . . . . 0.0 110.614 -176.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.445 ' CG ' ' HB ' ' A' ' 88' ' ' VAL . 21.1 ptmt -124.86 132.78 24.37 Favored Pre-proline 0 C--N 1.294 -1.836 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 176.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -76.05 121.06 5.98 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 121.458 1.438 . . . . 0.0 109.555 174.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -166.71 120.91 1.07 Allowed 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.421 ' HA ' ' HA ' ' A' ' 86' ' ' ASP . 24.4 t-20 -95.43 120.2 35.25 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.091 -175.092 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.72 164.18 35.93 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 51.2 m -103.83 149.18 25.29 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.933 -177.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.5 t80 -126.42 134.13 51.08 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 177.257 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.8 t -114.2 118.11 57.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.923 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 49.9 t-20 -68.62 130.68 43.54 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -95.58 -68.29 1.01 Allowed Glycine 0 N--CA 1.421 -2.344 0 C-N-CA 120.005 -1.093 . . . . 0.0 114.253 -172.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -135.31 14.4 3.5 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -170.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.499 ' HB2' ' HB3' ' A' ' 127' ' ' TRP . 0.0 OUTLIER -135.48 122.07 14.47 Favored Pre-proline 0 C--N 1.298 -1.642 0 C-N-CA 119.729 -0.788 . . . . 0.0 112.949 -177.802 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -67.22 120.66 7.74 Favored 'Trans proline' 0 N--CA 1.447 -1.209 0 N-CA-C 105.767 -2.436 . . . . 0.0 105.767 167.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.495 HG13 ' O ' ' A' ' 58' ' ' GLN . 49.4 mt -113.58 120.74 64.24 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.057 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.639 -171.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -73.84 122.78 27.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 176.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 44.8 p -102.42 170.35 8.11 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.884 -173.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -117.47 149.28 40.85 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 2.8 mp -111.58 133.19 58.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 121.082 0.468 . . . . 0.0 111.111 -178.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 84.29 -24.11 6.59 Favored Glycine 0 C--N 1.315 -0.615 0 N-CA-C 115.861 1.104 . . . . 0.0 115.861 171.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 65.5 m -160.46 146.67 11.67 Favored Pre-proline 0 C--N 1.311 -1.068 0 CA-C-N 118.216 1.008 . . . . 0.0 110.144 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.405 ' HG2' HG21 ' A' ' 44' ' ' THR . 58.9 Cg_endo -89.82 119.9 0.87 Allowed 'Trans proline' 0 N--CA 1.44 -1.638 0 C-N-CA 121.771 1.647 . . . . 0.0 111.732 175.221 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.458 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 88.2 m-85 -169.89 177.66 4.3 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 103.487 -2.782 . . . . 0.0 103.487 -179.082 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -89.95 -37.47 14.34 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 171.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -89.14 25.48 1.85 Allowed 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 114.751 -1.113 . . . . 0.0 111.138 -177.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.458 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -84.49 161.38 54.22 Favored Pre-proline 0 C--N 1.306 -1.309 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 178.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -47.66 135.12 21.98 Favored 'Trans proline' 0 C--N 1.364 1.35 0 C-N-CA 123.715 2.943 . . . . 0.0 114.722 -178.286 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 18.0 m -90.42 173.92 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 114.362 -1.29 . . . . 0.0 110.636 -178.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.86 28.53 2.04 Favored Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.535 177.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -151.08 128.59 2.64 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 120.001 -1.095 . . . . 0.0 112.567 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -128.12 127.76 43.61 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.751 -1.204 . . . . 0.0 107.751 173.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 55.0 tp -101.41 109.9 60.15 Favored Pre-proline 0 C--N 1.301 -1.509 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 178.151 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.22 154.06 51.54 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 122.46 2.107 . . . . 0.0 112.515 -178.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.53 141.48 51.9 Favored 'General case' 0 N--CA 1.438 -1.045 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.855 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.0 -7.13 67.14 Favored Glycine 0 N--CA 1.435 -1.412 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.618 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.04 136.56 34.45 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.902 0.351 . . . . 0.0 111.366 -178.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 47.6 m -103.77 112.9 26.05 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.7 mm -127.27 133.77 67.35 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -176.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 11.6 p -93.3 135.19 28.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.417 ' HA ' ' HB3' ' A' ' 99' ' ' TYR . 52.7 p90 -118.18 159.55 23.11 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -178.492 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.421 ' HA ' ' HA ' ' A' ' 50' ' ' ASN . 4.9 p-10 -130.12 -7.78 4.35 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 112.367 0.506 . . . . 0.0 112.367 -177.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.466 ' HG2' ' SG ' ' A' ' 89' ' ' CYS . 29.4 tt0 -131.36 120.83 23.67 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 -176.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.445 ' HB ' ' CG ' ' A' ' 47' ' ' LYS . 39.9 t -105.67 119.07 54.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.466 ' SG ' ' HG2' ' A' ' 87' ' ' GLU . 46.9 m -123.23 133.2 54.22 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -172.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 56.6 mt -97.7 113.86 33.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 CA-C-O 121.291 0.567 . . . . 0.0 109.942 173.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.507 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -121.42 134.04 55.09 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 172.145 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.62 117.05 1.84 Allowed 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 114.081 1.141 . . . . 0.0 114.081 -164.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 107.96 -22.61 27.33 Favored Glycine 0 N--CA 1.431 -1.681 0 CA-C-N 115.115 -0.948 . . . . 0.0 112.426 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . 0.438 ' HB2' ' NE1' ' A' ' 96' ' ' TRP . 57.9 m80 -144.45 169.22 18.36 Favored 'General case' 0 CA--C 1.509 -0.626 0 O-C-N 122.108 -0.642 . . . . 0.0 110.445 -176.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.6 tt -126.09 109.58 21.74 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.152 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 173.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.507 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 42.5 m95 -95.27 138.91 32.33 Favored 'General case' 0 C--N 1.279 -2.48 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.563 -167.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.453 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.8 pt -100.58 127.74 53.35 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 176.498 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.88 127.93 9.37 Favored Glycine 0 N--CA 1.421 -2.307 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.417 ' HB3' ' HA ' ' A' ' 85' ' ' TYR . 41.3 p90 -142.63 150.46 40.3 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -102.08 119.15 38.33 Favored 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.411 ' HB3' ' OD1' ' A' ' 105' ' ' ASN . . . -87.19 168.12 13.51 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 120.954 0.407 . . . . 0.0 110.838 -177.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -52.88 -25.52 11.93 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.397 1.479 . . . . 0.0 112.897 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -83.69 -3.44 57.77 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.454 0.645 . . . . 0.0 110.497 -176.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.19 7.07 73.88 Favored Glycine 0 CA--C 1.501 -0.8 0 CA-C-O 121.422 0.456 . . . . 0.0 112.038 176.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.411 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 13.8 p-10 -94.66 130.21 41.24 Favored 'General case' 0 C--N 1.29 -1.991 0 C-N-CA 123.147 0.579 . . . . 0.0 111.008 -177.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 26.6 tpt180 -84.1 102.93 12.9 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 178.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.8 t -97.71 139.34 20.22 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -173.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.453 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 79.0 m-85 -119.69 122.55 41.72 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 123.336 0.654 . . . . 0.0 109.725 177.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . 0.424 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 48.6 t -111.38 130.87 22.62 Favored Pre-proline 0 C--N 1.305 -1.369 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.032 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.1 -27.41 41.98 Favored 'Trans proline' 0 C--N 1.355 0.884 0 C-N-CA 122.815 2.343 . . . . 0.0 114.112 -176.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.303 18.9 m 51.19 -42.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.505 0 N-CA-C 118.446 2.758 . . . . 0.0 118.446 176.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.53 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 37.9 ptt180 -161.5 165.08 29.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-O 121.112 0.482 . . . . 0.0 110.634 -179.409 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.5 m -75.93 139.72 41.74 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 176.205 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 49.5 t -155.97 128.01 7.51 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.47 0.652 . . . . 0.0 110.962 178.209 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . 0.457 ' HA ' ' OE1' ' A' ' 115' ' ' GLN . 7.9 mm-40 -121.69 162.45 20.72 Favored 'General case' 0 C--N 1.288 -2.106 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.493 177.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 124.58 -174.38 17.07 Favored Glycine 0 N--CA 1.418 -2.51 0 C-N-CA 119.947 -1.121 . . . . 0.0 112.021 177.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 18.9 m -131.87 133.22 23.82 Favored Pre-proline 0 C--N 1.3 -1.549 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.508 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.543 ' HG2' ' CG ' ' A' ' 45' ' ' TRP . 88.2 Cg_exo -48.74 137.13 27.34 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 123.332 2.688 . . . . 0.0 113.417 -178.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 11.7 Cg_endo -91.09 1.09 64.32 Favored 'Cis proline' 0 C--O 1.245 0.86 0 C-N-CA 123.584 -1.423 . . . . 0.0 113.079 1.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -80.7 100.18 8.58 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 121.76 0.791 . . . . 0.0 110.36 -173.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.436 ' HB2' ' SG ' ' A' ' 114' ' ' CYS . 47.1 p-80 -105.5 131.33 53.03 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 114.606 -1.179 . . . . 0.0 112.098 -177.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.456 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.1 mm -105.74 99.8 23.83 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 178.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -84.96 139.69 7.47 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.391 2.061 . . . . 0.0 112.29 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -102.39 -133.01 7.89 Favored Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 177.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 61.5 t -82.97 129.3 37.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 110.129 -0.322 . . . . 0.0 110.129 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.53 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -93.62 143.82 25.96 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.823 176.543 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . 0.499 ' HB3' ' HB2' ' A' ' 58' ' ' GLN . 4.8 m0 -101.99 12.59 36.66 Favored 'General case' 0 C--O 1.251 1.154 0 CA-C-O 122.031 0.92 . . . . 0.0 110.345 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.63 179.59 36.92 Favored Glycine 0 N--CA 1.426 -1.99 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.936 -179.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.5 t -113.54 134.97 54.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -177.012 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -87.62 122.1 30.89 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? . . . . . 0 C--N 1.291 -1.943 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.866 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 12.4 m . . . . . 0 N--CA 1.44 -0.946 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -142.83 107.65 4.88 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.121 -179.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.86 115.69 22.39 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 174.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 51.6 tptt -77.03 -8.53 57.58 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 120.855 0.359 . . . . 0.0 111.337 -174.284 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 72.14 -54.04 0.69 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 124.762 1.225 . . . . 0.0 112.962 177.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 70.37 -65.1 0.34 Allowed 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.848 1.659 . . . . 0.0 108.318 -175.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 23.8 ptt? -100.12 102.22 13.48 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 172.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -85.57 115.07 23.05 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -176.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.9 ptmm? -148.14 -4.57 0.47 Allowed 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 -175.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.05 -131.07 4.25 Favored Glycine 0 N--CA 1.439 -1.126 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.164 -178.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 38.0 m -99.91 82.83 2.63 Favored 'General case' 0 C--N 1.291 -1.935 0 CA-C-O 121.81 0.814 . . . . 0.0 111.155 -179.329 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.0 m -94.9 -10.56 30.83 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.175 -0.92 . . . . 0.0 108.603 174.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.0 m -70.29 145.53 51.22 Favored 'General case' 0 N--CA 1.439 -1.012 0 CA-C-N 115.253 -0.885 . . . . 0.0 108.972 176.379 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.9 t -159.44 173.0 16.89 Favored 'General case' 0 N--CA 1.424 -1.746 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 -178.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 5.8 m -78.33 79.99 4.75 Favored 'General case' 0 N--CA 1.428 -1.563 0 CA-C-O 121.876 0.846 . . . . 0.0 109.301 -178.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 50.2 t -88.29 101.85 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 CA-C-N 115.217 -0.901 . . . . 0.0 108.93 -179.221 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 30.6 m -78.7 144.28 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 60.9 mttp 66.15 24.72 10.81 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 124.244 1.017 . . . . 0.0 111.229 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -58.12 119.07 6.18 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 123.49 0.716 . . . . 0.0 111.406 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.87 166.15 28.11 Favored Glycine 0 CA--C 1.493 -1.297 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -178.01 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -76.57 86.74 3.26 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 118.093 0.947 . . . . 0.0 109.588 179.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.7 m -101.82 -57.22 2.11 Favored 'General case' 0 N--CA 1.423 -1.824 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.6 -176.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.0 m -82.76 131.73 35.19 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.271 -177.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.4 p -81.71 -15.12 55.45 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 122.013 0.911 . . . . 0.0 109.376 176.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -150.37 141.11 22.71 Favored 'General case' 0 N--CA 1.429 -1.52 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 175.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.412 ' O ' ' HD3' ' A' ' 28' ' ' PRO . 19.6 m -66.21 -30.64 71.14 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.092 0.472 . . . . 0.0 110.231 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 28.5 m -102.91 99.82 14.95 Favored Pre-proline 0 N--CA 1.423 -1.802 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 173.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.412 ' HD3' ' O ' ' A' ' 26' ' ' SER . 3.8 Cg_exo -75.89 66.32 6.77 Favored 'Trans proline' 0 C--O 1.243 0.727 0 C-N-CA 123.124 2.55 . . . . 0.0 111.494 -178.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.439 ' HA ' ' HA ' ' A' ' 33' ' ' VAL . . . -112.75 3.43 16.5 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 114.169 -1.378 . . . . 0.0 108.676 177.467 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.8 p -91.02 -78.34 0.39 Allowed 'General case' 0 N--CA 1.428 -1.57 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.565 -178.091 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.578 ' HB3' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -88.34 -61.97 0.23 Allowed Pre-proline 0 C--N 1.309 -1.183 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.936 -177.78 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.578 ' HD3' ' HB3' ' A' ' 31' ' ' ARG . 56.7 Cg_endo -89.5 46.92 0.93 Allowed 'Trans proline' 0 C--N 1.368 1.566 0 CA-C-N 121.092 1.426 . . . . 0.0 110.133 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.439 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 5.8 p -45.02 98.12 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.35 0.606 0 C-N-CA 124.642 1.177 . . . . 0.0 113.342 -176.352 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.3 p 156.13 -35.96 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 129.657 3.183 . . . . 0.0 106.316 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 136.42 -88.01 0.23 Allowed Glycine 0 N--CA 1.423 -2.178 0 N-CA-C 108.451 -1.859 . . . . 0.0 108.451 -177.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 49.4 m -157.61 28.43 0.28 Allowed 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.013 -1.476 . . . . 0.0 107.013 174.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 73.0 m95 -90.03 145.66 24.92 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.296 -174.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.464 ' HE3' ' HA ' ' A' ' 38' ' ' LYS . 0.0 OUTLIER -131.93 146.68 52.25 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 174.881 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -93.77 133.6 36.98 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 -178.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 33.3 p30 -96.84 176.81 5.85 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 175.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -77.22 1.75 17.56 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.515 0.674 . . . . 0.0 112.214 -175.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.7 m-85 -98.72 7.9 45.56 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.139 178.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.19 17.51 77.41 Favored Glycine 0 C--N 1.338 0.65 0 CA-C-N 115.128 -0.942 . . . . 0.0 112.32 177.14 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.45 HG21 ' HG2' ' A' ' 67' ' ' PRO . 5.3 m -105.01 141.9 35.76 Favored 'General case' 0 N--CA 1.42 -1.937 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -177.341 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.454 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 87.5 m95 -96.46 129.18 43.87 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.41 ' HA ' ' O ' ' A' ' 88' ' ' VAL . 51.8 p90 -125.89 150.28 48.04 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 123.199 0.312 . . . . 0.0 110.383 -178.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 14.1 ptmm? -135.66 148.06 63.98 Favored Pre-proline 0 C--N 1.303 -1.43 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 175.377 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -71.24 128.86 15.21 Favored 'Trans proline' 0 N--CA 1.444 -1.386 0 C-N-CA 121.27 1.313 . . . . 0.0 109.013 170.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.448 ' HB3' HG23 ' A' ' 88' ' ' VAL . 9.2 tp10 -162.64 120.18 2.04 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.526 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 6.6 t30 -105.87 113.48 27.06 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.684 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.413 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.55 175.62 12.57 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 89.0 m -118.9 133.19 56.0 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 120.253 -0.579 . . . . 0.0 112.32 -176.702 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -107.89 129.11 55.11 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 176.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.1 t -110.35 115.1 48.88 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 176.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -69.16 148.64 49.63 Favored 'General case' 0 C--N 1.309 -1.178 0 O-C-N 123.408 0.442 . . . . 0.0 110.466 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -81.58 -144.76 4.55 Favored Glycine 0 N--CA 1.43 -1.756 0 CA-C-N 115.998 -0.547 . . . . 0.0 113.84 -177.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 31.2 p-10 -85.65 12.22 9.23 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 -171.702 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.439 ' HA ' ' HD3' ' A' ' 59' ' ' PRO . 0.8 OUTLIER -142.4 143.46 27.04 Favored Pre-proline 0 C--N 1.301 -1.516 0 C-N-CA 120.592 -0.443 . . . . 0.0 112.065 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 58' ' ' GLN . 12.8 Cg_exo -71.98 131.75 18.69 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.138 1.892 . . . . 0.0 111.437 177.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -107.58 132.7 54.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.037 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.5 p -79.97 136.2 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 176.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 53.4 p -111.98 167.03 10.71 Favored 'General case' 0 C--N 1.287 -2.138 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.651 -175.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.415 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 21.7 mmt180 -114.68 137.14 52.26 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.7 mt -93.33 123.85 45.57 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 CA-C-N 115.396 -0.82 . . . . 0.0 113.156 -172.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.79 -23.19 3.75 Favored Glycine 0 C--O 1.237 0.291 0 N-CA-C 115.906 1.123 . . . . 0.0 115.906 172.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.408 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 50.7 m -151.7 144.53 16.96 Favored Pre-proline 0 C--N 1.306 -1.288 0 CA-C-N 118.53 1.165 . . . . 0.0 111.54 -177.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.45 ' HG2' HG21 ' A' ' 44' ' ' THR . 1.2 Cg_endo -89.35 120.95 1.06 Allowed 'Trans proline' 0 N--CA 1.448 -1.168 0 C-N-CA 122.457 2.105 . . . . 0.0 110.597 173.245 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.567 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 59.6 m-85 -168.53 170.43 9.66 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 126.355 1.862 . . . . 0.0 106.322 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 95.8 mt -82.51 -30.96 29.48 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 172.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 17.6 m120 -102.97 26.22 8.42 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.732 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.567 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -75.2 156.79 85.58 Favored Pre-proline 0 C--N 1.308 -1.198 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.397 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -50.7 131.44 33.47 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 123.651 2.901 . . . . 0.0 113.48 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 6.8 p -101.31 174.17 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 C-N-CA 124.051 0.94 . . . . 0.0 108.928 -176.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.44 -4.74 13.36 Favored Glycine 0 N--CA 1.443 -0.84 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.023 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -110.81 123.78 6.71 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 177.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -122.09 134.48 54.77 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 117.356 0.578 . . . . 0.0 110.139 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.5 tp -100.83 118.87 59.79 Favored Pre-proline 0 C--N 1.308 -1.217 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -66.62 160.06 47.96 Favored 'Trans proline' 0 C--O 1.243 0.764 0 C-N-CA 122.478 2.119 . . . . 0.0 112.709 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.56 136.65 47.56 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.666 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.64 1.49 90.53 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 121.423 -0.418 . . . . 0.0 113.365 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.59 127.09 31.05 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.179 0.514 . . . . 0.0 111.861 -177.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 46.2 m -96.97 109.0 21.84 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 177.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.3 mm -118.79 120.8 65.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.096 -174.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.6 p -89.06 127.46 41.77 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.134 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.526 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 48.5 p90 -116.43 154.55 30.11 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -178.509 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -120.31 4.93 10.74 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-O 121.469 0.652 . . . . 0.0 110.561 -179.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -147.45 140.7 25.24 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.713 -175.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.448 HG23 ' HB3' ' A' ' 49' ' ' GLU . 86.7 t -124.04 133.19 69.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 176.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.544 ' HG ' ' HE2' ' A' ' 108' ' ' TYR . 61.5 m -130.27 135.18 47.83 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 122.315 0.246 . . . . 0.0 111.369 -176.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.4 mt -103.03 111.84 34.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 176.199 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.1 tp-100 -115.69 145.1 43.05 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 105.448 -2.056 . . . . 0.0 105.448 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.37 104.81 0.08 Allowed 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -174.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 115.31 -30.89 6.48 Favored Glycine 0 N--CA 1.434 -1.456 0 CA-C-N 115.61 -0.723 . . . . 0.0 113.836 177.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 64.0 m80 -145.46 150.97 37.47 Favored 'General case' 0 CA--C 1.504 -0.827 0 CA-C-N 118.196 0.998 . . . . 0.0 110.743 -175.018 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.8 tt -106.41 111.78 36.78 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 176.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 47.9 m95 -95.87 148.43 22.62 Favored 'General case' 0 C--N 1.285 -2.233 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.424 -169.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.5 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.4 pt -107.34 139.23 29.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.411 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -106.49 121.46 6.65 Favored Glycine 0 N--CA 1.431 -1.675 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -135.65 167.96 20.15 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.667 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -102.42 131.06 49.32 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.891 179.088 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -83.51 175.52 9.73 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 173.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 29.9 p90 -53.37 -36.24 61.19 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -178.499 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 25.6 p-10 -88.63 1.91 54.15 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 120.68 0.276 . . . . 0.0 111.322 -178.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.11 5.79 72.58 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 121.306 -0.473 . . . . 0.0 112.009 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 60.8 t30 -67.94 129.7 40.71 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 22.9 tpt180 -82.68 107.7 15.5 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 -178.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 27.8 t -111.62 142.85 22.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -178.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.544 ' HE2' ' HG ' ' A' ' 89' ' ' CYS . 85.0 m-85 -117.63 131.35 56.67 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 120.963 0.411 . . . . 0.0 110.628 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 45.3 t -112.9 134.47 21.75 Favored Pre-proline 0 C--N 1.302 -1.483 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -68.16 -27.14 35.68 Favored 'Trans proline' 0 C--N 1.358 1.038 0 C-N-CA 122.626 2.217 . . . . 0.0 113.35 -177.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.29 21.9 m 52.52 -46.59 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.284 0 N-CA-C 117.968 2.581 . . . . 0.0 117.968 176.47 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.546 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 37.1 ptt180 -161.63 163.55 29.87 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 123.157 0.583 . . . . 0.0 110.068 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.8 t -81.69 141.51 33.54 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 175.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.9 t -156.18 127.78 7.24 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -109.17 139.12 44.51 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 142.49 177.91 17.98 Favored Glycine 0 N--CA 1.42 -2.393 0 C-N-CA 119.059 -1.543 . . . . 0.0 113.668 175.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 16.2 m -141.42 145.4 37.77 Favored Pre-proline 0 C--N 1.299 -1.593 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 178.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 83.8 Cg_exo -49.2 138.41 28.94 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 122.897 2.398 . . . . 0.0 112.922 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 60.0 Cg_endo -85.29 -16.04 29.78 Favored 'Cis proline' 0 C--O 1.25 1.118 0 C-N-CA 123.366 -1.514 . . . . 0.0 113.618 0.198 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -80.54 100.98 8.85 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -171.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -106.41 123.95 48.85 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 114.336 -1.302 . . . . 0.0 111.29 178.152 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 70.4 mt -95.46 108.19 37.82 Favored Pre-proline 0 C--N 1.319 -0.73 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -84.23 130.67 4.76 Favored 'Trans proline' 0 C--O 1.249 1.04 0 C-N-CA 122.37 2.047 . . . . 0.0 112.841 -179.059 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -115.35 -147.93 9.26 Favored Glycine 0 N--CA 1.435 -1.374 0 C-N-CA 120.562 -0.827 . . . . 0.0 112.017 178.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.6 t -57.63 116.13 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.823 0 C-N-CA 123.819 0.848 . . . . 0.0 112.047 -179.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.546 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.19 143.87 26.0 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.431 173.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.6 m-90 -104.51 19.74 19.78 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.635 0.731 . . . . 0.0 109.584 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -165.77 -175.74 36.54 Favored Glycine 0 N--CA 1.428 -1.882 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 179.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 60.8 t -112.88 141.59 28.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -177.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -107.14 122.15 45.93 Favored 'General case' 0 C--N 1.321 -0.653 0 O-C-N 123.231 0.332 . . . . 0.0 110.54 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt . . . . . 0 C--N 1.297 -1.676 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 177.994 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 26.0 m . . . . . 0 N--CA 1.439 -1.013 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -166.56 108.19 0.69 Allowed 'General case' 0 C--N 1.319 -0.732 0 C-N-CA 123.473 0.709 . . . . 0.0 109.408 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -123.05 152.26 41.17 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 176.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 41.9 tttm -82.26 124.51 30.0 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -178.143 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 45.5 t30 -90.23 122.46 33.17 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 176.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 84.0 m-85 74.56 124.39 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.942 1.297 . . . . 0.0 110.92 -175.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 94.8 mmm -93.9 75.31 4.2 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 121.51 0.671 . . . . 0.0 109.289 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 31.3 p-10 -104.44 -176.1 2.98 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.985 -178.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 11.9 mptt 67.19 27.53 8.42 Favored 'General case' 0 N--CA 1.489 1.523 0 C-N-CA 124.427 1.091 . . . . 0.0 108.969 -172.548 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -94.23 80.67 0.96 Allowed Glycine 0 N--CA 1.421 -2.313 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.709 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 6.2 m -49.03 104.55 0.06 Allowed 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 123.744 0.818 . . . . 0.0 109.966 178.103 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.7 m -87.54 20.85 2.73 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 112.905 0.706 . . . . 0.0 112.905 -172.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.3 m -76.43 151.71 36.43 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.611 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.2 m -83.76 -26.08 29.97 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 120.618 -0.433 . . . . 0.0 111.395 -178.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.5 m 72.3 -28.79 0.19 Allowed 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 124.622 1.169 . . . . 0.0 113.11 178.028 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 15.7 m -76.61 83.73 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-O 122.188 0.994 . . . . 0.0 110.838 175.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 30.2 m -102.18 -9.31 9.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.821 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 23.2 tptm -74.22 88.92 2.01 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-O 121.336 0.589 . . . . 0.0 109.861 -178.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -155.96 104.16 2.27 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-N 115.321 -0.854 . . . . 0.0 108.723 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -159.95 58.61 0.32 Allowed Glycine 0 N--CA 1.431 -1.64 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.02 91.44 0.68 Allowed 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 -178.27 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.7 p -140.0 94.2 2.73 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.877 -177.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.0 m -82.18 104.39 12.48 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 11.9 m -62.17 -35.28 78.32 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.503 0.668 . . . . 0.0 109.402 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -126.82 109.47 12.03 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 173.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.2 m -100.99 -72.09 0.69 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 16.9 p -142.9 118.06 6.49 Favored Pre-proline 0 C--N 1.302 -1.46 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -59.19 -44.28 35.29 Favored 'Trans proline' 0 C--O 1.243 0.726 0 C-N-CA 121.934 1.756 . . . . 0.0 109.67 173.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 63.31 -175.24 0.15 Allowed 'General case' 0 C--O 1.246 0.88 0 C-N-CA 124.886 1.275 . . . . 0.0 111.274 179.066 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -82.15 79.53 8.61 Favored 'General case' 0 N--CA 1.431 -1.391 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.528 ' HB3' ' HD3' ' A' ' 32' ' ' PRO . 1.5 tmt_? -147.57 -54.92 0.02 OUTLIER Pre-proline 0 C--N 1.308 -1.236 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.267 -179.028 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.528 ' HD3' ' HB3' ' A' ' 31' ' ' ARG . 3.5 Cg_exo -81.91 92.09 1.01 Allowed 'Trans proline' 0 C--N 1.369 1.63 0 CA-C-N 120.66 1.271 . . . . 0.0 109.546 175.519 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 93.2 t -73.85 108.41 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.019 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.627 ' HA ' ' O ' ' A' ' 118' ' ' PRO . 7.6 p -80.43 148.75 30.41 Favored 'General case' 0 N--CA 1.411 -2.383 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.879 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -99.6 -146.05 19.26 Favored Glycine 0 N--CA 1.43 -1.733 0 CA-C-N 115.294 -0.866 . . . . 0.0 112.858 -179.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 6.0 m -85.44 27.41 0.82 Allowed 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 124.261 1.025 . . . . 0.0 111.278 -175.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 48.3 m95 -91.96 153.22 19.61 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.752 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -114.13 133.58 55.47 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -89.45 129.83 35.89 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 120.985 0.421 . . . . 0.0 111.201 -177.49 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 45.9 t-20 -99.83 160.0 14.64 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -65.26 -11.86 45.64 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -77.2 -5.57 49.7 Favored 'General case' 0 CA--C 1.541 0.633 0 CA-C-O 121.357 0.598 . . . . 0.0 109.996 176.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.26 1.83 83.7 Favored Glycine 0 CA--C 1.506 -0.492 0 N-CA-C 110.145 -1.182 . . . . 0.0 110.145 -177.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.424 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 9.2 m -89.42 141.01 28.94 Favored 'General case' 0 N--CA 1.415 -2.208 0 CA-C-N 113.86 -1.17 . . . . 0.0 109.299 -178.02 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.502 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 71.9 m95 -102.45 135.94 43.18 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 173.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.434 ' HA ' ' O ' ' A' ' 88' ' ' VAL . 32.0 p90 -137.4 155.47 49.33 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.702 -177.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -147.29 135.59 10.95 Favored Pre-proline 0 C--N 1.305 -1.364 0 CA-C-N 115.318 -0.855 . . . . 0.0 108.738 173.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -67.08 129.57 20.89 Favored 'Trans proline' 0 C--O 1.248 0.992 0 C-N-CA 122.264 1.976 . . . . 0.0 111.42 173.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -168.02 120.99 0.89 Allowed 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.567 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 15.9 m120 -88.57 109.5 20.13 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-O 120.906 0.384 . . . . 0.0 110.88 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.446 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -135.45 165.73 24.8 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 178.09 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.466 ' HB ' ' HG3' ' A' ' 131' ' ' LYS . 25.9 m -114.0 136.51 52.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-O 121.479 0.656 . . . . 0.0 111.964 -175.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 69.6 t80 -117.74 127.01 53.49 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 114.986 -1.007 . . . . 0.0 108.288 176.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 129' ' ' VAL . 46.0 t -105.41 105.6 18.97 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 178.301 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -76.42 121.51 23.16 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 178.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -149.63 -24.45 0.06 OUTLIER Glycine 0 C--N 1.309 -0.923 0 C-N-CA 118.325 -1.893 . . . . 0.0 114.654 -175.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -71.72 -53.14 14.45 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.172 0.511 . . . . 0.0 110.096 -177.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -156.21 159.83 31.2 Favored Pre-proline 0 C--N 1.312 -1.031 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.078 -176.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -67.77 131.67 24.8 Favored 'Trans proline' 0 C--O 1.248 0.991 0 C-N-CA 122.372 2.048 . . . . 0.0 110.135 173.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 47.4 mt -114.51 132.35 63.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -176.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.3 p -76.07 131.68 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.113 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 177.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 40.7 p -103.74 157.62 16.95 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.531 -177.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -110.78 143.88 40.63 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.3 mp -109.68 134.4 51.91 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 C-N-CA 120.531 -0.468 . . . . 0.0 111.22 -175.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.29 -22.74 1.99 Allowed Glycine 0 C--O 1.244 0.728 0 N-CA-C 117.157 1.623 . . . . 0.0 117.157 171.593 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.4 m -152.85 138.86 11.98 Favored Pre-proline 0 C--N 1.308 -1.197 0 CA-C-N 118.81 1.305 . . . . 0.0 111.462 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -89.75 120.49 0.94 Allowed 'Trans proline' 0 N--CA 1.441 -1.577 0 C-N-CA 121.992 1.795 . . . . 0.0 111.006 171.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.424 ' HA ' ' HG2' ' A' ' 91' ' ' GLN . 68.1 m-85 -166.58 166.33 16.21 Favored 'General case' 0 CA--C 1.493 -1.216 0 C-N-CA 126.63 1.972 . . . . 0.0 105.819 -178.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 86.3 mt -72.23 -41.28 67.03 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.436 0.636 . . . . 0.0 109.296 176.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 21.8 p-10 -97.47 25.63 5.55 Favored 'General case' 0 C--O 1.246 0.894 0 C-N-CA 124.477 1.111 . . . . 0.0 110.709 -177.578 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -65.84 153.32 91.51 Favored Pre-proline 0 C--O 1.249 1.077 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.627 -178.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -47.44 128.62 15.23 Favored 'Trans proline' 0 C--N 1.368 1.555 0 C-N-CA 124.205 3.27 . . . . 0.0 114.077 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.3 p -102.73 172.99 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.44 28.61 1.92 Allowed Glycine 0 N--CA 1.442 -0.903 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.649 -176.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -161.66 131.23 2.51 Favored Glycine 0 N--CA 1.433 -1.566 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 176.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -127.82 141.38 51.58 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 117.336 0.568 . . . . 0.0 110.272 -179.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 50.7 tp -100.96 113.26 65.78 Favored Pre-proline 0 C--N 1.301 -1.521 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.007 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -73.64 156.8 49.07 Favored 'Trans proline' 0 C--O 1.252 1.209 0 C-N-CA 122.405 2.07 . . . . 0.0 111.456 179.05 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.52 142.77 42.77 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 108.35 -22.46 26.8 Favored Glycine 0 N--CA 1.434 -1.475 0 N-CA-C 110.438 -1.065 . . . . 0.0 110.438 -176.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.5 126.77 30.56 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-O 121.349 0.595 . . . . 0.0 111.298 -178.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 17.0 m -98.67 110.77 23.31 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 177.613 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.1 mm -111.51 131.07 63.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.286 -173.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.6 p -108.67 112.48 40.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 CA-C-O 122.04 0.924 . . . . 0.0 109.074 175.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.567 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 46.9 p90 -97.45 149.32 22.28 Favored 'General case' 0 C--N 1.296 -1.744 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.363 -177.517 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -112.92 -9.9 13.58 Favored 'General case' 0 C--N 1.31 -1.139 0 O-C-N 123.804 0.69 . . . . 0.0 111.238 -176.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 46.3 tt0 -134.94 128.98 33.54 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -175.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 46' ' ' TYR . 13.8 t -107.89 126.71 64.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.424 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 62.5 m -128.94 139.02 52.3 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -177.135 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 46.9 mt -112.22 119.37 60.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 173.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.497 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -124.94 144.1 50.53 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 104.638 -2.356 . . . . 0.0 104.638 174.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -51.15 104.13 0.07 Allowed 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 113.353 0.871 . . . . 0.0 113.353 -172.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.45 -39.97 1.76 Allowed Glycine 0 N--CA 1.431 -1.642 0 CA-C-N 115.436 -0.802 . . . . 0.0 113.236 177.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 53.0 m80 -147.74 157.58 43.61 Favored 'General case' 0 CA--C 1.497 -1.091 0 O-C-N 122.083 -0.657 . . . . 0.0 110.602 -174.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.9 tt -96.78 128.28 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.714 0 N-CA-C 105.296 -2.112 . . . . 0.0 105.296 172.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.497 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 72.1 m95 -106.41 135.45 47.87 Favored 'General case' 0 C--N 1.266 -3.023 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -173.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.509 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.4 pt -100.38 126.38 53.97 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.894 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 177.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -100.29 124.23 8.18 Favored Glycine 0 N--CA 1.42 -2.422 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.173 -177.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -148.23 173.07 13.37 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 177.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -119.17 145.51 45.94 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 177.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.44 ' HB3' ' OD1' ' A' ' 105' ' ' ASN . . . -93.85 170.23 9.71 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -73.35 -9.8 59.07 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.141 0.496 . . . . 0.0 111.64 -176.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -72.63 -16.41 61.72 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 174.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 98.57 4.14 57.19 Favored Glycine 0 C--N 1.33 0.208 0 C-N-CA 121.062 -0.59 . . . . 0.0 111.964 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.44 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 23.5 p-10 -96.06 145.15 25.7 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 120.938 0.399 . . . . 0.0 110.968 -179.385 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 28.9 tpt180 -86.15 122.36 30.04 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 179.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 43.0 t -119.21 143.2 31.18 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.261 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 -173.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.509 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 86.3 m-85 -125.52 129.17 49.22 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 123.579 0.751 . . . . 0.0 110.134 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.4 t -109.3 135.06 20.29 Favored Pre-proline 0 C--N 1.299 -1.592 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 178.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -68.24 -23.24 39.2 Favored 'Trans proline' 0 C--N 1.365 1.416 0 C-N-CA 123.202 2.602 . . . . 0.0 114.38 -177.157 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.3 35.4 m 45.22 -53.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.286 0 N-CA-C 119.077 2.992 . . . . 0.0 119.077 176.054 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.442 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 33.2 ptt180 -158.7 152.87 23.86 Favored 'General case' 0 C--N 1.314 -0.964 0 O-C-N 121.718 -0.614 . . . . 0.0 110.47 -178.297 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.556 ' O ' ' HA ' ' A' ' 123' ' ' PRO . 13.7 m -63.88 127.48 31.58 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 174.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.41 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 99.6 m -152.92 118.76 5.39 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 123.477 0.711 . . . . 0.0 109.361 177.044 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 26.7 mt-30 -129.58 148.83 51.52 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.34 -167.86 30.82 Favored Glycine 0 N--CA 1.417 -2.602 0 C-N-CA 119.11 -1.519 . . . . 0.0 112.149 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 10.8 m -123.99 108.03 30.45 Favored Pre-proline 0 C--N 1.291 -1.971 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.627 ' O ' ' HA ' ' A' ' 34' ' ' THR . 60.6 Cg_exo -43.17 129.2 5.92 Favored 'Trans proline' 0 C--N 1.349 0.584 0 C-N-CA 124.004 3.136 . . . . 0.0 113.024 -175.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -90.53 10.77 60.32 Favored 'Cis proline' 0 C--O 1.242 0.694 0 C-N-CA 124.115 -1.202 . . . . 0.0 115.114 8.44 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -75.28 100.06 4.25 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 -179.046 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.431 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 45.8 p-80 -106.08 109.83 21.89 Favored 'General case' 0 C--N 1.289 -2.053 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.112 177.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.5 mt -94.82 105.21 17.49 Favored Pre-proline 0 C--N 1.299 -1.606 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.556 ' HA ' ' O ' ' A' ' 113' ' ' THR . 72.8 Cg_endo -84.4 153.67 12.22 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.58 2.187 . . . . 0.0 113.121 -176.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -125.81 -97.53 1.09 Allowed Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 178.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 40.5 t -96.68 118.67 43.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -178.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.442 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.06 120.34 34.19 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.179 178.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.8 m-90 -101.5 58.02 0.85 Allowed 'General case' 0 C--N 1.31 -1.149 0 CA-C-O 120.661 0.267 . . . . 0.0 111.345 -179.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . 155.85 -169.78 33.59 Favored Glycine 0 CA--C 1.497 -1.082 0 C-N-CA 119.693 -1.241 . . . . 0.0 112.499 178.15 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 54' ' ' VAL . 97.9 t -111.94 128.68 68.38 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -112.07 136.87 50.89 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.152 -176.635 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.466 ' HG3' ' HB ' ' A' ' 52' ' ' THR . 18.1 ptpt . . . . . 0 N--CA 1.433 -1.315 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 175.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 20.0 m . . . . . 0 N--CA 1.443 -0.794 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -88.36 -34.62 17.53 Favored 'General case' 0 CA--C 1.497 -1.061 0 C-N-CA 120.925 -0.31 . . . . 0.0 110.251 178.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 65.37 173.1 0.22 Allowed 'General case' 0 C--O 1.241 0.646 0 C-N-CA 124.732 1.213 . . . . 0.0 111.36 -177.392 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -125.55 94.06 4.03 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -81.95 139.38 34.63 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 176.164 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 68.75 38.21 2.23 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 -173.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 23.1 ptp -57.15 121.8 10.92 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.904 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -112.0 -168.22 1.28 Allowed 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 120.118 -0.633 . . . . 0.0 109.477 -175.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.576 ' H ' ' HD3' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -132.42 -174.99 3.61 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -171.754 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.6 -97.68 0.55 Allowed Glycine 0 C--N 1.296 -1.659 0 C-N-CA 119.884 -1.15 . . . . 0.0 113.629 175.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 26.3 m -61.41 -49.99 74.63 Favored 'General case' 0 C--O 1.245 0.845 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 -174.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.0 m 70.03 -35.38 0.32 Allowed 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 124.728 1.211 . . . . 0.0 112.202 -177.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.8 t -76.27 110.55 10.88 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 176.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 43.7 m -77.92 -35.53 50.47 Favored 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 46.1 m -69.9 127.96 34.69 Favored 'General case' 0 C--O 1.251 1.15 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 174.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.6 m -75.92 121.03 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.761 0 CA-C-O 121.613 0.72 . . . . 0.0 111.264 -178.06 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 12.0 p -85.57 -25.72 6.62 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.398 -0.819 . . . . 0.0 112.165 -173.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 74.7 mmtt -72.08 -27.48 62.69 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.27 -179.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -70.66 108.9 4.6 Favored 'General case' 0 C--O 1.249 1.049 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.175 177.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -133.71 56.15 0.73 Allowed Glycine 0 N--CA 1.42 -2.371 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 17.6 pttm -74.32 112.78 10.82 Favored 'General case' 0 N--CA 1.436 -1.164 0 CA-C-O 121.568 0.699 . . . . 0.0 110.292 178.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.3 p -125.62 -174.27 3.03 Favored 'General case' 0 C--N 1.289 -2.027 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.152 -178.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 38.0 t -57.89 121.83 11.48 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.7 m -102.76 116.59 32.88 Favored 'General case' 0 N--CA 1.429 -1.498 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.294 -175.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -99.9 101.23 12.28 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.395 -177.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 17.5 m -93.04 -37.92 11.91 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.362 -1.348 . . . . 0.0 107.362 173.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.6 m 48.33 93.45 0.05 OUTLIER Pre-proline 0 CA--C 1.546 0.827 0 C-N-CA 126.523 1.929 . . . . 0.0 114.623 173.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -69.07 85.75 0.51 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.701 2.268 . . . . 0.0 110.928 174.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -90.56 -44.9 9.26 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 18.7 m -74.06 -41.17 62.15 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 175.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 11.2 mtp-105 74.4 141.04 0.08 OUTLIER Pre-proline 0 C--N 1.356 0.87 0 C-N-CA 125.964 1.706 . . . . 0.0 111.823 177.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_endo -68.32 -61.74 0.07 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.961 0 N-CA-C 107.741 -1.677 . . . . 0.0 107.741 169.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 91.3 t -153.71 -48.77 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 105.708 -1.96 . . . . 0.0 105.708 172.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.595 ' HB ' ' O ' ' A' ' 37' ' ' TRP . 7.1 p -76.04 95.91 3.7 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 113.939 -1.482 . . . . 0.0 112.691 -179.125 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -107.96 -41.32 1.57 Allowed Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 176.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 49.8 m -81.34 -42.33 20.71 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 174.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . 0.595 ' O ' ' HB ' ' A' ' 34' ' ' THR . 92.1 m95 -85.47 127.25 34.34 Favored 'General case' 0 N--CA 1.436 -1.144 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.949 178.444 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -125.08 154.64 41.07 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.639 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -94.15 127.27 39.88 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 120.359 -0.536 . . . . 0.0 111.207 -176.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -84.48 151.28 24.72 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 174.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.9 pt20 -51.2 -27.45 8.92 Favored 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 123.739 0.816 . . . . 0.0 113.189 -178.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.437 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 50.2 m-85 -81.73 3.16 26.66 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -177.257 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.71 18.82 59.27 Favored Glycine 0 CA--C 1.5 -0.844 0 C-N-CA 120.333 -0.937 . . . . 0.0 111.628 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.524 HG22 ' HB2' ' A' ' 89' ' ' CYS . 12.3 m -105.21 132.98 50.73 Favored 'General case' 0 N--CA 1.416 -2.134 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 179.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -96.39 129.73 43.67 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 177.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -129.54 154.67 46.81 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.422 -175.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -135.76 145.91 54.96 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 173.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_exo -69.3 121.86 8.65 Favored 'Trans proline' 0 C--O 1.249 1.041 0 C-N-CA 121.737 1.625 . . . . 0.0 109.469 172.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.451 ' HB3' HG23 ' A' ' 88' ' ' VAL . 6.2 tp10 -150.18 120.9 7.53 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.446 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 3.0 t-20 -114.19 106.49 14.42 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.926 -0.71 . . . . 0.0 110.154 -175.617 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.89 -177.58 5.98 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.443 -178.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.468 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 13.3 m -104.68 150.12 24.98 Favored 'General case' 0 N--CA 1.429 -1.487 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -177.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -127.39 127.21 43.8 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 173.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 60.1 t -113.09 113.29 43.64 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.232 0 N-CA-C 106.795 -1.558 . . . . 0.0 106.795 176.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 53.2 t30 -64.76 152.57 42.27 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.639 -178.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -78.59 -146.3 3.12 Favored Glycine 0 N--CA 1.434 -1.434 0 CA-C-N 116.16 -0.473 . . . . 0.0 113.173 -177.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -86.97 7.54 27.07 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -173.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.453 ' HA ' ' HD3' ' A' ' 59' ' ' PRO . 0.3 OUTLIER -138.92 137.25 19.29 Favored Pre-proline 0 C--N 1.302 -1.484 0 C-N-CA 120.122 -0.631 . . . . 0.0 111.209 -175.213 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 58' ' ' GLN . 26.6 Cg_exo -65.58 128.99 21.27 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.415 2.077 . . . . 0.0 110.757 176.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.2 mt -108.02 125.81 64.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -177.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.3 p -78.89 137.58 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.669 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 60.2 p -117.26 178.41 4.38 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.003 -172.472 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 33.9 mmt180 -116.81 146.59 42.77 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 60.7 mt -109.82 131.32 61.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.43 -175.28 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.2 -22.86 4.19 Favored Glycine 0 C--N 1.318 -0.42 0 N-CA-C 115.969 1.148 . . . . 0.0 115.969 171.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.409 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 39.1 m -153.61 140.77 13.24 Favored Pre-proline 0 C--N 1.298 -1.669 0 CA-C-N 117.875 0.837 . . . . 0.0 109.154 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.442 ' HG2' HG21 ' A' ' 44' ' ' THR . 12.5 Cg_endo -89.69 119.4 0.86 Allowed 'Trans proline' 0 N--CA 1.433 -2.036 0 C-N-CA 121.189 1.259 . . . . 0.0 110.347 173.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.661 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 82.4 m-85 -168.89 173.9 6.77 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 104.716 -2.328 . . . . 0.0 104.716 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -89.28 -34.25 16.66 Favored 'General case' 0 C--N 1.291 -1.969 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 176.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -97.87 22.49 9.16 Favored 'General case' 0 CA--C 1.548 0.904 0 CA-C-O 121.993 0.901 . . . . 0.0 109.803 -178.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.661 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -77.57 162.72 67.43 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.79 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -48.87 124.35 11.14 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 123.343 2.695 . . . . 0.0 113.559 178.742 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.0 p -97.83 173.73 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.195 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.367 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.62 -1.68 13.84 Favored Glycine 0 CA--C 1.502 -0.77 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.517 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -113.88 117.49 4.17 Favored Glycine 0 N--CA 1.429 -1.793 0 N-CA-C 108.849 -1.701 . . . . 0.0 108.849 174.36 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -126.8 128.14 46.12 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 117.737 0.769 . . . . 0.0 110.344 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 41.2 tp -96.55 119.76 63.39 Favored Pre-proline 0 C--N 1.309 -1.154 0 C-N-CA 123.282 0.633 . . . . 0.0 110.19 -175.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.02 165.08 25.09 Favored 'Trans proline' 0 CA--C 1.542 0.912 0 C-N-CA 122.805 2.337 . . . . 0.0 112.728 179.28 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.75 147.31 45.71 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.784 -177.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 69.52 5.91 52.34 Favored Glycine 0 N--CA 1.463 0.446 0 N-CA-C 114.247 0.459 . . . . 0.0 114.247 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.76 126.59 29.89 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-O 120.892 0.377 . . . . 0.0 111.417 -177.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 25.7 m -92.59 113.09 25.27 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 177.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.9 mm -122.55 138.97 50.89 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -176.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 p -103.47 129.33 55.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 175.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.446 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 32.2 p90 -117.71 150.56 38.87 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.591 -177.809 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -108.57 -12.36 14.99 Favored 'General case' 0 C--N 1.316 -0.856 0 O-C-N 123.473 0.483 . . . . 0.0 110.42 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -140.4 136.59 33.24 Favored 'General case' 0 N--CA 1.428 -1.54 0 C-N-CA 120.346 -0.542 . . . . 0.0 111.206 -172.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.451 HG23 ' HB3' ' A' ' 49' ' ' GLU . 71.4 t -118.62 127.85 75.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 176.211 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.524 ' HB2' HG22 ' A' ' 44' ' ' THR . 19.6 p -135.46 147.73 49.01 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 120.898 0.38 . . . . 0.0 111.613 -175.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.5 mt -109.5 113.81 45.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-O 121.225 0.536 . . . . 0.0 110.546 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.595 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -110.42 122.56 47.99 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 104.761 -2.311 . . . . 0.0 104.761 174.457 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -47.85 114.29 0.88 Allowed 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 121.845 0.831 . . . . 0.0 113.068 -165.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 120.58 -25.15 7.38 Favored Glycine 0 N--CA 1.429 -1.826 0 CA-C-N 114.1 -1.409 . . . . 0.0 112.42 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 75.8 m80 -152.05 170.11 20.72 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 15.9 tt -111.62 136.44 47.72 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.179 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 172.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.595 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 48.2 m95 -121.96 139.07 54.12 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -173.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.509 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 47.5 pt -100.52 136.02 33.86 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.92 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 175.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -105.03 119.46 6.21 Favored Glycine 0 N--CA 1.419 -2.459 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -136.83 152.83 50.71 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 120.408 -0.517 . . . . 0.0 109.954 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -86.25 127.38 34.75 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 174.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -86.27 163.33 17.79 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 27.7 p90 -54.81 -31.36 59.03 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -176.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -76.29 -14.44 60.11 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-O 121.055 0.455 . . . . 0.0 111.046 -179.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 108.92 -9.58 34.19 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 121.137 -0.554 . . . . 0.0 113.279 178.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -75.84 148.08 38.63 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-O 120.754 0.311 . . . . 0.0 111.226 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . 0.437 HH11 ' HG2' ' A' ' 106' ' ' ARG . 0.5 OUTLIER -89.41 109.27 20.2 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 177.685 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 52.2 t -107.66 136.92 41.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.199 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -176.23 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.509 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 91.4 m-85 -116.33 126.0 52.91 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.4 t -105.44 131.85 21.39 Favored Pre-proline 0 C--N 1.301 -1.536 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -69.26 -11.4 31.39 Favored 'Trans proline' 0 C--N 1.364 1.375 0 C-N-CA 123.374 2.716 . . . . 0.0 113.794 -177.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.277 27.0 m 37.83 -63.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.148 0 N-CA-C 118.286 2.698 . . . . 0.0 118.286 174.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.524 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 34.9 ptt180 -153.06 149.79 28.48 Favored 'General case' 0 N--CA 1.429 -1.488 0 C-N-CA 122.872 0.469 . . . . 0.0 110.219 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 19.4 m -67.8 136.76 54.66 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 41.8 t -150.39 139.24 20.88 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -176.324 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 78.3 mm-40 -119.6 161.61 20.36 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 130.22 -171.75 20.45 Favored Glycine 0 N--CA 1.421 -2.363 0 C-N-CA 120.034 -1.079 . . . . 0.0 112.448 174.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.6 m -141.41 138.57 17.69 Favored Pre-proline 0 C--N 1.295 -1.787 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 90.6 Cg_exo -47.73 131.64 20.36 Favored 'Trans proline' 0 CA--C 1.539 0.736 0 C-N-CA 122.945 2.43 . . . . 0.0 112.786 -177.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 89.7 Cg_endo -96.65 7.5 40.89 Favored 'Cis proline' 0 CA--C 1.547 1.155 0 C-N-CA 124.492 -1.045 . . . . 0.0 113.884 1.19 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 44.4 t30 -76.27 102.39 5.83 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.636 0.732 . . . . 0.0 110.911 -175.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 -104.82 112.6 25.77 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 114.748 -1.115 . . . . 0.0 111.602 -178.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 59.3 mt -101.46 100.84 14.92 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -85.22 140.39 7.57 Favored 'Trans proline' 0 N--CA 1.452 -0.944 0 C-N-CA 122.87 2.38 . . . . 0.0 113.647 -177.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -110.66 -117.62 3.81 Favored Glycine 0 N--CA 1.436 -1.35 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 177.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 81.6 t -78.24 115.46 20.34 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 120.84 0.352 . . . . 0.0 110.861 -179.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.524 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.37 132.91 38.49 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.788 177.129 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.3 m-90 -102.35 8.07 40.36 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-O 121.488 0.661 . . . . 0.0 110.401 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.09 169.51 36.7 Favored Glycine 0 N--CA 1.431 -1.696 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 64.3 t -111.72 134.86 52.78 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 C-N-CA 122.895 0.478 . . . . 0.0 110.189 -175.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -97.68 132.62 43.16 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 178.124 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.468 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 48.7 tptt . . . . . 0 N--CA 1.413 -2.315 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -179.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 17.3 m . . . . . 0 N--CA 1.439 -1.004 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 31.7 p-10 -150.93 16.6 0.76 Allowed 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 122.426 0.291 . . . . 0.0 110.475 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -59.67 -48.58 81.1 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 123.199 0.312 . . . . 0.0 110.166 -178.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 12.7 mptt -93.0 -46.69 7.35 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 174.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 56.0 t30 70.69 137.21 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.426 1.491 . . . . 0.0 112.731 176.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -90.65 124.25 34.92 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 171.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -134.66 147.2 50.09 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -177.418 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -129.04 43.42 3.15 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 174.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.412 ' HE3' ' HA ' ' A' ' 9' ' ' LYS . 1.9 tpmt? -61.73 128.32 35.65 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.887 -175.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 102.29 -24.49 30.9 Favored Glycine 0 C--N 1.317 -0.502 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 -177.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.8 m -126.62 26.06 6.34 Favored 'General case' 0 C--N 1.308 -1.204 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 178.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.8 m -77.06 87.46 3.56 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 114.872 -1.058 . . . . 0.0 111.916 -174.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 25.8 m -146.2 75.57 1.41 Allowed 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 175.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 13.1 m -73.51 -51.32 17.48 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.358 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 31.6 m -123.92 124.24 42.19 Favored 'General case' 0 N--CA 1.419 -2.009 0 CA-C-N 115.549 -0.751 . . . . 0.0 108.994 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 35.0 m -86.2 142.82 12.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 174.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.9 t -115.61 -64.3 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 C-N-CA 120.798 -0.361 . . . . 0.0 111.683 -174.635 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 34.7 mtmm 65.51 -74.53 0.05 Allowed 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 125.344 1.458 . . . . 0.0 109.673 -174.164 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -169.71 144.51 2.89 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 105.578 -2.008 . . . . 0.0 105.578 177.122 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -89.84 -33.17 9.25 Favored Glycine 0 C--N 1.291 -1.956 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.793 -174.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 59.14 66.04 1.1 Allowed 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 -173.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 13.2 p -79.03 -74.9 0.26 Allowed 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.22 -179.527 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 39.2 m -132.7 11.07 4.37 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-O 122.601 1.191 . . . . 0.0 108.076 173.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 44.5 m -117.88 134.93 54.45 Favored 'General case' 0 N--CA 1.419 -1.994 0 CA-C-N 113.778 -1.555 . . . . 0.0 107.755 178.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 76.4 -49.67 0.58 Allowed 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 125.737 1.615 . . . . 0.0 111.106 -175.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.3 t -168.6 174.45 6.74 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 67.9 m -139.17 96.59 8.92 Favored Pre-proline 0 C--N 1.303 -1.45 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 175.269 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -76.69 96.29 1.08 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.795 2.33 . . . . 0.0 112.607 -178.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -149.69 -41.88 0.14 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.609 179.002 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 m -89.51 -37.11 14.98 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.094 -178.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.553 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 15.6 mmm180 -70.32 -58.53 4.81 Favored Pre-proline 0 CA--C 1.543 0.703 0 C-N-CA 120.772 -0.371 . . . . 0.0 110.487 175.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.553 ' HD3' ' HB2' ' A' ' 31' ' ' ARG . 5.4 Cg_exo -84.08 80.02 2.49 Favored 'Trans proline' 0 C--N 1.365 1.411 0 N-CA-C 108.273 -1.472 . . . . 0.0 108.273 169.183 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 14.7 p -98.27 143.02 13.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.112 -173.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 8.9 m -75.37 98.92 3.97 Favored 'General case' 0 N--CA 1.431 -1.398 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 167.98 -26.5 0.14 Allowed Glycine 0 C--N 1.305 -1.183 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -177.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 6.8 m -66.37 -31.99 73.11 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.709 0.766 . . . . 0.0 109.022 174.691 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 34.5 m95 -92.0 145.93 24.14 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 114.741 -1.118 . . . . 0.0 108.231 177.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -113.35 150.56 32.43 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.417 ' HG2' ' O ' ' A' ' 40' ' ' ASN . 38.2 ttpt -110.15 136.2 49.75 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 118.376 -1.33 . . . . 0.0 111.528 -178.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.417 ' O ' ' HG2' ' A' ' 39' ' ' LYS . 45.9 t-20 -94.35 161.67 14.14 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 105.955 -1.869 . . . . 0.0 105.955 175.079 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 34.7 mt-30 -67.28 -13.31 61.87 Favored 'General case' 0 C--O 1.213 -0.836 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -173.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 47.9 m-85 -76.3 -1.24 25.67 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.352 0.596 . . . . 0.0 110.214 177.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 80.39 24.26 59.3 Favored Glycine 0 CA--C 1.494 -1.266 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.526 HG22 ' HB2' ' A' ' 89' ' ' CYS . 13.5 m -105.37 124.66 49.92 Favored 'General case' 0 N--CA 1.414 -2.231 0 CA-C-N 114.662 -0.769 . . . . 0.0 109.608 -178.503 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.551 ' CG ' ' HG3' ' A' ' 118' ' ' PRO . 84.1 m95 -93.3 131.11 38.74 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.18 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.41 ' HB3' ' HB3' ' A' ' 89' ' ' CYS . 54.2 p90 -132.75 151.85 51.89 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -175.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.434 ' HG3' ' HB ' ' A' ' 88' ' ' VAL . 16.8 ptmt -129.02 132.47 24.39 Favored Pre-proline 0 C--N 1.303 -1.443 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.664 175.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_exo -72.78 122.05 7.87 Favored 'Trans proline' 0 C--O 1.244 0.79 0 C-N-CA 121.835 1.69 . . . . 0.0 111.001 175.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -162.25 131.49 4.38 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 177.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.419 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 23.8 t-20 -110.03 123.46 49.71 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 120.699 -0.4 . . . . 0.0 110.182 -177.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -160.07 177.2 10.95 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -108.22 152.01 25.16 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 121.022 0.439 . . . . 0.0 112.126 -178.752 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.443 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 91.4 t80 -122.55 123.66 41.73 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 176.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 43.7 t -103.17 104.88 17.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 29.1 t30 -76.98 123.52 26.44 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 175.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -147.1 24.32 1.59 Allowed Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 118.973 -1.584 . . . . 0.0 113.308 -177.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -113.77 -50.71 2.82 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.256 179.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -158.22 164.96 19.65 Favored Pre-proline 0 C--N 1.315 -0.921 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.462 ' HB3' HD21 ' A' ' 76' ' ' ASN . 18.0 Cg_exo -69.27 125.87 12.93 Favored 'Trans proline' 0 C--O 1.254 1.301 0 N-CA-C 108.121 -1.531 . . . . 0.0 108.121 170.164 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 41.4 mt -108.12 130.17 61.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 110.127 -0.323 . . . . 0.0 110.127 -173.267 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 39.7 t -69.16 122.16 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.817 0 CA-C-O 121.968 0.889 . . . . 0.0 110.308 176.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -96.16 155.9 16.56 Favored 'General case' 0 N--CA 1.405 -2.689 0 CA-C-N 114.181 -1.372 . . . . 0.0 108.651 -176.242 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 15.6 mmt180 -112.24 141.64 45.7 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -178.272 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.2 mt -109.39 120.29 60.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 113.11 0.782 . . . . 0.0 113.11 -173.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.67 -22.51 27.49 Favored Glycine 0 C--O 1.236 0.249 0 N-CA-C 116.343 1.297 . . . . 0.0 116.343 170.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.7 m -155.01 140.26 12.28 Favored Pre-proline 0 C--N 1.307 -1.257 0 CA-C-N 118.502 1.151 . . . . 0.0 111.292 -178.27 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -89.93 119.96 0.86 Allowed 'Trans proline' 0 N--CA 1.437 -1.844 0 C-N-CA 121.716 1.611 . . . . 0.0 110.778 172.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -162.5 162.76 27.58 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 68.3 mt -80.1 -13.99 58.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 121.748 0.785 . . . . 0.0 109.434 177.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.4 p-10 -116.19 19.52 14.85 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.606 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.83 146.1 95.33 Favored Pre-proline 0 C--O 1.243 0.757 0 CA-C-N 115.386 -0.825 . . . . 0.0 112.201 -176.076 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -48.76 131.66 24.92 Favored 'Trans proline' 0 C--O 1.249 1.035 0 C-N-CA 124.104 3.203 . . . . 0.0 113.916 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.1 m -97.41 174.59 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 CA-C-N 114.552 -1.204 . . . . 0.0 110.483 -178.207 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.92 28.12 2.12 Favored Glycine 0 C--N 1.305 -1.192 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.021 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.81 132.67 4.1 Favored Glycine 0 N--CA 1.427 -1.924 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 176.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.462 HD21 ' HB3' ' A' ' 59' ' ' PRO . 8.3 t30 -128.35 125.77 39.38 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 117.597 0.699 . . . . 0.0 110.918 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 65.3 tp -88.26 111.69 44.86 Favored Pre-proline 0 N--CA 1.426 -1.634 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -63.43 152.4 80.26 Favored 'Trans proline' 0 C--O 1.251 1.146 0 C-N-CA 122.147 1.898 . . . . 0.0 112.553 -179.288 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.41 138.16 41.5 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.292 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.82 3.13 62.45 Favored Glycine 0 N--CA 1.441 -0.997 0 N-CA-C 111.434 -0.666 . . . . 0.0 111.434 -178.6 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.49 139.07 31.15 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-O 121.171 0.51 . . . . 0.0 111.188 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 39.0 m -113.53 113.55 25.27 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 177.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.1 mm -110.18 139.87 31.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -176.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.0 p -95.31 127.13 47.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 176.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.452 ' HA ' ' HB3' ' A' ' 99' ' ' TYR . 46.3 p90 -110.11 154.44 23.28 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.472 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -116.35 -9.09 11.57 Favored 'General case' 0 C--O 1.25 1.089 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.36 -177.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -144.84 131.69 20.18 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.876 -174.114 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.434 ' HB ' ' HG3' ' A' ' 47' ' ' LYS . 32.1 t -109.61 124.56 66.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 105.832 -1.914 . . . . 0.0 105.832 175.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.526 ' HB2' HG22 ' A' ' 44' ' ' THR . 24.6 p -137.5 148.49 46.06 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.871 -0.732 . . . . 0.0 112.624 -175.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 68.8 mt -111.4 124.15 67.9 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-O 121.061 0.458 . . . . 0.0 110.623 179.389 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.501 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -125.14 112.98 17.11 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 103.827 -2.657 . . . . 0.0 103.827 171.446 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.96 106.12 0.1 Allowed 'General case' 0 N--CA 1.479 0.983 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -164.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 141.63 -33.03 2.0 Favored Glycine 0 N--CA 1.439 -1.149 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -177.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 56.3 m80 -152.02 163.37 39.44 Favored 'General case' 0 CA--C 1.505 -0.786 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.3 tt -106.65 135.07 46.38 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 171.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.501 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 58.7 m95 -118.12 140.31 49.96 Favored 'General case' 0 C--N 1.28 -2.419 0 O-C-N 122.209 -0.307 . . . . 0.0 110.475 -171.118 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 48.1 pt -100.6 131.53 48.0 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 174.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.34 121.52 7.21 Favored Glycine 0 N--CA 1.417 -2.599 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.452 ' HB3' ' HA ' ' A' ' 85' ' ' TYR . 39.0 p90 -132.17 146.58 52.12 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-O 121.466 0.651 . . . . 0.0 111.122 178.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -99.74 119.97 38.98 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.82 -1.082 . . . . 0.0 108.455 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.9 176.31 7.4 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.395 -177.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -66.0 -21.34 66.39 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.464 0.649 . . . . 0.0 112.019 -179.066 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -80.04 -14.52 58.48 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.985 177.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 84.62 5.59 86.53 Favored Glycine 0 C--O 1.24 0.475 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -174.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -80.79 132.98 35.56 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 27.2 tpt180 -88.48 104.89 17.23 Favored 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -178.082 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 15.5 t -107.12 142.75 19.13 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -175.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -125.61 127.1 45.81 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.088 0.471 . . . . 0.0 111.75 -178.184 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 52.8 t -107.51 135.4 19.73 Favored Pre-proline 0 C--N 1.307 -1.278 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -72.21 -12.63 27.93 Favored 'Trans proline' 0 C--N 1.36 1.156 0 C-N-CA 123.19 2.593 . . . . 0.0 114.503 -176.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.282 32.8 m 43.77 -56.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.516 2.827 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 175.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.527 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 38.2 ptt180 -159.98 151.05 19.29 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.03 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.2 t -73.42 143.14 46.86 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.9 t -155.26 136.98 14.35 Favored 'General case' 0 N--CA 1.421 -1.919 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -177.185 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 21.6 mt-30 -122.52 157.1 32.78 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 133.91 -163.83 24.47 Favored Glycine 0 N--CA 1.429 -1.815 0 C-N-CA 120.048 -1.072 . . . . 0.0 112.018 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 18.5 m -142.22 149.92 53.52 Favored Pre-proline 0 C--N 1.307 -1.272 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.551 ' HG3' ' CG ' ' A' ' 45' ' ' TRP . 33.3 Cg_endo -60.2 131.21 37.68 Favored 'Trans proline' 0 CA--C 1.541 0.843 0 C-N-CA 122.388 2.059 . . . . 0.0 112.412 -177.007 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 11.1 Cg_endo -99.59 8.81 26.2 Favored 'Cis proline' 0 C--O 1.251 1.154 0 C-N-CA 125.28 -0.717 . . . . 0.0 113.351 -0.454 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.1 t30 -75.04 100.63 4.24 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 122.106 0.955 . . . . 0.0 109.896 -177.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 48.3 p-80 -105.72 119.78 40.01 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 114.416 -1.266 . . . . 0.0 111.578 -177.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 62.1 mt -100.83 101.61 16.42 Favored Pre-proline 0 C--N 1.305 -1.35 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 175.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -85.06 130.45 4.08 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.732 2.288 . . . . 0.0 113.109 -177.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -103.87 -131.12 7.11 Favored Glycine 0 N--CA 1.433 -1.564 0 N-CA-C 111.199 -0.761 . . . . 0.0 111.199 177.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 48.8 t -68.05 120.03 14.77 Favored 'Isoleucine or valine' 0 C--O 1.252 1.195 0 C-N-CA 123.005 0.522 . . . . 0.0 111.003 -178.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.527 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -94.22 148.75 21.89 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.685 177.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 4.4 m-90 -116.2 8.28 14.32 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.399 0.619 . . . . 0.0 110.033 177.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.443 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -167.09 171.86 41.99 Favored Glycine 0 N--CA 1.431 -1.66 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 60.2 t -112.51 135.25 52.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 -177.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -85.8 121.99 29.23 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 176.148 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.284 -2.265 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 -175.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.444 -0.767 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -70.11 -46.27 65.18 Favored 'General case' 0 CA--C 1.502 -0.876 0 CA-C-O 121.308 0.575 . . . . 0.0 110.415 -179.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -94.3 120.0 33.91 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 175.508 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -115.42 133.28 56.18 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-O 121.081 0.467 . . . . 0.0 111.085 -176.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -157.01 97.65 1.69 Allowed 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 175.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -62.72 -49.7 74.01 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.131 -0.94 . . . . 0.0 111.267 -174.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 69.9 mtm -97.64 92.24 5.8 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 177.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -118.13 93.27 4.07 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.738 -174.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 31.2 mmtp 64.32 9.7 5.07 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 124.344 1.058 . . . . 0.0 112.392 173.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -81.83 68.29 3.51 Favored Glycine 0 N--CA 1.438 -1.221 0 N-CA-C 115.753 1.061 . . . . 0.0 115.753 -170.429 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 12.5 p -70.8 96.12 1.21 Allowed 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 171.007 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.7 m -64.73 -54.87 24.66 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 113.469 0.914 . . . . 0.0 113.469 -172.378 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.5 m -124.19 147.94 47.63 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -176.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.5 m -87.34 90.06 8.23 Favored 'General case' 0 N--CA 1.418 -2.057 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.595 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.6 t -77.95 -22.04 50.1 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 122.617 1.198 . . . . 0.0 107.835 177.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p -134.73 129.65 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.479 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 172.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 9.1 m -79.23 84.79 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 CA-C-O 122.283 1.039 . . . . 0.0 111.516 -178.013 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 22.5 ttmm -65.58 116.39 6.78 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 113.757 -1.565 . . . . 0.0 110.386 -177.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -121.52 114.33 21.08 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.011 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 164.75 -32.07 0.25 Allowed Glycine 0 N--CA 1.432 -1.608 0 C-N-CA 120.464 -0.874 . . . . 0.0 112.393 -179.294 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 60.9 tttm -89.7 65.31 6.81 Favored 'General case' 0 C--O 1.245 0.838 0 CA-C-O 121.818 0.818 . . . . 0.0 110.734 -178.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 94.0 m -163.97 104.82 0.9 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 124.857 1.263 . . . . 0.0 107.992 177.432 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.1 m -81.82 113.37 19.72 Favored 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 177.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 5.5 m -56.11 -45.18 79.55 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 124.176 0.99 . . . . 0.0 112.726 -174.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -143.79 105.25 4.28 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.213 0.53 . . . . 0.0 110.624 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 17.1 m -113.22 -32.19 6.38 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.954 177.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.5 p -78.44 121.57 83.91 Favored Pre-proline 0 N--CA 1.434 -1.266 0 CA-C-N 115.496 -0.775 . . . . 0.0 112.386 -176.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_exo -67.23 -25.4 42.99 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 122.913 2.409 . . . . 0.0 112.247 174.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 64.73 -163.33 0.26 Allowed 'General case' 0 C--O 1.248 0.999 0 C-N-CA 124.077 0.951 . . . . 0.0 109.581 -177.033 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.9 p -81.45 66.17 6.88 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.801 0.81 . . . . 0.0 111.184 179.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.519 ' H ' ' HD2' ' A' ' 32' ' ' PRO . 40.1 ttm180 -120.69 -53.44 0.04 OUTLIER Pre-proline 0 C--N 1.305 -1.354 0 CA-C-N 114.937 -1.029 . . . . 0.0 112.909 -177.09 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.519 ' HD2' ' H ' ' A' ' 31' ' ' ARG . 37.4 Cg_endo -70.23 98.52 0.74 Allowed 'Trans proline' 0 C--N 1.375 1.942 0 CA-C-N 120.643 1.265 . . . . 0.0 110.062 173.193 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 54.6 t -123.1 111.99 31.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 CA-C-O 121.085 0.469 . . . . 0.0 112.015 -173.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 15.0 t -115.79 0.97 13.33 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 170.101 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 81.89 -150.16 29.03 Favored Glycine 0 N--CA 1.426 -1.978 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.665 -178.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 3.3 p -93.12 19.19 8.23 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 123.792 0.837 . . . . 0.0 111.054 -179.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . 0.428 ' CZ3' HG13 ' A' ' 90' ' ' ILE . 30.4 m95 -91.67 141.37 28.77 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.712 -175.404 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -114.19 152.4 31.27 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 175.224 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -102.76 121.24 42.06 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.616 179.603 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.448 ' HB3' ' CE1' ' A' ' 46' ' ' TYR . 37.2 p30 -85.42 -178.29 6.67 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.774 -176.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -66.73 -16.67 64.4 Favored 'General case' 0 C--N 1.323 -0.575 0 C-N-CA 123.674 0.789 . . . . 0.0 113.037 -178.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 67.8 m-85 -93.77 2.69 56.18 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.449 0.643 . . . . 0.0 110.096 -177.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.8 25.56 66.91 Favored Glycine 0 N--CA 1.442 -0.942 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.457 HG22 ' HB2' ' A' ' 89' ' ' CYS . 12.8 m -105.26 141.21 37.19 Favored 'General case' 0 N--CA 1.425 -1.71 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -92.78 120.56 33.28 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 174.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.448 ' CE1' ' HB3' ' A' ' 40' ' ' ASN . 23.9 p90 -128.02 149.68 50.26 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 120.623 0.249 . . . . 0.0 110.611 -175.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.423 ' HE2' ' CZ2' ' A' ' 37' ' ' TRP . 52.2 pttt -139.33 140.4 25.75 Favored Pre-proline 0 C--N 1.295 -1.797 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 173.737 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_exo -71.23 127.23 13.18 Favored 'Trans proline' 0 C--O 1.255 1.36 0 C-N-CA 122.057 1.838 . . . . 0.0 110.314 174.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -164.78 120.85 1.46 Allowed 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -179.116 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.495 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 19.8 t-20 -103.02 109.54 21.12 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 120.962 0.41 . . . . 0.0 110.883 -174.647 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.452 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -145.28 172.35 13.27 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 14.1 m -107.68 134.76 50.19 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.939 0.4 . . . . 0.0 111.412 -173.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 72.9 t80 -112.36 122.46 47.77 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 39.0 t -108.23 103.77 16.01 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.866 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 178.645 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 30.2 t30 -76.4 131.61 39.21 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -144.68 2.52 1.25 Allowed Glycine 0 N--CA 1.432 -1.623 0 C-N-CA 119.307 -1.425 . . . . 0.0 113.546 -179.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -93.74 -52.06 4.63 Favored 'General case' 0 C--N 1.318 -0.789 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.826 -175.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 17.1 pt20 -159.25 171.64 7.12 Favored Pre-proline 0 C--N 1.314 -0.96 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -173.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.45 ' HB3' HD21 ' A' ' 76' ' ' ASN . 17.1 Cg_exo -69.0 122.11 8.99 Favored 'Trans proline' 0 N--CA 1.44 -1.655 0 N-CA-C 107.604 -1.729 . . . . 0.0 107.604 166.212 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 58.7 mt -107.84 123.32 63.19 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -175.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 25.9 m -79.93 139.42 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.366 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 175.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.5 p -118.36 178.94 4.26 Favored 'General case' 0 C--N 1.272 -2.781 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.918 -172.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.424 ' HG3' ' O ' ' A' ' 68' ' ' PHE . 82.0 mmt-85 -115.48 136.64 52.88 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 176.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 63.8 mt -97.24 121.29 47.61 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.64 -174.08 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 77.56 -16.87 5.89 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 116.034 1.173 . . . . 0.0 116.034 172.349 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.2 m -151.82 137.77 11.36 Favored Pre-proline 0 C--N 1.305 -1.336 0 CA-C-N 118.24 1.02 . . . . 0.0 110.204 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -89.93 119.19 0.8 Allowed 'Trans proline' 0 N--CA 1.434 -1.975 0 C-N-CA 121.163 1.242 . . . . 0.0 110.811 173.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.564 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 92.9 m-85 -169.55 168.73 9.14 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 178.6 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.96 -31.77 27.45 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 171.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -95.27 17.01 15.16 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.179 -0.918 . . . . 0.0 112.204 -178.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -79.0 162.75 63.43 Favored Pre-proline 0 C--N 1.311 -1.095 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -54.69 122.14 11.07 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 122.343 2.029 . . . . 0.0 112.438 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.413 HG22 ' H ' ' A' ' 74' ' ' GLY . 13.8 p -104.1 172.94 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.944 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.413 ' H ' HG22 ' A' ' 73' ' ' VAL . . . 120.33 -13.32 10.29 Favored Glycine 0 CA--C 1.502 -0.745 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 -179.067 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.46 108.83 3.08 Favored Glycine 0 N--CA 1.432 -1.597 0 N-CA-C 108.338 -1.905 . . . . 0.0 108.338 172.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.45 HD21 ' HB3' ' A' ' 59' ' ' PRO . 7.6 t30 -111.5 123.43 50.21 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 117.697 0.748 . . . . 0.0 110.339 -176.511 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 40.6 tp -98.83 114.27 65.27 Favored Pre-proline 0 C--N 1.302 -1.496 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -68.43 161.64 44.07 Favored 'Trans proline' 0 C--O 1.249 1.058 0 C-N-CA 122.236 1.957 . . . . 0.0 112.642 -178.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.41 139.42 42.32 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.83 5.82 58.41 Favored Glycine 0 N--CA 1.436 -1.352 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -85.86 128.84 34.92 Favored 'General case' 0 N--CA 1.432 -1.357 0 CA-C-O 121.033 0.444 . . . . 0.0 111.233 -178.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 37.0 m -103.91 110.25 22.31 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.1 mm -126.32 130.74 71.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 -175.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.9 p -88.69 133.93 29.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 176.246 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.495 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 40.1 p90 -109.98 151.17 27.47 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -124.67 -0.4 8.05 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 122.075 0.941 . . . . 0.0 110.391 -174.091 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -146.34 133.0 19.88 Favored 'General case' 0 N--CA 1.428 -1.526 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 -176.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 51.4 t -119.34 128.14 75.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.457 ' HB2' HG22 ' A' ' 44' ' ' THR . 23.5 p -141.51 145.46 35.21 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -176.314 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.428 HG13 ' CZ3' ' A' ' 37' ' ' TRP . 58.4 mt -107.16 117.04 52.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 175.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.507 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -118.12 117.59 29.59 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 103.327 -2.842 . . . . 0.0 103.327 171.211 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.47 110.44 0.34 Allowed 'General case' 0 C--N 1.315 -0.91 0 O-C-N 124.822 1.326 . . . . 0.0 112.876 -167.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 143.37 -42.86 1.05 Allowed Glycine 0 N--CA 1.42 -2.394 0 CA-C-N 113.582 -1.645 . . . . 0.0 109.345 -176.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . 0.439 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 73.7 m80 -153.4 165.93 34.26 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -179.256 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.5 tt -99.98 129.32 50.82 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 105.223 -2.14 . . . . 0.0 105.223 171.146 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.507 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 57.0 m95 -112.5 134.53 53.98 Favored 'General case' 0 C--N 1.274 -2.682 0 CA-C-O 120.997 0.427 . . . . 0.0 110.039 -172.029 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.547 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 44.8 pt -100.44 128.82 52.08 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 175.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -94.22 114.78 4.86 Favored Glycine 0 N--CA 1.416 -2.695 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 178.479 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 54.5 p90 -127.2 167.67 15.74 Favored 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 -178.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.1 m-80 -108.16 129.49 55.17 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -80.54 176.46 9.77 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -55.95 -27.16 51.2 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.961 0.905 . . . . 0.0 112.152 -178.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 32.9 p-10 -104.31 13.11 32.72 Favored 'General case' 0 C--N 1.322 -0.628 0 C-N-CA 123.241 0.616 . . . . 0.0 111.247 -175.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 77.88 21.78 70.54 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 121.089 -0.577 . . . . 0.0 113.28 177.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 50.2 t-20 -85.84 132.51 34.09 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 178.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -85.76 98.35 10.68 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 21.6 t -108.95 147.01 13.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 -175.322 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.547 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 94.7 m-85 -117.19 121.62 41.73 Favored 'General case' 0 C--N 1.314 -0.964 0 C-N-CA 122.494 0.317 . . . . 0.0 110.758 -178.072 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . 0.456 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 53.7 t -101.03 135.1 20.02 Favored Pre-proline 0 C--N 1.315 -0.902 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.05 -16.11 36.22 Favored 'Trans proline' 0 C--N 1.361 1.205 0 C-N-CA 123.322 2.681 . . . . 0.0 114.863 -176.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.308 33.0 m 42.21 -55.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.519 3.0 0 N-CA-C 118.837 2.903 . . . . 0.0 118.837 176.322 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.464 ' CZ ' ' HB2' ' A' ' 126' ' ' ALA . 8.2 ptp180 -153.97 148.98 26.76 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 123.868 0.867 . . . . 0.0 108.704 175.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.439 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 24.3 m -66.33 135.33 54.23 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 177.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 97.5 m -150.78 124.94 9.36 Favored 'General case' 0 CA--C 1.511 -0.524 0 CA-C-O 121.431 0.634 . . . . 0.0 112.467 -178.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -110.44 151.57 27.35 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 174.455 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.37 -171.25 22.64 Favored Glycine 0 C--N 1.3 -1.462 0 C-N-CA 118.251 -1.928 . . . . 0.0 114.092 177.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 64.9 t -137.44 127.67 15.69 Favored Pre-proline 0 C--N 1.309 -1.191 0 N-CA-C 105.947 -1.871 . . . . 0.0 105.947 -178.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 99.0 Cg_exo -46.36 137.18 14.72 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.371 2.714 . . . . 0.0 112.804 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 76.2 Cg_endo -86.61 -15.54 29.39 Favored 'Cis proline' 0 CA--C 1.542 0.877 0 C-N-CA 123.228 -1.572 . . . . 0.0 113.896 1.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -75.85 100.16 4.69 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 122.136 0.969 . . . . 0.0 111.645 -173.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 54.7 p-80 -106.34 138.53 42.35 Favored 'General case' 0 C--N 1.296 -1.717 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.808 176.109 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.0 mm -90.22 108.83 29.09 Favored Pre-proline 0 C--N 1.3 -1.565 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 176.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -84.66 123.91 2.98 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.457 2.105 . . . . 0.0 113.587 -176.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -95.25 -134.62 7.79 Favored Glycine 0 N--CA 1.436 -1.33 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 175.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 69.4 t -81.74 126.69 39.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 C-N-CA 122.982 0.513 . . . . 0.0 110.475 -179.418 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.464 ' HB2' ' CZ ' ' A' ' 112' ' ' ARG . . . -93.87 145.74 24.4 Favored 'General case' 0 CA--C 1.507 -0.689 0 O-C-N 123.75 0.657 . . . . 0.0 109.294 174.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.0 m-90 -110.33 18.3 20.0 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.344 0.592 . . . . 0.0 111.278 179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -166.57 -173.12 34.62 Favored Glycine 0 N--CA 1.432 -1.579 0 C-N-CA 120.045 -1.074 . . . . 0.0 112.173 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 48.7 t -110.98 131.11 63.1 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -103.54 120.44 40.87 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.299 -1.61 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 17.6 m . . . . . 0 N--CA 1.444 -0.767 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -85.5 79.96 9.24 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 177.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -162.67 115.77 1.67 Allowed 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.853 -177.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -93.44 124.37 37.39 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 173.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 7.9 t30 70.44 85.36 0.13 Allowed 'General case' 0 CA--C 1.508 -0.646 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 -169.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -74.82 89.1 2.31 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.084 -174.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 52.6 ttm -143.08 74.69 1.45 Allowed 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 172.294 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -165.26 73.77 0.21 Allowed 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 114.324 -1.307 . . . . 0.0 108.89 -178.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.3 ttmp? 173.78 122.65 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 125.09 1.356 . . . . 0.0 108.851 177.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -119.12 160.73 14.07 Favored Glycine 0 N--CA 1.421 -2.32 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 176.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 20.1 m -115.36 71.46 0.77 Allowed 'General case' 0 N--CA 1.419 -2.024 0 CA-C-O 121.915 0.864 . . . . 0.0 109.839 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 20.2 m -89.31 -15.83 32.53 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.298 177.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 34.9 t -120.82 121.18 37.59 Favored 'General case' 0 N--CA 1.423 -1.809 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 177.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.3 m -77.59 109.28 11.42 Favored 'General case' 0 N--CA 1.432 -1.339 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 175.232 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 31.8 m 76.64 160.12 0.22 Allowed 'General case' 0 CA--C 1.566 1.589 0 O-C-N 124.44 1.088 . . . . 0.0 108.234 -175.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 34.1 m -68.46 -20.31 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 O-C-N 121.378 -0.827 . . . . 0.0 111.137 -179.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.9 t 66.01 83.01 0.06 OUTLIER 'Isoleucine or valine' 0 C--O 1.247 0.954 0 C-N-CA 124.287 1.035 . . . . 0.0 109.599 -179.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 2.7 tmtp? -80.74 84.54 6.26 Favored 'General case' 0 N--CA 1.428 -1.532 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 178.488 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -167.15 141.69 3.88 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 -177.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -82.07 -78.37 1.01 Allowed Glycine 0 N--CA 1.43 -1.754 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 177.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 3.1 tppp? -153.08 75.36 1.07 Allowed 'General case' 0 N--CA 1.422 -1.836 0 CA-C-O 121.313 0.578 . . . . 0.0 109.804 177.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 31.7 m -97.6 -20.09 17.9 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-O 121.798 0.809 . . . . 0.0 109.169 176.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 34.0 t -82.33 102.58 11.31 Favored 'General case' 0 N--CA 1.425 -1.678 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.419 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 65.3 m -87.72 120.88 29.48 Favored 'General case' 0 N--CA 1.428 -1.527 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 173.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 70.25 -83.9 0.03 OUTLIER 'General case' 0 C--O 1.225 -0.198 0 C-N-CA 124.708 1.203 . . . . 0.0 110.349 -175.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 33.8 t -156.49 140.96 16.76 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.2 p -111.2 97.19 34.22 Favored Pre-proline 0 C--N 1.296 -1.728 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -61.39 -80.42 0.01 OUTLIER 'Trans proline' 0 N--CA 1.448 -1.183 0 C-N-CA 122.358 2.038 . . . . 0.0 113.384 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 52.71 26.3 4.36 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.366 0.666 . . . . 0.0 111.756 -178.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 m 65.85 16.47 10.49 Favored 'General case' 0 CA--C 1.57 1.748 0 C-N-CA 124.11 0.964 . . . . 0.0 111.349 -177.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.552 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 26.2 mtp180 -72.46 -46.93 10.1 Favored Pre-proline 0 CA--C 1.546 0.82 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 175.207 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.552 ' HD3' ' HB2' ' A' ' 31' ' ' ARG . 1.2 Cg_endo -91.81 136.87 1.81 Allowed 'Trans proline' 0 N--CA 1.439 -1.679 0 C-N-CA 121.805 1.67 . . . . 0.0 108.129 163.189 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.422 HG13 HG23 ' A' ' 34' ' ' THR . 7.3 p -74.54 -41.44 48.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.886 -0.725 . . . . 0.0 111.338 -179.177 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.422 HG23 HG13 ' A' ' 33' ' ' VAL . 22.5 p -88.73 74.43 8.35 Favored 'General case' 0 N--CA 1.429 -1.514 0 CA-C-O 121.202 0.525 . . . . 0.0 111.574 -177.159 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 66.49 -116.96 8.85 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.123 179.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.6 m -106.91 4.59 27.47 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-O 120.894 0.378 . . . . 0.0 110.438 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -91.95 130.53 37.68 Favored 'General case' 0 CA--C 1.513 -0.476 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.047 -177.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 53.2 tptt -120.31 153.9 35.76 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -95.94 125.44 40.49 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 118.917 -1.113 . . . . 0.0 110.458 -177.349 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.455 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 53.0 t30 -77.2 166.44 23.21 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.116 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 66.7 mm-40 -71.2 4.72 2.6 Favored 'General case' 0 C--N 1.312 -1.044 0 C-N-CA 123.548 0.739 . . . . 0.0 112.488 -174.214 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -104.5 -0.42 27.88 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.249 0.547 . . . . 0.0 110.493 175.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 91.51 -2.8 78.16 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.794 178.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.424 HG22 ' HB2' ' A' ' 89' ' ' CYS . 5.3 m -88.72 139.57 30.33 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 70.3 m95 -92.98 123.95 36.6 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.455 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 11.8 p90 -133.0 159.18 40.77 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.404 -174.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -147.96 142.29 16.42 Favored Pre-proline 0 C--N 1.297 -1.712 0 N-CA-C 106.031 -1.841 . . . . 0.0 106.031 172.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -72.4 134.38 22.54 Favored 'Trans proline' 0 N--CA 1.45 -1.073 0 C-N-CA 121.397 1.398 . . . . 0.0 110.475 174.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -150.94 121.4 7.38 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -101.84 106.14 17.08 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.55 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.78 176.56 11.66 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.477 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 24.0 m -113.58 151.03 32.21 Favored 'General case' 0 C--N 1.292 -1.904 0 CA-C-O 121.002 0.429 . . . . 0.0 111.163 -174.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.465 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 84.0 t80 -129.21 124.83 35.54 Favored 'General case' 0 N--CA 1.428 -1.526 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 174.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 33.6 t -108.54 110.04 30.55 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.11 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 62.5 t30 -77.07 130.4 37.36 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 177.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -122.58 -64.0 0.22 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 118.52 -1.8 . . . . 0.0 115.901 -173.135 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -68.71 -56.33 8.46 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 114.05 1.13 . . . . 0.0 114.05 -171.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 20.2 pt20 -134.39 157.88 76.45 Favored Pre-proline 0 C--N 1.292 -1.913 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.212 -170.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.4 ' HB3' HD21 ' A' ' 76' ' ' ASN . 19.7 Cg_exo -68.5 138.28 41.7 Favored 'Trans proline' 0 N--CA 1.445 -1.325 0 C-N-CA 121.76 1.64 . . . . 0.0 109.071 170.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.7 mt -113.39 133.38 59.48 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -177.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 9.5 p -84.3 128.05 39.26 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.083 0 CA-C-O 121.42 0.629 . . . . 0.0 109.76 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . 0.441 HG22 ' HA ' ' A' ' 109' ' ' CYS . 74.1 p -109.98 178.94 4.25 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.099 -173.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.57 ' HG2' ' CZ3' ' A' ' 96' ' ' TRP . 1.6 mmp_? -112.15 154.77 25.0 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 174.375 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 54.5 mt -119.26 126.1 75.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 120.759 -0.376 . . . . 0.0 111.045 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 85.08 -22.75 9.04 Favored Glycine 0 CA--C 1.519 0.337 0 N-CA-C 115.983 1.153 . . . . 0.0 115.983 171.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.1 m -153.99 142.65 14.49 Favored Pre-proline 0 C--N 1.309 -1.192 0 CA-C-N 118.276 1.038 . . . . 0.0 109.933 -178.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -90.63 119.14 0.67 Allowed 'Trans proline' 0 N--CA 1.443 -1.442 0 C-N-CA 121.806 1.67 . . . . 0.0 111.865 175.125 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.535 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 91.9 m-85 -168.9 168.94 10.06 Favored 'General case' 0 CA--C 1.49 -1.348 0 N-CA-C 104.584 -2.376 . . . . 0.0 104.584 179.216 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 85.2 mt -79.53 -37.86 35.57 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 171.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -88.84 12.09 16.12 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 114.32 -1.309 . . . . 0.0 112.101 -176.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.535 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.99 162.65 73.52 Favored Pre-proline 0 C--N 1.314 -0.966 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.561 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -46.94 123.18 7.03 Favored 'Trans proline' 0 C--N 1.367 1.518 0 C-N-CA 123.371 2.714 . . . . 0.0 113.797 -178.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.8 t -97.37 172.27 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.35 -30.03 5.94 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.84 126.98 10.02 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 178.011 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.4 HD21 ' HB3' ' A' ' 59' ' ' PRO . 9.3 t30 -128.47 130.5 47.64 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 117.118 0.459 . . . . 0.0 110.505 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 64.0 tp -97.63 113.55 63.67 Favored Pre-proline 0 C--N 1.3 -1.561 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -66.76 155.65 69.54 Favored 'Trans proline' 0 C--O 1.247 0.947 0 C-N-CA 122.505 2.136 . . . . 0.0 112.421 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.96 142.61 41.92 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.899 -0.592 . . . . 0.0 109.695 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.35 -4.57 70.29 Favored Glycine 0 N--CA 1.447 -0.602 0 N-CA-C 111.774 -0.531 . . . . 0.0 111.774 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -82.47 126.75 32.59 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 121.215 0.531 . . . . 0.0 111.528 -177.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 24.0 m -95.09 114.26 26.05 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 176.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.9 mm -119.02 134.0 64.06 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 -176.123 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.4 p -99.26 135.43 34.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.55 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 16.5 p90 -109.38 160.61 16.03 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.943 -0.703 . . . . 0.0 112.164 -178.272 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -124.8 -37.23 2.49 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.878 -1.056 . . . . 0.0 111.105 -176.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -118.26 131.92 56.33 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -175.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.4 t -121.43 125.27 73.42 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 176.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.534 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 13.8 p -134.09 140.45 46.63 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -175.538 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 71.8 mt -101.2 115.45 42.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 109.128 -0.694 . . . . 0.0 109.128 178.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.482 ' HG2' ' HA ' ' A' ' 68' ' ' PHE . 6.2 tp-100 -118.59 144.68 45.95 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 105.493 -2.04 . . . . 0.0 105.493 175.492 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -57.0 104.23 0.15 Allowed 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -175.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.58 -38.05 2.07 Favored Glycine 0 N--CA 1.439 -1.15 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.688 177.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 46.2 m80 -152.99 153.23 32.5 Favored 'General case' 0 N--CA 1.478 0.932 0 O-C-N 122.118 -0.636 . . . . 0.0 110.06 -176.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 13.6 tt -97.16 117.75 42.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.57 ' CZ3' ' HG2' ' A' ' 63' ' ' ARG . 65.2 m95 -100.61 134.11 44.05 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-O 120.922 0.391 . . . . 0.0 110.86 -171.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.5 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.6 pt -100.5 125.35 54.32 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.869 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 174.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -99.06 125.72 8.66 Favored Glycine 0 N--CA 1.414 -2.805 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 38.5 p90 -138.58 172.72 12.46 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-O 120.81 0.338 . . . . 0.0 110.524 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.442 ' HA ' ' O ' ' A' ' 105' ' ' ASN . 1.7 p-10 -115.5 120.04 38.18 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.687 -178.471 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.55 ' HB3' ' HB2' ' A' ' 105' ' ' ASN . . . -90.46 -174.7 4.22 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.447 -179.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 45.1 p90 -45.84 -32.25 2.51 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 116.246 1.943 . . . . 0.0 116.246 -176.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -108.37 15.79 23.68 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.034 0.921 . . . . 0.0 109.899 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 81.05 22.28 61.4 Favored Glycine 0 C--N 1.315 -0.621 0 N-CA-C 110.214 -1.155 . . . . 0.0 110.214 -177.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.55 ' HB2' ' HB3' ' A' ' 101' ' ' ALA . 8.9 m120 -67.78 121.1 15.24 Favored 'General case' 0 CA--C 1.494 -1.193 0 CA-C-N 114.732 -0.734 . . . . 0.0 109.141 -178.277 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 21.2 tpt180 -86.16 95.75 9.68 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 178.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.9 t -102.95 142.23 17.33 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.3 -174.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.5 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 86.8 m-85 -118.96 116.19 25.94 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 123.642 0.589 . . . . 0.0 110.163 -179.277 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . 0.441 ' HA ' HG22 ' A' ' 62' ' ' THR . 46.3 t -99.94 133.89 21.33 Favored Pre-proline 0 C--N 1.304 -1.376 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -69.7 -23.57 30.9 Favored 'Trans proline' 0 C--N 1.358 1.027 0 C-N-CA 123.227 2.618 . . . . 0.0 113.679 -176.35 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.291 30.8 m 48.95 -53.56 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.164 0 N-CA-C 117.972 2.582 . . . . 0.0 117.972 177.551 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.417 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 21.0 ptt180 -159.22 150.59 20.22 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 123.782 0.833 . . . . 0.0 108.837 -178.513 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 71.2 m -69.74 137.82 52.29 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 175.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 46.6 t -153.91 129.16 9.73 Favored 'General case' 0 N--CA 1.41 -2.473 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -177.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . 0.603 ' HA ' HE21 ' A' ' 115' ' ' GLN . 0.1 OUTLIER -96.72 146.0 25.28 Favored 'General case' 0 N--CA 1.408 -2.53 0 N-CA-C 103.285 -2.857 . . . . 0.0 103.285 172.288 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -167.07 142.12 7.36 Favored Glycine 0 N--CA 1.406 -3.31 0 C-N-CA 116.66 -2.686 . . . . 0.0 114.994 -177.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 6.2 m -131.59 97.47 19.22 Favored Pre-proline 0 C--N 1.279 -2.457 0 N-CA-C 104.501 -2.407 . . . . 0.0 104.501 171.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -48.31 139.68 21.6 Favored 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 123.456 2.771 . . . . 0.0 113.803 -170.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -85.97 6.74 63.45 Favored 'Cis proline' 0 CA--C 1.558 1.724 0 C-N-CA 124.288 -1.13 . . . . 0.0 114.051 0.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -70.46 102.64 2.25 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-O 121.541 0.686 . . . . 0.0 110.977 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 36.6 p-80 -105.3 117.25 33.53 Favored 'General case' 0 C--N 1.296 -1.717 0 CA-C-N 114.832 -1.077 . . . . 0.0 111.49 -178.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 53.1 mt -110.18 99.34 39.35 Favored Pre-proline 0 C--N 1.318 -0.782 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.53 141.73 8.98 Favored 'Trans proline' 0 C--O 1.247 0.931 0 C-N-CA 122.549 2.166 . . . . 0.0 112.683 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -106.84 -114.55 3.91 Favored Glycine 0 N--CA 1.433 -1.515 0 N-CA-C 110.616 -0.994 . . . . 0.0 110.616 176.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 85.8 t -88.97 127.17 41.88 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.065 0 CA-C-N 116.734 0.267 . . . . 0.0 110.43 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.417 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -94.16 143.05 26.72 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.306 177.208 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.1 m-90 -113.81 27.78 9.27 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 120.861 0.363 . . . . 0.0 110.551 179.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.465 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -169.92 -179.11 41.38 Favored Glycine 0 N--CA 1.429 -1.814 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 37.7 t -111.0 130.31 64.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -178.107 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -98.88 145.76 26.67 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-O 121.004 0.431 . . . . 0.0 110.792 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.477 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 88.1 tttt . . . . . 0 C--N 1.291 -1.967 0 N-CA-C 107.544 -1.28 . . . . 0.0 107.544 178.054 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 24.4 m . . . . . 0 N--CA 1.444 -0.755 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 43.6 t-20 -106.62 139.25 41.37 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 174.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.469 ' HA ' ' O ' ' A' ' 7' ' ' MET . . . -155.74 -153.53 0.44 Allowed 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 121.061 -0.255 . . . . 0.0 111.072 -171.139 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 81.33 -69.08 0.09 Allowed 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 126.561 1.944 . . . . 0.0 110.753 179.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -89.09 -70.26 0.66 Allowed 'General case' 0 C--N 1.324 -0.535 0 C-N-CA 119.47 -0.892 . . . . 0.0 111.55 -177.172 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 23.3 p90 -87.71 68.01 9.34 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -175.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . 0.469 ' O ' ' HA ' ' A' ' 3' ' ' ALA . 58.0 mtm 60.61 -158.62 0.32 Allowed 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 114.446 -1.252 . . . . 0.0 110.066 177.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -117.59 110.59 18.11 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 175.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.9 tppp? -95.67 105.39 17.38 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.32 56.97 2.41 Favored Glycine 0 C--O 1.245 0.817 0 N-CA-C 116.233 1.253 . . . . 0.0 116.233 -171.386 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 10.1 t -166.12 151.0 8.21 Favored 'General case' 0 N--CA 1.42 -1.945 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 175.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.1 m 72.76 132.36 0.04 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 124.751 1.22 . . . . 0.0 113.505 176.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.6 p -79.64 -18.33 51.72 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.386 177.347 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.5 m 74.74 86.91 0.09 Allowed 'General case' 0 N--CA 1.447 -0.604 0 C-N-CA 125.485 1.514 . . . . 0.0 111.278 177.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 49.3 m -94.92 104.14 16.02 Favored 'General case' 0 N--CA 1.417 -2.105 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.947 -178.218 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 28.9 t -114.72 78.59 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 104.852 -2.277 . . . . 0.0 104.852 171.137 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.7 t 68.22 -81.62 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 C-N-CA 124.734 1.214 . . . . 0.0 108.67 -169.7 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -162.24 -77.4 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 124.973 1.309 . . . . 0.0 108.625 177.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -159.74 146.29 16.24 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 105.68 -1.97 . . . . 0.0 105.68 -177.41 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -163.71 -104.0 0.18 Allowed Glycine 0 C--N 1.291 -1.938 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.08 24.47 1.54 Allowed 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.762 0.792 . . . . 0.0 111.06 177.774 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -70.42 -18.26 63.01 Favored 'General case' 0 N--CA 1.437 -1.122 0 C-N-CA 125.076 1.35 . . . . 0.0 110.263 176.544 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 38.0 t -150.12 147.01 27.24 Favored 'General case' 0 N--CA 1.413 -2.291 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.4 t -89.54 167.33 13.05 Favored 'General case' 0 C--O 1.265 1.88 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 173.243 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 58.15 37.41 26.33 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-O 121.987 0.899 . . . . 0.0 108.775 -175.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.513 ' O ' ' HD3' ' A' ' 28' ' ' PRO . 6.5 p -71.65 -1.97 15.59 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.262 -1.335 . . . . 0.0 114.026 -173.46 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.8 p -113.29 78.94 3.57 Favored Pre-proline 0 N--CA 1.434 -1.265 0 CA-C-O 120.828 0.347 . . . . 0.0 110.968 177.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.513 ' HD3' ' O ' ' A' ' 26' ' ' SER . 3.7 Cg_endo -88.36 2.77 6.16 Favored 'Trans proline' 0 C--N 1.36 1.173 0 C-N-CA 122.565 2.176 . . . . 0.0 112.092 -176.678 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -68.22 110.38 4.01 Favored 'General case' 0 N--CA 1.439 -1.005 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.776 -178.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . 0.276 73.4 p 66.78 -9.07 0.37 Allowed 'General case' 0 CA--C 1.549 0.936 0 N-CA-C 116.264 1.95 . . . . 0.0 116.264 176.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.57 ' HB2' ' HD3' ' A' ' 32' ' ' PRO 0.251 9.9 mpt_? -77.42 -66.89 0.29 Allowed Pre-proline 0 CA--C 1.54 0.58 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.265 177.144 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.57 ' HD3' ' HB2' ' A' ' 31' ' ' ARG . 2.4 Cg_endo -84.68 162.1 12.37 Favored 'Trans proline' 0 N--CA 1.437 -1.814 0 N-CA-C 107.439 -1.793 . . . . 0.0 107.439 167.34 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 t -84.2 73.05 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 C-N-CA 119.251 -0.979 . . . . 0.0 109.896 179.602 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 20.5 p -147.62 90.27 1.84 Allowed 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 125.145 1.378 . . . . 0.0 108.423 177.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.26 -66.47 2.02 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.813 -0.708 . . . . 0.0 111.472 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 35.8 t -123.45 -4.1 8.32 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 122.773 -0.251 . . . . 0.0 110.732 178.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 98.8 m95 -71.97 116.42 12.34 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 121.253 0.549 . . . . 0.0 109.962 179.15 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 7.1 tmtt? -120.56 139.15 53.36 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 105.461 -2.052 . . . . 0.0 105.461 -178.771 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -86.49 136.61 33.02 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.818 -0.753 . . . . 0.0 111.0 -175.392 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.402 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 45.3 t-20 -93.22 159.01 15.47 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 105.944 -1.873 . . . . 0.0 105.944 175.542 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -60.54 -22.28 63.46 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 123.467 0.707 . . . . 0.0 112.383 -174.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -79.13 2.34 21.2 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.865 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.11 10.72 80.05 Favored Glycine 0 CA--C 1.509 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.2 178.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.488 HG21 ' HG2' ' A' ' 67' ' ' PRO . 19.9 m -97.65 143.69 28.06 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 75.9 m95 -101.44 129.93 47.57 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.402 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 29.7 p90 -134.25 156.62 48.08 Favored 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.429 -177.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 49.2 pttt -135.96 132.23 19.24 Favored Pre-proline 0 C--N 1.293 -1.865 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 174.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -72.82 120.6 6.75 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 121.098 1.199 . . . . 0.0 109.007 174.126 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -154.45 130.14 10.01 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 -176.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -97.27 106.39 18.7 Favored 'General case' 0 C--N 1.307 -1.262 0 O-C-N 123.374 0.422 . . . . 0.0 109.963 -176.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.42 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -148.66 169.52 20.19 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 7.8 m -111.5 149.18 31.71 Favored 'General case' 0 C--N 1.298 -1.674 0 CA-C-O 120.981 0.42 . . . . 0.0 111.522 -173.172 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 85.4 t80 -130.58 131.36 44.96 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 174.291 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.424 HG22 HG23 ' A' ' 82' ' ' THR . 36.2 t -117.66 117.19 54.23 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 177.631 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -69.89 140.34 53.12 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -102.72 -73.97 1.0 Allowed Glycine 0 N--CA 1.432 -1.63 0 C-N-CA 120.306 -0.95 . . . . 0.0 114.75 -172.798 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -91.79 -69.13 0.75 Allowed 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 116.011 1.856 . . . . 0.0 116.011 -170.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -109.21 151.49 42.05 Favored Pre-proline 0 C--N 1.292 -1.914 0 O-C-N 121.828 -0.545 . . . . 0.0 111.192 -173.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.432 ' HA ' ' O ' ' A' ' 77' ' ' LEU . 50.0 Cg_exo -57.28 131.11 42.93 Favored 'Trans proline' 0 C--O 1.249 1.025 0 C-N-CA 122.171 1.914 . . . . 0.0 109.437 170.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -107.85 118.83 56.32 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -176.529 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 35.0 m -74.41 143.1 13.87 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.194 175.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 59.2 p -118.42 173.61 6.73 Favored 'General case' 0 C--N 1.277 -2.56 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.141 -173.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.466 ' HG3' ' O ' ' A' ' 68' ' ' PHE . 2.2 mmp_? -116.21 148.64 40.2 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.157 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 66.4 mt -112.21 131.26 64.15 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-O 120.62 0.248 . . . . 0.0 111.122 -177.303 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 85.98 -23.18 9.68 Favored Glycine 0 C--N 1.318 -0.423 0 N-CA-C 115.646 1.019 . . . . 0.0 115.646 171.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 49.0 m -157.87 142.23 11.67 Favored Pre-proline 0 C--N 1.296 -1.719 0 CA-C-N 117.51 0.655 . . . . 0.0 109.271 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.488 ' HG2' HG21 ' A' ' 44' ' ' THR . 60.9 Cg_endo -89.23 118.51 0.87 Allowed 'Trans proline' 0 N--CA 1.429 -2.306 0 C-N-CA 120.497 0.798 . . . . 0.0 110.089 172.276 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.489 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 90.8 m-85 -170.03 177.05 4.44 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 103.669 -2.715 . . . . 0.0 103.669 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -90.53 -37.81 13.62 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.411 0.624 . . . . 0.0 109.775 175.524 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -81.57 -2.33 49.62 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 114.772 -1.103 . . . . 0.0 111.035 -178.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.489 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -58.25 158.95 12.49 Favored Pre-proline 0 CA--C 1.547 0.828 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.547 -179.115 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_exo -47.11 134.73 18.9 Favored 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 123.823 3.015 . . . . 0.0 114.701 -178.289 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 26.6 m -90.63 173.53 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 CA-C-N 114.392 -1.276 . . . . 0.0 110.393 -178.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.44 6.22 12.04 Favored Glycine 0 C--N 1.314 -0.682 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.836 177.278 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -118.77 125.54 6.45 Favored Glycine 0 N--CA 1.432 -1.593 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.902 179.454 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -128.46 135.26 49.22 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 174.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.432 ' O ' ' HA ' ' A' ' 59' ' ' PRO . 53.9 tp -111.59 110.39 55.25 Favored Pre-proline 0 C--N 1.303 -1.422 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 176.523 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -67.47 166.14 24.78 Favored 'Trans proline' 0 CA--C 1.539 0.758 0 C-N-CA 122.699 2.266 . . . . 0.0 112.988 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.54 134.85 40.64 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.245 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.3 -10.81 73.56 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 121.236 -0.506 . . . . 0.0 112.298 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.76 129.38 39.56 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.902 0.382 . . . . 0.0 111.885 -176.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.424 HG23 HG22 ' A' ' 54' ' ' VAL . 52.9 m -104.98 117.02 32.96 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.121 179.545 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.0 mm -125.92 140.48 48.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -177.02 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.89 119.23 49.86 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-O 121.806 0.812 . . . . 0.0 108.864 175.362 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.42 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 39.4 p90 -97.37 148.4 23.2 Favored 'General case' 0 C--N 1.295 -1.799 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.929 -178.774 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -121.5 9.79 10.33 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 121.578 0.704 . . . . 0.0 110.231 -178.068 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -152.7 130.13 11.38 Favored 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -177.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 33.6 t -118.89 126.61 75.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 178.018 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.552 ' SG ' ' HB2' ' A' ' 96' ' ' TRP . 24.6 p -135.77 143.64 45.35 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.543 0.572 . . . . 0.0 112.543 -177.31 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 60.9 mt -102.32 116.83 46.7 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 CA-C-O 120.96 0.41 . . . . 0.0 110.003 177.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.582 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.8 tp-100 -124.27 121.77 35.94 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 174.117 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.89 107.95 0.16 Allowed 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 123.851 0.86 . . . . 0.0 113.14 -166.367 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 133.91 -33.97 2.46 Favored Glycine 0 N--CA 1.429 -1.81 0 CA-C-N 114.388 -1.278 . . . . 0.0 110.888 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -151.37 166.15 31.88 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -177.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 tt -107.71 119.13 56.78 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 171.211 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.582 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 55.4 m95 -100.77 134.11 44.23 Favored 'General case' 0 C--N 1.276 -2.612 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.9 -170.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 46.4 pt -100.12 133.7 42.2 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 176.272 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.13 121.97 7.21 Favored Glycine 0 N--CA 1.418 -2.564 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -126.13 147.04 49.7 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 176.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -93.96 112.85 24.75 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 -177.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.39 152.52 38.03 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -177.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -51.7 -30.12 20.95 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 124.313 1.045 . . . . 0.0 113.025 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -80.8 -5.52 57.33 Favored 'General case' 0 C--O 1.217 -0.644 0 CA-C-O 121.409 0.623 . . . . 0.0 110.829 -178.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 96.01 11.26 55.13 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.667 176.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -94.67 145.45 24.84 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.3 tpt180 -93.99 105.02 17.05 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 28.2 t -101.84 136.3 34.5 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -174.254 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.487 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 96.0 m-85 -116.09 126.04 53.2 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 123.419 0.688 . . . . 0.0 110.72 -178.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . 0.451 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 47.2 t -108.04 132.76 20.83 Favored Pre-proline 0 C--N 1.31 -1.123 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.143 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.06 -21.35 36.88 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 123.061 2.508 . . . . 0.0 114.683 -176.475 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.292 28.9 m 45.25 -53.71 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.914 0 N-CA-C 118.564 2.801 . . . . 0.0 118.564 176.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.453 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 28.8 ptt180 -154.67 142.05 19.61 Favored 'General case' 0 N--CA 1.44 -0.954 0 C-N-CA 123.826 0.851 . . . . 0.0 109.643 178.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 13.6 m -60.61 131.48 50.87 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.675 177.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.661 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 99.5 m -151.9 119.78 6.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.49 0.662 . . . . 0.0 112.091 -178.234 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -114.98 134.67 54.98 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 177.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 154.17 -175.97 32.2 Favored Glycine 0 CA--C 1.486 -1.768 0 C-N-CA 118.903 -1.618 . . . . 0.0 113.045 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.8 m -126.08 136.16 28.12 Favored Pre-proline 0 C--N 1.298 -1.644 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 179.37 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 92.5 Cg_exo -46.54 129.5 13.87 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 123.469 2.78 . . . . 0.0 113.332 -177.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 19.8 Cg_endo -96.18 -4.44 31.48 Favored 'Cis proline' 0 CA--C 1.542 0.908 0 C-N-CA 124.045 -1.231 . . . . 0.0 113.711 1.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -76.99 99.81 5.4 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-O 121.659 0.742 . . . . 0.0 110.868 -172.645 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 38.8 p-80 -106.99 132.79 52.53 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.334 176.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.661 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 46.6 mm -77.4 113.24 29.72 Favored Pre-proline 0 C--N 1.307 -1.262 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 174.302 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -84.55 124.42 3.13 Favored 'Trans proline' 0 N--CA 1.443 -1.457 0 C-N-CA 122.113 1.875 . . . . 0.0 112.528 -178.04 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.74 -139.19 9.85 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 176.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 58.4 t -80.62 123.43 37.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 -177.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.453 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -93.91 130.65 39.9 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 173.632 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.0 m-90 -95.66 12.63 29.12 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.635 0.731 . . . . 0.0 110.311 -178.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.03 -177.7 34.36 Favored Glycine 0 N--CA 1.421 -2.334 0 CA-C-N 115.196 -0.911 . . . . 0.0 111.298 -178.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 22.8 t -114.17 142.95 24.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -175.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -110.31 141.77 42.86 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.796 0.331 . . . . 0.0 111.289 -176.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? . . . . . 0 C--N 1.307 -1.27 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 172.534 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 N--CA 1.45 -0.462 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -94.87 83.82 4.07 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 172.137 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -70.68 131.95 44.68 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.63 -1.168 . . . . 0.0 110.43 -175.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 21.8 pttm -76.37 121.1 22.53 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 177.613 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 30.4 t30 69.76 89.97 0.1 Allowed 'General case' 0 C--N 1.313 -1.014 0 C-N-CA 123.941 0.897 . . . . 0.0 112.399 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -122.03 145.31 48.26 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 172.255 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 14.4 tpt 59.09 74.03 0.46 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.194 0.934 . . . . 0.0 108.737 -170.24 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -52.56 -58.04 8.04 Favored 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 114.514 -1.221 . . . . 0.0 112.815 -175.349 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.1 tttm 58.4 84.75 0.1 Allowed 'General case' 0 C--O 1.245 0.818 0 O-C-N 124.097 0.873 . . . . 0.0 110.645 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -156.09 37.25 0.6 Allowed Glycine 0 CA--C 1.489 -1.549 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -178.587 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 30.0 m -67.73 -43.52 79.75 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -178.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 20.3 m -86.01 91.37 8.38 Favored 'General case' 0 N--CA 1.427 -1.614 0 CA-C-O 121.43 0.633 . . . . 0.0 110.448 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 23.4 m -108.59 -41.85 4.7 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 175.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 13.8 m -91.21 85.84 5.98 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 177.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 88.3 m -155.63 128.86 8.22 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 -178.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 28.3 m -94.35 160.05 2.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 5.6 p -65.23 -47.85 85.78 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 CA-C-O 121.147 0.499 . . . . 0.0 109.942 178.107 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 49.9 tttm -165.81 147.97 7.31 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 178.543 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -140.34 -67.76 0.42 Allowed 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 175.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.87 -28.21 8.92 Favored Glycine 0 C--N 1.308 -0.973 0 C-N-CA 120.934 -0.65 . . . . 0.0 113.681 176.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 2.1 mppt? -88.85 -39.61 13.72 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 117.561 0.681 . . . . 0.0 109.871 -176.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 27.6 m -65.75 107.51 1.8 Allowed 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.195 -178.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.5 m -78.27 -12.97 60.04 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.558 -178.214 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.8 m -72.2 114.64 10.54 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.16 -179.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.11 99.55 9.27 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 176.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 14.2 m -51.4 138.28 21.94 Favored 'General case' 0 C--O 1.25 1.117 0 C-N-CA 124.024 0.93 . . . . 0.0 111.693 -178.191 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 27.6 p 52.69 68.91 2.67 Favored Pre-proline 0 CA--C 1.539 0.525 0 C-N-CA 124.69 1.196 . . . . 0.0 111.768 -175.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_exo -69.32 88.21 0.49 Allowed 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.13 2.553 . . . . 0.0 113.783 -174.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -111.1 -64.57 1.26 Allowed 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 174.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 p -65.0 -26.78 68.43 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 -176.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.448 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 8.9 mpt_? -77.69 -59.24 0.83 Allowed Pre-proline 0 C--N 1.318 -0.782 0 N-CA-C 113.167 0.802 . . . . 0.0 113.167 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.448 ' HD3' ' HB2' ' A' ' 31' ' ' ARG . 16.9 Cg_exo -71.43 -33.59 10.75 Favored 'Trans proline' 0 C--N 1.37 1.707 0 C-N-CA 121.489 1.459 . . . . 0.0 112.932 178.703 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 76.4 t -94.21 98.5 8.21 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 CA-C-O 121.717 0.77 . . . . 0.0 110.898 -177.23 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 46.5 m -149.3 95.69 2.4 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 176.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -117.32 -95.35 1.82 Allowed Glycine 0 N--CA 1.437 -1.268 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.447 -178.249 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 27.9 m -70.94 -35.73 72.33 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 179.235 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 95.5 m95 -86.07 120.49 27.5 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 175.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -113.66 149.67 34.31 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.3 tttm -92.13 120.48 32.77 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 121.806 0.812 . . . . 0.0 111.158 -177.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 30.3 t-20 -84.5 147.87 26.83 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 176.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.0 tm0? -53.61 -28.66 33.77 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.209 1.004 . . . . 0.0 111.869 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.401 ' HB3' ' CZ ' ' A' ' 68' ' ' PHE . 54.3 m-85 -74.0 -6.02 44.86 Favored 'General case' 0 CA--C 1.54 0.56 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -178.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.36 22.78 39.48 Favored Glycine 0 CA--C 1.495 -1.212 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -178.308 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.413 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 16.9 m -105.88 139.06 41.03 Favored 'General case' 0 N--CA 1.415 -2.222 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.175 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -102.59 133.25 47.9 Favored 'General case' 0 C--N 1.282 -2.366 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 175.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 35.9 p90 -138.94 158.97 43.23 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.436 -0.905 . . . . 0.0 112.286 -175.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.0 pttp -140.67 134.42 15.06 Favored Pre-proline 0 N--CA 1.431 -1.411 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 174.324 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -70.76 134.46 25.91 Favored 'Trans proline' 0 C--N 1.327 -0.597 0 C-N-CA 121.626 1.551 . . . . 0.0 110.566 177.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -163.62 121.09 1.83 Allowed 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.529 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 26.4 t-20 -95.35 106.06 18.07 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 177.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.473 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -144.03 168.83 19.06 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 -178.564 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.422 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 17.2 m -109.61 140.85 42.94 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.256 -174.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.469 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 91.7 t80 -120.9 133.65 55.29 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 176.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 81' ' ' ALA . 42.5 t -119.4 119.53 60.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.696 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.137 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -59.67 145.62 44.14 Favored 'General case' 0 C--O 1.246 0.916 0 O-C-N 123.518 0.511 . . . . 0.0 111.874 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -81.77 -122.34 0.63 Allowed Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.664 -0.698 . . . . 0.0 113.213 -178.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -95.88 -6.3 39.61 Favored 'General case' 0 C--N 1.315 -0.907 0 O-C-N 122.374 -0.486 . . . . 0.0 112.276 -175.427 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 9.5 pt20 -121.45 148.08 49.11 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.554 -178.62 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -72.37 135.59 24.81 Favored 'Trans proline' 0 N--CA 1.439 -1.722 0 C-N-CA 121.932 1.755 . . . . 0.0 107.813 168.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 57.8 mt -107.81 127.83 63.56 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -176.125 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.4 p -78.37 136.67 23.52 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.212 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 37.9 p -113.29 164.16 13.91 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 121.134 0.492 . . . . 0.0 112.043 -174.243 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.488 ' HE ' ' HA ' ' A' ' 63' ' ' ARG . 0.8 OUTLIER -109.63 147.01 33.81 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.392 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.0 mt -99.33 123.4 52.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 112.378 0.511 . . . . 0.0 112.378 -176.189 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 70.9 -22.27 0.58 Allowed Glycine 0 CA--C 1.521 0.41 0 N-CA-C 118.054 1.981 . . . . 0.0 118.054 170.705 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 41.6 m -140.73 136.16 16.18 Favored Pre-proline 0 C--N 1.298 -1.662 0 CA-C-N 119.074 1.437 . . . . 0.0 111.075 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -89.91 119.57 0.83 Allowed 'Trans proline' 0 N--CA 1.44 -1.661 0 C-N-CA 121.781 1.654 . . . . 0.0 110.484 172.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.422 ' HA ' ' HG2' ' A' ' 91' ' ' GLN . 55.3 m-85 -168.46 168.98 10.81 Favored 'General case' 0 CA--C 1.489 -1.367 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 -177.643 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.73 -8.77 53.89 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.536 0.684 . . . . 0.0 110.194 176.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 31.0 p30 -116.62 14.97 15.53 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.243 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.09 152.89 86.75 Favored Pre-proline 0 C--O 1.247 0.962 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.491 -175.229 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_exo -54.29 134.59 61.62 Favored 'Trans proline' 0 C--N 1.364 1.385 0 C-N-CA 123.66 2.907 . . . . 0.0 113.878 -179.064 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 32.3 m -90.1 174.42 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-N 114.564 -1.198 . . . . 0.0 110.234 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.36 28.75 1.9 Allowed Glycine 0 C--N 1.315 -0.611 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.851 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -148.06 127.99 2.74 Favored Glycine 0 N--CA 1.437 -1.248 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -128.12 127.14 42.48 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 26.1 tp -110.61 113.29 55.83 Favored Pre-proline 0 C--N 1.306 -1.325 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.695 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -62.21 162.31 23.73 Favored 'Trans proline' 0 N--CA 1.483 0.904 0 C-N-CA 123.461 2.774 . . . . 0.0 114.043 -176.067 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.96 144.67 48.81 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 178.456 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.73 11.15 85.61 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.478 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.41 ' O ' ' HA ' ' A' ' 54' ' ' VAL . . . -78.77 134.21 37.04 Favored 'General case' 0 N--CA 1.439 -1.01 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 178.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 42.1 m -104.47 108.84 20.46 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 45.5 mm -124.05 126.59 72.62 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-O 120.936 0.398 . . . . 0.0 110.518 -176.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 12.4 p -90.32 123.41 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.647 0 CA-C-O 121.486 0.66 . . . . 0.0 109.56 176.34 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.529 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 45.5 p90 -101.96 159.25 15.52 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.137 -178.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -118.29 -16.19 9.68 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 121.379 0.609 . . . . 0.0 111.786 -175.204 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -141.11 137.76 33.03 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.341 -175.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 67.6 t -112.28 125.76 69.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.74 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.413 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 57.9 m -127.24 142.5 51.46 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -175.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 55.0 mt -108.46 117.04 53.11 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 172.174 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.422 ' HG2' ' HA ' ' A' ' 68' ' ' PHE . 7.7 tp-100 -113.97 121.33 43.58 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 103.107 -2.923 . . . . 0.0 103.107 170.171 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.17 104.07 0.06 Allowed 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 113.697 0.999 . . . . 0.0 113.697 -165.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 132.56 -36.36 2.19 Favored Glycine 0 N--CA 1.435 -1.411 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.15 -177.439 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 41.5 m80 -146.09 149.39 33.96 Favored 'General case' 0 CA--C 1.504 -0.81 0 O-C-N 122.293 -0.533 . . . . 0.0 111.621 -178.253 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.8 tt -97.86 138.11 23.56 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.913 0 N-CA-C 105.777 -1.934 . . . . 0.0 105.777 175.203 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 71.6 m95 -120.22 138.06 53.85 Favored 'General case' 0 C--N 1.283 -2.308 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 -174.35 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.1 pt -101.05 128.9 52.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 175.312 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.19 119.87 6.6 Favored Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 179.246 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 55.2 p90 -138.35 171.97 13.6 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -109.21 131.97 54.57 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.331 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -98.12 170.9 8.59 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.703 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 31.1 p90 -50.18 -24.02 2.56 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 115.516 1.672 . . . . 0.0 115.516 -176.537 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -86.03 -9.92 55.92 Favored 'General case' 0 C--N 1.315 -0.926 0 O-C-N 121.498 -0.751 . . . . 0.0 110.59 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 88.94 17.14 56.89 Favored Glycine 0 CA--C 1.499 -0.926 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -174.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 42.2 t30 -93.95 136.14 34.56 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 113.822 -1.189 . . . . 0.0 109.399 -175.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 -78.57 113.71 16.85 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 47.3 t -121.14 143.37 33.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 -175.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.446 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 92.6 m-85 -120.79 127.21 51.74 Favored 'General case' 0 C--O 1.242 0.698 0 C-N-CA 122.977 0.511 . . . . 0.0 110.977 -179.138 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 53.0 t -104.48 133.46 20.18 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 178.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.59 -10.81 27.31 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 123.409 2.739 . . . . 0.0 114.267 -176.341 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.279 35.5 m 38.71 -61.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 N-CA-C 118.706 2.854 . . . . 0.0 118.706 174.6 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.545 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 35.6 ptt180 -154.99 150.33 27.24 Favored 'General case' 0 N--CA 1.439 -0.982 0 C-N-CA 123.287 0.635 . . . . 0.0 109.997 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.459 ' O ' ' HA ' ' A' ' 123' ' ' PRO . 82.4 m -68.95 135.61 51.23 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.637 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 95.2 m -151.09 110.92 4.06 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 123.001 0.52 . . . . 0.0 110.868 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 23.3 mp0 -98.71 160.95 13.92 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 176.545 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 128.02 -167.05 20.42 Favored Glycine 0 CA--C 1.487 -1.667 0 C-N-CA 118.768 -1.682 . . . . 0.0 113.508 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 27.9 m -138.13 151.13 69.22 Favored Pre-proline 0 C--N 1.304 -1.38 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 53.6 Cg_exo -56.0 137.01 77.74 Favored 'Trans proline' 0 CA--C 1.54 0.775 0 C-N-CA 122.349 2.033 . . . . 0.0 112.992 -179.49 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 1.3 Cg_endo -92.11 -11.65 27.86 Favored 'Cis proline' 0 C--O 1.25 1.087 0 C-N-CA 124.098 -1.209 . . . . 0.0 113.06 -2.242 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -75.82 101.15 4.99 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-O 122.207 1.003 . . . . 0.0 112.168 -173.093 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.41 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 32.6 p-80 -105.44 132.71 51.28 Favored 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 114.194 -1.366 . . . . 0.0 110.537 177.669 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.637 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 3.1 mp -94.15 105.5 17.8 Favored Pre-proline 0 C--N 1.299 -1.591 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 179.412 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.459 ' HA ' ' O ' ' A' ' 113' ' ' THR . 50.2 Cg_endo -84.31 143.18 9.93 Favored 'Trans proline' 0 N--CA 1.436 -1.864 0 C-N-CA 121.769 1.646 . . . . 0.0 112.813 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.7 -114.62 3.98 Favored Glycine 0 N--CA 1.426 -1.993 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 176.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 62.0 t -94.44 126.8 46.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.545 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.38 136.92 34.15 Favored 'General case' 0 N--CA 1.439 -1.015 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.349 175.199 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.0 m-90 -102.32 19.93 17.84 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.394 0.616 . . . . 0.0 110.939 -178.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.469 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -172.55 179.81 43.84 Favored Glycine 0 N--CA 1.427 -1.933 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.242 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 37.7 t -111.71 135.44 50.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -176.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -97.75 127.36 43.65 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.255 179.174 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 97.3 mttt . . . . . 0 C--N 1.29 -1.997 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 175.419 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 35.1 t . . . . . 0 N--CA 1.444 -0.739 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 16.0 m120 -87.39 110.27 20.15 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-O 120.651 0.263 . . . . 0.0 110.732 -178.044 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.22 65.69 8.37 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 176.591 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 65.7 tttp -118.98 -17.26 9.08 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 114.603 -1.18 . . . . 0.0 110.586 -176.535 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 31.3 p30 -84.75 -6.64 59.36 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.901 -177.353 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 70.29 1.17 3.47 Favored 'General case' 0 C--O 1.246 0.909 0 C-N-CA 124.365 1.066 . . . . 0.0 112.54 178.666 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 28.6 mmt -87.21 72.74 9.86 Favored 'General case' 0 N--CA 1.425 -1.702 0 CA-C-O 121.674 0.75 . . . . 0.0 109.935 -177.355 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -147.0 -39.09 0.2 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 114.326 -1.307 . . . . 0.0 107.529 173.318 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 5.2 tppp? -82.21 -59.88 2.4 Favored 'General case' 0 C--O 1.242 0.675 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 173.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -81.04 80.84 1.67 Allowed Glycine 0 N--CA 1.433 -1.561 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 176.382 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 34.3 m -145.03 133.84 22.32 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.8 p -76.95 114.8 16.14 Favored 'General case' 0 N--CA 1.42 -1.925 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 177.036 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 44.1 t -115.18 105.03 12.43 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -178.627 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 54.5 m 63.84 24.65 13.81 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 123.999 0.92 . . . . 0.0 110.561 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 5.6 m -95.97 71.35 2.92 Favored 'General case' 0 N--CA 1.424 -1.745 0 CA-C-O 121.825 0.822 . . . . 0.0 110.881 -175.747 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.6 m -113.06 23.99 4.7 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 177.544 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 9.2 p -62.07 133.04 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 CA-C-N 113.068 -1.878 . . . . 0.0 112.779 -175.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 28.1 tptp -100.78 116.87 33.7 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 106.155 -1.794 . . . . 0.0 106.155 171.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -56.58 110.25 0.75 Allowed 'General case' 0 C--O 1.239 0.508 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 176.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -80.31 144.91 26.23 Favored Glycine 0 N--CA 1.427 -1.915 0 CA-C-N 115.76 -0.655 . . . . 0.0 113.87 -171.088 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 61.1 tttm -72.58 107.93 5.35 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 177.25 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 8.5 m -130.55 154.49 47.76 Favored 'General case' 0 C--N 1.288 -2.085 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -174.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 30.2 m -80.94 131.94 35.37 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 173.337 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.3 m -47.39 116.42 1.42 Allowed 'General case' 0 C--O 1.243 0.763 0 C-N-CA 124.109 0.964 . . . . 0.0 111.838 -177.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -100.79 -163.88 1.06 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.135 -175.595 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 41.6 m 71.63 78.48 0.16 Allowed 'General case' 0 C--O 1.246 0.876 0 C-N-CA 124.187 0.995 . . . . 0.0 112.427 178.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.1 p -72.69 126.18 90.85 Favored Pre-proline 0 N--CA 1.42 -1.946 0 CA-C-N 114.567 -1.197 . . . . 0.0 108.461 175.024 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -44.88 -49.14 10.0 Favored 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 123.858 3.039 . . . . 0.0 113.623 -178.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 59.97 28.1 17.57 Favored 'General case' 0 C--O 1.246 0.896 0 O-C-N 124.203 0.939 . . . . 0.0 110.836 178.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.0 m 60.86 80.15 0.22 Allowed 'General case' 0 N--CA 1.438 -1.05 0 C-N-CA 124.74 1.216 . . . . 0.0 109.924 -176.454 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.411 ' HB3' ' HD3' ' A' ' 32' ' ' PRO . 41.0 ttm180 -153.81 -58.09 0.02 OUTLIER Pre-proline 0 CA--C 1.552 1.057 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.01 -177.176 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.411 ' HD3' ' HB3' ' A' ' 31' ' ' ARG . 57.8 Cg_endo -78.07 87.86 1.49 Allowed 'Trans proline' 0 C--N 1.377 2.061 0 N-CA-C 108.961 -1.207 . . . . 0.0 108.961 169.638 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -112.31 175.16 2.06 Favored 'Isoleucine or valine' 0 C--O 1.261 1.675 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.047 -175.142 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.2 m -74.18 70.76 1.63 Allowed 'General case' 0 N--CA 1.434 -1.255 0 CA-C-O 121.556 0.693 . . . . 0.0 109.771 178.008 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -119.31 -18.96 4.38 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 177.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 5.5 m -94.66 -21.9 18.5 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 121.706 0.765 . . . . 0.0 109.927 179.258 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 45.6 m95 -92.14 147.54 22.86 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.431 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.8 mtpp -121.84 152.06 39.97 Favored 'General case' 0 C--N 1.309 -1.196 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 177.449 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 56.7 tttp -101.65 135.41 43.22 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 34.9 p30 -95.09 174.69 6.95 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -64.18 -22.31 66.89 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 122.924 0.49 . . . . 0.0 111.937 -178.263 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -82.43 -5.56 58.75 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.486 -178.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 95.34 -3.82 66.55 Favored Glycine 0 N--CA 1.439 -1.114 0 C-N-CA 121.151 -0.547 . . . . 0.0 112.615 176.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 7.1 m -84.58 141.08 30.94 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 122.706 0.402 . . . . 0.0 110.126 -176.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 98.2 m95 -92.52 135.87 33.7 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 174.344 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -137.97 159.13 42.83 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 120.84 0.352 . . . . 0.0 110.983 -177.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 58.7 pttt -141.97 152.32 61.64 Favored Pre-proline 0 C--N 1.301 -1.507 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 174.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -80.21 121.85 4.51 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.017 1.812 . . . . 0.0 110.572 175.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.42 ' HB3' HG23 ' A' ' 88' ' ' VAL . 38.2 tt0 -155.42 130.72 9.58 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.285 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.557 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 27.2 t-20 -117.95 115.31 24.65 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -177.078 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.526 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -154.49 178.29 10.23 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -179.086 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 28.5 m -103.35 131.14 50.67 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 121.066 0.46 . . . . 0.0 111.038 -176.225 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.426 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 79.8 t80 -107.08 121.95 45.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 173.403 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 41.4 t -106.65 102.25 13.66 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.045 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.668 -178.379 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 56.0 t30 -77.44 151.63 34.64 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 173.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -142.05 -71.8 0.03 OUTLIER Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.017 -1.563 . . . . 0.0 115.537 -176.195 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.402 ' OD1' ' HG3' ' A' ' 58' ' ' GLN . 26.7 p30 -72.1 -38.27 69.37 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 116.161 1.912 . . . . 0.0 116.161 -169.146 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.402 ' HG3' ' OD1' ' A' ' 57' ' ' ASN . 0.1 OUTLIER -138.54 161.4 58.98 Favored Pre-proline 0 C--N 1.296 -1.752 0 C-N-CA 120.494 -0.482 . . . . 0.0 112.123 -177.031 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -78.08 151.0 26.76 Favored 'Trans proline' 0 N--CA 1.439 -1.717 0 C-N-CA 121.722 1.614 . . . . 0.0 109.578 175.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.6 mt -125.04 126.22 70.77 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -178.388 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.6 p -82.21 117.75 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.218 0 CA-C-O 122.119 0.961 . . . . 0.0 109.527 176.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.3 p -91.28 173.62 7.82 Favored 'General case' 0 C--N 1.289 -2.065 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.333 -176.131 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 74.4 mmt-85 -111.25 145.72 38.24 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-O 121.285 0.564 . . . . 0.0 110.23 -178.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.494 HG23 HD21 ' A' ' 105' ' ' ASN . 76.3 mt -94.89 112.35 27.23 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 CA-C-N 115.203 -0.908 . . . . 0.0 112.717 -176.156 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.11 -23.13 1.16 Allowed Glycine 0 CA--C 1.518 0.279 0 N-CA-C 116.849 1.5 . . . . 0.0 116.849 171.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.451 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 18.1 m -137.11 135.96 20.36 Favored Pre-proline 0 C--N 1.301 -1.541 0 CA-C-N 118.329 1.064 . . . . 0.0 111.168 -175.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 66' ' ' SER . 9.6 Cg_endo -89.98 120.28 0.87 Allowed 'Trans proline' 0 N--CA 1.438 -1.745 0 C-N-CA 121.888 1.725 . . . . 0.0 111.525 173.681 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.549 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 92.9 m-85 -165.42 161.92 19.11 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 103.848 -2.649 . . . . 0.0 103.848 179.024 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 64.9 mt -72.85 -40.08 66.0 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.17 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -97.36 17.49 17.34 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.221 -0.9 . . . . 0.0 111.172 -178.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.549 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -60.68 161.69 14.04 Favored Pre-proline 0 N--CA 1.48 1.06 0 C-N-CA 122.959 0.504 . . . . 0.0 111.624 -179.078 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -57.11 130.71 41.06 Favored 'Trans proline' 0 C--N 1.366 1.5 0 C-N-CA 122.955 2.436 . . . . 0.0 113.185 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 22.2 m -102.92 175.75 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 C-N-CA 124.56 1.144 . . . . 0.0 110.874 -179.537 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.84 3.84 10.76 Favored Glycine 0 C--N 1.309 -0.919 0 C-N-CA 121.308 -0.473 . . . . 0.0 112.175 -178.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -110.18 94.3 0.79 Allowed Glycine 0 N--CA 1.434 -1.442 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 173.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -87.38 122.31 30.97 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.989 -0.713 . . . . 0.0 110.463 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.9 tp -96.78 113.33 62.64 Favored Pre-proline 0 C--N 1.304 -1.384 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.33 159.89 47.94 Favored 'Trans proline' 0 C--O 1.251 1.154 0 C-N-CA 122.591 2.194 . . . . 0.0 113.348 -176.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.28 124.86 25.97 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.889 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.09 -0.54 54.68 Favored Glycine 0 C--N 1.306 -1.106 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.18 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.36 126.52 29.88 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.299 0.571 . . . . 0.0 111.247 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 14.4 m -99.45 108.87 21.44 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 178.217 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.9 mm -119.16 128.56 75.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 120.723 0.296 . . . . 0.0 111.333 -173.192 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.2 p -87.98 128.97 39.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 173.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.557 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 21.1 p90 -104.01 157.98 16.73 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.955 -0.298 . . . . 0.0 111.472 -178.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -114.97 -23.6 9.01 Favored 'General case' 0 C--O 1.247 0.945 0 CA-C-O 121.665 0.745 . . . . 0.0 111.495 -176.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -141.52 137.42 32.03 Favored 'General case' 0 C--N 1.294 -1.807 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.911 -170.575 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.42 HG23 ' HB3' ' A' ' 49' ' ' GLU . 96.0 t -113.73 132.86 61.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.583 ' HG ' ' HE2' ' A' ' 108' ' ' TYR . 56.9 m -131.85 153.75 49.87 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 120.548 0.214 . . . . 0.0 111.235 -176.141 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 55.3 mt -122.12 119.71 59.26 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 173.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.48 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 6.2 tp-100 -122.58 146.31 47.54 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 176.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.71 104.76 0.07 Allowed 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -169.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 108.47 -19.75 31.02 Favored Glycine 0 N--CA 1.436 -1.322 0 CA-C-N 114.853 -1.067 . . . . 0.0 113.999 175.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -145.17 147.01 32.0 Favored 'General case' 0 C--N 1.316 -0.858 0 O-C-N 121.535 -0.979 . . . . 0.0 111.998 -176.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.468 HG23 HG23 ' A' ' 111' ' ' VAL . 14.7 tt -92.64 143.85 10.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 105.461 -2.052 . . . . 0.0 105.461 174.132 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.48 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 70.0 m95 -126.92 148.61 50.03 Favored 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 -175.46 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.8 pt -117.67 137.52 51.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 174.148 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -110.83 131.62 10.48 Favored Glycine 0 N--CA 1.421 -2.329 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -138.62 169.7 17.32 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 177.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 51.8 t-20 -106.56 114.64 28.88 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.32 162.62 28.25 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -178.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -57.54 -17.9 16.4 Favored 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 -177.024 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 7.3 t30 -79.23 -14.83 58.8 Favored 'General case' 0 CA--C 1.547 0.861 0 CA-C-O 121.18 0.514 . . . . 0.0 110.598 178.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 92.21 17.02 48.38 Favored Glycine 0 C--N 1.325 -0.079 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -174.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.494 HD21 HG23 ' A' ' 64' ' ' ILE . 38.1 t30 -97.49 142.89 28.78 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 114.648 -0.776 . . . . 0.0 110.68 -178.267 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 19.2 tpt180 -88.39 107.34 18.79 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 179.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 43.0 t -107.96 139.61 29.41 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -176.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.583 ' HE2' ' HG ' ' A' ' 89' ' ' CYS . 90.5 m-85 -117.5 128.34 54.89 Favored 'General case' 0 C--N 1.32 -0.695 0 O-C-N 123.331 0.395 . . . . 0.0 110.817 -179.317 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 41.9 t -104.7 133.29 20.25 Favored Pre-proline 0 C--N 1.3 -1.547 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.03 -9.49 25.74 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 123.135 2.557 . . . . 0.0 114.001 -177.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.468 HG23 HG23 ' A' ' 95' ' ' ILE 0.307 27.1 m 39.1 -63.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 N-CA-C 118.361 2.726 . . . . 0.0 118.361 175.133 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.547 ' HB2' ' O ' ' A' ' 125' ' ' VAL . 36.0 ptt180 -162.59 164.38 26.78 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-O 121.177 0.513 . . . . 0.0 111.468 177.357 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 58.4 m -75.37 134.72 40.9 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.265 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.477 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 89.6 m -154.58 124.26 6.59 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 123.787 0.835 . . . . 0.0 110.026 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -105.48 160.54 15.07 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 179.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 134.83 -176.24 20.08 Favored Glycine 0 C--N 1.292 -1.872 0 C-N-CA 118.262 -1.923 . . . . 0.0 114.209 175.272 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 76.7 t -127.37 121.33 22.45 Favored Pre-proline 0 C--N 1.298 -1.632 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 99.5 Cg_exo -43.76 136.25 6.97 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 124.043 3.162 . . . . 0.0 113.18 -178.182 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 0.9 OUTLIER -86.13 -11.17 42.48 Favored 'Cis proline' 0 C--O 1.25 1.103 0 C-N-CA 124.007 -1.247 . . . . 0.0 114.25 3.77 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -76.22 102.16 5.7 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.951 0.881 . . . . 0.0 112.19 -172.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -106.09 124.87 50.25 Favored 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 114.073 -1.421 . . . . 0.0 110.83 176.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 55.3 mt -93.74 109.43 41.23 Favored Pre-proline 0 C--N 1.295 -1.768 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.83 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -81.97 150.38 16.04 Favored 'Trans proline' 0 C--O 1.246 0.907 0 C-N-CA 122.485 2.123 . . . . 0.0 114.295 -175.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.33 -125.36 4.3 Favored Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 175.003 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.547 ' O ' ' HB2' ' A' ' 112' ' ' ARG . 60.3 t -79.09 133.68 29.44 Favored 'Isoleucine or valine' 0 C--O 1.244 0.805 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.447 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -93.22 132.94 36.93 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 123.268 0.627 . . . . 0.0 109.857 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 8.6 m0 -107.68 13.38 26.63 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.462 0.649 . . . . 0.0 109.995 178.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.426 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -173.58 170.69 43.85 Favored Glycine 0 N--CA 1.425 -2.089 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 179.569 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 73.3 t -111.41 129.57 66.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 CA-C-N 116.981 0.391 . . . . 0.0 110.316 -176.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -94.4 129.58 41.07 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.079 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 28.0 ttpp . . . . . 0 N--CA 1.423 -1.817 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 -179.731 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 26.3 m . . . . . 0 N--CA 1.44 -0.935 0 CA-C-O 121.076 0.465 . . . . 0.0 110.908 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -78.5 108.19 11.69 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 176.047 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 75.03 153.56 0.14 Allowed 'General case' 0 C--O 1.253 1.239 0 C-N-CA 125.228 1.411 . . . . 0.0 111.08 -173.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 23.4 tptm -70.67 120.12 15.82 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -87.0 84.79 7.26 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.341 0.591 . . . . 0.0 111.926 -177.023 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 20.7 m-85 -165.04 113.06 1.02 Allowed 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 126.218 1.807 . . . . 0.0 108.917 177.469 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 94.9 mmm -81.79 91.8 6.55 Favored 'General case' 0 C--N 1.311 -1.091 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 173.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -62.85 144.41 56.64 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -177.123 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . 0.314 0.4 OUTLIER -79.36 81.73 5.58 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -174.227 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.48 62.51 0.54 Allowed Glycine 0 N--CA 1.414 -2.821 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 171.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 5.4 t -78.27 78.38 4.75 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-O 122.606 1.193 . . . . 0.0 111.595 -175.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.7 m -140.1 81.09 1.8 Allowed 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 175.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.431 ' HB2' HG22 ' A' ' 16' ' ' VAL . 5.4 m -67.62 124.91 24.58 Favored 'General case' 0 N--CA 1.435 -1.201 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.376 -178.439 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.8 m -71.68 67.83 0.58 Allowed 'General case' 0 C--N 1.314 -0.953 0 C-N-CA 123.547 0.739 . . . . 0.0 111.369 -177.272 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 46.5 m -170.62 -42.45 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 126.207 1.803 . . . . 0.0 106.872 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.431 HG22 ' HB2' ' A' ' 13' ' ' SER . 12.9 m -93.31 159.8 2.75 Favored 'Isoleucine or valine' 0 C--O 1.245 0.848 0 CA-C-N 115.067 -0.97 . . . . 0.0 111.373 -173.048 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 50.1 t -108.25 134.92 48.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 176.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -89.74 -68.28 0.79 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.719 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -171.62 151.93 3.05 Favored 'General case' 0 C--O 1.248 1.004 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.1 61.23 3.81 Favored Glycine 0 N--CA 1.443 -0.871 0 N-CA-C 111.196 -0.762 . . . . 0.0 111.196 177.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -84.93 -34.03 22.58 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.412 ' HB ' ' O ' ' A' ' 25' ' ' ALA . 2.5 p -77.98 79.85 4.43 Favored 'General case' 0 N--CA 1.419 -1.987 0 CA-C-O 122.086 0.946 . . . . 0.0 111.977 -178.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 20.7 p -97.32 -34.05 11.21 Favored 'General case' 0 N--CA 1.424 -1.74 0 CA-C-N 114.57 -1.196 . . . . 0.0 109.834 179.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.3 m -84.38 -24.3 29.74 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 175.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.412 ' O ' ' HB ' ' A' ' 22' ' ' THR . . . -103.25 92.73 4.64 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 175.303 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 16.8 m -60.66 103.67 0.27 Allowed 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.42 -176.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.8 m -85.31 120.99 73.81 Favored Pre-proline 0 N--CA 1.427 -1.597 0 CA-C-N 115.217 -0.901 . . . . 0.0 108.772 -179.224 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -61.88 -53.97 1.82 Allowed 'Trans proline' 0 C--N 1.357 1.02 0 C-N-CA 121.869 1.713 . . . . 0.0 111.572 179.103 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 59.3 -85.17 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 124.756 1.222 . . . . 0.0 112.144 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.4 t -85.63 -19.99 30.15 Favored 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 176.397 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -76.34 165.73 50.56 Favored Pre-proline 0 C--O 1.241 0.639 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 174.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -69.91 101.84 0.98 Allowed 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 122.319 2.012 . . . . 0.0 112.857 -173.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 48.6 t -70.72 -69.92 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.855 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 173.011 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 29.8 m 63.92 -48.43 0.27 Allowed 'General case' 0 CA--C 1.561 1.386 0 C-N-CA 125.433 1.493 . . . . 0.0 114.342 174.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -67.74 78.17 0.2 Allowed Glycine 0 C--N 1.337 0.625 0 C-N-CA 124.0 0.809 . . . . 0.0 111.838 178.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 47.6 m -168.09 -39.53 0.02 OUTLIER 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 103.941 -2.614 . . . . 0.0 103.941 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . 0.41 ' CE2' ' HD3' ' A' ' 47' ' ' LYS . 66.2 m95 -90.54 150.21 21.85 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.788 176.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.429 ' HD3' ' N ' ' A' ' 39' ' ' LYS . 12.4 tmtt? -135.18 137.89 43.13 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 177.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.429 ' N ' ' HD3' ' A' ' 38' ' ' LYS . 2.6 ttmp? -83.3 116.85 22.62 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.477 ' HB3' ' CE1' ' A' ' 46' ' ' TYR . 36.3 p30 -77.98 177.66 8.1 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 177.154 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -65.33 -7.41 13.36 Favored 'General case' 0 C--N 1.317 -0.819 0 C-N-CA 123.527 0.731 . . . . 0.0 112.525 -178.448 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.4 m-85 -102.25 4.27 39.08 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.497 0.665 . . . . 0.0 110.041 -178.514 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 78.44 16.15 79.85 Favored Glycine 0 N--CA 1.447 -0.591 0 CA-C-N 115.511 -0.768 . . . . 0.0 112.086 178.006 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 25.3 m -100.22 132.95 45.3 Favored 'General case' 0 N--CA 1.424 -1.743 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.042 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.407 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 75.1 m95 -87.93 125.31 34.44 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 176.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.477 ' CE1' ' HB3' ' A' ' 40' ' ' ASN . 50.9 p90 -130.31 151.52 50.73 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 121.184 -0.207 . . . . 0.0 111.156 -178.292 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.41 ' HD3' ' CE2' ' A' ' 37' ' ' TRP . 18.1 pttp -146.64 140.91 15.62 Favored Pre-proline 0 C--N 1.313 -0.985 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 173.104 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -79.61 120.96 4.51 Favored 'Trans proline' 0 C--O 1.244 0.8 0 C-N-CA 121.635 1.557 . . . . 0.0 112.559 -179.27 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.8 tt0 -158.14 125.21 4.97 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.063 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.404 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 26.0 t-20 -87.25 121.38 29.62 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.709 -175.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -150.27 169.52 21.17 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 19.9 m -116.14 143.41 45.53 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 -173.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -130.19 126.39 37.31 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 124.062 0.945 . . . . 0.0 108.964 175.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.1 t -111.41 109.01 26.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.671 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 37.9 t30 -77.09 131.27 38.28 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 175.428 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -156.91 83.27 0.15 Allowed Glycine 0 C--N 1.306 -1.103 0 C-N-CA 118.979 -1.581 . . . . 0.0 113.992 -176.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.473 ' HB3' ' OE1' ' A' ' 58' ' ' GLN . 40.3 t30 168.59 -67.86 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 125.269 1.427 . . . . 0.0 109.203 172.577 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.502 ' NE2' ' HB3' ' A' ' 127' ' ' TRP . 4.7 pm0 -111.89 152.24 44.08 Favored Pre-proline 0 C--N 1.304 -1.374 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.266 -175.244 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_exo -73.48 133.98 19.88 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.698 1.598 . . . . 0.0 108.051 170.046 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 61.1 mt -108.1 125.7 64.72 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -176.351 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.4 p -81.05 111.77 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.626 0 CA-C-O 122.066 0.936 . . . . 0.0 108.737 176.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 64.7 p -92.22 164.62 13.48 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.399 -176.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 17.2 mmt180 -105.41 135.49 46.7 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.635 -175.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.4 mt -98.9 125.56 52.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 N-CA-C 112.68 0.622 . . . . 0.0 112.68 -173.762 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.75 -21.87 1.52 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 116.388 1.315 . . . . 0.0 116.388 172.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.401 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 22.1 m -146.84 136.99 12.13 Favored Pre-proline 0 C--N 1.305 -1.335 0 CA-C-N 118.678 1.239 . . . . 0.0 111.063 -177.402 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 66' ' ' SER . 19.3 Cg_endo -90.3 120.43 0.82 Allowed 'Trans proline' 0 N--CA 1.437 -1.804 0 C-N-CA 121.925 1.75 . . . . 0.0 110.971 172.396 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.485 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 51.7 m-85 -167.03 171.45 11.07 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 179.685 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 69.4 mt -84.65 -28.46 26.42 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 107.481 -1.304 . . . . 0.0 107.481 172.418 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -96.68 19.78 11.88 Favored 'General case' 0 CA--C 1.549 0.936 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.294 179.524 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.485 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -71.21 155.28 93.24 Favored Pre-proline 0 C--N 1.315 -0.908 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.505 -176.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_exo -55.89 131.16 44.34 Favored 'Trans proline' 0 C--N 1.353 0.801 0 C-N-CA 123.404 2.736 . . . . 0.0 113.927 -179.726 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.3 m -97.54 174.62 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.259 178.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.66 -0.57 15.65 Favored Glycine 0 CA--C 1.496 -1.105 0 C-N-CA 120.071 -1.061 . . . . 0.0 112.235 178.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -111.43 96.23 0.87 Allowed Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 175.035 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -94.46 118.42 31.61 Favored 'General case' 0 C--N 1.288 -2.071 0 O-C-N 122.186 -0.596 . . . . 0.0 109.967 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 48.4 tp -90.69 117.75 68.18 Favored Pre-proline 0 C--N 1.306 -1.311 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.29 152.51 80.87 Favored 'Trans proline' 0 C--O 1.249 1.061 0 C-N-CA 122.289 1.992 . . . . 0.0 113.029 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.96 135.55 40.04 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 115.142 -0.935 . . . . 0.0 108.982 176.547 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.43 4.91 57.14 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.425 -179.568 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -93.28 130.48 38.99 Favored 'General case' 0 C--O 1.243 0.731 0 CA-C-O 121.151 0.501 . . . . 0.0 111.882 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.2 m -93.28 120.16 33.25 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.239 176.082 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.6 mm -119.94 118.63 57.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.884 -179.138 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 5.0 p -99.48 112.64 32.34 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 175.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.404 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 45.5 p90 -97.2 155.78 16.69 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.536 -173.17 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -115.54 -9.0 12.11 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -175.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -136.88 131.23 32.86 Favored 'General case' 0 C--N 1.309 -1.194 0 C-N-CA 120.531 -0.467 . . . . 0.0 109.755 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 24.2 t -102.02 129.4 53.42 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.752 ' HG ' ' HE2' ' A' ' 108' ' ' TYR . 43.9 m -134.88 145.93 48.73 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-N 117.84 0.291 . . . . 0.0 111.493 -176.406 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 65.1 mt -120.69 116.89 51.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 175.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.596 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -125.89 136.43 53.04 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 105.854 -1.906 . . . . 0.0 105.854 175.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.04 112.65 0.7 Allowed 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -171.132 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 125.43 -32.62 3.86 Favored Glycine 0 N--CA 1.437 -1.294 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.128 179.071 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 61.2 m80 -153.51 168.8 24.94 Favored 'General case' 0 N--CA 1.473 0.714 0 O-C-N 122.005 -0.703 . . . . 0.0 110.581 -176.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.9 tt -100.5 137.79 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.846 0 N-CA-C 103.449 -2.797 . . . . 0.0 103.449 167.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.596 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 69.5 m95 -118.73 136.76 53.78 Favored 'General case' 0 C--N 1.269 -2.913 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -173.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.449 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 48.3 pt -100.72 128.68 52.58 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.148 0 C-N-CA 119.896 -0.722 . . . . 0.0 109.43 177.592 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.33 118.83 6.25 Favored Glycine 0 N--CA 1.419 -2.458 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -142.83 168.68 19.14 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -114.72 138.08 51.15 Favored 'General case' 0 C--N 1.291 -1.967 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 176.322 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -81.98 -177.14 6.48 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.164 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -64.36 -21.67 66.7 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.319 0.581 . . . . 0.0 112.416 -177.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 48.8 t30 -77.74 -8.31 57.78 Favored 'General case' 0 CA--C 1.554 1.134 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.243 176.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 82.73 6.74 88.21 Favored Glycine 0 N--CA 1.461 0.354 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -177.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 43.3 t30 -82.87 133.38 35.13 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 124.067 0.947 . . . . 0.0 109.894 -176.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 16.3 tpp85 -75.29 119.37 19.3 Favored 'General case' 0 C--N 1.316 -0.858 0 O-C-N 123.849 0.718 . . . . 0.0 110.663 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.8 t -124.3 146.63 29.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.752 ' HE2' ' HG ' ' A' ' 89' ' ' CYS . 65.0 m-85 -119.39 131.71 55.71 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 123.477 0.711 . . . . 0.0 110.556 178.204 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 46.7 t -109.76 134.43 20.63 Favored Pre-proline 0 C--N 1.303 -1.454 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -68.7 -19.48 41.48 Favored 'Trans proline' 0 C--N 1.363 1.292 0 C-N-CA 123.135 2.556 . . . . 0.0 114.112 -177.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.296 30.6 m 44.79 -59.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.487 0 N-CA-C 118.394 2.738 . . . . 0.0 118.394 175.159 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.401 ' CB ' ' HA ' ' A' ' 126' ' ' ALA . 6.4 ptp180 -152.68 160.22 43.16 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.38 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.6 p -76.15 140.45 41.76 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.007 176.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 96.4 m -152.46 145.41 24.47 Favored 'General case' 0 CA--C 1.499 -1.019 0 CA-C-O 120.934 0.397 . . . . 0.0 111.177 -179.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -133.56 160.9 36.08 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.28 -1.748 . . . . 0.0 106.28 178.216 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.85 -173.44 21.83 Favored Glycine 0 C--N 1.3 -1.429 0 C-N-CA 118.596 -1.764 . . . . 0.0 113.939 175.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 21.1 m -138.24 123.88 12.51 Favored Pre-proline 0 C--N 1.311 -1.097 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.231 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.487 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 78.0 Cg_exo -46.53 128.43 12.69 Favored 'Trans proline' 0 CA--C 1.543 0.937 0 C-N-CA 123.521 2.814 . . . . 0.0 113.05 -178.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.487 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 91.7 Cg_endo -93.67 3.31 55.67 Favored 'Cis proline' 0 CA--C 1.551 1.373 0 N-CA-C 115.239 1.207 . . . . 0.0 115.239 5.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -78.71 102.27 7.98 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 122.199 1.0 . . . . 0.0 110.691 -176.359 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.429 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 35.6 p-80 -105.19 121.77 44.51 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-N 114.012 -1.449 . . . . 0.0 110.958 -177.454 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.4 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 58.3 mt -102.08 100.67 15.73 Favored Pre-proline 0 C--N 1.305 -1.36 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.094 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 121' ' ' HIS . 63.7 Cg_endo -85.7 135.14 4.86 Favored 'Trans proline' 0 CA--C 1.544 0.981 0 C-N-CA 122.872 2.381 . . . . 0.0 114.209 -177.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -112.11 -151.97 11.7 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 175.294 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 90.4 t -52.63 124.49 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.336 0 C-N-CA 123.938 0.895 . . . . 0.0 112.535 -178.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.401 ' HA ' ' CB ' ' A' ' 112' ' ' ARG . . . -93.77 143.7 26.09 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.871 175.29 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . 0.502 ' HB3' ' NE2' ' A' ' 58' ' ' GLN . 5.3 m-90 -105.47 17.24 24.21 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.327 0.584 . . . . 0.0 110.986 178.347 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -165.57 -170.43 30.5 Favored Glycine 0 N--CA 1.429 -1.804 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.171 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 98.8 t -111.23 133.04 58.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -178.171 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -104.43 127.6 52.14 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.4 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 14.7 tppt? . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 42.8 m . . . . . 0 CA--C 1.539 0.546 0 N-CA-C 108.798 -0.815 . . . . 0.0 108.798 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -80.51 -80.17 0.14 Allowed 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 112.957 0.725 . . . . 0.0 112.957 -176.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -124.25 19.11 9.04 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 120.856 0.36 . . . . 0.0 110.938 -174.401 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 60.6 tttm 64.34 12.64 7.4 Favored 'General case' 0 CA--C 1.557 1.233 0 C-N-CA 123.978 0.911 . . . . 0.0 111.92 177.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -91.41 85.22 5.72 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.639 0.733 . . . . 0.0 109.491 179.537 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -133.86 24.45 3.96 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 107.278 -1.378 . . . . 0.0 107.278 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 48.3 ttm -139.8 141.71 36.74 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 113.902 -1.499 . . . . 0.0 107.386 -179.507 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -96.5 157.39 15.92 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 178.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.5 pttm -126.24 72.05 1.29 Allowed 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.24 1.019 . . . . 0.0 111.254 176.229 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 80.66 -80.99 1.62 Allowed Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.473 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 6.3 t -124.94 104.2 8.45 Favored 'General case' 0 N--CA 1.418 -2.066 0 CA-C-O 122.348 1.07 . . . . 0.0 109.537 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.5 m -126.17 93.36 3.79 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 106.519 -1.66 . . . . 0.0 106.519 176.46 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.0 m -47.32 -36.16 9.0 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 115.21 1.559 . . . . 0.0 115.21 -171.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.1 m -78.35 -46.95 18.74 Favored 'General case' 0 C--N 1.31 -1.125 0 C-N-CA 120.051 -0.66 . . . . 0.0 110.696 178.61 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 21.9 m -67.34 -32.81 74.01 Favored 'General case' 0 CA--C 1.547 0.855 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -177.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 17.6 m -82.64 -5.48 9.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 O-C-N 122.291 -0.255 . . . . 0.0 110.945 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.0 t 60.63 74.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.243 0.749 0 C-N-CA 124.604 1.161 . . . . 0.0 110.001 -177.527 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 75.46 116.08 0.06 Allowed 'General case' 0 C--O 1.236 0.367 0 CA-C-N 114.191 -1.368 . . . . 0.0 112.059 -178.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -109.76 148.94 30.54 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.168 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -110.24 0.15 29.73 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 119.901 -1.142 . . . . 0.0 112.909 -177.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 34.8 mtmm -90.23 -51.04 5.65 Favored 'General case' 0 C--N 1.312 -1.027 0 O-C-N 122.296 -0.532 . . . . 0.0 111.395 -177.303 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 13.3 t -118.75 114.04 22.07 Favored 'General case' 0 N--CA 1.428 -1.547 0 CA-C-O 122.234 1.016 . . . . 0.0 110.677 179.4 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.8 p -129.58 165.39 21.82 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 114.726 -1.124 . . . . 0.0 110.169 -175.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.3 m -68.79 123.28 20.51 Favored 'General case' 0 C--O 1.252 1.199 0 C-N-CA 122.221 0.208 . . . . 0.0 110.648 -178.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 57.81 26.58 13.36 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 124.808 1.243 . . . . 0.0 111.871 177.615 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 28.0 m 65.79 -78.26 0.04 OUTLIER 'General case' 0 C--O 1.245 0.864 0 C-N-CA 124.344 1.058 . . . . 0.0 110.69 -175.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.9 t -155.28 87.3 3.24 Favored Pre-proline 0 N--CA 1.434 -1.273 0 N-CA-C 114.498 1.296 . . . . 0.0 114.498 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -97.88 4.2 1.39 Allowed 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 122.926 2.417 . . . . 0.0 108.477 164.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 52.93 -97.34 0.06 Allowed 'General case' 0 N--CA 1.447 -0.596 0 C-N-CA 126.066 1.746 . . . . 0.0 111.317 -174.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.6 m -143.71 25.01 1.67 Allowed 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 177.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 38.6 ttt180 -60.76 -55.31 46.05 Favored Pre-proline 0 C--N 1.346 0.445 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.618 178.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -78.81 92.25 1.15 Allowed 'Trans proline' 0 N--CA 1.441 -1.559 0 CA-C-N 120.192 1.104 . . . . 0.0 109.402 169.489 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 13.7 p -66.63 -41.9 88.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.961 0.41 . . . . 0.0 111.205 -176.307 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.7 t -108.17 -26.3 10.66 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 121.369 0.604 . . . . 0.0 110.36 178.696 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.78 128.47 6.03 Favored Glycine 0 N--CA 1.433 -1.551 0 C-N-CA 120.99 -0.624 . . . . 0.0 111.593 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 10.5 t 75.29 -40.58 0.43 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.43 1.492 . . . . 0.0 111.952 177.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . 0.525 ' CE2' ' HD2' ' A' ' 47' ' ' LYS . 86.2 m95 -70.28 138.4 51.54 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 177.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 53.5 mtmt -135.49 148.92 49.38 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 175.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -88.08 125.86 34.8 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.57 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 55.1 t30 -93.78 169.36 10.36 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 123.687 0.795 . . . . 0.0 110.545 -176.618 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -47.66 -34.81 8.54 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.926 2.091 . . . . 0.0 113.005 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -88.21 7.55 31.39 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.113 0.482 . . . . 0.0 111.703 -175.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.87 -13.02 60.15 Favored Glycine 0 CA--C 1.507 -0.462 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.453 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 5.3 m -71.84 137.09 47.27 Favored 'General case' 0 N--CA 1.42 -1.965 0 C-N-CA 124.55 1.14 . . . . 0.0 110.413 -177.79 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.4 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 66.5 m95 -90.03 133.75 34.65 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 173.549 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.57 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 8.6 p90 -132.3 149.12 52.43 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.865 -177.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.525 ' HD2' ' CE2' ' A' ' 37' ' ' TRP . 21.9 ptmt -137.19 146.85 56.05 Favored Pre-proline 0 C--N 1.305 -1.328 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 175.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -77.02 121.85 5.99 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.057 1.838 . . . . 0.0 109.862 173.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -157.98 120.86 3.86 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -178.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.488 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 4.9 t30 -103.35 117.03 33.56 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 -177.009 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.422 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -152.93 -177.9 6.57 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.525 ' HB ' ' HB3' ' A' ' 131' ' ' LYS . 32.3 m -118.05 152.68 35.07 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 120.627 0.251 . . . . 0.0 110.577 -177.044 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.498 ' CZ ' ' HA3' ' A' ' 128' ' ' GLY . 92.5 t80 -134.61 132.65 39.27 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 177.606 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.1 t -115.56 127.77 73.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.457 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -65.16 135.72 55.82 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.085 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -73.82 -90.91 0.15 Allowed Glycine 0 N--CA 1.44 -1.067 0 O-C-N 123.654 0.596 . . . . 0.0 113.804 -175.545 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -109.72 -47.03 3.41 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 114.097 1.147 . . . . 0.0 114.097 -174.528 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -116.95 152.25 48.44 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -174.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.47 ' HB3' HD21 ' A' ' 76' ' ' ASN . 51.9 Cg_exo -57.13 137.46 81.93 Favored 'Trans proline' 0 C--O 1.242 0.699 0 C-N-CA 122.856 2.37 . . . . 0.0 112.106 178.434 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 59.9 mt -108.98 125.85 66.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 -176.266 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 33.6 m -72.93 148.43 9.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 175.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 35.9 p -127.15 163.01 24.78 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 110.337 -0.245 . . . . 0.0 110.337 -175.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -110.18 141.85 42.53 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -178.523 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.7 mt -94.1 119.01 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.493 -175.561 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 72.18 -22.95 0.75 Allowed Glycine 0 CA--C 1.529 0.922 0 N-CA-C 117.273 1.669 . . . . 0.0 117.273 170.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.3 m -141.32 136.35 15.71 Favored Pre-proline 0 C--N 1.297 -1.69 0 CA-C-N 118.958 1.379 . . . . 0.0 110.862 -178.417 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -89.64 119.53 0.88 Allowed 'Trans proline' 0 N--CA 1.433 -2.055 0 C-N-CA 121.325 1.35 . . . . 0.0 110.47 172.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.458 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 72.0 m-85 -169.37 169.46 9.02 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 127.954 2.502 . . . . 0.0 104.61 -179.295 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -90.13 -17.87 26.86 Favored 'General case' 0 C--N 1.293 -1.879 0 CA-C-O 121.222 0.534 . . . . 0.0 110.75 175.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 27.8 p-10 -106.7 20.32 19.19 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.801 0.81 . . . . 0.0 109.665 177.303 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.458 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -72.59 156.4 90.18 Favored Pre-proline 0 C--O 1.25 1.101 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.734 179.022 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -54.58 122.97 12.52 Favored 'Trans proline' 0 C--N 1.357 1.024 0 C-N-CA 122.922 2.414 . . . . 0.0 112.372 -179.452 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.414 HG22 ' H ' ' A' ' 74' ' ' GLY . 8.5 p -103.45 174.24 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-N 114.916 -1.038 . . . . 0.0 108.235 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.414 ' H ' HG22 ' A' ' 73' ' ' VAL . . . 119.9 -6.43 12.26 Favored Glycine 0 CA--C 1.494 -1.258 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -178.383 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.23 131.55 10.62 Favored Glycine 0 N--CA 1.429 -1.773 0 N-CA-C 108.399 -1.88 . . . . 0.0 108.399 173.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.47 HD21 ' HB3' ' A' ' 59' ' ' PRO . 9.2 t30 -126.98 141.38 51.81 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 118.113 0.956 . . . . 0.0 111.564 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 51.5 tp -104.18 114.72 64.09 Favored Pre-proline 0 C--N 1.309 -1.171 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 176.09 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -62.7 160.42 32.76 Favored 'Trans proline' 0 C--O 1.243 0.75 0 C-N-CA 123.072 2.515 . . . . 0.0 112.81 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.67 137.49 46.06 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.327 -178.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 76.32 19.6 78.1 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.804 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -85.72 140.12 30.78 Favored 'General case' 0 C--N 1.317 -0.814 0 O-C-N 122.554 -0.38 . . . . 0.0 110.346 178.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 40.5 m -111.68 108.73 18.28 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.8 mm -116.52 136.51 53.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 122.889 0.475 . . . . 0.0 110.565 -175.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.4 p -102.92 128.24 55.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 174.46 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.488 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 42.5 p90 -117.63 157.74 25.88 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.559 -175.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -121.26 -5.99 9.39 Favored 'General case' 0 C--O 1.247 0.972 0 O-C-N 123.653 0.595 . . . . 0.0 111.261 -178.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -133.71 126.88 31.67 Favored 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -173.624 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.0 t -114.1 127.37 71.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 177.74 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.453 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 63.0 m -129.68 150.51 50.97 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 122.983 0.177 . . . . 0.0 111.469 -176.039 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 45.0 mt -121.28 117.29 52.3 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 172.526 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.409 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -111.39 144.46 40.56 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 104.261 -2.496 . . . . 0.0 104.261 173.185 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -50.8 104.07 0.07 Allowed 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -170.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 115.77 -23.94 10.58 Favored Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.471 -0.786 . . . . 0.0 113.677 178.304 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . 0.442 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 50.8 m80 -147.77 145.55 28.84 Favored 'General case' 0 CA--C 1.505 -0.786 0 O-C-N 121.559 -0.965 . . . . 0.0 112.204 -177.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.423 HG23 HG23 ' A' ' 111' ' ' VAL . 14.5 tt -93.9 139.01 19.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 105.552 -2.018 . . . . 0.0 105.552 173.692 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.409 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 74.5 m95 -124.02 139.01 54.36 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -174.563 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.448 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.3 pt -102.46 132.22 48.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 173.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -104.48 124.68 8.1 Favored Glycine 0 N--CA 1.425 -2.053 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -179.691 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -138.55 155.56 48.27 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 178.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -97.99 120.33 38.19 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 176.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.31 161.55 20.4 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -58.41 -14.09 6.9 Favored 'General case' 0 N--CA 1.483 1.212 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.245 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -77.62 -13.56 59.87 Favored 'General case' 0 CA--C 1.548 0.895 0 CA-C-O 121.5 0.667 . . . . 0.0 110.713 177.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 87.64 15.9 60.93 Favored Glycine 0 CA--C 1.497 -1.079 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -176.219 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 39.4 t-20 -97.1 132.82 42.51 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 114.239 -0.98 . . . . 0.0 109.226 -177.573 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 25.9 tpt180 -90.17 99.06 12.15 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 175.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 36.8 t -100.32 142.42 15.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.989 -173.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 81.5 m-85 -115.23 129.38 56.62 Favored 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 123.081 0.552 . . . . 0.0 110.223 178.23 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.1 t -108.32 133.45 20.56 Favored Pre-proline 0 C--N 1.306 -1.303 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.288 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.56 -10.06 24.8 Favored 'Trans proline' 0 C--N 1.364 1.344 0 C-N-CA 123.397 2.731 . . . . 0.0 114.729 -174.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.423 HG23 HG23 ' A' ' 95' ' ' ILE 0.293 27.2 m 38.19 -67.26 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 N-CA-C 118.026 2.602 . . . . 0.0 118.026 175.0 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.486 ' HE ' ' HB2' ' A' ' 126' ' ' ALA . 6.3 ptp85 -147.44 148.81 31.67 Favored 'General case' 0 N--CA 1.445 -0.7 0 C-N-CA 123.239 0.616 . . . . 0.0 109.603 176.078 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.442 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 66.8 m -67.95 133.98 50.0 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 176.386 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 86.3 m -151.34 103.82 3.03 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 122.886 0.474 . . . . 0.0 110.363 -179.173 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 45.8 mt-30 -88.85 141.14 28.75 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.193 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 139.7 178.04 16.31 Favored Glycine 0 N--CA 1.42 -2.386 0 C-N-CA 119.015 -1.564 . . . . 0.0 113.273 178.449 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 87.0 t -133.31 130.61 21.22 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 179.182 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.411 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 66.3 Cg_exo -43.46 132.51 7.1 Favored 'Trans proline' 0 CA--C 1.548 1.195 0 C-N-CA 123.44 2.76 . . . . 0.0 113.456 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.411 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 43.1 Cg_endo -89.31 -5.98 51.67 Favored 'Cis proline' 0 CA--C 1.541 0.826 0 C-N-CA 123.373 -1.511 . . . . 0.0 114.832 4.234 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -76.51 100.65 5.34 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-O 122.161 0.981 . . . . 0.0 112.409 -173.588 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 28.7 p-80 -105.43 126.57 52.27 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 113.845 -1.525 . . . . 0.0 111.007 178.509 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.564 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 60.7 mt -100.6 104.39 30.52 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 174.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -76.97 123.65 6.9 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.564 2.176 . . . . 0.0 113.171 -175.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -108.51 -141.86 9.76 Favored Glycine 0 N--CA 1.424 -2.12 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.586 177.242 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 67.0 t -75.21 122.28 28.57 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 C-N-CA 122.948 0.499 . . . . 0.0 111.996 -176.623 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.486 ' HB2' ' HE ' ' A' ' 112' ' ' ARG . . . -93.23 143.36 26.33 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.719 173.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.8 m-90 -106.03 14.61 27.61 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.951 0.881 . . . . 0.0 109.686 177.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.498 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -162.13 177.61 38.26 Favored Glycine 0 N--CA 1.407 -3.251 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.491 -179.426 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 57.5 t -111.52 118.82 58.45 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.192 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 -177.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 41.8 m-85 -78.74 132.77 37.08 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.525 ' HB3' ' HB ' ' A' ' 52' ' ' THR . 53.9 tptt . . . . . 0 N--CA 1.404 -2.767 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 19.4 m . . . . . 0 N--CA 1.446 -0.669 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 54.3 t30 -87.31 -75.01 0.42 Allowed 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.336 -176.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -98.34 -28.56 13.6 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-O 121.436 0.636 . . . . 0.0 110.865 -175.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -92.52 79.48 4.9 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 121.673 0.749 . . . . 0.0 109.503 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 42.0 t30 -166.63 138.48 3.55 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 106.584 -1.635 . . . . 0.0 106.584 178.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -130.05 137.03 50.02 Favored 'General case' 0 C--N 1.295 -1.784 0 C-N-CA 120.592 -0.443 . . . . 0.0 111.358 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 84.9 mtp -81.23 -38.27 27.22 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 174.228 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 37.0 t70 51.05 81.5 0.07 Allowed 'General case' 0 CA--C 1.516 -0.36 0 C-N-CA 125.46 1.504 . . . . 0.0 113.553 177.455 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 27.6 mmtp -145.2 86.94 1.79 Allowed 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.814 174.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.47 -35.09 18.04 Favored Glycine 0 N--CA 1.434 -1.455 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 175.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.4 m -91.35 102.65 15.34 Favored 'General case' 0 N--CA 1.427 -1.613 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.377 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.8 p -72.55 -42.44 64.67 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 122.149 0.976 . . . . 0.0 109.702 178.303 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 4.5 p -146.8 136.39 22.98 Favored 'General case' 0 N--CA 1.422 -1.828 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.227 178.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.8 p -103.59 104.61 14.69 Favored 'General case' 0 C--N 1.309 -1.152 0 N-CA-C 114.573 1.323 . . . . 0.0 114.573 -173.046 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 12.9 m 60.17 31.03 20.37 Favored 'General case' 0 CA--C 1.564 1.507 0 C-N-CA 124.383 1.073 . . . . 0.0 112.443 172.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.1 p -86.88 86.13 2.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 O-C-N 120.916 -1.115 . . . . 0.0 110.401 179.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.9 m -96.27 -12.81 8.34 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.473 178.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.507 ' HA ' ' HE2' ' A' ' 18' ' ' LYS . 0.2 OUTLIER -149.21 139.02 21.9 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 -179.255 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -92.22 24.35 3.39 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 122.792 0.437 . . . . 0.0 109.867 178.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.419 ' HA2' ' HB3' ' A' ' 25' ' ' ALA . . . -80.95 49.13 3.9 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -179.585 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 56.2 mtpt -140.31 -170.09 2.9 Favored 'General case' 0 C--N 1.288 -2.067 0 N-CA-C 105.804 -1.925 . . . . 0.0 105.804 -175.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.3 m -75.41 88.36 2.61 Favored 'General case' 0 N--CA 1.428 -1.554 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 174.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 55.0 m -157.99 -50.27 0.07 Allowed 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.178 -177.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.8 t -158.87 -41.29 0.06 Allowed 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 120.032 -0.667 . . . . 0.0 111.908 -178.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.419 ' HB3' ' HA2' ' A' ' 20' ' ' GLY . . . -62.1 -36.72 82.57 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 113.699 1.0 . . . . 0.0 113.699 -175.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 19.8 m -81.07 108.64 14.91 Favored 'General case' 0 C--O 1.248 1.015 0 CA-C-O 121.238 0.542 . . . . 0.0 111.121 -178.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.4 p -82.99 150.67 62.11 Favored Pre-proline 0 N--CA 1.436 -1.149 0 CA-C-N 115.298 -0.865 . . . . 0.0 111.618 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -75.57 85.64 1.57 Allowed 'Trans proline' 0 N--CA 1.451 -1.024 0 C-N-CA 122.791 2.327 . . . . 0.0 113.626 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -89.67 -14.26 35.2 Favored 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 170.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.421 ' O ' ' HD2' ' A' ' 32' ' ' PRO . 10.1 t -174.39 -172.69 0.7 Allowed 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 103.65 -2.722 . . . . 0.0 103.65 179.412 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.419 ' HB2' ' HD3' ' A' ' 32' ' ' PRO 0.349 10.5 mmt180 86.5 -91.02 0.0 OUTLIER Pre-proline 0 CA--C 1.565 1.521 0 C-N-CA 125.294 1.437 . . . . 0.0 113.667 -179.881 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.421 ' HD2' ' O ' ' A' ' 30' ' ' THR . 98.0 Cg_endo -82.84 33.66 0.53 Allowed 'Trans proline' 0 C--N 1.384 2.435 0 CA-C-N 123.104 2.144 . . . . 0.0 112.133 -178.555 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.2 m -80.68 4.18 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.718 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 12.0 p -73.15 -37.99 66.39 Favored 'General case' 0 N--CA 1.423 -1.819 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.443 176.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 56.07 -95.72 0.04 OUTLIER Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.319 -0.855 . . . . 0.0 114.261 175.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 21.8 t -77.58 -23.3 49.98 Favored 'General case' 0 C--N 1.311 -1.089 0 C-N-CA 123.603 0.761 . . . . 0.0 109.923 -178.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -77.74 117.23 18.93 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.965 0.412 . . . . 0.0 110.419 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 8.3 tmtm? -118.44 133.46 55.85 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -81.67 128.74 34.28 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 120.91 0.386 . . . . 0.0 111.723 -176.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -96.67 166.08 11.83 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 176.136 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -51.65 -27.79 12.56 Favored 'General case' 0 N--CA 1.489 1.485 0 C-N-CA 125.184 1.394 . . . . 0.0 113.082 -176.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 69.0 m-85 -87.5 10.11 18.76 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 121.498 0.666 . . . . 0.0 111.535 -175.445 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.54 14.36 82.1 Favored Glycine 0 CA--C 1.5 -0.89 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 178.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.551 HG22 ' HB2' ' A' ' 89' ' ' CYS . 6.8 m -96.14 127.7 42.38 Favored 'General case' 0 N--CA 1.409 -2.517 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -177.334 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 71.8 m95 -95.31 120.99 36.5 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.092 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -120.14 148.69 43.32 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.106 -177.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.1 pttm -134.95 151.4 75.45 Favored Pre-proline 0 C--N 1.305 -1.342 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -71.88 132.51 20.1 Favored 'Trans proline' 0 N--CA 1.45 -1.043 0 C-N-CA 121.678 1.585 . . . . 0.0 111.471 175.523 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -159.16 120.61 3.34 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 176.098 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.442 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 3.7 t-20 -107.39 115.73 30.68 Favored 'General case' 0 C--N 1.295 -1.783 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.328 -175.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -160.94 178.63 9.2 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.241 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 17.4 m -116.82 151.98 35.38 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -178.539 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.4 t80 -124.95 127.96 47.86 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 175.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 46.6 t -112.27 112.69 41.57 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.037 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 55.3 t30 -65.72 136.25 56.01 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.2 -179.026 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -119.07 -83.19 0.84 Allowed Glycine 0 N--CA 1.43 -1.739 0 N-CA-C 115.77 1.068 . . . . 0.0 115.77 -170.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -79.07 -23.28 44.31 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 115.365 1.617 . . . . 0.0 115.365 -166.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.439 HE21 ' HB2' ' A' ' 58' ' ' GLN . 0.0 OUTLIER -152.79 150.1 23.72 Favored Pre-proline 0 C--N 1.311 -1.102 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.277 -178.833 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 58' ' ' GLN . 16.5 Cg_exo -68.37 131.24 22.82 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.369 2.046 . . . . 0.0 109.739 177.536 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 51.2 mt -106.81 127.52 62.28 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.828 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -171.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -81.5 138.03 20.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 178.08 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 50.9 p -110.51 170.11 8.3 Favored 'General case' 0 C--N 1.295 -1.791 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.751 -174.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -117.29 138.12 51.96 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.185 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.7 mt -99.09 125.68 52.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.889 -174.086 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.39 -22.93 3.58 Favored Glycine 0 N--CA 1.448 -0.534 0 N-CA-C 115.772 1.069 . . . . 0.0 115.772 172.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.5 m -152.3 138.1 11.5 Favored Pre-proline 0 C--N 1.297 -1.696 0 CA-C-N 118.074 0.937 . . . . 0.0 110.065 -177.694 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -89.84 120.87 0.95 Allowed 'Trans proline' 0 N--CA 1.44 -1.674 0 C-N-CA 121.64 1.56 . . . . 0.0 111.008 173.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.524 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 93.5 m-85 -168.58 166.24 12.03 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 127.246 2.218 . . . . 0.0 105.021 179.174 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 96.5 mt -82.01 -19.74 39.83 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-O 121.357 0.598 . . . . 0.0 109.994 175.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -111.02 19.69 18.21 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.294 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.524 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -73.38 156.88 88.69 Favored Pre-proline 0 C--O 1.249 1.05 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.573 -178.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -46.97 127.36 12.32 Favored 'Trans proline' 0 C--N 1.365 1.404 0 C-N-CA 123.754 2.969 . . . . 0.0 113.806 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 10.9 p -99.89 172.71 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-N 114.304 -1.316 . . . . 0.0 107.95 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.91 11.55 7.6 Favored Glycine 0 C--N 1.318 -0.469 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -177.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -137.1 121.11 2.25 Favored Glycine 0 N--CA 1.423 -2.228 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 175.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -126.17 141.54 51.89 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 117.519 0.66 . . . . 0.0 109.899 -178.266 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 27.4 tp -101.41 113.61 65.8 Favored Pre-proline 0 N--CA 1.429 -1.48 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.21 166.72 22.32 Favored 'Trans proline' 0 C--O 1.249 1.033 0 C-N-CA 122.272 1.981 . . . . 0.0 113.32 -177.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.15 128.64 36.32 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.225 179.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.99 -5.34 61.47 Favored Glycine 0 N--CA 1.445 -0.717 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.873 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.84 128.55 36.72 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.013 0.435 . . . . 0.0 111.22 -179.199 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 44.3 m -104.08 111.55 24.17 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.593 -179.574 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 46.6 mm -116.99 130.27 72.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.28 -176.314 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.2 p -99.11 139.34 21.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 174.71 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 46.2 p90 -135.3 158.16 45.08 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.802 -176.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -128.34 -0.39 5.69 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.589 177.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -129.64 127.8 41.32 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.06 -178.236 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.6 t -123.66 126.94 73.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.551 ' HB2' HG22 ' A' ' 44' ' ' THR . 27.2 p -135.84 148.46 48.68 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -174.24 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 68.8 mt -106.03 121.96 59.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.996 178.123 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.449 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.9 tp-100 -125.7 144.85 50.43 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 173.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -51.05 107.23 0.16 Allowed 'General case' 0 C--N 1.317 -0.805 0 O-C-N 123.51 0.506 . . . . 0.0 111.535 -177.3 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 129.7 -41.62 1.52 Allowed Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.117 178.694 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . 0.502 ' CD2' ' HA ' ' A' ' 113' ' ' THR . 69.9 m80 -154.16 166.02 34.42 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 117.294 0.547 . . . . 0.0 110.915 -175.524 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.8 tt -105.26 110.15 30.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 173.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.524 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 45.2 m95 -96.74 142.66 28.5 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.784 -168.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.8 pt -100.2 134.22 40.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 174.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -101.96 124.63 8.27 Favored Glycine 0 N--CA 1.424 -2.158 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -149.72 169.92 19.93 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-O 121.018 0.437 . . . . 0.0 109.832 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -104.33 143.13 33.4 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.611 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -94.43 159.32 15.16 Favored 'General case' 0 C--N 1.291 -1.964 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 173.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -54.12 -21.92 9.83 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -179.064 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 11.4 t30 -92.59 7.31 43.87 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-O 121.973 0.892 . . . . 0.0 110.738 -177.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 83.02 13.41 77.53 Favored Glycine 0 C--N 1.321 -0.251 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.677 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 18.7 m120 -83.72 141.05 31.73 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.818 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 30.2 tpt180 -89.83 106.27 18.36 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 176.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.3 t -112.6 138.26 42.44 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 C-N-CA 119.895 -0.722 . . . . 0.0 110.512 -173.766 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.413 ' HE1' ' HG ' ' A' ' 89' ' ' CYS . 63.8 m-85 -117.17 126.8 53.36 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.452 -0.794 . . . . 0.0 110.002 176.643 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 48.7 t -109.07 130.63 22.5 Favored Pre-proline 0 C--N 1.304 -1.4 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -68.89 -22.26 36.49 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 122.819 2.346 . . . . 0.0 114.133 -176.423 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.298 34.4 m 49.3 -54.9 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.579 0 N-CA-C 117.771 2.508 . . . . 0.0 117.771 177.045 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -150.77 143.42 24.46 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 123.464 0.706 . . . . 0.0 109.67 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.502 ' HA ' ' CD2' ' A' ' 94' ' ' HIS . 69.1 m -71.61 127.87 33.96 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.732 178.443 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.511 ' SG ' ' HA ' ' A' ' 123' ' ' PRO . 94.5 m -149.49 140.51 22.93 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.06 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -125.12 153.99 42.14 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 105.788 -1.93 . . . . 0.0 105.788 178.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.84 -168.6 31.19 Favored Glycine 0 CA--C 1.483 -1.919 0 C-N-CA 118.633 -1.746 . . . . 0.0 112.275 178.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 65.6 t -138.82 121.52 10.63 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 179.134 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 88.5 Cg_exo -48.03 136.23 23.64 Favored 'Trans proline' 0 C--O 1.238 0.517 0 C-N-CA 123.175 2.583 . . . . 0.0 111.952 -179.501 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 90.8 Cg_endo -95.32 25.04 23.18 Favored 'Cis proline' 0 CA--C 1.548 1.193 0 C-N-CA 124.461 -1.058 . . . . 0.0 114.043 3.674 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -106.15 106.02 16.34 Favored 'General case' 0 C--N 1.315 -0.928 0 O-C-N 121.789 -0.57 . . . . 0.0 111.274 -178.383 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 25.2 p-80 -104.17 139.85 38.65 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.175 176.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 44.7 mm -104.02 107.4 56.9 Favored Pre-proline 0 C--N 1.293 -1.852 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.511 ' HA ' ' SG ' ' A' ' 114' ' ' CYS . 86.0 Cg_endo -79.57 147.57 19.94 Favored 'Trans proline' 0 C--O 1.247 0.933 0 C-N-CA 122.623 2.215 . . . . 0.0 113.989 -175.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -131.49 -124.73 2.6 Favored Glycine 0 N--CA 1.428 -1.854 0 CA-C-N 115.415 -0.812 . . . . 0.0 111.266 176.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.0 t -85.62 121.37 37.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -175.424 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.38 151.23 19.55 Favored 'General case' 0 C--O 1.246 0.894 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.158 173.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . 0.421 ' HH2' ' HE2' ' A' ' 94' ' ' HIS . 5.5 m-90 -109.1 6.54 25.02 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 179.536 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -160.82 -171.74 27.18 Favored Glycine 0 N--CA 1.428 -1.899 0 C-N-CA 120.64 -0.79 . . . . 0.0 111.271 -178.153 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 44.0 t -111.7 131.97 61.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -174.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -91.9 137.46 32.34 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 176.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt . . . . . 0 C--N 1.288 -2.078 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.684 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 14.6 m . . . . . 0 N--CA 1.438 -1.067 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 60.8 t30 -62.6 -40.97 98.62 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.349 0.595 . . . . 0.0 109.446 178.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -128.47 117.95 22.24 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.665 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 34.0 mmtp 66.22 178.24 0.21 Allowed 'General case' 0 C--O 1.242 0.663 0 CA-C-O 122.134 0.969 . . . . 0.0 112.961 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 29.1 p-10 -142.03 16.27 2.1 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 174.415 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 53.3 t80 -141.36 116.67 10.08 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 114.146 -1.388 . . . . 0.0 108.794 -173.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 53.0 ttm -103.64 132.99 49.4 Favored 'General case' 0 C--N 1.293 -1.868 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 175.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -67.12 -30.06 69.96 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 120.411 -0.516 . . . . 0.0 110.894 -178.334 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -91.3 96.61 10.64 Favored 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 174.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -127.86 54.81 0.77 Allowed Glycine 0 N--CA 1.43 -1.712 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -178.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 89.4 m -146.58 106.66 4.0 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.48 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.1 m -66.48 104.23 1.21 Allowed 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 173.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.1 m -65.25 107.26 1.54 Allowed 'General case' 0 N--CA 1.435 -1.178 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.427 -173.452 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 42.4 m 69.96 -18.9 0.21 Allowed 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 125.303 1.441 . . . . 0.0 114.263 177.256 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.5 m -84.11 97.59 9.42 Favored 'General case' 0 N--CA 1.434 -1.23 0 CA-C-O 120.923 0.392 . . . . 0.0 110.581 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 31.6 m -125.46 -37.39 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.884 178.034 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.0 m -143.18 164.34 16.06 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -178.606 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.6 tttp -110.38 76.76 1.0 Allowed 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 106.062 -1.829 . . . . 0.0 106.062 173.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -76.72 -35.51 57.77 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 113.555 -1.657 . . . . 0.0 113.92 -170.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -101.63 145.48 16.8 Favored Glycine 0 N--CA 1.436 -1.35 0 C-N-CA 119.867 -1.159 . . . . 0.0 115.838 -171.089 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.4 tttm 59.58 64.76 1.26 Allowed 'General case' 0 C--O 1.245 0.822 0 C-N-CA 126.055 1.742 . . . . 0.0 111.944 174.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 23.6 m -116.18 -2.83 12.09 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-N 114.376 -1.284 . . . . 0.0 108.468 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 88.7 p 62.29 -87.61 0.02 OUTLIER 'General case' 0 C--O 1.236 0.369 0 C-N-CA 126.609 1.964 . . . . 0.0 110.166 -173.048 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 49.2 m -161.7 -70.04 0.06 Allowed 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 123.731 0.812 . . . . 0.0 109.244 175.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 174.92 -164.38 0.03 OUTLIER 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 -177.353 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.3 p -70.6 -12.52 61.62 Favored 'General case' 0 CA--C 1.548 0.896 0 CA-C-O 121.521 0.677 . . . . 0.0 111.194 175.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 21.5 m -108.33 99.47 32.52 Favored Pre-proline 0 N--CA 1.436 -1.139 0 N-CA-C 106.189 -1.782 . . . . 0.0 106.189 171.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -90.66 -26.03 0.36 Allowed 'Trans proline' 0 N--CA 1.452 -0.92 0 N-CA-C 117.228 1.972 . . . . 0.0 117.228 -172.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 64.6 36.11 8.69 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -173.305 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 m 60.72 83.9 0.14 Allowed 'General case' 0 CA--C 1.549 0.917 0 CA-C-N 114.151 -1.386 . . . . 0.0 111.818 -178.028 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -132.12 -64.89 0.02 OUTLIER Pre-proline 0 CA--C 1.544 0.713 0 N-CA-C 112.818 0.673 . . . . 0.0 112.818 -178.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.26 -20.3 32.65 Favored 'Trans proline' 0 C--N 1.373 1.833 0 CA-C-N 120.692 1.283 . . . . 0.0 111.431 177.305 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.4 t 73.42 68.68 0.06 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-O 123.143 1.449 . . . . 0.0 109.925 -178.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.0 p -102.41 80.07 1.9 Allowed 'General case' 0 N--CA 1.408 -2.548 0 CA-C-N 113.382 -1.736 . . . . 0.0 109.742 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -87.8 -53.53 2.7 Favored Glycine 0 N--CA 1.43 -1.751 0 CA-C-N 115.298 -0.865 . . . . 0.0 111.127 -178.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.7 m -89.55 -28.56 19.51 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 178.624 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -78.35 127.38 32.13 Favored 'General case' 0 N--CA 1.442 -0.841 0 CA-C-O 121.551 0.691 . . . . 0.0 111.791 -177.072 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.6 tmtt? -130.3 140.98 50.63 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.334 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -85.84 146.16 26.88 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.396 0.617 . . . . 0.0 112.371 -173.049 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 48.2 t-20 -109.75 153.83 23.78 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 124.988 1.315 . . . . 0.0 107.622 178.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 7.9 tt0 -53.88 -26.5 25.18 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 125.443 1.497 . . . . 0.0 112.48 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -75.3 -7.91 55.23 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.359 0.6 . . . . 0.0 111.63 -179.609 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.02 -13.32 63.59 Favored Glycine 0 N--CA 1.437 -1.275 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 -178.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 7.3 m -68.63 147.98 51.12 Favored 'General case' 0 N--CA 1.421 -1.879 0 C-N-CA 124.954 1.301 . . . . 0.0 109.073 179.285 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.458 ' CG ' ' HG2' ' A' ' 118' ' ' PRO . 64.7 m95 -111.31 142.28 43.74 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 173.611 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -139.1 156.99 46.75 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-O 121.087 0.47 . . . . 0.0 111.531 -179.084 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -138.48 132.51 16.57 Favored Pre-proline 0 C--N 1.295 -1.779 0 CA-C-N 114.905 -1.043 . . . . 0.0 108.223 174.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.52 121.16 7.9 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 N-CA-C 108.752 -1.288 . . . . 0.0 108.752 173.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -168.03 124.9 1.09 Allowed 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -176.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -93.47 138.91 31.31 Favored 'General case' 0 CA--C 1.483 -1.61 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.341 -176.342 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.475 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -164.01 160.71 22.1 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 175.074 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.491 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 16.1 m -105.6 132.58 51.57 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.378 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -108.15 121.06 44.07 Favored 'General case' 0 N--CA 1.422 -1.825 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 175.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 42.5 t -107.19 119.25 56.49 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.078 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 176.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.428 ' ND2' HG12 ' A' ' 60' ' ' ILE . 46.4 t-20 -68.99 123.21 20.41 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.248 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -143.44 39.85 1.27 Allowed Glycine 0 N--CA 1.417 -2.624 0 C-N-CA 120.098 -1.048 . . . . 0.0 111.937 -176.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 20.7 t-20 -145.55 -66.73 0.31 Allowed 'General case' 0 C--N 1.31 -1.119 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.074 177.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -157.43 161.34 29.41 Favored Pre-proline 0 C--N 1.317 -0.806 0 CA-C-O 118.872 -0.585 . . . . 0.0 109.76 -178.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.24 137.88 81.38 Favored 'Trans proline' 0 C--N 1.357 0.994 0 C-N-CA 122.96 2.44 . . . . 0.0 112.279 -179.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.59 HG21 ' SG ' ' A' ' 109' ' ' CYS . 32.7 mm -106.95 140.55 24.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.996 -174.799 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.27 107.85 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.256 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 172.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 57.7 p -93.72 153.67 18.2 Favored 'General case' 0 C--N 1.294 -1.836 0 CA-C-N 115.067 -0.969 . . . . 0.0 110.37 -176.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -106.44 140.39 39.43 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -177.411 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.3 mp -105.53 125.14 60.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-O 121.282 0.563 . . . . 0.0 111.672 -175.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.32 -22.78 11.4 Favored Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 115.533 0.973 . . . . 0.0 115.533 172.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 41.9 m -152.91 136.67 10.19 Favored Pre-proline 0 C--N 1.305 -1.337 0 CA-C-N 118.12 0.96 . . . . 0.0 110.385 -178.076 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -90.04 119.61 0.81 Allowed 'Trans proline' 0 N--CA 1.439 -1.718 0 C-N-CA 121.434 1.422 . . . . 0.0 110.986 173.544 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.44 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 76.3 m-85 -169.41 175.09 5.66 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 105.151 -2.166 . . . . 0.0 105.151 -179.46 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -88.62 -29.74 19.74 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 172.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -92.32 20.39 6.15 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.784 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.44 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -80.56 159.38 69.63 Favored Pre-proline 0 C--N 1.309 -1.161 0 CA-C-O 119.644 -0.217 . . . . 0.0 110.733 -176.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -57.12 144.06 91.29 Favored 'Trans proline' 0 C--N 1.358 1.063 0 C-N-CA 123.405 2.737 . . . . 0.0 113.989 -177.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.7 m -101.81 174.53 1.04 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.062 0 C-N-CA 124.437 1.095 . . . . 0.0 110.458 -179.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.8 26.91 2.43 Favored Glycine 0 C--N 1.306 -1.118 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -179.255 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.88 109.63 0.59 Allowed Glycine 0 N--CA 1.423 -2.185 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -108.04 126.04 52.26 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-O 120.856 0.36 . . . . 0.0 110.102 178.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.49 ' HB3' ' HB ' ' A' ' 60' ' ' ILE . 33.1 tp -107.56 109.22 62.42 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 107.043 -1.466 . . . . 0.0 107.043 175.323 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -71.08 159.94 50.74 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.191 1.928 . . . . 0.0 112.195 -177.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.78 133.52 46.62 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 177.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.5 -10.52 56.31 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 121.046 -0.597 . . . . 0.0 111.971 -178.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.09 138.24 51.83 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.904 0.383 . . . . 0.0 110.682 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.7 m -117.89 110.17 17.42 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.259 -179.191 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.1 mm -120.89 120.3 61.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 CA-C-O 120.732 0.301 . . . . 0.0 110.62 -176.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 6.6 p -91.67 111.37 23.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-O 121.649 0.738 . . . . 0.0 109.404 175.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.475 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 46.6 p90 -97.12 168.6 10.35 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.963 -174.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -117.68 -17.59 9.87 Favored 'General case' 0 C--N 1.316 -0.857 0 O-C-N 123.858 0.724 . . . . 0.0 112.255 -176.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -135.66 133.92 38.66 Favored 'General case' 0 N--CA 1.432 -1.339 0 C-N-CA 119.891 -0.723 . . . . 0.0 110.905 -173.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.7 t -105.55 127.1 60.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 35.1 m -127.35 148.44 50.26 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 117.742 0.246 . . . . 0.0 110.927 -176.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 39.9 mt -119.14 120.18 63.09 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 CA-C-O 121.039 0.447 . . . . 0.0 109.964 172.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.501 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.2 tp-100 -122.51 118.58 28.62 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 103.514 -2.773 . . . . 0.0 103.514 172.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.45 107.3 0.12 Allowed 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 113.728 1.01 . . . . 0.0 113.728 -165.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 137.41 -31.4 2.52 Favored Glycine 0 N--CA 1.435 -1.391 0 CA-C-N 114.417 -1.265 . . . . 0.0 110.533 -179.252 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . 0.421 ' HA ' ' H ' ' A' ' 114' ' ' CYS . 73.0 m80 -151.13 163.97 37.57 Favored 'General case' 0 CA--C 1.483 -1.633 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.555 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.2 tt -103.9 133.92 46.57 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.742 0 N-CA-C 104.504 -2.406 . . . . 0.0 104.504 170.009 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.501 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 68.3 m95 -115.59 140.07 49.52 Favored 'General case' 0 C--N 1.27 -2.86 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -172.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.423 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.6 pt -100.98 130.02 51.0 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.315 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -101.27 120.4 6.86 Favored Glycine 0 N--CA 1.419 -2.464 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.163 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 44.4 p90 -142.83 144.47 32.54 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -101.93 126.13 48.77 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 175.451 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -93.45 167.84 11.45 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.238 -176.618 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 31.6 p90 -63.19 -2.21 1.29 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 113.859 1.059 . . . . 0.0 113.859 -178.361 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -88.09 -6.7 57.77 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 175.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 90.72 -0.47 76.94 Favored Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 111.808 -0.517 . . . . 0.0 111.808 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 21.2 p30 -96.36 147.67 23.57 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -177.046 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 9.7 tpp85 -92.13 111.56 23.16 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 175.128 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 40.5 t -111.99 143.58 21.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 -176.782 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.423 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 95.4 m-85 -119.33 129.28 54.78 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.027 0.441 . . . . 0.0 110.915 178.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . 0.59 ' SG ' HG21 ' A' ' 60' ' ' ILE . 43.1 t -110.56 127.97 26.1 Favored Pre-proline 0 C--N 1.302 -1.497 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -71.57 -5.63 17.46 Favored 'Trans proline' 0 C--N 1.359 1.123 0 C-N-CA 123.462 2.775 . . . . 0.0 115.243 -175.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.304 30.1 m 37.33 -59.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.515 2.775 0 N-CA-C 118.881 2.919 . . . . 0.0 118.881 175.26 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.464 ' CZ ' ' HB2' ' A' ' 126' ' ' ALA . 7.8 ptp180 -150.72 156.36 41.15 Favored 'General case' 0 C--O 1.248 0.994 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.485 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.2 m -67.27 132.63 48.11 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 176.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.421 ' H ' ' HA ' ' A' ' 94' ' ' HIS . 53.5 m -152.09 110.52 3.75 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.803 0.811 . . . . 0.0 111.449 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -102.93 143.72 32.14 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 106.119 -1.808 . . . . 0.0 106.119 178.144 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 147.71 -170.85 28.37 Favored Glycine 0 CA--C 1.489 -1.566 0 C-N-CA 118.207 -1.949 . . . . 0.0 113.488 178.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 84.7 t -134.67 123.27 16.11 Favored Pre-proline 0 C--N 1.304 -1.386 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 179.221 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 96.0 Cg_exo -45.86 135.53 13.76 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.76 2.974 . . . . 0.0 113.304 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 28.3 Cg_endo -95.1 17.82 37.08 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 C-N-CA 124.283 -1.132 . . . . 0.0 113.493 1.402 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -94.8 101.91 13.75 Favored 'General case' 0 C--N 1.312 -1.028 0 C-N-CA 120.491 -0.484 . . . . 0.0 110.405 -177.625 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 10.9 p-80 -104.63 138.99 40.14 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.902 177.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 50.6 mm -102.31 99.54 13.09 Favored Pre-proline 0 C--N 1.301 -1.502 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 172.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -84.52 147.61 11.14 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 122.82 2.347 . . . . 0.0 113.989 -174.634 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.07 -145.02 6.61 Favored Glycine 0 N--CA 1.419 -2.497 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.28 175.414 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.5 t -60.67 122.72 11.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 C-N-CA 123.727 0.811 . . . . 0.0 111.868 -177.26 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.464 ' HB2' ' CZ ' ' A' ' 112' ' ' ARG . . . -94.22 145.06 24.99 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.501 174.608 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.8 m-90 -105.59 18.69 21.79 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.341 0.591 . . . . 0.0 110.907 177.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -166.99 -165.89 25.16 Favored Glycine 0 N--CA 1.427 -1.933 0 C-N-CA 119.788 -1.196 . . . . 0.0 112.791 -179.727 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 48.7 t -124.03 139.12 51.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -178.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -105.09 134.41 48.24 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 177.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.298 -1.667 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 42.6 t . . . . . 0 CA--C 1.514 -0.412 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.458 ' O ' ' HD2' ' A' ' 6' ' ' TYR . 3.4 m-20 -75.55 -44.01 45.62 Favored 'General case' 0 CA--C 1.506 -0.718 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -179.172 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 56.0 -74.01 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 125.47 1.508 . . . . 0.0 114.25 175.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -142.49 -73.3 0.3 Allowed 'General case' 0 N--CA 1.431 -1.414 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -129.2 94.83 3.89 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.38 0.609 . . . . 0.0 111.876 -177.468 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . 0.458 ' HD2' ' O ' ' A' ' 2' ' ' ASN . 97.2 m-85 -137.69 74.99 1.5 Allowed 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 104.21 -2.515 . . . . 0.0 104.21 168.165 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 66.6 mtt -108.26 15.2 24.3 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 114.444 -1.253 . . . . 0.0 113.257 -167.9 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -68.36 99.24 0.91 Allowed 'General case' 0 C--O 1.247 0.923 0 CA-C-O 121.372 0.606 . . . . 0.0 111.187 177.1 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.8 tptt -79.66 127.48 32.22 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 178.213 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.43 -21.51 12.84 Favored Glycine 0 N--CA 1.435 -1.375 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -177.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 23.6 p 55.03 74.08 0.38 Allowed 'General case' 0 C--O 1.24 0.558 0 C-N-CA 125.092 1.357 . . . . 0.0 113.611 -178.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.2 m -77.54 125.84 29.97 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.503 -1.226 . . . . 0.0 108.287 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 41.4 m -148.62 143.8 26.79 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 73.5 m 66.56 -172.22 0.19 Allowed 'General case' 0 C--O 1.242 0.687 0 C-N-CA 124.521 1.128 . . . . 0.0 112.695 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.0 m -78.66 87.72 4.58 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-O 121.421 0.629 . . . . 0.0 111.026 -177.317 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 31.4 m -118.76 145.23 25.09 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 174.422 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.4 p -87.0 -34.08 7.34 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.167 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.842 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt 60.05 69.48 0.7 Allowed 'General case' 0 C--O 1.242 0.669 0 N-CA-C 106.016 -1.846 . . . . 0.0 106.016 -172.254 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -69.28 107.42 3.26 Favored 'General case' 0 CA--C 1.505 -0.756 0 CA-C-N 114.109 -1.405 . . . . 0.0 110.808 -171.578 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.93 -128.48 7.55 Favored Glycine 0 N--CA 1.422 -2.273 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -177.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -138.53 -62.22 0.57 Allowed 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.219 0.533 . . . . 0.0 110.346 178.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.412 ' HB ' ' HB2' ' A' ' 25' ' ' ALA . 44.7 m -84.73 130.01 34.75 Favored 'General case' 0 N--CA 1.425 -1.683 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.3 m -65.74 127.75 33.21 Favored 'General case' 0 C--O 1.248 1.004 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.085 -177.517 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.1 m 61.12 33.93 19.23 Favored 'General case' 0 C--O 1.239 0.51 0 C-N-CA 124.236 1.015 . . . . 0.0 111.457 177.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.412 ' HB2' ' HB ' ' A' ' 22' ' ' THR . . . -67.75 -42.13 82.29 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 176.534 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 22.5 t -113.17 161.11 17.54 Favored 'General case' 0 N--CA 1.411 -2.382 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 173.472 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 43.5 p 53.94 62.71 8.62 Favored Pre-proline 0 CA--C 1.557 1.215 0 C-N-CA 123.631 0.772 . . . . 0.0 112.148 -175.593 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -80.99 98.53 1.05 Allowed 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 122.453 2.102 . . . . 0.0 112.401 -178.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -102.95 -63.9 1.12 Allowed 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 176.035 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 m -79.6 30.86 0.24 Allowed 'General case' 0 CA--C 1.561 1.372 0 C-N-CA 124.027 0.931 . . . . 0.0 111.319 -176.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.412 ' H ' ' HD2' ' A' ' 32' ' ' PRO . 12.4 mmt180 -124.03 -63.16 0.03 OUTLIER Pre-proline 0 C--N 1.312 -1.045 0 O-C-N 121.428 -0.795 . . . . 0.0 110.618 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.412 ' HD2' ' H ' ' A' ' 31' ' ' ARG . 53.9 Cg_endo -68.62 -11.26 31.42 Favored 'Trans proline' 0 C--N 1.385 2.451 0 C-N-CA 122.197 1.932 . . . . 0.0 113.967 178.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 96.7 t -68.29 -49.56 65.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 174.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.7 p -94.26 60.14 2.69 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 114.753 -1.112 . . . . 0.0 109.501 178.023 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -78.58 90.81 1.15 Allowed Glycine 0 CA--C 1.495 -1.158 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.392 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 46.5 m 75.58 -39.87 0.4 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.252 1.421 . . . . 0.0 111.084 -176.294 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 98.7 m95 -70.35 125.01 25.58 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 175.498 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -140.41 145.53 37.15 Favored 'General case' 0 C--N 1.281 -2.406 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 179.571 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 24.5 ttmm -84.7 109.25 17.88 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-O 121.182 0.515 . . . . 0.0 109.83 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.47 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 44.2 t30 -78.35 168.5 19.73 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.655 -179.44 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -58.28 -12.11 3.37 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -174.524 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -91.84 2.26 56.63 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-O 121.195 0.521 . . . . 0.0 109.87 179.249 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.07 -12.51 57.84 Favored Glycine 0 C--N 1.33 0.205 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -178.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.479 HG21 ' HG2' ' A' ' 67' ' ' PRO . 14.6 m -76.56 140.57 41.14 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 124.638 1.175 . . . . 0.0 110.592 -176.316 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -90.8 131.97 36.14 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 175.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.47 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 11.0 p90 -136.88 159.43 41.89 Favored 'General case' 0 C--N 1.292 -1.915 0 C-N-CA 120.006 -0.677 . . . . 0.0 109.733 -179.541 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 19.7 pttm -155.09 141.33 13.04 Favored Pre-proline 0 N--CA 1.431 -1.394 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 170.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -71.23 122.46 8.73 Favored 'Trans proline' 0 C--O 1.247 0.941 0 C-N-CA 121.873 1.715 . . . . 0.0 110.593 175.517 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -154.71 120.95 5.3 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 -178.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.549 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 7.6 t30 -104.93 117.68 34.64 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.625 -172.747 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.458 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -151.69 173.57 14.54 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 179.674 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 31.1 m -113.58 129.78 56.5 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -176.125 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -107.98 131.69 54.29 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 176.341 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 52.4 t -113.94 112.89 42.14 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 175.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -71.19 139.87 50.3 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -76.89 -117.8 0.16 Allowed Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 114.865 0.706 . . . . 0.0 114.865 -173.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -109.98 10.49 24.23 Favored 'General case' 0 C--N 1.311 -1.08 0 O-C-N 122.303 -0.528 . . . . 0.0 112.016 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -131.38 138.53 32.97 Favored Pre-proline 0 C--N 1.299 -1.609 0 C-N-CA 120.805 -0.358 . . . . 0.0 110.286 -175.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -69.7 141.43 45.45 Favored 'Trans proline' 0 C--O 1.242 0.695 0 C-N-CA 121.898 1.732 . . . . 0.0 109.822 174.344 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 64.4 mt -121.04 125.15 73.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -178.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 29.1 m -80.97 140.05 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.172 0 CA-C-O 121.803 0.811 . . . . 0.0 109.19 175.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . 0.438 HG22 ' HA ' ' A' ' 109' ' ' CYS . 37.3 p -124.24 164.16 20.13 Favored 'General case' 0 C--N 1.272 -2.796 0 CA-C-N 115.095 -0.957 . . . . 0.0 110.814 -171.412 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -107.81 143.58 36.18 Favored 'General case' 0 C--N 1.317 -0.804 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -177.087 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.5 mt -106.09 130.21 58.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-O 121.229 0.538 . . . . 0.0 112.128 -174.247 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.48 -23.05 5.8 Favored Glycine 0 CA--C 1.521 0.417 0 N-CA-C 116.207 1.243 . . . . 0.0 116.207 171.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 52.1 m -156.94 142.28 12.51 Favored Pre-proline 0 C--N 1.308 -1.202 0 CA-C-N 118.448 1.124 . . . . 0.0 110.077 179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.479 ' HG2' HG21 ' A' ' 44' ' ' THR . 90.8 Cg_endo -89.95 119.8 0.84 Allowed 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 121.581 1.521 . . . . 0.0 111.856 175.159 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.481 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 91.7 m-85 -168.78 164.18 11.91 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 104.764 -2.31 . . . . 0.0 104.764 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 81.0 mt -85.79 -17.84 34.65 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 173.297 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -95.38 -0.47 52.56 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.921 178.402 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.481 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -68.83 157.7 88.08 Favored Pre-proline 0 N--CA 1.472 0.654 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.256 -176.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -55.71 122.18 11.27 Favored 'Trans proline' 0 C--N 1.365 1.404 0 C-N-CA 122.951 2.434 . . . . 0.0 112.749 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.4 HG22 ' H ' ' A' ' 74' ' ' GLY . 7.3 p -98.95 173.38 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 179.094 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.4 ' H ' HG22 ' A' ' 73' ' ' VAL . . . 119.78 -3.37 13.29 Favored Glycine 0 C--N 1.308 -1.015 0 C-N-CA 120.319 -0.943 . . . . 0.0 111.565 -178.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -98.94 127.09 9.14 Favored Glycine 0 N--CA 1.432 -1.609 0 N-CA-C 107.932 -2.067 . . . . 0.0 107.932 172.059 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -116.82 140.6 49.25 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 118.292 1.046 . . . . 0.0 110.582 -177.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 48.6 tp -114.19 112.5 46.79 Favored Pre-proline 0 C--N 1.307 -1.273 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 177.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.41 164.3 34.72 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 122.344 2.03 . . . . 0.0 113.06 -178.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.86 139.79 45.28 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.471 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.98 -0.59 86.32 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 121.314 -0.47 . . . . 0.0 112.396 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -72.76 126.26 29.48 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 121.099 0.476 . . . . 0.0 110.865 -178.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 53.6 m -99.7 115.76 30.24 Favored 'General case' 0 N--CA 1.425 -1.677 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.018 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.4 mm -126.05 128.84 72.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 110.256 -0.275 . . . . 0.0 110.256 -175.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.6 p -93.46 123.3 45.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 175.15 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.549 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 40.9 p90 -107.37 145.23 33.16 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.899 -178.666 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -111.93 -15.75 13.26 Favored 'General case' 0 C--N 1.31 -1.143 0 O-C-N 124.002 0.814 . . . . 0.0 112.494 -175.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -136.58 138.51 41.3 Favored 'General case' 0 N--CA 1.437 -1.09 0 C-N-CA 120.21 -0.596 . . . . 0.0 109.758 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 61.5 t -114.84 132.02 65.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 69.6 m -127.47 135.32 50.24 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 120.743 0.306 . . . . 0.0 110.924 -177.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 65.6 mt -103.66 116.88 48.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 CA-C-O 121.296 0.569 . . . . 0.0 110.121 177.053 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.554 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 7.5 tp-100 -124.96 118.96 27.42 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 103.981 -2.6 . . . . 0.0 103.981 175.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.14 106.19 0.1 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 -167.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 138.78 -41.17 1.38 Allowed Glycine 0 N--CA 1.421 -2.333 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.798 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 57.3 m80 -147.2 154.77 41.44 Favored 'General case' 0 CA--C 1.494 -1.181 0 O-C-N 122.142 -0.622 . . . . 0.0 110.206 -178.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.9 tt -96.98 125.77 49.9 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 175.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.554 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 68.2 m95 -105.03 133.97 48.91 Favored 'General case' 0 C--N 1.274 -2.683 0 CA-C-O 121.178 0.513 . . . . 0.0 110.355 -173.407 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.473 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 43.8 pt -100.12 120.84 50.1 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.323 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 175.486 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -94.77 114.15 4.76 Favored Glycine 0 N--CA 1.411 -2.97 0 N-CA-C 109.326 -1.509 . . . . 0.0 109.326 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -132.2 154.16 49.85 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -177.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -89.28 114.96 26.39 Favored 'General case' 0 C--N 1.272 -2.77 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 174.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -78.23 165.35 24.01 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-O 121.114 0.483 . . . . 0.0 110.846 -176.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.6 p90 -69.19 -2.79 11.33 Favored 'General case' 0 C--N 1.312 -1.034 0 C-N-CA 123.9 0.88 . . . . 0.0 112.162 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -95.45 -7.0 39.47 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.321 177.344 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 96.51 -7.8 66.14 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.907 -0.588 . . . . 0.0 113.665 176.062 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 15.3 p-10 -96.69 151.12 19.93 Favored 'General case' 0 C--N 1.296 -1.72 0 C-N-CA 122.972 0.509 . . . . 0.0 112.039 -178.244 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 14.5 tpp180 -84.29 108.47 17.17 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.067 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 25.8 t -110.94 146.62 15.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.022 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -176.525 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 88.2 m-85 -117.05 123.19 46.24 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . 0.438 ' HA ' HG22 ' A' ' 62' ' ' THR . 50.8 t -104.67 132.2 21.14 Favored Pre-proline 0 C--N 1.303 -1.424 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.361 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -69.84 -17.07 37.44 Favored 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 123.051 2.501 . . . . 0.0 114.372 -177.502 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.299 33.2 m 40.91 -58.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.52 3.032 0 N-CA-C 118.815 2.894 . . . . 0.0 118.815 175.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 33.3 ptt180 -153.96 150.6 28.49 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 123.577 0.751 . . . . 0.0 109.009 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 17.8 m -66.66 139.05 57.84 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.742 179.042 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.581 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 92.1 m -154.65 127.03 7.89 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 123.009 0.524 . . . . 0.0 111.17 179.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -125.83 122.49 36.3 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 177.655 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 168.84 175.03 37.96 Favored Glycine 0 N--CA 1.416 -2.696 0 C-N-CA 119.932 -1.128 . . . . 0.0 111.897 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 60.2 t -129.17 128.32 23.29 Favored Pre-proline 0 C--N 1.288 -2.076 0 N-CA-C 105.248 -2.13 . . . . 0.0 105.248 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -43.26 137.53 5.11 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 123.71 2.94 . . . . 0.0 113.027 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -81.88 -14.87 33.76 Favored 'Cis proline' 0 CA--C 1.553 1.467 0 C-N-CA 123.331 -1.529 . . . . 0.0 114.543 3.052 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -79.41 100.33 7.6 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.768 0.794 . . . . 0.0 112.952 -171.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 38.9 p-80 -106.99 112.73 25.83 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 114.869 -1.059 . . . . 0.0 111.164 175.628 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.581 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 49.4 mt -91.94 113.51 59.16 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 110.607 -0.146 . . . . 0.0 110.607 -178.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -84.48 164.75 12.54 Favored 'Trans proline' 0 C--O 1.246 0.918 0 C-N-CA 123.029 2.486 . . . . 0.0 113.36 -178.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.92 -130.96 2.92 Favored Glycine 0 N--CA 1.434 -1.473 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 176.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 80.7 t -73.81 122.3 26.62 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 C-N-CA 122.387 0.275 . . . . 0.0 111.287 -178.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.49 147.46 23.23 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.281 176.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 6.5 m0 -107.57 11.4 28.69 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.923 0.392 . . . . 0.0 111.792 179.213 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -161.66 -168.38 23.47 Favored Glycine 0 N--CA 1.436 -1.365 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.616 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 27.1 t -111.88 139.98 33.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -178.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 -118.32 123.16 44.67 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.426 0.155 . . . . 0.0 111.341 -175.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.1 pttm . . . . . 0 N--CA 1.433 -1.291 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 171.932 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 13.3 m . . . . . 0 N--CA 1.443 -0.793 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -67.63 -48.11 67.69 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 174.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -89.44 95.79 10.43 Favored 'General case' 0 N--CA 1.427 -1.62 0 N-CA-C 107.767 -1.198 . . . . 0.0 107.767 175.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 59.2 mttm -71.61 -39.23 70.6 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 -178.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.686 ' HB3' ' HA ' ' A' ' 8' ' ' ASP . 85.1 m-20 -122.35 132.61 54.47 Favored 'General case' 0 N--CA 1.426 -1.656 0 N-CA-C 106.314 -1.735 . . . . 0.0 106.314 172.293 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 35.5 t80 -88.0 -51.36 5.86 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 120.795 0.331 . . . . 0.0 110.617 -176.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 1.6 pmm? -105.59 -7.58 18.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.125 0.488 . . . . 0.0 109.88 177.493 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.686 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . 25.0 t70 75.49 92.17 0.07 Allowed 'General case' 0 CA--C 1.498 -1.047 0 C-N-CA 125.437 1.495 . . . . 0.0 112.053 -178.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.6 tmtm? -125.93 116.51 21.61 Favored 'General case' 0 N--CA 1.427 -1.588 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 147.27 -72.02 0.32 Allowed Glycine 0 N--CA 1.436 -1.321 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 6.8 t -163.23 135.9 5.43 Favored 'General case' 0 N--CA 1.428 -1.548 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.3 m -97.99 3.15 49.52 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 178.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.2 m 64.77 89.27 0.1 Allowed 'General case' 0 C--N 1.347 0.485 0 C-N-CA 124.901 1.28 . . . . 0.0 110.528 -177.561 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.4 m -140.91 108.36 5.56 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.637 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.9 m -77.17 109.66 11.21 Favored 'General case' 0 N--CA 1.427 -1.581 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.313 -178.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 33.7 m -92.73 -4.26 10.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -175.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 7.1 p -76.23 78.66 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.068 0 CA-C-O 122.935 1.35 . . . . 0.0 110.914 176.733 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 53.7 pttt -163.99 120.27 1.65 Allowed 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 113.504 -1.68 . . . . 0.0 108.358 -178.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -170.21 176.26 4.63 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -178.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 126.71 141.63 5.48 Favored Glycine 0 N--CA 1.434 -1.472 0 C-N-CA 120.426 -0.892 . . . . 0.0 112.131 176.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.486 ' HD3' ' H ' ' A' ' 21' ' ' LYS . 0.0 OUTLIER -67.25 112.5 4.55 Favored 'General case' 0 C--O 1.249 1.07 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 176.232 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 27.4 m 72.06 117.76 0.05 OUTLIER 'General case' 0 CA--C 1.547 0.856 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -171.537 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 12.8 m -53.95 -46.96 71.75 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 113.58 0.955 . . . . 0.0 113.58 -174.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.8 t -140.42 140.82 35.52 Favored 'General case' 0 N--CA 1.421 -1.903 0 C-N-CA 120.424 -0.51 . . . . 0.0 109.808 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.14 103.07 4.45 Favored 'General case' 0 N--CA 1.431 -1.395 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.158 177.376 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 12.7 m -89.67 114.1 25.68 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.317 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 23.9 m -121.26 94.73 48.74 Favored Pre-proline 0 C--N 1.303 -1.448 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.652 -179.024 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.535 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 2.0 Cg_endo -89.1 -77.18 0.0 OUTLIER 'Trans proline' 0 N--CA 1.434 -1.979 0 C-N-CA 122.002 1.801 . . . . 0.0 112.97 173.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 65.63 -72.26 0.08 Allowed 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 124.81 1.244 . . . . 0.0 109.242 -175.456 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 32.1 m -103.28 -49.48 3.72 Favored 'General case' 0 N--CA 1.423 -1.788 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 173.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 64.1 mtp180 -145.62 127.36 7.73 Favored Pre-proline 0 N--CA 1.467 0.423 0 C-N-CA 123.901 0.88 . . . . 0.0 109.14 -179.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.535 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 12.9 Cg_endo -57.19 90.91 0.05 OUTLIER 'Trans proline' 0 C--N 1.362 1.251 0 C-N-CA 123.243 2.628 . . . . 0.0 113.54 175.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.6 m -73.31 -27.49 24.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.76 0.79 . . . . 0.0 109.112 178.55 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 20.1 p -134.28 134.4 41.87 Favored 'General case' 0 N--CA 1.413 -2.282 0 CA-C-N 114.214 -1.357 . . . . 0.0 107.546 174.247 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -118.74 -136.21 5.36 Favored Glycine 0 C--N 1.3 -1.459 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 11.1 m -85.77 1.03 51.23 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 121.541 0.686 . . . . 0.0 109.467 177.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.6 m95 -75.12 127.76 33.95 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.956 -178.585 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -113.64 156.14 24.23 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 175.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -101.4 126.2 48.14 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.559 -178.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.409 ' HB2' ' CD1' ' A' ' 46' ' ' TYR . 36.6 t-20 -89.39 164.57 14.82 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 -177.383 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -64.91 -15.14 61.67 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.309 1.043 . . . . 0.0 111.213 -176.164 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 46.0 m-85 -74.66 -18.02 60.6 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.916 177.4 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.12 -8.13 59.01 Favored Glycine 0 CA--C 1.507 -0.453 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -175.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 11.2 m -80.67 138.84 36.41 Favored 'General case' 0 N--CA 1.427 -1.611 0 C-N-CA 124.724 1.21 . . . . 0.0 110.703 -178.072 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.412 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 65.2 m95 -93.44 139.05 31.14 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 174.463 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.409 ' CD1' ' HB2' ' A' ' 40' ' ' ASN . 37.0 p90 -142.47 151.37 41.64 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 120.691 -0.403 . . . . 0.0 111.241 -178.455 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 pttm -144.18 151.48 51.91 Favored Pre-proline 0 C--O 1.25 1.081 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 173.222 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -73.5 122.12 7.64 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 121.952 1.768 . . . . 0.0 110.548 175.494 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -156.57 121.6 4.64 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.492 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 20.5 t-20 -101.55 115.71 31.12 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.146 -176.005 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.84 176.49 10.68 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.5 m -118.47 138.36 52.55 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 121.192 0.52 . . . . 0.0 111.978 -175.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 80.5 t80 -115.63 123.17 47.72 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 175.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 45.1 t -104.87 110.86 32.13 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 177.204 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.583 ' OD1' ' HA ' ' A' ' 79' ' ' ALA . 22.6 t-20 -66.15 128.09 34.72 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.318 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -136.5 -11.28 1.16 Allowed Glycine 0 N--CA 1.441 -0.993 0 C-N-CA 118.997 -1.573 . . . . 0.0 114.71 -176.787 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.496 ' OD1' ' HG3' ' A' ' 58' ' ' GLN . 15.5 t-20 -95.26 -74.51 0.55 Allowed 'General case' 0 C--N 1.319 -0.753 0 C-N-CA 119.073 -1.051 . . . . 0.0 110.876 -178.051 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.496 ' HG3' ' OD1' ' A' ' 57' ' ' ASN . 0.0 OUTLIER -141.14 167.4 17.44 Favored Pre-proline 0 C--N 1.305 -1.329 0 CA-C-O 118.948 -0.549 . . . . 0.0 110.471 -179.199 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -62.35 130.33 29.9 Favored 'Trans proline' 0 C--N 1.356 0.951 0 C-N-CA 121.824 1.683 . . . . 0.0 109.264 173.339 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 58.9 mt -107.13 125.03 63.3 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 C-N-CA 120.323 -0.551 . . . . 0.0 109.708 -173.641 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 14.7 p -82.66 119.4 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.83 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 176.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 75.6 p -95.86 178.96 5.26 Favored 'General case' 0 C--N 1.285 -2.209 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.131 -172.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.45 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 82.2 mmt-85 -118.35 139.93 50.61 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 175.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 67.4 mt -99.13 129.84 48.96 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 CA-C-O 121.451 0.643 . . . . 0.0 111.895 -175.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 77.11 -22.51 2.41 Favored Glycine 0 C--N 1.318 -0.426 0 N-CA-C 116.023 1.169 . . . . 0.0 116.023 173.028 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 16.5 m -147.22 138.24 13.0 Favored Pre-proline 0 C--N 1.303 -1.44 0 CA-C-N 117.981 0.89 . . . . 0.0 109.941 -176.324 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -89.73 118.62 0.79 Allowed 'Trans proline' 0 N--CA 1.433 -2.062 0 C-N-CA 120.776 0.984 . . . . 0.0 110.006 171.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.576 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 68.9 m-85 -169.06 178.35 4.49 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 104.27 -2.492 . . . . 0.0 104.27 -179.195 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -89.0 -40.12 13.22 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 174.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -96.84 25.46 5.26 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 121.942 0.877 . . . . 0.0 110.524 -177.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.576 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -75.61 159.74 80.83 Favored Pre-proline 0 C--N 1.307 -1.254 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.391 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_exo -47.4 123.03 7.36 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 122.98 2.454 . . . . 0.0 113.482 -179.002 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 6.4 t -98.52 172.6 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 -178.108 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.6 3.48 14.16 Favored Glycine 0 C--N 1.312 -0.77 0 C-N-CA 120.057 -1.068 . . . . 0.0 112.227 -179.212 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -115.51 111.77 2.52 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 175.607 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 38.6 t30 -107.49 130.13 54.88 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 117.318 0.559 . . . . 0.0 109.716 -178.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 46.8 tp -95.56 112.28 58.41 Favored Pre-proline 0 N--CA 1.431 -1.385 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 177.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -61.87 152.1 76.89 Favored 'Trans proline' 0 C--O 1.243 0.761 0 C-N-CA 122.471 2.114 . . . . 0.0 112.379 -177.119 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.583 ' HA ' ' OD1' ' A' ' 55' ' ' ASN . . . -68.18 134.52 50.62 Favored 'General case' 0 N--CA 1.436 -1.145 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.332 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.72 7.96 65.99 Favored Glycine 0 N--CA 1.436 -1.365 0 CA-C-N 115.417 -0.81 . . . . 0.0 112.623 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.33 132.75 37.55 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.116 0.484 . . . . 0.0 111.126 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 26.2 m -102.34 112.63 25.42 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 40.2 mm -115.65 121.8 68.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.836 -176.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.2 p -87.9 123.51 40.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 172.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.492 ' O ' ' HA ' ' A' ' 50' ' ' ASN . 39.2 p90 -108.88 142.41 39.52 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -178.618 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -115.9 -10.96 11.58 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.719 0.771 . . . . 0.0 110.915 -174.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -131.65 134.42 45.95 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 50.3 t -117.87 133.11 65.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.329 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.503 ' SG ' ' HE2' ' A' ' 108' ' ' TYR . 67.1 m -132.02 140.4 48.9 Favored 'General case' 0 C--N 1.312 -1.051 0 O-C-N 123.317 0.386 . . . . 0.0 111.446 -177.403 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 52.0 mt -107.69 112.57 40.69 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.906 -0.496 . . . . 0.0 109.745 174.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.593 ' HB3' ' CD1' ' A' ' 96' ' ' TRP . 6.0 tp-100 -118.64 120.37 37.24 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 174.397 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -48.61 109.63 0.26 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 113.48 0.919 . . . . 0.0 113.48 -165.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 132.44 -34.82 2.44 Favored Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.27 -1.332 . . . . 0.0 110.793 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 68.5 m80 -148.8 159.33 44.25 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.7 tt -102.09 119.03 49.81 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 172.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.593 ' CD1' ' HB3' ' A' ' 91' ' ' GLN . 61.7 m95 -99.81 134.73 42.28 Favored 'General case' 0 C--N 1.276 -2.596 0 CA-C-O 121.186 0.517 . . . . 0.0 110.581 -171.445 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.483 ' O ' ' HA ' ' A' ' 108' ' ' TYR . 49.0 pt -100.22 131.92 46.8 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.131 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.15 127.04 9.05 Favored Glycine 0 N--CA 1.425 -2.099 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -178.078 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 27.4 p90 -151.36 166.64 30.39 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 120.976 0.417 . . . . 0.0 109.975 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -118.84 130.39 55.74 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.331 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -96.17 147.78 23.39 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.046 -178.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 29.8 p90 -46.96 -21.52 0.23 Allowed 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 126.246 1.818 . . . . 0.0 115.158 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -89.16 3.99 50.03 Favored 'General case' 0 CA--C 1.561 1.398 0 CA-C-O 121.665 0.745 . . . . 0.0 111.053 -177.579 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 91.59 16.92 51.13 Favored Glycine 0 CA--C 1.502 -0.748 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.135 177.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -96.06 124.08 39.93 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 120.991 0.424 . . . . 0.0 111.35 -176.322 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 30.3 tpt180 -82.91 109.09 16.73 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 105.127 -2.175 . . . . 0.0 105.127 172.397 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 20.1 t -118.81 140.19 43.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 C-N-CA 119.449 -0.901 . . . . 0.0 112.029 -171.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.503 ' HE2' ' SG ' ' A' ' 89' ' ' CYS . 66.8 m-85 -122.58 124.14 42.82 Favored 'General case' 0 N--CA 1.435 -1.219 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.205 174.664 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . 0.418 ' O ' ' HA ' ' A' ' 96' ' ' TRP . 48.7 t -108.83 132.66 21.03 Favored Pre-proline 0 C--N 1.304 -1.372 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.358 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.74 -21.16 33.96 Favored 'Trans proline' 0 C--N 1.358 1.064 0 C-N-CA 123.092 2.528 . . . . 0.0 114.214 -176.816 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . 0.317 33.2 m 45.85 -55.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.51 2.529 0 N-CA-C 118.67 2.841 . . . . 0.0 118.67 176.193 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.447 ' HB3' ' HA ' ' A' ' 126' ' ' ALA . 34.2 ptt180 -153.6 149.11 27.26 Favored 'General case' 0 N--CA 1.441 -0.914 0 C-N-CA 122.966 0.507 . . . . 0.0 110.639 177.592 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.4 m -63.0 127.98 33.76 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 177.324 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.645 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 88.3 m -151.94 117.32 5.31 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.592 0.711 . . . . 0.0 111.363 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -114.35 144.84 42.62 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.121 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 141.41 -169.49 25.08 Favored Glycine 0 N--CA 1.429 -1.83 0 C-N-CA 119.769 -1.205 . . . . 0.0 111.454 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 15.4 m -136.68 142.23 38.23 Favored Pre-proline 0 C--N 1.298 -1.656 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 71.9 Cg_exo -43.92 127.46 6.61 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 123.784 2.989 . . . . 0.0 113.207 -178.235 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 11.2 Cg_endo -96.21 -9.97 19.97 Favored 'Cis proline' 0 C--O 1.245 0.828 0 C-N-CA 124.195 -1.169 . . . . 0.0 114.12 1.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 57.9 t30 -72.67 100.86 2.91 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 121.998 0.904 . . . . 0.0 111.557 -172.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 33.4 p-80 -106.66 125.15 50.63 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.304 -1.316 . . . . 0.0 110.699 177.086 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.645 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 49.8 mm -85.66 107.96 14.62 Favored Pre-proline 0 C--N 1.306 -1.286 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 176.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_endo -84.89 123.8 2.86 Favored 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 122.723 2.282 . . . . 0.0 112.967 -177.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -98.74 -110.25 3.0 Favored Glycine 0 N--CA 1.433 -1.543 0 N-CA-C 111.374 -0.69 . . . . 0.0 111.374 177.583 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 48.1 t -94.79 122.38 46.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 -177.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.447 ' HA ' ' HB3' ' A' ' 112' ' ' ARG . . . -94.27 136.5 34.49 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.272 175.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 5.6 m-90 -102.04 16.07 27.15 Favored 'General case' 0 C--O 1.251 1.162 0 CA-C-O 121.581 0.705 . . . . 0.0 111.467 179.48 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -171.29 -171.57 36.6 Favored Glycine 0 N--CA 1.43 -1.74 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.064 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 59.1 t -111.51 125.41 68.83 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 123.508 0.723 . . . . 0.0 109.167 -177.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -93.58 135.12 35.17 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.015 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 96.0 mttt . . . . . 0 C--N 1.293 -1.856 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 179.067 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 15.1 m . . . . . 0 CA--C 1.546 0.824 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -84.13 88.6 7.2 Favored 'General case' 0 CA--C 1.5 -0.975 0 CA-C-O 121.428 0.632 . . . . 0.0 111.188 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.13 30.61 1.41 Allowed 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.062 -177.509 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -78.0 72.82 4.55 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.779 0.8 . . . . 0.0 110.491 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -143.21 35.01 1.34 Allowed 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 106.298 -1.741 . . . . 0.0 106.298 176.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -87.08 162.54 17.52 Favored 'General case' 0 N--CA 1.436 -1.133 0 CA-C-N 114.403 -1.271 . . . . 0.0 108.944 -175.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 75.2 mtm 82.42 -29.69 0.1 Allowed 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 125.268 1.427 . . . . 0.0 111.254 -178.208 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -76.79 118.5 19.46 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 169.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 23.2 ttmm -137.77 159.27 42.45 Favored 'General case' 0 C--N 1.284 -2.266 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 -176.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.97 82.43 0.23 Allowed Glycine 0 N--CA 1.442 -0.91 0 N-CA-C 110.471 -1.051 . . . . 0.0 110.471 175.593 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 22.5 m -93.72 -44.27 8.24 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 123.201 0.6 . . . . 0.0 110.233 -176.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.1 m -83.21 -28.6 29.14 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 176.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.9 p -125.29 85.47 2.41 Favored 'General case' 0 N--CA 1.427 -1.58 0 CA-C-O 121.785 0.802 . . . . 0.0 110.133 176.586 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 26.0 m -86.84 93.82 9.39 Favored 'General case' 0 N--CA 1.429 -1.525 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.221 -178.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 4.6 p -80.57 -49.31 11.47 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.179 178.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.8 p -78.38 67.25 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.038 0 CA-C-O 122.957 1.36 . . . . 0.0 112.343 -179.076 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.4 m -119.81 -17.66 6.37 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.069 0 CA-C-N 114.162 -1.381 . . . . 0.0 109.732 175.191 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 58.5 mtpt -121.17 87.54 2.77 Favored 'General case' 0 N--CA 1.434 -1.254 0 CA-C-N 115.078 -0.965 . . . . 0.0 109.05 178.559 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -126.74 -36.91 2.18 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 176.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 116.63 148.47 8.97 Favored Glycine 0 N--CA 1.413 -2.89 0 CA-C-N 114.392 -1.276 . . . . 0.0 110.978 178.092 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.15 134.71 34.61 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 120.547 -0.461 . . . . 0.0 109.993 177.415 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.1 m -70.68 -21.53 62.58 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.552 -175.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.5 m 67.92 23.97 8.16 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 123.987 0.915 . . . . 0.0 108.65 -177.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 21.2 t -147.22 93.68 2.28 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 -175.543 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -132.76 10.64 4.32 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.725 178.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 27.9 p 52.57 -171.58 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.301 1.44 . . . . 0.0 112.949 -177.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 21.7 p -104.82 118.44 56.29 Favored Pre-proline 0 C--N 1.295 -1.771 0 O-C-N 122.014 -0.429 . . . . 0.0 109.848 176.679 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -57.85 -35.0 99.02 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 122.334 2.023 . . . . 0.0 111.129 175.671 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 27.02 95.18 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 126.233 1.813 . . . . 0.0 114.295 172.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 24.8 m 86.87 -22.11 0.17 Allowed 'General case' 0 CA--C 1.557 1.245 0 C-N-CA 125.249 1.419 . . . . 0.0 110.274 -175.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.495 ' HB3' ' CD ' ' A' ' 32' ' ' PRO . 2.0 mpp_? -98.57 173.14 4.1 Favored Pre-proline 0 CA--C 1.561 1.377 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 170.624 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.495 ' CD ' ' HB3' ' A' ' 31' ' ' ARG . 9.9 Cg_exo -68.42 118.98 6.01 Favored 'Trans proline' 0 C--N 1.371 1.725 0 C-N-CA 122.522 2.148 . . . . 0.0 115.051 -170.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.2 p -111.3 85.57 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.362 0 CA-C-O 122.449 1.118 . . . . 0.0 108.88 174.171 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 36.6 m -146.78 138.67 24.57 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.203 -178.357 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.79 -67.32 0.34 Allowed Glycine 0 CA--C 1.49 -1.482 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 -179.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 14.7 m -76.02 -49.79 16.6 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 173.175 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . 0.524 ' CZ2' ' HD2' ' A' ' 47' ' ' LYS . 94.1 m95 -91.75 132.5 36.35 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 174.683 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -125.51 140.73 52.51 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 -179.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 59.8 tttp -89.63 118.04 28.95 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.192 0.52 . . . . 0.0 110.596 -177.509 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -89.85 152.24 21.36 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 175.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.7 tp60 -61.04 -13.68 18.3 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 123.745 0.818 . . . . 0.0 113.094 -173.675 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 62.9 m-85 -74.84 -9.05 58.18 Favored 'General case' 0 CA--C 1.542 0.649 0 CA-C-O 121.247 0.546 . . . . 0.0 109.838 176.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.77 20.17 54.47 Favored Glycine 0 CA--C 1.496 -1.116 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -176.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 89' ' ' CYS . 22.1 m -105.81 129.08 54.06 Favored 'General case' 0 N--CA 1.408 -2.542 0 CA-C-N 114.13 -1.035 . . . . 0.0 108.679 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 81.0 m95 -92.48 132.07 37.1 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 175.344 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 31.8 p90 -130.69 147.74 52.4 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.991 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.524 ' HD2' ' CZ2' ' A' ' 37' ' ' TRP . 20.7 ptmt -125.1 141.99 40.07 Favored Pre-proline 0 C--N 1.294 -1.844 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.57 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -73.22 120.83 6.78 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 N-CA-C 108.699 -1.308 . . . . 0.0 108.699 172.403 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -168.12 121.53 0.9 Allowed 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 -178.419 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' TYR . 19.8 t-20 -104.79 128.55 52.98 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.929 -173.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.535 ' HB3' ' CZ ' ' A' ' 85' ' ' TYR . . . -156.59 170.15 23.04 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 177.525 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.422 ' HA ' ' HA ' ' A' ' 84' ' ' VAL . 2.4 m -112.92 122.25 47.08 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.668 -174.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -95.82 124.24 39.75 Favored 'General case' 0 C--N 1.312 -1.062 0 O-C-N 121.969 -0.457 . . . . 0.0 110.582 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.439 HG22 HG23 ' A' ' 82' ' ' THR . 38.2 t -110.56 112.59 41.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 176.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -68.34 137.03 54.29 Favored 'General case' 0 C--O 1.248 0.995 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -124.73 -57.63 0.17 Allowed Glycine 0 N--CA 1.424 -2.135 0 C-N-CA 118.934 -1.603 . . . . 0.0 115.654 -170.699 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -83.02 -53.46 5.8 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -170.058 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -142.62 154.68 63.32 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 119.942 -0.703 . . . . 0.0 111.082 -174.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -60.03 132.75 46.28 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 122.707 2.271 . . . . 0.0 110.213 176.251 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 41.8 mt -108.19 120.83 60.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -174.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.5 p -79.38 115.09 21.12 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.136 0 CA-C-O 121.753 0.787 . . . . 0.0 109.471 175.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 56.3 p -89.49 178.87 6.19 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 115.191 -0.913 . . . . 0.0 111.657 -173.104 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 84.6 mmt-85 -117.52 137.67 52.41 Favored 'General case' 0 N--CA 1.439 -0.978 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 176.203 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 72.3 mt -95.29 123.7 47.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.139 -176.247 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.87 -22.55 3.42 Favored Glycine 0 C--N 1.317 -0.505 0 N-CA-C 116.205 1.242 . . . . 0.0 116.205 171.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.3 m -152.32 140.61 13.54 Favored Pre-proline 0 C--N 1.306 -1.311 0 CA-C-N 118.322 1.061 . . . . 0.0 110.455 -177.208 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -90.05 118.89 0.76 Allowed 'Trans proline' 0 N--CA 1.433 -2.05 0 C-N-CA 121.03 1.154 . . . . 0.0 110.662 172.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.543 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 97.0 m-85 -169.04 166.99 10.86 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 104.134 -2.543 . . . . 0.0 104.134 179.076 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -79.22 -36.14 40.54 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 175.336 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.5 p-10 -96.06 19.99 10.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.336 -177.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.543 ' HB2' ' HB2' ' A' ' 68' ' ' PHE . . . -74.96 156.25 86.28 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 176.089 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -48.07 123.33 8.58 Favored 'Trans proline' 0 C--O 1.255 1.345 0 C-N-CA 123.385 2.723 . . . . 0.0 113.828 179.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 34.2 m -94.29 174.43 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.609 -1.178 . . . . 0.0 109.949 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 119.43 11.34 7.38 Favored Glycine 0 N--CA 1.439 -1.132 0 C-N-CA 120.17 -1.014 . . . . 0.0 112.909 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -119.78 130.13 8.31 Favored Glycine 0 N--CA 1.436 -1.324 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 174.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -128.36 130.16 47.31 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 118.024 0.912 . . . . 0.0 110.439 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 46.1 tp -101.16 110.31 60.95 Favored Pre-proline 0 C--N 1.3 -1.552 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.074 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -69.13 166.91 25.2 Favored 'Trans proline' 0 C--O 1.244 0.822 0 C-N-CA 122.57 2.18 . . . . 0.0 112.481 -177.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -75.43 141.08 43.24 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.468 -179.215 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.53 -23.78 32.3 Favored Glycine 0 C--O 1.244 0.761 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.05 128.22 35.13 Favored 'General case' 0 C--O 1.244 0.78 0 CA-C-O 121.13 0.49 . . . . 0.0 110.453 -178.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.439 HG23 HG22 ' A' ' 54' ' ' VAL . 39.9 m -111.88 121.58 45.44 Favored 'General case' 0 N--CA 1.416 -2.151 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.437 -178.565 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.1 mm -125.87 128.55 72.12 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 -178.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 52' ' ' THR . 12.9 p -83.92 133.2 29.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 175.64 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.535 ' CZ ' ' HB3' ' A' ' 51' ' ' ALA . 50.6 p90 -116.09 137.66 51.93 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.01 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -111.36 -10.5 14.22 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 122.232 1.015 . . . . 0.0 109.568 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.4 ' CD ' HH22 ' A' ' 106' ' ' ARG . 39.8 tt0 -125.71 120.05 29.62 Favored 'General case' 0 N--CA 1.423 -1.804 0 CA-C-N 114.454 -1.248 . . . . 0.0 109.119 -176.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 45.0 t -106.58 130.51 58.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.64 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.457 ' HB3' ' CG2' ' A' ' 44' ' ' THR . 62.1 m -129.08 153.18 47.89 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 120.882 0.372 . . . . 0.0 111.97 -174.41 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.3 mt -124.91 117.04 49.01 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 171.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.563 ' HB3' ' NE1' ' A' ' 96' ' ' TRP . 5.5 tp-100 -124.13 126.8 46.8 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 104.469 -2.419 . . . . 0.0 104.469 174.18 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -49.2 113.2 0.75 Allowed 'General case' 0 C--N 1.321 -0.645 0 O-C-N 124.789 1.306 . . . . 0.0 112.586 -168.704 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 131.68 -35.8 2.34 Favored Glycine 0 N--CA 1.432 -1.602 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.66 -176.606 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -154.19 168.41 26.63 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 122.418 -0.46 . . . . 0.0 110.257 -178.07 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 112' ' ' ARG . 15.4 tt -98.36 140.81 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 N-CA-C 103.724 -2.695 . . . . 0.0 103.724 168.159 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.563 ' NE1' ' HB3' ' A' ' 91' ' ' GLN . 49.8 m95 -125.15 147.83 48.85 Favored 'General case' 0 C--N 1.28 -2.447 0 CA-C-N 118.117 0.417 . . . . 0.0 110.308 -172.155 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 49.9 pt -110.49 131.31 61.93 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.022 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 172.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.55 121.1 7.05 Favored Glycine 0 N--CA 1.424 -2.113 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.324 -178.575 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -140.29 164.3 30.45 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-O 121.074 0.464 . . . . 0.0 110.688 178.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 31.0 t30 -120.74 127.02 51.6 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 178.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -84.55 172.32 11.73 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.064 0.459 . . . . 0.0 111.717 -176.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -60.47 -25.9 66.38 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.199 1.0 . . . . 0.0 112.603 -176.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 26.5 p-10 -92.78 -0.6 57.23 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.253 -177.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 91.67 9.62 62.59 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.481 178.656 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -78.55 122.3 25.71 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . 0.4 HH22 ' CD ' ' A' ' 87' ' ' GLU . 11.2 tpt85 -88.18 98.29 11.48 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 -179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 16.5 t -103.86 139.91 23.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 CA-C-O 121.126 0.488 . . . . 0.0 111.066 -171.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -118.34 122.27 42.45 Favored 'General case' 0 N--CA 1.432 -1.367 0 CA-C-N 115.407 -0.815 . . . . 0.0 108.991 174.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' CYS . . . . . . . . . . . . . 42.2 t -104.06 129.77 24.6 Favored Pre-proline 0 C--N 1.301 -1.541 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -178.511 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.98 -2.83 12.82 Favored 'Trans proline' 0 C--N 1.361 1.206 0 C-N-CA 123.329 2.686 . . . . 0.0 114.852 -177.195 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 28.3 m 29.59 -52.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.522 3.147 0 N-CA-C 120.116 3.376 . . . . 0.0 120.116 172.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.407 ' O ' HG22 ' A' ' 95' ' ' ILE . 59.5 ttt180 -156.8 141.65 17.0 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 123.828 0.851 . . . . 0.0 109.23 -176.183 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 28.1 m -71.83 132.09 43.95 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 120.797 0.332 . . . . 0.0 110.183 177.756 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 122' ' ' ILE . 86.1 m -151.47 143.52 23.92 Favored 'General case' 0 N--CA 1.437 -1.086 0 C-N-CA 123.729 0.812 . . . . 0.0 109.054 178.507 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 7.8 tt0 -134.26 133.78 41.19 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 178.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 156.25 -172.59 34.11 Favored Glycine 0 N--CA 1.437 -1.287 0 C-N-CA 119.925 -1.131 . . . . 0.0 112.096 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 31.0 m -129.68 148.51 69.74 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 119' ' ' PRO . 75.4 Cg_exo -51.55 131.79 38.29 Favored 'Trans proline' 0 CA--C 1.545 1.063 0 C-N-CA 122.801 2.334 . . . . 0.0 113.125 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 118' ' ' PRO . 6.4 Cg_endo -100.24 10.17 23.42 Favored 'Cis proline' 0 CA--C 1.544 1.005 0 C-N-CA 124.779 -0.925 . . . . 0.0 113.044 -3.235 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -93.55 102.31 14.51 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.793 0.806 . . . . 0.0 112.096 -174.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 39.3 p-80 -104.68 138.52 40.87 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.11 178.648 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.447 ' O ' ' HA ' ' A' ' 114' ' ' CYS . 70.2 mt -92.68 110.37 44.87 Favored Pre-proline 0 C--N 1.305 -1.351 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 173.702 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -84.59 126.09 3.46 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 122.659 2.239 . . . . 0.0 113.942 -177.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -102.76 -138.34 9.95 Favored Glycine 0 N--CA 1.437 -1.28 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 176.374 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 60.4 t -73.85 127.83 35.92 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 C-N-CA 122.996 0.518 . . . . 0.0 111.801 -177.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -94.11 141.72 28.22 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.147 177.49 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 7.6 m0 -99.59 -4.89 30.07 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 119.59 -0.844 . . . . 0.0 111.615 177.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -160.61 -175.27 31.43 Favored Glycine 0 N--CA 1.43 -1.703 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -177.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 46.9 t -110.95 134.76 52.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 C-N-CA 122.963 0.505 . . . . 0.0 109.675 -174.084 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -101.03 110.92 23.0 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.6 tptt . . . . . 0 C--N 1.294 -1.84 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -177.786 . . . . . . . . 0 0 . 1 stop_ save_